DIRECTORATE GENERAL HEALTH SERVICES
KHYBER PAKHTUNKHWA

DG Office Phone No. 091-9210269
MCC Phone/ Fax No. 091-9211702
Email Address: mccdgdcps@gmail.com

No. 274-281/MCC
Date. 25/05/2026

OFFICE ORDER

Pursuant to the decision of the Procurement Committee (S&RCC), the Bid Evaluation Report (BER-Technical) of the Govt. MCC FY 2026-27 is hereby approved, and announced under Rule 45 of the KP-PPRA Rules 2014 in accordance with Section 3 & 14 (A) (B) of the KP-PPRA Act 2012.

All applicant firms participating in the tender process of Govt. MCC FY 2026-27 are hereby informed that any grievance regarding the BER-Technical shall be submitted online through EPADS portal (https://kp.eprocure.gov.pk/#/auth/login), positively, not later than June, 6th 2026.

Director General Health Services
Chairman S&RCC Govt. MCC FY 2026-27

Endst No. & Date Even:
Copy for information to:

1. Director General Drug Control & Pharmacy Services, Khyber Pakhtunkhwa.
2. Additional DGHS (M&E)/Chairman T&E Govt. MCC FY 2026-27.
3. All Member (s) of the S&RC Committee of Govt. MCC FY 2026-27.
4. All Members (s) of the T&E Committee of Govt. MCC FY 2026-27.
5. Managing Director, KP- PPRA Khyber Pakhtunkhwa
6. PS to Minister Health Government of Khyber Pakhtunkhwa.
7. PS to Secretary Health Government of Khyber Pakhtunkhwa.
8. All applicant firms participating in the tender process of Govt. MCC FY 2026-27.

Director General Health Services
Chairman S&RCC Govt. MCC FY 2026-27

Evaluation Criteria for Manufacturers of Non Drugs Items for Govt MCC 2026-27

Name of the firm: 3N Life Med Lahore

Technical Evaluation Matrix

S.No	Product General Information					Factory Technical Evaluation Parameter								Factory Evaluated Score						Product Evaluated Score	Total Technical Score
						Documents Based Factory Score				Evaluation Visit Score											
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks (The document shall be attested by a Senior executive of the firm)	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. **(as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.**	Adherence to Current Good Manufacturing Practices in line with the DRAP regulations. **(to be evaluated by the MCC expert/s, Non compliance to cGMP shall lead to disqualification of the relevant section or firm)**	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section (s) / firm.**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC** **(Certificates duly attested by Senior Executive of the firm)**	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than 2 years) from other Secondary & Tertiary Govt. Hospitals outside Khyber Pakhtunkhwa or JCI accredited private entities/hospitals of other provinces of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks **Note.** **Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entity/purchasing agency/ies, etc. Copies of the supply orders/purchase orders shall not considered as tender approval.**	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **(Online verification link shall be provided.)** In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	6	5	5	5	5	**39**	5	5	5	6	10	**31**	**70**
1	101	Activated Charcoal	25 gram bottle	Powder	Lifemed Activated Charcoal	3	5	5	2	The firm was inspected as per technical evaluation criteria. Current Good Manufacturing Practices (cGMP) certificate was expired at the time of inspection (expiry date: 26-07-2025). Moreover, Satisfactory inspection report of the area Federal Inspector of Drugs (FID) duly signed by him/her on the original inspection book of the manufacturer was not shown to the inspection team at the time of inspection. Hence, the firm is NOT RECOMMENDED for award of factory evaluation visit score for the quoted items.				**15**					10	**10**	**25**
2	651	Haemodialysis Concentrate	Part-A: 4 Liter Can Part-B: 504 gram Powder	Solution, 4000ml	Lifemed Bicarb Concentrate	3	5	5	2					**15**					10	**10**	**25**
3	907	Sodium hypchlorite	10% 5 Liter Can	Solution, 500ml	Lifemed Hypochloride 10%	3	5	5	2					**15**					10	**10**	**25**

Scrutiny Report

1The firm quoted wrong formulary numbers of the quote items at Page 4 and did not submitted its bid according to the revised BSDs i.e.,99 instead of 101, 641 instead of 651, 895 instead of 907
2Sodium Hypchlorite is not covered in the Maunfacturing liscense at page 44 and 47 (cGMP)
3The CGMP attached at page 47 is expired on 25-07-2025, and inspection report attached at page 50 is for previous cGMP. (date of inspection is 26-07-2024)
4The firm did not submitted the mandatory valid cGMP or inspection report as per the advertised BSDs
5Irrelevat documents regarding HR data, company profile and orders and BSDs are attached in the bid.
6Caliberation certificate attached at Page 424 are expired in 09-09-2023
7The tender approvals attached are not according to the advertisted cirteria.
8Original Mandatory forms in Hard are not submitted to the MCC.

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: AJ MIRZA KARACHI

Technical Evaluation Matrix

S. No.	Product General Information					Principal's and Importer's Evaluation Parameters								Suppliers Technical Score	Product Technical Evaluation							Product Availability	Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation					Importer's Evaluation				Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
						Valid ISO 13485/14585 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid accreditation of manufacturing unit or its relevant sections's by the US-FDA or WHO or official accreditation body/ies /regulatory body in the case of SRA/WLA countries (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Availability of minimum 20% inventory of the total import of the quoted item/s having last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the ware house at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good storage practices (GSP) for storage of finished goods, Functional and effective Air-conditioning & Ventilation System and effective cold chain (thermo-labile drugs). **Nonadherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s (care mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and/or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and/or In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and/or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / biosimilarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids.	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 15, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (API/s) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ FMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLA country (ies). Etail of principal manufacturer shall be established from the respective GD, CoA and other supporting documents. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT/bid submission. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, API/s source accreditation shall be awarded only where these documents are submitted for all API/s/components of the quoted products	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) / Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) and / or Valid certificate of the availability of the quoted item in the US market. **(Online verification link shall be provided)** 2 mark for each certification, up to a maximum of 06 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with invoice/proof of purchase: **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this colusmn for the respective item.** For award of marks, the certificate of analysis must clearly mentions: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health. Less than 5 % market share = 0 mark 5-10% market share = 01 mark 11-30% market share = 02 marks 31-50% market share = 03 marks 50% and above market share = 05 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than 2 years) from other Secondary & Tertiary Govt. Hospitals outside Khyber Pakhtunkhwa or JCI accredited private entities/hospitals of other provinces of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks **Note.** **Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form.**		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	2	5	5	4	5	5	30	5	5	5	5	6	4	5	5	40	70
Jiangsu Hengrui China	130	Caspofungin	50mg/Vial	Inj	Caspogin 50mg	2	2	0	**0**	0	**4**	**5**	**5**	**18**	**0**	0	0	0	**0**	**0**	**0**	**0**	**0**	**18**
Shenyang Sunshine China	295	Epoetin-a	4000IU	Vial	EPAO 4000IU	2	2	0	**0**	0	**4**	**5**	**5**	**18**	**0**	0	0	0	**0**	**0**	**0**	**0**	**0**	**18**
Shenyang Sunshine China	296	Epoetin-a	10000IU	Vial	EPAO 10000IU	2	2	0	**0**	0	**4**	**5**	**5**	**18**	**0**	0	0	0	**0**	**0**	**0**	**0**	**0**	**18**
Biens Biochemicals Canada	682	Bovine Lipid Extract Surfactant	27mg/ml	Inj	Bles 5ml	0	0	0	**5**	0	**4**	**5**	**5**	**19**	**0**	0	0	0	**2**	**0**	**0**	**0**	**2**	**21**

SCRUTINY REPORT
AIRWAYBILS ARE NOT ATTACHED WITH GD
PICTURES OF QUOTED PRODUCTS ARE NOT ATTACHED IN IMMEDIATE CONTAINER.

		TECHNICAL EVALUATION PROFORMA, FOR PROCUREMENT OF ANTICANCER MEDICINES IN GOVT. MCC FY 2026-27								
		Name of the firm with Complete Address	**A.J Mirza, Karachi**							
		Manufacturer / Importer	**Importer**							
		Mandatory Requirements.	**YES / NO**		**In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:**		**YES/NO**	**In case of being Importers, the Firm should provide attested copies of the following documents also:**		**YES/NO**
1		**National Tax Number (NTN) of the Firm for Income Tax, and**	Yes		1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and		1	Valid Drugs Sales License for the importer; and	Yes
2		**Last year Income Tax Return of the Firm; and**	Yes		2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.		2	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	Yes
3		**Sale Tax Registration Certificate of the Firm; and**	Yes		3	Valid DRAP Approved Price List of the quoted item/s.		3	Valid Agency Agreement with the Foreign Principal Manufacturer/ entity/ies; and	Yes
4		**Certificate of Professional Tax of the Firm.**	Yes					4	Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and	Yes
5		**Certificate of compliance to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR. Non-Compliance to international reference standards or absence of Cold Chain requirements shall lead to disqualification of the relevant product that requires cold chain.**	Yes					5	Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s. Non provision of this document shall lead to disqualification of the firm; and	
								6	Valid DRAP approved Price List of the quoted items.	Yes

			Technical Evaluation Parameters			Active Pharmaceutical Ingredient source gradation (For API or finished product). i) The bidder (local manufacturer / multi-national manufacturer / importer) shall provide Analytical/ Quality Assurance/ Approval Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades. Certificate of Analysis/ Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreement/ approval with the original manufacturer duly attested/verified by official of the company. Detailed purchase trail of the Active Pharmaceutical Ingredient/ Finished product from the claimed source must be submitted (any proof of purchase such as Goods Declaration Certificate along with Airway Bill/ Bill of Lading/invoice etc.) by the bidder. Maximum marks for this criterion are 40.		Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW) Study/Certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities)/ WHO Listed Authorities WLA Countries (BE/BS Certificate with evidence as to its authenticity) from Category A countries. Bio-Equivalence (BE) of the quoted product to be conducted against the originator. Original innovator products do not require bio- equivalence certificate and shall get 10 marks automatically.The bidder shall provide the documents to establish the proof of inventor/ originator. All other branded generics require BE studies Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid. Maximum marks for this criterion are 10.			Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug. In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article) Mandatory: Online verification link must be provided to verify the Clinical Trial/ Clinical Studies submitted for the quoted items.			Factory/ Importer Based Evaluation Score		Sample Evaluation by End User Committee Samples will be examined per following parameters as follows: a. Labeling and Packing Rules 1986 b. Outer packing c. Inner packing d. Physical appearance. Product which has unsatisfactory packing/labeling will be technically Disqualified. Maximum score for this criterion is 1.		Past Performance (Last two years). 1) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks. 2) Only supply orders will not get any marks. 3) The bidders have to undertake that they have never been blacklisted or debarred. Maximum marks for this criterion are 5. 4) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.	Total Technical Score
						Category A – Approval By: • United States Food & Drug Administration (US-FDA) • European Medicines Agency (EMA) • Medicines & Healthcare Products Regulatory Agency (MHRA), UK • Therapeutic Goods Administration (TGA), Australia. • Pharmaceutical Medical Agency (PHARMAC), New Zealand • Pharmaceutical & Medical Devices Agency (PMDA), Japan • Swiss Agency For therapeutic drugs (Swiss-medic), Switzerland • Health Canada • Health Sciences Authority (HAS), Singapore • National Administration of Drugs, Food & Medical technology (ANMAT), Argentina Drug Regulatory Authorities of the SRA (Stringent Regulatory Authorities) / WHO Listed Authorities WLA countries	Category B – Approved By: • Agência Nacional de Vigilância Sanitária (ANVS), Brazil • Central Drug Standard Control Organization (CDSCO), India • Drug Regulatory Authority, Pakistan • National Pharmaceutical Control Bureau (NPCB), Malaysia • Food & Drug Administration, South Korea • Ministry of Health, Egypt • Ministry of Health, Turkey • China Food & Drug Administration • Any other source not mentioned in Category-A	Study/certificate accepted/certified by a Category A Country Regulatory Authority. BE testing must be done using at least 12 subjects. Bio-waiver is acceptable only to injectable forms if issued by Category A Country.	BE/BS/BW certificate obtained for a quoted product from Category B Country (as mentioned at S No. 1 above).	No BE/BS/BW Certificate.	In case the study is published in Category "W" journal listed in HEC Journal Recognition System (HJRS) Database/ Journals & Publication Policy 2024 and List of National Recognized Journals as per HEC, 3 marks per original research article shall be awarded maximum up to 9 marks).	In case the study is published in Category "X" journal listed in HEC Journal Recognition System (HJRS) Database/ Journals & Publication Policy 2024 and List of National Recognized Journals as per HEC, 2 marks per original research article shall be awarded maximum up to 6 marks).	Studies/original article published in category "Y" journal of the HJRS/ Journals & Publication Policy 2024 and List of National Recognized Journals as per HEC shall not be awarded marks.	The Physical Inspection of the premises of the bidders (Manufacturer/Importer) shall be carried out in accordance with ITB 25.4(h), SCC 5 (GCC 8.3), Section V (1) of the approved BSDS of Govt. MCC FY 2026-27		Satisfactory	Unsatisfactory	1) Substantial quantity of Supplies of anti-cancer medicines made to private sector Teaching Hospitals namely: The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar, CMH Rawalpindi and Hayatabad Medical Complex, Peshawar , Shifa Interntional hospital Islamabad, with Good/Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 24 months. No marks will be given for supply orders except CMH Rawalpindi where supply orders coupled with delivery challans & invoices will be considered for award of marks. 1 mark per agreement up to a maximum of 5 marks	
SOURCE	**MCC formulary No.**	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**40**	**30**	**10**	**5**	**0**	**9**	**6**	**0**	**5**		**1**	**0**	**5**	**70**
QILU PHARMACEUTICAL CO. LTD, CHINA	1437	Abiraterone Acetate	250mg	Tab	Abirone		**30**	**10**						**5**		**1**		**3**	**49**
Jiangsu Hansoh, China	1462	Bortezomib	3.5mg	Inj	Bortesoh		**30**	**10**						**5**		**1**		**3**	**49**
Jiangsu Hansoh, China	1498	Decitabine	50mg	Inj	Decibine		**30**	**10**						**5**		**1**		**3**	**49**
Jiangsu Hansoh, China	1517	Fulvestrant	250mg	Inj	Vestrant		**30**	**10**						**5**		**1**		**3**	**49**
QILU PHARMACEUTICAL CO. LTD, CHINA	1530	Imatinib	100mg	Tab	Imatinib Qilu		**30**	**10**						**5**		**SNP**		**3**	**48**
QILU PHARMACEUTICAL CO. LTD, CHINA	1531	Imatinib	400mg	Tab	Imatinib Qilu		**30**	**10**						**5**		**SNP**		**3**	**48**
Jiangsu Hengrui, China	1588	Oxaliplatin	100mg	Inj	Oxaliplatin		**30**	**10**			6			**5**		**1**		**3**	**55**
Jiangsu Hengrui, China	1590	Oxaliplatin	50mg	Inj	Oxaliplatin		**30**	**10**			6			**5**		**1**		**3**	**55**
Jiangsu Hansoh, China	1604	Pemetrexed	100mg	Inj	Pemsoh		**30**	**10**						**5**		**1**		**3**	**49**
Jiangsu Hansoh, China	1605	Pemetrexed	500mg	Inj	Pemsoh		**30**	**10**						**5**		**1**		**3**	**49**

Scrutiny Report

1 Article at page 389 in respect of oxaliplatin is conducted on rats instead of humans, hence marks not awarded

2 Past performance of HMC attached at page 414 & 415 does not bear dates and reference numbers

3 Past performance of CMH Rawalpindi is not coupled with invoices at page 424-426

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: ABBOTT LABORATORIES KARACHI

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters										
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to ACMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to ACMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient's (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registeration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. Copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or when the CoA of Glass material is not provided, shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the QA/ incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 0-10% market share = 1 mark 11-10% market share = 2 marks 11-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specification / strength / dosage form. Moreover, the approval(s) shall be issued by the procurement agencies and must be supported by purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/past/basing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70
10X10	41	Diclofenac Sodium enteric coa	50 mg	Tab.	ARTIFEN	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41
10X10	43	Ibuprofen	200 mg	Tab.	BRUFEN	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	5	0	0	5	5	25	51
120ML	45	Ibuprofen	200 mg/5 ml	Susp.	BRUFEN	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	5	0	0	5	5	25	51
90ML	46	Ibuprofen	100 mg/5 ml	Susp.	BRUFEN DS	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	5	0	0	5	5	25	51
	121	N-acetylcysteine	200 mg	Sachet	MUCOACTOR SACHET	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	0	0	5	15	41
30	150	Betahistine	8 mg	Tab.	SERC	Toll Manufactured	0	0	5	5	6	2	2	2	2	2	26	0	0	0	0	0	0	Toll Manufactured	5	5	31
30	151	Betahistine	16 mg	Tab.	SERC	Toll Manufactured	0	0	5	5	6	2	2	2	2	2	26	0	0	0	0	0	0	Toll Manufactured	5	5	31
10	234	Clarithromycin	250 mg	Tab.	KLARICID	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	3	18	44
10	235	Clarithromycin	500 mg	Tab.	KLARICID	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	3	18	44
60ML	236	Clarithromycin	250 mg/5 ml	Dry Susp.	KLARICID DS GRANULES	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	3	18	44
60ML	237	Clarithromycin	125 mg/5 ml	Dry Susp.	KLARICID	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	3	18	44
5	275	Moxifloxacin	400 mg	Tab.	MOXSI	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	1	16	42
120ML	497	Aluminium Hydroxide + Magne	mg+80mg+25mg/	Susp.	DJEX MP	0	0	0	5	5	6	2	2	2	2	2	26	0	5	0	0	0	0	5	2	12	38
10	510	Itopride	150 mg	Tab.	GANATON OD	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	3	18	44
120ML	511	Lactulose	3.35gm/5ml	Syp.	DUPHALAC	Toll Manufactured	0	0	5	5	6	2	2	2	2	2	26	0	0	0	0	0	0	Toll Manufactured	5	5	31
120ML	512	Liquid Paraffin + Magnesium H	1.25ml + 3.5ml	Emul.	CREMAFFIN	0	0	0	5	5	6	2	2	2	2	2	26	0	5	0	0	0	0	5	5	15	41
20	539	Dydrogesterone	10 mg	Tab.	DUPHASTON	Toll Manufactured	0	0	5	5	6	2	2	2	2	2	26	0	5	0	0	0	0	Toll Manufactured	5	10	36
120ML	765	Sodium Valproate	250 mg/5ml	Syp.	EPIVAL	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	5	20	46

SCRUTINY REMARKS

1	
2	ISO CERTIFICATES AT 47 PAGE IS NOT FROM PNAC ACCREDITED BODIES
3	Document at page 252 does not meet the biowaiver criteria for the award of marks
4	immediate container mandatory pictures not uploaded for diclofenac , Page 166
5	immediate container mandatory pictures not uploaded for Ibuprofen , Page 245
6	immediate container mandatory pictures not uploaded for Mucolator , Page 560
7	Page 576 & 581, 655, 1275 Serc (page 655), Duphaston, & Duphalac are toll manufactured by Highnoon instead of Abbott
8	Picture of the DRAP approved immediate container packaging are not submitted for each quoted item in the bid. Hence, Marks not awarded in immediate container of all the quoted products
9	COA of Betahistine is not attached in the bid at page 592
10	Bioequivalence study at page 1047 for moxifloxacin is not done from a WHO audited lab as per the advertised criteria hence marks not awarded
11	COA of Dijex (Al-OH, Mg-OH, and Simethicone) are not attached in the bid, page 1133-1153
12	COA of Cremaffin not attached in the bid page 1341
13	cGMP attached at 1402 in respect of duphaston is issued to Abbott Biologicals B.V Netherland however, GD shows Abbott Healthcare Products B.V
14	COA of duphaston at 1397 is issued by Abbott biologicals B.V. instead of Abbott Healthcare Products as mentioned in the GD at page 1394
	Stability study of n-Acetyl cystine not attached in the bid, page 519

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

S. No.	Name of Firm	AGP Limited Karachi				Technical Evaluation Matrix																			
		Product General Information				Factory Technical Evaluation Parameters										Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score					Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm)**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs,	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01).**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this colounm for the respective item.**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**5**	**5**	**5**	**5**	**5**	**40**	**73**
1	35	Acelofenac	100 mg Tablets Tablets	Acemed 100 mg Tablets T-20	Acemed	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	5	0	0	5	1	**21**	**49**
2	51	Meloxicam 15mg	15 mg Tablets	Melfax 15mg Tablets	Melfax	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	**16**	**44**
3	52	Meloxicam 7.5mg	7.5 mg Tablets	Melfax 7.5mg Tablets	Melfax 7.5mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	**16**	**44**
4	65	Orphenadrine citrate 35mg + Paracetamol 450mg	35 mg + 450 mg Tablets	Sinaxamol 450mg/35mg Tablets	Sinaxamol 450mg/35mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	**16**	**44**
5	66	Tramadol HCl 37.5mg + Acetaminophen 325mg	37.5 mg + 325 mg Tablets	Calfina Plus 37.5mg/325mgTablets	Calfina Plus 37.5mg/325mgTablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	**15**	**43**
6	68	Tizanidine 4 mg	4 mg Tablets	Tennelin 4 mg Tablets	Tennelin 4 mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	**16**	**44**
7	141	Itraconazole (as Microspheres 100 mg)	100 mg Capsules	Cap-Itra Capsules	Cap-Itra Capsules	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	**15**	**43**
8	153	Cetirizine 10mg	10 mg Tablets	Rigix 10mg Tablets	Rigix 10mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	5	**20**	**48**
9	154	Cetirizine 5mg/5ml 120 ml	5 mg / 5 ml Solution	Rigix Oral 5mg/5ml 120 ml Solution	Rigix Oral 5mg/5ml 120 ml Solution	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	5	20	**48**
10	160	Montelukast Sodium 10mg	10 mg Tablets	Lucast 10mg Tablets	Lucast 10mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
11	161	Montelukast Sodium 5mg	5 mg Tablets	Lucast 5mg Tablets	Lucast 5mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
12	189	Azithromycin Dihydrate	250 mg Capsules	Azomax 250 mg Capsules	Azomax 250 mg Capsules	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	2	17	**45**
13	190	Azithromycin Dihydrate	500 mg Tablets	Azomax 500 mg Tablets	Azomax 500 mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	2	17	**45**
14	192	Azithromycin Dihydrate	200 mg/5ml Dry Syp Suspension	Azomax 200 mg/5ml Dry Syp 25ml	Azomax 200 mg/5ml Dry Syp 25ml	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	2	17	**45**
15	196	Cefaclor 50mg	50 mg Drops	Ceclor 50mg Drops	Ceclor 50mg Drops	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	5	0	0	5	5	25	**53**
16	198	Cefaclor 125mg	125 mg Suspension	Ceclor 125mg Suspension	Ceclor 125mg Suspension	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	5	0	0	5	5	25	**53**
17	199	Cefaclor 250mg	250 mg Suspension	Ceclor 250mg Suspension	Ceclor 250mg Suspension	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	5	0	0	5	5	25	**53**
18	204	Cefixime 400mg	400 mg Capsules	Cinklare 400mg Capsule	Cinklare 400mg Capsule	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
19	205	Cefixime 100mg/5ml	100 mg / 5ml Suspension	Cinklare 100mg/5ml Suspension	Cinklare 100mg/5ml Suspension	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
20	206	Cefixime 200mg/5ml	200 mg / 5 ml Suspension	Cinklare 200mg/5ml Suspension	Cinklare 200mg/5ml Suspension	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
21	230	Ciprofloxacin Hydrochloride	250 mg Tablets	Axcin 250 mg Tablets	Axcin 250 mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
22	231	Ciprofloxacin Hydrochloride	500 mg Tablets	Axcin 500 mg Tablets	Axcin 500 mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
23	264	Levofloxacin	250 mg Tablets	Levofin 250 mg Tablets	Levofin 250 mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
24	265	Levofloxacin	500 mg Tablets	Levofin 500 mg Tablets	Levofin 500 mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
25	291	Rifaximin 200mg	200 mg Tablets	Zerifax 200mg Tablets	Zerifax 200mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
26	292	Rifaximin 550mg	550 mg Tablets	Zerifax 550mg Tablets	Zerifax 550mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
27	372	Iron Hydroxide Polymaltose Complex	50 mg Syrup	Rubifer 50 mg Syrup 120ml	Rubifer 50 mg Syrup 120ml	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
28	373	Iron Hydroxide Polymaltose Complex	50mg Drops	Rubifer 50 mg Drops	Rubifer 50 mg Drops	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
29	375	Iron Sucrose 100mg/5ml	100 mg/5ml Injection	Rubiject 100mg/5ml injection	Rubiject 100mg/5ml Injection	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
30	376	Mecobalamin 500mcg	500 mcg Injection	Mecovate 500mcg/IM Injection	Mecovate 500mcg/IM Injection	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
31	377	Mecobalamin 500mcg	500 mcg Tablets	Mecovate 500mcg Tablets 20's	Mecovate 500mcg Tablets 20's	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
32	388	Tranexamic acid 500mg	500 mg Capsules	Maxna 500mg Capsules	Maxna 500mg Capsules	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
33	390	Tranexamic acid 500mg	500 mg Injection	Maxna 500mg Injection	Maxna 500mg Injection	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
34	401	Amlodipine	5mg Tablets	Norvasc 5mg Tablets	Norvasc 5mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
35	402	Amlodipine	10mg Tablets	Norvasc 10mg Tablets	Norvasc 10mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
36	507	Famotidine	40 mg Tablets	Nocid 40 mg Tablets	Nocid 40 mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
37	518	Esomeprazole 40mg	40 mg Capsules	Axid Neo 40mg Capsule	Axid Neo 40mg Capsule	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
38	519	Ondansetron Hydrochloride	8 mg Tablets	Zofran 8 mg Tablets	Zofran 8 mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	0	0	5	0	0	5	0	10	**38**
39	520	Ondansetron Hydrochloride	8 mg Ampoule	Zofran 8 mg injection	Zofran 8 mg injection	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	0	0	5	0	0	5	0	10	**38**
40	523	Trimethyl Phloroglucinol 80mg+Phloroglucinol 80mg	80 mg + 80 mg Tablets	Anafortan Plus 80mg/80mg Tablets	Anafortan Plus 80mg/80mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	2	17	**45**
41	524	Trimethyl Phloroglucinol 0.04mg+Phloroglucinol 40mg	0.04 mg + 40 mg Injection	Anafortan Plus 0.04mg/40mg Injection	Anafortan Plus 0.04mg/40mg Injection	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	2	17	**45**
42	525	Prucalopride Succinate	2 mg Tablets	Rucalo 2mg Tablets 10's	Rucalo 2mg Tablets 10's	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	5	0	0	5	1	21	**49**
43	540	Empagliflozin 10 mg	10 mg Tablets	Truglif Tablets 10 mg	Truglif Tablets 10 mg	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
44	541	Empagliflozin 25 mg	25 mg Tablets	Truglif Tablets 25 mg	Truglif Tablets 25 mg	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
45	549	Glimepiride 1mg	1 mg Tablets	Gluconorm 1mg Tablets	Gluconorm 1mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**

46	550	Glimepiride 2mg	2 mg Tablets	Gluconorm 2mg Tablets	Gluconorm 2mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
47	551	Glimepiride 3mg	3 mg Tablets	Gluconorm 3mg Tablets	Gluconorm 3mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
48	552	Glimepiride 4mg	4 mg Tablets	Gluconorm 4mg Tablets	Gluconorm 4mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
49	581	Sitagliptin 50mg+Metformin 500mg	50 mg + 500 mg Tablets	GlyziaMet 50/500 Tablets	GlyziaMet 50/500 Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
50	582	Sitagliptin 50mg+Metformin 1000mg	50 mg + 1000 mg Tablets	GlyziaMet 50/1000 Tablets	GlyziaMet 50/1000 Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
51	696	Solifenacin Succinate 10mg	10 mg Tablets	Urgesin 10mg Tablets	Urgesin 10mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
52	709	Clomipramine	25 mg Tablets	Clomfranil 25 mg Tablets	Clomfranil 25 mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	5	20	**48**
53	713	Clozapine 25 mg	25 mg Tablets	Clozaril 25 mg Tablet	Clozaril 25 mg Tablet	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	0	0	0	0	0	0	3	3	**31**
54	714	Clozapine 100 mg	100 mg Tablets	Clozaril 100 mg Tablet	Clozaril 100 mg Tablet	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	0	0	0	0	0	0	3	3	**31**
55	725	Escitalopram 10mg	10 mg Tablets	Esi-Dep 10 mg Tablets	Esi-Dep 10 mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
56	754	Pregablin	75mg Capsules	Lyrica 75mg Capsules	Lyrica 75mg Capsules	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	5	0	0	5	0	20	**48**
57	755	Pregablin	150 mg Capsules	Lyrica 150 mg Capsules	Lyrica 150 mg Capsules	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	5	0	0	5	0	20	**48**
58	761	Risperidone 2 mg Tablets	2 mg Tablets	Xiton Tablet 2 mg	Xiton Tablet 2 mg	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
59	762	Risperidone 4 mg Tablets	4 mg Tablets	Xiton Tablet 4 mg	Xiton Tablet 4 mg	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
60	771	Venlafaxine	75 mg Capsules	Efexor XR 75 mg Capsules	Efexor XR 75 mg Capsules	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
61	808	Ketotifen	1mg Tablets	Zatofen 1mg Tablets	Zatofen 1mg Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	5	20	**48**
62	809	Ketotifen	0.2 mg/ml Syrup Syrup	Zatofen 0.2 mg/ml Syrup 60 ml	Zatofen 0.2 mg/ml Syrup 60 ml	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	5	20	**48**
63	912	Ossein Hydroxyapetite Compound 830mg + Vitamin-D 400IU	830 mg + 400 IU Tablets	Osnate D 830mg/400 IU Tablets	Osnate D 830mg/400 IU Tablets	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	5	0	0	5	5	25	**53**
64	913	Ossein Hydroxyapetite Compound 400mg + Vitamin-D 400IU	400 mg + 400IU Suspension	Osnate D 400mg/400IU 120ml Suspension	Osnate D 400mg/400IU 120ml Suspension	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	5	0	0	5	5	25	**53**
65	1549	Leuprorelin Acetate	3.75 mg Vial	Lectrum 3.75 mg Injection	Lectrum 3.75 mg Injection	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	5	0	0	0	5	20	**48**
66	1550	Leuprorelin Acetate	7.5 mg Vial	Lectrum 7.5 mg Injection	Lectrum 7.5 mg Injection	**2**	**2**	**3**	5	0	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	5	0	0	0	5	20	**48**

Scrutiny Report

Calibration certificate attached at page No. 100-236 do not cover overall equipments for Assays, Analysis, measuring and weighing necessary during in process, raw materials or Finish goods.

Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies) has not been provided in the bid

GD of ondansetron attached at page No. 338-355 is not coupled with AWB or BL, hence marks may not be awarded

GDs/COA does not show any correlation with the DRAP liscense of the product (Clozaril) nor with the FORM-3 and FORM-7

Valid WHO prequalification or Valid product registration in SRA/WLA countries, or valid Free sale by any SRA/WLA country is not provided in the bid

No proof of purchase/Invoice has been attached for immediate container of the quoted products in the original bid (Page No. (852-920)

IMS/IQVIA ranking of the products availability in pakistani market for Lyrica, Norvasc and Venlafaxine is not attached in the original bid page No. 921-926

Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 and Form-7 is not provided in the bid

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27														
Name of the firm						Akram Brothers NDI Lahore														
						Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm) **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevent certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
Foosin Medical Supplies, China	1332	7mm, 1/2 circle, micro-point spatula needle, strand length 45cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 7/0 7mm, 1/2 circle, micro-point spatula needle, strand length 45cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical Supplies. Inc. Ltd. China	3	5	Not attached	5	6	6	**25**	5	0	0	0	2	16	**23**	**48**
Foosin Medical Supplies, China	1371	6.5mm, 3/8 circle round bodied taper point double armed needle, strand length 40cm	WEGO Prolene Polypropylene Size 8/0 6.5mm, 3/8 circle round bodied taper point double armed needle, strand length 40cm		WEGO Prolene Polypropylene Foosin Medical Supplies. Inc. Ltd. China	3	5	Not attached	5	6	6	**25**	5	0	0	0	2	16	**23**	**48**
Foosin Medical Supplies, China	1372	9.3mm, 3/8 circle round bodied taper point double armed needle, strand length 60cm	WEGO Prolene Polypropylene Size 7/0 9.3mm, 3/8 circle round bodied taper point double armed needle, strand length 60cm		WEGO Prolene Polypropylene Foosin Medical Supplies. Inc. Ltd. China	3	5	Not attached	5	6	6	**25**	5	0	0	0	2	16	**23**	**48**
Foosin Medical Supplies, China	1393	6.5mm, 3/8 circle micro-point spatula double needle, strand length 30cm	WEGO Nylon Size 10/0 6.5mm, 3/8 circle micro-point spatula double needle, strand length 30cm		WEGO Nylon Foosin Medical Supplies. Inc. Ltd. China	3	5	Not attached	5	6	6	**25**	5	0	0	0	2	16	**23**	**48**
Foosin Medical Supplies, China	1394	48mm, 1/2 circle round bodied taper point, strand length 150cm	WEGO Nylon Size 1 48mm, 1/2 circle round bodied taper point, strand length 150cm		WEGO Nylon Foosin Medical Supplies. Inc. Ltd. China	3	5	Not attached	5	6	6	**25**	5	0	0	0	2	16	**23**	**48**
Foosin Medical Supplies, China	1399	13mm, 3/8 circle round bodied taper point double armed needle, strand length 45cm	WEGO PDO Polydioxanone Size 7/0 13mm, 3/8 circle round bodied taper point double armed needle, strand length 45cm		WEGO PDO Polydioxanone Foosin Medical Supplies. Inc. Ltd. China	3	5	Not attached	5	6	6	**25**	5	0	0	0	2	16	**23**	**48**

						Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27														
					Name of the firm	Akram Brothers Lahore														
S. No.		Product General Parameter				Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the time of inspection at the warehouse at the tim eof inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** **(Certificate duly attaested by senior executive of the firm)**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US free sale certificate of the quoted products, **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **Online verification link shall be provided.** **(copies of relevant certificates duly attested by the senior executive of the firm)**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	5	6	29	5	5	5	6	10	10	41	70
Kollsut Interna	1311	20mm, 1/2 circle round bodied taper point needle, strand length 70cm	KOLGUT CHROME CATGUT CHROMIC Size 4/0 20mm, 1/2 circle round bodied taper point needle, strand length 70cm		KOLGUT CHROME CATGUT CHROMIC, Kollsut International.Inc USA			5					**5**	5	0	4	composition of fluid not mentioned on label	10	**19**	**24**
Kollsut Interna	1312	20mm, 1/2 circle round bodied taper point needle, strand length 70cm	KOLGUT CHROME CATGUT CHROMIC Size 3/0 20mm, 1/2 circle round bodied taper point needle, strand length 70cm		KOLGUT CHROME CATGUT CHROMIC, Kollsut International.Inc USA			5					**5**	5	0	4		10	**19**	**24**
Kollsut Interna	1313	30mm, 1/2 circle round bodied taper point needle, strand length 70cm	KOLGUT CHROME CATGUT CHROMIC Size 2/0 30mm, 1/2 circle round bodied taper point needle, strand length 70cm		KOLGUT CHROME CATGUT CHROMIC, Kollsut International.Inc USA			5					**5**	5	0	4		10	**19**	**24**
Kollsut Interna	1314	26mm, 1/2 circle round bodied taper point needle, strand length 70cm	KOLGUT CHROME CATGUT CHROMIC Size 2/0 26mm, 1/2 circle round bodied taper point needle, strand length 70cm		KOLGUT CHROME CATGUT CHROMIC, Kollsut International.Inc USA			5					**5**	5	0	4		10	**19**	**24**
Kollsut Interna	1315	40mm, 1/2 circle round bodied taper point needle, strand length 70cm	KOLGUT CHROME CATGUT CHROMIC Size 0 40mm, 1/2 circle round bodied taper point needle, strand length 70cm		KOLGUT CHROME CATGUT CHROMIC, Kollsut International.Inc USA			5					**5**	5	0	4		10	**19**	**24**
Kollsut Interna	1316	30mm, 1/2 circle round bodied taper point needle, strand length 70cm	KOLGUT CHROME CATGUT CHROMIC Size 0 30mm, 1/2 circle round bodied taper point needle, strand length 70cm		KOLGUT CHROME CATGUT CHROMIC, Kollsut International.Inc USA			5					**5**	5	0	4		10	**19**	**24**
Kollsut Interna	1317	40mm, 1/2 circle round bodied taper point needle, strand length 70cm	KOLGUT CHROME CATGUT CHROMIC Size 1 40mm, 1/2 circle round bodied taper point needle, strand length 70cm		KOLGUT CHROME CATGUT CHROMIC, Kollsut International.Inc USA			5					**5**	5	0	4		10	**19**	**24**
Kollsut Interna	1318	30mm, 3/8 circle round bodied taper point needle, strand length 70cm	KOLGUT CHROME CATGUT CHROMIC Size 1 30mm, 3/8 circle round bodied taper point needle, strand length 70cm		KOLGUT CHROME CATGUT CHROMIC, Kollsut International.Inc USA			5					**5**	5	0	4		10	**19**	**24**
Kollsut Interna	1319	40mm, 1/2 circle round bodied taper point needle, strand length 70cm	KOLGUT CHROME CATGUT CHROMIC Size 2 40mm, 1/2 circle round bodied taper point needle, strand length 70cm		KOLGUT CHROME CATGUT CHROMIC, Kollsut International.Inc USA			5					**5**	5	0	4		10	**19**	**24**
Foosin Medical Supplies,	1320	17mm, 1/2 circle round bodied taper point needle, strand length 75cm	WEGO Black Braided Silk Size 4/0 17mm, 1/2 circle round bodied taper point needle, strand length 75cm		WEGO Black Braided Silk Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1321	30mm, 1/2 circle round bodied taper point needle, Strand length 75cm	WEGO Black Braided Silk Size 3/0 30mm, 1/2 circle round bodied taper point needle, Strand length 75cm		WEGO Black Braided Silk Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1322	26mm, 1/2 circle round bodied taper point needle, Strand length 75cm	WEGO Black Braided Silk Size 3/0 26mm, 1/2 circle round bodied taper point needle, Strand length 75cm		WEGO Black Braided Silk Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1323	26mm, 3/8 circle conventional or curved cutting needle, Strand length 45 cm	WEGO Black Braided Silk Size 3/0 26mm, 3/8 circle conventional or curved cutting needle, Strand length 45cm		WEGO Black Braided Silk Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1324	17mm, 1/2 circle round bodied taper point needle, Strand length 75cm	WEGO Black Braided Silk Size 3/0 17mm, 1/2 circle round bodied taper point needle, Strand length 75cm		WEGO Black Braided Silk Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1325	31mm, 1/2 circle round bodied, taper point needle, Strand length 75cm	WEGO Black Braided Silk Size 2/0 31mm, 1/2 circle round bodied, taper point needle, Strand length 75cm		WEGO Black Braided Silk Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1326	26mm, 1/2 circle round bodied taper point needle, Strand length 75cm	WEGO Black Braided Silk Size 2/0 26mm, 1/2 circle round bodied taper point needle, Strand length 75cm		WEGO Black Braided Silk Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1327	31mm, 1/2 circle round bodied taper point needle, Strand length 75cm	WEGO Black Braided Silk Size 0 31mm, 1/2 circle round bodied taper point needle, Strand length 75cm		WEGO Black Braided Silk Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1328	40mm, 1/2 circle round bodied taper point needle, Strand length 75cm	WEGO Black Braided Silk Size 1 40mm, 1/2 circle round bodied taper point needle, Strand length 75cm		WEGO Black Braided Silk Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1329	30mm, 1/2 circle round bodied taper point needle, Strand length 75cm	WEGO Black Braided Silk Size 1 30mm, 1/2 circle round bodied taper point needle, Strand length 75cm		WEGO Black Braided Silk Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**0**	5	0	2	10	10	**27**	**27**
Foosin Medical Supplies,	1330	40mm, 3/8 circle conventional or curved cutting needle, Strand length 75cm	WEGO Black Braided Silk Size 1 40mm, 3/8 circle conventional or curved cutting needle, Strand length 75cm		WEGO Black Braided Silk Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1331	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	WEGO Black Braided Silk Size 1 40mm, 1/2 circle round bodied taper point needle, strand length 75cm		WEGO Black Braided Silk Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**0**	5	0	2	10	10	**27**	**27**
Foosin Medical Supplies,	1332	7mm, 1/2 circle, micro-point spatula needle, strand length 45cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 7/0 7mm, 1/2 circle, micro-point spatula needle, strand length 45cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**0**	5	0	2	10	10	**27**	**27**
Foosin Medical Supplies,	1333	8mm, 1/4 circle spatulated needle, strand length 45cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 6/0 8mm, 1/4 circle spatulated needle, strand length 45cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**0**	5	0	2	10	10	**27**	**27**
Foosin Medical Supplies,	1334	11mm, 3/8 circle reverse cutting needle, strand length 45 cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 6/0 11mm, 3/8 circle reverse cutting needle, strand length 45 cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**5**	5	0	2	10	10	**27**	**32**

Foosin Medical Supplies,	1335	13mm, 1/2 circle round bodied taper point needle, strand length 45 cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 6/0 13mm, 1/2 circle round bodied taper point needle, strand length 45 cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**0**	5	0	2	10	10	**27**	**27**
Foosin Medical Supplies,	1336	11mm, 3/8 circle reverse cutting needle, Strand length 45 cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 5/0 11mm, 3/8 circle reverse cutting needle, Strand length 45 cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1337	13mm, 3/8 circle conventional or curved cutting needle, Strand length 45 cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 5/0 13mm, 3/8 circle conventional or curved cutting needle, Strand length 45cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1338	13mm, 1/2 circle round bodied taper point needle, strand length 45 cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 5/0 13mm, 1/2 circle round bodied taper point needle, strand length 45cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1339	16mm, 3/8 circle conventional or curved cutting needle, strand length 75cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 4/0 16mm, 3/8 circle conventional or curved cutting needle, strand length 75cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1340	19mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 4/0 19mm, 3/8 circle conventional or curved cutting needle, strand length 45cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1341	19mm, 3/8 circle reverse cutting needle, strand length 75cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 4/0 19mm, 3/8 circle reverse cutting needle, strand length 75cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1342	22mm, 1/2 circle round bodied taper point, strand length 70 cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 4/0 22mm, 1/2 circle round bodied taper point, strand length 70 cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1343	16mm, 3/8 circle conventional or curved cutting needle, Strand length 75cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 3/0 16mm, 3/8 circle conventional or curved cutting needle, Strand length 75cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1344	19mm, 3/8 circle reverse cutting needle, Strand length 75cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 3/0 19mm, 3/8 circle reverse cutting needle, Strand length 75cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1345	22mm, 1/2 circle round bodied taper point, strand length 70 cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 3/0 22mm, 1/2 circle round bodied taper point, strand length 70 cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1346	26mm, 1/2 circle round bodied taper point, Strand length 70 cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 3/0 26mm, 1/2 circle round bodied taper point, Strand length 70 cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1347	26mm, 1/2 circle round bodied taper point, strand length 70 cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 2/0 26mm, 1/2 circle round bodied taper point, strand length 70 cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1348	31mm, 1/2 circle round bodied taper point, Strand length 70 cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 2/0 31mm, 1/2 circle round bodied taper point, Strand length 70 cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1349	36mm, 1/2 circle round body taper cut needle, strand length 90 cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 2/0 36mm, 1/2 circle round body taper cut needle, strand length 90 cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1350	45mm, 1/2 circle round bodied taper cut needle, strand length 75 cm	WEGO PGA POLY LACTIC CO GLYCOLIC ACID 910 Size 2/0 45mm, 1/2 circle round bodied taper cut needle, strand length 75 cm		WEGO PGA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1351	36mm, 1/2 circle round bodied taper cut needle, strand length 90 cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 0 36mm, 1/2 circle round bodied taper cut needle, strand length 90 cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1352	40mm, 1/2 circle round bodied taper point, strand length 90 cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 0 40mm, 1/2 circle round bodied taper point, strand length 90 cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1353	40mm, 1/2 circle round bodied taper point, strand length 70 cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 1 40mm, 1/2 circle round bodied taper point, strand length 70 cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1354	45mm, 1/2 circle round bodied taper cut needle, strand length 75cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 1 45mm, 1/2 circle round bodied taper cut needle, strand length 75cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**5**	5	0	2	DTL substandard	10	**17**	**22**
Foosin Medical Supplies,	1355	40mm, 1/2 circle round bodied taper point, strand length 90 cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 2 40mm, 1/2 circle round bodied taper point, strand length 90 cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1356	45mm, 1/2 circle round bodied taper cut needle, strand length 75cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 2 45mm, 1/2 circle round bodied taper cut needle, strand length 75cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1357	17mm, 1/2 circle round bodied taper point needle, Strand length 70cm	WEGO PGA Polyglycolic Acid Size 5/0 17mm, 1/2 circle round bodied taper point needle, Strand length 70cm		WEGO PGA Polyglycolic Acid Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1358	17mm, 1/2 circle round bodied needle, Strand length 75cm	WEGO PGA Polyglycolic Acid Size 4/0 17mm, 1/2 circle round bodied needle, Strand length 75cm		WEGO PGA Polyglycolic Acid Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1359	22mm, 1/2 circle round bodied tapper point needle, Strand length 75cm	WEGO PGA Polyglycolic Acid Size 4/0 22mm, 1/2 circle round bodied tapper point needle. Strand length 75cm		WEGO PGA Polyglycolic Acid Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1360	22mm, 1/2 circle round bodied taper point, strand length 75 cm	WEGO PGA Polyglycolic Acid Size 3/0 22mm, 1/2 circle round bodied taper point, strand length 75 cm		WEGO PGA Polyglycolic Acid Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1361	25mm, 1/2 circle round bodied taper point, strand length 75 cm	WEGO PGA Polyglycolic Acid Size 2/0 25mm, 1/2 circle round bodied taper point, strand length 75 cm		WEGO PGA Polyglycolic Acid Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1362	30mm, 1/2 circle round bodied taper point, strand length 75 cm	WEGO PGA Polyglycolic Acid Size 2/0 30mm, 1/2 circle round bodied taper point, strand length 75 cm		WEGO PGA Polyglycolic Acid Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1363	40mm, 1/2 circle round bodied tapper point needle, strand length 75 cm	WEGO PGAPolyglycolic Acid Size 0 40mm, 1/2 circle round bodied tapper point needle, strand length 75 cm		WEGO PGA Polyglycolic Acid Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1364	30mm, 1/2 circle round bodied tapper point needle, strand length 75 cm	WEGO PGA Polyglycolic Acid Size 1 30mm, 1/2 circle round bodied tapper point needle, strand length 75 cm		WEGO PGA Polyglycolic Acid Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1365	40mm, 1/2 circle round bodied tapper point needle, strand length 75 cm	WEGO PGA Polyglycolic Acid Size 1 40mm, 1/2 circle round bodied tapper point needle, strand length 75 cm		WEGO PGA Polyglycolic Acid Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1366	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm	WEGO PGA Polyglycolic Acid Size 2 40mm, 1/2 circle round bodied taper point needle, strand length 75 cm		WEGO PGA Polyglycolic Acid Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1367	48mm, 1/2 circle round bodied taper point needle, strand length 75 cm	WEGO PGA Polyglycolic Acid Size 2 48mm, 1/2 circle round bodied taper point needle, strand length 75 cm		WEGO PGA Polyglycolic Acid Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1371	8.5mm, 3/8 circle round bodied taper point double armed needle, strand length 40cm	WEGO Prolene Polypropylene Size 8/0 6.5mm, 3/8 circle round bodied taper point double armed needle, strand length 40cm		WEGO Prolene Polypropylene Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1372	9.3mm, 3/8 circle round bodied taper point double armed needle, strand length 60cm	WEGO Prolene Polypropylene Size 7/0 9.3mm, 3/8 circle round bodied taper point double armed needle, strand length 60cm		WEGO Prolene Polypropylene Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1373	12mm, 3/8 circle reverse cutting needle, strand length 60cm	WEGO Prolene Polypropylene Size 6/0 12mm, 3/8 circle reverse cutting needle, strand length 60cm		WEGO Prolene Polypropylene Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1374	13mm, 1/2 circle round bodied taper point double armed needle, strand length 60cm	WEGO Prolene Polypropylene Size 6/0 13mm, 1/2 circle round bodied taper point double armed needle, strand length 60cm		WEGO Prolene Polypropylene Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**

Foosin Medical Supplies,	1375	13mm, 3/8 circle round bodied taper point double armed needle, strand length 60cm		WEGO Prolene Polypropylene Size 6/0 13mm, 3/8 circle round bodied taper point double armed needle, strand length 60cm	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1376	16mm, 3/8 circle curved cutting needle, strand length 90cm		WEGO Prolene Polypropylene Size 6/0 16mm, 3/8 circle curved cutting needle, strand length 90cm	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1377	13mm, 1/2 circle round bodied taper point double armed needle, strand length 60cm		WEGO Prolene Polypropylene Size 5/0 13mm, 1/2 circle round bodied taper point double armed needle, strand length 60cm	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1378	16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm		WEGO Prolene Polypropylene Size 5/0 16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1379	16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm		WEGO Prolene Polypropylene Size 4/0 16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1380	26mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm		WEGO Prolene Polypropylene Size 4/0 26mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1381	19mm, 3/8 circle conventional or curved cutting needle, strand length 45cm		WEGO Prolene Polypropylene Size 3/0 19mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1382	26mm, 1/2 circle round bodied taper point double armed needle, strand length 75cm		WEGO Prolene Polypropylene Size 3/0 26mm, 1/2 circle round bodied taper point double armed needle, strand length 75cm	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1383	30 mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm		WEGO Prolene Polypropylene Size 3/0 30 mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1384	26mm, 1/2 circle round bodied taper point needle, strand length 75cm		WEGO Prolene Polypropylene Size 2/0 26mm, 1/2 circle round bodied taper point needle, strand length 75cm	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1385	26mm, 3/8 circle reverse cutting needle, strand length 45cm		WEGO Prolene Polypropylene Size 2/0 26mm, 3/8 circle reverse cutting needle, strand length 45cm	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1386	26mm, 3/8 circle conventional or curved cutting needle, strand length 45cm		WEGO Prolene Polypropylene Size 2/0 26mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1387	26mm, 1/2 circle round bodied taper cut double armed needle, strand length 75cm		WEGO Prolene Polypropylene Size 2/0 26mm, 1/2 circle round bodied taper cut double armed needle, strand length 75cm	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1388	30mm, 1/2 circle round bodied taper point needle, strand length 75cm		WEGO Prolene Polypropylene Size 2/0 30mm, 1/2 circle round bodied taper point needle, strand length 75cm	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1389	55mm, straight cutting needle, strand length 75cm		WEGO Prolene Polypropylene Size 2/0 55mm, straight cutting needle, strand length 75cm	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1390	60mm, straight cutting needle, strand length 75cm		WEGO Prolene Polypropylene Size 2/0 60mm, straight cutting needle, strand length 75cm	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1391	40mm, 1/2 circle round bodied taper point needle, strand length 75cm		WEGO Prolene Polypropylene Size 0 40mm, 1/2 circle round bodied taper point needle, strand length 75cm	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1392	40mm, 1/2 circle round bodied taper point needle, strand length 75cm		WEGO Prolene Polypropylene Size 1 40mm, 1/2 circle round bodied taper point needle, strand length 75cm	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1393	6.5mm, 3/8 circle micro-point spatula double needle, strand length 30cm		WEGO Nylon Size 10/0 6.5mm, 3/8 circle micro-point spatula double needle, strand length 30cm	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1394	48mm, 1/2 circle round bodied taper point, strand length 150cm		WEGO Nylon Size 1 48mm, 1/2 circle round bodied taper point, strand length 150cm	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1395	26mm, 1/2 circle round bodied taper point double needle, strand length		WEGO Polyester Size 3/0 26mm, 1/2 circle round bodied taper point double needle, strand length 100cm	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1396	17mm, 1/2 circle round bodied taper cut double needle, strand length 75cm		WEGO Polyester Size 2/0 17mm, 1/2 circle round bodied taper cut double needle, strand length 75cm	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1397	26mm, 1/2 circle round bodied taper cut double needle, strand length 75cm		WEGO Polyester Size 2/0 26mm, 1/2 circle round bodied taper cut double needle, strand length 75cm	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1398	26mm, 1/2 circle round bodied taper point double needle, strand length		WEGO Polyester Size 2/0 26mm, 1/2 circle round bodied taper point double needle, strand length 90cm	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1399	13mm, 3/8 circle round bodied taper point double armed needle, strand		WEGO PDO Polydiaxanone Size 7/0 13mm, 3/8 circle round bodied taper point double armed needle, strand length 45cm	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1400	13mm, 1/2 circle round bodied taper point needle, strand length 45cm		WEGO PDO Polydiaxanone Size 6/0 13mm, 1/2 circle round bodied taper point needle, strand length 45cm	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1401	13mm, 3/8 circle round bodied taper point double armed needle, strand		WEGO PDO Polydiaxanone Size 6/0 13mm, 3/8 circle round bodied taper point double armed needle, strand length 45cm	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1403	13mm, 1/2 circle round bodied taper point double armed needle, strand		WEGO PDO Polydiaxanone Size 5/0 13mm, 1/2 circle round bodied taper point double armed needle, strand length 75cm	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1404	13mm, 1/2 circle round bodied taper point needle, strand length 75cm		WEGO PDO Polydiaxanone Size 5/0 13mm, 1/2 circle round bodied taper point needle, strand length 75cm	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1405	17mm, 1/2 circle round bodied taper point double needle, strand length		WEGO PDO Polydiaxanone Size 5/0 17mm, 1/2 circle round bodied taper point double needle, strand length 75cm	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1408	17mm, 1/2 circle round bodied taper point needle, strand length 75cm		WEGO PDO Polydiaxanone Size 4/0 17mm, 1/2 circle round bodied taper point needle, strand length 75cm	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1409	17mm, 1/2 circle round bodied taper point double armed, strand length		WEGO PDO Polydiaxanone Size 4/0 17mm, 1/2 circle round bodied taper point double armed, strand length 75cm	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1410	20mm, 1/2 circle round bodied taper point needle, strand length 70cm		WEGO PDO Polydiaxanone Size 4/0 20mm, 1/2 circle round bodied taper point needle, strand length 70cm	3	5	0					**0**	0	0	2	DTL substandard	10	**12**	**12**
Foosin Medical Supplies,	1411	26mm, 1/2 circle round bodied taper point needle, strand length 75cm		WEGO PDO Polydiaxanone Size 4/0 26mm, 1/2 circle round bodied taper point needle, strand length 75cm	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1412	20mm, 1/2 circle round bodied taper point needle, strand length 70cm		WEGO PDO Polydiaxanone Size 3/0 20mm, 1/2 circle round bodied taper point needle, strand length 70cm	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1413	26mm, 1/2 circle round bodied taper point needle, strand length 75cm		WEGO PDO Polydiaxanone Size 3/0 26mm, 1/2 circle round bodied taper point needle, strand length 75cm	3	5	0					**0**	0	0	2	DTL substandard	10	**12**	**12**
Foosin Medical Supplies,	1414	30mm, 1/2 circle round bodied taper point needle, strand length 75cm		WEGO PDO Polydiaxanone Size 3/0 30mm, 1/2 circle round bodied taper point needle, strand length 75cm	3	5	0					**5**	5	0	2	10	10	**27**	**32**

Foosin Medical Supplies,	1415	26mm, 1/2 circle round bodied taper point needle, strand length 70cm	WEGO PDO Polydiaxanone Size 2/0 26mm, 1/2 circle round bodied taper point needle, strand length 70cm		WEGO PDO Polydiaxanone Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1416	30mm, 1/2 circle round bodied taper point needle, strand length 75cm	WEGO PDO Polydiaxanone Size 2/0 30mm, 1/2 circle round bodied taper point needle, strand length 75cm		WEGO PDO Polydiaxanone Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1417	36mm, 1/2 circle round bodied taper point needle, strand length 75cm	WEGO PDO Polydiaxanone Size 2/0 36mm, 1/2 circle round bodied taper point needle, strand length 75cm		WEGO PDO Polydiaxanone Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1418	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	WEGO PDO Polydiaxanone Size 2/0 40mm, 1/2 circle round bodied taper point needle, strand length 75cm		WEGO PDO Polydiaxanone Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1419	40mm, 1/2 circle round bodied taper point needle, strand length 150cm,	WEGO PDO Polydiaxanone Size 0 40mm, 1/2 circle round bodied taperpoint needle, strand length 150cm.		WEGO PDO Polydiaxanone Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1420	40mm, 1/2 circle round bodied taper point needle, Strand length 70cm	WEGO PDO Polydiaxanone Size 0 40mm, 1/2 circle round bodied taper point needle, Strand length 70cm		WEGO PDO Polydiaxanone Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1421	36mm, 1/2 circle round bodied taper point needle, strand length 75cm	WEGO PDO Polydiaxanone Size 1 36mm, 1/2 circle round bodied taper point needle, strand length 75cm		WEGO PDO Polydiaxanone Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1422	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	WEGO PDO Polydiaxanone Size 1 40mm, 1/2 circle round bodied taper point needle, strand length 75cm		WEGO PDO Polydiaxanone Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1423	6 mm, 3/8 circle micro point spatula double needle, strand length 30cm	WEGO Nylon Size 10/0 6 mm, 3/8 circle micro point spatula double needle, strand length 30cm		WEGO Nylon Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1424	6.2mm, 3/8 circle micro point spatula double needle, strand length 30cm	WEGO Nylon Size 10/0 6.2mm, 3/8 circle micro point spatula double needle, strand length 30cm		WEGO Nylon Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1425	48mm, 1/2 circle round bodied taper cut point needle, strand length 45cm	WEGO Stainless Steel Size no 548mm, 1/2 circle round bodied taper cut point needle, strand length 45cm		WEGO Stainless Steel Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1426	48mm, 1/2 circle round bodied taper cut point needle, strand length 45cm	WEGO Stainless Steel Size no 4 48mm, 1/2 circle round bodied taper cut point needle, strand length 45cm		WEGO Stainless Steel Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**0**	0	0	2	10	10	**22**	**22**
Foosin Medical Supplies,	1427	Polypropylene	WEGO Prolene Polypropylene Mesh Size 30cm x 30cm		WEGO Prolene Polypropylene Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1428	Polypropylene	WEGO Prolene Polypropylene Mesh Size 15cm x 15cm		WEGO Prolene Polypropylene Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1429	Polypropylene	WEGO Prolene Polypropylene Mesh Size 15cm x 6cm		WEGO Prolene Polypropylene Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
Foosin Medical Supplies,	1430	Polypropylene	WEGO Prolene Polypropylene Mesh Size 6cm x 11cm		WEGO Prolene Polypropylene Foosin Medical Supplies, Inc. Ltd. China	3	5	0					**5**	5	0	2	10	10	**27**	**32**
			Observations																	

Page 210, 217: Kollsut USA 14001 and 13485 verification link are not provided.

COA of formulary No: 1329, 1331, 1332, 1333, 1335, 1350, 1351, 1357, 1361, 1363, 1371, 1372, 1376, 1378, 1390, 1392, 1393, 1394, 1395, 1399, 1400, 1401-03-04-05-08-09-10-11-13- 22-24-25 are not attached in the bid.

Tender approvals attached are not according to the advertised criteria.

						Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27														
Name of the firm						Akram Brothers Lahore														
S. No.		Product General Parameter				Technical Evaluation Matrix													Product Evaluated Score	Total Technical Score
						Principal's and Importer's Evaluation Parameters														
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score	Product Technical Evaluation						
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the time of inspection at the warehouse at the tim eof inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evalauted by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** **(Certificate duly attaested by senior executive of the firm)**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note, Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US free sale certificate of the quoted products, **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **Online verification link shall be provided.** **(copies of relevant certificates duly attested by the senior executive of the firm)**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	5	6	**29**	5	5	5	6	10	10	**41**	**70**
Foosin Medical Supplies, China	1332	7mm, 1/2 circle, micro-point spatula needle, strand length 45cm	WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Size 7/0 7mm, 1/2 circle, micro-point spatula needle, strand length 45cm		WEGO PGLA POLY LACTIC CO GLYCOLIC ACID 910 Foosin Medical Supplies. Inc. Ltd. China	3	5	0	5	5	6		5	0	0	2	10			
Foosin Medical Supplies, China	1371	6.5mm, 3/8 circle round bodied taper point double armed needle, strand length 40cm	WEGO Prolene Polypropylene Size 8/0 6.5mm, 3/8 circle round bodied taper point double armed needle, strand length 40cm		WEGO Prolene Polypropylene Foosin Medical Supplies. Inc. Ltd. China	3	5	0	5	5	6		5	0	0	2	10			
Foosin Medical Supplies, China	1372	9.3mm, 3/8 circle round bodied taper point double armed needle, strand length 60cm	WEGO Prolene Polypropylene Size 7/0 9.3mm, 3/8 circle round bodied taper point double armed needle, strand length 60cm		WEGO Prolene Polypropylene Foosin Medical Supplies. Inc. Ltd. China	3	5	0	5	5	6		5	0	0	2	10			
Foosin Medical Supplies, China	1393	6.5mm, 3/8 circle micro-point spatula double needle, strand length 30cm	WEGO Nylon Size 10/0 6.5mm, 3/8 circle micro-point spatula double needle, strand length 30cm		WEGO Nylon Foosin Medical Supplies. Inc. Ltd. China	3	5	0	5	5	6		5	0	0	2	10			
Foosin Medical Supplies, China	1394	48mm, 1/2 circle round bodied taper point, strand length 150cm	WEGO Nylon Size 1 48mm, 1/2 circle round bodied taper point, strand length 150cm		WEGO Nylon Foosin Medical Supplies. Inc. Ltd. China	3	5	0	5	5	6		5	0	0	2	10			
Foosin Medical Supplies, China	1399	13mm, 3/8 circle round bodied taper point double armed needle, strand length 45cm	WEGO PDO Polydioxanone Size 7/0 13mm, 3/8 circle round bodied taper point double armed needle, strand length 45cm		WEGO PDO Polydioxanone Foosin Medical Supplies. Inc. Ltd. China	3	5	0	5	5	6		5	0	0	2	10			
Foosin Medical Supplies, China	1423	6 mm, 3/8 circle micro point spatula double needle, strand length 30cm	WEGO Nylon Size 10/0 6 mm, 3/8 circle micro point spatula double needle, strand length 30cm		WEGO Nylon Foosin Medical Supplies. Inc. Ltd. China	3	5	0	5	5	6		5	5	0	2	10			
Foosin Medical Supplies, China	1424	6.2mm, 3/8 circle micro point spatula double needle, strand length 30cm	WEGO Nylon Size 10/0 6.2mm, 3/8 circle micro point spatula double needle, strand length 30cm		WEGO Nylon Foosin Medical Supplies. Inc. Ltd. China	3	5	0	5	5	6		5	0	0	2	10			
Foosin Medical Supplies, China	1425	48mm, 1/2 circle round bodied taper cut point needle, strand length, 45cm	WEGO Stainless Steel Size no 548mm, 1/2 circle round bodied taper cut point needle, strand length 45cm		WEGO Stainless Steel Foosin Medical Supplies. Inc. Ltd. China	3	5	0	5	5	6		5	0	0	2	10			
Foosin Medical Supplies, China	1426	48mm, 1/2 circle round bodied taper cut point needle, strand length, 45cm	WEGO Stainless Steel Size no 4 48mm, 1/2 circle round bodied taper cut point needle, strand length 45cm		WEGO Stainless Steel Foosin Medical Supplies. Inc. Ltd. China	3	5	0	5	5	6		5	5	0	2	10			
Foosin Medical Supplies, China	1427	Polypropylene	WEGO Prolene Polypropylene Mesh Size 30cm x 30cm		WEGO Prolene Polypropylene Foosin Medical Supplies. Inc. Ltd. China	3	5	0	5	5	6		5	5	0	2	10			
Foosin Medical Supplies, China	1428	Polypropylene	WEGO Prolene Polypropylene Mesh Size 15cm x 15cm		WEGO Prolene Polypropylene Foosin Medical Supplies. Inc. Ltd. China	3	5	0	5	5	6		5	5	0	2	10			
Foosin Medical Supplies, China	1429	Polypropylene	WEGO Prolene Polypropylene Mesh Size 15cm x 6cm		WEGO Prolene Polypropylene Foosin Medical Supplies. Inc. Ltd. China	3	5	0	5	5	6		5	5	0	2	10			
Foosin Medical Supplies, China	1430	Polypropylene	WEGO Prolene Polypropylene Mesh Size 6cm x 11cm		WEGO Prolene Polypropylene Foosin Medical Supplies. Inc. Ltd. China	3	5	0	5	5	6		5	5	0	2	10			

Page 210, 217: Kollsut USA 14001 and 13485 verification link are not provided.

COA of formulary No: 1329, 1331, 1332, 1333, 1335, 1350, 1351, 1357, 1361, 1363, 1371, 1372, 1376, 1378, 1390, 1392, 1393, 1394, 1395, 1399, 1400, 1401-03-04-05-08-09-10-11-13- 22-24-25 are not attached in the bid.

Tender approvals attached are not according to the advertised criteria.

TECHNICAL EVALUATION PROFORMA, FOR PROCUREMENT OF ANTICANCER MEDICINES IN GOVT. MCC FY 2026-27

Name of the firm with Complete Address	**Al-Habib Pharmaceuticals, 81-B, Abdullah House, Block-B, S.M.C.S, Karachi. Focal Person- Mukhtiar Ali 0333-1545315, Email- universalmedicine29@gmail.comAl-Habib Pharmaceuticals, 81-B, Abdullah House, Block-B, S.M.C.S, Karachi. Focal Person- Mukhtiar Ali 0333-1545315, Email- universalmedicine29@gmail.com.**
Manufacturer / Importer	

		Mandatory Requirements.	**YES / NO**		**In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:**		**YES/NO**
1		**National Tax Number (NTN) of the Firm for Income Tax, and**	YES		1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and	NA
2		**Last year Income Tax Return of the Firm; and**	YES		2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.	NA
3		**Sale Tax Registration Certificate of the Firm; and**	YES		3	Valid DRAP Approved Price List of the quoted item/s.	NA
4		**Certificate of Professional Tax of the Firm.**	NO				
5		**Certificate of compliance to cold chain standards issued by an authorized Body (WHO-GDP, PIC/S-GDP, PCSIR, Non-Compliance to international reference standards or absence of Cold Chain requirements shall lead to disqualification of the relevant product that requires cold chain.**	YES				

Cold chain facility with

	In case of being Importers, the Firm should provide attested copies of the following documents also:	**YES/NO**	
1	Valid Drugs Sales License for the importer; and		
2	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	YES	
3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	YES	
4	Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (CMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and	YES	See comments on COPP at the end of reoprt
5	Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods. Non provision of this document shall lead to disqualification of the firm; and	YES	
6	Valid DRAP approved Price List of the quoted item/s.	NO	

				Technical Evaluation Parameters			**Active Pharmaceutical Ingredient source gradation** **(For API or finished product). i) The bidder (local manufacturer / multi-national manufacturer / importer) shall provide Analytical/Quality Assurance / Approval Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades.** **Certificate of Analysis/ Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreement/ approval with the original manufacturer duly attested/verified by official of the company.** **Detailed purchase trail of the Active Pharmaceutical Ingredient/ Finished product from the claimed source must be submitted (any proof of purchase such as Goods Declaration Certificate along with Airway Bill/ Bill of Lading/ Invoice etc.) by the bidder.** **Maximum marks for this criterion are 40.**		**Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW) Study/Certificate from an accredited lab. of SRA countries (Stringent Regulatory Authorities)/ WHO Listed Authorities WLA Countries** **(BE/BS Certificate with evidence as to its authenticity) from Category A countries.** **Bio-Equivalence (BE) of the quoted product to be conducted against the originator.** **Original innovator products do not require bio- equivalence certificate and shall get 10 marks automatically.The bidder shall provide the documents to establish the proof of inventor/ originator. All other branded generics require BE studies** **Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid.** **Maximum marks for this criterion are 10.**			**Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug, In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article)** **Mandatory: Online verification link must be provided to verify the Clinical Trial/ Clinical Studies submitted for the quoted items.**		**Factory/ Importer Based Evaluation Score (MANDATORY)**	**Sample Evaluation by End User Committee** **Samples will be examined per following parameters as follows:** **a. Labeling and Packing Rules 1986** **b. Outer packing** **c. Inner packing** **d. Physical appearance.** **Product which has unsatisfactory packing/labeling will be technically Disqualified.** **Maximum score for this criterion is 1.**		**Past Performance (last two years).** **i) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks.** **ii) Only supply orders will not get any marks.** **iii) The bidders must undertake that they have never been blacklisted or debarred.** **Maximum marks for this criterion are 5.** **iv) Those firms who have not been regular in supplies to SIUT, Indus Hospital, Aga Khan Cancer Patients' at KHC, Peshawar, TMO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.**	**Total Technical Score**
							Category A – Approved By: • Australia's Therapeutic Goods Administration (TGA-TGO) • European Medicines Agency (EMA) • Medicines & Healthcare Products Regulatory Agency (MHRA), UK • Therapeutic Goods Administration (TGA), Australia • Pharmaceutical Medical Agency (PHARMAC), New Zealand • Pharmaceutical & Medical Devices Agency (PMDA), Japan • Swiss Agency For therapeutic drugs (Swiss medic), Switzerland • Health Canada • Health Sciences Authority (HSA), Singapore • National Administration of Drugs, Food & Medical technology (ANMAT), Argentina Drug Regulatory Authorities of the SRA (Stringent Regulatory Authorities) / WHO Listed Authorities WLA countries	Category B – Approved By: • Food & Drug Administration, USA • National Drug Surveillance Unit (NDSU), Malaysia • Ministry of Health, Turkey • China Food & Drug Administration • Any other source not mentioned in Category A	Study/certificate acceptable/accepted by a Category A Country Regulatory Authority. Bio Waiving must be done using at least 12 subjects BE/BS certificate only acceptable from a reputable source of a country by Category A Country.	BE/BS/BW certificate obtained from a reputable source from Category A Country or as mentioned at S.No. 1 above).	BE/BS/BW Certificate.		As per the clinical trial category "B" journal listed in the Publication Policy 2018 and List of National Recognized Journals as per HEC, 2 marks per original research article shall be awarded maximum up to 6 marks).	Review the study is published in category "B" journal listed in the Publication Policy 2018 and List of National Recognized Journals as per HEC, 2 marks per original research article shall be awarded maximum up to 6 marks).		The original Import/ Factory Inspection Report of the quoted item/s by a Category "A" Regulatory Authority of the Country of Origin/ Manufacturing as per WHO Technical Report Policy 2010 and List of National Recognized Journals as per HEC, mark and No awarded marks.	**The Physical inspection of the premises of the bidder/ manufacturer/ importer/ supplier will be conducted with PB-BLBS, BCS &SOC & By-laws-7 (1) (i) (ii) of the approved BSDs of Govt. MCC FY 2026-27**	Satisfactory	Unsatisfactory	**i) Substantial quantity of supplies of anti-cancer medicines to Sindh Institute of Urology and Transplantation, Karachi, The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar, CMH Rawalpindi and Hyderabad Medical Complex, Peshawar With International hospital Islamabad, with satisfactory performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 24 months. No marks will be given for supply orders except CMH Rawalpindi where supply orders will be considered. Tenders & invoices will be considered for award of marks.** **ii) Those firms who have not been regular in supplies to SIUT, Indus Hospital, Aga Khan Cancer Patients' at KHC, Peshawar, TMO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.** a mark per agreement up to a maximum of 5 marks		
	SOURCE	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	**40**	**10**	**10**	**5**	**0**	**9**	**6**	**0**	**5**	**1**	**0**	**5**	**70**
Argentina GMP	Laboratorios IMA	1439	Bortezomib	3.5mg	Inj.	Imebizor	**40**		0			0			5	**1**			46
Argentina GMP	Laboratorios IMA	1427	Azacitidine	100mg	Inj.	Mydaza	**40**		0			0			5	**1**			46
Italfo Bulgaria	Fourtitz India	1416	Abiraterone Acetate	250mg	Tab.	AHP-ABIRA	**40**		0			0			5	**1**			46
Argentina GMP	Laboratorios IMA	1502	Idarubicin	10mg	Inj.	AHP Idarubicin	**40**		0			0			5	**SNP**			45
Argentina GMP	Laboratorios IMA	1493	Fulvestrant	250mg	Inj.	Festo V	**40**		0			0			5	**1**			46
Argentina GMP	Laboratorios IMA	1501	Pemetrexed	500mg	Inj.	SMTA-AHP	**40**		0			0			5	**1**			46
Italfo Swiss	Jabs China	1510	Irinotecan	100mg	Inj.	AHP-IRITO	**40**		0			0			5	**1**			46
Argentina GMP	Laboratorios IMA	1491	Thiotepa	10mg	Inj.	Thiotepa AHP	**40**		0			0			5	**1**			46
Argentina GMP	Laboratorios IMA	1568	Paclitaxel	100mg	Inj.	Paclitaxel AHP	**40**		0			0			5	**1**			46
Argentina GMP	Laboratorios IMA	1567	Paclitaxel	150mg	Inj.	Paclitaxel AHP	**40**		0			0			5	**1**			46
Italfo Portugal	Infar exports India	1448	Capecitabine	500mg	Tab.	CITA-AHP	**40**		0			0			5	**1**			46
Argentina GMP	Laboratorios IMA	1496	Gemcitabine	1g	Inj.	Gemstar	**40**		0			0			5	**1**			46
Argentina GMP	Laboratorios IMA	1497	Gemcitabine	200mg	Inj.	Gemstar	**40**		0			0			5	**1**			46
Italfo Hungary	Rajorail India	1448	Capecitabine	500mg	Tab.	Supercap	**40**		0			0			5	**1**			46
Argentina GMP	Laboratorios IMA	1475	Docetaxel	20mg	Inj.	Docetaxel AHP	**40**		0			0			5	**1**			46
Argentina GMP	Laboratorios IMA	1476	Docetaxel	80mg	Inj.	Docetaxel AHP	**40**		0			0			5	**1**			46
Argentina GMP	Laboratorios IMA	1564	Oxaliplatin	50mg	Inj.	Oxaliplatin AHP	**40**		0			0			5	**1**			46
Argentina GMP	Laboratorios IMA	1566	Oxaliplatin	100mg	Inj.	Oxaliplatin AHP	**40**		0			0			5	**1**			46
Italfo Hungary	Rajorail India	1436	Bicalutamide	50mg	Tab.	MACARI	**40**		0			0			5	**1**			46
Italfo Hungary	Rajorail India	1479	Doxorubicin	50mg	Inj.	Supradox	**40**		0			0			5	**1**			46
Italfo Netherland	Kimia Polypharm Chem	1445	Leucovorin/Calcium Folinate	100mg	Inj.	Kuteyin	**40**		0			0			5	**1**			46
Italfo Hungary	Rajorail India	1415	Fluorouracil	500mg	Inj.	Fluoxo	**40**		0			0			5	**1**			46
Korea GMP	Korea United korea	1543	Mitomycin	10mg	Inj.	KU Mitomycin C		30	0			0			5	**1**			36
Korea GMP	Korea United korea	1468	Dactinomycin	0.5mg	Inj.	KU Dactinomycin		30	0			0			5	**1**			36

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27														
Name of the firm						Al hamd Enterprises NDI Karachi FY 2026-27														
						Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevent certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
	1290	Urine Bag With let 2000ml	2000ML	2000ML	CIKINA	Not attached	5	Not attached				**5**	5	5	237-277 Bank statement is unclear		2	Not recommended	**12**	**17**

2 Complete address of manufacturer

M/s Shandong Qinkai Medical Industry Co. Ltd.

(South section of Quancheng road in industrial park), Medical Equipment Industrial park, Chengwu County, Heze, 274200, Shangdong, China

						Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27														
					Name of the firm	Al Hamd Enterprises MD Karachi FY 2026-27														
S. No.		Product General Parameter				Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the time of inspection at the warehouse at the tim eof inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** **(Certificate duly attaested by senior executive of the firm)**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US free sale certificate of the quoted products, **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **Online verification link shall be provided.** **(copies of relevant certificates duly attested by the senior executive of the firm)**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	5	6	**29**	5	5	5	6	10	10	**41**	**70**
1	919	Adhesive Tapes (Paper)	1" Inch x 5 Yards	1" Inch x 5 Yards	KOHLCAN	3	5	73- FDA US agent certificate attached instead of US FDA	5	5	6	**24**	**5**	5	93-122 Tender approvals are incomplete	2	10	10	**27**	**32**
2	920	Adhesive Tapes (Paper)	2" Inch x 5 Yards	2" Inch x 5 Yards	KOHLCAN	3	5		5	5	6	**24**	**5**	5	93-122 Tender approvals are incomplete	2	10	10	**27**	**32**
3	921	Adhesive Tapes (Paper)	3" Inch x 5 Yards	3" Inch x 5 Yards	KOHLCAN	3	5		5	5	6	**24**	**5**	5	93-122 Tender approvals are incomplete	2	10	10	**27**	**32**
4	922	Adhesive Tapes (Paper)	4" Inch x 5 Yards	4" Inch x 5 Yards	KOHLCAN	3	5		5	5	6	**24**	**82-GD not attached**	89-COA marks are subject to GD	93-122 Tender approvals are incomplete	2	10	10	**22**	**#VALUE!**
5	1123	I/V Cannula Size 18G (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	18G	18G	INPHARVEN	3	5	Not attached	5	5	6	**24**	**5**	5	156-177 Tender approvals are incomplete	2	DTL Substandard	10	**17**	**22**
6	1123	I/V Cannula Size 18G (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	18G	18G	KN	Not attached	5	Not attached	5	5	6	**21**	**5**		Not attached	2	10	10	**22**	**27**
7	1126	I/V Cannula Size 20G (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	20G	20G	INPHARVEN	3	5	Not attached	5	5	6	**24**	**5**	5	93-122 Tender approvals are incomplete	2	DTL Substandard	10	**17**	**22**
8	1126	I/V Cannula Size 20G (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	20G	20G	KN	Not attached	5	Not attached	5	5	6	**21**	**5**		Not attached	2	10	10	**22**	**27**
9	1129	I/V Cannula Size 22G (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	22G	22G	INPHARVEN	3	5	Not attached	5	5	6	**24**	**5**	5	156-177 Tender approvals are incomplete	2	DTL Substandard	10	**17**	**22**
10	1129	I/V Cannula Size 22G (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	22G	22G	KN	Not attached	5	Not attached	5	5	6	**21**	5		Not attached	2	10	10	**22**	**27**
11	1133	I.V Cannula 24(Sterile having wings with heparin stopper inside sterilized blister packing, The cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	24G	24G	INPHARVEN	3	5	Not attached	5	5	6	**24**	148-149-GD not attached	COA not attached	156-177 Tender approvals are incomplete	2	DTL Substandard	10	**12**	**#VALUE!**
12	1134	I.V Cannula 24(Sterile having wings with heparin stopper inside sterilized blister packing, The cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	24G	24G	FARCOCATHE	3	5	Not attached	5	5	6	**24**	**5**	5	156-177 Tender approvals are incomplete	2	DTL Substandard	10	**17**	**22**

13	1134	I.V Cannula 24(Sterile having wings with heparin stopper inside sterilized blister packing, The cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	24G	24G	KN	Not attached	5	Not attached	5	5	6	**21**	5	5	Not attached	2	DTL Substandard	10	**17**	**22**
14	1307	Zinc Oxide Adhesive Plaster (Cloth Tap)	2.5cm x 5M	2.5cm x 5M	KOHLCAN	3	5	73- FDA US agent certificate attached instead of US FDA	5	5	6	**24**	5	5	93-122 Tender approvals are incomplete	2	DTL Substandard	10	**17**	**22**
15	1308	Zinc Oxide Adhesive Plaster (Cloth Tap)	5cm x 5M	5cm x 5M	KOHLCAN	3	5		5	5	6	**24**	5	5	93-122 Tender approvals are incomplete	2	DTL Substandard	10	**17**	**22**
16	1309	Zinc Oxide Adhesive Plaster (Cloth Tap)	7.5cm x 5M	7.5cm x 5M	KOHLCAN	3	5		5	5	6	**24**	5	5	93-122 Tender approvals are incomplete	2	DTL Substandard	10	**17**	**22**
17	1310	Zinc Oxide Adhesive Plaster (Cloth Tap)	10cm x 5M	10cm x 5M	KOHLCAN	3	5		5	5	6	**24**	5	5	93-122 Tender approvals are incomplete	2	DTL Substandard	10	**17**	**22**

M/s Zhejiang Kekang Medical Technology Co., Ltd

SouthVillage, Hongqiao town, Yueqing City, Zhejiang China

Name and complete address of manufacturer:

M/s Farcomake For Advanced Medical Industries (S.A.E)

Borg Al-Arab, 4th Industrial Zone, Block-2, Part 7/16 Alexandria Egypt.

M/s Changzhou Kenno Medical Instruments Co., LTd.

No. 2188 Longcheng Road, Xinza Street, Zhonglou District, Changzhou 213012, Jiangsu, China

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: Allied Dibributors Karachi

S. No.		Product General Information				Technical Evaluation Matrix																
						Principal's and Importer's Evaluation Parameters								Product Technical Evaluation								
						Principal Manufacturer Evaluation					Importer's Evaluation				Product Technical Parameters						Product Availability		
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
						Valid ISO 18001-ISMS certificate of the facility where the quoted product is manufactured issued by authorized body of the country with International Accreditation Forum (IAF), duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 14000 certificate of the facility where the quoted product is manufactured issued by authorized body of the country with International Accreditation Forum (IAF), duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country with International Accreditation Forum (IAF), duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid accreditation of manufacturing and QC labs relevant enclosure by the US-FDA/cGMP/ official accreditation body/ies regulatory body of MoH/WLAs country (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid calibration certificate for equipment / instruments used in the factory For Measuring, weighing, Assay and testing instruments used in the material and finished products for the manufacturing of the quoted products. **Valid Calibration Certificates attested by Quality head of the firm).**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect to be issued by the authorized officer of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the user house at the time of inspection of the inspector shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good storage practices (GSP) for storage of finished goods, functional and effective Air-conditioning and temperature mapping (effective only for items/tablet-dosage). The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down item/s and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non/Reference to GSP, as evaluated by the MCC experts at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, Pharmacist (Category-A Pharmacist/A-1(or mandatory) & relevant Human Resource. **Certified by the senior executive of the firm & evaluated / confirmed by MCC experts at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Bioavailability/ Bioequivalence study conducted by WHO / Stringent/Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of MoH/WLAs country (ies). and / or For biologicals, bio-similarity studies shall be provided for item/s of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 2L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill / bill of lading / shipping bill (not more than 24 months on the date of submission). **In case of purchase through third party importers a valid test/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be mandatory to Get NOC following the product in Govt. MCC**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) and duly attested by the Quality head by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient's (API's) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of MoH/WLAs country (ies). Dull of principal manufacturer shall be established from the respective GD, CoA and other supporting documents. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA country(ies) / Valid free sale certificate issued by regulatory body of any SRA/MLA country(ies). and / or Valid certificate of the availability of the quoted item in the US market. **03 marks shall be awarded to the Primary certificate and 1 mark for additional certificate, up to a maximum of 04 (04+01=05) marks.** **Certificates on company's own letter heads shall not be acceptable.** **Copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided**	Valid Certificate of Analysis of the Type-I Glass of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mentions: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type-of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type-of Glass material for Oral Powder Suspension must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** a. For Dry Powder Injectables, a. For USP Type-1 glass 4 marks will be awarded. b. For USP Type-2 Glass 2 marks will be awarded. c. For products whose USP Type-3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm)**	Stability studies of quoted item/s duly attested by the QC incharge of the firm).	Availability of quoted item/s in Pakistan market as per recent issue date of MM/SQ/VIA Health not older than twelve (12) months. 0-10% market share = 1 mark 11-50% market share = 2 marks 51-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 01 Tender approvals= 01 marks 02 Tender approvals= 02 marks 06 Tender approvals= 03 marks 04 Tender approvals= 04 marks 05 or more Tender approvals= 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. However, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with **Purchase Order(s) (PO(s)) issued by the concerned procuring entity** (i.e., the concerned procuring entity/purchasing agency (ies), etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
Principal Manufacturer	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	2	5	5	4	5	5	30	5	5	5	5	6	4	5	5	40	70
Primal Etc. USA(P)		Zedburate	100 ml	Inj. for Inh.	Restore, 1's Bottle	0	0	0	5	5	4	5	5	24	5	5	5	5	5	4	5	5	33	61
Dangkook Korea(P)		Progofer	10mg/ml, 20 ml	Inj.	Refol, 5's Ampoule	2	2	0	5	5	4	5	5	28	0	5	5	5	5	4	5	5	32	60
Primal Inc. USA(P)		Sevofluzane	250 ml	Inj. for Inh.	Insoure, 1's Bottle	0	0	0	5	5	4	5	5	24	5	5	5	5	6	4	5	5	40	64

Observations

ISO 18001, 14001 and 9001 are not attached for Primal C.C. Inc USA.
ISO 9001 of Dangkook Korea not attached.
B.E not attached for Prepofol.
Original Mandatory forms in hard are not submitted to the MCC.

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2025-26

Name of Firm

S. No.	Product General Information				Technical Evaluation Matrix																		
					Principal's and Importer's Evaluation Parameters									Product Technical Evaluation									
					Principal Manufacturer Evaluation					Importer's Evaluation			Suppliers Technical Score	Product Technical Parameters							Product Availability	Product Evaluated Score	Total Technical Score
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or WHO or official accreditation body/ies /regulatory body in the case of SRA countries (duly attested by senior executive of the firm)	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the ware house at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good storage practices (GSP) for storage of finished goods. Functional and effective Air-conditioning & Ventilation System and effective cold chain (thermo-labile drugs). **Nonadherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is/are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and/or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and/or In case of Large volume parenteral (>100ml to 5L as per USP) product validation report shall be submitted. and/or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / biosimilarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facility, a valid trail link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 15, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	API/s source accredited by WHO, US-FDA, EMA, MHRA, TGA, PMDA, Swiss Medic or Health Canada or by regulatory authority of SRAs countries. Trail of principal manufacturer shall be established from the respective GD. CoA and other supporting documents. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) / Valid free sale certificate issued by regulatory body of any SRA country(ies) and / or Valid certificate of the availability of the quoted item in the US market. 2 mark for each certification, up to a maximum of 06 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with invoice/proof of purchase: For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health. Less than 5 % market share = 0 mark 5-10% market share = 01 mark 11-30% market share = 02 marks 31-50% market share = 03 marks 50% and above market share = 05 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than 2 years) from other Secondary & Tertiary Govt. Hospitals outside Khyber Pakhtunkhwa or JCI accredited private entities/hospitals of other provinces of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks **Note.** **Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength**		
	Ref. No. of item in MCC formulary	Generic Name of Item	Dosage Form with Strength	Trade Name	**2**	**2**	**2**	**5**	**5**	**4**	**5**	**5**	**30**	**5**	**5**	**5**	**5**	**6**	**4**	**5**	**5**	**40**	**70**
													0									**0**	**0**

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: Allmed Laboratories, Karachi

S. No.		Product General Information				Technical Evaluation Matrix																	
						Principal's and Importer's Evaluation Parameters								Suppliers Technical Score	Product Technical Evaluation							Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation					Importer's Evaluation				Product Technical Parameters						Product Availability			
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
						Valid ISO 13485:(GDP) certificate of the facility where the quoted product is manufactured/packed/stored and issued in the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured/packed/stored and issued in the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured/packed/stored and issued in the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid accreditation of manufacturing unit in its relevant sectors by the US-FDA or any other equivalent regulatory body in the case of SRA/WLA countries duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid calibration certificates for equipment / instruments used in the manufacturing/packing/testing and Analysis of raw material, in-process, material and finished products for the manufacturing of the quoted products. **Valid Calibration Certificates attested by Quality head of the firm).**	Availability of minimum 20% inventory of the total import of the quoted items in the form of Purchase Order (PO) duly signed by the senior executive of the firm & evaluated by the MCC team(s). **Non availability of the 20% stock at the time of inspection at the importer shall lead to disqualification of the quoted item/s / firm).**	Adherence to Good storage practices (GSP) for storage of finished goods. Temperature mapping, air conditioning & ventilation System and effective cold Units (thermo-labile drugs). The physical inspection committee/ MCC team(s) may visit the premises for the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Nonadherence to GSP, as evaluated by the MCC experts at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacists from mandatory) & relevant Human Resource **(Could be the senior executive of the firm) duly attested by the MCC experts at the time of inspection in non-compliance to this parameter shall lead to disqualification of the firm).**		Bioavailability/ Bioequivalence study conducted by WHO-Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA/WLAs country (ies). and / or For biologicals, bio-similarity studies shall be provided for swatd of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries. (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 1L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of investor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of exported finished quoted item/s from Pakistan customs (GD) duly verified by customs with a or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of purchases through third-party importers a valid trail link (GD/Clearance/ NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC.**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as per WHO / US-FDA / EMA / MHRA / TGA / PMDA/ Swiss Medic provided in column 15, duly attested by the senior executive of the firm. **In case of Non-provision of matching of the marks for CoA will not be entertained.**	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA/WLAs country (ies). Trail of principal manufacturer shall be established from the respective GD, CoA and other supporting documents. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA country(ies) / Valid Non-sale certificate issued by regulatory body of any SRA/WLA country(ies) and / or Valid certificate of the availability of the quoted item in the US-market. **All marks shall be awarded to the Primary certificate, and 1 mark for additional certificate, up to a maximum of 06 (04+01+01) marks.** **Certificates on company's own letter heads shall not be acceptable.** **Copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: i. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE), or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical Type. ii. Type of Glass material for Liquid antipodes must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). iii. Type of Glass material for Oral Syrups / Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** i. For Dry Powder Injectables a. For USP Type 1 Glass 4 marks will be awarded. b. For USP Type 1 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm)**	Validity marker of quoted item's duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistan market as per recent stock data of IMS/EQVIA Health not older than twelve (12) months. 0-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/EQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage forms. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transactions against the cheque received shall also be submitted with each purchase order.			
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	2	5	5	4	5	5	30	5	5	5	5	6	4	5	5	40	70
Zhejiang Ruibang Labs China	79	Cyclosporine	25 mg	Caps	Bioral	0	0	0	5	0	4	5	5	19	0	5	5	0	0	0	0	0	15	34
Zhejiang Ruibang Labs China	80	Cyclosporine	50 mg	Caps	Bioral	0	0	0	5	0	4	5	5	19	0	5	5	0	0	0	0	0	10	29
Zhejiang Ruibang Labs China	81	Cyclosporine	100 mg	Caps	Bioral	0	0	0	5	0	4	5	5	19	0	5	5	0	2	0	0	0	10	29
Pharmacosmos, Denmark	374	Iron Isomaltoside	100 mg 1ml	inj	Monofer	0	0	0	5	0	4	5	5	19	0	5	5	0	2	0	0	0	12	31

Observations:
1Page 42- Certificate of GMP compliance of Pharmacosmos A/S is expired on 14-10-2025
2Agency Agreement of Pharmacosmos Denmark and ZRL china not attached,
3Page: 60-65 The Cyclosporine 50mg and 100 mg are not registered in China.
4Page 54, 60, and 65 are contrary to its contents , for 25mg, 50mg and 100mg. (Unregistered products in China)
5Page 105-110, The calibiberation certificates attached are not according to the criteria (weighing, measuring, assay/analysis of in process, raw and finished goods)
6Page 132- BE study is not WHO accreditated LAB.
7Page 198- The FGIs for SRA countries are on company own letter head.
8Page 238- COA of finished good/Cap cyclosporin is attached instead of Active pharmaceutical ingredient.
9Picture of the DRAP approved immediate container not attached in the bid.
10Page No: 290-319- Stability studies do not mention the strength of the quoted products of ZRL China.
11Page: 353 The ITC is issued to ADNON pharma instead of Pharmacosmos.
12Proof of purchase not attached with COA of immediate containers.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: ALLMED PVT LIMITED LAHORE

S. No.	Product General Information					Technical Evaluation Matrix																							
						Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters									Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters										
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001:45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, as the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert's). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP. **(Certified by the senior executive of the firm & evaluated by MCC expert's at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/GSP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC.**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/Components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registeration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. Copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non-provision of the above shall lead to award of zero marks in this colmunn for the respective item.** For award of marks, the certificate of analysis must clearly mention: i. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health est older than twelve (12) months. i-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals -02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same composition, formulations and strength/ dosage from the respective tender opening. It shall be duly attested by the concerned procuring agents and accompanied with purchase orders, delivery challies, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statements showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70
	518	Isoflurane 250ml	250ml	Liq. for Inh.	Isoflo	2	2	3	0	5	0	2	2	2	2	2	22	0	5	5	0	0	4	5	0	19	41
	521	Enoflurane 250ml	250ml	Liq. for Inh.	Enoflo	2	2	3	0	5	0	2	2	2	2	2	22	0	5	5	0	0	4	5	0	19	41
	589	Mycophenolate Mofetil	500mg	Tablet	Suprimun	2	2	3	0	5	0	2	2	2	2	2	22	0	5	5	5	0	4	5	0	24	46
	603	Sirolimus 1mg	1 mg	Tablet	Sirolt	2	2	3	0	5	0	2	2	2	2	2	22	0	5	5	0	0	0	5	0	15	37
	644	Tacrolimus	1 mg	Capsule	Tacrigen	2	2	3	0	5	0	2	2	2	2	2	22	0	5	5	5	0	0	5	0	24	46
	645	Tacrolimus	0.5 mg	Capsule	Tacrigen	2	2	3	0	5	0	2	2	2	2	2	22	0	5	5	5	0	4	5	0	24	46
	1018	Zeforaxinre	1.0mg	Tablet	Zefox	2	2	3	0	5	0	2	2	2	2	2	22	0	5	5	5	0	4	5	5	29	51
	1013	Zeforaxinre	500mg	Tablet	Zefox	2	2	3	0	5	0	2	2	2	2	2	22	0	5	5	5	0	4	5	0	24	46
	6465	Noradrenaline / Norepinephrine	1mg/ml	Injection	Xpinor	2	2	3	0	5	0	2	2	2	2	2	22	0	5	5	0	0	4	5	0	19	41
	12513	Dolutegravir	5mg	Tablet	Anosmad	2	2	3	0	5	0	2	2	2	2	2	22	0	5	5	5	0	4	5	0	24	46
	12525	Dolutegravir	2.5 mg/ml	Injection	Anosmad	2	2	3	0	5	0	2	2	2	2	2	22	0	5	5	5	0	4	5	0	24	46
	12807	Tamsulosin HCl	0.4mg	Capsule	Xoflow	2	2	3	0	5	0	2	2	2	2	2	22	0	5	5	0	0	4	5	0	19	41

Observations:
1The FBR documents attached at page No: 53 are in the name of an individual person i.e. Sadaf Mirza and not the bidder firm i.e. Allmed Pvt limited Lahore. The same is also contrary to the TRC at Page 15, 16 in terms of title and adresses.
2The FBR nstrums of Allmed Laboratories at Page: 23 are the same as of Allmed Pvt Limited, though both are independent bidders in different categories (Manufacturers, importers)
3The Tax Payer Registeration Certificate at Page 15 and FBR Returns at Page 53 are not matching in terms of title and adresses with all other mandatory documents
4The IMS/IQVIA Ranking attached at page 62 is issued to Allmed Pvt Limited Karachi, and the firm is Lahore based.
5The Bank statement at Page 620-624, 640-645 are not matching with the supply order
6Cheque is not attached with the Tender approval at page 646
7The US FDA certificate and link attached at Page 576-579 and 661-664 are not matching in terms of adress and postal codes of the principal manufacturer.
8The tender approval attached at page number 697-703 are matching with bank statements and cheques.
9Cheque is not attached with the Tender approval at page 710.
10The IMS/IQVIA Ranking attached at page 736 is issued to Allmed Pvt Limited Karachi, and the firm is Lahore based. (Blackbook Verification), additionally the ISOFLO and ISVORLO are also shown in it.
11The IMS/IQVIA does not show Unit share of the quoted items.
12The US FDA Certificate attached at page 747 is issued to Unit III, while the Sirolimus is imported from Unit-I, marks not awarded.
13Proof of purchase not attached with COA of immediate container at Page 756
14All IMS/IQVIA for the quoted items shows vaule share instead of Unit Share.

							Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27																
	Name of the firm						Alpha 6 (Pvt) Ltd																
							Technical Evaluation Matrix																
							Principal's and Importer's Evaluation Parameters							Product Technical Evaluation							Product Evaluated Score	Total Technical Score
							Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score										
		MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
							Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevent certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
		MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
M/S Demophorius Ltd, 196 Archbishop Makarios III Av. Limassol 3030, Cyprus	1	946	Blood Transfusion Set	Sterile and Pyrogenic Free Minimum 125 cc tube		Demotek	0	0	0	5	6	6	**17**	0	0	0	0	0	16	**16**	**33**

Scrutiny Report

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm	AMGOMED ISLAMABAD

S. No.		Product General Information				Technical Evaluation Matrix																	
						Principal's and Importer's Evaluation Parameters									Product Technical Evaluation								
						Principal Manufacturer Evaluation					Importer's Evaluation			Suppliers Technical Score	Product Technical Parameters							Product Availability	Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/ies /regulatory body in the case of SRA/WLA countries (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm)**.	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the ware house at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good storage practices (GSP) for storage of finished goods. Functional and effective Air-conditioning & Ventilation System and effective cold chain (thermo-labile drugs). The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non-adherence to**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is/are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities).	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 15, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies). Trail of principal manufacturer shall be established from the respective GD, CoA and other supporting documents. Moreover, in case of product/quoted item having multiple APIs, the marks for GD,	Valid WHO prequalification and / or Valid product registration in SRA country(ies) / Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) and / or Valid certificate of the availability of the quoted item in the US market. **04 marks shall be awarded to the Primary certificate, and 1 mark for additional certificate, up to a maximum of 06 (04+01+01)**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase: **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this colounm for the respective item.** For award of	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	2	5	5	4	5	5	30	5	5	5	5	6	4	5	5	40	70
	Beijing SL Pharma China	85	Filgrastim	300 mcg	Inj.	Amgofil 300 mcg	0	0	0	0	4	5	5	14	0	5	5	0	0	0	0	0	10	24
	PT Fonko International, Indonesia	99	Zoledronic Acid	4 mg	Inj.	Fondronic 4 mg	0	0	5	0	4	5	5	19	0	5	5	5	0	0	0	0	15	34

Firm name not menioned on Bankers cheque

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2025-26

Name of Firm

S. No.	Product General Information				Technical Evaluation Matrix									Product Technical Evaluation								Product Availability	Product Evaluated Score	Total Technical Score
					Principal's and Importer's Evaluation Parameters									Product Technical Parameters										
					Principal Manufacturer Evaluation					Importer's Evaluation			Suppliers Technical Score										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or WHO or official accreditation body/ies /regulatory body in the case of SRA countries (duly attested by senior executive of the firm)	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the ware house at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good storage practices (GSP) for storage of finished goods. Functional and effective Air-conditioning & Ventilation System and effective cold chain (thermo-labile drugs). **Nonadherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s i/s/are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and/or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and/or In case of Large volume parenteral (>100ml to 5L as per USP) product validation report shall be submitted. and/or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / biosimilarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 15, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	API/s source accredited by WHO, US-FDA, EMA, MHRA, TGA, PMDA, Swiss Medic or Health Canada or by regulatory authority of SRAs countries. Trail of principal manufacturer shall be established from the respective GD. CoA and other supporting documents. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) / Valid free sale certificate issued by regulatory body of any SRA country(ies) and / or Valid certificate of the availability of the quoted item in the US market. 2 mark for each certification, up to a maximum of 06 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with invoice/proof of purchase: For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent imost data of IMS/IQVIA Health. Less than 5 % market share = 0 mark 5-10% market share = 01 mark 11-30% market share = 02 marks 31-50% market share = 03 marks 50% and above market share = 05 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than 2 years) from other Secondary & Tertiary Govt. Hospitals outside Khyber Pakhtunkhwa or JCI accredited private entities/hospitals of other provinces of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks **Note.** **Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications /**		
	Ref. No. of item in MCC formulary	Generic Name of Item	Dosage Form with Strength	Trade Name	**2**	**2**	**2**	**5**	**5**	**4**	**5**	**5**	**30**	**5**	**5**	**5**	**5**	**6**	**4**	**5**	**5**	**40**	**70**
													0									**0**	**0**

TECHNICAL EVALUATION PROFORMA, FOR PROCUREMENT OF ANTICANCER MEDICINES IN GOVT. MCC FY 2026-27

	Name of the firm with Complete Address	**AMGOMED, Office no.4, First Floor, Ghousia Plaza, Jinnah Avenue, Blue Area, Islamabad.,Phone: 051 227 4145-6 Fax: 051 260 4471, Focal Person: Dr. Abdul Hafeez CNIC: 14101-9079488-1 Mobile: 0321 858 1124 E-Mail: info@amgomed.org Website: www.amgomed.org**
	Manufacturer / Importer	

		Mandatory Requirements.	**YES / NO**		**In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:**		**YES/NO**		**In case of being Importers, the Firm should provide attested copies of the following documents also:**		**YES/NO**	
1		**National Tax Number (NTN) of the Firm for Income Tax, and**	YES		1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and		1	Valid Drugs Sales License for the importer; and	YES		
2		**Last year Income Tax Return of the Firm; and**	YES		2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.		2	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	YES		
3		**Sale Tax Registeration Certificate of the Firm; and**	YES		3	Valid DRAP Approved Price List of the quoted item/s.		3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	YES		
4		**Certificate of Professional Tax of the Firm.**	YES					4	Valid cGMP/ Certificate of Pharmaceutical Product (CGPP)/ Certificate of Medicinal Product (CDMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s, Certificate on company's own letter head shall not be	YES		
5		**Certificate of compliance to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR. Non-Compliance to international reference standards or absence of Cold Chain requirements shall lead to disqualification of the relevant product that requires cold chain.**	YES					5	Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods. Non provision of this document shall lead to disqualification of the firm; and	YES		
								6	Valid DRAP approved Price List of the quoted	YES		

			Technical Evaluation Parameters			**Active Pharmaceutical Ingredient source gradation** **(For API or finished product). i) The bidder (local manufacturer / multi-national manufacturer / importer) shall provide Analytical/Quality Assurance/ Approval Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades.** **Certificate of Analysis/ Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement.** **Importers must submit agency agreement/ approval with the original manufacturer duly attested/ verified by official of the company.** **Detailed purchase trail of the Active Pharmaceutical Ingredient/ Finished product from the claimed source must be submitted (any proof of purchase such as Goods Declaration Certificate along with Airway Bill/ Bill of Lading/Invoice etc.) by the bidder.** **Maximum marks for this criterion are 40.**		**Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW) Study/Certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities)/ WHO Listed Authorities WLA Countries** **BE/BS Certificate with evidence as to its authenticity) from Category A countries.** **Bio-Equivalence (BE) of the quoted product to be conducted against the originator. Original innovator products do not require bio- equivalence certificate and shall get 10 marks automatically. The bidder shall provide the documents to establish the proof of inventor/ originator. All other branded generics require BE studies** **Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid.** **Maximum marks for this criterion are 10.**			**Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug. In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article)** **Mandatory: Online verification link must be provided to verify the Clinical Trial/ Clinical Studies submitted for the quoted items.**			**Factory/ Importer Based Evaluation Score (MANDATORY)**	**Sample Evaluation by End User Committee** **Samples will be examined per following parameters as follows:** **a. Labeling and Packing Rules 1986** **b. Outer packing** **c. Inner packing** **d. Physical appearance.** **Product which has unsatisfactory packing/labeling will be technically Disqualified.** **Maximum score for this criterion is 1.**		**Post Performance (Last two years).** **i) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks.** **ii) Only supply orders will not get any marks.** **iii) The bidders have to undertake that they have never been blacklisted or debarred.** **Maximum marks for this criterion are 5.** **iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO marks shall be deducted for poor part performance irrespective of substantial**	**Total Technical Score**
						Category A – Approved By: • United States Food & Drug Administration (US-FDA) • European Medicines Agency (EMA) • Medicines & Healthcare Products Regulatory Agency (MHRA), UK • Therapeutic Goods Administration (TGA), Australia • Pharmaceutical Medical Agency (PHARMAC), New Zealand • Pharmaceutical & Medical Devices Agency (PMDA), Japan • Swissmedic, Switzerland • Drugs (human med.), Switzerland • Health Canada • Health Sciences Authority (HAS), Singapore • National Administration of Drugs, Food & Medical Technology (ANMAT), Argentina Drug Regulatory Authorities of the SRA (Stringent Regulatory Authorities) / WHO Listed Authorities WLA countries	Category B – Approved By: • Agência Nacional de Vigilância Sanitária (ANVISA), Brazil • Central Drug Standard Control Organization (CDSCO), India • Drug Regulatory Authority, Malaysia • National Pharmaceutical Control Bureau (NPCB), Malaysia • Food & Drug Administration, North Korea • Ministry of Health, Egypt • Ministry of Health, Turkey • China Food & Drug Administration • Any other source not mentioned in Category-A	Study/certificate accepted /certified by a Category-A Country Regulatory Authority (i.e. mentioned at S No. 1 above). Must (12 subjects). Bio-waiver is acceptable only to injectable forms if issued by Category-A country.	BE/BS/BW certificate obtained for a quoted product from Category-B Country (as mentioned at S No. 1 above).	No BE/BS/BW Certificate.	In case the study is published in Web of Science/ Scopus indexed or MEC Journal Recognition System (HERD) Database/ Journals & Publication Policy 2024 and List of National Journals as per HEC. 7 marks per original research article shall be awarded maximum up to 9 marks).	In case the study is published in Web of Science/ Scopus indexed or MEC Journal Recognition System (HERD) Database/ Journals & Publication Policy 2024 and List of National Journals as per HEC. 2 marks per original research article shall be awarded maximum up to 6 marks).	Studies/original article published in Web of Science/ Scopus indexed or HERD Journals & Publication Policy 2024 and List of National Journals as per HEC. Shall not be awarded marks.	**The Physical inspection of the premises of the bidders (Manufacturer/Importer) shall be carried out in accordance with 29 (5-A)(h), SCC 5 (SCC 8.3), Section V (1) (i) (k) of the approved PC&S of Govt. MCC FY 2026-27**	Satisfactory	Unsatisfactory	1) Substantial quantity of supplies of anti-cancer medicines made to private sector hospitals/institutes (in namely). The Aga Khan university Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar, CMH Rawalpindi/Kharian, Rashidabd Medical Complex, Peshawar, Shifa International Hospital Islamabad, with Good/Satisfactory Performance Certificates from these institutions (mandatory). Marks will be given for supplies in last 24 months. No marks will be given for supply orders except CMH Rawalpindi where supply orders coupled with delivery challans & Payment will be considered for award of marks. 1 mark per agreement up to a maximum of 5 marks	
SOURCE	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	**40**	**30**	**10**	**5**	**0**	**9**	**6**	**0**	**5**	**1**	**0**	**5**	**70**
Synthon Netherlands/Hispania SL	1437	Abiraterone Acetate	250 mg	Tablets	Abiraterone 250 mg	40					**0**			**5**	**1**		**4**	**50**
Deva Holding, Turkey	1437	Abiraterone Acetate	250 mg	Tablets	Abyga 250 mg	40					**0**			**5**	**1**		**4**	**50**
Synthon Netherlands/Hispania SL	1448	Axitinib	5 mg	Tablets	Axinib 5 mg	40			5		**0**			**5**	**SNP**		**4**	**54**
PT Fonko International, Indonesia	1462	Bortezomib	3.5 mg	Inj.	Fonkozomib 3.5 mg	40					**0**			**5**	**1**		**4**	**50**
Pharmacare Premium, Malta	1471	Capecitabine	500 mg	Tablets	Capecitabine PCM 500 mg	40					**0**			**5**	**1**		**4**	**50**
Deva Holding, Turkey	1472	Carboplatin	150 mg	Inj.	Carbodex 150 mg	40					**0**			**5**	**SNP**		**4**	**49**
Deva Holding, Turkey	1473	Carboplatin	450 mg	Inj.	Carbodex 450 mg	40					**0**			**5**	**SNP**		**4**	**49**
Deva Holding, Turkey	1504	Doxorubicin	50 mg	Inj.	Adrimisin 50 mg	40					**0**			**5**	**1**		**4**	**50**
Synthon Chile	1544	Lenvatinib	10 mg	Tablets	Levelar 10 mg	40			5		**0**			**5**	**SNP**		**4**	**54**
cGMP on Page 648 Synthon Chile	1545	Lenvatinib	4 mg	Tablets	Levelar 4 mg	40			5		**0**			**5**	**SNP**		**4**	**54**
cGMP on Page 648 Deva Holding, Turkey	1546	Letrozole	2.5 mg	Tablets	Letrasan 2.5 mg	40			5		6			**5**	**1**		**4**	**61**
Dongkook Pharma, Republic of Korea	1549	Leuprolide Acetate	3.75 mg	Inj.	Lorelin 3.75 mg	40					3			**5**	**1**		**4**	**53**
Dongkook Pharma, Republic of Korea	1550	Leuprolide Acetate	7.5 mg	Inj.	Lorelin 7.5 mg	40					3			**5**	**1**		**4**	**53**
Dongkook Pharma, Republic of Korea	1551	Leuprolide Acetate	11.25 mg	Inj.	Lorelin 11.25 mg	40					3			**5**	**1**		**4**	**53**
CSPC Ouyi Pharmaceutical Co. Ltd, China	1556	Liposomal Doxorubicin	20 mg	Inj.	Lipad 20 mg	40					9			**5**	**1**		**4**	**59**
PT Fonko International, Indonesia	1592	Paclitaxel	300 mg	Inj.	Paclitaxel 300 mg	40					0			**5**	**1**		**4**	**50**

Scrutiny Report
1The clinical study at Page 545 shows Capecitabine manufactured by Intas Pharmaceutical India- while the offered product is of Malta- There is no trail of the quoted product with Intas India.
2Study ending on Page 560 is without conclusion
3The clinical study at Page 561 shows Capecitabine manufactured by Hetero Labs India- while the offered product is of Malta- There is no trail of the quoted product with Hetero India.
4US FDA report at Page 637 ho hidden content
5Study at Page 681 is attached twice
6POs of CMH Rawalpindi are without DCs and invoice

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name **AMSON VACCINES & PHARMA PVT LTD**

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate,**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
1	234	Clarrithromycin	250mg	Tablet	Newmac	0	0	0	2	5	6	2	2	2	2	2	**23**	0	5	5	Not attached	0	0	5	0	**15**	**38**
2	235	Clarrithromycin	500mg	Tablet	Newmac	0	0	0	2	5	6	2	2	2	2	2	**23**	0	5	5	Not attached	0	0	5	0	**15**	**38**
3	366	Ferrous Fumarate+Folic A	150/0.5mg	Tablet	Fefan	0	0	0	2	5	6	2	2	2	2	2	**23**	0	5	5	Not attached	0	0	5	0	**15**	**38**
4	532	Zinc Sulphate	20mg	Tablet	Orazinc Dispersible	0	0	0	2	5	6	2	2	2	2	2	**23**	0	5	5	Not attached	0	4	5	0	**19**	**42**
5	557	Hydrocortisone	100mg	Injection	Hyzonate	0	0	0	2	5	6	2	2	2	2	2	**23**	0	5	5	Not attached	0	4	5	2	**21**	**44**
6	558	Hydrocortisone	250mg	Injection	Hyzonate	0	0	0	2	5	6	2	2	2	2	2	**23**	0	5	5	Not attached	0	4	5	2	**21**	**44**
7	596	Hepatitis B Vaccine	10mcg/0.5ml	Injection	Amvax B	0	0	0	2	5	6	2	2	2	2	2	**23**	0	5	5	Not attached	0	4	5	2	**21**	**44**
8	596	Hepatitis B Vaccine	20mcg/1ml	Injection	Amvax B	0	0	0	2	5	6	2	2	2	2	2	**23**	0	5	5	Not attached	0	4	5	2	**21**	**44**
9	623	Tetatnus Toxoid	0.5ml	Injection	Imatet	0	0	0	2	5	6	2	2	2	2	2	**23**	0	5	5	Not attached	0	4	5	5	**24**	**47**
10	620	Snake Venom Antiserum	10ml	Injection	Polyvalent Anti Snake Venom Serum (liquid)	0	0	0	2	5	6	2	2	2	2	2	**23**	0	5	5	Not attached	0	4	5	0	**19**	**42**

Cadia Healthcare Ltd	11	626	Typhoid Vaccine		Injection	Typbar	0	0	0	2	5	6	2	2	2	2	2	**23**	0	5	5	Not attached	0	4	5	1	**20**	**43**
	12	915	Pyridoxine Hcl	50mg	Tablet	Amdoxin	0	0	0	2	5	6	2	2	2	2	2	**23**	0	5	5	Not attached	0	0	5	0	**15**	**38**

Scrutiny Report

1Valid ISO 45001 certificate at pdf page No. 214, ISO 14001 at pdf page No. 217 & ISO 9001 certificate at pdf page No. of 220 of the technical bid, are not issued by PNAC Accredited body.
2IMS/IQVIA market share of Zinc Sulphate and Snake venum serum could not be found in the documents attached at pdf page No. 224-230 of the technical bid.
3Hydocortisone is quoted from two different prinicpal manufacturers (Curia Spain and Symbiotic India). Need clarification in terms of soruce of API for supplies.
4For award of marks in immediate container for Tablets, documents for immediated container such as PVC are nto attached technical bid.
5ISO 45001 at pdf page No. 214 is issued by Tuv Austria instead of PNAC Accredited body i.e. TUV Austria Beureau of Inspection and Certification (PVT) ltd.

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposibles and Sutures for Government MCC 2026-27

Name of the firm | **AMSON PHARMA AND VACCINE**

Technical Evaluation Matrix

		Product General Information				**Factory Technical Evaluation Parameter**								**Factory Evaluated Score**	**Product technical Evaluation Parameters**						**Product Evaluated Score**	**Total Technical Score**
						Documents Based Factory Score				**Evaluation Visit Score**												
S.No	MCC formulary No.	**1**	**2**	**3**	**4**	**5**	**6**	**7**	**8**	**9**	**10**	**11**	**12**	**13**	**14**	**15**	**16**	**17**	**18**	**19**	**20**	**21**
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. **(as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.**	Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAP regulations. **(to be evaluated by the MCC expert/s at the time of inspection. Noncompliance to cGMP shall lead to disqualification of the relevant section or firm)**	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section / firm.**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC** **(Certificate Duly attested by Senior Executive of the firm)**	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and / or valid product registration in SRA/WLA country(ies) / and / or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **Copies of relevant certificates**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	**3**	**5**	**5**	**6**	**3**	**3**	**2**	**2**	**29**	**5**	**5**	**5**	**6**	**10**	**10**	**41**	**70**
1	1015	Disposable Auto Disable Syringe 0.5ml	0.5ml	Auto Disable Syringe	Apple K1 0.5 ml (Auto Disable Syringe)	0	0	**5**	**6**	**3**	**3**	**2**	**2**	**21**	0	0	**0**	2	**10**	**10**	**22**	**43**
2	1016	Disposable Auto Disable Syringe 1ml	1ml	Auto Disable Syringe	Apple K1 1 Auto Disable Syringe 1ml	0	0	**5**	**6**	**3**	**3**	**2**	**2**	**21**	0	0	**0**	0	**10**	**10**	**20**	**41**
3	1017	Disposable Auto Disable Syringe 2ml	2ml	Auto Disable Syringe	Apple K1 2 ml (Auto Disable Syringe)	0	0	**5**	**6**	**3**	**3**	**2**	**2**	**21**	0	0	**0**	0	**10**	**10**	**20**	**41**
4	1018	Disposable Auto Disable Syringe 3ml	3ml	Auto Disable Syringe	Apple K1 3 ml (Auto Disable Syringe)	0	0	**5**	**6**	**3**	**3**	**2**	**2**	**21**	0	0	**0**	0	**10**	**10**	**20**	**41**
5	1019	Disposable Auto Disable Syringe 5ml	5ml	Auto Disable Syringe	Apple K1 5ml (Auto Disable Syringe)	0	0	**5**	**6**	**3**	**3**	**2**	**2**	**21**	0	0	**0**	0	**10**	**10**	**20**	**41**
Non Formulary	6	1023	Disposable Syringe 10ml.	10ml	Disposable Syringe	Apple Disposable Syringe 10ml	0	0	**5**	**6**					**11**	0	0	**0**	0	Non Formulary		**0**	**11**

Scrutiny Report

1. ISO Certificate 14001 issued by TUV Austria attached at pdf page No. 1303 of the technical bid is not from PNAC Accredited body.
2. ISO Certificate 13485 of SGS UK at pdf Page No. 1305 of the technical bid is not from the PNAC Accredited body.
3. GDs for Syringes caps (raw materials) not attached in the bid.
4. GDs and COA of Printing ink/material for all quoted syringes are not attahed in the bid.
5. GDs and COA for blister pack of the syringes are not attached in the bid.
6. Documents for Tender Approval attached from pdf page No. 1619 to 1870 are inconclusive, total amounts are either not matching with the bank cheques or not clearly visible.
7. The documents attached at pdf page No. 1871 to 1880 of the technical bid doesn't cover the 2ml & 5ml Auto-disable syringe (the offered products), infact these are only awarded to RUP syringes 2ml & 5ml. Moreover, the WHO prequalification certificate only cover 0.5ml Auto Disable syringe of the firm.
8. The Advertised specifications in the approved BSDs of Govt. MCC FY 2026-27 for formulary No. 1023 is Disposable Syringe Ordinary (Blister packing) sterile (10ml) whereas the firm has offered Autodisable syringe 10ml in its technical proposal at pdf page No. 1246 of the bid. Hence, the item quoted by the firm at formulary No. 1023 is Non-formulary.

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposibles and Sutures for Government MCC 2026-27

Name of the firm	Anax Pvt Limited Lahore

		Product General Information				Technical Evaluation Matrix															
						Factory Technical Evaluation Parameter									Product technical Evaluation Parameters						
						Documents Based Factory Score				Evaluation Visit Score				Factory Evaluated Score							Product Evaluated Score	Total Technical Score
S.No	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. **(as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.**	Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAP regulations. **(to be evaluated by the MCC expert/s at the time of inspection. Noncompliance to cGMP shall lead to disqualification of the relevant section or firm)**	Availability of, Functional and validated HVAC., with all relevant equipment, testing, and logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section / firm.**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC** **(Certificate Duly attested by Senior Executive of the firm)**	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and / or valid product registration in SRA/WLA country(ies) / and / or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	6	3	3	2	2	29	5	5	5	6	10	10	41	70
	1053	MedPro Standard Surgical Gwon (Isolation- Green Un Sterilized)	MedPro Standard Surgical Gwon (Isolation- Green Un Sterilized)	Medpro (Anax Associates (Pvt) Ltd		0	0	0	2	The firm was inspected as per technical evaluation criteria. The mandatory cGMP certificate was expired at the time of inspection (Expiry: 01-11-2025). Hence, the firm is NOT RECOMMENDED for award of factory evaluation visit score for the quoted items.				2	0	0	0	0	0	10	10	12
		Medpro Standard Surgical Gown (30 GSM Blue Sterilized)	Medpro Standard Surgical Gown (30 GSM Blue Sterilized)	Medpro (Anax Associates (Pvt) Ltd		0	0	0	2					2	0	0	0	0	0	10	0	2
		Medpro Standard Surgical Gown	Medpro Standard Surgical Gown			0	0	0	2					2	0	0	0	0	0	10	0	2
		45 GSM, 3MM1 Fabric (Sterilized)	45 GSM, 3MM1 Fabric (Sterilized)			0	0	0	2					2	0	0	0	0	0	10	0	2
	1068	Disposable OT Cap Different Sizes	Medpro Reinforced Surgical Gown			0	0	0	2					2	0	0	0	0	0	10	0	2
	1069	Disposable OT Drapes Different Sizes	45 GSM, 3MM1 Fabric Reinforcement on Chest & Arms (Sterilized)			0	0	0	2					2	0	0	0	0	0	10	0	2
			Medpro OT Cap Disposable	Medpro (Anax Associates (Pvt) Ltd		0	0	0	2					2	0	0	0	0	0	10	0	2
			Medpro OT Sheet Sterile 75 CM x 90 CM	Medpro (Anax Associates (Pvt) Ltd		0	0	0	2					2	0	0	0	0	0	10	0	2
			Medpro OT Sheet Sterile 100 CM x 100 CM	Medpro (Anax Associates (Pvt) Ltd		0	0	0	2					2	0	0	0	0	0	10	0	2
	1152	Disposable Face Mask, (Medical mask, good breathability)	Medpro OT Sheet Sterile 100 CM x 150 CM	Medpro (Anax Associates (Pvt) Ltd		0	0	0	2					2	0	0	0	0	0	10	0	2
			Medpro OT Sheet Sterile 150 CM x 200 CM	Medpro (Anax Associates (Pvt) Ltd		0	0	0	2					2	0	0	0	0	0	10	0	2
			Medpro Surgical Face Mask With Ear Loops	Medpro (Anax Associates (Pvt) Ltd		0	0	0	2					2	0	0	0	0	0	10	0	2

Observations
Page 195. CGMP is expired on 21-08-2025
Page 322-324 ISO attached are not from PNAC accreditated body.
Mandatory Bid form 03 is not attached in the bid.
Claiberation certificates as per column 07 are not attached in the bid.

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27														
Name of the firm						Aqib Trading Company Nowshera														
						Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals-01 mark 04 Tender approvals-02 marks 06 Tender approvals-03 marks 08 Tender approvals-04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission.	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered.	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
Jaingxi Hongda Medical Equipment Gp ltd	947	Blood Collection Tubes (Purple Top)	3ml	AT-TUBE				0	5	6	6	**17**	5	5	Tender approvals are incomplete	Not attached	2	16	**28**	**45**
Jaingxi Hongda Medical Equipment Gp ltd	950	Blood Collection Tubes (Green Top)	3ml	AT-TUBE				0	5	6	6	**17**	5	5	Tender approvals are incomplete	Not attached	2	16	**28**	**45**
Jaingxi Hongda Medical Equipment Gp ltd	951	Blood Collection Tubes (Yellow Top	3ml	AT-TUBE				0	5	6	6	**17**	5	5	Tender approvals are incomplete	Not attached	2	16	**28**	**45**
Jaingxi Hongda Medical Equipment Gp ltd	952	Blood Collection Tubes (Blue Top)	3ml	AT-TUBE				0	5	6	6	**17**	0	0	Tender approvals are incomplete	Not attached	2	16	**18**	**35**
Jaingxi Hongda Medical Equipment Gp ltd	1011	Disposable Endotracheal Tube with Cuff	6.5mm	AT-TT				0	5	6	6	**17**	0	0	Tender approvals are incomplete	Not attached	2	16	**18**	**35**
Jaingxi Hongda Medical Equipment Gp ltd	1012	Disposable Endotracheal Tube with Cuff	7mm	AT-TT				0	5	6	6	**17**	0	0	Tender approvals are incomplete	Not attached	2	16	**18**	**35**

						Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27													
					Name of the firm	Aqib Trading Company, Nowshera													
S. No.		Product General Parameter				Technical Evaluation Matrix												Product Evaluated Score	Total Technical Score
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the time of inspection at the warehouse at the tim eof inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US free sale certificate of the	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	5	6	**29**	5	5	5	6	10	10	**41**	**70**
Jiangxi HMEGI	**8**	1015	Disposable Auto Disable Syringe (Blister packing) sterile	0.5ml	AT-INGE	0	0	0	5	5	6	**16**	0	0	Tender approvals are	2	10	10	**22**	**38**
Jiangxi HMEGI	**9**	1016	Disposable Auto Disable Syringe (Blister packing) sterile	1ml	AT-INGE	0	0	0	5	5	6	**16**	0	0	Tender approvals are	2	10	10	**22**	**38**
Jiangxi HMEGI	**10**	1018	Disposable Auto Disable Syringe (Blister packing) sterile	3 ml	AT-INGE	0	0	0	5	5	6	**16**	5	5	Tender approvals are	2	10	10	**32**	**48**
Jiangxi HMEGI	**11**	1019	Disposable Auto Disable Syringe (Blister packing) sterile	5 ml	AT-INGE	0	0	0	5	5	6	**16**	5	0	Tender approvals are	2	10	10	**27**	**43**
Jiangxi HMEGI	**12**	1021	Disposable Insulin Syringe Ordinary sterile	30 G / 31 G 1ml	AT-SULIN	0	0	0	5	5	6	**16**	0	0	Tender approvals are	2	10	10	**22**	**38**
Jiangxi HMEGI	**13**	1022	Disposable Syringe Ordinary (Blister packing) sterile	1ml	AT-INGE	0	0	0	5	5	6	**16**	0	0	Tender approvals are	2	10	10	**22**	**38**
Jiangxi HMEGI	**14**	1023	Disposable Syringe Ordinary (Blister packing) sterile	10ml	AT-INGE	0	0	0	5	5	6	**16**	5	5	Tender approvals are	2	10	10	**32**	**48**
Jiangxi HMEGI	**15**	1024	Disposable Syringe Ordinary (Blister packing) sterile	20ml	AT-INGE	0	0	0	5	5	6	**16**	0	0	Tender approvals are	2	10	10	**22**	**38**
Jiangxi HMEGI	**16**	1025	Disposable Syringe Ordinary (Blister packing) sterile	50ml	AT-INGE	0	0	0	5	5	6	**16**	5	5	Tender approvals are	2	10	10	**32**	**48**
Jiangxi HMEGI	**17**	1026	Disposable Syringe Ordinary (Blister packing) sterile	60ml	AT-INGE	0	0	0	5	5	6	**16**	5	5	Tender approvals are	2	10	10	**32**	**48**
Jiangxi HMEGI	**30**	1119	I/V fluid administration set	sterile and pyrogen free, minimum 150cm tube length, blister pack	AT-SET	0	0	0	5	5	6	**16**	0	0	Tender approvals are	2	10	10	**22**	**38**
Jiangxi HMEGI	**31**	1120	I/V fluid administration set with additional "Y" injection port	Sterile, minimum 150cm length tubing, latex, and pyrogen free, blister pack	AT-SET	0	0	0	5	5	6	**16**	0	0	Tender approvals are	2	10	10	**22**	**38**

Jiangxi HMEGl	32	1123	I/V Cannula(Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	18G	AT-CAN	0	0	0	5	5	6	**16**	5	5	Tender approvals are	2	10	10	**32**	**48**
Jiangxi HMEGl	33	1126	I/V Cannula(Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	20G	AT-CAN	0	0	0	5	5	6	**16**	5	5	Tender approvals are	2	DTL Substandard	10	**22**	**38**
Jiangxi HMEGl	34	1129	I/V Cannula(Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	22G	AT-CAN	0	0	0	5	5	6	**16**	5	5	Tender approvals are	2	DTL Substandard	10	**22**	**38**
Jiangxi HMEGl	35	1134	I/V Cannula(Sterile having wings + injection port with heparin stopper inside sterilized blister packing, The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	24G	AT-CAN	0	0	0	5	5	6	**16**	0	0	Tender approvals are	2	10	10	**22**	**38**

Observations

Page 78	DRAP Registeration of 60ml (1027) not attached.
Page: 58	The Manufacturer's auhtorization of Jiangxi HMEG does not cover the quoted products/specifications.
Page 93	ISO 14001 of Jiangxi HMEGL verification link not attached.
Page 96	ISO 13485 of Jiangxi HMEGL verification link not attached.
	ISO 14001 of Bergamont not attached.
Page 98	ISO 13485 of BERGAMONT verification link not attached.
Page 100-03	US FDA 510 K are attached instead of Unit Accredition for Jiangxi HMEGL
Page 107	Link attached instead of Certificate (Bergamont)
Page 142	Notice of Revalidation of single use devices attached instead of Unit accreditation of Jiangxi HMEGL.
Page 144-145	WHO product PQ for 3 ml and 5 ml are valid till May 2025.
Page 146	The TGA certificate is issued to MEDISUPPLIES for general purpose syringes.
Page 147	The appended lists of MHLW certificates are in foreign language other than English.
Page 168	IV flow regulator, NG Tubes, Sterile disposable Hemo blood tubing are not covered in the EC.
	IV flow regulator, NG Tubes,
Page 264, 395	GD & COA of Urine bag with let not attached in the bid.
Page 271	GD and COA of I.V set y port not attached.
Page 272 & 277	GD and COA Of I.V Canula 24 gauge are not matching with advertised specification, the I.V cannula have no injection port.
Page 296-299-308	GD and AWB and NAC of Blood tubing set, AV fistula, Hemodialyzer and Syringe 0.5cc are not matching
Page 310	GD of 100 % Silicon of 18FR attached instead of advertised specs at 1268
Page 310 and 326 and	GD and AWB at Page 327 are not matching for 1cc, 1cc insulin, Burette 100 ml, I.V set Y port,
Page 353	COA of I.V Cannula 24 G with injection port attahced, wihout Heparin.
	GD of Urine bag with Let not attached in the bid.
	GD and COA of 20 ml not attached.
Page 384	COA of ETT 6.5, and 7.0 not attached 384

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: ARIES PHARMA PESHAWAR

S. No.		Product General Information				Technical Evaluation Matrix																					
						Factory Technical Evaluation Parameters												Product Evaluation Parameters									
						Documents Based Factory Score						Factory Evaluation Visit Score					Total Factory Evaluated Score	Product Technical Parameters							Total Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 13485/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan. **12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as per Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC experts's, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adherence to cGMP guidelines, as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC experts's at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC experts at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA/WLAs country (yes)) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid Avail-link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to disqualification of the respective item/s/s for the respective bids.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspension must be USP	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals= 01 mark 04 Tender approvals= 02 marks 06 Tender approvals= 03		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**5**	**3**	**4**	**5**	**5**	**37**	**70**
	2	Metronidazole	400 mg	Tab.	Flagynase DS	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	4	Metronidazole	500 mg	Inf.	Flagynase	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	40	Diclofenac Sodium (IM/IV for Infusion)	25 mg/ml	Inj.	Volfenac	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	42	Fentanyl Citrate	0.05 mg/ml	Inj.	Fenject	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	56	Nalbuphine	10 mg	Inj.	Kinal	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	66	Paracetamol + Tramadol	325mg/37.5mg	Tab.	Ultram	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	69	Tramadol HCl	50 mg/ml	Inj.	Naxel	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	165	Amikacin Sulphate	50 mg	Inj.	Amitax	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	166	Amikacin Sulphate	100 mg	Inj.	Amitax	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	168	Amikacin Sulphate	500 mg	Inj.	Amitax	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	189	Azithromycin	250 mg	Tab./Cap.	Macrocap	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	202	Cefepime	500 mg/vial	Inj.	Kion	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	203	Cefepime	1 gm/vial	Inj.	Kion	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	204	Cefixime	400 mg	Cap.	Spectracef	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	205	Cefixime	100 mg/5ml	Dry Susp.	Spectracef	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	206	Cefixime	200 mg/5ml	Dry Susp.	Spectracef	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	207	Cefoperazone + Sulbactam	1 gm/vial	Inj.	Aricef Plus	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	208	Cefoperazone + Sulbactam	2 gm/vial	Inj.	Aricef Plus	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	217	Ceftriaxone	500 mg/vial	Inj.	Arizon	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	218	Ceftriaxone	1 gm/vial	Inj.	Arizon	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	219	Ceftriaxone	2 gm/vial	Inj.	Arizon	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	271	Linezolid	2 mg/ml	Inf.	Oxalid	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	276	Moxifloxacin	400 mg/250ml	Inf.	Moxi	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	376	Mecobalamin	500 mcg	Inj.	Neurozone	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	389	Tranexamic Acid	250 mg	Inj.	Tranis	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	390	Tranexamic Acid	500 mg	Inj.	Tranis	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	482	Combined Oral Contraceptives	21 tab. (0.03mg estradiol	Tab.	Preva-28F	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	516	Omeprazole	40 mg/vial	Inj.	Omec	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	519	Ondansetron	8 mg	Tab.	Averon	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	520	Ondansetron	2 mg/ml	Inj.	Averon	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	700	Alprazolam	0.5 mg	Tab.	Pranax	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	718	Diazepam	10 mg/ml	Inj.	Diazep	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**
	740	Midazolam	5 mg/ml	Inj.	Midaron	**2**	**2**	**3**	0	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**26**	0	0	0	0	0	0	**5**	0	**5**	**31**

Scruitny report

DRAP registration of Diazepam Inj 10mg/ml, paracetamol+Tramadol, Tramadol 50mg inj and diclofenac 25mg/ml inj are not attached in the bid

Immediate container attached at 337-447 need clarification for the award of marks

AIFA GMP for API source is not not verificable online, need clarification

Certain submitted documents, including GD, COA, and immediate container-related records of the firm are vague

COA at page 516 for Azithromycin need clarification regarding its authenticity, hence marks not awarded in GD and COA Column

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: Arreta Pharmaceutical (pvt) Ltd

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters: Documents Based Factory Score						Factory Evaluation Visit Score					Total Factory Evaluated Score	Product Evaluation Parameters: Product Technical Parameters								Total Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities).	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this colourns for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70
1	41	Diclofenac Sodium enteric coate	40mg Tab	Tab	Ticclo SR Tab 100mg	2	2	3		5	2	The inspection team during inspection made following observations; Compromised cGMP Non adherence to QC procedure • It was observed that most chemical solutions in the Quality Control Laboratory were expired (H2SO4, AgNo3, Nitric Acid Exp-01/2025). • Expired Lab reagents were present in Lab (1-Pentane sulfonic acid 12/2024). • During the inspection, working standards/reference standards, were observed stored in a disorganized and improper manner. Items were haphazardly packed in transparent plastic bags and stuffed inside cardboard boxes without proper segregation, labeling, or systematic arrangement, indicating inadequate compliance with Good Manufacturing Practices (GMP) and Good Storage Practices (GSP). Non Compliance to RMS procedure: • Multiple materials in the RMS were found without proper identification labels. In addition, no temperature control system was available in the Cephalosporin RMS. Poor environmental/HVAC control • Multiple thermo-hygrometers were showing minimum recorded temperature of above 20 C while the readings noted in the logs were below 20 C (Throughout the month of April 2026) which shows nonadherence good documentation practices. • Several controlled items were found without proper labelling and identification. • Expired Raw material was found in released area of RMS (Neotame- Expiry- 03-06-2025) which indicates poor inventory and expiry management. • Packing materials and raw materials were observed to be stored together in the same storage area. • WFI Stock was placed directly on floor without pellets. • Equipment were found covered with dust, indicating poor housekeeping practices and inadequate GMP compliance. • Multiple in-process materials were observed without proper identification labels. • Incorrect labels/tags were observed on machines in the production area. • The sieve at the base of the inside of Fluid Bed Dryer (FBD) was found rusted and not in an acceptable condition for use while it was labelled as "CLEANED". • Several equipment items were found uncleaned after use, indicating non-compliance with cleaning procedures. Based on the above observations, the firm is **Not Recommended.**						14	0	5	5	5		4	5	0	24	38
2	51	Meloxicam	15mg Tab	Tab	Maxreta 15mg Tablet	2	2	3		5	2						14	0	5	5	5		4	5	0	24	38
3	52	Meloxicam	7.5mg tab	Tab	Maxreta 7.5mg Tablet	2	2	3		5	2						14	0	5	5	5		4	5	0	24	38
4	59	Paracetamol 500mg	500mg Tab	Tab	Timol 500mg Tablet	2	2	3		5	2						14	0	0	0	0		4	5	0	9	23
5	189	Azithromycin 250mg	250mg tab	Tab	Azereta 250mg Capsule	2	2	3		5	2						14	0	5	5	5		4	5	0	24	38
6	202	Cefepime 500mg	500mg Inj	Inj	Aripime 500mg Injection	2	2	3		5	2						14	0	5	5	5		0	5	0	20	34
7	203	Cefepime 1gm	1GM	Inj	Aripime 1gm Injection	2	2	3		5	2						14	0	5	5	5		0	5	0	20	34
8	207	Cefoparazon Sulbactum 1gm	500mg/500mg	Inj	Cefzed 1gm Injection	2	2	3		5	2						14	0	5	5	5		0	5	0	20	34
9	208	Cefoparazon Sulbactum 2gm	2gm	Inj	Cefzed 2gm Injection	2	2	3		5	2						14	0	5	5	5		0	5	0	20	34
10	209	Cefotaxim sodium	1gm	Inj	Ovicef 1gm Injection	2	2	3		5	2						14	0	5	5	0		0	5	0	15	29
11	210	Cefotaxim sodium	500mg	Inj	Ovicef 500mg Injection	2	2	3		5	2						14	0	5	5	0		0	5	0	15	29
12	217	Ceftriaxone	500mg	Injection	Cefrre 500mg IM Injection	2	2	3		5	2						14	0	5	5	5		0	5	0	20	34
13	217	Ceftriaxone	500mg	Injection	Cefrre 500mg IV Injection	2	2	3		5	2						14	0	5	5	5		0	5	0	20	34
14	218	Ceftriaxone	1gm	Injection	Cefrre 1gm IV Injection	2	2	3		5	2						14	0	5	5	5		0	5	0	20	34
15	219	Ceftriaxone	2gm	Injection	Cefrre 2g IV injection	2	2	3		5	2						14	0	5	5	5		0	5	0	20	34
16	230	Ciprofloxacin	250mg	Tablet	Arrepcin 250mg Tablet	2	2	3		5	2						14	0	5	5	5		4	5	0	24	38
17	231	Ciprofloxacin	500mg	Tablet	Arrepcin 500mg Tablet	2	2	3		5	2						14	0	5	5	5		4	5	0	24	38
18	264	Levofloxacin	250mg	Tablet	Arrefloxacin 250mg Tablet	2	2	3		5	2						14	0	0	0	0		4	5	0	9	23
19	265	Levofloxacin	500mg	Tablet	Arrefloxacin 500mg Tablet	2	2	3		5	2						14	0	0	0	0		4	5	0	9	23
20	268	Linezolid	600mg	Tablet	Zvox 600mg Tablet	2	2	3		5	2						14	0	5	5	0		4	5	0	19	33
21	275	Moxifloxacin	400mg	Tablet	Myflox 400mg Tablet	2	2	3		5	2						14	0	5	5	5		4	5	0	24	38
22	505	Drotaverine	40mg	Tablet	Ryospan 40mg Tablet	2	2	3		5	2						14	0	5	5	5		4	5	0	24	38
23	517	Omerprazole	40mg	Capsule	Ozymap 40mg Capsule	2	2	3		5	2						14	0	0	0	0		0	5	0	5	19
24	518	Esomeprazole	40mg	Injection	Eyzo 40mg Capsule	2	2	3		5	2						14	0	0	0	0		0	5	0	5	19
25	581	Sitagliptin + Metformin	50/500mg	Tablet	M-Silreta 50/500 mg Tablet	2	2	3		5	2						14	0	5	5	0		4	5	0	19	33
26	582	Sitagliptin + Metformin	50/1000mg	Tablet	M-Silreta 50/1000 mg Tablet	2	2	3		5	2						14	0	5	5	0		4	5	0	19	33
27	685	Febuxostat	40mg	Tablet	Arrestat 40mg Tablet	2	2	3		5	2						14	0	5	5	5		4	5	0	24	38
28	753	Pregabalin	50mg	Capsule	Regapen 50mg Capsule	2	2	3		5	2						14	0	5	5	5		0	5	0	20	34
29	754	Pregabalin	75mg	Capsule	Regapen 75mg Capsule	2	2	3		5	2						14	0	5	5	5		0	5	0	20	34

Note: Formulary No of cefotaxim sodium mentioned in PDF is 209 while in the officail formulary it is 211 in Pdf page no 2 e is 209 while in the officail formulary it is 211.
Good declaration of paracetamol is not avaialable while certificate of analaysis is avaialabe on page no 562.
API Source of Cefepime is not available on page no 524 of PDF.
Batch no of Levofloxacin is not clear on page no ge no 630, 632 and 637
API SOURCE OF Linzolide is not avaialable on PDF Page no 525.
GD and API source of Omeprazole and Esomeprazole is not available in the PDF file while COA of both drugs is attached.
API Source of Sitagliptin is not avaialable in PDF File . While API Source of Metformine is attached.
API source for glass container of injection is type 11 USP that's why not full filling criteris for approval
Capsules shells (Immediate conatainer) is not mentioned with pharmaceutical grade , USP, BP, JAPANESE PHARMACOPIA (Page no 747, 748, 749)
IMS and IQVIA Data is not avaialable in the PDF

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: ARSONS PHARMA LAHORE

S. No.		Product General Information				Technical Evaluation Matrix																				
						Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters							Total Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to GMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to GMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection. Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, regs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Emavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). in case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registeration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. Copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this subsome for the respective item.** For award of marks, the certificate of analysis must clearly mention: i. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the QC incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older then twelve (12) months. 0-10% market share = 1 mark 11-20% market share = 2 marks 21-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**5**	**3**	**4**	**5**	**5**	**37**	**70**
	2	Metronidazole	400 mg	Tab.	Arsodazole	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41
	41	Diclofenac Sodium	50 mg	Tab.	Voltrex	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41
	49	Mefenamic Acid	500 mg	Tab.	Armenac	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41
	51	Meloxicam	15 mg	Tab.	Arsocam	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41
	52	Meloxicam	7.5 mg	Tab.	Arsocam	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41
	59	Paracetamol	500 mg	Tab.	Parcol	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41
	65	Paracetamol+Orphenadrine	450 mg/35 mg	Tab.	Arsonadin	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41
	66	Paracetamol+Tramadol	325 mg/37.5 mg	Tab.	Tramadol P	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41
	132	Clotrimazole	500 mg	Tab	Arsizole Vaginal	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41
	137	Fluconazole	150 mg	Cap.	Arsazole	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45
	153	Cetirizine	10 mg	Tab.	Citriclor	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41
	158	Levocetirizine	5 mg	Tab.	Clantin	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	0	5	0	5	31
	160	Montelukast	10 mg	Tab.	Melukast	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41
	189	Azithromycin	250 mg	Tab.	Arsomycin	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	0	5	0	5	31
	190	Azithromycin	500 mg	Tab.	Arsomycin	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	0	5	0	5	31
	230	Ciprofloxacin	250 mg	Tab.	Ciprovac	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41
	231	Ciprofloxacin	500 mg	Tab.	Ciprovac	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41
	251	Doxycycline	100 mg	Cap.	Arsidox	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45
	264	Levofloxacin	250 mg	Tab.	Arsomasin	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41
	265	Levofloxacin	500 mg	Tab.	Arsomasin	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41
	275	Moxifloxacin	400 mg	Tab.	Arsomasin	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41
	300	Artemether+Lumefantrine	40 mg/240 mg	Tab.	Arsomether-L 40/240	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41
	407	Atenolol	50 mg	Tab.	Arsonol	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	0	5	0	5	31
	408	Atenolol	100 mg	Tab.	Arsonol	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	0	5	0	5	31
	503	Domperidone	10 mg	Tab.	Arsomet	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41
	513	Loperamide	2 mg	Cap.	Lopium	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	5	0	9	35
	517	Omeprazole	40 mg	Cap.	Romeprazole	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	5	0	9	35
	518	Esomeprazole	40 mg	Cap.	Reciper	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	0	0	14	40
	522	Pantoprazole	40 mg	Cap.	Tonazole	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45
	864	Clotrimazole 1%	1% 10gm	Cream	Arsiazlin	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45
	870	Fusidic acid	2% 15gm	Cream	Arsibact	2	2	3	0	5	4	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45
	877	Hydrocortisone 1%	1%	Cream	Arsocortisone	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	4	5	0	9	35
	891	Silver Sulfadiazine	1% 50gm	Cream	Bunilax	2	2	3	0	5	4	2	2	2	2	2	26	0	0	0	0	0	0	5	0	5	31

SCRUTINY REPORT

DRAP APPROVED PRICE LIST NOT ATTACHED INSTEAD PRICE LIST ON COMPANY OWN LETTER HEAD IS ATTACHED

EDQM certificate for Metronidazole is attached in API column.

USFDA of Henan Diagtai at page 349 has hidden information hence marks not awarded to diclofenac

Mandatory pictures of immediate container are not attached in the bid.

Levocitercine, azithromycin, loperamide, omeprazole, and hydrocortisone GD and COA are not attached

GD at page 1487 of atenolol is not coupled with Airway bill

Proof of purchase of tablets (ALU-ALU, ALU-PVC) is not matching with invoices

GD of silver sulfadiazine is older than 2 years

Certain submitted documents, including GD, COA, and immediate container-related records of the firm are vague

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposibles and Sutures for Government MCC 2026-27

Name of the firm ARSONS PHARMA LAHORE

Technical Evaluation Matrix

	Product General Information				Factory Technical Evaluation Parameter								Factory Evaluated Score	Product technical Evaluation Parameters						Product Evaluated Score	Total Technical Score
					Documents Based Factory Score				Evaluation Visit Score												
MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. **(as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.**	Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAP regulations. **(to be evaluated by the MCC expert/s at the time of inspection, Noncompliance to cGMP shall lead to disqualification of the relevant section or firm)**	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section / firm.**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection. Non-availability shall lead to disqualification of the section/s or firm).**		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC** **(Certificate Duly attested by Senior Executive of the firm)**	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and / or valid product registration in SRA/WLA country(ies) / and / or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies). In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**3**	**5**	**5**	**6**	**3**	**3**	**2**	**2**	**29**	**5**	**5**	**5**	**6**	**10**	**10**	**41**	**70**
919	Adhesive Tapes (Paper)	1" x 5yards		Arsopore	**3**	**5**	**5**	**4**	**3**	**3**	**2**	**2**	**27**	**0**	**0**	0	**0**	**10**	**10**	**10**	**37**
920	Adhesive Tapes (Paper)	2" x 5yards		Arsopore	**3**	**5**	**5**	**4**	**3**	**3**	**2**	**2**	**27**	**0**	**0**	0	**0**	**10**	**10**	**10**	**37**
921	Adhesive Tapes (Paper)	3" x 5yards		Arsopore	**3**	**5**	**5**	**4**	**3**	**3**	**2**	**2**	**27**	**0**	**0**	0	**0**	**10**	**10**	**10**	**37**
922	Adhesive Tapes (Paper)	4" x 5yards		Arsopore	**3**	**5**	**5**	**4**	**3**	**3**	**2**	**2**	**27**	**0**	**0**	0	**0**	**10**	**10**	**10**	**37**
923	Adhesive Tapes (Plastic)	1" x 10yards		Multipore	**3**	**5**	**5**	**4**	**3**	**3**	**2**	**2**	**27**	**0**	**0**	0	**0**	**10**	**10**	**10**	**37**
924	Adhesive Tapes (Plastic)	2" x 10yards		Multipore	**3**	**5**	**5**	**4**	**3**	**3**	**2**	**2**	**27**	**0**	**0**	0	**0**	**10**	**10**	**10**	**37**
925	Adhesive Tapes (Plastic)	3" x 10yards		Multipore	**3**	**5**	**5**	**4**	**3**	**3**	**2**	**2**	**27**	**0**	**0**	0	**0**	**10**	**10**	**10**	**37**
926	Adhesive Tapes (Plastic)	4" x 10yards		Multipore	**3**	**5**	**5**	**4**	**3**	**3**	**2**	**2**	**27**	**0**	**0**	0	**0**	**10**	**10**	**10**	**37**
1307	Zinc oxide adhesive Plaster (Cloth Tape)	2.5 cm x 5m		Zinco	**3**	**5**	**5**	**4**	**3**	**3**	**2**	**2**	**27**	**0**	**0**	0	**0**	**10**	**10**	**10**	**37**
1308	Zinc oxide adhesive Plaster (Cloth Tape)	5 cm x 5m		Zinco	**3**	**5**	**5**	**4**	**3**	**3**	**2**	**2**	**27**	**0**	**0**	0	**0**	**DTL substandard**	**10**	**0**	**27**
1309	Zinc oxide adhesive Plaster (Cloth Tape)	7.5 cm x 5m		Zinco	**3**	**5**	**5**	**4**	**3**	**3**	**2**	**2**	**27**	**0**	**0**	0	**0**	**10**	**10**	**10**	**37**
1310	Zinc oxide adhesive Plaster (Cloth Tape)	10 cm x 5 m		Zinco	**3**	**5**	**5**	**4**	**3**	**3**	**2**	**2**	**27**	**0**	**0**	0	**0**	**DTL substandard**	**10**	**0**	**27**

SCRUTINY REPORT

TENDER APPROVALS ARE NOT ATTESTED FROM THE PROCURING ENTITY CONCERNED

Certain submitted documents, including GD, COA, and immediate container-related records of the firm are vague

Evaluation Criteria for Manufacturers of Cotton & Related Goods for Government MCC 2026-27

		Name of Firm	ARSONS PHARMA LAHORE																	
S. No.		General Product Information				Technical Evaluation Matrix														
						Factory Technical Evaluation Parameters										Product Evaluation Parameters				
						Documents Based Factory Score						Evaluation visit Score				Factory Evaluated Score			Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body. (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e FY 2023-24 or latest. A minimum turnover of PKR 100 million is required for award of marks in this parameter. (The document shall be attested by a Senior executive of the firm)	Functional and effective Airconditioning & Ventilation System as per the requirements laid down by DRAP **(Evaluated by the MCC expert/s at the time of inspection, Non functionality of the Air Conditioning & Ventilation system in specified section shall lead to disqualification of the section or firm)**	Adequate availability of equipment / instruments in QC labs performing relevant official tests as well as compliance to Good laboratory practices (GLP) in all Labs and Current Good Manufacturing Practices (cGMP) throughout the production facility. **(Evaluated by the MCC expert/s at the time of inspection, Non availability of adequate and appropriate equipment / instruments and non-compliance to GLP , cGMP shall lead to disqualification of the relevant section or firm)**	Appropriate storage of raw material, in process and finished goods with compliance to Good storage practices (GSP) **(To be evaluated by the MCC expert/s at the time of inspection, Non compliance to GSP shall lead to disqualification of the relevant section or firm)**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**3**	**3**	**3**	**4**	**5**	**3**	**6**	**6**	**6**	**6**	**45**	**5**	**10**	**10**	**25**	**70**
	981	Crepe Bandages BPC	7.5cm x 4.5m		Crepe Bandage	**3**	**3**	**3**	**4**	**5**	**3**	**6**	**6**	**6**	**6**	**45**	0	Non Formulary		**0**	**45**
	982	Crepe Bandages BPC	10 cm x 4.5m		Crepe Bandage	**3**	**3**	**3**	**4**	**5**	**3**	**6**	**6**	**6**	**6**	**45**	0	10	10	**20**	**65**
	983	Crepe Bandages BPC	15cm x 4.5m		Crepe Bandage	**3**	**3**	**3**	**4**	**5**	**3**	**6**	**6**	**6**	**6**	**45**	0	DTL Substandard	10	**10**	**55**
	1097	Gauze Cloth Roll packing	100 cm x 20 m		Care Gauze	**3**	**3**	**3**	**4**	**5**	**3**	**6**	**6**	**6**	**6**	**45**	0	10	10	**20**	**65**
	1098	Gauze Cloth Roll packing	100 cm x 40 m		Care Gauze	**3**	**3**	**3**	**4**	**5**	**3**	**6**	**6**	**6**	**6**	**45**	0	10	10	**20**	**65**
	1220	Sterilized Gauze Dressing Pad	10 x 10 x 8 Ply		Care Gauze	**3**	**3**	**3**	**4**	**5**	**3**	**6**	**6**	**6**	**6**	**45**	0	10	10	**20**	**65**

TENDER APPROVALS ARE NOT ATTESTED FROM THE PROCURING ENTITY CONCERNED

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: Atco Laboratories

S. No.	Product General Information				Factory Technical Evaluation Parameters — Documents Based Factory Score						Factory Evaluation Visit Score					Total Factory Evaluated Score	Technical Evaluation Matrix				Product Evaluation Parameters — Product Technical Parameters			Total Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 13485/14501 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body, duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs. • Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection. Non-availability shall lead to**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs countriy (ies) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities) In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/EP guidelines) shall be submitted.	Goods Declaration certificate of Imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources, valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid mail/tele/DRAP clearance NOC between the principal**	Certificate of Analysis of API from the Principal /Manufacturer as mentioned in the goods declaration (GD) provided in column 18i, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 form of undertaking to accompany an application for License to import Drug(s). and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies). **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this colounm for the respective item.** For award of marks, the certificate of analysis must clearly mention: i. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistan market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**5**	**3**	**4**	**5**	**5**	**37**	**70**
	66	Tramadol Hydrochloride + Paracetamol	37.5 /325 mg	Tablet	Dostalgesic	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	**15**	**43**
	96	Tofacitinib	5 mg	Tablet	Jakanz	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	3	**18**	**46**
	125	Prednisone Chloride	1 ml	injection	P-Doxime	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	5	**20**	**48**
	137	Fluconazole	150 mg	Capsule	Fonaz	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	**16**	**44**
	141	ITRACONAZOLE CAPSULES USP	100 mg	Capsule	ITRAZ	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	**16**	**44**
	147	Terbinafine Hcl	250 mg	Forte Tablet	Terbiderm	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	**16**	**44**
	149	Voriconazole	200 mg	Tablet	Vorinaz	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	**15**	**43**
	159	Loratadine	10mg	Tablet	Xytor	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	**15**	**43**
	385	Rivaroxaban	100 mg	Tablet	Revoban	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
	396	Acetyle salicylic Acid	75 mg	Tablet	Aicard	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
	403	Valsartan + Amlodipine	5/80 mg	Tablet	Zeoplus	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
	404	Valsartan + Amlodipine	5/160 mg	Tablet	Zeoplus	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
	405	Valsartan + Amlodipine	10/160 mg	Tablet	Zeoplus	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
	410	Bisoprolol Fumarate	5 mg	Tablet	Aitbeta	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
	411	Bisoprolol Fumarate	10 mg	Tablet	Aitbeta	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
	433	Glyceryl Trinitrate	2.6 mg	Tablet	Cardnit	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	3	18	**46**
	434	Glyceryl Trinitrate	6.4 mg	Tablet	Cardnit	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	3	18	**46**
	448	Lisinopril	5 mg	Tablet	LAME	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	0	0	0	0	0	0	0	0	**28**
	449	Lisinopril	10 mg	Tablet	LAME	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	0	0	0	0	0	0	0	0	**28**
	455	Metaprolol	25 mg	Tablet	Merol	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
	456	Metaprolol	50 mg	Tablet	Merol	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
	457	Metaprolol	100 mg	Tablet	Merol	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
	460	MILRINONE LACTATE	1 mg/ml	Injection	MILRON	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	5	20	**48**
	465	Norepinephrine Bitartarate	4 mg/ml	Injection	Nor-Adrin	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	2	17	**45**
	466	Phenylephrine Hcl	10 mg /ml	Tablet	Synephrine	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	5	0	0	5	2	22	**50**
	471	Rosuvastatin	10 mg	Capsule	Rovator	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
	519	Ondansetron	8 mg	Tablet	Zibkino	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	0	0	0	0	0	0	1	1	**29**
	533	Elemental Zinc sulphate	20 mg /5 ml	Syrup	Zincat OD	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	2	17	**45**
	540	Empagliflozin	10 mg	Tablet	Adrance	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
	541	Empagliflozin	25 mg	Tablet	Adrance	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
	572	Misoprostol	200 mcg	Tablet	Ipsotec	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	15	**43**
	581	Sitagliptin + Metformin	50/500 mg	Tablet	Neoglip	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	5	0	0	5	1	21	**49**
	582	Sitagliptin + Metformin	50/1000 mg	Tablet	Neoglip	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	5	0	0	5	1	21	**49**
	586	Metaglipzin	50 mg	Tablet	Viglip	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	0	0	10	**38**
	719	Duloxetine Hcl	30 mg	Capsule	Dicym DR	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
	753	Pregablin	50 mg	Capsule	Syngab	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	1	5	1	16	**44**
	754	Pregablin	75 mg	Capsule	Syngab	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
	806	Ipratropium Bromide	250 mcg /ml	Injection	Ethi19	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	2	17	**45**
	812	Salbutamol syp	2mg/5ml	Syrup	Bronkol	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
	832	Dorzolamide 2%+Timolol 0.5%	2%+0.5%/5ml	Eye Drop	Glanmim	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
	839	Moxifloxacin	0.5% /5ml	Eye Drop	Oxcin	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
	851	Tobramycin 0.3%	0.3%/5ml	Eye Drop	Bracin	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**
	852	Tobramycin+Dexamethasone	3mg+1mg/ 5ml	Eye Drop	Bracin-D	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	10	**38**
	860	Betamethasone+Gentamycin	012mg+017mg, 15m	Cream	Betagenic	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	0	0	0	0	0	5	1	6	**34**
	861	Betamethasone+Gentamycin	0.5mg+0.1mg+1.5mg	Ointment	Betagenic	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	0	0	0	0	0	5	1	6	**34**
	863	Clobetasol propionate	20 mg	Cream	Clobaderm	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
	870	Fusidic acid 2%	2 %- 15gm	Cream	Fulas	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	0	0	0	0	0	0	0	17	**45**
	885	Permethanin 5%	5 % - 30gm	Cream	Scabfree	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	2	17	**45**
	886	Permethanin 5%	5 % - 60ml	lotion	Scabfree	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	2	17	**45**
	887	Bcitracin.+Polymaxin+ B.sul. Neo, Lido	500unit+500unit+3.5 mg+40.0mg	Ointment	Healit	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	0	0	0	0	0	0	2	2	**30**
	894	Terbinafine Hcl 1%	1%- 10gm	Cream	Terbiderm	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
	895	Terbinafine Hcl 1% W/V	1% W/V - 20ml	Topical Solution	Terbiderm	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
	899	Chlorhexidine Gluconate	10gm	Gel	Limbitica	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	1	16	**44**
	914	Cholecalciferol	1ml	Injection	D-All	**2**	**2**	**3**	**5**	0	**6**	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	0	5	0	15	**43**

Scrutiny Report

Proof of purchase/invoice is not attached for immediate container for quoted items in the bid

IMS/IQVIA share of the quoted item for LAME is not provided in the original bid

IMS/IQVIA share of the LENAIDO could not be verified from the bid, due to affixed stamp on respective page No. 232

IMS/IQVIA share of the product CAPCITAB, EC40MASIN is not provided in the original bid

Calibration certificates are attached for Stability chamber and Hygrometer only no supporting document for instruments used in in-Process, Raw material assays or Finished products is attached in the bid

Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs countriy (ies) is not provided in the bid

GD is not available for Healit (Lidocaine) provided at page No. 3081-3082

GD and COA of the Capcitab is not matchable provided in the bid at page No. 3371

GD of Betagenic cream attached at page No. 2680 is not readable

GD and COA of the Gentamicine in Betagenic ointment is not matchable provided at page No. 2690

GD and AWB o f Lenaldo is not clear povided in the original bid

GD of Exemestin is missing provided at page No. 3500

Air Way bill for LAME provided at page No. 1057 and 1119 is not readable

GD is not coupled with AWB or BL for the quoted product UBKINO attached at page No. 1637-1689

No stability data has been provided for UBKINO in the original bid Page No. 1637-1689

GD/COA for ACULELTZ has not been provided in the original bid

Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) is not provided in the bid

Valid WHO prequalification or Valid product registration in SRA/WLA country(ies) is not provided in the bid

Vallid Proof of purchase/ invoice for immediate continer has not been provided in the bid

TECHNICAL EVALUATION PROFORMA, FOR PROCUREMENT OF ANTICANCER MEDICINES IN GOVT. MCC FY 2026-27

Name of the firm with Complete Address

Manufacturer / Importer

		Mandatory Requirements.	YES / NO		In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:		YES/NO		In case of being Importers, the Firm should provide attested copies of the following documents also:		YES/NO	
1		National Tax Number (NTN) of the Firm for Income Tax, and			1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and		1	Valid Drugs Sales License for the importer; and			
2		Last year Income Tax Return of the Firm; and			2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.		2	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and			
3		Sale Tax Registration Certificate of the Firm; and			3	Valid DRAP Approved Price List of the quoted item/s.		3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and			
4		Certificate of Professional Tax of the Firm.						4	Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods/s, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and			
5		Certificate of compliance to cold chain requirements from independent third party e.g. DRAP, PSQCA, PCSIR. Non-Compliance to international reference standards or absence of Cold Chain requirements shall lead to disqualification of the relevant product that requires cold chain.						5	Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods/s. Non provision of this document shall lead to disqualification of the firm; and			
								6	Valid DRAP approved Price List of the quoted items.			

		Technical Evaluation Parameters			Active Pharmaceutical Ingredient source gradation (For API or finished product). i) The bidder (local manufacturer / multi-national manufacturer / importer) shall provide Analytical/Quality Assurance/ Approved Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades. Certificate of Analysis/ Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreement/ approval with the original manufacturer duly verified/attested by official of the company. Detailed purchase trail of the Active Pharmaceutical Ingredient/ Finished product from the claimed source must be submitted (any proof of purchase such as Goods Declaration Certificate along with Airway Bill/ Bill of Lading/Invoice etc.) by the bidder. Maximum marks for this criterion are 40.		Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW) study Certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities)/ WHO Listed Authorities WLA Countries OR BE/ BS Certificate with evidence as to its authenticity) from Category A countries. OR Bio-Equivalence (BE) of the quoted product to be conducted against the originator. Original Innovator products do not require bio- equivalence certificate and shall get 10 marks automatically.The bidder shall provide the documents to establish the proof of inventor / originator. All other branded generics require BE studies. Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid. Maximum marks for this criterion are 10.			Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug. In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article) Mandatory: Online verification link must be provided to verify the Clinical Trial/ Clinical Studies submitted for the quoted items.		Factory/ Importer-Based Evaluation Score (MANDATORY)	Sample Evaluation by End User Committee Samples will be examined per following parameters as follows: a. Labeling and Packing Rules 1986 b. Outer packing c. Inner packing d. Physical appearance. Product which has unsatisfactory packing/labeling will be technically Disqualified. Maximum score for this criterion is 1.		Post Performance (Last two years). i) Good Performance Certificates of these institutions must be produced in order to be eligible for 5 mark per institution upto a maximum of 5 marks. ii) Only supply orders will not get any marks. iii) The bidders have to undertake that they have never been blacklisted or debarred. Maximum marks for this criterion are 5. iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.	Total Technical Score
					Category A – Approved By: • United States Food & Drug Administration (USFDA) • European Medicines Agency (EMA) • Medicines & Healthcare Products Regulatory Agency (MHRA), UK • Therapeutic Goods Administration (TGA), Australia • Pharmaceutical Medical Agency (PHARMAC), New Zealand • Pharmaceutical & Medical Devices Agency (PMDA), Japan • Swissmedic Agency For therapeutic drugs (swissmedic), Switzerland • Health Canada • Health Sciences Authority (HAS), Singapore • National Administration of Drugs, Food & Medicines (ANMAT), Argentina Drug Regulatory Authorities of the FRA (Stringent Regulatory Authorities) / WHO Listed Authorities WLA countries.	Category B – Approved By: • Agência Nacional de Vigilância Sanitária (ANVS), Brazil • Central Drugs Standard Organization (CDSCO), India • Drug Regulatory Authority, Pakistan • National Pharmaceutical Control Bureau (NPCB), Malaysia • Food & Drug Administration, South Korea • Ministry of Health, Egypt • Ministry of Health, KSA • China Food & Drug Administration • Any other source not mentioned in Category-A	Study/Certificate conducted/verified by a Category A Drug Regulatory Authority. BE testing must be done using at least 12 subjects. Bio-waiver is acceptable only for products listed in Category A Country.	Bio-BE/BW certificate obtained for a quoted product from a Category B country mentioned at S No. 2 above.	Bio-BE/BW certificate.	In case the study is published in Category "A" journal listed in HEC Journal Recognition System (HJRS) Database (HJRS-ID) Notification Policy 2024 and List of National Recognized Research Journals per HEC, 3 marks per original research article shall be awarded (maximum up to 6 marks).	In case the study is published in Category "A" journal listed in HEC Journal Recognition System (HJRS) Database (HJRS-ID) Notification Policy 2024 and List of National Recognized Research Journals as per HEC, 2 marks per original research article shall be awarded (maximum up to 6 marks).	Bioequivalent/ waiver certificate not category "A" approved of the HJRS Journals Notification Policy 2024 and List of National Recognized Research Journals as per HEC shall not be awarded marks.	For Physical inspection of the premises of the bidders the Technical Evaluation Committee shall be carried out in accordance with the Rule 25(4)(b), 3(2) & (3), 3(3)(c) & (d), 3(4)(b) & (c) of the Khyber Pakhtunkhwa Public Procurement Regulatory Authority Ordinance, 2014 read with Rule 25(4)(b), 3(2) & (3), 3(3)(c) & (d), 3(4)(b) & (c) of the Khyber Pakhtunkhwa Public Procurement Regulatory Authority Rules, 2020 and the Standard Operating Procedures (SOPs) issued by the Authority vide Notification No. PPRA/Secy/SOPs/2021/1 dated 15th June, 2021 and Notification No. PPRA/Secy/SOPs/2021/2 dated 15th June, 2021 and Notification No. PPRA/Secy/SOPs/2021/3 dated 15th June, 2021 and Notification No. PPRA/Secy/SOPs/2021/4 dated 15th June, 2021 and Notification No. PPRA/Secy/SOPs/2021/5 dated 15th June, 2021 and Notification No.

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: ATLANTIC , KARACHI

S. No.	Product General Information					Technical Evaluation Matrix																		
						Principal's and Importer's Evaluation Parameters								Suppliers Technical Score	Product Technical Evaluation							Product Availability	Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation					Importer's Evaluation				Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
						Valid ISO 14001:4245 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid accreditation of manufacturing unit in relevant sections by the US-FDA or official accreditation body/ies regulatory body in the case of SRA/WLA countries duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **Valid Calibration Certificates attested by Quality head of the firm).**	Availability of maximum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the store house at the time of inspection of the inspector shall lead to disqualification of the quoted item/s / firm).**	Adherence to Good Storage practices (GSP) for storage of finished goods. Functional and effective Air-conditioning & Ventilation System and effective cold chain (thermo-tubble-drugs). The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales/ Rules/ Medical Device Rules/Regulations framed by the DRAP. **Nonadherence to GSP, as evaluated by the MCC experts at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, Presence of Category-A Pharmacist/s (one mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC experts at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/Body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for at least 3 marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 1L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Letter of inventor / innovator products from relevant body shall be provided where the firm claims that the biosimjsoviknce / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill/ at Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for the conduct of field. **In case of purchase through third party/ importers a valid trail/link/DRAP clearance NOC between the principal manufacturer & the importer/firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 15, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (API/s) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies). Detail of principal manufacturer shall be established from the respective GD. CoA and other supporting documents. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA country(ies) / Valid free-sale certificate issued by regulatory body of any SRA/WLA country(ies) and / or Valid certificate of the availability of the quoted item in the US market. **04 marks shall be awarded to the Primary certificate, and 1 mark for additional certificate, up to a maximum of 06 (04+01+01) marks.** **Certificates on company's own letter heads shall not be acceptable.** **Copies of relevant certificates duly attested by the senior executive of the firm).** **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / ions of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, or other pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. Marks shall be awarded in the following manner: 02 Tender approvals= 01 mark 04 Tender approvals= 02 marks 06 Tender approvals= 03 marks 08 Tender approvals= 04 marks 10 or more Tender approvals= 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Stability studies of quoted item/s duly attested by the QC incharge of the firm/s	Availability of quoted item/s in Pakistani market as per recent/ most data of MHRD/EVA/ Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks. For items specifically used in institutions/ where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals= 01 mark 04 Tender approvals= 02 marks 06 Tender approvals= 03 marks 08 Tender approvals= 04 marks 10 or more Tender approvals= 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**2**	**5**	**5**	**4**	**5**	**5**	**30**	**5**	**5**	**5**	**5**	**6**	**4**	**5**	**5**	**40**	**70**
	Purified Vero Cell Rabies Vaccine (PVRV)			Inj.	Rabio	0	**2**	**0**	0	**5**	**4**	**5**	**5**	**21**	**0**	**5**	**5**	0	**0**	0	5	0	**15**	**36**

SCRUTINY REPORT

1 ISO 45001 NOT ATTACHED IN THE BID

IMMEDIATE CONTAINER PICTURES NOT UPLOADED. HENCE MARKS NOT AWARDED

CGMP IS NOT EMBASY ATTESTED /APPOSTILE AT PAGE 69

THAILAND GDMP IS ATTACHED FOR UNIT ACCREDITATION WHICH DOES NOT FULFILL THE CRITERIA FOR THE AWARD OF MARKS AT PAGE 93

ISO 9001 AT PAGE 91 IS NOT VERIFIABLE ONLINE. HENCE MARKS NOT AWARDED

TENDER APPROVALS ATTACHED AT PAGE 181 & ONWARDS ARE NOT FULFILLING THE CRITERIA FOR THE AWARD OF MARKS

THE DOCUMENTS ATTACHED AT PAGE 180 IS ONLY FOR RESEARCH PURPOSE WITH A VALUE OF 10 DOLLARS ONLY AND DOES NOT FULFILL ANY CRITERIA FOR THE AWARD OF MARKS

CLINICAL STUDY ATTACHED AT PAGE 134 IS ON COMPANYS OWN/N LETTER HEAD HENCE DOES NOT FULFILL THE CRITERIA FOR THE AWARD OF MARKS

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27														
					Name of the firm															
						Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevent certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
	946	Blood transfusion Set	minimum 125cm		Sangofix	3	5	5	5	6	6	**30**	5	5		1	2	16	24	29
	1075	Epidural Kit	G18		Perifix G18	3	5	5	5	6	6	**30**	5	5		1	2	16	24	29
	1044	Disposable Spinal Needle	G20		Spinocan G20	3	5	5	5	6	6	**30**	5	5		1	2	16	24	29
	1045	Disposable Spinal Needle	G22		Spinocan G22	3	5	5	5	6	6	**30**	5	5		1	2	16	24	29
	1046	Disposable Spinal Needle	G23		Spinocan G23	3	5	5	5	6	6	**30**	5	5		1	2	16	24	29
	1047	Disposable Spinal Needle	G25		Spinocan G25	3	5	5	5	6	6	**30**	5	5		1	2	16	24	29
	1048	Disposable Spinal Needle	G27		Spinocan G27	3	5	5	5	6	6	**30**	5	5		1	2	16	24	29

						Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27														
					Name of the firm	BBRaun Karachi													
S. No.		Product General Parameter				Technical Evaluation Matrix												Product Evaluated Score	Total Technical Score
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the time of inspection at the warehouse at the tim eof inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** **(Certificate duly attaested by senior executive of the firm)**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note, Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US free sale certificate of the quoted products, **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **Online verification link shall be provided.** **(copies of relevant certificates duly attested by the senior executive of the firm)**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	5	6	**29**	5	5	5	6	10	10	**41**	**70**
	1123	I/V Cannula with Inj Port	G18		Vasofix G18	3	5	5	5	5	6	**29**	5	5		2	DTL substandard	10	**22**	**51**
	1124	I/V Cannula with Safety Clip	G18		Vasofix Safety G18	3	5	5	5	5	6	**29**	5	5		2	10	10	**32**	**61**
	1126	I/V Cannula with Inj Port	G20		Vasofix G20	3	5	5	5	5	6	**29**	5	5		2	10	10	**32**	**61**
	1127	I/V Cannula with Safety Clip	G20		Vasofix Safety G20	3	5	5	5	5	6	**29**	5	5		2	10	10	**32**	**61**
	1129	I/V Cannula with Inj Port	G22		Vasofix G22	3	5	5	5	5	6	**29**	5	5		2	10	10	**32**	**61**
	1130	I/V Cannula with Safety Clip	G22		Vasofix Safety G22	3	5	5	5	5	6	**29**	5	5		2	DTL substandard	10	**22**	**51**
	1134	I/V Cannula with Heparin Cap	G24		Introcan G24	3	5	5	5	5	6	**29**	5	5		2	10	10	**32**	**61**
	1232	Stopcock 3 Way with Ext			Discofix Tubing	3	5	5	5	5	6	**29**	5	5		2	10	10	**32**	**61**

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: BAYER, KARACHI

S. No.		Product General Information				Technical Evaluation Matrix																			
						Principal's and Importer's Evaluation Parameters								Suppliers Technical Score	Product Technical Evaluation								Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation					Importer's Evaluation				Product Technical Parameters							Product Availability			
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
						Valid ISO 18001/45001 certificate of the facility/ manufacturing site of the manufacturer issued/renewed by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility/ manufacturing site of the manufacturer issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility/ manufacturing site of the manufacturer issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid accreditation of manufacturing unit from any stringent regulatory body (US FDA, MHRA) or accreditation body/ies /regulatory body in the case of SRA/WLA countries (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid calibration certificates for equipment/instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Availability of minimum 20% inventory of the quoted items, manufactured during last one year (certificate to this effect duly signed by the senior executive of the firm & evaluated by the MCC experts). **Non availability of the 20% stock at the time of factory/ site inspection of the importer shall lead to disqualification of the quoted item/ firm)**	Adherence to Good storage practices (GSP) for storage of finished goods (Validated and effective Air-conditioning & Ventilation System and effective cold chain (thermo-labile drugs). The physical inspection committee/ MCC experts shall verify the compliance in the light of WHO-GSP, SRA/WLA criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Nonadherence to GSP, as evaluated by the MCC experts at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, Pharmacist (Category-A Pharmacist's is not mandatory), & relevant Human Resource **Certified by the senior executive of the firm & evaluated / confirmed by MCC experts at the time of inspection. Non-compliance to this parameter shall lead to disqualification of the firm).**		Bioavailability/ Bioequivalence study conducted by WHO prequalified labs, available on WHO Website/ US-FDA/ EMA/ MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies). and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 1000ml, bio-equivalence studies as per WHO/US-FDA/USP guidelines shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported quoted item duly verified by the Customs, supplied with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of purchases through third party/importers, the valid mail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of finished quoted item from the principal manufacturer duly nominated in the goods declaration/GD provided in column 15, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredients (API) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies). Trail of principal manufacturer shall be established from the respective GD, CoA and other supporting documents. Moreover, in case of product/quoted item having multiple APIs, the marks for this CoA, the information/ documents shall be awarded only if all APIs documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation/ certificate, the accreditation/ certificate shall be considered valid only if it was issued within the last Two (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA country(ies) / Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies). and / or Valid certificate of the availability of the quoted item in the US market. **04 marks shall be awarded to the Primary certificate, and 1 mark for additional certificate, up to a maximum of 05 (04+01=05) marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non-provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: i. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical Grade. ii. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). iii. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** iv. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 2 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm)**	Stability studies of quoted item/s duly attested by the QC incharge of the firm).	Availability of quoted item/s in Pakistan market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. Marks: 0-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 12 Tender approvals= 01 mark 06 Tender approvals= 02 marks 96 Tender approvals= 03 marks 88 Tender approvals= 04 marks 50 or more Tender approvals =05 marks Note, Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entities against the supply, etc. The bidder shall submit copies of respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**2**	**5**	**5**	**4**	**5**	**5**	**30**	**5**	**5**	**5**	**5**	**6**	**4**	**5**	**5**	**40**	**70**
	484	Levonorgestrel	75mg	Implant	Jadelle Inserter Impant	0	**2**	0	**5**	0				**7**	**5**	0	0	0	**4**	0	0	0	**9**	**16**

GD is not coupled with airway bill
TENDER APPROVALS ARE NOT ATTESTED FROM THE PROCURING ENTITY CONCERNED
Original Mandatory forms in Hard are not submitted to the MCC

The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents [DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COPQ] for the quoted items were checked, and following observations were made;

1. Bayer Oy Finland: Valid Original Agency Agreement, Valid original cGMP and Valid free sale certificate of all the quoted items duly attested from the embassy concerned were NOT present at the time of inspection.

2. 20% Inventory of the quoted items, adequate qualified HR, Cold Chain facility, Good Storage practices and SOPs for expiry management were satisfactory/present at the time of inspection.

In view of the above the firm is NOT-RECOMMENDED for the award of marks in importer's evaluation parameters for the quoted items.

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2025-26

Name of Firm

S. No.	Product General Information				Technical Evaluation Matrix																		
					Principal's and Importer's Evaluation Parameters									Product Technical Evaluation									
					Principal Manufacturer Evaluation					Importer's Evaluation			Suppliers Technical Score	Product Technical Parameters							Product Availability	Product Evaluated Score	Total Technical Score
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with international Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or WHO or official accreditation body/ies /regulatory body in the case of SRA countries (duly attested by senior executive of the firm)	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the ware house at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good storage practices (GSP) for storage of finished goods. Functional and effective Air-conditioning & Ventilation System and effective cold chain (thermo-labile drugs). **Nonadherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is/are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and/or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and/or In case of Large volume parenteral (>100ml to 5L as per USP) product validation report shall be submitted. and/or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / biosimilarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facility, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 15, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	API/s source accredited by WHO, US-FDA, EMA, MHRA, TGA, PMDA, Swiss Medic or Health Canada or by regulatory authority of SRAs countries. Trail of principal manufacturer shall be established from the respective GD. CoA and other supporting documents. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) / Valid free sale certificate issued by regulatory body of any SRA country(ies) and / or Valid certificate of the availability of the quoted item in the US market. 2 mark for each certification, up to a maximum of 06 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with invoice/proof of purchase: For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent imost data of IMS/IQVIA Health. Less than 5 % market share = 0 mark 5-10% market share = 01 mark 11-30% market share = 02 marks 31-50% market share = 03 marks 50% and above market share = 05 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than 2 years) from other Secondary & Tertiary Govt. Hospitals outside Khyber Pakhtunkhwa or JCI accredited private entities/hospitals of other provinces of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks **Note.** **Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications /**		
	Ref. No. of item in MCC formulary	Generic Name of Item	Dosage Form with Strength	Trade Name	**2**	**2**	**2**	**5**	**5**	**4**	**5**	**5**	**30**	**5**	**5**	**5**	**5**	**6**	**4**	**5**	**5**	**40**	**70**
													0									**0**	**0**

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: Biogen Life Sciences, Plot #260 Industrial Triangle, Kahuta Road, Islamabad, 8km Chakbeli Road, Rawat, Rawalpindi, Phone: 0303-5553493

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters									Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters										
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP), in area / section of the quoted product (s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be	Goods Declaration certificate of imported API of the quoted items/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this colounm for the respective item.** For award of marks, the	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
	47	Ketorolac	30mg	Injection	Biolec	2	2	3	0	5	2	The inspection team during inspection made following observations; Compromised cGMP Non adherence to QC procedure • Several raw material items were observed without proper identification labels, including quarantine labels, while several items were found with incorrect labelling. • The calibration status of the instrument in the RMS quarantine area had expired on 14.04.2026. • Wrong expiry dates were mentioned on labelling of Sodium Meta Bisulphate. • Released status labels were found missing in the designated released area. • The calibration validity of the thermo hygrometer installed in the RMS expired in 12/2025. • The air conditioning system in the raw material store was found non-functional at the time of inspection. • The pressure gauges installed on the dispensing booths in both the general and steroid sections were found non-functional. • The calibration validity of the hotplate/stirrer had expired. • Trial items placed in the stability chamber were found without proper identification labels. • An expired working standard was observed in the Quality Control area. • Certain refrigerated items in the Quality Control department were found without expiry information/details. • Several equipment items were found operating without valid calibration status. • The overall cleanliness and housekeeping of the facility were found unsatisfactory and not in compliance with GMP requirements. • Vials stored in the in-process quarantine area were found covered with dust. • Several in-process products were observed without proper identification labels, indicating inadequate compliance with Good Manufacturing Practices (GMP). • Broken wall / floor corners were observed at multiple places. • Look alike vials of different items were kept in the in-process room without proper labelling. **Based on the above observations the firm is Not Recommended**	**14**	0	0	0	0	0	0	0	0	**0**	**14**
	56	Nalbuphine HCL	10mg/ml	Injection	Nabal	2	2	3	0	5	2						**14**	0	5	5	0	0	0	0	0	**10**	**24**
	57	Nalbuphine HCL	20mg/ml	Injection	Nabal	2	2	3	0	5	2						**14**	0	5	5	0	0	0	0	0	**10**	**24**
	66	Paracetamol + Tramadol	37.5/325mg	Tablet	Paratrol-T	2	2	3	0	5	2						**14**	0	0	0	0	0	0	0	0	**0**	**14**
	147	Terbinafine HCL	250mg	Tablet	Terbigen	2	2	3	0	5	2						**14**	0	0	0	0	0	0	0	0	**0**	**14**
	204	Cefexime	400mg	Capsule	Cefebio	2	2	3	0	5	2						**14**	0	0	0	0	0	0	0	0	**0**	**14**
	205	Cefexime	100mg	Suspension	Cefebio (without water)	2	2	3	0	5	2						**14**	0	0	0	0	0	0	0	0	**0**	**14**
	206	Cefexime	200mg	Suspension	Cefebio (without water)	2	2	3	0	5	2						**14**	0	0	0	0	0	0	0	0	**0**	**14**
	207	Cefaperazon + Salbactum	1g	Injection	Bio-Bactum	2	2	3	0	5	2						**14**	0	5	5	0	0	0	0	0	**10**	**24**
	208	Cefaperazon + Salbactum	2g	Injection	Bio-Bactum	2	2	3	0	5	2						**14**	0	5	5	0	0	0	0	0	**10**	**24**
	217	Ceftrixone Sodium	500mg	Injection	Ceftigen	2	2	3	0	5	2						**14**	0	5	5	0	0	0	0	0	**10**	**24**
	218	Ceftrixone Sodium	1g	Injection	Ceftigen	2	2	3	0	5	2						**14**	0	5	5	0	0	0	0	0	**10**	**24**
	219	Ceftrixone Sodium	2g	Injection	Ceftigen	2	2	3	0	5	2						**14**	0	5	5	0	0	0	0	0	**10**	**24**
	272	Meropenem	500mg	Injection	Biopene	2	2	3	0	5	2						**14**	0	5	5	0	0	0	0	0	**10**	**24**
	273	Meropenem	1g	Injection	Biopene	2	2	3	0	5	2						**14**	0	5	5	0	0	0	0	0	**10**	**24**
	275	Moxifloxacin	400mg	Tablet	Floxagen	2	2	3	0	5	2						**14**	0	0	0	0	0	0	0	0	**0**	**14**
	516	Omeprazole	40mg	Injection	Bio-Om	2	2	3	0	5	2						**14**	0	5	5	0	0	0	0	0	**10**	**24**
	557	Hydrocortisone	100mg	Injection	Succigen	2	2	3	0	5	2						**14**	0	5	5	0	0	0	0	0	**10**	**24**
	558	Hydrocortisone	250mg	Injection	Succigen	2	2	3	0	5	2						**14**	0	5	5	0	0	0	0	0	**10**	**24**
	647	ORS	Sodium Chloride 2.6g/L, Glucose anhydrous 13.5g/L	Sachet	Aggen	2	2	3	0	5	2						**14**	0	0	0	0	0	0	0	0	**0**	**14**
	894	Terbinafine HCL	10mg	Cream	Terbigen 1%	2	2	3	0	5	2						**14**	0	0	0	0	0	0	0	0	**0**	**14**
	895	Terbinafine HCL	20ml	Lotion	Terbigen 1%	2	2	3	0	5	2						**14**	0	0	0	0	0	0	0	0	**0**	**14**

Scrutiny report
1CoAs of packing material attached at page 104-112 are not done by pricipal manufacturer of the immediate container
2Images / Pictures of DRAP approved packaging are not present in the bid.
3Page 169 Terbinafine- only COA is attached. No GD attached.
4On Page 207, and 172- CoAs for Moxifloxacin and Cefixime are attached respectively but invoices in its support are not present.
5GDs and CoAs of all ingredients if ORS are not present in the bid
6Stability studies for all quoted items are not provided.
7IMS data/ranking not present.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: BIO LABS PVT LTD

S. No.		Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured , issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
Drap registration																											
73089	1	**4**	Metronidazole	500mg	Inf.	METROZOLE	2	2	3	2	5	6	2	2	2	2	2	**30**	0	0	0	0	0	0	5	0	**5**	**35**
84344	2	**47**	Ketorolac	30mg/ml	Inj.	BIOROLAC	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	**19**	**49**
84339	3	**56**	Nalbuphine	10mg	Inj.	BIO-NAL PLUS	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	5	0	4	5	0	**24**	**54**
Drap registration	4	**63**	Paracetamol	1000mg	Inf.	Cetozek	2	2	3	2	5	6	2	2	2	2	2	**30**	0	0	0	0	0	4	5	0	**9**	**39**
63401	5	**68**	Tizanidine	4mg	Tab.	ZADIN	2	2	3	2	5	6	2	2	2	2	2	**30**	0	0	0	0	0	0	5	0	**5**	**35**
46308	6	**76**	Mebendazole	100mg/5ml	Susp.	Mebzole 30ml	2	2	3	2	5	6	2	2	2	2	2	**30**	0	0	0	5	0	0	5	0	**10**	**40**
Drap registration	7	**148**	Voriconazole	200mg	Inj.	Voritic	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	**19**	**49**
115363	8	**149**	Voriconazole	200mg	Tab.	Voritic	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	**19**	**49**
46099	9	**160**	Montelukast	10mg	Tab.	MONEST	2	2	3	2	5	6	2	2	2	2	2	**30**	0	0	0	0	0	0	5	0	**5**	**35**
46100	10	**161**	Montelukast	5mg	Tab.	MONEST	2	2	3	2	5	6	2	2	2	2	2	**30**	0	0	0	0	0	0	5	0	**5**	**35**
54771	11	**204**	Cefixime	400mg	Cap.	BIOZIL	2	2	3	2	5	6	2	2	2	2	2	**30**	0	0	0	0	0	0	5	0	**5**	**35**
54769	12	**205**	Cefixime	100mg/5ml	Dry Susp.	BIOZIL	2	2	3	2	5	6	2	2	2	2	2	**30**	0	0	0	0	0	4	5	0	**9**	**39**
54770	13	**206**	Cefixime	200mg/5ml	Dry Susp.	BIOZIL	2	2	3	2	5	6	2	2	2	2	2	**30**	0	0	0	0	0	4	5	0	**9**	**39**
54580	14	**207**	Cefoperazone + Sulbactam	1gm/Vial	Inj.	Parazactam	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	0	5	0	**15**	**45**
54851	15	**208**	Cefoperazone + Sulbactam	2gm/Vial	Inj.	Parazactam	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	0	5	0	**15**	**45**
Drap registration	16	**217**	Ceftriaxone	500mg/Vial	Inj.	TUFF	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	0	5	0	**15**	**45**
Drap registration	17	**218**	Ceftriaxone	1gm/Vial	Inj.	TUFF	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	0	5	0	**15**	**45**
111071	18	**219**	Ceftriaxone	2 gm Vial	Inj.	TUFF	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	**19**	**49**
012072-Ex	19	**243**	Colistin	2 MIU/vial	Inj.	Contram 6omg (3MIU), 2omg (1MIU), 10mg	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	5	0	4	5	0	**24**	**54**
82407	20	**244**	Colistin	1 MIU/vial	Inj.		2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	5	0	0	5	0	**20**	**50**
Drap registration	21	**294**	Tigecycline	50 mg /Vial	Inj.	TIGABIO	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	0	5	0	**15**	**45**
75190	22	**295**	Vancomycin	500 mg/Vial	Inj.	MYVAN	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	0	5	0	**10**	**40**
75191	23	**296**	Vancomycin	1gm/Vial	Inj.	MYVAN	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	0	5	0	**15**	**45**
73084	24	**375**	Iron Sucrose	20 mg/ml	Inj.	IROPAS	2	2	3	2	5	6	2	2	2	2	2	**30**	0	0	0	0	0	0	5	0	**5**	**35**
48069	25	**454**	Methyldopa	250 mg	Inj.	Bimet	2	2	3	2	5	6	2	2	2	2	2	**30**	0	0	0	0	0	4	0	0	**4**	**34**
75061	26	**516**	Omeprazole	40 mg / Vial	Inj.	Acichek	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	5	0	4	5	0	**24**	**54**
Drap registration	27	**517**	Omeprazole	40 mg	Inj.	Acichek	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	5	0	0	5	0	**20**	**50**
46302	28	**518**	Esomeprazole	40mg	Cap.	E-ZOLE	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	0	0	0	**10**	**40**
93251	29	**519**	Ondansetron	8 mg	Tab.	Vemtix	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	0	0	0	**10**	**40**
77812	30	**894**	Terninafine	1%	Cream	Funasoie	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	0	0	0	**10**	**40**
121492	31	895	Terninafine	20ml	Lot.	Funasole	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	0	0	0	**10**	**40**
9325	32	1585	Ondansetron	8mg	Inj.	Vemtix 8mg/4ml	2	2	3	2	5	6	2	2	2	2	2	**30**	0	0	0	0	0	0	5	0	**5**	**35**

Scrutiny Report

DRAP Registration number of Inj Cetrozek 1000mg is attached in the PDF. Inj cetrozek 10mg is attcahed only.
DRAP Registration number of Inj Cetrozek 1000mg is attached in the PDF. Inj cetrozek 10mg is attcahed only.
DRAP Registration of Inj Verotic 200mg is not attached in PDF
DRAP Registration if Inj TUFF 500mg and TUFF inj 1gm is not attached in PDF
DRAP Registration of inj Tigabio is not attached in PDF.
DRAP Rgestration of Capsule Achichek 40mg is not attached in PDF.
GD of Mebendazole is not clear with tha airway bill so marked as zero in GD and COA.
Iron sucrose: Page no 411 the GD Source of raw material is Sambolife pharma while in COA the firm mentined is Global Calcium.
Tizanidine ZADINE packing material picture is not available in PDF.
Mebzole suspension: bottle specifications are not avaialable in PDF While picture of paking material (package) is available.
Metrozol pakage picture is not attached.
Cap Biozil and Cap Acichek 40mg : immediate container capsule shell specifications, GD AND COA is not attached in PDF.
Cap Ezole : Immediate container capsue shell is not attached in PDF.
INJ PRAZACTUM
COLICRAFT IN2: Picture of pkaging material is not available in PDF.
MYVEN INJ 500MG: PICTURE OF CONTAINER IS NOT ATTACHED IN PDF.
VEMTEX 8MG IN2: Specification of ampules are not attached in PDF.
GD and COA of ointment and lotion containeres are not attached.
CTUM 1GM AND 2GM: Pictur of pakaging material is not attached.
Original Mandatory forms in Hard are not submitted to the MCC.
Bidding firm name not mentioned on the mandatory CDR

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm — RF BIOSCIENCES LAHORE

S. No.		Product General Information				Technical Evaluation Matrix																						
						Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters									Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters										
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 13485:2016/ ISO 14001:2015 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Months) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to GMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. Copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP-class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better (**Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the Q.C. (incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA. Wealth not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**5**	**3**	**4**	**5**	**5**	**37**	**70**
	47	Ketorolac Tromethamine 30	30mg/ml	Inj.	**Kedol**	**2**	**2**	**3**	**4**	**5**	6	**2**	**2**	**2**	**2**	**2**	**32**	0	**5**	**5**	0	0	4	5	0	**19**	**51**
	69	Tramadol Hydrochloride	50mg/ml	Inj.	**Tramafer**	**2**	**2**	**3**	**4**	**5**	6	**2**	**2**	**2**	**2**	**2**	**32**	0	**5**	**5**	0	0	4	5	0	**19**	**51**
	85	Filgrastim 300mcg	300mcg	Inj.	**Filgen**	**2**	**2**	**3**	**4**	**5**	6	**2**	**2**	**2**	**2**	**2**	**32**	0	**5**	**5**	5	0	4	5	5	**29**	**61**
	148	Voriconazole 200mg	200mg	Inj.	**Vorif**	**2**	**2**	**3**	**4**	**5**	6	**2**	**2**	**2**	**2**	**2**	**32**	0	**5**	**5**	0	0	4	5	1	**20**	**52**
	191	Azithromycin 500mg	500mg	Inj.	**Azobar**	**2**	**2**	**3**	**4**	**5**	6	**2**	**2**	**2**	**2**	**2**	**32**	0	**5**	**5**	0	0	4	5	1	**20**	**52**
	321	Acyclovir 250mg	250mg	Inj.	**Acylex**	**2**	**2**	**3**	**4**	**5**	6	**2**	**2**	**2**	**2**	**2**	**32**	0	**5**	**5**	0	0	4	5	5	**24**	**56**
	322	Acyclovir 500mg	500mg	Inj.	**Acylex**	**2**	**2**	**3**	**4**	**5**	6	**2**	**2**	**2**	**2**	**2**	**32**	0	**5**	**5**	0	0	4	5	5	**24**	**56**
	350	Enoxaparin Sodium 20mg	20mg	Inj.	**Noxane PFS**	**2**	**2**	**3**	**4**	**5**	6	**2**	**2**	**2**	**2**	**2**	**32**	0	**5**	**5**	0	0	4	5	1	**20**	**52**
	351	Enoxaparin Sodium 40mg	40mg	Inj.	**Noxane PFS**	**2**	**2**	**3**	**4**	**5**	6	**2**	**2**	**2**	**2**	**2**	**32**	0	**5**	**5**	0	0	4	0	1	**15**	**47**
	352	Enoxaparin Sodium 60mg	60mg	Inj.	**Noxane PFS**	**2**	**2**	**3**	**4**	**5**	6	**2**	**2**	**2**	**2**	**2**	**32**	0	**5**	**5**	0	0	4	0	1	**15**	**47**
	353	Enoxaparin Sodium 80mg	80mg	Inj.	**Noxane PFS**	**2**	**2**	**3**	**4**	**5**	6	**2**	**2**	**2**	**2**	**2**	**32**	0	**5**	**5**	0	0	4	5	1	**20**	**52**
	354	Erythropoietin 2000 IU	2000IU	Inj.	**Eritrogen**	**2**	**2**	**3**	**4**	**5**	6	**2**	**2**	**2**	**2**	**2**	**32**	0	0	0	0	0	4	5	2	**11**	**43**
	355	Erythropoietin 4000 IU	4000IU	Inj.	**Eritrogen**	**2**	**2**	**3**	**4**	**5**	6	**2**	**2**	**2**	**2**	**2**	**32**	0	0	0	0	0	4	5	2	**11**	**43**
	356	Erythropoietin 10000 IU	10000IU	Inj.	**Eritrogen**	**2**	**2**	**3**	**4**	**5**	6	**2**	**2**	**2**	**2**	**2**	**32**	0	0	0	0	0	4	5	2	**11**	**43**
	370	Heparin Sodium	5000IU	Inj.	**Heprin**	**2**	**2**	**3**	**4**	**5**	6	**2**	**2**	**2**	**2**	**2**	**32**	0	**5**	**5**	0	0	4	5	1	**20**	**52**
	516	Omeprazole 40mg	40mg	Inj.	**Omega**	**2**	**2**	**3**	**4**	**5**	6	**2**	**2**	**2**	**2**	**2**	**32**	0	**5**	**5**	0	0	4	5	1	**20**	**52**
	531	Terlipressin Acetate 1mg	1mg	Inj.	**Novapressin**	**2**	**2**	**3**	**4**	**5**	6	**2**	**2**	**2**	**2**	**2**	**32**	0	0	0	0	0	4	5	5	**14**	**46**
	560	Insulin Biphasic (70/30)	/30, 100IU/	Inj.	**Feralin**	**2**	**2**	**3**	**4**	**5**	6	**2**	**2**	**2**	**2**	**2**	**32**	0	**5**	**5**	0	0	4	5	1	**20**	**52**
	561	Insulin Human (R)	0IU/ml (10m	Inj.	**Feralin-R**	**2**	**2**	**3**	**4**	**5**	6	**2**	**2**	**2**	**2**	**2**	**32**	0	**5**	**5**	0	0	4	5	0	**19**	**51**
	566	Insulin Human (N)	0IU/ml (10m	Inj.	**Feralin-N**	**2**	**2**	**3**	**4**	**5**	6	**2**	**2**	**2**	**2**	**2**	**32**	0	**5**	**5**	0	0	4	5	0	**19**	**51**
	1585	Ondansetron 8mg	8mg/4ml	Inj.	**Serenety**	**2**	**2**	**3**	**4**	**5**	6	**2**	**2**	**2**	**2**	**2**	**32**	0	**5**	**5**	0	0	4	5	0	**19**	**51**
	1601	Peg-Filgrastim	6.00mg	Inj.	**Peg Filgen**	**2**	**2**	**3**	**4**	**5**	6	**2**	**2**	**2**	**2**	**2**	**32**	0	**5**	**5**	0	0	4	5	1	**20**	**52**
	1602	Peg interferon alfa-2a	180mcg	Inj.	**Peg-INF**	**2**	**2**	**3**	**4**	**5**	6	**2**	**2**	**2**	**2**	**2**	**32**	0	**5**	**5**	0	0	4	5	1	**20**	**52**

PAGE 279, USFDA ATTACHED FOR KETOROLAC IS OLDER THAN 10 YEARS & IS ISSUED TO HEBEI CHANGSHAN BIOCHEM INSTEAD OF SAURAV CHEMICALS INDIA

PAGE 348-393 BIOSIMILARITY STUDY FOR FILGEN IS NOT CONDUCTED BY WHO AUDITED LAB HENCE MARKS NOT AWARDED

BIOEQUIVALENCE STUDY AT PAGE 742 IS NOT CONDUCTED BY THE WHO AUDITED LAB FOR ENOXAPARIN

STABILITY STUDIES OF 40MG AND 60MG NOT ATTACHED PAGE 817-831

GD ERYTHROMPOIETIN AT PAGE 1005 IS NOT READIBALE

GD AT PAGE 1373 IS NOT READABLE

BIOSIMILARITY STUDY AT PAGE 1766 IS NOT CONDUCTED BY THE WHO AUDITED LAB FOR Peg Interferon Alfa

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: BOSCH PHARMACEUTICALS KARACHI

S. No.		Product General Information				Technical Evaluation Matrix: Factory Technical Evaluation Parameters — Documents Based Factory Score						Factory Evaluation Visit Score					Total Factory Evaluated Score	Product Evaluation Parameters — Product Technical Parameters							Total Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001:45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body. (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body. (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body. (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) as all times. Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC. experts, as, non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC experts). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to the cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP. **(Certified by the senior executive of the firm & evaluated by MCC. expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC experts at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the month/ date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid mail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Two (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **All marks shall be awarded to the Primary certificate, and If/ mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Material/s e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or most clearly mentioned in the Drug Master File (DMF) of the material. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better (**Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**5	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approval/s (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govts. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note, Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70
Mallinckrodt, UK	1	56	inj.Nalbuphone	10 mg	Ampoule	inj.Bunail 10mg	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	4	5	1	20	46
Mallinckrodt, UK	2	63	Inf Paracetamol	1000 mg/100 ml	Vial	Inf.Bofalgan 1000mg/100ml	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	2	5	1	18	44
Shandong Anxin Pharmaceuticals Co. China	3	167	inj.Amikacin Sulphate	250 mg	Ampoule	inj.Amkay 250mg	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	5	0	4	5	2	26	52
Shandong Anxin Pharmaceuticals Co. China	4	168	inj.Amikacin Sulphate	500 mg	Ampoule	inj.Amkay 500mg	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	5	0	4	5	2	26	52
Sinopharm Weigida China (Jiangsu)anan), Amoxicillin (Saakh Pharma)	5	175	Tab Amoxycillin+ Clavulanic Acid	625 mg	Tablet	Tab.Calamox 625mg	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	2	5	2	19	45
Sinopharm Weigida China (Jiangsu)anan), Amoxicillin (Saakh Pharma)	6	176	Tab Amoxycillin+ Clavulanic Acid	1 GM	Tablet	Tab.Calamox 1gm	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	2	5	2	19	45
Sinopharm Weigida China (Jiangsu)anan), Amoxicillin (Saakh Pharma)	7	177	Susp Amoxycillin+ Clavulanic Acid	125mg +31.5mg/5ml (60ml)	Suspension	Susp.Calamox 156.25mg/5ml (60ml) bottle	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	4	5	2	21	47
Sinopharm Weigida China (Jiangsu)anan), Amoxicillin (Saakh Pharma)	8	179	Susp Amoxycillin+ Clavulanic Acid	250mg + 62.5mg/5ml (60ml)	Suspension	Susp.Calamox DS 312.50mg/5ml (60ml) bottle	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	4	5	2	21	47
Sinopharm Weigida China Amoxicillin sodium & k clavulanate	9	180	Inj.Amoxycillin+ Clavulanic Acid	500+100mg/Vial	Vial	Inj.Calamox 600mg	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	API source certificate needs clarification.	0	4	5	2	21	47
Sinopharm Weigida China Amoxicillin sodium & k clavulanate	10	181	Inj.Amoxycillin+ Clavulanic Acid	1000+200mg/Vial	Vial	Inj.Calamox 1.2gm	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	API source certificate needs clarification.	0	4	5	2	21	47
Ningxia Taiycin Biotech Co Ltd	11	191	Inj.Azithromycine	500mg/Vial	Vial	Inj.Zecnit 500mg	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	4	5	1	20	46
Qilu Antibiotics Co Ltd CN	12	202	Inj.Cefepime	500mg/Vial	Vial	Inj.Nuvipim 500mg	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	5	0	4	5	0	24	50
Qilu Antibiotics Co Ltd CN	13	203	Inj.Cefepime	1gm/Vial	Vial	Inj.Nuvipim 1gm	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	5	0	4	5	0	24	50
Qilu Antibiotics Co Ltd CN	14	207	Inj.Ceftoperazone + Sulbactam	1gm/Vial	Vial	Inj.Cefzac 1gm	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	5	0	4	5	0	24	50
Qilu Antibiotics Co Ltd CN	15	208	Inj.Ceftoperazone + Sulbactam	2gm/Vial	Vial	Inj.Cefzac 2gm	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	5	0	4	5	0	24	50
Zhejiang Jingxin pharma	16	232	Inf.Ciprofloxacin	200mg/100ml	Vial	Inf.Quinoflox 200mg/100ml	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	API source certificate needs clarification.	0	2	5	1	18	44
Shenzen Haibin Pharma cb	17	260	Inj.Imipenem+ Cilastatin	500+500 mg/Vial	Vial	Inj.Cilapen 500mg	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	GMP Certificate is expired on 31-12-2024 at pdf Page No. 169	0	4	5	1	20	46
Optimus Drugs Pvt Ltd, India	18	271	Inf.Linezolid	2 mg/ml (300ml)	Vial	Inf.Zolreed 600mg/300ml	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	API source certificate needs clarification.	0	2	5	1	18	44
Shandong Anhong Pharmaceutical CN	19	272	Inj.Meropenem	500mg/Vial	Vial	Inj.Dohmero 500mg	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	API Source certificae is not of principal manufacturer. Need clarification	0	Picture of immediate contrainer is not attached at pdf page No.806.	5	0	15	41
Shandong Anhong Pharmaceutical CN	20	273	Inj.Meropenem	1 gm/Vial	Vial	Inj.Dohmero 1gm	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	API Source certificae is not of principal manufacturer. Need clarification	0	Picture of immediate contrainer is not attached at pdf page No.830.	5	0	15	41
Enalbac Labs Pvt Ltd India	21	276	Inf Moxifloxacine	400mg/250ml	Vial	Inf.Intlon 400mg/250ml	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	2	5	0	17	43
Fuan Group Kingday	22	294	Inj.Tigecycline	50 mg/Vial	Vial	Inj.Bing 50mg	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45
Livzon Group CN	23	295	Inj.Vancomycine	500 mg/Vial	Vial	Inj.Vinpec 500mg	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	5	0	4	5	1	25	51
Livzon Group CN	24	296	Inj.Vancomycine	1 gm/Vial	Vial	Inj.Vinpec 1gm	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	5	0	4	5	1	25	51
Metrochem Pvt Ltd	25	516	Inj.Omeprazole	40mg/Vial	Vial	Inj.Omezol 40mg	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	API source certificate at page No. 929 needs clarification.	0	4	5	1	20	46

SCRUTINY REPORT

1	73-78	ISO certificates for 45001, 14001 and 9001 certificates are not from PNAC accredited body.
2	280	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by US-FDA for Nalbuphine at page No. 280 of the technical bid needs clarification.

Evaluation Criteria for Manufacturers of Non Drugs Items for Govt MCC 2026-27

Name of the firm: BQ PHARMACEUTICALS AND MEDICAL DEVICES

Technical Evaluation Matrix

		Product General Information			Factory Technical Evaluation Parameter															
					Documents Based Factory Score				Evaluation Visit Score				Factory Evaluated Score						Product Evaluated Score	Total Technical Score
S.No	MCC formulary No.	1	2	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
					Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. **(as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.**	Adherence to Current Good Manufacturing Practices in line with the DRAP regulations. **(to be evaluated by the MCC expert/s, Non compliance to cGMP shall lead to disqualification of the relevant section or firm)**	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section (s) / firm.**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC** **(Certificates duly attested by Senior Executive of the firm)**	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Brand Name	3	5	5	6	5	5	5	5	**39**	5	5	5	6	10	**31**	**70**
DRAP REG																				
	1	947	Blood collection Tube (Purple Top)	Various sizes	Vaccutube	0	0	5	0	The firm was inspected as per technical evaluation criteria. The firm complied with the physical inspection criteria/checklist; however, the mandatory cGMP inspection was conducted on 17/03/2026 while bid opening date was 17/02/2026. cGMP was issued on 30/04/2026 which is after bid opening date so the firm is NOT RECOMMENDED.				**5**	5	5	3	0		**13**	**18**
	2	948	Blood collection Tube (Red Top)	Various sizes	Vaccutube	0	0	5	0				**5**	5	5	2	0		**12**	**17**
	3	950	Blood collection Tube (Green Top)	Various sizes	Vaccutube	0	0	5	0				**5**	5	5	3	0		**13**	**18**
	4	951	Blood collection Tube (Yellow Top)	Various sizes	Vaccutube	0	0	5	0				**5**	5	5	3	0		**13**	**18**
	5	952	Blood collection Tube (Blue Top)	Various sizes	Vaccutube	0	0	5	0				**5**	5	5	2	0		**12**	**17**

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm | **Brookes Pharma, Karachi**

S. No.		Product General Information				Technical Evaluation Matrix																					
						Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP), in terra / section of the quoted product (s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in terra / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA,. APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission.	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this colounm for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
	10	Atracurium Besylate	10mg/ml	Inj. 3ml	Acuron	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	0	0	0	4	5	0	**14**	**44**
	11	Atracurium Besylate	10mg/ml	Inj. 5ml	Acuron	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	0	0	0	4	5	0	**14**	**44**
	12	Bupivacaine Hydrochloride	5.0mg	Inj. 10ml	Sensocain	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	0	0	0	4	0	0	**9**	**39**
	13	Bupivacaine Spinal HCL	0.75%	Inj. 2ml	Sensocain Spinal	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	0	0	0	4	5	0	**14**	**44**
	14	Cisatracurium	10mg/5ml	Inj. 5ml	Cis-Curon	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	**19**	**49**
	15	Dexmedetomidine	200mcg	Inj. 2ml	Predicex	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	**19**	**49**
	16	Glycopyrrolate + Neostigmine Methylsulphate	0.5/2.5mg	Inj. 1ml	Neo-Pyrolate	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	**19**	**49**
	17	Glycopyrrolate	0.2mg/ml	Inj. 1ml	Pyrolate	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	**19**	**49**
	29	Rocuronium Bromide	50mg/5ml	Inj. 5ml	Rescuron	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	**19**	**49**
	41	Diclofenac Sodium	50mg	Tab	Arnil	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	0	5	0	**15**	**45**
	56	Nalbuphine HCl	1ml	Inj.	Sonotic	2	2	3	2	5	6	2	2	2	2	2	**30**	0	0	0	0	0	4	5	0	**9**	**39**
	63	Paracetamol	100ml	Infu.	Bramol	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	69	Tramadol HCL	100mg	Inj. 2ml	Lamadol	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	**19**	**49**
	218	Ceftriaxone Sodium IV	1gm	Inj.	Rxon	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	0	5	0	**15**	**45**
	230	Ciprofloxacin	250mg	Tab	Gen-Cipro	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	0	5	0	**15**	**45**
	231	Ciprofloxacin	500mg	Tab	Gen-Cipro	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	0	5	0	**15**	**45**
	264	Levofloxacin	250mg	Tab	Gen-Levo	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	0	5	0	**15**	**45**
	265	Levofloxacin	500mg	Tab	Gen-Levo	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	0	5	0	**15**	**45**
	292	Rifaximin	550mg	Tab	Xifax	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	0	5	0	**15**	**45**
	537	Dexamethasone as Sodium Phosphate	4mg/ml	Inj. 1ml	D-Cort	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	**19**	**49**
	725	Escitalopram	10mg	Tab	Re-Uptol	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	0	0	0	0	5	0	**10**	**40**
	896	Tetrachloro deoxide	50ml	Solution	Oxoferin	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	905	Povidone Iodine	10%	Solution 450ml	Pyodine solution	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	906	Povidone Iodine	7.50%	Scrub 450ml	Pyodine Surgical Scrub	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**

Scrutiny Report

1CoA of API of Atracurium, Bupivacaine, Escitalopram, issued by pricipal manufacturer of the API are not present in the bid.
2Stability studies of Sensocain Injection are not present.
3CoA of Aluminium foil for Tablets Arnil, Gen levo, Gen Cipro and Rifaxa are not present.
4Airway bill for Nalbuphine is not present,
5Inj. Ceftriaxone (Rxon) is offered with type-III glass vial which shall lead to disqualification of the product as Type-III glass vials are not allowed for Dry powder injectables as per the advertised criteria
6IMS data product wise market share is not provided.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm | CARAWAY PHARMACEUTICALS PVT. LIMITED

S. No.		Product General Information				Technical Evaluation Matrix											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Factory Technical Evaluation Parameters												Product Technical Parameters										
						Documents Based Factory Score						Factory Evaluation Visit Score																
	MCC formulary	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this colounm for the respective item.** For award of marks, the certificate of analysis	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**5**	**3**	**4**	**5**	**5**	**37**	**70**
1	11	Injection Atracurium Besylate 50mg	5mg	Injection	A-care 50mg	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	No Proof of purchase for immediate container has been attached in the bid	5	0	**15**	**42**
2	13	Injection Bupivacaine HCl	7.5 mg/ml	Injection	Cabocin 0.75%	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	No Proof of purchase for immediate container has been attached in the bid	Stability of quoted strength 7.5mg/ml is not provided at page No. 256-261	0	**10**	**37**
3	14	Injection Cisatracurium Besylate 2mg/ml	2mg/ml	Injection	Cisatracar 10mg/5ml	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	No Proof of purchase for immediate container has been attached in the bid	5	0	**15**	**42**
4	15	Injection Dexmedetomidine 0.1mg/ml	0.1mg/ml	Injection	Dexmed 200mg/2ml	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	4	5	0	**19**	**46**
5	16	Injection Glycopyrlate 0.5mg Neostigimine methylsulphate	1.5mg+2.5ml	Injection	Neocare-P	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	No Proof of purchase for immediate container has been attached in the bid	5	0	**15**	**42**
6	47	Injection Ketorolac Tromatamol equivalent to Ketorolac 30 mg	30mg/ml	Injection	Caralac 30mg	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	GD is expired at page No. 428	AWB is not matchable with GD	0	0	No Proof of purchase for immediate container has been attached in the bid	5	0	**5**	**32**
7	56	Injection Nalbuphine Hydrochloride 10mg	10mg	Injection	Kolbi 10mg	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	No Proof of purchase for immediate container has been attached in the bid	5	0	**15**	**42**
8	166	Injection Amikacin as Sulphate 100mg	100mg	Injection	Amifate 100mg	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	No Proof of purchase for immediate container has been attached in the bid	5	0	**15**	**42**
9	167	Injection Amikacin as Sulphate 250mg	250mg	Injection	Amifate 250mg	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	No Proof of purchase for immediate container has been attached in the bid	5	0	**15**	**42**
10	168	Injection Amikacin as Sulphate 500mg	500mg	Injection	Amifate 500mg	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	No Proof of purchase for immediate container has been attached in the bid	5	0	**15**	**42**
11	207	**Injection Cefoperazone as Sodium 500mg + Sulbutam vs**	**1g**	**Injection**	**Sactum 1gm**	**2**	**2**	**3**	**1**	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**27**	0	**0**	**0**	**0**	0	**Type III glass is used, hence disqualified**	**0**	0	**0**	**27**
12	208	**Injection Cefoperazone as Sodium 1g + Sulbutam vs**	**2g**	**Injection**	**Sactum 2gm**	**2**	**2**	**3**	**1**	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**27**	0	**0**	**0**	**0**	0	**Type III glass is used, hence disqualified**	**0**	0	**0**	**27**
13	219	**Injection Ceftriaxone (as Sodium) 2gm**	**2gm**	**Injection**	**Odmi 2gm IV**	**2**	**2**	**3**	**1**	**5**	**4**	**2**	**2**	**2**	**2**	**2**	**27**	0	**0**	**0**	**0**	0	**Type III glass is used, hence disqualified**	0	0	**0**	**27**
14	375	Injection Iron Sucrose complex eq. to Elemental iron 100mg	5ml	Injection	Cara-fer 100mg/5ml	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	No Proof of purchase for immediate container has been attached in the bid	No data provided at page No. 830	0	**10**	**37**

15	389	Injection Tranexamic Acid 250mg	250mg	Injection	Vasamin 250mg	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	4	5	0	**19**	**46**
16	390	Injection Tranexamic Acid 500mg	500mg	Injection	Vasamin 500mg	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	4	5	0	**19**	**46**
17	426	Injection Dobutamine HCl eq to Dobutamine 250 mg	250mg	Injection	Cara-Doba 250mg	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	No Proof of purchase for immediate container has been attached in the bid	5	0	**15**	**42**
18	427	Injection Dopamine 200mg	200mg	Injection	Carapamin 200mg	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	No Proof of purchase for immediate container has been attached in the bid	5	0	**15**	**42**
19	433	Tab Glyceryl trinitrate 2.6 mg	2.6mg	Tablets	Nitras 2.6mg	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	No proof of purchase attached in the Bid P#1049-1053	5	0	**15**	**42**
20	434	Tab Glyceryl trinitrate 6.4 mg	6.4mg	Tablets	Nitras 6.4mg	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	No proof of purchase attached in the Bid P#1049-1053	5	0	**15**	**42**
21	519	Tab Ondansetron 8mg	8mg	Tablets	Ondelnes 8mg	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	4	5	0	**19**	**46**
22	520	Injection Ondansetron 8mg	8mg	Injection	Ondelnes 8mg/4ml	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	4	5	0	**19**	**46**
23	683	Injection Calcitrol 1mcg/ml	1 mcg/ml	Injection	Trolsum 1mcg Injection	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	5	0	No proof of purchase attached in the Bid P#1233-1234	5	0	**20**	**47**
24	708	Injection Citicoline as Sodium 250mg	250mg/ml	Injection	Citograin injection 250mg	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	No proof of purchase attached in the Bid	5	0	**15**	**42**
25	725	Tab 10mg Escitalopram 10mg	10mg	Tablets	Vepram 10mg	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	No proof of purchase attached in the Bid P#1291-1293	0	0	**10**	**37**
26	742	Tablet Olanzapine 5mg	5mg	Tablets	Olizap 5mg	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	GD attached at Page No. 1331-1333 is older than 24 months	0	0	0	No proof of purchase attached in the Bid P#1343-1345	5	0	**5**	**32**
27	743	Tablet Olanzapine 10mg	10mg	Tablets	Olizap 10mg	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	GD attached at Page No. 1331-1333 is older than 24 months	0	0	0	No proof of purchase attached in the Bid P#1343-1345	5	0	**5**	**32**
28	753	Cap Pregabalin 50mg	50mg	Capsules	Pregabalin 50mg	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	No proof of purchase attached in the Bid P#1449-1451	5	0	**15**	**42**
29	754	Cap Pregabalin 75mg	75mg	Capsules	Pregabalin 75mg	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	No proof of purchase attached in the Bid P#1449-1451	5	0	**15**	**42**
30	755	Cap Pregabalin 150mg	150mg	Capsules	Cap Pregabalin 150mg	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	No proof of purchase attached in the Bid P#1449-1451	5	0	**15**	**42**
31	760	Tab Quetiapine 100mg	100mg	Tablets	Scrizolin 100mg	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	No proof of purchase attached in the Bid	5	0	**15**	**42**
32	761	Tab Risperidone 2mg	2mg	Tablets	Resigrin 2mg	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	GD attached at Page No. 1621 is older than 24 months	0	0	0	No proof of purchase attached in the Bid	5	0	**5**	**32**
33	860	Cream Betamethasone dipropionate + Gentamicin sulphate	15gm	Cream	Betavias-G	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	GD of Betamethasone 1675-1690 is not provided in the bid	0	0	0	No proof of purchase attached in the Bid P#1685-1687	5	0	**5**	**32**
34	862	Cream Clotrimazole 1%	1%	Cream	Clotrimazole 1%	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	No proof of purchase attached in the Bid	5	0	**15**	**42**
35	884	Cream Loratadine 5% w/w	5%	Cream	Loratadine 5% w/w	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	Not provided in the bid	Not provided in the bid	0	0	No proof of purchase attached in the Bid	0	0	**0**	**27**
36	852	Cream Terbinafine as HCL 10mg	10mg	Cream	Terbinafine 10mg	2	2	3	1	5	4	**2**	**2**	**2**	**2**	**2**	**27**	0	5	5	0	0	No proof of purchase attached in the Bid P#1783-1785	5	0	**15**	**42**

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27														
Name of the firm						Care and Cure RY Khan														
						Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facility/third party, a valid trail link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal as Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 01 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note, Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevent certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
AnHui AnYu Latex Products	1052	Disposable Sterile Latex Surgical Gloves (Powder Free)	6.5	Cure Surgical Gloves 6.5 (Powder Free)		0	0	0	The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COFG) for the quoted items were checked, and following observations were made; 1. SHANDONG CHENGWU MEDICAL PRODUCTS FACTORY CHINA Original DRAP registration, Agency agreement and valid original free sale certificate were produced at the time of inspection. CE confirmation letter was not produced in original to the inspection team. 2. ANHUI ANYU LATEX PRODUCTS COMPANY LTD. CHINA Valid original embassy/ apostille attested documents, of the principal manufacturer, as per the advertised criteria were present at the time of inspection. 3. TG MEDICAL SDN BHD MALAYSIA Original DRAP registration, Agency agreement and valid original free sale certificate were produced at the time of inspection. However, Declaration of conformity was not produced at the time of inspection. Moreover, minimum 20% inventory of Nitrile Examination gloves was not available at the time of inspection. In view of the above the firm is NOT RECOMMENDED Except for the	**0**	5	5	0	0	0		**10**	**10**
AnHui AnYu Latex Products	1052	Disposable Sterile Latex Surgical Gloves (Powder Free)	7	Cure Surgical Gloves 7.0 (Powder Free)		0	0	0				**0**	5	5	0	0	0		**10**	**10**
AnHui AnYu Latex Products	1052	Disposable Sterile Latex Surgical Gloves (Powder Free)	7.5	Cure Surgical Gloves 7.5 (Powder Free)		0	0	0				**0**	5	5	0	0	0		**10**	**10**
AnHui AnYu Latex Products	1052	Disposable Sterile Latex Surgical Gloves (Powder Free)	8.5	Cure Surgical Gloves 8.5 (Powder Free)		0	0	0				**0**	5	5	0	0	0		**10**	**10**
AnHui AnYu Latex Products	1053	Disposable Sterile Latex Surgical Gloves (Powdered)	6.5	Cure Surgical Gloves 6.5 (Powdered)		0	0	0				**0**	5	5	0	0	0		**10**	**10**
AnHui AnYu Latex Products	1053	Disposable Sterile Latex Surgical Gloves (Powdered)	7	Cure Surgical Gloves 7.0 (Powdered)		0	0	0				**0**	5	5	0	0	0		**10**	**10**

						Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27															
Name of the firm						**Care & Cure RY Khan**															
S. No.		**Product General Parameter**				**Technical Evaluation Matrix**													**Product Evaluated Score**	**Total Technical Score**	
						Principals and Importer's Evaluation Parameters							**Product Technical Evaluation**								
						Principal Manufacturer Evaluation			**Importer's Evaluation**			**Suppliers Technical Score**										
	MCC formulary No.	**1**	**2**	**3**	**4**	**5**	**6**	**7**	**8**	**9**	**10**	**11**	**12**	**13**	**14**	**15**	**16**	**17**	18	20	
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the time of inspection at the warehouse at the tim eof inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s / are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** **(Certificate duly attaested by senior executive of the firm)**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note, Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US free sale certificate of the quoted products, **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **Online verification link shall be provided.** **(copies of relevant certificates duly attested by the senior executive of the firm)**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	5	6	**29**	5	5	5	6	10	10	**41**	**70**	
Shandong Chengwu China	1119	I/V fluid administration set	Sterile and pyrogen free, minimum 150cm tube length, blister pack		Cure	**0**	5	0	The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/CDFG) for the quoted items were checked, and following observations were made; 1. SHANDONG CHENGWU MEDICAL PRODUCTS FACTORY CHINA Original DRAP registration, Agency agreement and valid original free sale certificate were produced at the time of inspection. CE confirmation letter was not produced in original to the inspection team. 2. ANHUI ANYU LATEX PRODUCTS COMPANY LTD. CHINA Valid original embassy/ apostille attested documents, of the principal manufacturer, as per the advertised criteria were present at the time of inspection. 3. TG MEDICAL SDN BHD MALAYSIA Original DRAP registration, Agency agreement and valid original free sale certificate were produced at the time of inspection. However, Declaration of conformity was not produced at the time of inspection. Moreover, minimum 20% inventory of Nitrile Examination gloves was not available at the time of inspection. In view of the above the firm is NOT RECOMMENDED Except for the quoted products of ANHUI ANYU LATEX PRODUCTS COMPANY LTD. CHINA and marks in importer's evaluation parameters for the quoted items may be awarded.			0		0	0	0	0			**0**	**0**	
Shandong Chengwu China	1120	I/V fluid administration set with additional "Y" injection port	Sterile, minimum 150cm length tubing, latex, and pyrogen free, blister pack		Cure	**0**	0	0					0	0	0	0			**0**	**0**	

Observations	Mandatory Attested Copy of the Focal Person as Clause 3 of the bid form -1 is not attached in the bid.
	The bid is not signed by the Senior Executive of the firm/bidder except pages 1-14.
Page 233	COMP is expired on 09-11-2024
	312Y-port is not covered in the COMP
	319The Disposable infusion set with burrette is not covered.
Pag 327	Disposable Infusion set with burrette is not covered in the online verification QR code.
	323Y-port is not covered in the confirmation letter
	328Mandatory DRAP Registeration of I.V set at 1119 is not attached.
	385COA of Infusion chamber is unsigned.
	349Tender approval are not according to the advertised criteria
509-515	GD and COA of I.V sets are not matching (Zibo and Shandong Chengu)

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: CCL Pharmaceuticals Pvt Ltd, 65- Quaid e Azam Industrial estate, Kot Lakpat Lahore

Technical Evaluation Matrix

S. No.	Product General Information					Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters										
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade.	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
	343	Velpatasvir + Sofosbuvir	100 + 400 mg	Tablet	Abriva Plus	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	2	5	1	**18**	**46**
	190	Azithromycin	500 mg	Tablet	Acasia	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	2	5	0	**17**	**45**
	110	Deferasirox	250 mg	Tablet	Desirox	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	2	5	5	**22**	**50**
	112	Deferasirox	400 mg	Tablet	Desirox	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	2	5	5	**22**	**50**
	113	Deferasirox	500 mg	Tablet	Desirox	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	2	5	5	**22**	**50**
	95	Tacrolimus	0.5 mg	Capsule	Tacgraf	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	2	5	2	**19**	**47**
	94	Tacrolimus	1 mg	Capsule	Tacgraf	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	2	5	2	**19**	**47**
	89	Mycophenolate Mofetil	500 mg	Tablet	Myclolate	2	2	3	5	0	6	2	2	2	2	2	**28**	0	0	0	0	0	2	5	1	**8**	**36**
	581	Sitagliptin + Metformin	50 mg/500 mg	Tablet	Sita-met 50/500	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	2	5	2	**19**	**47**
	582	Sitagliptin + Metformin	50 mg/1000 mg	Tablet	Sita-met 50/1000	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	2	5	2	**19**	**47**
	421	Clopidogrel	75 mg	Tablet	Noclot 75	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	2	5	1	**18**	**46**

Scrcutiny report.

1The calibration certificates for major equipment used for analysis /assay are not present in thebid. Only manometers, pressure guages and weighing balances calibration certificates are present.
2German GMP of Riuyuan HEC is expired on 28.11.2022- Hence marks for API source of Velpatasvir cannot be awarded- (Page No. 1262)
Original Mandatory forms in Hard are not submitted to the MCC

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: CHIESI PHARMA LAHORE

S. No.		Product General Information				Technical Evaluation Matrix																	
						Principal's and Importer's Evaluation Parameters									Product Technical Evaluation								
						Principal Manufacturer Evaluation					Importer's Evaluation			Suppliers Technical Score	Product Technical Parameters						Product Availability		Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid accreditation of manufacturing unit or its relevant sections by the US-FDA or official accreditation body/ies /regulatory body in the case of SRA/WLA countries (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **Valid Calibration Certificates attested by Quality head of the firm).**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC experts). **Non availability of the 20% stock at the ware house at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good storage practices (GSP) for storage of finished goods. Functional and effective Air-conditioning & Ventilation System and effective cold chain (thermo-labile drugs). The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Nonadherence to GSP, as evaluated by the MCC experts at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, Pharmacist or Category-A Pharmacist/s (size mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 2L, product's validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the biosimilar/ent / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of purchases through third party importers a valid read/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 15, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (API/s) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies). Trail of principal manufacturer shall be established from the respective GD. CoA and other supporting documents. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, API/s source accreditation shall be awarded only where these documents are submitted for all API/s/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA country(ies) / Valid free-sale certificate issued by regulatory body of any SRA/WLA country(ies) and / or Valid certificate of the availability of the quoted item in the US market. **04 marks shall be awarded as the Primary certificate, and 1 mark for additional certificate, up to a maximum of 06 (04+01+01) marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with invoice/proof of purchase. **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: i. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. ii. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). iii. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm)**	Stability studies of quoted item/s duly stamped by the QC incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/HQVIA. Health not older than twelve (12) months. 0-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/HQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form, Maniwise, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challas, stock's/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**2**	**5**	**5**	**4**	**5**	**5**	**30**	**5**	**5**	**5**	**5**	**6**	**4**	**5**	**5**	**40**	**70**
	691	Proactant alfa	120 mg/ 1.5ml	Inj.	CUROSURF	**2**	**2**	0	5	**5**	**4**	**5**	**5**	**28**	**0**	**5**	**5**	**5**	**0**	0	5	0	**20**	**48**
	692	Proactant alfa	240 mg/ 3ml	Inj.	CUROSURF	**2**	**2**	0	5	**5**	**4**	**5**	**5**	**28**	**0**	**5**	**5**	**5**	**0**	0	5	0	**20**	**48**
	790	Beclomethasone	800 mcg/2ml Soln. 2 ml	Soln.	Clenil Nebulizer Solution	**2**	**2**	0	5	**5**	**4**	**5**	**5**	**28**	**0**	**5**	**5**	**5**	**0**	0	5	5	**25**	**53**
	805	Ipratropium Bromide	500mcg/2ml	Soln.	Atem Nebulizer Solution	**2**	**2**	0	5	**5**	**4**	**5**	**5**	**28**	**0**	**5**	**5**	**5**	**0**	0	5	3	**23**	**51**

Proof of innovator is on company's own letter head
For Curosurf only stopper COA is provided in immediate container

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm | **CITI PHARMA LAHORE**

S. No.		Product General Information				Technical Evaluation Matrix																				
						Factory Technical Evaluation Parameters										Total Factory Evaluated Score	Product Evaluation Parameters							Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score					Product Technical Parameters								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	22	23	24	25	26
						Valid ISO 13001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firms.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml upto 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate consiner of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate consinme packaging shall be submitted for each quoted item. Non-provision of the above shall lead to award of zero marks in this columnn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
Pack Size	**MCC formulary No.**	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**5**	**4**	**5**	**5**	**37**	**70**
100s	43	Ibuprofen	200mg	Tab.	Kalos	**2**	**2**	**3**	**0**	**5**	**6**						**10**	0	**5**	**5**	0	0	5	**0**	**15**	**33**
100s	44	Ibuprofen	400mg	Tab.	Kalos	**2**	**2**	**3**	**0**	**5**	**6**						**10**	0	**5**	**5**	0	0	0	**0**	**10**	**28**
120ml	46	Ibuprofen	100mg/5ml	Susp.	Kalos	**2**	**2**	**3**	**0**	**5**	**6**						**10**	0	**5**	**5**	0	4	5	**0**	**19**	**37**
200s	59	Paracetamol	500mg	Tab.	Askprol	**2**	**2**	**3**	**0**	**5**	**6**						**10**	0	**5**	**5**	0	4	5	**0**	**19**	**37**
120ml	60	Paracetamol	120mg/5ml	Susp.	Askprol	**2**	**2**	**3**	**0**	**5**	**6**						**10**	0	**5**	**5**	0	4	5	**0**	**19**	**37**
7s	136	Fluconazole	50mg	Cap.	Flucogals	**2**	**2**	**3**	**0**	**5**	**6**						**10**	0	**5**	**5**	0	4	5	**0**	**19**	**37**
1s	137	Fluconazole	150mg	Cap.	Flucogals	**2**	**2**	**3**	**0**	**5**	**6**						**10**	0	**5**	**5**	0	4	5	**0**	**19**	**37**
10s	153	Cetirizine 2HCl	10mg	Tab.	Avazin	**2**	**2**	**3**	**0**	**5**	**6**						**10**	0	**5**	**5**	0	4	5	**0**	**19**	**37**
14s	160	Montelukast	10mg	Tab.	Cingol	**2**	**2**	**3**	**0**	**5**	**6**						**10**	0	**5**	**5**	0	4	5	**0**	**19**	**37**
6s	189	Azithromycin	250mg	Cap.	Zyask	**2**	**2**	**3**	**0**	**5**	**6**						**10**	0	**5**	**5**	0	4	5	**0**	**19**	**37**
15ml	192	Azithromycin	200mg/5ml	Dry Susp.	Zyask	**2**	**2**	**3**	**0**	**5**	**6**						**10**	0	**5**	**5**	0	4	5	**0**	**19**	**37**
5s	204	Cefixime	400mg	Cap.	Cefask	**2**	**2**	**3**	**0**	**5**	**6**						**10**	0	**5**	**5**	0	4	5	**0**	**19**	**37**
30ml	205	Cefixime	100mg/5ml	Dry Susp.	Cefask	**2**	**2**	**3**	**0**	**5**	**6**						**10**	0	**5**	**5**	0	4	5	**0**	**19**	**37**
1s	217	Ceftriaxone	500mg/Vial	Inj.	Triaxonectt (IV)	**2**	**2**	**3**	**0**	**5**	**6**						**10**	0	**5**	**5**	5	2	5	**0**	**22**	**40**
1s	218	Ceftriaxone	1gm/Vial	Inj.	Triaxonectt (IV)	**2**	**2**	**3**	**0**	**5**	**6**						**10**	0	**5**	**5**	5	2	5	**0**	**22**	**40**
1s	219	Ceftriaxone	2gm/Vial	Inj.	Triaxonectt (IV)	**2**	**2**	**3**	**0**	**5**	**6**						**10**	0	**5**	**5**	5	2	5	**0**	**22**	**40**
10s	230	Ciprofloxacin	250mg	Tab.	Floxicp	**2**	**2**	**3**	**0**	**5**	**6**						**10**	0	**5**	**5**	5	4	5	**0**	**24**	**42**
10s	231	Ciprofloxacin	250mg	Tab.	Floxicp	**2**	**2**	**3**	**0**	**5**	**6**						**10**	0	**5**	**5**	5	4	5	**0**	**24**	**42**
10s	264	Levofloxacin	250mg	Tab.	Lenon	**2**	**2**	**3**	**0**	**5**	**6**						**10**	0	**5**	**5**	5	4	5	**0**	**24**	**42**
10s	265	Levofloxacin	500mg	Tab.	Lenon	**2**	**2**	**3**	**0**	**5**	**6**						**10**	0	**5**	**5**	5	4	5	**0**	**24**	**42**

KALOS TABLET 200MG AND 400MG COA & PROOF OF PURCHASE ARE NOT MATCHING, ONLY COA OF RIGID PVC AND ALU-ALU FOIL IS PROVIDED

DRAP APPROVED PICTIRES OF IMMEDIATE CONTAINER FOR KALOS 200MG/ 400MG & CETRIZINE ARE NOT PROVIDED.

STABILITY STUDY OF TABLET KALOS 400MG IS NOT ATTACHED

FDA REGISTRAION LINK OF MS Shaoxing Jingxin Pharmaceutical Co., Ltd. IS PROVIDED ONLY. CERTIFICATE NOT PROVIDED. FURTHERMORE, CITI PHARMA IS ALSO MANUFACTURING API OF LEVOFLOXACIN

Evaluation Criteria for Manufacturers of Cotton & Related Goods for Government MCC 2026-27

		Name of Firm	Cotton Craft (Pvt.) Ltd Plot No. 407-408, Sunder Industrial estate, Raiwind Road Lahore 042-35297901-04, Focal Person Muhammad Ayub Contact No. 0321-8482839																		
S. No.		General Product Information				Technical Evaluation Matrix															
						Factory Technical Evaluation Parameters															
						Documents Based Factory Score						Evaluation visit Score				Factory Evaluated Score	Product Evaluation Parameters			Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body. (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e FY 2023-24 or latest. A minimum turnover of PKR 100 million is required for awards of marks in this parameter. (The document shall be attested by a Senior executive of the firm)	Functional and effective Airconditioning & Ventilation System as per the requirements laid down by DRAP **(Evaluated by the MCC expert/s at the time of inspection, Non functionality of the Air Conditioning & Ventilation system in specified section shall lead to disqualification of the section or firm)**	Adequate availability of equipment / instruments in QC labs performing relevant official tests as well as compliance to Good laboratory practices (GLP) in all Labs and Current Good Manufacturing Practices (cGMP) throughout the production facility. **(Evaluated by the MCC expert/s at the time of inspection, Non availability of adequate and appropriate equipment / instruments and non-compliance to GLP , cGMP shall lead to disqualification of the relevant section or firm)**	Appropriate storage of raw material, in process and finished goods with compliance to Good storage practices (GSP) **(To be evaluated by the MCC expert/s at the time of inspection, Non compliance to GSP shall lead to disqualification of the relevant section or firm)**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	3	3	**4**	5	3	6	6	6	6	**45**	5	10	10	**25**	**70**
	969	Absorbent Cotton Wool BPC	200gm	Roll Each / 1's	Cotton Wool	3	3	3	**4**	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**
	970	Absorbent Cotton Wool BPC	100gm	Roll Each / 1's	Cotton Wool	3	3	3	**4**	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**
	971	Cotton Bandage BP Type-2	6.5cm x 4m	Dzn Pack of 12 Pcs	Open Wove Bandages	3	3	3	**4**	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**
	972	Cotton Bandage BP Type-2	7.5cm x 4m	Dzn Pack of 12 Pcs	Open Wove Bandages	3	3	3	**4**	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**
	973	Cotton Bandage BP Type-2	10cm x 4m	Dzn Pack of 12 Pcs	Open Wove Bandages	3	3	3	**4**	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**
	974	Cotton Bandage BP Type-2	15cm x 4m	Dzn Pack of 12 Pcs	Open Wove Bandages	3	3	3	**4**	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**
	981	Cotton Crepe Bandage BPC	7.5cm x 4.5m	No. Each / 1's	Elastocraft	3	3	3	**4**	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**
	982	Cotton Crepe Bandage BPC	10cm x 4.5m	No. Each / 1's	Elastocraft	3	3	3	**4**	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**
	983	Cotton Crepe Bandage BPC	15cm x 4.5m	No. Each / 1's	Elastocraft	3	3	3	**4**	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**
	1081	Optic Eye Pad (Sterile) (packing: Box of 50)	6cm x 8cm	Box Box of 50 Pcs	Optic Eye Pad	3	3	3	**4**	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**
	1097	Absorbent Gauze BPC (Pro-Med Roll)	100cm x 20m	Roll Each / 1's	Absorbent Gauze	3	3	3	**4**	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**
	1098	Absorbent Gauze BPC (Pro-Med Roll)	100cm x 40m	Roll Each / 1's	Absorbent Gauze	3	3	3	**4**	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**

Evaluation Criteria for Manufacturers of Non Drugs Items for Govt MCC 2026-27

Name of the firm: Cotton Craft Lahore

Technical Evaluation Matrix

S.No	MCC formulary No.	Product General Information				Factory Technical Evaluation Parameter								Factory Evaluated Score						Product Evaluated Score	Total Technical Score
						Documents Based Factory Score				Evaluation Visit Score											
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. **(as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.**	Adherence to Current Good Manufacturing Practices in line with the DRAP regulations. **(to be evaluated by the MCC expert/s, Non compliance to cGMP shall lead to disqualification of the relevant section or firm)**	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. **(As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section (s) / firm.**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC** **(Certificates duly attested by Senior Executive of the firm)**	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	6	5	5	5	5	**39**	5	5	5	6	10	**31**	**70**
	1139	Pro-Max Non-Woven Swab (Alcohol Swab) (Box of 200)	3cm x 3cm 2Ply	ox Box of 200 P	Pro-Max Alcohol Swab	3	5	5	6	5	5	5	5	**39**	0	0	Tender approvals are incomplete	Not attached	10	**10**	**49**

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: Cunningham Pharmaceuticals Pvt Ltd, Lahore,

Technical Evaluation Matrix

S. No.	Product General Information					Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th positions shall be awarded 1 mark.**	Valid calibration certificates for equipment/ instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP). **(Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC experts). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the sections or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP. **(Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC experts at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/ USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient's (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with freeze/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this column for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Flasks (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or more clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the Q.C. incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent more data of IMS/IQVIA /Health not older than twelve (12) months. 0-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health-related Govt. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be from different procuring entities/purchasing agencies. Supply orders, purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
	207	Cefoperazone + Sulbactam	1g	Inj	Zomiper	0	0	0	0	0	2	The inspection team at the time of inspection observed that,. Non Adherence to Good Storage Practices i. In the Raw Material Store (RMS) of Cephalosporins, the temperature was uncontrolled (30.9°C). The installed AC was set to 32°C, whereas the temperature should not exceed 30°C. ii. In the RMS, excipients and Active Pharmaceutical Ingredients (Ceftriaxone sodium) were stored on excipient racks. iii. In Finish Good Store, cartons were placed directly on the surface of floor instead of pallets. iv. In RMS, the dispensing area was under maintenance, the dispensing booth was not calibrated and the DOP test for Hepa filter was not shown to the inspection team. The balance kept in the dispensing booth was also not calibrated. v. In the external corridor, leaflets of Ceftriaxone sodium were placed unlabeled and without any status. vi. The water supply system was rusted and that was a potential source of contamination for sterile products. vii. In the vial filling area, semi-automatic machine was installed, section was non-operational and HVAC was non-functional at the time of inspection. In view of the above, the firm is NOT RECOMMENDED for award of factory evaluation visit score for the quoted items.					**2**	0	5	5	0	0	0	5	0	**35**	**17**
	217	Ceftriaxone	500mg	Inj	Axitrin	0	0	0	0	0	2						**2**	0	5	5	0	0	0	5	0	**35**	**17**
	218	Ceftriaxone	1g	Inj	Axitrin	0	0	0	0	0	2						**2**	0	5	5	0	0	0	5	0	**35**	**17**

Scrutiny report
1Only 2 valid calibration certificates are attached- one for UV Visible spectrophotometer and one for HPLC
2ISO 9001, 14001 and 45001 certificates at Page Nos. 40,42 and 41 respectively are not from a PNAC accredited body
3IMS data/ranking not present.
4CoA of type of material used for immediate container are not present.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: DANAS PHARMACEUTICALS PVT LTD

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm**).	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products.	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: i. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European,	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**5**	**3**	**4**	**5**	**5**	**37**	**70**
Pack size																											
1	41	Diclofenac Sodium Enteric Coated	50mg	Tablet	Cyclofen	2	2	3	0	5	4	2	2	2	2	2	**26**	0	5	5	0	0	4	0	0	**14**	**40**
100s																											
2	49	Mefenamic Acid	500mg	Tablet	Gripan Forte	2	2	3	0	5	4	2	2	2	2	2	**26**	0	0	0	0	0	0	0	0	**0**	**26**
100s																											
3	51	Meloxicam	15mg	Tablet	Coxibit	2	2	3	0	5	4	2	2	2	2	2	**26**	0	0	0	0	0	0	0	0	**0**	**26**
10s																											
4	65	Paracetamol + Orphenadrine	450mg + 35mg	Tablet	Norden	2	2	3	0	5	4	2	2	2	2	2	**26**	0	0	0	0	0	0	0	0	**0**	**26**
100s																											
5	66	Paracetamol + Tramadol	325mg + 37.5mg	Tablet	Tramadan Plus	2	2	3	0	5	4	2	2	2	2	2	**26**	0	0	0	0	0	0	0	0	**0**	**26**
10s																											
6	137	Fluconazole	150mg	Capsule	Danflu	2	2	3	0	5	4	2	2	2	2	2	**26**	0	0	0	0	0	0	0	0	**0**	**26**
1s																											
7	147	Terbinafine	250mg	Tablet	Danabid	2	2	3	0	5	4	2	2	2	2	2	**26**	0	0	0	0	0	0	0	0	**0**	**26**
10s																											
8	153	Cetirizine	10mg	Tablet	D-Zine	2	2	3	0	5	4	2	2	2	2	2	**26**	0	5	5	0	0	4	0	0	**14**	**40**
30S																											
9	160	Montelukast	10mg	Tablet	Monkast	2	2	3	0	5	4	2	2	2	2	2	**26**	0	5	5	0	0	4	0	0	**14**	**40**
14s																											
10	230	Ciprofloxacin	250mg	Tablet	Danpro	2	2	3	0	5	4	2	2	2	2	2	**26**	0	5	5	0	0	4	0	0	**14**	**40**
10s																											
11	231	Ciprofloxacin	500mg	Tablet	Danpro	2	2	3	0	5	4	2	2	2	2	2	**26**	0	5	5	0	0	4	0	0	**14**	**40**
10s																											
12	251	Doxycycline	100mg	Capsule	Hyclodox	2	2	3	0	5	4	2	2	2	2	2	**26**	0	0	0	0	0	0	0	0	**0**	**26**
100																											
13	264	Levofloxcain	250mg	Tablet	Levoden	2	2	3	0	5	4	2	2	2	2	2	**26**	0	5	5	0	0	4	0	0	**14**	**40**
10s																											

Rutu

10s	14	265	Levofloxcain	500mg	Tablet	Levoden	2	2	3	0	5	4	2	2	2	2	2	**26**	0	5	5	0	0	4	0	0	**14**	**40**
5s	15	267	Lincomycin	300mg/ml (2ml)	Inj	Lincodan	2	2	3	0	5	4	2	2	2	2	2	**26**	0	5	5	0	0	Alu-Glass	0	0	**10**	**36**
5s	16	275	Moxifloxacin	400mg	Tablet	Moxitex	2	2	3	0	5	4	2	2	2	2	2	**26**	0	5	5	0	0	4	0	0	**14**	**40**
5s	17	375	Iron Sucrose	20mg/ml	Inj	Danfer	2	2	3	0	5	4	2	2	2	2	2	**26**	0	5	5	0	0	4	0	0	**14**	**40**
10s	18	376	Mecobalamin	500mcg	Inj	Methyvit	2	2	3	0	5	4	2	2	2	2	2	**26**	0	5	5	0	0	0	0	0	**10**	**36**
20s	19	451	Losartan Potassium	25mg	Tablet	Dansart	2	2	3	0	5	4	2	2	2	2	2	**26**	0	5	5	0	0	4	0	0	**14**	**40**
20s	20	452	Losartan Potassium	50mg	Tablet	Dansart	2	2	3	0	5	4	2	2	2	2	2	**26**	0	5	5	0	0	4	0	0	**14**	**40**
50s	21	503	Domperidone	10mg	Tablet	Vomistop	2	2	3	0	5	4	2	2	2	2	2	**26**	0	5	5	0	0	4	0	0	**14**	**40**
10s	22	507	Famotidine	40mg	Tablet	Gastapil	2	2	3	0	5	4	2	2	2	2	2	**26**	0	5	5	0	0	4	0	0	**14**	**40**
14s	23	518	Esomeprazole	40mg	Capsule	Esodin	2	2	3	0	5	4	2	2	2	2	2	**26**	0	0	0	0	0	0	0	0	**0**	**26**
5s	24	520	Ondansetron	2mg/ml	Injection	Dansetron	2	2	3	0	5	4	2	2	2	2	2	**26**	0	5	5	0	0	4	0	0	**14**	**40**
25s	25	537	Dexamethasone	4mg/ml	Injection	Danadex	2	2	3	0	5	4	2	2	2	2	2	**26**	0	0	0	0	0	Glass	0	0	**0**	**26**
1s	26	585	Trriamcinolone Acetonide	40mg	Injection	Danacort	2	2	3	0	5	4	2	2	2	2	2	**26**	0	5	5	0	0	Alu-Glass	0	0	**10**	**36**
14s	27	753	Pregabalin	50mg	Capsule	Gabfast	2	2	3	0	5	4	2	2	2	2	2	**26**	0	5	5	0	0	4	0	0	**14**	**40**
14s	28	754	Pregabalin	75mg	Capsule	Gabfast	2	2	3	0	5	4	2	2	2	2	2	**26**	0	5	5	0	0	4	0	0	**14**	**40**
14s	29	755	Pregabalin	150mg	Capsule	Gabfast	2	2	3	0	5	4	2	2	2	2	2	**26**	0	5	5	0	0	4	0	0	**14**	**40**
10s	30	761	Resperidone	2mg	Tablet	Autist	2	2	3	0	5	4	2	2	2	2	2	**26**	0	5	5	0	0	4	0	0	**14**	**40**
10s	31	762	Resperidone	4mg/ml	Tablet	Autist	2	2	3	0	5	4	2	2	2	2	2	**26**	0	5	5	0	0	4	0	0	**14**	**40**
20s	32	764	Sertraline	100mg	Tablet	Sertral	2	2	3	0	5	4	2	2	2	2	2	**26**	0	5	5	0	0	4	0	0	**14**	**40**
15g	33	870	Fusidic Acid	2% 15gm	Cream	Sidik	2	2	3	0	5	4	2	2	2	2	2	**26**	0	5	5	0	0	4	0	0	**14**	**40**
60ml	34	886	Permethrin	60ml	Lotion	Permite lot	2	2	3	0	5	4	2	2	2	2	2	**26**	0	0	0	0	0	0	0	0	**0**	**26**
10g	35	894	Terbindafine	1% 10gm	Cream	Danabid	2	2	3	0	5	4	2	2	2	2	2	**26**	0	0	0	0	0	0	0	0	**0**	**26**

SCRUTINY REPORT

1 Prinicipal Manufacture for Meloxicam in GD and COA are not matching at pdf page No. 365-379.

2 GD and COA of itemssuch as Terbinfine and Fluconazole at formulary No. 137, 147 and 894 are not matching from the documents attached at pdf page No. 380-398 of the technical bid.

3 Batch number of the item quoted at formuly No. 518 (Esomeprazole) are not mentioned in the GDs and the prinicpal manufacturer source in the COA are also not matching with the GD at pdf page No. 400-449 of the technical bid.

4 GD of the Doxycycline are older than the advertised criteria at pdf page No. 450-466 of the technical bid.

5 GD of Paracetamol is not attached in the bid, wheras GD of Tramadol attached in the technical bid at Pdf Page No. 527 is older than the advertised criteria. Hence, marks may not be awarded in respective column,

6 GD of Cetirizine is of Symbolife Pharma whereas the prinicipal manufacturer shown in the COA is a different firm name Mahrshee at pdf page No. 563.

7 GD of Dexamethasone at pdf Page No. 632 of the technical bid is older than the advertised criteria. Hence, marks may not be awarded.

8 Valid WHO prequalification or valid product registration in SRA/WLA countries or Valid free sale certificate by SRA/WLA could not be found in the technical bid.

9 At pdf Page No. 917, the aluminium collapsable tube for sidik cream COA states food grade lacquer instead of Pharmaceutical grade.

10 At pdf Page No. 929, the aluminium collapsable tube for Damabid cream COA states food grade lacquer instead of Pharmaceutical grade.

11 At page No. 971-972, COA of Amber colour glass doesnot stated any USP type of glass material.

12 Stability studies attached from pdf page No. 1133 to 1221 of thr technical bid are not duly attested by the QC incharge of the firm. Hence, doesn't fulfill the advertised criteria.

13 No supportive documents related to column 8, 17 & 24 are attached.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: Davis Pharmaceuticals , 121, Industrial Triangle Area, Kahuta Road, Islamabad, 051-4490459, 4491851-52, Focal Person: Muhammad Saqib S/O Ishfaq Ahmed, Contact Number: 0312-9162003, Email: instsales.davis@gmail.com

Technical Evaluation Matrix

S. No.	Product General Information					Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters									Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters										
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
	647	Flavored Oral Rehydration Salt (Low Osmolarity)	Sodium Chloride Sachet (2.6 g/L) Glucose Anhydrous (13.5 g/L) Potassium Chloride (1.5 g/L)	Sachet	Davisalts ORS	2	2	3	2	5	4	2	2	2	2	2	**28**	0	0	0	0	0	0	5	0	**5**	**33**
	407	Atenolol	50 mg	Tab.	Ezilife	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	0	0	0	5	0	**15**	**43**
	736	Levetiracetam	500 mg	Tab.	Lovitrim	2	2	3	2	5	4	2	2	2	2	2	**28**	0	0	0	0	0	0	5	0	**5**	**33**
	870	Fusidic acid	2%	Cream	Pathoderm Cream 15gm	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	0	0	0	0	5	0	**10**	**38**
	452	Losartan Potassium	50 mg	Tab.	Prozar	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	0	0	0	5	0	**15**	**43**
	581	Sitagliptin + Metformin	50 mg/500 mg	Tab.	Siglamet 50/500mg	2	2	3	2	5	4	2	2	2	2	2	**28**	0	0	0	0	0	0	5	0	**5**	**33**
	190	Azithromycin	500 mg	Tab. / Cap.	Zithro	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	0	0	0	5	0	**15**	**43**

Scrutiny report
1IMS share for the quoted products is less tan 1%.
2DRAP approved price list is not present
3Images / Pictures of DRAP approved packaging are not attached in the bid for award of marks in respective criteria
4GD, COA of Sitagliptin + Metformin are not present
5GDs and COAs of all ingredients of ORS are not present in the bid.
6CoA of fusidic acid is not present.
7GD and CoA of Levetiracetam are not present in the bid.
Bidding firm name not mentioned on the mandatory CDR

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm | **Dewmax Pharmaceuticals , Plot No. 6, Street No. N-SS-4, National Industrial Zone (RCCI), Rawat, Islamabad, Focal Person: Shah Muhammad, Email: info@dewmaxpharmaceuticals.com, Contact Number: 0315-9138834**

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm)**.	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this colounm for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
	45	Ibuprofen	200mg/5ml	Suspension, 120ml	Dewrof DS	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	0	5	0	**15**	**39**
	46	Ibuprofen	100mg/5ml	Suspension, 90ml	Dewrof	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	0	5	0	**15**	**39**
	60	Paracetamol plain 5mg/5ml	120mg/5ml	Suspension, 120ml	Dewmol	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	0	5	0	**15**	**39**
	61	Paracetamol 6 plus 5mg/5ml	250mg/5ml	Suspension, 90ml	Dewmol 6 plus	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	0	0	0	**10**	**34**
	65	Paracetamol + Orphenadrine	450/35mg	Tablet, 100s	Pauco	2	2	3	0	5	2	2	2	2	2	2	**24**	0	0	0	0	0	0	5	0	**5**	**29**
	66	Tramadol 37.5mg + Paracetamol 325mg	37.5mg/325mg	Tablet, 30s	Nitram	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	0	5	0	**15**	**39**
	68	Tizanidine	4mg	Tablet, 10s	N-Tiz	2	2	3	0	5	2	2	2	2	2	2	**24**	0	0	0	0	0	0	5	0	**5**	**29**
	137	Fluconazole	150mg	Capsule, 4s	E-brus	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	2	5	0	**17**	**41**
	141	Itraconazole	100mg	Capsule, 4s	Fewnaz	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	2	5	0	**17**	**41**
	147	Terbinafine	250mg	Tablet, 10s	Tinadew	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	0	5	0	**15**	**39**
	517	Omeprazole	40mg	Capsule, 100s packing	O-Dew	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	2	5	0	**17**	**41**
	518	Esomeprazole	40mg	Capsule- 100s packing	ES-Dew	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	2	5	0	**17**	**41**
	802	Doxophylin	100mg/5ml	Syrup, 60ml	Dewlin	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0		5	0	**15**	**39**
	272	Meropenem	500mg	injection	Dewnem	2	2	3	0	5	2	The inspection team during inspection made following observations; Poor Environmental/HVAC control • The Calibration of thermo-hygrometer in the injectable (carbapenem) filling area expired in Jan 2026. • There was no production in the injectable area. • During the inspection, the silica gel desiccant placed between the double-paned windows in the Carbapenem clean rooms was found saturated and discolored, indicating failure of the window sealing system and ingress of moisture/humid air between the panes. Such condition reflects inadequate environmental and HVAC control measures affecting humidity regulation and maintenance of cleanroom pressure differentials.					**14**	0	5	5	0	0	0	5	0	**15**	**29**
	273	Meropenem	1gm	injection	Dewnem	2	2	3	0	5	2	Non adherence to GMP: • The compromised integrity of the double-paned cleanroom windows in the Carbapenem sterile manufacturing area constitutes a major cGMP deficiency, as it may permit exchange of contaminated air/moisture with the cleanroom environment, thereby compromising contamination control, aseptic conditions, and the integrity of the sterile manufacturing environment. **Recommended for oral products only.**					**14**	0	5	5	0	0	0	5	0	**15**	**29**

Scrutiny report

1 EDQM Document at Page 350 does not fulfill the advertised criteria
2 CoA of 20ml vial at Page 430 does not mention the tupe of glass material
3 CoA of 15ml vial is not present
4 CoA of Aluminum foil is not present
5 CoA of Syrup bottles is not present
6 API Source US FDA at Page No 431 is not supported with form3 and form7
7 GD of tizanidine at Page 316 is older than 2 years
8 GD of orphenadrine is not present
9 Stability studies of Paracetamol 250mg Susp not rpesent
10 Tender approvals from Page Nos. 451 are attached instead of IMS/IQVIA.

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27														
Name of the firm						DKT Pakistan Ltd- Plot No. 34-C, Khalid Commercial Street-1, DHA Phase-7 Ext.,Karachi. Tel: 021-38651019 Cell: 0321-2444739 E-mail: info@dktpakistan.org Web: www.dktpakistan.org														
						Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevent certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
Thai Nippon Rubber Industry Public Company Limited, Thailand.	485	Male Latex Condom		Condom	JOSH CLASSIC	3	5	0	5	6	6	**25**	0	0	0	1	2	16	**19**	**44**

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: INDUS VALLEY PHARMA L. 6429262

S. No.		Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Technical Evaluation Matrix	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid WHO GMP/ISO 13485/ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PSQCA/ Provincial Drug Authority/ Drug Control Authority/ Health Department of the same country (Attested by Notary Public/ Oath Commissioner/ Home/ Consular Authority) (Attested by notary public/ oath commissioner/ Home/ Consular Authority) (Attested by notary public/ oath commissioner/ Home/ Consular Authority) (Attested by notary public/ oath

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposibles and Sutures for Government MCC 2026-27

Name of the firm Essity Pakistan Pvt. Ltd

		Product General Information				Technical Evaluation Matrix															
						Factory Technical Evaluation Parameter								Factory Evaluated Score	Product technical Evaluation Parameters						
						Documents Based Factory Score				Evaluation Visit Score										Product Evaluated Score	Total Technical Score
S.No	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. **(as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.**	Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAP regulations. **(to be evaluated by the MCC expert/s at the time of inspection, Noncompliance to cGMP shall lead to disqualification of the relevant section or firm)**	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section / firm.**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC** **(Certificate Duly attested by Senior Executive of the firm)**	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and / or valid product registration in SRA/WLA country(ies) / and / or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	6	3	3	2	2	29	5	5	5	6	10	10	41	70
	981	Crepe Bandages BPC 7.5cm x 4.5m	1 Pcs / 1x1	Roll	Elastocrepe	3	5	5	6	3	3	2	2	29	5	5	0	0	10	10	20	49
	982	Crepe Bandages BPC 10cm x 4.5m	1 Pcs / 1x1	Roll	Elastocrepe	3	5	5	6	3	3	2	2	29	5	5	0	0	10	10	20	49
	983	Crepe Bandages BPC 15cm x 4.5m	1 Pcs / 1x1	Roll	Elastocrepe	3	5	5	6	3	3	2	2	29	5	5	0	0	10	10	20	49
	1192	POP Bandages 15cm x 2.7m	1 Pcs / 1x1	Roll	Gypsona	3	5	5	6	3	3	2	2	29	5	5	0	0	10	10	20	49
	1193	POP Bandages 10cm x 2.7m	1 Pcs / 1x1	Roll	Gypsona	3	5	5	6	3	3	2	2	29	5	5	0	0	10	10	20	49
	1307	Zinc oxide adhesive Plaster (Cloth Tape) 2.5 cm x 5m	1 Pcs / 1x1	Spool	Paragon	3	5	5	6	3	3	2	2	29	5	5	0	0	10	10	20	49
	1308	Zinc oxide adhesive Plaster (Cloth Tape) 5 cm x 5m	1 Pcs / 1x1	Spool	Paragon	3	5	5	6	3	3	2	2	29	5	5	0	0	10	10	20	49
	1309	Zinc oxide adhesive Plaster (Cloth Tape) 7.5 cm x 5m	1 Pcs / 1x1	Spool	Paragon	3	5	5	6	3	3	2	2	29	5	5	0	0	10	10	20	49
	1310	Zinc oxide adhesive Plaster (Cloth Tape) 10 cm x 5m	1 Pcs / 1x1	Spool	Paragon	3	5	5	6	3	3	2	2	29	5	5	0	0	10	10	20	49

SCRUTINEY REPORT

Valid WHO prequalification and / or valid product registration in SRA/WLA country(ies) / and or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) is not attached in the original bid
Tender approvals attached in the original bid are not as per criteria (Attestation has not been sought from the procurement officer, Bank statements, cheques and SOs are not matchable)

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: Evolution Pharma

S. No.		Product General Information				Technical Evaluation Matrix																				
						Factory Technical Evaluation Parameters												Product Evaluation Parameters								
						Documents Based Factory Score						Factory Evaluation Visit Score					Total Factory Evaluated Score	Product Technical Parameters								Total Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month)**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this colounm for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
1	65	Paracetamol 450mg + Orphenadrine Citrate 35mg		Tab	Corilax Tablets 450/35mg	2	2	3	2	5	4						**18**	0	0	0	0	0	aluminium foil COA missing on page 436	5	0	**5**	**23**
2	66	Tramadol Hydrochloride 37.5mg + Paracetamol 325mg		Tab	Traligix Plus Tablets 37.5/325mg	2	2	3	2	5	4						**18**	0	0	0	0	0	aluminium foil COA missing on page 467	5	0	**5**	**23**
3	141	Itraconazole 100mg		Cap	Itrevo Capsules 100mg	2	2	3	2	5	4						**18**	0	5	5	0	0	aluminium foil COA missing on page 484	5	0	**15**	**33**
4	202	Cefepime HCl 500mg		Inj	Adipine Injection 500mg IV	2	2	3	2	5	4						**18**	0	5	5	0	0	vial COA not provided page 506	5	0	**15**	**33**
5	203	Cefepime HCl 1g		Inj	Adipine Injection 1g IV	2	2	3	2	5	4						**18**	0	5	5	0	0	vial Coa not provided page 555	5	0	**15**	**33**
6	269	Linezolid 100mg		DS	Linbatc Dry Susp. 100mg	2	2	3	2	5	4	The mandatory requirement "cGMP certificate" of the firm at the time of inspection was found expired. The same is attached in the technical bid. **Hence Not Recommended**					**18**	0	5	5	0	0	no COA of amber bottle on page 555	5	0	**15**	**33**
7	513	Loperamide HCl 2mg		Cap	Coliper Capsules 2mg	2	2	3	2	5	4						**18**	0	5	5	0	0	no COA of immediate container on page 570	5	0	**15**	**33**
8	726	Fluoxetine Hydrochloride 20mg		Cap	Setinevo Capsules 20mg	2	2	3	2	5	4						**18**	0	5	5	0	0	no COA of al foil on page 598	5	0	**15**	**33**
9	870	Fusicid Acid 2%/w/w		Cream	Evocort Cream 2%/w/w	2	2	3	2	5	4						**18**	0	5	5	0	0	no COA of immediate container on page 619	5	0	**15**	**33**
10	891	Silver Sulfadiazine 1%/w/w		Cream	Silevo Cream 1% w/w	2	2	3	2	5	4						**18**	0	5	5	0	0	no COA of immediate container on page 644	5	0	**15**	**33**
11	905	Povidone-Iodine 10%/w/v		Sol	Ponvid Topical Solution 10%/w/v	2	2	3	2	5	4						**18**	0	5	5	0	0	no COA of immediate container on page 667	5	1	**16**	**34**

Report

1

Report
1.PO attached inmstaed of CDR
2.CGMP expired
3.COAs of immediate container are incomplete

						Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27														
					Name of the firm:	ESSITY PAKISTAN LIMITED													
S. No.		Product General Parameter				Technical Evaluation Matrix												Product Evaluated Score	Total Technical Score
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score							
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the time of inspection at the warehouse at the tim eof inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** **(Certificate duly attaested by**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US free sale certificate of the quoted products, **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**3**	**5**	**5**	**5**	**5**	**6**	**29**	**5**	**5**	**5**	**6**	**10**	**10**	**41**	**70**
	932	Bacterial Binding Dressing	7.5cm x 8.5cm	Dressing	Cutimed Sorbact Hydroactive	**3**	**5**	**5**	**5**	**5**	**6**	**29**	**5**	5	No tender approvals attached in the bid	6	**10**	**10**	**31**	**36**
	932	Bacterial Binding Dressing	14cm x 14cm	Dressing	Cutimed Sorbact Hydroactive	**3**	**5**	**5**	**5**	**5**	**6**	**29**	**5**	5	No tender approvals attached in the bid	6	**10**	**10**	**31**	**36**
	960	Casting Tape 6"	12.5cm x 3.6m	Roll	Flashcast	**3**	**5**	**5**	**5**	**5**	**6**	**29**	**5**	5	No tender approvals attached in the bid	6	**10**	**10**	**31**	**36**
	961	Casting Tape 4"	10cm x 3.6m	Roll	Flashcast	**3**	**5**	**5**	**5**	**5**	**6**	**29**	**5**	5	No tender approvals attached in the bid	6	**10**	**10**	**31**	**36**
	1092	Fiberglass Splint	10cm x 30cm	Roll	Dynacast	**3**	**5**	**5**	**5**	**5**	**6**	**29**	**5**	5	No tender approvals attached in the bid	6	**10**	**10**	**31**	**36**
	1092	Fiberglass Splint	12.5cm x 65cm	Roll	Dynacast	**3**	**5**	**5**	**5**	**5**	**6**	**29**	**5**	5	No tender approvals attached in the bid	6	**10**	**10**	**31**	**36**
	1110	Hydrogel dressing	15cm x 20cm	Dressing	Cutimed Sorbact Gel	**3**	**5**	**5**	**5**	**5**	**6**	**29**	**5**	5	No tender approvals attached in the bid	6	**10**	**10**	**31**	**36**
	1110	Hydrogel dressing	7.5cm x 15cm	Dressing	Cutimed Sorbact Gel	**3**	**5**	**5**	**5**	**5**	**6**	**29**	**5**	5	No tender approvals attached in the bid	6	**10**	**10**	**31**	**36**
	1110	Hydrogel dressing	7.5cm x 7.5cm	Dressing	Cutimed Sorbact Gel	**3**	**5**	**5**	**5**	**5**	**6**	**29**	**5**	5	No tender approvals attached in the bid	6	**10**	**10**	**31**	**36**
Non formulary	1163	Non-Medicated sterillized adhesive post operative wound dressing **9x10cm**	**10cm x 8cm**	Dressing	Leukomed	**NF**	**NF**	**NF**	**5**	**5**	**6**	**16**			No tender approvals attached in the bid	0	**10**	**10**	**20**	**20**
Non formulary	1164	Non-Medicated sterillized adhesive post operative wound dressing **9x15cm**	**15cm x 8cm**	Dressing	Leukomed	**NF**	**NF**	**NF**	**5**	**5**	**6**	**16**			No tender approvals attached in the bid	0	**10**	**10**	**20**	**20**
	1165	Non-Medicated sterillized adhesive post operative wound dressing 9x20cm	20cm x 10cm	Dressing	Leukomed	**3**	**5**	**5**	**5**	**5**	**6**	**29**	5	5	No tender approvals attached in the bid	6	**10**	**10**	**31**	**36**
	1166	Non-Medicated sterillized adhesive post operative wound dressing 9x25cm	25cm x 10cm	Dressing	Leukomed	**3**	**5**	**5**	**5**	**5**	**6**	**29**	5	5	No tender approvals attached in the bid	6	**10**	**10**	**31**	**36**
	1167	Non-Medicated sterillized adhesive post operative wound dressing 9x30cm	30cm x 10cm	Dressing	Leukomed	**3**	**5**	**5**	**5**	**5**	**6**	**29**	5	5	No tender approvals attached in the bid	6	**10**	**10**	**31**	**36**
	1168	Non-woven Fabric Surgical Adhesive Fix Roll	10cm x 10cm	Roll	Fixomull	**3**	**5**	**5**	**5**	**5**	**6**	**29**	5	5	No tender approvals attached in the bid	6	**10**	**10**	**31**	**36**
	1168	Non-woven Fabric Surgical Adhesive Fix Roll	10cm x 10cm	Roll	Fixomull	**3**	**5**	**5**	**5**	**5**	**6**	**29**	5	5	No tender approvals attached in the bid	6	**10**	**10**	**31**	**36**
	1184	Paraffin Gauze dressing (Tulle) with Chlorhexidine 10x10 cm		Dressing	Bactigras	**3**	**5**	**5**	**5**	**5**	**6**	**29**	5	5	No tender approvals attached in the bid	6	**10**	**10**	**31**	**36**
	1194	PU Adhesive Incise Drape Film 10 cm x 14cm	10cm x 14cm	Incise Drape	Opsite	**3**	**5**	**5**	**5**	**5**	**6**	**29**	5	5	No tender approvals attached in the bid	6	**10**	**10**	**31**	**36**
	1195	PU Adhesive Incise Drape Film 15 cm x 28cm	28cm x 15cm	Incise Drape	Opsite	**3**	**5**	**5**	**5**	**5**	**6**	**29**	5	5	No tender approvals attached in the bid	6	**10**	**10**	**31**	**36**
	1196	PU Adhesive Incise Drape Film 30 cm x 28cm	28cm x 30cm	Incise Drape	Opsite	**3**	**5**	**5**	**5**	**5**	**6**	**29**	5	5	No tender approvals attached in the bid	6	**10**	**10**	**31**	**36**
	1197	PU Adhesive Incise Drape Film 45 cm x 28cm	28cm x 45cm	Incise Drape	Opsite	**3**	**5**	**5**	**5**	**5**	**6**	**29**	5	5	No tender approvals attached in the bid	6	**10**	**10**	**31**	**36**
	1198	PU Adhesive Incise Drape Film 55 cm x 44cm	55cm x 45cm	Incise Drape	Opsite	**3**	**5**	**5**	**5**	**5**	**6**	**29**	5	5	No tender approvals attached in the bid	6	**10**	**10**	**31**	**36**
	1287	Transparent IV Dressing Different Sizes	6cm x 8cm	Dressing	Leukomed IV	**3**	**5**	**5**	**5**	**5**	**6**	**29**	5	5	No tender approvals attached in the bid	6	**10**	**10**	**31**	**36**
	1287	Transparent IV Dressing Different Sizes	7cm x 9cm	Dressing	Leukomed IV	**3**	**5**	**5**	**5**	**5**	**6**	**29**	5	5	No tender approvals attached in the bid	6	**10**	**10**	**31**	**36**
	1287	Transparent IV Dressing Different Sizes	8.5cm x 11.5cm	Dressing	Leukomed IV	**3**	**5**	**5**	**5**	**5**	**6**	**29**	5	5	No tender approvals attached in the bid	6	**10**	**10**	**31**	**36**

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: FAHMIR PHARMA (Pvt) Ltd. M/S FAHMIR PHARMA (Pvt) Ltd. 26-KM, Lahore Road Jaranwala Road,Main Stop Mandiawala, Tehsil Sharaqpur,District Sheikhupura. Phone Numbers

Technical Evaluation Matrix

S. No.	Product General Information					Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters									Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters										
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L,	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to Import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70
	60	Paracetamol	500 mg	Tab.	Paredadol	2	2	3	0	5	0						12	0	0	0	0	0	2	5	0	7	19
	67	Paracetamol + Tramadol	325 mg / 37.5 mg	Tab.	Tramir	2	2	3	0	5	0						12	0	0	0	0	0	0	5	0	5	17
	93	Tacrolimus	1 mg	Tab. / Cap.	Merograf 1 mg	2	2	3	0	5	0						12	0	5	5	0	0	2	0	0	12	24
	94	Tacrolimus	0.5 mg	Tab. / Cap.	Merograf 0.5	2	2	3	0	5	0						12	0	5	5	0	0	2	0	0	12	24
	135	Fluconazole	150 mg	Tab. / Cap.	Zublimir 150	2	2	3	0	5	0						12	0	0	0	0	0	2	5	0	7	19
	158	Montelukast	10 mg	Tab.	Montimir 10	2	2	3	0	5	0						12	0	0	0	0	0	0	0	0	0	12
	159	Montelukast	5 mg	Tab.	Montimir 5	2	2	3	0	5	0						12	0	0	0	0	0	0	5	0	5	17
	160	Montelukast	4 mg	Sachet	Montimir Sachet	2	2	3	0	5	0						12	0	0	0	0	0	0	0	0	0	12
	189	Azithromycin	250 mg	Tab. / Cap.	Azomyr 250	2	2	3	0	5	0						12	0	0	0	0	0	0	5	0	5	17
	190	Azithromycin	500 mg	Tab. / Cap.	Azomyr 500	2	2	3	0	5	0						12	0	0	0	0	0	0	0	0	0	12
	230	Ciprofloxacin	250 mg	Tab.	Cipromir 250	2	2	3	0	5	0						12	0	5	5	0	0	0	0	0	10	22
	231	Ciprofloxacin	500 mg	Tab.	Cipromir 500	2	2	3	0	5	0						12	0	5	5	0	0	0	5	0	15	27
	234	Clarithromycin	250 mg	Tab.	Clarifah 250	2	2	3	0	5	0						12	0	0	0	0	0	0	0	0	0	12
	235	Clarithromycin	500 mg	Tab.	Clarifah 500	2	2	3	0	5	0						12	0	0	0	0	0	0	0	0	0	12
	264	Levofloxacin	250 mg	Tab.	Levomir 250	2	2	3	0	5	0						12	0	0	0	0	0	0	0	0	0	12
	265	Levofloxacin	500 mg	Tab.	Levomir 500	2	2	3	0	5	0						12	0	0	0	0	0	0	5	0	5	17
	275	Moxifloxacin	400 mg	Tab.	Fahmox 400	2	2	3	0	5	0						12	0	0	0	0	0	0	5	0	5	17
	406	Atenolol	50 mg	Tab.	Atelomir 50	2	2	3	0	5	0						12	0	0	0	0	0	2	5	0	7	19
	407	Atenolol	100 mg	Tab.	Atelomir 100	2	2	3	0	5	0						12	0	0	0	0	0	2	0	0	2	14
	516	Omeprazole	40 mg	Cap.	Omir 40	2	2	3	0	5	0						12	0	5	5	0	0	0	5	0	15	27
	517	Esomeprazole	40 mg	Cap.	BFR 40	2	2	3	0	5	0						12	0	5	5	0	0	0	0	0	10	22
	572	Sitagliptin + Metformin	50 mg / 500 mg	Tab.	Metomir 50/500	2	2	3	0	5	0						12	0	0	0	0	0	0	0	0	0	12
	573	Sitagliptin + Metformin	50 mg / 1000 mg	Tab.	Metomir 50/1000	2	2	3	0	5	0						12	0	0	0	0	0	0	0	0	0	12
	713	Escitalopram	10 mg	Tab.	Escitofahm	2	2	3	0	5	0						12	0	0	0	0	0	0	0	0	0	12

The inspection team at the time of inspection observed that,
Non Adherence to current Good Manufacturing Practices (cGMP)
i. In deducting area, vacuum cleaner out of order.
ii. In RMS, the sampling balance was not calibrated and when standard dead weight of 50gm was checked on the balance, it showed 30.34gm. The epoxy floor was damaged in the sampling room.
iii. In API raw material store, hygrometer logbook was not available. Pressure
iv. HVAC was non-functional in the capsule filling & tablet compression area.
v. Flies were moving hither and thither in the main corridor. No insect killer were installed.
vi. Samples retaining room was not properly labelled, stored and master shipper cartons were directly lying on the floor.
vii. Real time stability chamber was out of range, the humidity observed was 52% RH.
viii. HVAC system was non-functional at the time of inspection. Moreover, majority of the HVAC ducts were loosely fitted.
ix. Capsule filling area was non-functional at the time of inspection.
Hence, the firm is NOT RECOMMENDED for award of factory evaluation visit score for the quoted items.

Scrutiny report
1Esomeprazole 20mg stability is attached-page 263. while quoted item is 40mg
2GDs for Paracetamol, Fluconazole, Levofloxacin, Atenolol, Metformin, Sitagliptin, Escitalopram are not present in the bid.
3CoA cannot be awarded in absence of GDs
4CoAs of immediate container for Alu Alu blisters are not complete. Only atenolol and paracetamol tabs are awarded 2 marks each being Alu-PVC
5Income tax return / FBR document not attached therfore financial turnover cannot be ascertained.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: **Focus & Rulz, 44-Industrial Triangle, Kahuta Road, Islamabad**

S. No.		Product General Information				Technical Evaluation Matrix												Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Technical Parameters									
						Documents Based Factory Score						Factory Evaluation Visit Score															
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm)**.	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this colounm for the respective item.** For award of marks, the certificate of analysis must	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
	65	Paracetamol + Orphenadrine	450mg/35mg	Tab.	Molodrin	2	2	3	0	0	6	2	2	2	2	2	**23**	0	5	5	0	0	0	5	0	**15**	**38**
	132	Clotrimazole	500mg Vaginal tablet with applicator	Tab.	CandiEase-V	2	2	3	0	0	6	2	2	2	2	2	**23**	0	5	5	0	0	0	5	0	**15**	**38**
	159	Loratadine	10mg	Tab.	Senergy OD	2	2	3	0	0	6	2	2	2	2	2	**23**	0	5	5	0	0	0	5	0	**15**	**38**
	160	Montelukast	10mg	Tab.	Lakas	2	2	3	0	0	6	2	2	2	2	2	**23**	0	5	5	0	0	0	5	0	**15**	**38**
	160	Montelukast	5mg	Tab.	Lakas	2	2	3	0	0	6	2	2	2	2	2	**23**	0	5	5	0	0	0	5	0	**15**	**38**
	230	Ciprofloxacin	250mg	Tab.	Ciprulz	2	2	3	0	0	6	2	2	2	2	2	**23**	0	0	0	0	0	0	5	0	**5**	**28**
	231	Ciprofloxacin	500mg	Tab.	Ciprulz	2	2	3	0	0	6	2	2	2	2	2	**23**	0	0	0	0	0	0	0	0	**0**	**23**
	264	Levofloxacin	250mg	Tab.	Woff	2	2	3	0	0	6	2	2	2	2	2	**23**	0	0	0	0	0	0	5	0	**5**	**28**
	265	Levofloxacin	500mg	Tab.	Woff	2	2	3	0	0	6	2	2	2	2	2	**23**	0	0	0	0	0	0	brand is different	0	**0**	**23**
	275	Moxifloxacin	400mg	Tab.	Moxirulz	2	2	3	0	0	6	2	2	2	2	2	**23**	0	5	5	0	0	0	5	0	**15**	**38**
	300	Artemether + Lumefantrine	40mg + 240mg	Tab.	Arther DS	2	2	3	0	0	6	2	2	2	2	2	**23**	0	5	5	0	0	0	5	0	**15**	**38**
	301	Artemether + Lumefantrine	80mg + 480mg	Tab.	Arther Forte	2	2	3	0	0	6	2	2	2	2	2	**23**	0	5	5	0	0	0	5	0	**15**	**38**
	302	Artemether + Lumefantrine	15mg + 90mg / 5ml, 60ml	Syp.	Arther	2	2	3	0	0	6	2	2	2	2	2	**23**	0	5	5	0	0	0	5	0	**15**	**38**
	371	Iron (III) Hydroxide Polymaltose Complex	100mg	Tab.	M-Fer	2	2	3	0	0	6	2	2	2	2	2	**23**	0	5	5	0	0	0	5	0	**15**	**38**
	507	Famotidine	40mg	Tab.	Ulfam	2	2	3	0	0	6	2	2	2	2	2	**23**	0	0	0	0	0	0	5	0	**5**	**28**
	517	Omeprazole	40mg	Cap.	Helezol	2	2	3	0	0	6	2	2	2	2	2	**23**	0	5	5	0	0	0	brand is different	0	**10**	**33**
	518	Esomeprazole	40mg	Cap.	Esro	2	2	3	0	0	6	2	2	2	2	2	**23**	0	5	5	0	0	0	5	0	**15**	**38**
	533	Zinc Sulphate	Syrup 60ml	Syp.	Rulozine	2	2	3	0	0	6	2	2	2	2	2	**23**	0	0	0	0	0	0	brand is different	0	**0**	**23**
	808	Ketotifen	1mg	Tab.	Aria	2	2	3	0	0	6	2	2	2	2	2	**23**	0	5	5	0	0	0	5	0	**15**	**38**
	809	Ketotifen	0.2mg/ml 60ml	Syp.	Aria	2	2	3	0	0	6	2	2	2	2	2	**23**	0	5	5	0	0	0	5	0	**15**	**38**
	870	Fusidic Acid	Cream 2%, 15gm	Cream	Sirulz	2	2	3	0	0	6	2	2	2	2	2	**23**	0	5	5	0	0	0	5	0	**15**	**38**
	736	Levetiracetam	500mg	Tab.	Lectom	2	2	3	0	0	6	2	2	2	2	2	**23**	0	5	5	0	0	0	5	0	**15**	**38**

Scrutiny report

1 Airway bill for levetiracetam is not present.
2 GD for fusidic acid is notpresent.
3 Pictures/Images of DRAp approved packaging are not provided in the bid.
4 Brand names for Levofloxacin 500mg, Omeprazole 40mg Cap, Zinc sulphate syp are different in the stability studies.
5 Stability for Ciprofloxacin 500mg is not provided in the bid
6 Calibration certificates for major equipment are notprovided in thebid (as per advertised criteria)
Original Mandatory forms in Hard are not submitted to the MCC

							Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27															
					Name of the firm		FRESENIUS MEDICAL CARE LAHORE															
							Technical Evaluation Matrix															
							Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
							Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score									
		MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
							Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facility/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal/ Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevent certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
		MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
Fresenius Medical Care	Dialyzer: MDIR-0000799; Bloodline: MDIR-0001627	1106	Hemodialyzer with tubing Adult (>1m²) – Fresenius Helixone membrane FX-Class Low Flux dialyzer FX8, Surface Area 1.4m² with Fresenius Blood Tubing Line 6.5 mm (One Fluid barrier)	FX8 Dialyzer, Bloodline 6.5mm		Fresenius	3	5	0	5	6	6	**25**	5	5	Not attached	1	0	16	**27**	**52**
Fresenius Medical Care	Dialyzer: MDIR-0000799; Bloodline: MDIR-0001627	1106	Hemodialyzer with tubing Adult (>1m²) – Fresenius Helixone membrane FX-Class Low Flux dialyzer FX10, Surface Area 1.8m² with Fresenius Blood Tubing Line 6.5 mm (One Fluid barrier)	FX10 Dialyzer, Bloodline 6.5mm		Fresenius	3	5	0	5	6	6	**25**	5	5	Not attached	1	0	16	**27**	**52**
Fresenius Medical Care	Dialyzer: MDIR-0000799; Bloodline: MDIR-0001627	1107	Hemodialyzer with tubing Pediatric (≤1m²) – Fresenius Helixone membrane FX-Class Low Flux dialyzer FX5, Surface Area 1.0m² with Fresenius Blood Tubing Line 6.5 mm (One Fluid barrier)	FX5 Dialyzer, Bloodline 6.5mm		Fresenius	3	5	0	5	6	6	**25**	5	5	Not attached	1	0	16	**27**	**52**
Fresenius Medical Care	Dialyzer: MDIR-0000985; Bloodline: MDIR-0001627	1107	Hemodialyzer with tubing Pediatric (≤1m²) – Fresenius polysulfone membrane low flux dialyzer F4HPS, Surface Area 0.8m² with Fresenius Blood Tubing Line 6.5 mm (One Fluid barrier)	F4HPS Dialyzer, Bloodline 6.5mm		Fresenius	3	5	0	5	6	6	**25**	5	5	Not attached	1	0	16	**27**	**52**

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: FRIENDS PHARMA PVT LTD.

Technical Evaluation Matrix

S. No.	Product General Information					Factory Technical Evaluation Parameters										Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score					Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body, duly attested by senior executive of the firm)	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body, duly attested by senior executive of the firm)	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body, duly attested by senior executive of the firm)	Latest IMS/IQVIA ranking of the loading manufacturer firm (by value) in Pakistan . **12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks, Financial turnover of more than PKR 500 million and upto 1000 million – 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good documentation practices (cGDP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP). **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chamber/s and non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, in-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to cGSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), to area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in Schedule-B of DRAP. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the sections or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to disqualification of the relevant section or firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the enroll date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid wall/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) of consignment volume 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to Import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type -I glass of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this colusmn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 2. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or higher (Non-compliance shall lead to disqualification of the quoted product). 3. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 3 glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA/ Health not older than twelve (12) months. 1-10% market share = 1 mark 11-20% market share = 2 marks 21-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary Care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Stability studies of quoted item/s daily attested by the QC incharge of the firm).		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	30	5	5	5	5	3	4	5	5	37	70
1	74208	40 Ondansetron Trishydrathmide 20mg	20 MG	Injection	Fandanto-20	0	0	0	0	5	4	2	2	2	2	2	15	0	0	0	0	0	0	0	0	0	0
2	54518	41 Mebeverin 135mg	135mg	Tablets	Mebmyfan	0	0	0	0	5	4	2	2	2	2	2	15	0	0	0	0	0	0	0	0	0	0
3	54218	42 Orphenadrine Citrate 25mg + Paracetamol 450mg	25+450MG	Tablets	Knoxpharn	0	0	0	0	5	4	2	2	2	2	2	15	0	0	0	0	0	0	0	0	0	0
4	54218	43 Chlorthalidone 50mg	50MG	Tablets	Chlorthalexia	0	0	0	0	5	4	2	2	2	2	2	15	0	0	0	0	0	0	0	0	0	0
5	54218	44 Nifedipine 10mg	10MG	Tablets	Corinfin	0	0	0	0	5	4	2	2	2	2	2	15	0	0	0	0	0	0	0	0	0	0
6	74218	45 Chlorpheniramine 2%	2% Cream	Cream	Sunrise-Cream	0	0	0	0	5	4	2	2	2	2	2	15	0	0	0	0	0	0	0	0	0	0
7	54218	46 Lamivudine 150mg/Zidovudine 300mg	450	Tablets	Zovidlivu	0	0	0	0	5	4	2	2	2	2	2	15	0	0	0	0	0	0	0	0	0	0
8	54218	47 Lansoprazole 30mg	30MG	Tablets	Lansamine	0	0	0	0	5	4	2	2	2	2	2	15	0	0	0	0	0	0	0	0	0	0
9	69018	48 Levofolinate Ascorbate 250mg	250MG	Injection	Folzita	0	0	0	0	5	4	2	2	2	2	2	15	0	0	0	0	0	0	0	0	0	0
10	69018	49 Levofolinate Ascorbate 300mg	300MG	Injection	Folzita	0	0	0	0	5	4	2	2	2	2	2	15	0	0	0	0	0	0	0	0	0	0
11	54218	50 Mercaptobenzene 300mg	300MG	Tablets	Uribamin	0	0	0	0	5	4	2	2	2	2	2	15	0	0	0	0	0	0	0	0	0	0
12	54218	51 Atenolol 50mg	50MG	Tablets	Atemo-Heart	0	0	0	0	5	4	2	2	2	2	2	15	0	0	0	0	0	0	0	0	0	0
13	54218	52 Atenolol 100mg	100MG	Tablets	Atemo-Heart	0	0	0	0	5	4	2	2	2	2	2	15	0	0	0	0	0	0	0	0	0	0
14	54218	53 Carvedilol 40mg	40MG	Tablets	Carmol	0	0	0	0	5	4	2	2	2	2	2	15	0	0	0	0	0	0	0	0	0	0
15	54218	54 Carvedilol 10mg	10MG	Tablets	Carmol	0	0	0	0	5	4	2	2	2	2	2	15	0	0	0	0	0	0	0	0	0	0
16	69018	55 Cefoxitin Sodium 1g	1g	Injection	Cefoxitin-1G	0	0	0	0	5	4	2	2	2	2	2	15	0	0	0	0	0	0	0	0	0	0
17	69018	56 Cefoxitin HCl 2mg	2MG	Injection	Cefoxitin-2G	0	0	0	0	5	4	2	2	2	2	2	15	0	0	0	0	0	0	0	0	0	0
18	69018	57 Mitoxantrone HCl 20mg	20MG	Injection	Procoltenide	0	0	0	0	5	4	2	2	2	2	2	15	0	0	0	0	0	0	0	0	0	0
19	72418	58 Lopinavir /ritonavir Sodium eq. to Omeprazole 40mg	80MG	Injection	Hivacin-L	0	0	0	0	5	4	2	2	2	2	2	15	0	0	0	0	0	0	0	0	0	0
20	72418	59 Escitalopram Oxalate eq. to Escitalopram 10mg	10MG	Tablets	Tropin	0	0	0	0	5	4	2	2	2	2	2	15	0	0	0	0	0	0	0	0	0	0
21	54218	60 Betamethasone Dipropionate 0.5mg + Gentamycin Sulphate 1mg	0.5MG+1MG	Cream	Beguvate	0	0	0	0	5	4	2	2	2	2	2	15	0	0	0	0	0	0	0	0	0	0
22	74208	61 Tinidazol Acid Vidamin D3 5mg	5MG	Injection	Bi-D3	0	0	0	0	5	4	2	2	2	2	2	15	0	0	0	0	0	0	0	0	0	0

Scrutiny Report

Formulary Number of each quoted product are incorrect.
DRAP Renewal application and certificate of these drugs are not attached in the bid (Mebsidhen, Fricoephen, Fendiveo, Fricoclorn)
ISO 14001, 9001, 45001 certificate are not issued by PNAC.
GD of all quoted products are attached in the bid.
API source certificates of the quoted items are not attached.
Certificate of Analysis for immediate container are not attached with the pictures of the immediate container.
IMS/IQVIA certificates of the quoted items are not attached in the bid
WHO prequalification are not attached in the bid.

Inends Pharma Manufacturer The inspection team at the time of inspection observed that,
In Raw Material Store, released and quarantine items were not properly segregated. Released Paracetamol bearing batch No. 2055330754 were lying in the quarantine area.
Finished products namely of Fendicopen Tablet 100mg (Nitrendubb) bearing batch No. 2874101 in finished form were placed directly on the floor in corrugated without pallets.
Filled and unlabeled ampoules in polyethylene bags were lying on floor without pallets in in-process quarantine room.
Capsule filling machine and core mixer were in the same section of capsule filling area.
HVAC system was found non-functional in tablet compression area, capsule and ampoule filling area. Dust of Nimesulide powder were also found even in the HVAC inlets and outlets.
Stability of Nimesulide and area monitoring record for parenteral products were not produced to the inspection team.
Hence, the firm is NOT RECOMMENDED for award of factory evaluation visit score for the quoted items.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: Frontier Dextrose Limited Hattar

Technical Evaluation Matrix

S. No.	Product General Information					Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm)**.	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
1	4	Metronidazole	500mg	Infusion	Sterimet	2	2	0	0	5	6	2	2	2	2	2	**25**	0	5	5	0	0	4	5	0	**19**	**44**
2	63	Paracetamol	1000mg	Infusion	Stericetamol	2	2	0	0	5	6	2	2	2	2	2	**25**	0	5	5	0	0	4	5	0	**19**	**44**
3	232	Ciprofloxacin	200mg/100ml	Infusion	Stericipro	2	2	0	0	5	6	2	2	2	2	2	**25**	0	5	5	0	0	4	5	0	**19**	**44**
4	263	Levofloxacin	5mg/ml	Infusion	Sterilevo	2	2	0	0	5	6	2	2	2	2	2	**25**	0	5	5	0	0	4	5	0	**19**	**44**
5	276	Moxifloxacin	400mg/250ml	Infusion	Sterimox	2	2	0	0	5	6	2	2	2	2	2	**25**	5	5	5	0	0	4	5	0	**24**	**49**
6	636	Dextrose	10%/500ml	Infusion	Sterifluid 10%	2	2	0	0	5	6	2	2	2	2	2	**25**	5	0	0	0	0	4	5	0	**14**	**39**
7	637	Dextrose	10%/1000ml	Infusion	Sterifluid 10%	2	2	0	0	5	6	2	2	2	2	2	**25**	5	0	0	0	0	4	5	0	**14**	**39**
8	638	Dextrose	5%/100ml	Infusion	Sterifluid 5%	2	2	0	0	5	6	2	2	2	2	2	**25**	0	0	0	0	0	4	5	0	**9**	**34**
9	640	Dextrose	5%/500ml	Infusion	Sterifluid 5%	2	2	0	0	5	6	2	2	2	2	2	**25**	5	0	0	0	0	4	5	0	**14**	**39**
10	641	Dextrose	5%/1000ml	Infusion	Sterifluid 5%	2	2	0	0	5	6	2	2	2	2	2	**25**	5	0	0	0	0	4	5	0	**14**	**39**
11	642	Dextrose + Sodium Chloride	5% + 0.45%/500ml	Infusion	Sterifluid DS 1/2	2	2	0	0	5	6	2	2	2	2	2	**25**	5	0	0	0	0	4	5	0	**14**	**39**
12	644	Dextrose + Sodium Chloride	5% + 0.9%/500ml	Infusion	Sterifluid DS	2	2	0	0	5	6	2	2	2	2	2	**25**	5	0	0	0	0	4	5	0	**14**	**39**
13	645	Dextrose + Sodium Chloride	5% + 0.9%/1000ml	Infusion	Sterifluid DS	2	2	0	0	5	6	2	2	2	2	2	**25**	5	0	0	0	0	4	5	0	**14**	**39**
14	655	Mannitol	20%/500ml	Infusion	Steriflutol	2	2	0	0	5	6	2	2	2	2	2	**25**	5	0	0	0	0	4	5	0	**14**	**39**
15	656	Normal Saline	0.9%/100ml	Infusion	Sterifluid NS	2	2	0	0	5	6	2	2	2	2	2	**25**	0	5	5	0	0	4	5	0	**19**	**44**
16	658	Normal Saline	0.90%	Infusion	Sterifluid NS	2	2	0	0	5	6	2	2	2	2	2	**25**	5	5	5	0	0	4	5	0	**24**	**49**
17	660	Normal Saline	0.90%	Infusion	Sterifluid NS	2	2	0	0	5	6	2	2	2	2	2	**25**	5	5	5	0	0	4	5	0	**24**	**49**
18	665	Potassium Chloride	7.46% w/v	Injection	Mini KCL	2	2	0	0	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	**24**	**49**
19	667	Ringer's Lactate + Dextrose 5% Soln	500ml	Infusion	Sterifluid RLD	2	2	0	0	5	6	2	2	2	2	2	**25**	5	0	0	0	0	4	5	0	**14**	**39**
20	668	Ringer's Lactate + Dextrose 5% Soln	1000ml	Infusion	Sterifluid RLD	2	2	0	0	5	6	2	2	2	2	2	**25**	5	0	0	0	0	4	5	0	**14**	**39**
21	670	Ringer's Lactate Soln	500ml	Infusion	Sterifluid RL	2	2	0	0	5	6	2	2	2	2	2	**25**	5	5	5	0	0	4	5	0	**24**	**49**
22	671	Ringer's Lactate Soln	1000ml	Infusion	Sterifluid RL	2	2	0	0	5	6	2	2	2	2	2	**25**	5	5	5	0	0	4	5	0	**24**	**49**
23	675	Sodium Bicarbonate	8.4%/20 ml	Injection	Mini BC	2	2	0	0	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	**24**	**49**
24	675	Sodium Bicarbonate	8.4%/50ml	Injection	Mini BC	2	2	0	0	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	**24**	**49**
25	676	Sodium Chloride + Dextrose	0.18% + 4.3%/500ml	Infusion	Sterifluid Paeds	2	2	0	0	5	6	2	2	2	2	2	**25**	5	0	0	0	0	4	5	0	**14**	**39**

26	677	Sterile Water for Injection	5ml	Injection	Mini WFI	2	2	0	0	5	6	2	2	2	2	2	**25**	0	0	0	0	0	4	5	0	**9**	**34**

Scrutiny Report

Page	Remarks
122-123	ISO 9001 Verification link not provided.
729-737 & 809-816	AWB for Dextrose Monohydrate not clear.
839, 1335	German GMP is expired on 14-09-2025.

Page	Remarks
1577, 1582, 1593, 1624, 1629, 1663, 1668, 1674	B.S is not visible
1650	B.S not attached.
1681	Eurocap is supplied instead of regular.
1685	10 ml WFI is not quoted.
1694	SKMCH not attested
1719	Scap (U.S small cap) is supplied instead of regular.
1575	ESCAP supplied instead of regular
1577-1783	All supplied are made in SCAP or EUROCap

Ringer's Lactate			
	1183	Sodium Lactate	
		Calcium Chloride	
		Pottasium Chloride	
		Sodium Chloride	German GMP is expired on 14-09-2025.
Ringer's Lactate + Dextrose 5% Soln			
	1183	Sodium Lactate	
		Calcium Chloride	
		Pottasium Chloride	
		Sodium Chloride	German GMP is expired on 14-09-2025.
		Dextrose anhydrous	AWB for Dextrose Monohydrate not clear.

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27													
Name of the firm						FujiFilm Karachi													
						Technical Evaluation Matrix													
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation					Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score							
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNPPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facility/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevent certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
Fujifilm Corporation Japan	1298	X-Ray Film RXN 8x10 (100 Sheets)	8x10	Fujifilm Japan		3	5	5	5	6	6	**30**	5	5	0	0	4	16	**30**	**60**
Fujifilm Corporation Japan	1299	X-Ray Film RXN 12x15 (100 Sheets)	12x15	Fujifilm Japan		3	5	5	5	6	6	**30**	5	5	0	0	4	16	**30**	**60**
Fujifilm Corporation Japan	1300	X-Ray Film RXN 10x12 (100 Sheets)	10x12	Fujifilm Japan		3	5	5	5	6	6	**30**	5	5	0	0	4	16	**30**	**60**
Fujifilm Corporation Japan	1302	X-Ray film CR DIHL (150-sheets) Valid where FUJI CR installed	8x10	Fujifilm Japan		3	5	5	5	6	6	**30**	5	5	0	0	4	16	**30**	**60**
Fujifilm Corporation Japan	1302	X-Ray CR Film 10x14 DIHL (150-Sheets) Valid where FUJI CR installed	10x14	Fujifilm Japan		3	5	5	5	6	6	**30**	5	5	0	0	4	16	**30**	**60**
Fujifilm Corporation Japan	1303	X-Ray Films CT scan 14x17 DIHL (100-sheets)	14x17	Fujifilm Japan		3	5	5	5	6	6	**30**	5	5	0	0	4	16	**30**	**60**

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm

S. No.	Product General Information				Technical Evaluation Matrix												Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
					Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Technical Parameters									
					Documents Based Factory Score						Factory Evaluation Visit Score															
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of investor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columnn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
1	40	Diclofenac Sodium	75mg/3ml	Inj.	Vovoren	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	5	0	4	5	1	**25**	**53**
2	47	Ketorolac	30 mg/ml	Inj.	Torek	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	0	0	4	5	0	**19**	**47**
3	66	Paracetamol + Tramadol	325mg + 37.5 mg	Tab.	Talobil-P	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	5	0	4	5	0	**24**	**52**
4	69	Tramadol HCl	50 mg/ml	Inj.	T-Mod	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	5	0	4	5	0	**24**	**52**
5	137	Fluconazole	150 mg	Cap.	Candila	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	0	0	4	5	0	**19**	**47**
6	157	Levocetirizine	2.5 mg/5 ml	Syp.	Leve-Cit	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	5	0	4	5	0	**24**	**52**
7	189	Azithromycin	250 mg	Cap.	Acrin	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	0	0	4	5	0	**19**	**47**
8	190	Azithromycin	500 mg	Tab.	Azure	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	0	0	4	5	0	**19**	**47**
9	204	Cefixime	400 mg	Cap.	Dispel	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	0	0	4	5	0	**19**	**47**
10	205	Cefixime	100 mg/5ml	Dry Susp	Dispel	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	0	0	4	5	0	**19**	**47**
11	206	Cefixime	200 mg/5ml	Dry Susp	Dispel DS	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	0	0	4	5	0	**19**	**47**
12	207	Cefoperazone + Sulbactam	1gm/Vial	Inj.	Suzone	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	4	5	0	4	5	0	**24**	**52**
13	208	Cefoperazone + Sulbactam	2 gm/Vial	Inj.	Suzone	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	5	0	4	5	0	**24**	**52**
14	210	Cefotaxime Sodium	500 mg/Vial	Inj.	Otaxam	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	0	0	4	5	0	**19**	**47**
15	211	Cefotaxime Sodium	1gm/Vial	Inj.	Otaxam	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	0	0	4	5	0	**19**	**47**
16	217	Ceftriaxone	500 mg/Vial	Inj.	Rainicef	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	5	0	4	5	0	**24**	**52**
17	218	Ceftriaxone	1gm/Vial	Inj.	Rainicef	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	5	0	4	5	0	**24**	**52**
18	219	Ceftriaxone	2 gm Vial	Inj.	Rainicef	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	4	0	4	5	0	**24**	**52**
19	225	Cephradine	500mg	Cap.	Rodin	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	0	0	4	5	0	**19**	**47**
20	244	Colistimethate Sodium	1 MIU/vial	Inj.	Cincolist	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	0	0	4	5	0	**15**	**43**
21	265	Levofloxacin	500 mg	Tab.	Lurk	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	5	0	4	5	0	**24**	**52**
22	295	Vancomycin	500 mg/Vial	Inj.	Vancotech	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	5	0	4	5	0	**24**	**52**
23	296	Vancomycin	1gm/Vial	Inj.	Vancotech	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	5	0	4	5	0	**24**	**52**
24	372	Iron hydroxide poly maltose cor	50 mg/5ml	Syp.	Macsfor	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	0	0	4	5	0	**19**	**47**
25	426	Dobusamine HCl	50 mg/ml	Inj.	Biotamin	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	0	0	4	5	0	**19**	**47**
26	450	Losartan + Hydrochlorothiazide	50mg + 12.5mg	Tab.	Correct	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	0	0	4	5	0	**19**	**47**
27	452	Losartan Potassium	50 mg	Tab.	Losartan	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	0	0	4	5	0	**19**	**47**
28	471	Rosuvastatin	10 mg	Tab.	Rozavel	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	5	0	4	5	0	**24**	**52**
29	505	Drotaverine	40 mg	Tab.	Drospa	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	4	5	0	4	5	1	**20**	**48**
30	506	Drotaverine	20 mg/ml	Inj.	Drospa	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	0	0	4	5	1	**20**	**48**
31	516	Omeprazole	40 mg / Vial	Inj.	Pymezole	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	5	0	4	5	0	**24**	**52**
32	519	Ondansetron	8 mg	Tab.	Onvin	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	0	0	4	5	0	**19**	**47**
33	520	Ondansetron	2 mg/ml	Inj.	Onvin	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	0	0	4	5	0	**19**	**47**
34	742	Olanzapine	5mg	Tab.	Olpine	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	0	0	4	5	0	**19**	**47**
35	743	Olanzapine	10 mg	Tab.	Olpine	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	0	0	4	5	0	**19**	**47**
36	860	Betamethasone Dipropionate +	0.05 % + 0.1%	Cream	Diprit	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	4	5	0	4	5	0	**19**	**47**
37	870	Fusidic acid	0.02	Cream	Fymsum	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	0	0	0	4	5	0	**14**	**42**
38	894	Terbinafine	0.01	Cream	Terbitec	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	5	0	4	5	0	**24**	**52**
39	914	Cholecalciferol (vitamin D3)	200000 IU	Inj.	Pycalci	2	2	3	2	5	4	2	2	2	2	2	**28**	0	5	5	0	0	4	5	0	**15**	**43**

Page No	Observations
571	API Source of Paracetamol not attached.
610, 643, 704	API Source not attached.
727	2nd EUDRA GMP is expired 04-08-2021
769	Colistimate is 80 mg instead of 1 MIU.
780	Link attached instead of certificate.
874	EDQM certificate is attached instead of advertised Criteria
884	Link attached instead of certificate.
1007	Link attached instead of certificate.
1035	Chinese COPP attached.
1041, 42, 43	GD, AWB, clearance certificate are not matching

Evaluation Criteria for Manufacturers of Cotton & Related Goods for Government MCC 2026-27

		Name of Firm	GENERAL PHARMA KAMOKE DISTRICT GUJRANWALA																			
S. No.		General Product Information				Technical Evaluation Matrix																
						Factory Technical Evaluation Parameters											Factory Evaluated Score	Product Evaluation Parameters			Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Evaluation visit Score										
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body. (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e FY 2023-24 or latest. A minimum turnover of PKR 100 million is required for award of marks in this parameter. (The document shall be attested by a Senior executive of the firm)	Functional and effective Airconditioning & Ventilation System as per the requirements laid down by DRAP **(Evaluated by the MCC expert/s at the time of inspection, Non functionality of the Air Conditioning & Ventilation system in specified section shall lead to disqualification of the section or firm)**	Adequate availability of equipment / instruments in QC labs performing relevant official tests as well as compliance to Good laboratory practices (GLP) in all Labs and Current Good Manufacturing Practices (cGMP) throughout the production facility. **(Evaluated by the MCC expert/s at the time of inspection, Non availability of adequate and appropriate equipment / instruments and non-compliance to GLP , cGMP shall lead to disqualification of the relevant section or firm)**	Appropriate storage of raw material, in process and finished goods with compliance to Good storage practices (GSP) **(To be evaluated by the MCC expert/s at the time of inspection, Non compliance to GSP shall lead to disqualification of the relevant section or firm)**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	3	3	**4**	5	3	6	6	6	6	**45**	5	10	10	**25**	**70**
	969	Cotton (Surgical) Corded BPC	200gm	Surgical Dressing	HOSPITEX	3	3	3	**4**	0	3	6	6	6	6	**40**	0	10	10	**20**	**60**
	970	Cotton (Surgical) Corded BPC	100gm	Surgical Dressing	HOSPITEX	3	3	3	**4**	0	3	6	6	6	6	**40**	0	10	10	**20**	**60**
	971	Cotton Bandage(Surgical) B.P Type II	6.5cm x4M	Surgical Dressing	HOSPITEX	3	3	3	**4**	0	3	6	6	6	6	**40**	0	10	DTL Substandard	**10**	**50**
	972	Cotton Bandage(Surgical) B.P Type II	7.5cm x4M	Surgical Dressing	HOSPITEX	3	3	3	**4**	0	3	6	6	6	6	**40**	0	10	DTL Substandard	**10**	**50**
	973	Cotton Bandage(Surgical) B.P Type II	10cm x4M	Surgical Dressing	HOSPITEX	3	3	3	**4**	0	3	6	6	6	6	**40**	0	10	DTL Substandard	**10**	**50**
	1097	Gauze Cloth Roll Packing	100cm x20M	Surgical Dressing	HOSPITEX	3	3	3	**4**	0	3	6	6	6	6	**40**	0	10	10	**20**	**60**
	1098	Gauze Cloth Roll Packing	100cm x40M	Surgical Dressing	HOSPITEX	3	3	3	**4**	0	3	6	6	6	6	**40**	0	10	10	**20**	**60**
	1219	Sterile Gauze Dressing Pad (X-ray detectable radiopaque) BP (Blister Pack)	30cm x30cm,4ply	Surgical Dressing	HOSPITEX	3	3	3	**4**	0	3	6	6	6	6	**40**	0	10	10	**20**	**60**
	1220	Sterile Gauze Dressing Pad BP	10cm x10cm, 8ply	Surgical Dressing	HOSPITEX	3	3	3	**4**	0	3	6	6	6	6	**40**	0	10	10	**20**	**60**

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: GENETICS PHARMA LAHORE

S. No.	MCC formulary No.	Product General Information				Technical Evaluation Matrix																					
						Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score					Factory Evaluation Visit Score							Product Technical Parameters									
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	22	23	24	25	26
						Valid ISO 13485/14500 1 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualifications of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC.**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacoporial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better (**Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**5**	**5**	**6**	2	2	2	2	2	**33**	**5**	**5**	**5**	**5**	**4**	**5**	**5**	**37**	**70**
	35	Aceclofenac	100mg	Tab.	Aceford	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**1**	**20**	**50**
	66	Tramadol/Paracetamol	37.5mg/325mg	Tab.	Trampol	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	68	Tizanidine	4mg	Tab.	Zandilex	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**5**	**4**	**5**	**0**	**24**	**54**
	137	Fluconazole	150mg	Cap.	Candizol	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**5**	**4**	**5**	**0**	**24**	**54**
	150	Betahistine	8mg	Tab.	Vergo	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	151	Betahistine	16mg	Tab.	Vergo	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	160	Montelukast	10mg	Tab.	Monberta	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	161	Montelukast	5mg	Tab.	Monberta	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	189	Azithromycin	250mg	Cap.	Zithrolide	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	190	Azithromycin	500mg	Tab.	Zithrolide	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	264	Levofloxacin	250mg	Tab.	Termigen	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	265	Levofloxacin	500mg	Tab.	Termigen	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	275	Moxifloxacin	400mg	Tab.	Navillox	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	403	Amlodipine/Valsartan	5/80mg	Tab.	Emhart	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**5**	**4**	**5**	**0**	**24**	**54**
	404	Amlodipine/Valsartan	5/160mg	Tab.	Emhart	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**5**	**4**	**5**	**0**	**24**	**54**
	405	Amlodipine/Valsartan	10/160mg	Tab.	Emhart	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**5**	**4**	**5**	**0**	**24**	**54**
	471	Rosuvastatin	10mg	Tab.	Rosugen	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	518	Esomeprazole	40mg	Cap.	Nesogen	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	521	Pantoprazole	20mg	Tab.	Genopra DR	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	522	Pantoprazole	40mg	Tab.	Genopra DR	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	540	Empagliflozin	10mg	Tab.	Diblay	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	541	Empagliflozin	25mg	Tab.	Diblay	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	542	Empagliflozin/Linagliptin	10/5mg	Tab.	Diblay-L	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**0**	**0**	**14**	**44**
	543	Empagliflozin/Linagliptin	25/5mg	Tab.	Diblay-L	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**0**	**0**	**14**	**44**
	581	Sitagliptin/Metformin	50/500mg	Tab.	Glycon M	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	582	Sitagliptin/Metformin	50/1000mg	Tab.	Glycon M	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	702	Aripiprazole	15mg	Tab.	Profy	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	716	Desvenlafaxine	50mg	Tab.	Venadex ER	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	717	Desvenlafaxine	100mg	Tab.	Venadex ER	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	719	Duloxetine	30mg	Cap.	Dobalta	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	720	Duloxetine	60mg	Cap.	Dobalta	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	721	Divalproex	500mg	Tab.	Revalp	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	722	Divalproex	250mg	Tab.	Revalp	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	725	Escitalopram	10mg	Tab.	Prolexa	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	726	Fluoxetine	20mg	Cap.	Geozit	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	733	Lamotrigine	50mg	Tab.	Lamitor	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	734	Carbidopa/Levodopa	25/250mg	Tab.	Codopa	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
	735	Levetiracetam	250mg	Tab.	Lepsi	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**5**	**4**	**5**	**0**	**24**	**54**
	736	Levetiracetam	500mg	Tab.	Lepsi	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**5**	**4**	**5**	**0**	**24**	**54**

737	Levetiracetam	100mg/ml	Oral Soln.	Lepsi	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**5**	**4**	**0**	**0**	**19**	**49**
742	Olanzapine	5mg	Tab.	Neolepra	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**5**	**4**	**5**	**0**	**24**	**54**
743	Olanzapine	10mg	Tab.	Neolepra	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**5**	**4**	**5**	**0**	**24**	**54**
753	Pregabalin	50mg	Cap.	Lingab	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
754	Pregabalin	75mg	Cap.	Lingab	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
755	Pregabalin	150mg	Cap.	Lingab	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
760	Quetiapine	100mg	Tab.	Prequel	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
761	Risperidone	2mg	Tab.	Vepridone	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
762	Risperidone	4mg	Tab.	Vepridone	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
764	Sertraline	100mg	Tab.	Cetalex	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**5**	**0**	**19**	**49**
766	Topiramate	50mg	Tab.	Topagen	**0**	**2**	**3**	**4**	**5**	**6**	2	2	2	2	2	**30**	**0**	**5**	**5**	**0**	**4**	**0**	**0**	**14**	**44**

ISO 45001 NOT ATTACHED

WHO DOCUMENT FRO API AT PAGE 487 IS NOT ACCORDING TO ADVERTISED CRITERIA

FDA EIR ATTACHED AT PAGE 495 IS FOR LEVITERACETAM AND HAS SOME HIDDEN TEXT. HENCE MARKS NOT AWARDED

GD AT PAGE 701 IS NOT COUPLED WITH AIRWAY BILL FOR ROSUVASTATIN

USFDA EIR ATTACHED AT PAGE 701 IS NOT FOR ROSUVASTATIN

USFDA EIR AT PAGE 759 IS NOT AS PER THE ADVERTISED CRITERIA AND HAS HIDDEN TEXT (M/S METROCHEM)

STABILITY STUDIES OF EMPA/LINA NOT ATTACHED IN THE BID

STABILITY STUDIES OF ORAL SOLUTION NOT ATTACHED IN THE BID

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm GENIX PHARMA KARACHI

S. No.		Product General Information				Technical Evaluation Matrix																				
						Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters							Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products.	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies). and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying	Stability studies of quoted item/s duly attested by the Q/C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner:		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70
	321	Acyclovir	250mg	Inj	Aclovir	2	2	3	4	5	6	2	2	2	2	2	32		GD NOT ATTACHED 390 PAGE	0	0	0	4	5	0	9	41
	322	Acyclovir	500mg	Inj	Aclovir	2	2	3	4	5	6	2	2	2	2	2	32		GD NOT ATTACHED 390 PAGE	0	0	0	4	5	0	9	41
	260	Imipenem / Cilastatin	500/500mg	Inj	Cilenem	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	914	Cholecalciferol (Vitamin D3)	5mg	Inj	D4U	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	1ML COA NOT ATTACHED	5	0	15	47
	324	Daclatasvir 60mg	60mg	Tab	Daclit	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	540	Empagliflozin	10mg	Tab	Emglif	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	541	Empagliflozin	25mg	Tab	Emglif	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	405	Amlodipine + Valsartan	10/160mg	Tab	Exval-A	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	404	Amlodipine + Valsartan	5/160mg	Tab	Exval-A	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	403	Amlodipine + Valsartan	5/80mg	Tab	Exval-A	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	302	Artemether + Lumefantrine	15/90mg	Susp	Gen-M	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	2	21	53
	304	Artesunate	120mg	Inj	Gen-M	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	2	21	53
	303	Artesunate	60mg	Inj	Gen-M	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	2	21	53
	301	Artemether + Lumefantrine	80/480mg	Tab	Gen-M	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	2	21	53
	192	Azithromycin	200mg/5ml	Susp	Gentro	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	189	Azithromycin	250mg	Tab	Gentro	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	190	Azithromycin	500mg	Tab	Gentro	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	342	Tenofovir Disoproxil Fumarate	300mg	Tab	Gentovir	2	2	3	4	5	6	2	2	2	2	2	32		5	5	Address of principal manufacturer in WHO certificate (1452) are not matchable with	0	4	5	0	19	51
	582	Sitagliptin + Metformin	50/1000mg	Tab	Gvia-M	2	2	3	4	5	6	2	2	2	2	2	32		5	5	Address of principal manufacturer in WHO certificate	0	4	5	0	19	51
	581	Sitagliptin + Metformin	50/500mg	Tab	Gvia-M	2	2	3	4	5	6	2	2	2	2	2	32		5	5	Address of principal manufacturer in WHO certificate	0	4	5	0	19	51
	388	Tranexamic Acid	500mg	Cap	Haemic	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	390	Tranexamic Acid	500mg	Inj	Haemic	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	NA	5	0	15	47
	688	Ibandronic Acid	3mg/3ml	Inj	Ibnate	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	689	Ibandronate Sodium	150mg	Tab	Ibnate	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	805	Ipratropium Bromide	Ipratropium 0.025%	N.Sol	Itramide	2	2	3	4	5	6	2	2	2	2	2	32		NA	NA	0	0	NA	NA	0	0	32
	807	Ipratropium Bromide + Salbutamol	Ipratropium 0.5mg + Salbutamol 2.5mg	N.Sol	Itramide-S	2	2	3	4	5	6	2	2	2	2	2	32		NA	NA	0	0	NA	NA	0	0	32
	237	Clarithromycin	125mg/5ml	Susp	Larith	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	236	Clarithromycin	250mg/5ml	Susp	Larith DS	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	234	Clarithromycin	250mg	Tab	Larith	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	235	Clarithromycin	500mg	Tab	Larith	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	516	Omeprazole	40mg	INF	Mep	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	273	Meropenem	1g	Inj	Olver	2	2	3	4	5	6	2	2	2	2	2	32		5	5	5	0	4	5	0	24	56
	272	Meropenem	500mg	Inj	Olver	2	2	3	4	5	6	2	2	2	2	2	32		5	5	5	0	4	5	0	24	56
	912	Ossein Mineral Complex + Vitamin D	Ossein 830 Vit D 400	Tab	OMC-D	2	2	3	4	5	6	2	2	2	2	2	32		5	5	5	0	4	5	0	24	56
	375	Iron Sucrose	100mg/5ml	Inj	RBC	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	NA	5	0	15	47
	737	Levetiracetam	500mg/5ml	Inj	Recetam	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	NA	5	0	15	47
	735	Levetiracetam	250mg	Tab	Recetam	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	NA	NA	0	10	42
	736	Levetiracetam	500mg	Tab	Recetam	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	NA	NA	0	10	42
	1523	Granisetron Hydrochloride	3mg/3ml	Inj	Sitensa	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	1522	Granisetron Hydrochloride	2mg (Non-Formulary, 1mg advertised)	Tab	Sitensa	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	NA	NA	0	10	42
	341	Sofosbuvir	400mg	Tab	Sofos	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	696	Solifenacin Succinate	10mg	Tab	Solif	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	697	Tamsulosin	0.4mg	Cap	Tampro	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	296	Vancomycin HCl	1g	Inj	Vancom	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	15ML NA	5	0	15	47
	295	Vancomycin HCl	500mg	Inj	Vancom	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	15ML NA	5	0	15	47
	586	Vildagliptin	50mg	Tab	Velon	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	343	Sofosbuvir 400mg + Velpatasvir 100mg	100/400mg	Tab	Velso	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	149	Voriconazole	200mg	Tab	Vorcaz	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51

	275	Moxifloxacin As Hcl	400mg	Tab	X-Gen	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51
	207	Cefoperazone + Sulbactam	1g	Inj	Xytol	2	2	3	4	5	6	2	2	2	2	2	32		DANEEN PHARMA DOCS ATTACHED page 1085	DANEEN PHARMA DOCS ATTACHED page 1085	0	0	DANEEN PHARMA DOCS ATTACHED page 1085	DANEEN PHARMA DOCS ATTACHED page 1085	0	0	32
	208	Cefoperazone + Sulbactam	2g	Inj	Xytol	2	2	3	4	5	6	2	2	2	2	2	32		DANEEN PHARMA DOCS ATTACHED page 1085	DANEEN PHARMA DOCS ATTACHED page 1085	0	0	DANEEN PHARMA DOCS ATTACHED page 1085	DANEEN PHARMA DOCS ATTACHED page 1085	0	0	32
	57	Nalbuphine HCL	10mg/ml	Inj	Zerfin	2	2	3	4	5	6	2	2	2	2	2	32		NA	NA	NA	NA	NA	NA	0	0	32
	268	Linezolid	600mg	Tab	Zyspan	2	2	3	4	5	6	2	2	2	2	2	32		5	5	0	0	4	5	0	19	51

DRAP APPROVED PRICE LIST NOT ATTACHED PAGE 50

1859 PAGE: VELPATASVIR IS NOT COVERED IN CGMP

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: GENOME PHARMACEUTICALS HATTAR / HARIPUR

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters										
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firms).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this colounm for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
	109	Deferasirox	180 mg	Tab.	Arefed	2	2	3	0	0	4	2	2	2	2	2	**21**	0	5	5	0	0	0	5	0	**15**	**36**
	110	Deferasirox	250 mg	Tab.	Arefed	2	2	3	0	0	4	2	2	2	2	2	**21**	0	5	5	0	0	0	5	0	**15**	**36**
	111	Deferasirox	360 mg	Tab.	Arefed	2	2	3	0	0	4	2	2	2	2	2	**21**	0	5	5	0	0	0	5	0	**15**	**36**
	113	Deferasirox	500 mg	Tab.	Arefed	2	2	3	0	0	4	2	2	2	2	2	**21**	0	5	5	0	0	0	5	0	**15**	**36**

939 millions

Scrutiny report
1Calibration certificates are expired in July 2025.
2Proof of purchase is not accompanied with CoA of immediate container (only Alufoil CoA attached)
3Tender approvals criteria is not applicable to the offered products.

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27														
					Name of the firm	**Genome Pharma - Islamabad**														
						Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters							**Product Technical Evaluation**						**Product Evaluated Score**	**Total Technical Score**
						Principal Manufacturer Evaluation			**Importer's Evaluation**			**Suppliers Technical Score**								
	MCC formulary No.	**1**	**2**	**3**	**4**	**5**	**6**	**7**	**8**	**9**	**10**	**11**	**12**	**13**	**14**	**15**	**16**	**17**	**18**	**19**
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facility/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal/ Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevent certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
Demophorius Ltd, 195 Archbishop Makarios III Av, Limassol 3030 Cyprus	940	Blood Bags (CPDA-1) Single	450 ml	Single Bag	Demotek	0	5	0	5	6	6	**22**	5	5	0	1	2	16	**29**	**51**
Demophorius Ltd, 195 Archbishop Makarios III Av, Limassol 3030 Cyprus	942	Blood Bags (CPDA-1) Double	450 ml	Double Bag	Demotek	0	5	0	5	6	6	**22**	5	5	0	1	2	16	**29**	**51**
Demophorius Ltd, 195 Archbishop Makarios III Av, Limassol 3030 Cyprus	944	Blood Bags (CPDA-1) Triple	450 ml	Triple Bag	Demotek	0	5	0	5	6	6	**22**	5	5	0	1	2	16	**29**	**51**

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: GEOFMAN PHARMA KARACHI

S. No.	Product General Information					Technical Evaluation Matrix																						
						Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters									Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters										
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21–40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment/ instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC experts/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs, **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or those clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product) 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better (**Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product**). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note, Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**5**	**3**	**4**	**5**	**5**	**37**	**70**
	132	Clotrimazole	500mg	Vaginal Tab.	Dermotrim	**2**	**2**	**3**	**0**	**5**	**6**	The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/ CoPP/ COFG) for the quoted items were checked, and following observations were made; Non-Compliance with Current Good Manufacturing Practices (cGMP) 1. During the inspection, no active production activities were observed in any manufacturing sections, including Cephalosporin, Penicillin, Oral Liquid, Oral Powder, Liquid Injectable, and Cream/Ointment. Only packaging and sertical testing operations were in progress at the time of inspection. 2. In the Cephalosporin section, the Active Pharmaceutical Ingredients (APIs) were found stored without appropriate labeling or identification tags, making it impossible to ascertain their status and traceability, which constitutes a deviation from cGMP requirements related to material management and traceability. 3. The technical staff present consisted of only one pharmacist with one year of experience, who was unable to adequately explain the processes being carried out in the section. This raises concerns regarding personnel competency, training adequacy, and compliance with Batch Manufacturing Record (BMR) and SOP requirements, thereby compromising overall cGMP adherence. 4. No auxiliary/technical support staff were present in the production area at the time of inspection. The Director of Operations informed the inspection team that such staff had been temporarily reassigned to other sections due to the current lack of production activity. 5. The In-Process Finished Goods Store was equipped with only one wall-mounted air conditioner, providing inadequate control of temperature and humidity. The recorded conditions were 28°C and 62% RH, respectively. Furthermore, lighting was insufficient, hindering proper visual inspection for product-to-product or batch-to-batch differentiation. These conditions do not meet standard storage and environmental monitoring requirements under cGMP. 6. The blistering area was found equipped with wall-mounted air conditioners only; no proper centralized HVAC system was operational, compromising control of environmental parameters and product quality during packaging operations. 7. The ointment filling and in-process packing areas were found sealed and locked with chains, restricting access and raising concerns regarding availability for inspection, cleaning, and maintenance, which is not in accordance with cGMP requirements for facility access control. Poor Compliance with Good Storage Practices (GSP) 1. Food-grade sugar used as an excipient was found stored in the Raw Material Store (RMS) without adherence to Good Storage Practices. No comprehensive Quality Control (QC) testing records for the received APIs were provided upon request. 2. The inspection team requested the qualitative test records for anhydrous sugar, which were not presented at the time of inspection, indicating gaps in documentation and QC compliance. 3. Material stacking was observed directly against warehouse walls without adequate spacing, hindering ventilation and air circulation and violating recommended storage layout requirements under GSP. 4. Wall-mounted air conditioners were found installed in the Raw Material Store; however, no appropriate condensate water disposal system was in place. The collected water was being stored improperly in drums inside the warehouse, posing potential contamination and safety risks. The firm was inspected as per technical evaluation criteria. PARTIALLY RECOMMENDED for Oral Syrup and Liquid injectable only for award of factory evaluation visit score for the quoted items	**18**	**0**	**5**	**5**	**0**	**0**	**4**	**5**	**0**	**19**	**37**
	169	Amoxycillin	250mg	Cap.	GEOMOXIN	**2**	**2**	**3**	**0**	**5**	**6**		**18**	**0**	**5**	**5**	**0**	**0**	**4**	**5**	**0**	**19**	**37**
	170	Amoxycillin	500mg	Cap.	GEOMOXIN	**2**	**2**	**3**	**0**	**5**	**6**		**18**	**0**	**5**	**5**	**0**	**0**	**4**	**5**	**0**	**19**	**37**
	189	Azithromycin	250mg	Cap.	Geozit	**2**	**2**	**3**	**0**	**5**	**6**		**18**	**0**	**5**	**5**	**0**	**0**	**4**	**5**	**0**	**19**	**37**
	204	Cefixime	400mg	Cap.	Septipan	**2**	**2**	**3**	**0**	**5**	**6**		**18**	**0**	**5**	**5**	**0**	**0**	**4**	**5**	**0**	**19**	**37**
	205	Cefixime	100mg/5ml	Susp.	Septipan	**2**	**2**	**3**	**0**	**5**	**6**		**18**	**0**	**5**	**5**	**0**	**0**	**4**	**5**	**0**	**19**	**37**
	206	Cefixime	200mg/5ml	Susp.	Septipan DS	**2**	**2**	**3**	**0**	**5**	**6**		**18**	**0**	**5**	**5**	**0**	**0**	**4**	**5**	**0**	**19**	**37**
	207	Cefoperazone Sodium + Sulbactum Sodium	1gm	Dry Powder Inj.	Geofbac	**2**	**2**	**3**	**0**	**5**	**6**		**18**	**0**	**5**	**5**	**5**	**0**	**2**	**5**	**0**	**22**	**40**
	208	Cefoperazone Sodium + Sulbactum Sodium	2gm	Dry Powder Inj.	Geofbac	**2**	**2**	**3**	**0**	**5**	**6**		**18**	**0**	**5**	**5**	**5**	**0**	**2**	**5**	**0**	**22**	**40**
	215	Ceftazidime	500mg	Dry Powder Inj.	Sefta	**2**	**2**	**3**	**0**	**5**	**6**		**18**	**0**	**5**	**5**	**5**	**0**	**2**	**5**	**0**	**22**	**40**
	216	Ceftazidime	1 gm	Dry Powder Inj.	Sefta	**2**	**2**	**3**	**0**	**5**	**6**		**18**	**0**	**5**	**5**	**5**	**0**	**2**	**5**	**0**	**22**	**40**
	217	Ceftriaxone	500mg	Dry Powder Inj.	Tyroxone	**2**	**2**	**3**	**0**	**5**	**6**		**18**	**0**	**5**	**5**	**5**	**0**	**2**	**5**	**0**	**22**	**40**
	218	Ceftriaxone	1 gm	Dry Powder Inj.	Tyroxone	**2**	**2**	**3**	**0**	**5**	**6**		**18**	**0**	**5**	**5**	**5**	**0**	**2**	**5**	**0**	**22**	**40**
	230	Ciprofloxacin	250mg	Tab.	Megaflox	**2**	**2**	**3**	**0**	**5**	**6**		**18**	**0**	**5**	**5**	**0**	**0**	**4**	**5**	**0**	**19**	**37**
	231	Ciprofloxacin	500mg	Tab.	Megaflox	**2**	**2**	**3**	**0**	**5**	**6**		**18**	**0**	**5**	**5**	**0**	**0**	**4**	**5**	**0**	**19**	**37**
	259	Gentamycin Sulphate	80mg/2ml	Inj.	Genom	**2**	**2**	**3**	**0**	**5**	**6**		**18**	**0**	**5**	**5**	**0**	**0**	**4**	**5**	**0**	**19**	**37**
	376	Mecobalmin	500mcg/ml	Inj.	Geocobalmin	**2**	**2**	**3**	**0**	**5**	**6**		**18**	**0**	**0**	**0**	**0**	**0**	**4**	**5**	**0**	**9**	**27**
	522	Pantoprazol	40mg	Tab.	Gatracid	**2**	**2**	**3**	**0**	**5**	**6**		**18**	**0**	**5**	**5**	**0**	**0**	**4**	**5**	**0**	**19**	**37**
	537	Dexamethasone	4mg/1ml	Inj.	Dexamedron	**2**	**2**	**3**	**0**	**5**	**6**		**18**	**0**	**5**	**5**	**0**	**0**	**4**	**5**	**0**	**19**	**37**
	574	Oxytocin	5 I.U	Inj.	Tocinox	**2**	**2**	**3**	**0**	**5**	**6**		**18**	**0**	**5**	**5**	**0**	**0**	**4**	**5**	**0**	**19**	**37**
	576	Prednisolone	5mg	Tab.	Pressolone	**2**	**2**	**3**	**0**	**5**	**6**		**18**	**0**	**5**	**5**	**0**	**0**	**4**	**5**	**0**	**19**	**37**
	864	Clotrimazole	1%	Cream	Dermotrim	**2**	**2**	**3**	**0**	**5**	**6**		**18**	**0**	**5**	**5**	**0**	**0**	**4**	**5**	**0**	**19**	**37**

MECOBALAMIN GD AND AIRWAY BILL ATTACHED AT 191 AND 192 ARE NOT MATCHING

MECOBALAMIN IS IMPORTED FROM SYMBOLIFE PHARMA HOWEVER COA IS ISSUED BY BAJAJ STEROIDS

		TECHNICAL EVALUATION PROFORMA, FOR PROCUREMENT OF ANTICANCER MEDICINES IN GOVT. MCC FY 2026-27															
		Name of the firm with Complete Address	**GETZ PHARMA KARACHI (IMPORTER)**														
		Manufacturer / Importer															
		Mandatory Requirements.	**YES / NO**		**In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:**		**YES/NO**		**In case of being Importers, the Firm should provide attested copies of the following documents also:**		**YES/NO**					
1		**National Tax Number (NTN) of the Firm for Income Tax, and**	YES		1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and			1	Valid Drugs Sales License for the importer; and	YES						
2		**Last year Income Tax Return of the Firm; and**	YES		2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition; and			2	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	YES						
3		**Sale Tax Registration Certificate of the Firm; and**	YES		3	Valid DRAP Approved Price List of the quoted item/s.			3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	NO						
4		**Certificate of Professional Tax of the Firm.**	YES						4	Valid eCoDP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and	YES						
5		**Certificate of compliance to cold chain standards issued by an authorized third party (e.g. DRAP, PSQCA, PCSIR, Non-C compliance to international reference standards or absence of Cold Chain requirements shall lead to disqualification of the relevant product that requires cold chain.**	YES						5	Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods. Non provision of this document shall lead to disqualification of the firm; and	NO						
									6	Valid DRAP approved Price List of the quoted items.	NO						

			Technical Evaluation Parameters			**Active Pharmaceutical Ingredient source gradation** **(For API or finished product), i) The bidder (local manufacturer / multi-national manufacturer / importer) shall provide Analytical/Quality Assurance/ Approval Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades.** **Certificate of Analysis/ Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreement/ approval with the original manufacturer duly attested/verified by official of the company.** **Detailed purchase trail of the Active Pharmaceutical Ingredient/ Finished product from the claimed source must be submitted (any proof of purchase such as Goods Declaration Certificate along with Airway Bill/ Bill of Lading/Invoice etc.) by the bidder.** **Maximum marks for this criterion are 45.**		**Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW) Study/Certificate from an accredited lab of WHA countries (Stringent Regulatory Authorities)/ WHO Listed Authorities WLA Countries** **BE/BS Certificate with evidence as to its authenticity) from Category A countries.** **Bio-Equivalence (BE) of the quoted product to be conducted against the originator.** **Original innovator products do not require bio- equivalence certificate and shall get 10 marker automatically.The bidder shall provide the documents to establish the proof of inventor/ originator. All other branded generics require BE studies** **Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid.** **Maximum marks for this criterion are 10.**			**Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug. In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article)** **Mandatory: Online verification link must be provided to verify the Clinical Trial/ Clinical Studies submitted for the quoted items.**			**Factory/ Importer Based Evaluation Score (MANDATORY)**	**Sample Evaluation by End User Committee** **Samples will be examined per following criteria (Maximum):** **a. Labeling and Packing Rules 1986** **b. Outer packing** **c. Inner packing** **d. Physical appearance.** **Product which has unsatisfactory packing/labeling will be technically disqualified.** **Maximum score for this criterion is 1.**		**Past Performance (Last two years):** **i) Good Performance Certificates of these items/ similar items (Maximum) will be eligible for 1 mark per institution upto a maximum of 5 marks.** **ii) Only supply orders will not get any marks.** **iii) The bidders have to undertake that they have never been blacklisted or debarred.** **Maximum marks for this criterion are 5.** **iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients at NIMC, Peshawar, TWO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.**	**Total Technical Score**
						Category A – Approved By • United States Food & Drug Administration (US FDA) • European Medicines Agency (EMA) • Medicines & Healthcare Products Regulatory Agency (MHRA, UK) • Therapeutic Goods Administration (TGA), Australia • Pharmaceutical Medical Agency (PHARMAC), New Zealand • Pharmaceutical & Medical Devices Agency (PMDA), Japan • Swiss Agency For Therapeutic drugs (Swissmedic), Switzerland • Health Canada • Health Sciences Authority (HAS), Singapore • National Administration of Drugs, Food & Medical technology (ANMAT), Argentina • Brazilian Health Surveillance Agency (ANVISA) • Stringent Regulatory Authority(s) / WHO Listed Authorities WLA countries	Category B – Approved By • Agência Nacional de Vigilância Sanitária (ANVS), Brazil • Central Drug Standard Control Organization (CDSCO), India • Drug Regulatory Authority, Pakistan • National Pharmaceutical Control Bureau (NPCB), Malaysia • Food & Drug Administration, South Korea • Ministry of Health, Egypt • Ministry of Health, Turkey • China Food & Drug Administration • Any other source not mentioned in Category A	Study/certificate issued/verified/ by a Category A Country Regulatory Authority. BE testing must be done using the WHO Protocol. Bio-waiver is acceptable only to injectable forms if issued by Category A Country.	80-89.99% certificate obtained for a quoted product from Category B Country (as mentioned at S.No. 2 above)	No 80-99.99% certificate.	To see the study is published in Category "X" journal listed in HEC Journal Recognition System (HJRS) Database – Research & Publication Policy 2023 and List of National Recognized Journals as per HEC. 3 marks per original research article shall be awarded maximum upto 9 marks).	To see the study is published in Category "Y" journal listed in HEC Journal Recognition System (HJRS) Database – Research & Publication Policy 2023 and List of National Recognized Journals as per HEC. 2 marks per original research article shall be awarded maximum upto 6 marks).	Studies/ original work/ articles published in category "Z" journal of the HJRS/ Journals as per HEC shall not be awarded marks.	**The Physical inspection of the premises of the bidders (Manufacturer/Importer) shall be carried out in accordance with the DI(Lab), GCP & QL Section V (1) (c) (i) of the Approved SSDD of Govt. MCC FY 2026-27**	Satisfactory	Unsatisfactory	Q – Substantial quantity of supplies of anti-cancer medicines made to private sector Teaching Hospitals, namely: The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar, Clifton Rawalpindi and Hyderabad Medical Complex, Peshawar will be considered as substantial supplies. Good Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued for the last 24 months. No marks will be given	
SOURCE	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	**40**	**10**	**10**	**5**	**0**	**0**	**6**	**0**	**5**	**1**	**0**	**5**	**70**
Biocon India-Ireland cGMP	1634	Trastuzumab	440mg	Inj	Trastaget	**40**		**0**			**0**			**0**		**0**	**1**	**41**
Qilu China, Argentina cGMP	1499	Denuscmab	120mg	Inj	Dsemab	**40**		**0**			**3**			**0**		**0**	**0**	**43**
Eczane Argentina-Argentina cGMP	1471	Capecitabine	500mg	Tab	Xebstab	**40**		**0**			**0**			**0**		**0**	**0**	**40**

Scrutiny report

1Documents of Eczan Argentina are not in English language therfore not understnadable (for capecitabine)
2Trials and studies on company own letter head are submitted form which journal could not be ascertained therefore cannot be evaluated with the respective criteria
3Image of Ogivri 420mg is attached in bid while the offered product is Trastuget 440mg
4Valid agency agreement with principal manufacturer of offered products is not present
5Valid free sale certificate/ CoPP not present for offered products
6The bidder, having availed multiple trainings, submitted a technical bid that contains huge irrelevant documentation contrary to the advertised criteria.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: GETZ PHARMA KARACHI

Technical Evaluation Matrix

S. No.	Product General Information					Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this colomn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade.	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. /Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
	47	Ketorolac	30 mg/ml	Injections	KETOROGET INJ 30MG/ML TP 5'S	2	2	3	5	0	6	2	2	2	2	2	**28**	0	OLDER THAN 24 MONTHS	0	0	0	0	5	0	**5**	**33**
	202	Cefepime	500 mg/Vial	Injections	FECTOPIME INJ 500MG TP 1'S	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	0	5	0	**15**	**43**
	209	Cefotaxime Sodium	250mg/Vial	Injections	XIMATOF INJ 250MG TP 1'S	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	0	5	0	**15**	**43**
	210	Cefotaxime Sodium	500MG/Vial	Injections	XIMATOF INJ 500MG TP 1'S	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	0	5	0	**15**	**43**
	211	Cefotaxime Sodium	1gm/Vial	Injections	GETOFIN IV 1G TP 1'S	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	0	5	0	**15**	**43**
	217	Ceftriaxone	500 mg/Vial	Injections	GETOFIN IV 500MG TP 1'S	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	0	5	0	**15**	**43**
	218	Ceftriaxone	1 gm/Vial	Injections	GETOFIN IV 1G TP 1'S	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	0	5	0	**15**	**43**
	219	Ceftriaxone	2g/Vial	Injections	GETOFIN IV 2G TP 1'S	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	0	5	0	**15**	**43**
	272	Meropenem	1 gm/Vial	Injections	MEROGET IV 1G TP 1'S	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	0	5	1	**16**	**44**
	273	Meropenem	500 mg/Vial	Injections	MEROGET IV 500MG TP 1'S	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	0	5	1	**16**	**44**
	276	Moxifloxacin	400 mg/250 ml	Infusion	MOXIGET IV 400MG/250ML TP 1'S	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	0	5	1	**16**	**44**
	376	Mecobalamine	500mcg	Injections	Nervon	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	0	5	0	**15**	**43**
	520	Ondansetron	2 mg/ml	Injections	ONSEGET INJ 8MG/4ML TP 1'S	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	0	5	0	**15**	**43**
	560	Human Insulin 70/30	100 IU/ml	Injections	INSUGET INJ 70/30 10ML TP 1'S	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	0	5	2	**17**	**45**
	561	Insulin Regular (Human)	100 IU/ml	Injections	INSUGET INJ REGULAR 10ML TP 1'S	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	0	5	1	**16**	**44**
	737	Levetiracetam	100 mg/ml	Injections	XETICAN IV 500MG/5ML TP 1'S	2	2	3	5	0	6	2	2	2	2	2	**28**	0	5	5	0	0	0	5	0	**15**	**43**

Scrutiny report

1. Calibration certificates for climatic chambers are attached only, which does not fulfill the advertised criteria
2. EIR clarification of biocon is required
3. Items with less than 1% IMS market share are not awarded
4. In immediate container only documents of rubber stoppers are provided which does not fulfill the criteria and cannot be awarded.
5. DRAP approved price list is not present
6. GD of ketrolac is older than 2 yrs . CoA cannot be awarded in cases where GD is invalid.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: GlaxoSmithKline Pakistan Ltd, 35 Dockyard Road, West Wharf Karachi.

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters										
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority /body of SRAs/W	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA / TGA/ PMDA / Swiss Medic or Health Canada or by regulatory	Valid WHO prequalification and / or Valid product registration in SRA/ WLA country(ies) and / or Valid free sale certificate issued by	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
	167	Amoxicillin	250mg	Capsules	AMOXIL CAPSULE	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	0	0	0	0	5	**20**	**53**
	168	Amoxicillin	500mg	Capsules	AMOXIL CAPSULE	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	0	0	0	0	5	**20**	**53**
	188	Ampicillin+Clo	250mg	Capsules	AMPICLOX	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	0	0	5	**15**	**48**
	185	Ampicillin+Clo	500mg	Capsules	AMPICLOX	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	0	0	5	**15**	**48**
	179	Amoxicillin +	312.5mg	Suspension	AUGMENTIN	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	0	0	2	5	5	**27**	**60**
	176	Amoxicillin +	1gm	Tablets	AUGMENTIN BD	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	0	0	2	5	5	**27**	**60**
	174	Amoxicillin +	375mg	Tablets	AUGMENTIN	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	0	0	2	5	5	**27**	**60**
	175	Amoxicillin +	625mg	Tablets	AUGMENTIN	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	0	0	2	5	5	**27**	**60**
	488	Betamethason	7.5 ml	Drop	BETNESOL N	2	2	3	5	5	6	2	2	2	2	2	**33**	0	0	0	0	0	0	0	2	**2**	**35**
	844	Betamethason	0.05%	Ointment	BETNOVATE	2	2	3	5	5	6	2	2	2	2	2	**33**	0	0	0	0	0	0	5	1	**6**	**39**
	62	Paracetamol	250MG/5ML	Suspension	CALPOL 6 PLUS	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	2	5	2	**19**	**52**
	61	Paracetamol	120 MG/5ML	Suspension	CALPOL	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	2	5	2	**19**	**52**
	60	Paracetamol	500 mg	Tablets	CALPOL TABLET	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	0	5	2	**17**	**50**
	416	Captopril	25mg	Tablets	CAPOTEN TABLET	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	0	5	5	**20**	**53**
	231	Ciprofloxacin	500mg	Tablets	CIPVAL TABLET	2	2	3	5	5	6	2	2	2	2	2	**33**	0	0	0	0	0	0	0	0	**0**	**33**
	851	Clobetasole	0.05%	Cream	DERMOVATE	2	2	3	5	5	6	2	2	2	2	2	**33**	0	0	0	0	0	0	5	0	**5**	**38**
	205	Cefixime Syp	100mg/5ml	Suspension	FIXVAL	2	2	3	5	5	6	2	2	2	2	2	**33**	0	0	0	0	0	0	0	0	**0**	**33**
	206	Cefixime Syp	200mg/5ml	Suspension	FIXVAL	2	2	3	5	5	6	2	2	2	2	2	**33**	0	0	0	0	0	0	0	0	**0**	**33**
	216	Ceftazidim	1 gm vial	Injection	Fortum injection 1GM 1'S	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	0	0	Type III Vial COA is attached-	0	2	**17**	**50**
	215	Ceftazidim	500 vial	Injection	FORTUM INJECTION - VIAL 500 MG 1'S	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	0	0	Type III Vial COA is attached-	0	2	**17**	**50**
	833	Polymyxin B sulphate	10000 iu+500iu	Ointment	POLYFAX OINTMENT - EYE	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	0	0	5	**15**	**48**
	876	Polymyxin B Sulphate	10000 iu+500iu	Ointment	POLYFAX OINTMENT	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	0	0	5	**15**	**48**
	247	Co-Trimoxazol	400+80 mg per 5ml	Suspension	SEPTRAN DS	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	0	5	5	**20**	**53**
	246	Co-Trimoxazol	800mg+160mg	Tablets	SEPTRAN DS	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	0	5	5	**20**	**53**
	248	Co-Trimoxazol	200+40 mg per 5ml	Suspension	SEPTRAN	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	0	5	5	**20**	**53**
	245	Co-Trimoxazole (Sulphametho	400mg+80mg	Tablets	SEPTRAN TABLET 400/80MG 40X10	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	0	Stability not present	5	**15**	**48**
	226	Cephradine	1 gm	Injection	VELOSEF INJECTION 1G 1'S	2	2	3	5	5	6	2	2	2	2	2	**33**	5	0	0	0	0	Type III Vial COA is attached-	0	5	**10**	**43**
	224	Cephradine	250mg	Capsules	VELOSEF	2	2	3	5	5	6	2	2	2	2	2	**33**	5	0	0	0	0	2	0	5	**12**	**45**
	225	Cephradine	500mg	Capsules	VELOSEF	2	2	3	5	5	6	2	2	2	2	2	**33**	5	0	0	0	0	2	5	5	**17**	**50**
	228	Cephradine	125mg/5ml	Suspension	VELOSEF SUSPENSION 125MG X90ML	2	2	3	5	5	6	2	2	2	2	2	**33**	5	0	0	0	0	CoA of Glass bottle not attached	0	5	**10**	**43**
	229	Cephradine	250mg/5ml	Suspension	VELOSEF SUSPENSION 250MG/5ML 1 X	2	2	3	5	5	6	2	2	2	2	2	**33**	5	0	0	0	0	CoA of Glass bottle not attached	5	5	**15**	**48**
	227	Cephradine	500 mg	Injection	VELOSEF INJECTION 500MG 1'S	2	2	3	5	5	6	2	2	2	2	2	**33**	5	0	0	0	0	Type III Vial COA is attached-	0	5	**10**	**43**
	801	Salbutamol	5mg per ml	Solution	VENTOLIN	2	2	3	5	5	6	2	2	2	2	2	**33**	0	0	0	0	0	0	5	4	**9**	**42**

	800	Salbutamol	2mg per 5ml	Syrup	VENTOLIN SYRUP	2	2	3	5	5	6	2	2	2	2	2	**33**	0	0	0	0	0	2	5	4	**11**	**44**
	72	Albendazole	100 mg	Suspension	ZENTEL	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	0	5	5	**20**	**53**
	71	Albendazole	200mg tab	Tablets	ZENTEL TABLET	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	0	5	5	**20**	**53**
	221	Cefuroxime	250 mg	Tablets	ZINACEF TABLET	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	2	0	5	**17**	**50**
	135	Fluconazole	150 mg	Capsules	ZOLANIX	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	0	5	2	**17**	**50**
	152	Cetirizine	0.10%	Solution	ZYRTEC ORAL	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	2	5	2	**19**	**52**
	151	Cetirizine	10mg	Tablets	ZYRTEC TABLETS	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	0	5	2	**17**	**50**

Page 356- only CoA of Rigid PVC is attached, with no proof of purchase (Calpol Tab)
CoA of Capsule shells is not attached
Type III vial is used-Type III vial is a disqualification point.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm | **Glitz Pharma, Islamabad.**

S. No.		Product General Information				Technical Evaluation Matrix																					
						Factory Technical Evaluation Parameters												Product Evaluation Parameters									
						Documents Based Factory Score						Factory Evaluation Visit Score					Total Factory Evaluated Score	Product Technical Parameters								Total Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month)**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 100 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm**.	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm**).	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g.,	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
	36	Aceclofenac	100 mg	Tab.	**Glif-A Tablet**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	0	0	0	0	2	5	0	**7**	**37**
	47	Ibuprofen	100 mg/ 5ml	Susp.	**Glitfen Suspension**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	52	Meloxicam	15 mg	Tab.	**Megit Tablet 15 mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	53	Meloxicam	7.5 mg	Tab.	**Megit Tablet 7.5 mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	69	Tizanidine	4mg	Tab.	**Relaxit 4mg Tablets**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	1	**18**	**48**
	86	Hydroxyurea	500 mg	Cap.	**Hydroxea 500mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	5	0	2	5	0	**22**	**52**
	93	Tacrolimus	1mg	Tab. /Cap.	**Aerograf 1mg Capsule**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	94	Tacrolimus	0.5 mg	Tab./ Cap.	**Aerograf 0.5mg Capsule**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	108	Deferasirox	250mg	Tab.	**Desirox 250mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	5	0	2	5	0	**22**	**52**
	111	Deferasirox	500mg	Tab.	**Desirox 500mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	5	0	2	5	0	**22**	**52**
	130	Clotrimazole	500mg	Vaginal tablet with applicator	**Wormclo-1**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	1	**18**	**48**
	131	Clotrimazole	1%	Vaginal Cream with applicator	**Wormclo 1%**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	1	**18**	**48**
	154	Chlorpheniramine Maleate	2 mg/ 5 ml	Syp./Oral Solution	**Clomin Oral Solution**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	155	Levocetirizine	2.5mg/5ml	Tab.	**Zeocit 2.5mg/5ml**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	156	Levocetirizine	5 mg	Tab.	**Zeocit 5 mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	158	Montelukast	10 mg	Tab.	**Mac-10**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	older than 2 years -06/2022- Page 1300	0	0	0	2	5	0	**7**	**37**
	189	Azithromycin	250 mg	Tab. / Cap.	**Azinyth 250 mg Tablet**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	190	Azithromycin	500 mg	Tab. / Cap.	**Azinyth 500 mg Tablet**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	192	Azithromycin	200 mg/5ml	Dry Susp.	**Azinyth Suspension**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	230	Ciprofloxacin	250 mg	Tab.	**Glirox Tablet 250 mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	231	Ciprofloxacin	500 mg	Tab.	**Glirox Tablet 500 mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	237	Clarithromycin	125 mg/5ml	Dry Susp.	**Clatz Suspension 125mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	Page 1322-1323- Invoice of Canny enterprises, CoA of Ningxia taiyicin biotech china- no detail of canny	0	0	0	2	5	0	**7**	**37**

	264	Levofloxacin	250 mg	Tab.	**Lezov Tablet 250 mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	265	Levofloxacin	500 mg	Tab.	**Lezov Tablet 500 mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	366	Ferrous Sulphate	200mg		**Ferolitz Tablet**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	367	Ferrous Sulphate	100mg/5ml		**Ferolitz Syrup**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	370	Iron Hydroxide poly maltose complex	100 mg	Tab.	**Gloft Tablet**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	371	Iron Hydroxide poly maltose complex	50 mg/5ml	Syp.	**Gloft Syrup**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	376	Mecobalamin	500mcg	Tab.	**G-cobal Tablet 500 mcg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	408	Bisoprolol	2.5mg	Tab.	**Bisgit 2.5mg Tablet**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	5	0	2	5	0	**22**	**52**
	409	Bisoprolol	5 mg	Tab.	**Bisgit 5mg Tablet**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	5	0	2	5	0	**22**	**52**
	410	Bisoprolol	10 mg	Tab.	**Bisgit 10mg Tablet**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	5	0	2	5	0	**22**	**52**
	417	Carvedilol	6.25 mg	Tab.	**Vedigit 6.25mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	418	Carvedilol	12.5 mg	Tab.	**Vedigit 12.5mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	5	0	2	5	0	**22**	**52**
	419	Carvedilol	25 mg	Tab.	**Vedigit 25mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	5	0	2	5	0	**22**	**52**
	420	Clopidogrel	75 mg	Tab.	**Gitlot 75mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	429	Furosemide	40 mg	Tab.	**G-mide 40 mg Tablet**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	5	0	2	5	0	**22**	**52**
	468	Porporanolol	40 mg	Tab.	**Opinol 40mg Tablet**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	Not present	0	0	0	2	5	0	**7**	**37**
	470	Rosuvastatin	10 mg	Tab.	**Rosir 10mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	5	0	2	5	0	**22**	**52**
	503	Domperidone	5 mg/5ml	Susp.	**Dom-D Suspension 5mg/5ml**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	506	Famotidine	40 mg	Tab.	**Litz 40mg Tablet**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	516	Omeprazole	40 mg	Cap.	**Omiglit 40mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	517	Esomeprazole	40mg	Cap.	**Eger Capsule 40 mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	older than 24 months, 5/23- page 1480	0	0	0	2	5	0	**7**	**37**
	532	Zinc Sulphate	20 mg/5ml	Syp.	**Ziglit Oral Solution 60ml**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	637	Flavored Oral Rehydration Salt (Low Osmolarity)	Sodium Chloride Sachet (2.6 g/L) Glucose Anhydrous (13.5 g/L) Potassium Chloride (1.5 g/L)	Sachet	**Oragil Sachet**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	AWB of KCl is not pre	0	0	0	2	5	0	**7**	**37**
	690	Aripiprazole	15 mg	Tab.	**Arigit Tablet 15mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	694	Citalopram	10 mg	Tab.	**Glitpam 10mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	5	0	2	5	1	**23**	**53**
	701	Clozapine	25mg	Tab.	**Glipin Tablet 25 mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	2	**19**	**49**
	702	Clozapine	100 mg	Tab.	**Glipin Tablet 100 mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	2	**19**	**49**
	707	Duloxetine	30 mg	Cap.	**Depfree 30mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	1	**18**	**48**
	708	Duloxetine	60 mg	Cap.	**Depfree 60mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	1	**18**	**48**
	713	Escitalopram	10 mg	Tab.	**Esglit Tablet 10 mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	5	0	2	5	0	**22**	**52**
	714	Fluoxetine HCl	20 mg	Cap.	**Galaxy Capsule 20 mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	1	**18**	**48**
	718	Haloperidol	5 mg	Tab.	**Sera Tablet 5 mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	720	Imipramine	25mg		**Imigit Tablet**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	0	0	0	0	2	5	0	**7**	**37**
	721	Lamotrigine	50 mg	Tab.	**Lamepil Tablet 50 mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	0	1	**13**	**43**
	723	Levetiracetam	250 mg	Tab.	**Seitam 250mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	5	0	2	5	0	**22**	**52**
	724	Levetiracetam	500mg	Tab.	**Seitam 500mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	5	0	2	5	0	**22**	**52**
	729	Mirtazapine	15mg	Tab.	**Mitaz 15mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	1	**18**	**48**
	730	Olanzapine	5mg	Tab.	**O-Zip Tablet 5 mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	731	Olanzapine	10 mg	Tab.	**O-Zip Tablet 10 mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	741	Pregabalin	50 mg	Cap.	**P-Gab 50mg Capsules**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	742	Pregabalin	75mg	Cap.	**P-Gab 75mg Capsules**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	743	Pregabalin	150 mg	Cap.	**P-Gab 150mg Capsules**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	746	Procyclidine HCl	5mg	Tab.	**Procye Tablet 5mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	1	**18**	**48**

	748	Quetiapine	100 mg	Tab.	**Qutia 100mg Tablets**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	5	0	2	5	1	**23**	**53**
	749	Risperidone	2mg	Tab.	**Raze Tablet 2mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	1	**18**	**48**
	750	Risperidone	4 mg	Tab.	**Raze 4mg Tabs**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	1	**18**	**48**
	752	Sertraline	100 mg	Tab.	**Graset Tablet 100mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	5	0	2	5	1	**23**	**53**
	753	Sodium Valproate	250 mg/5ml	Syp.	**Vazipro 120ml Syp**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	754	Topiramate	50 mg	Tab.	**Zopir Tablet 50 mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	1	**18**	**48**
	758	Venlafaxine	37.5 mg	Tab.	**Pracit Tablet 37.5mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	1	**18**	**48**
	759	Venlafaxine	75 mg	Tab.	**Pracit Tablet 75mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	1	**18**	**48**
	788	Diphenhydramine+ Aminophylline+ Ammonium Chloride	8mg+32mg+30 mg /5ml	Syp.	**Dryglit Cough Syrup**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	858	Fusidic acid	2%	Cream	**Usid Cream 2 %**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	879	Silver Sulfadiazine	1%	Cream	**SSD 1% Cream**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	880	Silver Sulfadiazine	1%	Cream	**SSD 1% Cream**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	882	Terbinafine 1%	1%	Cream	**Goter 1% Cream**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	900	Ossein Mineral Complex + Vitamin D	830mg + 400iu	Tab.	**Osilex-D Tablets**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	901	Ossein Mineral Complex + Vitamin D	250mg+400iu/5ml	Syp.	**Osilex-D Suspension**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**
	903	Pyridoxine HCl	50 mg	Tab.	**Vitox Tablet 50 mg**	2	2	3	2	5	6	2	2	2	2	2	**30**	0	5	5	0	0	2	5	0	**17**	**47**

Scrutiny Report
1IMS share below 1% is not awarded
2CoAs are not awarded where GDs are not present or are invalid.
Original Mandatory forms in Hard are not submitted to the MCC
Bidding firm name not mentioned on the mandatory CDR

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm | **Global Pharmaceuticals Islamabad**

S. No.		Product General Information				Technical Evaluation Matrix												Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Factory Technical Evaluation Parameters																					
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered.	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
1	47	Ketorolac Tromethamine	30mg	Inj.	Toralac Inj (I.M/I.V)	2	2	3	0	5	6	2	2	2	2	2	**28**	0	5	5	0	0	4	5	0	**19**	**47**
2	56	Nalbuphine	10mg	Inj.	Nalbin 10mg Inj.	2	2	3	0	5	6	2	2	2	2	2	**28**	0	5	5	5	0	4	5	0	**24**	**52**
3	57	Nalbuphine	20mg	Inj.	Nalbin 20mg Inj.	2	2	3	0	5	6	2	2	2	2	2	**28**	0	5	5	5	0	4	5	0	**24**	**52**
4	272	Meropenem	500mg	Inj.	Merem 500mg IV Inj.	2	2	3	0	5	6	2	2	2	2	2	**28**	0	5	5	0	0	0	5	0	**15**	**43**
5	273	Meropenem	1gm	Inj.	Merem 1gm IV Inj.	2	2	3	0	5	6	2	2	2	2	2	**28**	0	5	5	0	0	0	5	0	**15**	**43**
6	279	Piperacillin + Tazobactam	2.25gm	Inj.	Zoycin 2.25gm Inj.	2	2	3	0	5	6	2	2	2	2	2	**28**	0	5	5	0	0	0	5	0	**15**	**43**
7	280	Piperacillin + Tazobactam	4.5gm	Inj.	Zoycin 4.5gm Inj.	2	2	3	0	5	6	2	2	2	2	2	**28**	0	5	5	0	0	0	5	0	**15**	**43**
8	376	Mecobalamin	500mcg	Inj.	Mecomed 500mcg Inj.	2	2	3	0	5	6	2	2	2	2	2	**28**	0	5	5	0	0	4	5	0	**19**	**47**
9	698	Dutasteride + Tamsulosin	0.5mg + 0.4mg	Cap.	Tamsol-D Cap.	2	2	3	0	5	6	2	2	2	2	2	**28**	0	5	5	0	0	4	5	0	19	**47**
10	914	Cholecalciferol (Vitamin D3)	200000IU	Inj.	Calciferol Inj.	2	2	3	0	5	6	2	2	2	2	2	**28**	0	0	0	0	0	4	5	0	9	**37**

Page	Remarks
43	The IMS Ranking is a combined standing of Global and Vision Pharma, which are independent bidders, and does not reflect the market share of Global only, as readwith gross turnover at page 35, and 92
192	Link attached instead of USFDA certificate.
239	Clearance Certificate of Zoycin 4.5 immediate container is attached instead of Merem 1 gm.
244	Rubber stopper of Norbac 0.5 mg is attached instead of Merem 1 gm.
271 & 308	Link attached instead of USFDA certificate.
275	GD of 25ml Glass bottle of USP-type-I of merem 500mg is attached for Zoycin 2.25ml.
375-380	COA of Alu-alu printing foil for Tamsol D are not attached.
406-409	GD and COA of Cholecalciferol are not matching and 40MIU are attached instead of 20 MIU.
112, 142, 172, 214, 252, 292, 330, 356, 395, 419	IMS product share of all quoted products is incomplete and do not show the date/quarter.

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: GRATON PHARMA KARACHI

S. No.		Product General Information				Technical Evaluation Matrix									Product Technical Evaluation							Product Availability	Product Evaluated Score	Total Technical Score
						Principal's and Importer's Evaluation Parameters								Suppliers Technical Score	Product Technical Parameters										
						Principal Manufacturer Evaluation					Importer's Evaluation														
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
						Valid ISO 13485:2016 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid accreditation of manufacturing unit in its relevant sections by the US-FDA or official accreditation body/ies /regulatory body in the case of SRA/WLA countries (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid calibration certificates for equipment / instruments used in the Factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **Valid Calibration Certificates attested by Quality head of the firm).**	Availability of minimum 20% inventory of the total import of the quoted item(s) during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert(s)). **Non availability of the 20% stock at the ware house at the time of inspection of the importer shall lead to disqualification of the quoted item/s / item)**	Adherence to Good storage practices (GSP) for storage of finished goods. Functional and effective Air-conditioning & Ventilation System and effective cold chain (thermo-labile drugs). The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the bid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Nonadherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to disqualification of the firm.**	Adequate availability of qualified, Presence of Category-A Pharmacist(s) (Case mandatory), & relevant Human Resource **Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Bioavailability/ Bioequivalence study conducted by WHO-Audited Labs, available on WHO/Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) For hydrogels, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 2L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, for the dispatched prior to the cutoff date for submission of bids. **In case of purchases through third party importers a valid trail/link/DRAP approved NOC for the particular principal manufacturer for the quoted item shall be established with the firm offering the product in Govt. MCC**	A certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 15, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies). Trail of principal manufacturer shall be established from the respective GD, CoA and other supporting documents. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO pre-qualification and / or Valid product registration in SRA country(ies) / Valid free-sale certificate issued by regulatory body of any SRA/WLA country(ies) and / or Valid certificate of the availability of the quoted item/s in the US market. **Full marks shall be awarded to the Primary certificate. In the absence of primary certificate, up to a maximum of 06 (04+01+01) marks.** **Certificates on company's own letter heads shall not be acceptable.** **Copies of relevant certificates duly attested by the senior executive of the firm).** **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, or other pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm)**	Validity marks of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistan market as per recent store data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-20% market share = 2 marks 21-30% market share = 3 marks 30% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 01 Tender approvals- 01 mark 02 Tender approvals- 02 marks 03 Tender approvals- 03 marks 04 Tender approvals- 04 marks 05 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the encashment/ clearance against the cheque received shall also be submitted with each purchase order.		
Source	**MCC formulary No.**	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**2**	**5**	**5**	**4**	**5**	**5**	**30**	**5**	**5**	**5**	**5**	**6**	**4**	**5**	**5**	**40**	**70**
Beijing Beilu Pharmaceuticals Company Limited China	775	Dimeglumine Gadopentetate	469 mg/10mL	Inj.	Omnivist	**2**	**0**	**2**	**5**	**5**				**14**	**5**	**5**	0	**0**	**0**	**0**	0	0	**10**	**24**
Beijing Beilu Pharmaceuticals Company Limited China	775	Dimeglumine Gadopentetate	469 mg/15mL	Inj.	Omnivist	**2**	**0**	**2**	**5**	**5**				**14**	**5**	**5**	0	**0**	**0**	**0**	0	0	**10**	**24**
Beijing Beilu Pharmaceuticals Company Limited China	775	Dimeglumine Gadopentetate	469 mg/20mL	Inj.	Omnivist	**2**	**0**	**2**	**5**	**5**				**14**	**5**	**5**	0	**0**	**0**	**0**	0	0	**10**	**24**
Beijing Beilu Pharmaceuticals Company Limited China	777	Iohexol 350mg/ml	USP 350mg/ml 100ml	Inj.	Monopaque	**2**	**0**	**2**	**5**	**5**				**14**	**5**	**5**	0	**0**	**0**	**0**	5	0	**15**	**29**
Beijing Beilu Pharmaceuticals Company Limited China	778	Iohexol 350mg/ml	USP 350mg/ml 50ml	Inj.	Monopaque	**2**	**0**	**2**	**5**	**5**				**14**	**5**	**5**	0	**0**	**0**	**0**	5	0	**15**	**29**

FORMULARY NUMBER OF ALL QUOTED PRODUCTS WERE WRONGLY ENTERED. RECTIFIED
CGMP OF BEIJING BEILU IS EXPIRED AT PAGE 96-104
FREE SALE OF IODIXIRUBICIN IS NOT ATTACHED
Price list attached is on companys own letter head at page 153
BIOSIMILARITY STUDY ATTACHED AT PAGE 404, 541 IS NOT CONDUCTED BY WHO AUDITED LAB INSTEAD ON COMPANY'S OWN LETTER HEAD
EDQM CERTIFICATES ARE ATTACHED WHICH ARE NOT ACCEPTABLE FOR THE AWARD OF MARKS AS PER THE ADVERTISED CRITERIA AT PAGE 1615

TECHNICAL EVALUATION PROFORMA, FOR PROCUREMENT OF ANTICANCER MEDICINES IN GOVT. MCC FY 2026-27

		Name of the firm with	GRATON PHARMA KARACHI
		Manufacturer / Importer	IMPORTER

		Mandatory Requirements.	YES / NO		In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:		YES/NO	In case of being Importers, the Firm should provide attested copies of the following documents also:		YES/NO	
1		National Tax Number (NTN) of the Firm for Income Tax, and	Yes		1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and		1	Valid Drugs Sales License for the importer; and	Yes	
2		Last year Income Tax Return of the Firm; and	Yes		2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.		2	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	Yes	
3		Sale Tax Registration Certificate of the Firm; and	Yes		3	Valid DRAP Approved Price List of the quoted item/s.		3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	Yes	
4		Certificate of Professional Tax of the Firm.	Yes					4	Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and	Yes	
5		Certificate of compliance to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR. Non-Compliance to international reference standards or absence of Cold Chain requirements shall lead to disqualification of the relevant product that requires cold chain.	Yes					5	Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s. Non provision of this document shall lead to disqualification of the firm; and	Yes	
								6	Valid DRAP approved Price List of the quoted items.	Yes	

		Technical Evaluation Parameters	Active Pharmaceutical Ingredient source gradation (for API or finished product). i) The bidder (local manufacturer / multi-national manufacturer / importer) shall provide Analytical/Quality Assurance/ Approval Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades. Certificate of Analysis/ Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreement/ approval with the original manufacturer duly attested/verified by official of the company. Detailed purchase trail of the Active Pharmaceutical Ingredient/ Finished product from the claimed source must be submitted (any proof of purchase such as Goods Declaration Certificate along with Airway Bill/ Bill of Lading/invoice etc.) by the bidder. Maximum marks for this criterion are 40.		Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW) Study/Certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities)/ WHO Listed Authorities MLA Countries BE/ BS Certificate with evidence as to its authenticity) from Category A countries. Bio-Equivalence (BE) of the quoted product to be conducted against the originator. Original innovator products do not require bio- equivalence certificate and shall get 10 marks automatically.The bidder shall provide the documents to establish the proof of inventor/ originator. All other branded generics require BE studies Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid. Maximum marks for this criterion are 10.			Clinical Trial / Clinical studies assessing the safety and efficacy of the quoted drug, In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article) Mandatory: Online verification link must be provided to verify the Clinical Trial / Clinical Studies submitted for the quoted items.			Factory/ Importer Based Evaluation Score (MANDATORY)	Sample Evaluation by End User Committee Samples will be examined per following parameters as follows: a. Labeling and Packing Rules 1986 b. Outer packing c. Inner packing d. Physical appearance. Product which has unsatisfactory packing/labeling will be technically Disqualified. Maximum score for this criterion is 1.		Past Performance (Last two years). i) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks. ii) Only supply orders will not get any marks. iii) The bidders have to undertake that they have never been blacklisted or debarred. Maximum marks for this criterion are 5. iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TMO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.	Total Technical Score
			Category A – Approved By: • United States Food & Drug Administration (US-FDA) • European Medicines Agency (EMA) • Pharmaceuticals & Medical Products Regulatory Agency (MHRA), UK • Therapeutic Goods Administration (TGA), Australia. • Pharmaceutical/Medical Agency (PHARMAC), New Zealand • Pharmaceutical & Medical Devices Agency (PMDA), Japan • Swiss Agency for therapeutic drugs (Swiss-medic), Switzerland • Health Canada • Health Sciences Authority (HAS), Singapore • National Administration of Drugs, Food & Medical technology (ANMAT), Argentina Drug Regulatory Authorities of the MA (Stringent Regulatory Authorities) / WHO Listed Authorities MLA countries	Category B – Approved By: • Agência Nacional de Vigilância Sanitária (ANVS), Brazil • Central Drug Standard Control Organization (CDSCO), India • Drug Regulatory Authority, Pakistan • Food and Drug Safety Center, Komitmatunu (NPCB), Malaysia • Food & Drug Administration, South Korea • Ministry of Health, Egypt • Ministry of Health, Turkey • China Food & Drug Administration • Any other source not mentioned in Category-A	Study/certificate accepted/certified by a Category A Country Regulatory Authority. BE study should be conducted using at least 12 subjects. Bio-waiver is acceptable only to injectable forms if issued by Category A Country.	No BE/ BW certificate obtained for acquired product from Category A Country (as mentioned at S No. 1 above).	Yes-BE/BS-/BW Certificate.	In case the study is published in Category "A" journal listed in HEC Journal Recognition System (HJRS) Database/ Journals & Publication Policy 2024 and List of National Recognized Journals as per HEC, 2 marks per original research article shall be awarded maximum up to 6 marks).	In case the study is published in Category "X" journal listed in HEC Journal Recognition System (HJRS) Database/ Journals & Publication Policy 2024 and List of National Recognized Journals as per HEC, 2 marks per original research article shall be awarded maximum up to 6 marks).	0	Shall be assigned by the Technical Committee of the HMC/ Journals & Publication Policy 2024 and List of National Recognized Journals as per HEC/ shall not be awarded marks.	The Physical inspection of the premises of the bidders (Manufacturer/Importer) shall be carried out in accordance with ITB 28.4(b), SCC 5 (SCC-5.3), Section V (3) (3.9) of the approved BSDS of Govt. MCC FY 2026-27	Satisfactory	Unsatisfactory	1) Substantial quantity of Supplies of anti-cancer medicines made to private sector Teaching Hospitals namely: The Aga Khan University Hospital, Karachi; Shaukat Khanum Hospital, Lahore/ Peshawar, Clik-Hospital, Lahore/ Peshawar, Rehman Medical Institute, Peshawar (Atlis international hospital Islamabad, with Good/Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 24 months. No marks will be given for supply orders except CMH Rawalpindi where supply orders along with delivery challans & invoices will be considered for award of marks. 1 mark per agreement up to a maximum of 5 marks	
SOURCE	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	40	30	10	5	0	9	6	0	5	1	0	5	70
Yangtze River Pharmaceutical Group Co. Ltd China	1468	Calcium Folinate	100mg	Inj.	Cafol	0	0	0	0	0	0	0	0	5	1		0	6
Dalas Exporin Pvt. Ltd. India	1427	Abiraterone Acetate	250mg	Tab.	Xabiron	0	0	0	0	0	0	0	0	5			0	5
Dalas Exporin Pvt. Ltd. India	1519	Gefitinib	250mg	Tab.	Gefiton	0	0	0	0	0	0	0	0	5	1		0	6
Dalas Exporin Pvt. Ltd. India	1449	Anastadine	100mg	Inj.	Grana	0	0	0	0	0	0	0	0	5	1		0	6
Dalas Exporin Pvt. Ltd. India	1503	Doxorubicin	10mg	Inj.	Cloadin	0	30	0	0	0	0	0	0	5	1		0	36
Dalas Exporin Pvt. Ltd. India	1504	Doxorubicin	50mg	Inj.	Cloadin	0	30	0	0	0	0	0	0	5	1		0	36
Dalas Exporin Pvt. Ltd. India	1556	Liposomal Doxorubicin	10ml/20mg	Inj.	Cloadin-LP	0	0	0	0	0	0	0	0	5			0	5

WRONG FORMULARY NUMBERS OF ALL QUOTED PRODUCTS WERE ENTERED. ALL NUMBERS RECTIFIED
FREE SALE CERTIFICATE OF JODAS EXPOIM INDIA ATTACHED AT PAGE 112 IS EXPIRED (21-12-2021) FOR ABIRATERONE, GERTINIB WHILE ONLY VALID FOR ICHEKOL 300MG &350MG ATTACHED AT PAGE 118-119
FREE SALE OF CALCIUM FOLINATE IS EXPIRED. VAUID TILL 7-11-2025 AT PAGE 145
FREE SALE OF LIPOSOMAL DOXURUBICIN NOT ATTACHED
FREE SALE OF CALCIUM FOLINATE IS EXPIRED HENCE MARKS IN ELIGIVKAMP ALSO NOT AWARDED (PAGE 185-186)
IN PAST PERFORMANCE ONLY SUPPLY ORDERS ARE ATTACHED HENCE MARKS NOT AWARDED
BIOSIMILAR STUDY AT PAGE 1059 IS NOT CONDUCTED BY WHO AUDITED LAB

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27														
					Name of the firm	**Green Star Marketing Karachi**														
						Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters							**Product Technical Evaluation**						**Product Evaluated Score**	**Total Technical Score**
						Principal Manufacturer Evaluation			**Importer's Evaluation**			**Suppliers Technical Score**								
	MCC formulary No.	**1**	**2**	**3**	**4**	**5**	**6**	**7**	**8**	**9**	**10**	**11**	**12**	**13**	**14**	**15**	**16**	**17**	**18**	**19**
						Valid ISO 14001 certificate of the facility where the quored product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm).**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevent certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s, Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
	485	Male Latex Condom	Plain Condoms		Sathi	3	5		5	6	6	**25**	5	5	0	1	2	16	**29**	**54**
																			0	**0**
																			0	**0**
																			0	**0**

Page	Remarks
135	Tender approval attached are not according to the advertised criteria.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: GT Pharma, Lahore

Technical Evaluation Matrix

S. No.	Product General Information					Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded in top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) as all labs + Functional Stability Chamber (Both Accelorated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC experts's, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC experts's). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP. **(Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs, **(As evaluated by the MCC expert/s at the time of inspection).**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the transfr date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC.**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (G.D) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quantd item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. Atypine of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non-provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the QC incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent store data of IMS/IQVIA Health not older than two/so (12) months. 5-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than two/for 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note, Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
1	883	Phytomenadione Injection 2mg/0.2ml	10mg/ml	Inj	K cot injection	0	0	0	0	0	4	2	2	2	2	2	**14**	0	0	0	0	0	0	0	0	**5**	**19**
2	3643	Vitamin k 10mg/ml	10mg/ml	Inj	K Inf Injection	0	0	0	0	0	4	2	2	2	2	2	**14**	0	0	0	0	0	0	0	0	**5**	**19**
3	3645	Tranexamic Acid 250mg/5ml	250mg/5ml	Inj	Tomtas Injection	0	0	0	0	0	4	2	2	2	2	2	**14**	0	0	0	0	0	0	0	0	**5**	**19**
4	3647	Tranexamic Acid 500mg/5ml	500mg/5ml	Inj	Tromas Injection	0	0	0	0	0	4	2	2	2	2	2	**14**	0	0	0	0	0	0	0	0	**10**	**24**
5	1928	Azithromycin 200mg/5ml	5ml, 200mg/5ml	Suspension	AZ Azithro Suspension	0	0	0	0	0	4	2	2	2	2	2	**14**	0	0	0	0	0	0	0	0	**10**	**24**
6	2053	Azithromycin 250mg/Cap	cap, 250mg	cap	AZ Azithro cap 250mg	0	0	0	0	0	4	2	2	2	2	2	**14**	0	0	0	0	0	0	0	0	**10**	**24**
7	2712	Linezolid	inf, 600mg/300ml	Inj	Ezi line inf 600mg/300ml	0	0	0	0	0	4	2	2	2	2	2	**14**	0	0	0	0	0	0	0	0	**10**	**24**
8	2713	Linezolid	inf, 600mg/300ml	Inj	Ezi line inf 600mg/300ml	0	0	0	0	0	4	2	2	2	2	2	**14**	0	0	0	0	0	0	0	0	**10**	**24**
9	3703	Iron Sucrose	Inj 20mg/5ml	Inj	Surfer inj	0	0	0	0	0	4	2	2	2	2	2	**14**	0	0	0	0	0	0	0	0	**10**	**24**
10	83	Paracetamol	Inf, 1000mg/100ml	Inj	Pyrarest inf 1000mg/10 0ml	0	0	0	0	0	4	2	2	2	2	2	**14**	0	0	0	0	0	0	0	0	**5**	**19**
11	1808	Montelukast	Sachi, 4mg	Sachets	GT-mont Sachet	0	0	0	0	0	4	2	2	2	2	2	**14**	0	0	0	0	0	0	0	0	**10**	**24**
12	5428	Ondansetron	2mg/ml	Inj	IO Vom injection	0	0	0	0	0	4	2	2	2	2	2	**14**	0	0	0	0	0	0	0	0	**5**	**19**
13	3145	Colicalciferol	600000IU	Inj	IO 3 Injection	0	0	0	0	0	4	2	2	2	2	2	**14**	0	0	0	0	0	0	0	0	**5**	**19**

Page	Remarks
10	Mandatory Bid form 3 is not according to the advertised criteria (clause 03 committed)
81	ISOs are expired on 16-01-2026
93-102	Caliberation certificates are not according to the advertised criteria.
105-110	GD and COA of vitamin K are not matching
118-127	COA Of azithromycin is not attached
126-137	COA of Linezolid is not attached
138	COA of iron sucrose not attached.
143-152	COA of Vitamin D3 are not matching with GD
160	GD of ondansetron is older than 24 months
171	COA of Montelukast not attached
172	GD of paracetamol not attached.
	Stability Studies of Ondansetron and Colicalciferol not attached
	Immediate container not attached.

Evaluation Criteria for Manufacturers of Cotton & Related Goods for Government MCC 2026-27

			Name of Firm	HAFIZ PHARMA PVT LTD																								
				Technical Evaluation Matrix																								
				Factory Technical Evaluation Parameters																								
	S. No.		General Product Information	Documents Based Factory Score										Evaluation visit Score				Factory Evaluated Score	Product Evaluation Parameters			Product Evaluated Score	Total Technical Score
		MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
							Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body. (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e FY 2023-24 or latest. A minimum turnover of PKR 100 million is required for award of marks in this parameter. (The document shall be attested by a Senior executive of the firm)	Functional and effective Airconditioning & Ventilation System as per the requirements laid down by DRAP **(Evaluated by the MCC expert/s at the time of inspection, Non functionality of the Air Conditioning & Ventilation system in specified section shall lead to disqualification of the section or firm)**	Adequate availability of equipment / instruments in QC labs performing relevant official tests as well as compliance to Good laboratory practices (GLP) in all Labs and Current Good Manufacturing Practices (cGMP) throughout the production facility. **(Evaluated by the MCC expert/s at the time of inspection, Non availability of adequate and appropriate equipment / instruments and non-compliance to GLP , cGMP shall lead to disqualification of the relevant section or firm)**	Appropriate storage of raw material, in process and finished goods with compliance to Good storage practices (GSP) **(To be evaluated by the MCC expert/s at the time of inspection, Non compliance to GSP shall lead to disqualification of the relevant section or firm)**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)		
	DRAP REG		MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	3	3	**4**	5	3	6	6	6	6	**45**	5	10	10	**25**	**70**
	MDME:0000249	1	969	Cotton (Surgical) Corded BPC	200 GM	Absorbency	SURGEON	3	3	3	4	5	3					**21**	0			**0**	**21**
	MDME:0000249	2	970	Cotton (Surgical) Corded BPC	100 GM	Absorbency	SURGEON	3	3	3	4	5	3					**21**	0			**0**	**21**
	MDMR:000334	3	971	Cotton Bandage (Surgical) B.P Type II	6.5cm x 4m	Dressing	SURGEON	3	3	3	4	5	3					**21**	1			**1**	**22**
	MDMR:000334	4	972	Cotton Bandage (Surgical) B.P Type II	7.5cm x 4m	Dressing	SURGEON	3	3	3	4	5	3					**21**	1			**1**	**22**
	MDMR:000334	5	973	Cotton Bandage (Surgical) B.P Type II	10cm x 4m	Dressing	SURGEON	3	3	3	4	5	3					**21**	0			**0**	**21**
	MDMR:000334	6	974	Cotton Bandage (Surgical) B.P Type II	15cm x 4m	Dressing	SURGEON	3	3	3	4	5	3					**21**	0			**0**	**21**
	MDME:0000046	7	981	Cotton Crepe Banddage BPC	7.5cm x 4.5m	Dressing	SURGEON	3	3	3	4	5	3					**21**	1			**1**	**22**
	MDME:0000046	8	982	Cotton Crepe Banddage BPC	10cm x 4.5m	Dressing	SURGEON	3	3	3	4	5	3					**21**	2			**2**	**23**
	MDME:0000046	9	983	Cotton Crepe Banddage BPC	15cm x 4.5m	Dressing	SURGEON	3	3	3	4	5	3					**21**	2			**2**	**23**
		10	1097	Gauze Cloth Roll Packing BPC	100cm x 20m	Dressing	SURGEON	3	3	3	4	5	3					**21**	0			**0**	**21**
		11	1098	Gauze Cloth Roll Packing BPC	100cm x 40m	Dressing	SURGEON	3	3	3	4	5	3					**21**	0			**0**	**21**
	MDMR:000516	12	1219	Sterile Gauze Dressing Pad (X-Ray Detectable) BP Type II	30cm x 30cm (4-Ply)	Dressing	SURGEON	3	3	3	4	5	3					**21**	0			**0**	**21**
	MDMR:000334	13	1220	Sterile Gauze Dressing Pad BP	10cm x 10cm (8-Ply)	Dressing	SURGEON	3	3	3	4	5	3					**21**	0			**0**	**21**
	MDMR:000334	14	1221	Sterile Gauze Dressing Pad BP	15cm x 15cm (8-Ply)	Dressing	SURGEON	3	3	3	4	5	3					**21**	0			**0**	**21**

During the inspection, the inspection team identified several critical deficiencies related to cGMP compliance and Good Storage Practices (GSP), as outlined below:
Poor Adherence to cGMP
1. The absence of a qualified microbiologist at the time of inspection highlighted a weakness in the facility's quality control system, particularly concerning microbiological analysis and environmental monitoring functions.
2. Only one registered pharmacist was available on-site during the inspection, which was deemed insufficient to provide effective oversight of manufacturing, quality control, and storage activities in line with GMP and regulatory requirements.
3. Materials located in the Raw Material Store (RMS) and packaging storage area were found without appropriate labeling, indicating non-compliance with essential GSP requirements for material identification, traceability, and status control.
4. The technical staff failed to produce Batch Manufacturing Record (BMR) of any batch to the inspection team.
Poor Good Storage Practices (GSP)
5. Finished goods were stored directly on the floor without the use of pallets or racks, creating an increased risk of contamination and product damage due to inadequate storage arrangements.
6. No temperature or relative humidity records were available for the production or storage areas, demonstrating a significant lapse in environmental monitoring and documentation practices.
7. The Raw Material Store (RMS), in-process areas, and Finished Goods Store (FGS) lacked hygrometers or humidity monitoring devices, making it impossible to monitor environmental conditions necessary for preserving material quality and stability.
In view of the above, the firm is NOT RECOMMENDED for award of marks under the manufacturer evaluation parameters for the quoted items.

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: Hakim Sons Impex Karachi

Technical Evaluation Matrix

S. No.		Product General Information					Principal's and Importer's Evaluation Parameters								Suppliers Technical Score	Product Technical Evaluation								Product Evaluated Score	Total Technical Score
							Principal Manufacturer Evaluation					Importer's Evaluation				Product Technical Parameters						Product Availability			
	MCC formulary No.	1	2	3	4		5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
							Valid ISO 13485 certificate of the facility verified from issuing authority. Or manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 13485 certificate of the facility verified from issuing authority. Or manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility verified from issuing authority. Or manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid accreditation of manufacturing site from relevant regulatory authority or any other official accreditation body for regulatory body to the case of SRA/WLA countries duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid calibration certificates for equipments/instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished product for the manufacturing of the quoted products. **Valid Calibration Certificates attested by Quality head of the firm)**	Availability of mentioned 20% inventory in the Importer's warehouse at the time of placing last one year (certificate to the effect duly signed by the senior executive of the firm is evaluated by the MCC experts). **Non-availability of the 20% stock at the time frame at the time of inspection of the importer shall lead to disqualification of the quoted items).**	Adherence to Good storage practices (GSP) in the warehouse (Temperature & Ventilation System and effective cold chain (Intermediate shipp). the physical inspection committee/ MCC experts at the time of inspection to check GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Nonadherence to GSP, as evaluated by the MCC experts/ at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, experienced and trained staff members (core mandatory), & relevant Human Resource **(Certified by the senior executive of the firm and evaluated by the MCC experts at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Non-toxicology/ Non-genotoxicity Study conducted by WHO prequalified Labs, available on WHO Website/ US-FDA / EMA/ MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA/WLAs country (ies). For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or the waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). in case of Large volume parenteral i.e., greater than 100ml up to 1L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of invention / innovative products from relevant body shall be provided where the firm claims that the lesser/evidence / non-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration/Certificate of shipment (Export Declaration) issued by Customs, coupled with valid airway bill or Bill of Lading for the quoted items, duly attested by the senior executive of the firm for submission of bids. **In case of purchases through third party importers a valid waiver/NOC/ clearance/ NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC.**	Certificate of Analysis of finished quoted product from the manufacturer as mentioned in the goods declaration (GD) awarded in column 13, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredients (API) / bulk raw materials certificate issued by WHO / US-FDA / EMA / MHRA / TGA / PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA/WLAs country (ies). Brief of principal manufacturer shall be established from the respective GD. CoA and other supporting documents. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO -prequalification and / or Valid product registration in SRA country(ies) / Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) And / or Valid certificate of the availability of the quoted item in the US market. **Full marks shall be awarded in the Primary certificate and 3 mark for additional certificate, up to a maximum of 06 (04+01+01) marks.** **Certificates on company's own letter heads shall not be acceptable.** **copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / Class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/ proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non-provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: a. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical Grade. b. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). c. Glass material for Powder/ Syrup/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** i. For Dry Powder Injectables, a. For USP Type 1 glass 6 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided, 0 marks will be awarded in this regard. **(Documents duly attested by the Senior executive of the firm)**	Validity studies of quoted item/s duly attested by the QC incharge of the firm).	Availability of quoted item/s in Pakistan market as per recent mass data of PHMA/QAA. Health not older than twelve (12) months. 1-10% market share = 1 mark 11-20% market share = 2 marks 21-30% market share = 3 marks 30%, and above market share = 5 marks No items specifically used in institutions where BOS/QAA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICT accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: (a) Tender approvals- 01 mark (b) Tender approvals- 02 marks (c) Tender approvals- 03 marks (d) Tender approvals- 04 marks (e) or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) must be issued by the procurement agency/ies and must be supported by copies of purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
Source	Pack Size	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	2	5	5	4	5	5	30	5	5	5	5	6	4	5	5	40	70
Zydus Lifesciences Ltd. India	1 ml	4310	Purified Chick Embryo Cell Rabies Vaccine (PCECV)	2.5 ml	inj.	Vaxirab-N	0360 -2003 (Gold) Verification link not	0360 Verification link not provided	Not attached	0	3022-71 list attached instead of calibration certificate	4	5	5	14	1288 WHO-guidelines are attached instead of studies	0	0	0	0	3183 COA by Zydus attached instead of vial manufacturer	5	256-917 Tender approvals are not according to the ad. Criteria	5	19
Rahamat Serum and Vaccine, India	10 ml	4321	Snake Venom Antiserum (Lyophilized) with diluent	10 ml vial (Lyophilized)	inj.	Snake Venom Antiserum Lyophilized	2141 Verification link NA	2141 Verification link NA	2141 Verification link NA	0	Page 2169: Calib Certi not attached	4	5	5	14	1288 WHO-guidelines are attached instead of studies	0	5	0	0	3580-2582 COA by BSC attached instead of vial manufacturer SDG Pharma India	5	5	20	34
Rahamat Serum and Vaccine, India	5 ml	4308	Anti Rabies Serum 200 IU/ml	200 IU/1 ml, 5ml	inj.	Equirab	2141 Verification link NA	2141 Verification link NA	2141 Verification link NA	0	Page 2169: Calib Certi not attached	4	5	5	14	1288 WHO-guidelines are attached instead of studies	0	5	0	0	2295-98 COA by BSC attached instead of vial manufacturer SDG Pharma India	5	5	20	34
TSL Behring GmbH /AG	1 ml	4297	Hepatitis B Immunoglobulin (Adult). Inj	200 IU/1 ml	PFS	Hepatitis B Ig Behring	Not attached	Not attached	Not attached	5	5	4	5	5	24	1288 WHO-guidelines are attached instead of studies	5	5	0	0	4	5	5	24	48
TSL Behring GmbH /AG	1 ml	4298	Hepatitis B Immunoglobulin (Neonatal) Inj		PFS	Hepatitis B Ig Behring	Not attached	Not attached	Not attached	5	5	4	5	5	24	1288 WHO-guidelines are attached instead of studies	5	5	0	0	4	5	256-917 Tender approvals are not according to the ad. Criteria	19	43
TSL Behring GmbH /AG	2 ml PFS	4315	Rho (D) Immunoglobulin 300 mcg Inj	300 mcg/2 ml	PFS	Rhophylac 300 mcg	Not attached	Not attached	Not attached	5	5	4	5	5	24	1288 WHO-guidelines are attached instead of studies	0	0	0	0	4	5	256-917 Tender approvals are not according to the ad. Criteria	9	33
TSL Behring GmbH /AG	50 ml	4272	Safi-free Albumin 20% Soln. 50 ml I/V Inf.	20% Soln. 50 ml	Infusion bottle with 50 ml	Human Albumin 20% Behring 50 ml	Not attached	Not attached	Not attached	5	5	4	5	5	24	1288 WHO-guidelines are attached instead of studies	5	5	0	0	15327type II 100 ml glass attached 2 Marks	5	256-917 Tender approvals are not according to the ad. Criteria	15	39
TSL Behring GmbH /AG	100 ml	4273	Safi-free Albumin 20% Soln. 100 ml I/V Inf.	20% Soln. 100 ml	Infusion bottle with 100 ml	Human Albumin 20% Behring 100	Not attached	Not attached	Not attached	5	5	4	5	5	24	1288 WHO-guidelines are attached instead of studies	5	5	0	0	1739 Type II 50 ml glass attached 2 Marks	5	256-917 Tender approvals are not according to the ad. Criteria	15	39
Rahamat Serum and Vaccine, India	5 ml	4355	Anti-Thymocyte globulin (ATG)	250 mg/5 ml	inj.	Thymogam	2141 Verification link NA	2141 Verification link NA	2141 Verification link NA	0	Page 2169: Calib Certi not attached	4	5	5	14	1288 WHO-guidelines are attached instead of studies	0	5	0	0	3803 COA by BSV attached instead of vial manufacturer West Pharmaceuticals Services India	5	256-917 Tender approvals are not according to the ad. Criteria	15	29

Pages
190-200
2231-2247
2249
3118-3123

Remarks
GDs of importer are attached instead of Principal manufacturer.
COA not attached which in not in English language, expired on 13-05-2019
Edit: WHO PQ verification link not attached.
Verification link
90% documents are irrelevant and haphazard.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm | **HALEON PAKISTAN LIMITED KARACHI**

S. No.	Product General Information					Technical Evaluation Matrix																												Total Product Evaluated Score	Total Technical Score
						Factory Technical Evaluation Parameters													Total Factory Evaluated	Product Evaluation Parameters																
						Documents Based Factory Score						Factory Evaluation Visit Score								Product Technical Parameters																	
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26								
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th positions shall be awarded 1 mark.**	Valid calibration certificates for equipment instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) as all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP). **(Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC experts). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the sections/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the transfr date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC.**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies): and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies): **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates-on company's own letter heads shall not be acceptable. copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials used: Amber Vial, PVC Capsule Shells, Plastic (HDPE, LDPE) or Glass bottles and closures used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better.**(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products whose USP Type 3 glass is used or where the CoA of Glass	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA. Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the tender shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**								
	58	Paracetamol	80mg/0.8ml	Oral Drops	Panadol Drops 20ml	0	0	3	5	5	6	2	2	2	2	2	**29**	0	5	5	0	0	4	5	2	**21**	**50**								
	157	Levocetirizine	2.5 mg/5 ml	Syp.	7-Day Syrup 60ml	0	0	3	5	5	6	2	2	2	2	2	**29**	0	5	5	0	0	4	5	1	**20**	**49**								
	158	Levocetirizine	5 mg	Tab.	7-Day Tablet 30's	0	0	3	5	5	6	2	2	2	2	2	**29**	0	5	5	0	0	4	5	1	**20**	**49**								

Scrutiny Report

Valid ISO certificate 18001/45001 and 14001 is not attached in the Bid
Bioavailability/Bioequivalance study by WHO accredited Labs or by regulatory authority / body of any SRAs country is not attached in the bid
Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) is not provided in the bid
No valid WHO prequalification or Valid product registration in SRA/WLA countries or Valid Free sale certificate is not attached in the bid
Bank Gaurantee expiry is 30-06-27.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: Hansel Pharma Lahore Head office: 18-Skinder Block, Allama Iqbal Town, Lahore.b) Main Warehouse: 30 K.M, Multan Road, at Hansel Pharmaceuticals Pvt Limited, Lahore.042-35975213-35975216Fax No. 042-35975217iii) Mobile numbers of Focal Person:Ch. Muhammad Ha

Technical Evaluation Matrix

S. No.	Product General Information					Factory Technical Evaluation Parameters: Documents Based Factory Score						Factory Evaluation Visit Score					Total Factory Evaluated Score	Product Evaluation Parameters: Product Technical Parameters								Total Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this colounm for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade.	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**5**	**3**	**4**	**5**	**5**	**37**	**70**
	204	Cefixime	400mg	Caps	Cefsel	2	2	3	0	5	4	The firm was inspected as per technical evaluation criteria and the following observations were noted; 1. The weighing balance at dispensing booth of Raw Material Store was not calibrated. 2. Hepa filter Dop test of Dispensing booth was not shown to the inspection team. 3. In RMS, both quarantine and released raw material were placed mixed together. 4. In RMS an ordinary freezer containing batch of Dinoprostone USP bearing lot No. API034-2025001 was placed at a temperature of 0.3 , however the required temperature as per label claim was -20 ± 5 . 5. Similarly, Cholecalciferol API was stored at a temperature of -1.5 whereas the required storage temperature as per label claim of the API was 2-8 . 6. In cephalosporin section RMS, ceiling were cracked in material transfer corridor and had open drains. 7. In Cephalosporin RMS, the temperature observed was 26.3 and the required temperature was 25 . 8. Neither temperature and humidity record was available nor hygrometer was available in Cephalosporin Oral RMS. 9. In filling and sealing section, monometer was not functional. 10. In Quality Control, vitamin D and Dinoprostone reference standards were stored in refrigerator instead of the claimed temperature i.e. 2-8 for Vitamin D and -20 ±5 for Dinoprostone (which the ordinary freezer cannot maintain). 11. In Accelerator stability chamber not a single product was found at the time of inspection for the quoted items. 12. Unlabelled vials were found in the shelves of QC lab which is the violation of Good Laboratory Practices guidelines. In view of the above, the firm is NOT RECOMMENDED for award of factory evaluation visit score for the quoted items.	16	0	5	5	0	0	0	5	0	15	31
	207	Cefoperazone + Sulbactam	1g	Injection	Daffodel	2	2	3	0	5	4						16	0	5	5	0	0	0	Not provided	0	10	26
	208	Cefoperazone + Sulbactam	2g	Injection	Daffodel	2	2	3	0	5	4						16	0	5	5	0	0	0	5	0	15	31
	211	Ceftriaxone	1g	Injection	Hantox	2	2	3	0	5	4						16	0	GD not present	0	0	0	0	5	0	5	21
	366	Ferrous Fumarate BP.....150 mg Folic Acid BP 0.5 mg	Tablet	Tablet	Fefolic	2	2	3	0	5	4						16	0	GD of folic acid is not present	0	0	0	0	5	0	5	21
	482	Combine Oral Contraceptive Tablets Levonorgestrel BP 0.15mg Ethinylestradiol BP 0.03mg Ferrous Fumarate BP 75mg	Queen F	Tablet	Queen-F	2	2	3	0	5	4						16	0	5	Ethinyl estradiol CoA not present	0	0	0	5	0	10	26
	483	Medroxyprogesterone	150mg	Injection	Depo-Queen	2	2	3	0	5	4						16	0	5	5	API source on page 599 is not matching with pricipal manufacturer of Medroxyprogesterone	0	0	5	0	15	31
	538	Dinoprostone	3mg	Vaginal Tablet	Vprestone-2	2	2	3	0	5	4						16	0	5	CoA not present	0	0	0	5	0	10	26
	697	Tamsulosin	0.4mg	Caps	Optiflo	2	2	3	0	5	4						16	0	GD not present	0	0	0	0	5	0	5	21
	839	Moxifloxacin	5ml	Eye Drops	Q-Mox	2	2	3	0	5	4						16	0	5	5	0	0	0	5	0	15	31
	870	Fusidic Acid	2%, 15g	Cream	Futril	2	2	3	0	5	4						16	0	5	5	0	0	0	5	0	15	31
	914	Cholecalciferol	5mg	Injection	Vitadol-D	2	2	3	0	5	4						16	0	5	5	0	0	0	5	0	15	31

Scrutiny

Pictures / Images of DRAP approved packaging are not provided therefore marks for immediate container CoA cannot be awarded

						Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27														
Name of the firm						Hashir Surgical Services, Medical Devices, Peshawar														
S. No.		Product General Parameter				Technical Evaluation Matrix													Product Evaluated Score	Total Technical Score
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation							
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the time of inspection at the warehouse at the tim eof inspection of the importer shall lead to disqualification of the quoted item/s / firm).**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP.	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
Prinicpal	MCC formulary No	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	5	6	**29**	5	5	5	6	10	10	**41**	**70**
RIASA SRL Argentina	919	Adhesive Tapes (Paper)	1" (2.5cm) x 4.5m	HIPOALERGIC PORE		Not attached	5	Not attached	5	5	6	**21**	**5**	5	Tender approvals a	2	10	10	**32**	**53**
YAFHO BCL China	919	Adhesive Tapes (Paper)	1" (2.5cm) x 4.5m	BIOPORE		Not attached	5	Not attached	5	5	6	**21**	**5**	5	Tender approvals a	2	10	10	**32**	**53**
YAFHO BCL China	920	Adhesive Tapes (Paper)	2" (5cm) x 4.5m	BIOPORE		Not attached	5	Not attached	5	5	6	**21**	**5**	5	Tender approvals a	2	10	10	**32**	**53**
YAFHO BCL China	923	Adhesive Tapes (Plastic)	1" (2.5cm) x 4.5m	BIOPORE		Not attached	5	Not attached	5	5	6	**21**	**5**	5	Tender approvals a	2	10	10	**32**	**53**
YAFHO BCL China	924	Adhesive Tapes (Plastic)	2" (5cm) x 4.5m	BIOPORE		Not attached	5	Not attached	5	5	6	**21**	**5**	5	Tender approvals a	2	10	10	**32**	**53**
Fenglin Medical Appliances China	1018	Disposable Auto Disable Syringe (Blister Packing) Sterile	3ML	BIO SOFT		Not attached	Not attached	Not attached	5	5	6	**16**	**5**	5	Tender approvals a	2	10	10	**32**	**48**
Fenglin Medical Appliances China	1019	Disposable Auto Disable Syringe (Blister Packing) Sterile	5ML	BIO SOFT		Not attached	Not attached	Not attached	5	5	6	**16**	5	5	Tender approvals a	2	10	10	**32**	**48**
Jiangxi Fenglin China	1119	IV Fluid Administration Set (Sterile & Pyrogen Free, minimum 150 cm Tube Length, Blister Pack)	150cm, Blister Pack	BIO SOFT		3	5	Not attached	5	5	6	**24**	5	5	Tender approvals a	2	10	10	**32**	**56**
Shangdong Yixing China	1119	IV Fluid Administration Set (Sterile & Pyrogen Free, minimum 150 cm Tube Length, Blister Pack)	150cm, Blister Pack	BIO FLOW		Not attached	5	Not attached	5	5	6	**21**	5	5	Tender approvals a	2	10	10	**32**	**53**
Shangdong Yixing China	1120	IV Fluid Administration Set with additional "Y" Injection Port (Sterile & Pyrogen Free, minimum 150 cm Tube Length, Blister Pack)	150cm, Y-Port, Blister Pack	BIO FLOW		Not attached	5	Not attached	5	5	6	**21**	5	5	Tender approvals a	2	10	10	**32**	**53**

Jiangxi Fenglin China	1123	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free).	With Wings+ G-18, Pack)	Inj: Port+ (Blister	FLOWCATH		3	5	Not attached	0	0	0	**8**	5	5	Tender approvals a	2	DTL Substandard	10	**22**	**30**
USM Vietnam	1123	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free).	With Wings+ G-18, Pack)	Inj: Port+ (Blister	FAVOCATH		3	5	0	5	5	6	**24**	5	5	Tender approvals a	2	10	10	**32**	**56**
PENTAMASTER MEDIQ MALAYSIA	1123	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free).	With Wings+ G-18, Pack)	Inj: Port+ (Blister	KAWANA		Not attached	5	Not attached	5	5	6	**21**	5	5	Tender approvals a	2	10	10	**32**	**53**
PENTAMASTER MEDIQ MALAYSIA	1124	I/V Cannula (Sterile having wings + injection port with auto passive safety clip in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	With Wings+ G-18, Pack)	Inj: Port+ (Blister	KAWANA SAFETY		Not attached	5	Not attached	5	5	6	**21**	5	5	Tender approvals a	2	10	10	**32**	**53**
Jiangxi Fenglin China	1125	I/V Cannula (Sterile having wings + injection port with Heparin Stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	With Wings+ G-18, Pack)	Inj: Port+ (Blister	FLOWCATH		3	5	Not attached	5	5	6	**24**	5	5	Tender approvals a	2	10	10	**32**	**56**
USM Vietnam	1125	I/V Cannula (Sterile having wings + injection port with Heparin Stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	With Wings+ G-18, Pack)	Inj: Port+ (Blister	FAVOCATHU		3	5	0	5	5	6	**24**	5	5	Tender approvals a	2	10	10	**32**	**56**
PENTAMASTER MEDIQ MALAYSIA	1125	I/V Cannula (Sterile having wings + injection port with Heparin Stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	With Wings+ G-18, Pack)	Inj: Port+ (Blister	KAWANA		Not attached	5	Not attached	5	5	6	**21**	5	5	Tender approvals a	2	DTL Substandard	10	**22**	**43**
Jiangxi Fenglin China	1126	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free).	With Wings+ G-20, Pack)	Inj: Port+ (Blister	FLOWCATH		3	5	Not attached	0	0	0	**8**	5	5	Tender approvals a	2	10	10	**32**	**40**
USM Vietnam	1126	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free).	With Wings+ G-20, Pack)	Inj: Port+ (Blister	FAVOCATH		3	5	0	5	5	6	**24**	5	5	Tender approvals a	2	10	10	**32**	**56**
PENTAMASTER MEDIQ MALAYSIA	1126	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free).	With Wings+ G-20, Pack)	Inj: Port+ (Blister	KAWANA		Not attached	5	Not attached	5	5	6	**21**	5	5	Tender approvals a	2	DTL Substandard	10	**22**	**43**
PENTAMASTER MEDIQ MALAYSIA	1127	I/V Cannula (Sterile having wings + injection port with auto passive safety clip in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	With Wings+ G-20, Pack)	Inj: Port+ (Blister	KAWANA SAFETY		Not attached	5	Not attached	5	5	6	**21**	5	5	Tender approvals a	2	10	10	**32**	**53**
Jiangxi Fenglin China	1128	I/V Cannula (Sterile having wings + injection port with Heparin Stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	With Wings+ G-20, Pack)	Inj: Port+ (Blister	FLOWCATH		3	5	Not attached	5	5	6	**24**	5	5	Tender approvals a	2	10	10	**32**	**56**
USM Vietnam	1128	I/V Cannula (Sterile having wings + injection port with Heparin Stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	With Wings+ G-20, Pack)	Inj: Port+ (Blister	FAVOCATHU		3	5	0	5	5	6	**24**	5	5	Tender approvals a	2	10	10	**32**	**56**
PENTAMASTER MEDIQ MALAYSIA	1128	I/V Cannula (Sterile having wings + injection port with Heparin Stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	With Wings+ G-20, Pack)	Inj: Port+ (Blister	KAWANA		Not attached	5	Not attached	5	5	6	**21**	5	5	Tender approvals a	2	10	10	**32**	**53**
Jiangxi Fenglin China	1129	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free).	With Wings+ G-22, Pack)	Inj: Port+ (Blister	FLOWCATH		3	5	Not attached	0	0	0	**8**	5	5	Tender approvals a	2	10	10	**32**	**40**
USM Vietnam	1129	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free).	With Wings+ G-22, Pack)	Inj: Port+ (Blister	FAVOCATH		3	5	0	5	5	6	**24**	5	5	Tender approvals a	2	10	10	**32**	**56**
PENTAMASTER MEDIQ MALAYSIA	1129	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free).	With Wings+ G-22, Pack)	Inj: Port+ (Blister	KAWANA		Not attached	5	Not attached	5	5	6	**21**	5	5	Tender approvals a	2	10	10	**32**	**53**
PENTAMASTER MEDIQ MALAYSIA	1130	I/V Cannula (Sterile having wings + injection port with auto passive safety clip in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	With Wings+ G-22, Pack)	Inj: Port+ (Blister	KAWANA SAFETY		Not attached	5	Not attached	5	5	6	**21**	5	5	Tender approvals a	2	10	10	**32**	**53**
Jiangxi Fenglin China	1131	I/V Cannula (Sterile having wings + injection port with Heparin Stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	With Wings+ G-22, Pack)	Inj: Port+ (Blister	FLOWCATH		3	5	Not attached	5	5	6	**24**	5	5	Tender approvals a	2	10	10	**32**	**56**
USM Vietnam	1131	I/V Cannula (Sterile having wings + injection port with Heparin Stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	With Wings+ G-22, Pack)	Inj: Port+ (Blister	FAVOCATHU		3	5	0	5	5	6	**24**	5	5	Tender approvals a	2	DTL Substandard	10	**22**	**46**
PENTAMASTER MEDIQ MALAYSIA	1131	I/V Cannula (Sterile having wings + injection port with Heparin Stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	With Wings+ G-22, Pack)	Inj: Port+ (Blister	KAWANA		Not attached	5	Not attached	5	5	6	**21**	5	5	Tender approvals a	2	10	10	**32**	**53**
Jiangxi Fenglin China	1132	I/V Cannula (Sterile having wings + injection port with Heparin Stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	With Wings+ G-24, Pack)	Inj: Port+ (Blister	FLOWCATH		3	5	Not attached	5	5	6	**24**	5	5	Tender approvals a	2	10	10	**32**	**56**
USM Vietnam	1132	I/V Cannula (Sterile having wings + injection port with Heparin Stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	With Wings+ G-24, Pack)	Inj: Port+ (Blister	FAVOCATHU		3	5	0	5	5	6	**24**	5	5	Tender approvals a	2	10	10	**32**	**56**

PENTAMASTER MEDIQ MALAYSIA	1132	I/V Cannula (Sterile having wings + injection port with Heparin Stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	With Wings+ Inj: Port+ G-24, (Blister Pack)	KAWANA		Not attached	5	Not attached	5	5	6	**21**	5	5	Tender approvals a	2	10	10	**32**	**53**
PENTAMASTER MEDIQ MALAYSIA	1133	I/V Cannula (Sterile having wings + injection port with auto passive safety clip in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	With Wings+ Inj: Port+ G-24, (Blister Pack)	KAWANA SAFETY		Not attached	5	Not attached	5	5	6	**21**	5	5	Tender approvals a	2	10	10	**32**	**53**
Jiangxi Fenglin China	1134	I/V Cannula (Sterile having wings with heparin stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free).	With Small Wings+ Heparin Stopper G-24, (Blister Pack)	FLOWCATH		3	5	Not attached	5	5	6	**24**	5	5	Tender approvals a	2	DTL Substandard	10	**22**	**46**

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27														
Name of the firm						Hashir Surgical Services, NDI, Peshawar														
						Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 01 Tender approvals- 01 mark 02 Tender approvals- 02 marks 04 Tender approvals- 03 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevent certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
Principal Manufacture	MCC formulary No.	Generic Name of item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
NAZ Medical Malyasia	1056	Disposable Non-sterile Latex Examination Gloves (Powder Free)	Small, Medium, Large	NAZCARE		3	5	0	5	6	6	**25**	5	5	Tendder approvals are incomplete	0	2	16	**28**	**53**
NAZ Medical Malyasia	1057	Disposable Non-sterile Latex Examination Gloves (Powdered)	Small, Medium, Large	NAZCARE		3	5	0	5	6	6	**25**	5	5	Tendder approvals are incomplete	0	2	16	**28**	**53**
Jiangxi Fenglin China	1137	Infusion Chamber (Burette Type) Sterile, Disposable	100ml	BIO SOFT		3	5	0	5	6	6	**25**	5	5	Tendder approvals are incomplete	0	2	16	**28**	**53**
YAFHO BCL China	1168	Non Woven Fabric Surgical Adhasive Fix Roll	10cmx10m	BIOPORE FIX ROLL		Not attached	5	0	5	6	6	**22**	5	5	Tendder approvals are incomplete	0	2	16	**28**	**50**
HuaiAn TianDa MI China	1235	Surgical Blade (Steel carbon, black/ blue/ Stainless Steel)	Size.15	BIO SOFT		Not attached	5	0	5	6	6	**22**	5	5	Tendder approvals are incomplete	0	2	16	**28**	**50**
HuaiAn TianDa MI China	1238	Surgical Blade (Steel carbon, black/ blue/ Stainless Steel)	Size.22	BIO SOFT		Not attached	5	0	5	6	6	**22**	5	5	Tendder approvals are incomplete	0	2	16	**28**	**50**
HuaiAn TianDa MI China	1239	Surgical Blade (Steel carbon, black/ blue/ Stainless Steel)	Size.23	BIO SOFT		Not attached	5	0	5	6	6	**22**	5	5	Tendder approvals are incomplete	0	2	16	**28**	**50**
HuaiAn TianDa MI China	1240	Surgical Blade (Steel carbon, black/ blue/ Stainless Steel)	Size.24	BIO SOFT		Not attached	5	0	5	6	6	**22**	5	5	Tendder approvals are incomplete	0	2	16	**28**	**50**
Jiangxi Fenglin China	1258	Two-Way Foley Catheter 100% Silicon	Size.16FR	Uro Cath Foley Catheter		3	5	0	5	6	6	**25**	5	5	Tendder approvals are incomplete	0	2	16	**28**	**53**
Jiangxi Fenglin China	1262	Two-Way Foley Catheter (Silicon Coated)	Size.6FR	Uro Cath Foley Catheter		3	5	0	5	6	6	**25**	5	5	Tendder approvals are incomplete	0	2	16	**28**	**53**
Jiangxi Fenglin China	1263	Two-Way Foley Catheter (Silicon Coated)	Size.8FR	Uro Cath Foley Catheter		3	5	0	5	6	6	**25**	GD not attached	Page 437	Tendder approvals are incomplete	0	2	16	**18**	**43**
Jiangxi Fenglin China	1264	Two-Way Foley Catheter (Silicon Coated)	Size.10FR	Uro Cath Foley Catheter		3	5	0	5	6	6	**25**	5	5	Tendder approvals are incomplete	0	2	16	**28**	**53**
Jiangxi Fenglin China	1265	Two-Way Foley Catheter (Silicon Coated)	Size.12FR	Uro Cath Foley Catheter		3	5	0	5	6	6	**25**	GD not attached	Page 437	Tendder approvals are incomplete	0	2	16	**18**	**43**
Jiangxi Fenglin China	1266	Two-Way Foley Catheter (Silicon Coated)	Size.14FR	Uro Cath Foley Catheter		3	5	0	5	6	6	**25**	5	5	Tendder approvals are incomplete	0	2	16	**28**	**53**
Jiangxi Fenglin China	1267	Two-Way Foley Catheter (Silicon Coated)	Size.16FR	Uro Cath Foley Catheter		3	5	0	5	6	6	**25**	5	5	Tendder approvals are incomplete	0	2	16	**28**	**53**
Jiangxi Fenglin China	1268	Two-Way Foley Catheter (Silicon Coated)	Size.18FR	Uro Cath Foley Catheter		3	5	0	5	6	6	**25**	GD not attached	Page 437	Tendder approvals are incomplete	0	2	16	**18**	**43**
Jiangsu Kangjin MI China	1290	Urine bag with let	2000ml, With T-Valve	Bio Bag		Not attached	5	0	5	6	6	**22**	5	5	Tendder approvals are incomplete	0	2	16	**28**	**50**

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: HEAL PHARMACEUTICALS PVT. LTD.

S. No.		Product General Information				Technical Evaluation Matrix: Factory Technical Evaluation Parameters — Documents Based Factory Score						Factory Evaluation Visit Score					Total Factory Evaluated	Product Evaluation Parameters — Product Technical Parameters								Total Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declartation (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead	Stability studies of quoted item/s duly attested by the QLC incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	5	6	7	8	9	10	11	12	13	14	15	**33**	17	18	19	20	21	22	23	24	**37**	**70**
	1	Metronidazole	200mg	Tablet	Hedazol 200mg Tablet	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	4	5	0	**19**	**43**
	2	Metronidazole	400mg	Tablet	Hedazol 400 mg Tablet	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	4	5	0	**19**	**43**
	3	Metronidazole Benzoate	200mg/5ml	Suspension	Hedazol 200mg/5ml Susp.	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	4	5	0	**19**	**43**
	35	Aceclofenac	100mg	Tablet	Aceclofen 100mg Tablet	2	2	3	0	5	2	2	2	2	2	2	**24**	0	0	No COA povided (Page No. 298)	0	0	4	5	0	**9**	**33**
	46	Ibuprofen	100mg/5ml	Suspension	Hebofen 100mg/5ml Susp.	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	4	5	0	**19**	**43**
	51	Meloxicam	15mg	Tablet	Healcam 15 mg Tablet	2	2	3	0	5	2	2	2	2	2	2	**24**	0	GD older than 24 months (page 321)	0	0	0	4	5	0	**9**	**33**
	52	Meloxicam	7.5mg	Tablet	Healcam 7.5 mg Tablet	2	2	3	0	5	2	2	2	2	2	2	**24**	0	GD older than 24 months (page 336)	0	0	0	4	5	0	**9**	**33**
	59	Paracetamol	500mg	Tablet	Hepmol 500mg Tablet	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	4	5	0	**19**	**43**
	60	Paracetamol	120mg/5ml	Suspension	Hepmol 120mg/5ml Susp	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	4	5	0	**19**	**43**
	61	Paracetamol	250mg/5ml	Suspension	Hepmol Forte 250mg/5ml Susp.	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	4	5	0	**19**	**43**

	137	Fluconazole	150mg	Capsule	Difazon 150mg Capsule	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	4	5	0	**19**	**43**
	138	Fluconazole	50mg/5ml	Dry Suspension	Difazon 50mg Dry Powder	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	4	5	0	**19**	**43**
	153	Cetirizine	10mg	Tablet	Healazine 10mg Tablet	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	4	5	0	**19**	**43**
	154	Cetirizine	5mg/5ml	Syrup	Healazin 5mg/5ml Syrup	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	4	5	0	**19**	**43**
	158	Levocetirizine	5mg	Tablet	Healazin-L 5mg Tablets	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	4	5	0	**19**	**43**
	159	Loratadine	10mg	Tablet	Lorated 10 mg Tablet	2	2	3	0	5	2	2	2	2	2	2	**24**	0	GD is older than 24 months (Page 249)	0	0	0	4	5	0	**9**	**33**
	160	Montelukast	10mg	Tablet	Healkast 10mg Tablet	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	4	5	0	**19**	**43**
	162	Montelukast	4mg	Sachet	Healkast 4mg Sachet	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	4	5	0	**19**	**43**
	189	Azithromycin	250mg	Tablet	Azithrolide 250mg Tablet	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	4	5	0	**19**	**43**
	190	Azithromycin	500mg	Tablet	Azithrolide 500mg Tablet	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	4	5	0	**19**	**43**
	192	Azithromycin	200mg/5ml	Dry Suspension	Azithrolide 200mg/5ml Dry Susp.	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	4	5	0	**19**	**43**
	229	Cephradine	250mg/5m1	Dry Suspension	Healcef 250mg/5ml Dry Susp.	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	4	5	0	**19**	**43**
	230	Ciprofloxacin	250mg	Tablet	Hepro 250mg Tablet	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	4	5	0	**19**	**43**
	231	Ciprofloxacin	500mg	Tablet	Hepro 500mg Tablet	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	4	5	0	**19**	**43**
	264	Levofloxacin	250mg	Tablet	Vaflox 250 mg Tablet	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	4	5	0	**19**	**43**

	265	Levofloxacin	500mg	Tablet	Vaflox 500 mg Tablet	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43
	275	Moxifloxacin	400mg	Tablet	Mosac 400mg Tablets	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43
	301	Artemether + Lumefantrine	80mg + 480mg	Tablet	Healtrem 80mg/480mg Tablet	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43
	371	Iron (III) Hydroxide Polymaltose	100mg	Tablet	Healtofer 100mg Tablet	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43
	372	Iron (III) Hydroxide Polymaltose Complex = Iron (Element)	50mg/5ml	Syrup	Healtofer 50mg/5ml Syrup	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43
	377	Mecobalamine	500mcg	Tablet	Necobal 500mcg Tablet	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43
	401	Amlodipine	5mg	Tablet	Hodip 5mg Tablet	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43
	402	Amlodipine	10mg	Tablet	Hodip 10mg Tablet	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43
	451	Losartan Potassium	25mg	Tablet	Loze 25 mg Tablet	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43
	452	Losartan Potassium	50mg	Tablet	Loze 50 mg Tablet	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43
	503	Domperidone	10mg	Tablet	H-Done 10mg Tablet	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43
	504	Domperidone as Maleat	5mg/5ml	Suspension	H-Done 5mg/5ml Suspension	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43
	507	Famotidine	40mg	Tablet	Hepsin 40mg Tablet	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43
	517	Omeprazole	40mg	Capsule	Opra 40mg Capsule	2	2	3	0	5	2	2	2	2	2	2	24	0	Size of the capsule for the quoted item is "0" need clarification (page No. 867)	0	0	0	4	5	0	9	33
	518	Esomeprazole	40mg	Capsule	Healso 40mg Capsule	2	2	3	0	5	2	2	2	2	2	2	24	0	5	5	0	0	4	5	0	19	43

	522	Pantoprazole Sodium	40mg	Tablet	Biskar 40mg Tablet	2	2	3	0	5	2	2	2	2	2	2	**24**	0	5	5	0	0	4	5	0	**19**	**43**
	647	Dextrose Anhydrous 13.50gms, Sodium Chloride 2.60gms, Potassium Chloride 1.50gms, Sodium Citrate 2.90gms		Sachet	Safelyte	2	2	3	0	5	2	2	2	2	2	2	**24**	0	GDs of all ingredients have not been provided in the original bid	0	0	0	Need clarification (No pharma grade mentioned page No. 914)	5	0	**5**	**29**
	204	Cefixime	400mg	Capsule	Hefixim 400mg Capsule	2	2	3	0	5	2	The firm was inspected by the inspection team as per technical evaluation criteria, and the following observations were made; I. The HVAC system in Cephalosporin section was not functional at the time of inspection. II. No hygrometers in the Cephalosporin RMS was found. III. No record of humidity and temperature control in cephalosporin section. IV. No environmental controls were observed in the RMS of cephalosporin. V. No raw materials of cephalosporin were present at the time of inspection. VI. The cephalosporin section was not operational at the time of inspection. Furthermore, the firm is RECOMMENDED for award of marks in the technical evaluation criteria for quoted items except Cephalosporin section.						**14**	0	5	5	0	0	4	5	0	**19**	**33**
	205	Cefixime	100mg/5ml	Dry Suspension	Hefixim 100mg/5ml Dry Susp.	2	2	3	0	5	2						**14**	0	5	5	0	0	4	5	0	**19**	**33**
	206	Cefixime	200mg/5ml	Dry Suspension	Hefixim 200mg/5ml Dry Susp.	2	2	3	0	5	2						**14**	0	5	5	0	0	4	5	0	**19**	**33**
	213	Cefpodoxime	40mg/5ml	Dry Suspension	Xetodem 40mg Dry Susp.	2	2	3	0	5	2						**14**	0	5	5	0	0	4	5	0	**19**	**33**
	224	Cephradine	250mg	Capsule	Healcef 250mg Capsule	2	2	3	0	5	2						**14**	0	5	5	0	0	4	5	0	**19**	**33**
	225	Cephradine	500mg	Capsule	Healcef 500mg Capsule	2	2	3	0	5	2						**14**	0	5	5	0	0	4	5	0	**19**	**33**
	228	Cephradine	125mg/5m1	Dry Suspension	Healcef 125mg/5ml Dry Susp.	2	2	3	0	5	2						**14**	0	5	5	0	0	4	5	0	**19**	**33**

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: HERBION PAKISTAN Pvt. Ltd.

S. No.	Product General Information					Technical Evaluation Matrix																							
						Factory Technical Evaluation Parameters											Total Factory Evaluated	Product Evaluation Parameters										Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters											
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26		
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **i. Firm having (12-Month) Ranking in top-20 positions shall**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection. Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e.,	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: i. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**5**	**3**	**4**	**5**	**5**	**37**	**70**		
	151	Cetirizine	10mg	Tab.	Zanlan Tablets	2	2	3	Not provided	Not provided	6	**2**	**2**	**2**	**2**	**2**	**23**	0	5	5	Not provided	0	4	5	Not provided	**19**	**42**		
	152	Cetirizine	5mg/5ml	Soln.	Zanlan Oral Solution	2	2	3	Not provided	Not provided	6	**2**	**2**	**2**	**2**	**2**	**23**	0	5	5	Not provided	0	4	5	Not provided	**19**	**42**		
	157	Loratadine	10mg	Tab.	Tirlor Tablets 10 mg	2	2	3	Not provided	Not provided	6	**2**	**2**	**2**	**2**	**2**	**23**	0	5	5	5	0	4	5	Not provided	**24**	**47**		
	158	Montelukast	10mg	Tab.	Montelo 10 mg Tablets	2	2	3	Not provided	Not provided	6	**2**	**2**	**2**	**2**	**2**	**23**	0	5	5	5	0	4	5	Not provided	**24**	**47**		
	159	Montelukast	5mg	Tab.	Montelo 5 mg chewable Tablets	2	2	3	Not provided	Not provided	6	**2**	**2**	**2**	**2**	**2**	**23**	0	5	5	5	0	4	5	Not provided	**24**	**47**		
	189	Azithromycin	250mg	Cap.	Azovant 250 mg Capsules	2	2	3	Not provided	Not provided	6	**2**	**2**	**2**	**2**	**2**	**23**	0	5	5	Not provided	0	4	5	Not provided	**19**	**42**		
	190	Azithromycin	500mg	Tab.	Azovant 500 mg Tablets	2	2	3	Not provided	Not provided	6	**2**	**2**	**2**	**2**	**2**	**23**	0	5	5	Not provided	0	4	5	Not provided	**19**	**42**		
	264	Levofloxacin	250mg	Tab.	Efloxin 250 mg Tablets	2	2	3	Not provided	Not provided	6	**2**	**2**	**2**	**2**	**2**	**23**	0	5	5	Not provided	0	4	5	Not provided	**19**	**42**		
	265	Levofloxacin	500mg	Tab.	Efloxin 500 mg Tablets	2	2	3	Not provided	Not provided	6	**2**	**2**	**2**	**2**	**2**	**23**	0	5	5	Not provided	0	4	5	Not provided	**19**	**42**		
	275	Moxifloxacin	400mg	Tab.	MXF 400 mg Tablet	2	2	3	Not provided	Not provided	6	**2**	**2**	**2**	**2**	**2**	**23**	0	5	5	Not provided	0	4	5	Not provided	**19**	**42**		
	402	Amlodipine + Valsartan	5mg + 80mg	Tab.	Valspine 5/80 mg Tablet	2	2	3	Not provided	Not provided	6	**2**	**2**	**2**	**2**	**2**	**23**	0	5	5	Not provided	0	4	5	Not provided	**19**	**42**		
	403	Amlodipine + Valsartan	5mg + 160mg	Tab.	Valspine 5/160 mg tablet	2	2	3	Not provided	Not provided	6	**2**	**2**	**2**	**2**	**2**	**23**	0	5	5	Not provided	0	4	5	Not provided	**19**	**42**		
	511	Lactulose	3.35gm/5ml	Syp.	LacNovex Syrup	2	2	3	Not provided	Not provided	6	**2**	**2**	**2**	**2**	**2**	**23**	0	not provided in the bid	Not provided in the bid	Not applicable if GD is not provided	0	4	5	Not provided	**9**	**32**		
	517	Esomeprazole	40mg	Cap.	Esnovex 40 mg Capsules	2	2	3	Not provided	Not provided	6	**2**	**2**	**2**	**2**	**2**	**23**	0	5	5		0	4	5	Not provided	**19**	**42**		
	539	Empagliflozin	10mg	Tab.	Synjard 10mg tablet	2	2	3	Not provided	Not provided	6	**2**	**2**	**2**	**2**	**2**	**23**	0	GD provided at page No. 683 is older than 24 months	GD expired	Not provided	0	4	5	Not provided	**9**	**32**		
	540	Empagliflozin	25mg	Tab.	Synjard 25 mg tablet	2	2	3	Not provided	Not provided	6	**2**	**2**	**2**	**2**	**2**	**23**	0	GD provided at page No. 683 is older than 24 months	GD expired	Not provided	0	4	5	Not provided	**9**	**32**		
	572	Sitagliptin + Metformin	50mg + 500mg	Tab.	SGP-Met 50/500mg Tablet	2	2	3	Not provided	Not provided	6	**2**	**2**	**2**	**2**	**2**	**23**	0	GD provided at page No. 773 for Metformin is older than 24 months	GD expired	Not provided	0	4	5	Not provided	**9**	**32**		
	573	Sitagliptin + Metformin	50mg + 1000mg	Tab.	SGP-Met 50/1000mg Tablet	2	2	3	Not provided	Not provided	6	**2**	**2**	**2**	**2**	**2**	**23**	0	GD provided at page No. 773 for Metformin is older than 24 months	GD expired	Not provided	0	4	5	Not provided	**9**	**32**		
	677	Ibandronic acid	150mg	Tab.	Stark 150mg	2	2	3	Not provided	Not provided	6	**2**	**2**	**2**	**2**	**2**	**23**	0	5	5	0	0	4	5	Not provided	**19**	**42**		

S. No.	MCC Formulary No.	Drug Name	Strength	Dosage form	Brand Name	Pack Size
1	151	Cetirizine	10mg	Tab.	Zanlan Tablets	30's
2	152	Cetirizine	5mg/5ml	Soln.	Zanlan Oral Solution	60ml
3	157	Loratadine	10mg	Tab.	Tirlor Tablets 10 mg	10's
4	158	Montelukast	10mg	Tab.	Montelo 10 mg Tablets	14's
5	159	Montelukast	5mg	Tab.	Montelo 5 mg chewable Tablets	14's
6	189	Azithromycin	250mg	Cap.	Azovant 250 mg Capsules	10's
7	190	Azithromycin	500mg	Tab.	Azovant 500 mg Tablets	6's
8	264	Levofloxacin	250mg	Tab.	Efloxin 250 mg Tablets	10's
9	265	Levofloxacin	500mg	Tab.	Efloxin 500 mg Tablets	10's
10	275	Moxifloxacin	400mg	Tab.	MXF 400 mg Tablet	5's
11	402	Amlodipine + Valsartan	5mg + 80mg	Tab.	Valspine 5/80 mg Tablet	14's
12	403	Amlodipine + Valsartan	5mg + 160mg	Tab.	Valspine 5/160 mg tablet	14's
13	511	Lactulose	3.35gm/5ml	Syp.	LacNovex Syrup	120ml
14	517	Esomeprazole	40mg	Cap.	Esnovex 40 mg Capsules	7's
15	539	Empagliflozin	10mg	Tab.	Synjard 10mg tablet	14's
16	540	Empagliflozin	25mg	Tab.	Synjard 25 mg tablet	14's
17	572	Sitagliptin + Metformin	50mg + 500mg	Tab.	SGP-Met 50/500mg Tablet	14's
18	573	Sitagliptin + Metformin	50mg + 1000mg	Tab.	SGP-Met 50/1000mg Tablet	14's

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: HIGHNOON LABORATORIES PVT LTD

S. No.		Product General Information				Technical Evaluation Matrix: Factory Technical Evaluation Parameters — Documents Based Factory Score						Factory Evaluation Visit Score					Total Factory Evaluated Score	Product Evaluation Parameters — Product Technical Parameters								Total Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 13001/14500 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer form (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment/ instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million – 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC experts), as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, in-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC experts). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP. **(Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid lead link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificates, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/ bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free-sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. Copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analyses of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Please of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Oral Liquid Suspensions: USP class 1 (Neo-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better (**Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** a. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products when USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistan market as per recent store data of IMS/IQVIA. Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Teritary care Govt. Hospitals, Health related Govt. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70
1	300	ARTEMETHER & LUMEFANTRINE			ARTECOIN FORTE TABLET 4D/240	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45
2	301	ARTEMETHER & LUMEFANTRINE			ARTECOIN PLUS TABLET 80/480	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45
3	407	ATENOLOL			BLOKIUM TABLET 50 MG	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41
4	408	ATENOLOL			BLOKIUM 100MG TABLET	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	0	15	41
5	403	AMLODIPINE 5MG+VALSARTAN 80MG			BIFORGE 5/80 MG TABLET 30's	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	4	5	1	20	46
6	404	AMLODIPINE 5MG+VALSARTAN 160MG			BIFORGE 5/160MG TABLET 30's	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	4	5	1	20	46
7	405	AMLODIPINE 10MG+VALSARTAN 160MG			BIFORGE 10/160MG TABLET 30's	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	4	5	1	20	46
8	471	ROSUVASTATIN AS CALCIUM			ROSUIN 10MG TABLET	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	4	5	1	20	46
9	324	DACLATASVIR			DACLATA 60MG TABLET	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45
10	343	SOFOSBUVIR + Velpatasvir			FOSBU V 400/100MG TABLET	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	4	5	1	20	46
11	341	SOFOSBUVIR			FOSBU 400MG TABLET	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45
12	395	ASPIRIN			LOPRIN 75MG TABLET	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	2	17	43
13	796	FORMOTEROL FUMARATE + BUDESONIDE 100mcg/6mcg			COMBIVAIR 100 mcg/6mcg ROTACAPS	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	4	5	3	22	48
14	797	FORMOTEROL FUMARATE + BUDESONIDE 200mcg/6mcg			COMBIVAIR 200 mcg/6mcg ROTACAPS	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	4	5	3	22	48
15	798	FORMOTEROL FUMARATE + BUDESONIDE400mcg/6mcg			COMBIVAIR 400 mcg/6mcg ROTACAPS	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	4	5	3	22	48
16	799	FORMOTEROL FUMARATE + BUDESONIDE 400mcg/12mcg			COMBIVAIR FORTE 400mcg/12mcg ROTACAPS	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	4	5	3	22	48
17	518	ISOMEPRAZOLE (AS TRIHYDRATE)			AXESOM CAPS 40 MG	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	4	5	1	20	46
18	406	AMLODIPINE 10MG, VALSARTAN 160MG & HYDROCHLORTHIAZIDE 12.5MG			TRIFORGE 10/160/12.5 TABLET	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45
19	478	SACUBITRIL/VALSARTAN			SACUVIA 100MG TABLET	0	0	0	5	5	6	2	2	2	2	2	26	0	5	5	0	0	4	5	0	19	45

Scrutiny Report

Bid Form 1 is not as per advertised specifications.
2. The documents attached at pdf page number 43-48 for ISO 9001, 14001 & 45001 certificate needs clarifications.
3. Certificate of analysis for PVC need clarification.
4. Documents required for award of marks in column No. 17, 20 & 21 could not be found.
5. Focal person information and details are not given in the technical bid.

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm	HIGHSEA LAHORE

S. No.		Product General Information				Technical Evaluation Matrix																		
						Principal's and Importer's Evaluation Parameters									Product Technical Evaluation									
						Principal Manufacturer Evaluation					Importer's Evaluation			Suppliers Technical Score	Product Technical Parameters							Product Availability	Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid accreditation of manufacturing unit or its relevant sections/s by the US-FDA or official accreditation body/ies /regulatory body in the case of SRA/WLA countries (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **Valid Calibration Certificates attested by Quality head of the firm).**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC-expert/s). **Non availability of the 20% stock at the ware house at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good storage practices (GSP) for storage of finished goods. Functional and effective Air-conditioning & Ventilation System and effective cold chain (thermo-labile drugs). The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Nonadherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is/are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	**Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids.** **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 15, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies). Trail of principal manufacturer shall be established from the respective GD, CoA and other supporting documents. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) / Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) and / or Valid certificate of the availability of the quoted item in the US market. **04 marks shall be awarded to the Primary certificate, and 1 mark for additional certificate, up to a maximum of 06 (04+01+01) marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material complied with Invoice/proof of purchase: **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: E. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. C. Type of Glass material for Liquid ampoules must be USP class 1 Glass ampoules shall have	Stability studies of quoted item/s duly attested by the QA/ incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	**2**	**2**	**2**	**5**	**5**	**4**	**5**	**5**	**30**	**5**	**5**	**5**	**5**	**6**	**4**	**5**	**5**	**40**	**70**
	18	Isoflurane	100ml	Inhaled Anesthetic	Aislar	0	0	0	0	0	The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/(COFG) for the quoted items were checked, and following observations were made; **FUJIAN HIGHSEA UNITED PHARMACEUTICAL CO. LTD. CHINA** Valid Original DRAP Registration certificates for the quoted items. Valid Original Drug Sale License, valid letter of Authorization of the Principal Manufacturers were present at the time of inspection. However, Valid Original COPP duly attested from embassy concerned/apostilled was not available at the time of inspection. In view of the above the firm is NOT RECOMMENDED and marks in importer's evaluation parameters for the quoted items may NOT be awarded.	**0**	**0**	0	0	0	**0**	0	5	0	**5**	**5**

Scrutiny report
1Bioequivalence study on own letter head does not fulfill the advertised criteria
2DRAP Approved price list is not present
3GD of offered product is not present
4Proof of purchase is not present with glass bottle (Immediate container @page No. 169- Also picture of packaging is not provided
5Tender approvals are not as per the advertised criteria

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: HIMMEL Pharma LAHORE

S. No.	Product General Information					Technical Evaluation Matrix																	
						Principal's and Importer's Evaluation Parameters								Suppliers Technical Score	Product Technical Evaluation								
						Principal Manufacturer Evaluation					Importer's Evaluation				Product Technical Parameters							Product Availability	Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/ies /regulatory body in the case of SRA/WLA countries (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm)**.	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the ware house at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good storage practices (GSP) for storage of finished goods. Functional and effective Air-conditioning & Ventilation System and effective cold chain (thermo-labile drugs). The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Nonadherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is/are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities).	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 15, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies). Trail of principal manufacturer shall be established from the respective GD. CoA and other supporting documents. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA APIs source accreditation shall be awarded only	Valid WHO prequalification and / or Valid product registration in SRA country(ies) / Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) and / or Valid certificate of the availability of the quoted item in the US market. **04 marks shall be awarded to the Primary certificate, and 1 mark for additional certificate, up to a maximum of 06 (04+01+01) marks.** **Certificates an**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase: **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention:	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	**2**	**2**	**2**	**5**	**5**	**4**	**5**	**5**	**30**	**5**	**5**	**5**	**5**	**6**	**4**	**5**	**5**	**40**	**70**
	32	Sevoflurane	250ml	Injection	Norevell Inh 250ml	0	0	0	0	0	The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COFG) for the quoted items were checked, and following observations were made; 1. Valid Original cGMP of the Principal Manufacturers i.e., Beacon Bangladesh, Aqvida Germany, Onko Ilac Turkey, Pharmidea Latvia, Everpharma, Austria/Germany, Samyang Korea and Valid Free Sale certificates duly attested by the embassy concerned/Apostille for the quoted item/s were present at the time of inspection. However, the Original Agency Agreement & COPP for Norwell (Sevoflurane), Original COPP of Neutromax (Filgrastim), Original Letter of Authorization of Zolanko (Zoledronic Acid), Original COPP and LOA of Atabay Ilac Kimya (Enoxaparin), Original LOA of Clotastop (Heparin sodium), and Original COPP of PT Novell Indonesia (Salt free Albumin) was not available at the time of inspection. 2. 20% Inventory of the quoted items, adequate qualified HR, Cold Chain facility, Good Storage practices and SOPs for expiry management were satisfactory/present. In view of the above the firm is RECOMMENDED and marks in importer's evaluation parameters for the quoted items may be awarded Except for the items i.e., Sevoflurane, Filgrastim, Zoledronic Acid, Enoxaparin, Heparin sodium, and Salt free Albumin.					**0**		5	0	0	**0**	0	0	0	**5**	**5**
	85	Filgrastim	300mcg	Injection	Neutromax 300mcg	2	2	0	5	0				**9**		5	0	0	**4**	4	5	0	**18**	**27**
	97	Zoledronic Acid	4mg/Vial	Injection	Zolonko 4mg	2	2	0	5	0				**9**		0	0	0	**0**	0	5	0	**5**	**14**
	350	Enoxaparin	40mg	Injection	Enox 40mg	0	0	0	0	0				**0**		5	5	0	**0**	0	5	0	**15**	**15**
	351	Enoxaparin	60mg	Injection	Enox 60mg	0	0	0	0	0				**0**		5	5	0	**0**	0	5	0	**15**	**15**
	352	Enoxaparin	80mg	Injection	Enox 80mg	0	0	0	0	0				**0**		Only 40 and 60mg mentioned in GD	0	0	**0**	0	0	0	**0**	**0**
	369	Heparin Sodium	5000 IU/ml	Injection	Clotastop	0	0	0	0	0				**0**		0	0	0	**0**	0	5	0	**5**	**5**

	395	Adenosine	6mg/2ml	Injection	Caden 6mg / 2ml	0	0	0	5	0		**5**		5	0	0	**0**	4	0	0	**9**	**14**
	661	Salt Free Albumin 20% Sol	100ml	Injection	Albumin 20% 100ml	0	0	0	5	0		**5**		5	0	0	**0**	4	0	0	**9**	**14**

Scrutiny report

1 Proper calibration certificates of equipment as per advertised criteria are not present for Biosidus
2 Calibration certificates are not understandable (Mostly turkish language)
3 Company name not mentioned in some calibration certificates
4 US FDA at Page 989 does not have the scope mentioned and only 1 page of report is attached.
5 Documents at page No. 998-1007 are not understandable
6 Unit accreditation of Atabay Ilac Turkey on Page 1013 is expired
7 Documents at page No. 1017-1023 and 1025-1032 are not understandable
8 CoA of Glass bottle for sevofliurane (1050-1065) is not from principal manufacturer of Glass bottle
9 CoAs on Page No. 1066-1068, 1074-1076, 1081-82, 1087 , 1098-99, G49does not have a proof of purchase

		TECHNICAL EVALUATION PROFORMA, FOR PROCUREMENT OF ANTICANCER MEDICINES IN GOVT. MCC FY 2026-27				
		Name of the firm with	**HIMMEL PHARMACEUTICALS (PVT.) LTD LAHORE**			
		Manufacturer / Importer	**IMPORTER**			
		Mandatory Requirements.	**YES / NO**		**YES/NO**	
1		**National Tax Number (NTN) of the Firm for Income Tax, and**	YES		YES	
2		**Last year Income Tax Return of the Firm; and**	YES		YES	
3		**Sale Tax Registration Certificate of the Firm; and**	YES		YES	
4		**Certificate of Professional Tax of the Firm.**	YES		NO	CGMP OF Aqvida, Onkoilac, Pharmidea and Evervalinject are expired
5		**Certificate of compliance to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR. Non-Compliance to international reference standards or absence of Cold Chain requirements shall lead to**	NO		YES	
					YES	

		Technical Evaluation Parameters				**Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug. In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article)** **Mandatory: Online verification link must be provided to verify the Clinical Trial/ Clinical Studies submitted for**	**Factory/ Importer Based Evaluation Score (MANDATORY)**	**Sample Evaluation by End User Committee** **Samples will be examined per following parameters as follows:** **a. Labeling and Packing Rules 1986** **b. Outer packing** **c. Inner packing** **d. Physical appearance.** **Product which has unsatisfactory packing/labeling will be technically Disqualified.** **Maximum score for this criterion is 1.**		**Past Performance (Last two years).** **1) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks.** **2) Only supply orders will not get any marks.** **3) The bidders have to undertake that they have never been blacklisted or debarred.** **Maximum marks for this criterion are 5.** **4) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO marks shall be deducted for poor past**	**Total Technical Score**
						Studies/original article published in category "Y" journal of the HJRS/ Journals & Publication Policy 2024 and List of National Recognized Journals as per HEC shall not be awarded marks.	**The Physical Inspection of the premises of the bidders (Manufacturer/Importer) shall be carried out in accordance with ITB 25.4(h), SCC 5 (GCC 8.3), Section V (1) (J) (K) of the approved BSDS of Govt. MCC FY 2026-27**	Satisfactory	Unsatisfactory	1) Substantial quantity of Supplies of anti-cancer medicines made to private sector Teaching Hospitals namely: The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar, CMH Rawalapindi and Hayatabad Medical Complex, Peshawar , Shifa Interntional hospital Islamabad, with Good/Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 24 months. No marks will be given for supply orders except CMH Rawalpindi where supply orders coupled with delivery challans & invoices will be considered for award of marks. 1 mark per agreement up	
SOURCE	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	**0**	**5**	**1**	**0**	**5**	**70**

Beacon Bangladesh	1426	Axitinib	5mg	Tablet	Axinix 5mg		**5**	Manufacturing license & MA. No. not mentioned on the packing (inner & outer). However, the firm is an importer.		2	42
Aqvida Germany	1432	Bendamustine	100mg	Injection	Bendamustine 100mg		**5**	1		2	38
Onko Ilac Turkey	1436	Bicalutamide	50mg	Tablet	Casomid 50mg		**5**	1		2	38
Pharmidea Latvia	1439	Bortezomib	3.5mg	Injection	Bortezomib Pharmidea 3.5mg		**5**	1		2	38
Everpharma, Austria/Germany	1439	Bortezomib	3.5mg	Injection	Bortezomib Ever Pharma 3.5mg		**5**	1		2	38
Everpharma, Austria/Germany	1441	Cabazitaxel	60mg	Injection	Cabazitaxel Ever Pharma 60mg		**5**	1		2	38
Beacon Bangladesh	1442	Cabozantinib	20mg	Tablet	Cabozanix 20mg		**5**	Manufacturing license & MA. No. not mentioned on the packing (inner & outer). However, the firm is an importer.		2	42
Onko Ilac Turkey	1449	Carboplatin	150mg	Injection	Carplatu 150mg		**5**	1		2	38
Onko Ilac Turkey	1450	Carboplatin	450mg	Injection	Carplatu 450mg		**5**	1		2	38
Onko Ilac Turkey	1455	Cisplatin	50mg	Injection	Cipintu 50mg		**5**	1		2	38
Samyang Korea / Aqvida Germany	1475	Docetaxel	80mg	Injection	Docetaxel Aqvida 80mg		**5**	1		2	38
Samyang Korea / Aqvida Germany	1476	Docetaxel	20mg	Injection	Docetaxel Aqvida 20mg		**5**	1		2	38
Onko Ilac Turkey	1477	Doxorubicin	50mg	Injection	Doxo Onko 50mg		**5**	1		2	38
Beacon Bangladesh	1482	Eltrombopag	25mg	Tablet	Elbonix 25mg		**5**		SNP	2	42
Beacon Bangladesh	1483	Eltrombopag	50mg	Tablet	Elbonix 50mg		**5**		SNP	2	42
Everpharma, Austria/Germany	1493	Fulvestrant	250mg	Injection	Fulvestrant 250mg Inj		**5**	1		2	38
Beacon Bangladesh	1501	Ibrutinib	140mg	Capsule	Ibrutix 140mg		**5**	Manufacturing license & MA. No. not mentioned on the packing (inner & outer). However, the firm is an importer.		2	42
Beacon Bangladesh	1506	Imatinib	100mg	Capsule	Imanix 100mg		**5**	Manufacturing license & MA. No. not mentioned on the packing (inner & outer). However, the firm is an importer.		2	42
Aqvida Germany	1510	Irinotecan	100mg	Injection	Irinotecan HCL Aqvida 100mg		**5**	1		2	38
Beacon Bangladesh	1518	Lenalidomide	10mg	Tab/Cap	Linamide 10mg		**5**	Manufacturing license & MA. No. not mentioned on the packing (inner & outer). However, the firm is an importer.		2	37
Beacon Bangladesh	1519	Lenalidomide	25mg	Tab/Cap	Linamide 25mg		**5**	Manufacturing license & MA. No. not mentioned on the packing (inner & outer). However, the firm is an importer.		2	37
Beacon Bangladesh	1520	Lenvatinib	10mg	Tablet	Lenvanix 10mg		**5**	Manufacturing license & MA. No. not mentioned on the packing (inner & outer). However, the firm is an importer.		2	37
Beacon Bangladesh	1521	Lenvatinib	4mg	Tablet	Lenvanix 4mg		**5**	Manufacturing license & MA. No. not mentioned on the packing (inner & outer). However, the firm is an importer.		2	37
Beacon Bangladesh	1553	Niratinib	40mg	Tablet	Hernix 40mg		**5**	Manufacturing license & MA. No. not mentioned on the packing (inner & outer). However, the firm is an importer.		2	42
Beacon Bangladesh	1554	Nilotinib	200mg	Capsule	Nilonix 200mg		**5**	Manufacturing license & MA. No. not mentioned on the packing (inner & outer). However, the firm is an importer.		2	42
Beacon Bangladesh	1559	Olaparib	150mg	Tablet	Olaparix 150mg		**5**	Manufacturing license & MA. No. not mentioned on the packing (inner & outer). However, the firm is an importer.		2	37
Beacon Bangladesh	1563	Osimertinib	80mg	Tablet	Tagrix 80mg		**5**	Manufacturing license & MA. No. not mentioned on the packing (inner & outer). However, the firm is an importer.		2	42
Aqvida Germany	1564	Oxaliplatin	100mg	Injection	Oxaliplatin Aqvida 100mg		**5**	1		2	38
Aqvida Germany	1566	Oxaliplatin	50mg	Injection	Oxaliplatin Aqvida 50mg		**5**	1		2	38
Aqvida Germany	1567	Paclitaxel	150mg	Injection	Paclitaxel Aqvida 150mg		**5**	1		2	38
Aqvida Germany	1568	Paclitaxel	300mg	Injection	Paclitaxel Aqvida 300mg		**5**	1		2	38
Beacon Bangladesh	1569	Palbociclib	100mg	Injection	Palbonix 100mg		**5**	Manufacturing license & MA. No. not mentioned on the packing (inner & outer). However, the firm is an importer.		2	42
Beacon Bangladesh	1570	Palbociclib	125mg	Injection	Palbonix 125mg		**5**	Manufacturing license & MA. No. not mentioned on the packing (inner & outer). However, the firm is an importer.		2	42
Beacon Bangladesh	1588	Ponatinib	15mg	Tablet	Ponatinib 15mg		**5**	Manufacturing license & MA. No. not mentioned on the packing (inner & outer). However, the firm is an importer.		2	42
Beacon Bangladesh	1589	Ponatinib	45mg	Tablet	Ponatinib 45mg		**5**	Manufacturing license & MA. No. not mentioned on the packing (inner & outer). However, the firm is an importer.		2	42

Beacon Bangladesh	1593	Regorafenib	40mg	Tablet	Regonix 40mg		**5**	Manufacturing license & MA. No. not mentioned on the packing (inner & outer). However, the firm is an importer.		2	37
Beacon Bangladesh	1602	Sorafenib	200mg	Tablet	Soranix 200mg		**5**	Manufacturing license & MA. No. not mentioned on the packing (inner & outer). However, the firm is an importer.		2	42

Scrutiny Report
1German cGMP of Aqvida is expired- 07-12-2025
2Latvian cGMP of Pharmidea is expired 01-12-2024
3German cGMP of Ever Valinject is expired on 11-04-2025
4Study at Page No. 2148, 2157, 2160, 2168, 2215, 2224, 2242, 2249, 2261, does not have name of quoted product or its principal manufacturer
5Performance certificate at Page Nos. 2460, 2461 are older than 2years
6The bidder, having availed multiple trainings, submitted a technical bid that contains huge irrelevant documentation contrary to the advertised criteria.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: HIRANIS PHARMACEUTICALS PVT. LTD.

S. No.	Product General Information					Factory Technical Evaluation Parameters					Factory Evaluation Visit Score					Total Factory Evaluated	Technical Evaluation Matrix								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score											Product Evaluation Parameters Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)in in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-**	Raw material, in-process and Finished good storage (as in Schedule B of DRAP) is evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection. Non-availability shall lead to disqualification of**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or system unless has**		Biouvailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Strongest Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the tariff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid tradlink/DRAP clearance NOC (wherein the invoice/**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA shall not be**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item/s. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE), or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).**	Availability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA. Health not older than twelve (12) months. 1-10% market share = 1 mark 11-20% market share = 2 marks 21-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govts. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**5**	**3**	**4**	**5**	**5**	**37**	**70**
	9	Tinidazole	500mg	Tablet	TINDAMAX	2	2	3		5	6	**The firm was inspected as per technical evaluation criteria and following observations were made;** **Non-functional HVAC and poor environmental controls:** **1. Hygrometer were not installed in the production area, such as Tablet compression, granulation section, coating section, and packing section.** **2. All the doors were not having auto-lock or air lock system or sealing and were prone contamination and poor environmental control.** **3. The temperature and relative humidity (RH) at the production areas were out of range in contravention to the respective SOPs/guidelines.** **Compromised Good Storage Practices (GSP):** **4. Unlabeled finished and raw material were placed in an undesignated area in the production section.** **5. API, excipients, packing and packaging materials were placed haphazardly in one section in the RMS.** **Non adherence to cGMP:** **6. Ordinary lock and chain were observed on the doors in the production area.** **7. Ordinary iron pipes were used in the production area instead of stainless steel, which are prone to rusting and contamination.** **8. The paints on the wall of the granulation section were peeled off.** **9. No metal detector was used during the production/ compression of tablets.** **10. Under maintenance Machines/ equipment were placed in the production area, which were full of dust/dirt.** **In view of the above facts the firm is NOT-RECOMMENDED.**	18	0	GD provided at Page No. 541-42 is not matchable with AWB/ BL	0	0	0	4	5	Not attached	9	27
	89	Mycophenolat Mofetil	500mg	Tablet	MYCOFENTIL	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	94	Tacrolimus	1mg	Capsule	TACROGRAF	2	2	3		5	6						18	0	GD provided at Page No. 540 is not coupled with AWB/ BL	0	0	0	4	5	Not attached	9	27
	95	Tacrolimus	0.5mg	Capsule	TACROGRAF	2	2	3		5	6						18	0	GD provided at Page No. 540 is not coupled with AWB/ BL	0	0	0	4	5	Not attached	9	27
	96	Tofacitinib	5mg	Tablet	TOFAJAK	2	2	3		5	6						18	0	GD and AWB provided at page no. 543-544 are not matchable	0	0	0	4	5	Not attached	9	27
	97	Tofacitinib	10mg	Tablet	TOFAJAK	2	2	3		5	6						18	0	GD and AWB provided at page no. 543-544 are not matchable	0	0	0	4	5	Not attached	9	27
	137	Fluconazole	150mg	Capsule	LOGICAN	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	141	Itraconazole	100mg	Capsule	TOLSURA	2	2	3		5	6						18	0	GD and AWB provided at page no. 945-946 are not matchable		0	0	4	5	Not attached	9	27
	147	Terbinafine	250mg	Tablet	CAWEDA	2	2	3		5	6						18	0	AWB/BL provided at page No. 491 is not readable	0	0	0	4	5	Not attached	9	27
	189	Azithromycin	250mg	Tablet	ATIZOR	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	190	Azithromycin	500mg	Tablet	ATIZOR	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	192	Azithromycin	200mg/5ml	Suspension	ATIZOR	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	230	Ciprofloxacin	250mg	Tablet	ZOLINA	2	2	3		5	6						18	0	GD provided at page No. 553 is older than 24 months	0	0	0	4	5	Not attached	9	27
	231	Ciprofloxacin	500mg	Tablet	ZOLINA	2	2	3		5	6						18	0	GD provided at page No. 553 is older than 24 months	0	0	0	4	5	Not attached	9	27
	264	Levofloxacin	250mg	Tablet	OLEVO	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	265	Levofloxacin	500mg	Tablet	OLEVO	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	266	Lincomycin	500mg	Capsule	LOCOMIN	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	275	Moxifloxacin	400mg	Tablet	HIRAMOX	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	403	Amlodipine + Valsartan	5mg+80mg	Tablet	FORGEX	2	2	3		5	6						18	0	GD provided at Page No. 500-501 is older than 24 months	0	0	0	4	5	Not attached	9	27
	404	Amlodipine + Valsartan	5mg+160mg	Tablet	FORGEX	2	2	3		5	6						18	0	GD provided at Page No. 500-501 is older than 24 months	0	0	0	4	5	Not attached	9	27
	405	Amlodipine + Valsartan	10mg+160mg	Tablet	FORGEX	2	2	3		5	6						18	0	GD provided at Page No. 500-501 is older than 24 months	0	0	0	4	5	Not attached	9	27
	471	Rosuvastatin	10mg	Tablet	ROSUVAST	2	2	3		5	6						18	0	GD /AWB/BL attached at Page No. 538-539 are not matchable	0	0	0	4	5	Not attached	9	27
	510	Itopride	150mg	Tablet	ITOTAB - GD	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	518	Esomeprazole	40mg	Capsule	LOMAC	2	2	3		5	6						18	0	NO GD/ AWB/ BL provided in the bid		0	0	4	5	Not attached	9	27
	522	Pantoprazole	40mg	Tablet	GLOVAR	2	2	3	Page No. 62 Ranking on firm own letter head, not applicable	5	6						18	0	GD provided at page no. 1739 is older than 24 months	0	0	0	4	5	Not attached	9	27
	576	Prednisolone	5mg	Tablet	INFLAGIC - EC	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	581	Metformin + Sitagliptin	500mg+50mg	Tablet	VIASIT-M	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	582	Metformin + Sitagliptin	1000mg+50mg	Tablet	VIASIT-M	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	703	Carbamazepine	200mg	Tablet	CARBAGEN	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	704	Carbamazepine	100mg/5ml	Suspension	CARBAGEN	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	719	Duloxetine	30mg	Capsule	ENLON	2	2	3		5	6						18	0	NO GD/ AWB/ BL provided in the bid		0	0	4	5	Not attached	9	27
	721	Divalproex Sodium	250mg	Tablet	DIVANZA	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	722	Divalproex Sodium	500mg	Tablet	DIVANZA	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	735	Levetiracitam	250mg	Tablet	LEKRA	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	736	Levetiracitam	500mg	Tablet	LEKRA	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	742	Olanzapine	5mg	Tablet	LINZAP	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	743	Olanzapine	10mg	Tablet	LINZAP	2	2	3		5	6						18	0	NO GD/ AWB/ BL provided in the bid		0	0	4	5	Not attached	9	27
	753	Pregabalin	50mg	Capsule	PAVESCA	2	2	3		5	6						18	0	GD/ AWB/BL attached at page No. 530-531 are not matchable	0	0	0	4	5	Not attached	9	27
	754	Pregabalin	75mg	Capsule	PAVESCA	2	2	3		5	6						18	0	GD/ AWB/BL attached at page No. 530-531 are not matchable	0	0	0	4	5	Not attached	9	27
	761	Risperidone	2mg	Tablet	CARGUS	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	765	Sodium Valproate (Valproic Ac	250mg/5ml	Syrup	DIVANZA	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	801	Doxofylline	400mg	Tablet	AGOLIX	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	802	Doxofylline	100mg/5ml	Syrup	AGOLIX	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	860	Betamethasone + Gentamicin	0.5mg/1mg	Cream	GEN-BETA CREAM	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	870	Fusidic Acid Cream	20mg	Cream	HIFUZIN CREAM	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	885	Permethrin Cream	5mg/g	Cream	PLAVEO CREAM	2	2	3		5	6						18	0	GD/ AWB/BL attached at page No. 532-533 are not matchable	0	0	0	4	5	Not attached	9	27
	886	Permethrin Lotion	50mg	Lotion	PLAVEO LOTION	2	2	3		5	6						18	0	GD/ AWB/BL attached at page No. 532-533 are not matchable	1	0	0	4	5	Not attached	10	28
	894	Terbinafine HCL	10mg	Cream	CAWEDA CREAM	2	2	3		5	6						18	0	AWB/BL provided at page No. 491 is not readable	0	0	0	4	5	Not attached	9	27
	912	Diosmin Mineral Complex + Vita	450mg + 400 I.U	Tablet	DISICOM-D	2	2	3		5	6						18	0	5	5	0	0	4	5	Not attached	19	37
	913	Diosmin Mineral Complex + Vita	250mg + 400 I.U	Susp	DISICOM-D	2	2	3	Page No. 62 Ranking on firm own letter head, not applicable	5	6						18	0	5	5	0	0	4	5	Not attached	19	37

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: HOECHST PAKISTAN LTD PAKISTAN

S. No.	Product General Information					Technical Evaluation Matrix																	
						Principal's and Importer's Evaluation Parameters								Suppliers Technical Score	Product Technical Evaluation							Product Availability	Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation					Importer's Evaluation				Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/ies /regulatory body in the case of SRA/WLA countries (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the ware house at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good storage practices (GSP) for storage of finished goods. Functional and effective Air-conditioning & Ventilation System and effective cold chain (thermo-labile drugs). The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Nonadherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is/are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 15, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies). Trail of principal manufacturer shall be established from the respective GD. CoA and other supporting documents. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) / Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) and / or Valid certificate of the availability of the quoted item in the US market. **04 marks shall be awarded to the Primary certificate, and 1 mark for additional certificate, up to a maximum of 06 (04+01+01) marks.** **Certificates on company's own letter**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase: **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	2	5	5	4	5	5	30	5	5	5	5	6	4	5	5	40	70
Sanofi Winthrop Industrie, France	351	Enoxaparin Injection 40 mg 1x2	40 mg	Pre-filled Pen	Clexane Injection 40 mg	2	2	2	0	5	4	5	5	25	0	5	5	5	1	4	5	5	30	55
Sanofi Winthrop Industrie, France	352	Enoxaparin Injection 60 mg 1x2	60 mg	Pre-filled Pen	Clexane Injection 60 mg	2	2	2	0	5	4	5	5	25	0	5	5	5	1	4	5	5	30	55
Sanofi Winthrop Industrie, France	353	Enoxaparin Injection 80 mg 1x2	80 mg	Pre-filled Pen	Clexane Injection 80 mg	2	2	2	0	5	4	5	5	25	0	5	5	5	1	4	5	5	30	55
Chinon Pharmaceutical and Chemi	506	Drotaverine Injection 40mg/2ml	40/2ml	Ampoule	No-Spa Injection 40mg/2ml	2	2	2	0	5	0	0	0	11	0	5	5	5	1	4	5	5	30	41
Aventis Pharma Gmbh, Germany	562	Insulin Glargine 100 IU/ml 5x3mL	100IU/3ml	Pre-filled Pen	Lantus SoloStar 100 IU/mL	2	2	2	0	5	4	5	5	25	0	5	5	5	1	4	5	5	30	55
Aventis Pharma Gmbh, Germany	563	Insulin Glargine Injection 100	100IU/1ml	Pre-filled Pen	Lantus Injection 100 IU/mL	2	2	2	0	5	4	5	5	25	0	5	5	5	1	4	5	5	30	55
Aventis Pharma Gmbh, Germany	564	Insulin Glulisine 100 IU/ml 5x3mL	100 IU/ml	Pre-filled Pen	Apidra SoloStar 100 IU/mL	2	2	2	0	5	4	5	5	25	0	5	5	5	1	4	5	5	30	55
Opella HC Italy	498	Bscillus Clausii Spores	2 Billions	Susp	Enterogermina Oral Suspension	2	2	2	0	5	4	5	5	25	0	5	5	5	1	4	5	5	30	55

Bank Gaurantee expiry is 21-01-27

Enoxaparin Injection 40 mg 1x2	40 mg	Pre-filled Pen	Clexane Injection 40 mg	0.4 ml
Enoxaparin Injection 60 mg 1x2	60 mg	Pre-filled Pen	Clexane Injection 60 mg	0.6 ml
Enoxaparin Injection 80 mg 1x2	80 mg	Pre-filled Pen	Clexane Injection 80 mg	0.8 ml
Drotaverine Injection 40mg/2 ml 25's	40/2ml	Ampoule	No-Spa Injection 40mg/2 ml	1*25
Insulin Glargine 100 IU/ml 5x3mL	100IU/3 ml	Pre-filled Pen	Lantus SoloStar 100 IU/mL	1*5
Insulin Glargine Injection 100 IU/ml 1x10 mL	100IU/1 ml	Pre-filled Pen	Lantus Injection 100 IU/mL	1*1

Insulin Glulisine 100 IU/ml 5x3mL	100 IU/ml	Pre-filled Pen	Apidra SoloStar 100 IU/mL	1*5
Bscillus Clausii Spores	2 Billions	Susp	Enterogermina Oral Suspension	1*20

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: HOECHST PAKISTAN LTD PAKISTAN

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real TimeKas in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities).	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01)** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner:		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
1	2	Metronidazole	400mg	Tab	Flagyl	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	4	5	5	**24**	**57**
2	3	Metronidazole	200mg/5ml	Tab	Flagyl	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	4	5	5	**24**	**57**
3	4	Metronidazole	500mg	Infusion	Flagyl	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	2	5	5	**22**	**55**
4	209	Cefotaxime	250mg	Vial	Claforan	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	4	5	3	**22**	**55**
5	210	Cefotaxime	500mg	Vial	Claforan	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	4	5	3	**22**	**55**
6	211	Cefotaxime	500mg	Vial	Claforan	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	4	5	3	**22**	**55**
7	217	Ceftriaxone	500mg	Vial	Aventriax	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	4	5	0	**19**	**52**
8	218	Ceftriaxone	1gm	Vial	Aventriax	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	4	5	0	**19**	**52**
9	430	Furesemide	40mg	Tab	Lasix	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	4	5	5	**24**	**57**
10	505	Drotaverine	40mg	Tab	Nospa	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	4	5	5	**24**	**57**
11	543	Glibenclamide	5mg	Tab	daonil	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	4	5	5	**24**	**57**
12	568	Metformin GCL	500mg	Tab	Neodipar	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	4	5	1	**20**	**53**
13	648	Gelatin Polypeptide	3.5%/500ml	Infusion	Haemacel	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	4	5	5	**24**	**57**

Report
1.Type 2 class in ifusion bottles of metronidazole on page 213
2.No Api source is attached.
3. No WHO prequalification with any item hence no mraks awarded
4. No DML attached only CGMPat page 32
6.bank guarantee expiry on 29.01.2027

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27																
Name of the firm						HOORA PHARMA KARACHI																
						Technical Evaluation Matrix																
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation							Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facility/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevent certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
	928	EDTA tube (purple top) 3ml / 13*75 mm / 100 tubes per pack	Improve Medical, China						The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COFG) for the quoted items were checked, and following observations were made;			**0**							**0**	**0**
	931	Heparin Tubes 4ml/13*75 mm (Green top) / 100 tubes per pack	Improve Medical, China						1. Ethicon Endo-Surgery USA: DRAP Registration of the quoted items, not provided during inspection. Valid Original free sale certificate/US FDA certificate of the foreign government/cGMP of all the quoted items duly attested from the embassy concerned were not present at the time of inspection.			**0**							**0**	**0**
	932	Gel tube (yellow top) 5 ml /13*75 mm / 100 tubes per pack	Improve Medical, China						2. Guangzhou Improve Instruments Co. Ltd. China: DRAP Registration of the quoted items, were not provided at the time of inspection. EC and Valid free sale certificates of all the quoted items duly attested from the embassy concerned were not present at the time of inspection.			**0**							**0**	**0**
	933	Sodium Citrate tube 1.8ml / 13*75 mm (blue top) / 100 tubes per pack	Improve Medical, China						2. 20% inventory of the quoted items, adequate qualified HR, Cold Chain facility, Good Storage practices and SOPs for expiry management were satisfactory/present at the time of inspection.			**0**							**0**	**0**
	934	Sodium Fluoride Tube 3ml 13*75 mm (Grey top) / 100 tubes per pack	Improve Medical, China						In view of the above facts the firm is NOT-RECOMMENDED.			**0**							**0**	**0**

						Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27														
					Name of the firm	HOORA PHARMA KARACHI													
S. No.		Product General Parameter				Technical Evaluation Matrix												Product Evaluated Score	Total Technical Score
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the time of inspection at the warehouse at the tim eof inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** **(Certificate duly attaested by senior executive of the firm)**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US free sale certificate of the quoted products, **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **Online verification link shall be provided.** **(copies of relevant certificates duly attested by the senior executive of the firm)**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	5	6	**29**	5	5	5	6	10	10	**41**	**70**
	946	Circular Stapler/ CDH21B / 21mm	ETHICON ENDO SURGERY, USA						The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COPG) for the quoted items were checked, and following observations were made; 1. Ethicon Endo-Surgery USA: DRAP Registration of the quoted items, not provided during inspection. Valid Original free sale certificate/US FDA certificate of the foreign government/cGMP of all the quoted items duly attested from the embassy concerned were not present at the time of inspection. 2. Guangzhou Improve Instruments Co. Ltd. China: DRAP Registration of the quoted items, were not provided at the time of inspection. EC and Valid free sale certificates of all the quoted items duly attested from the embassy concerned were not present at the time of inspection. 2. 20% inventory of the quoted items, adequate qualified HR, Cold Chain facility, Good Storage practices and SOPs for expiry management were satisfactory/present at the time of inspection. In view of the above facts the firm is NOT-RECOMMENDED.			**0**							**0**	**0**
	946	Circular Stapler/ CDH25B/ 25mm	ETHICON ENDO SURGERY, USA									**0**							**0**	**0**
	946	Circular Stapler/ CDH29B/ 29mm	ETHICON ENDO SURGERY, USA									**0**							**0**	**0**
	946	Circular Stapler/ CDH33B / 33mm	ETHICON ENDO SURGERY, USA									**0**							**0**	**0**
	1169	Reloadable Linear cutter Stapler/ TLC55 / RELOADABLE TITANIUM LINEAR CUTTER STAPLER 55MM	ETHICON ENDO SURGERY, USA									**0**							**0**	**0**
	1169	Reloadable Linear cutter Stapler/ TLC75/ RELOADABLE TITANIUM LINEAR CUTTER STAPLER 75MM	ETHICON ENDO SURGERY, USA									**0**							**0**	**0**
	1184	Skin Staple Remover / PSX	ETHICON ENDO SURGERY, USA									**0**							**0**	**0**
	1185	Skin Stapler Straight / PROXIMATE PLUS MD SKIN STAPLER PMW35	ETHICON ENDO SURGERY, USA									**0**							**0**	**0**
Ethicon Endo surgery USA-Site: Nypro Healthcare Baja Mexico	1255	Titanium Ligation clips / Titanium ligaclips LT300 for endo and open appliers 6/cartridge	ETHICON ENDO SURGERY, USA					5				**5**				2			**2**	**7**
Ethicon Endo surgery USA-Site: Nypro Healthcare Baja Mexico	1256	Titanium Ligation clips / Titanium ligaclips LT400 for endo and open appliers 6/cartridge	ETHICON ENDO SURGERY, USA					5				**5**				2			**2**	**7**

Mandatory DRAP registration of Staplers is not present

						Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27														
					Name of the firm	HOSPITAL SERVICES AND SALES KARACHI													
S. No.		Product General Parameter				Technical Evaluation Matrix												Product Evaluated Score	Total Technical Score
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score							
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF). (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the time of inspection at the warehouse at the tim eof inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** **(Certificate duly attaested by senior executive of the firm)**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US free sale certificate of the quoted products, **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **Online verification link shall be provided.** **(copies of relevant certificates duly attested by the senior executive of the firm)**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	5	6	**29**	5	5	5	6	10	10	**41**	**70**
Wuxi Yushou China	1018	Auto disable syringe	3ml with 24G needle	Syringe	Yushou	3	5	0	5	5	6	**24**	**5**	5	0	2	10	10	**32**	**56**
Wuxi Yushou China	1019	Auto disable syringe	5ml with 23G needle	Syringe	Yushou	3	5	0	5	5	6	**24**	**5**	5	0	2	10	10	**32**	**56**

Scrutiny report

1Tender approvals are not as per advertised criteria

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: HUDSON PHARMA PVT. LTD.

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters — Documents Based Factory Score						Factory Evaluation Visit Score					Total Factory Evaluated	Product Evaluation Parameters — Product Technical Parameters								Total Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
	167	Amikacin Sulphate	250mg/2ml	Injection	Amak Injection 250mg	2	2	3	No IMS/IQVIA related data has been provided in the bid	5	6	2	2	2	2	2	**28**	No Bioavailability/ Bioequivalence study related data has been provided in the Bid	5	5	US-FDA provided at page No. 123 is not according to the documents	0	4	5	IMS/IQVIA data of the quoted items has not been provided	**19**	**47**
	168	Amikacin Sulphate	500mg/2ml	Injection	Amak Injection 500mg	2	2	3	No IMS/IQVIA related data has been provided in the bid	5	6	2	2	2	2	2	**28**	No Bioavailability/ Bioequivalence study related data has been provided in the Bid	5	5	US-FDA provided at page No. 123 is not according to the documents	0	4	5	IMS/IQVIA data of the quoted items has not been provided	**19**	**47**
	375	Iron Sucrose	100mg/5ml	Injection	Ferris 100mg Injection	2	2	3	No IMS/IQVIA related data has been provided in the bid	5	6	2	2	2	2	2	**28**	No Bioavailability/ Bioequivalence study related data has been provided in the Bid	5	5	Not provided	0	4	5	IMS/IQVIA data of the quoted items has not been provided	**19**	**47**
	790	Beclomethasone Dipropionate	0.8mg/2ml	Nebules	Beeko Suspension for Nebulization 0.8mg/2ml	2	2	3	No IMS/IQVIA related data has been provided in the bid	5	6	2	2	2	2	2	**28**	No Bioavailability/ Bioequivalence study related data has been provided in the Bid	5	5	5	0	4	5	IMS/IQVIA data of the quoted items has not been provided	**24**	**52**
	805	Ipratropium Bromide	0.025%/2ml	Nebules	Easehale Respules 0.025% 2ml	2	2	3	No IMS/IQVIA related data has been provided in the bid	5	6	2	2	2	2	2	**28**	No Bioavailability/ Bioequivalence study related data has been provided in the Bid	5	5	Not provided	0	4	5	IMS/IQVIA data of the quoted items has not been provided	**19**	**47**
	807	Ipratropium Bromide + Salbutamol	0.5mg+2.5mg/2.5ml	Nebules	CombiHale Respules 0.5mg+2.5mg /2.5ml	2	2	3	No IMS/IQVIA related data has been provided in the bid	5	6	2	2	2	2	2	**28**	No Bioavailability/ Bioequivalence study related data has been provided in the Bid	5	5	Not provided	0	4	5	IMS/IQVIA data of the quoted items has not been provided	**19**	**47**
	824	Brinzolamide + Brimonidine Tartrate	10mg+2mg/5ml	Eye Drops	Cobrinzo Eye Drops	2	2	3	No IMS/IQVIA related data has been provided in the bid	5	6	2	2	2	2	2	**28**	No Bioavailability/ Bioequivalence study related data has been provided in the Bid	5	5	5	0	4	5	IMS/IQVIA data of the quoted items has not been provided	**24**	**52**
	832	Dorzolamide + Timolol Maleate	20mg+5mg/5ml	Eye Drops	Cosdrop Eye Drops	2	2	3	No IMS/IQVIA related data has been provided in the bid	5	6	2	2	2	2	2	**28**	No Bioavailability/ Bioequivalence study related data has been provided in the Bid	5	5	Not provided	0	4	5	IMS/IQVIA data of the quoted items has not been provided	**19**	**47**
	852	Tobramycin + Dexamethasone	0.3%+0.1%/5ml	Eye Drops	Tobcoid Eye Drops	2	2	3	No IMS/IQVIA related data has been provided in the bid	5	6	2	2	2	2	2	**28**	No Bioavailability/ Bioequivalence study related data has been provided in the Bid	5	5	5	0	4	5	IMS/IQVIA data of the quoted items has not been provided	**24**	**52**
	853	Travoprost	0.004%/2.5ml	Eye Drops	Travson Eye Drops	2	2	3	No IMS/IQVIA related data has been provided in the bid	5	6	2	2	2	2	2	**28**	No Bioavailability/ Bioequivalence study related data has been provided in the Bid	5	5	5	0	4	5	IMS/IQVIA data of the quoted items has not been provided	**24**	**52**

	914	Cholecalciferol	5mg/1ml	Injection	Vydee Injection	2	2	3	No IMS/IQVIA related data has been provided in the bid	5	6	2	2	2	2	2	**28**	No Bioavailability/ Bioequivalence study related data has been provided in the Bid	5	5	5	0	4	5	IMS/IQVIA data of the quoted items has not been provided	**24**	**52**

Original Mandatory forms in Hard are not submitted to the MCC

						Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27														
Name of the firm:						IBL KARACHI													
S. No.		Product General Parameter				Technical Evaluation Matrix												Product Evaluated Score	Total Technical Score
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided**	Availability of minimum 20% inventory of the total import of the quoted item's during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the time of inspection at the warehouse at the tim eof inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** **(Certificate duly attaested by senior executive of the firm)**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US free sale certificate of the quoted products, **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	5	6	**29**	5	5	5	6	10	10	**41**	**70**
Shandong Weigao Group Medical Polymer Co. China	1119	IV fluid administration set	sterile and pyrogen free, minimum 150cm tube length, blister pack	IV Set	WEGO, DRAP Reg # MDIR-0000003	3	5	**The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COFG) for the quoted items were checked, and following observations were made;** **1. Shandong Weigao China: Valid Original agency agreement and Valid Original free sale certificates of all the quoted items duly attested from the embassy concerned were present, and Valid full quality assurance confirmation letter was not embassy attested at the time of inspection.** **2. Suzhou Zoey Medical Devices Co. Ltd. China: Valid Original agency agreement and Valid Original free sale certificates of all the quoted items duly attested from the embassy concerned were present, and Valid full quality assurance confirmation letter was not embassy attested at the time of inspection.** **3. Ultramed Egypt: Valid Original agency agreement and Valid Original free sale certificates of all the quoted items duly attested from the embassy concerned were present, and Valid full quality assurance confirmation letter was not embassy attested at the time of inspection.** **4. Kawasumi Thailand: Valid Original agency agreement and Valid Original free sale certificates of all the quoted items duly attested from the embassy concerned were present, and Valid full quality assurance confirmation letter was not embassy attested at the time of inspection.** **5. 20% inventory of the quoted items, adequate qualified HR, Cold Chain facility, Good Storage practices and SOPs for expiry management were satisfactory/present at the time of inspection.** **In view of the above the firm is NOT-RECOMMENDED.**						**8**	**0**	0	0	2			**2**	**10**
Shandong Weigao Group Medical Polymer Co. China	1120	IV fluid administration sets (sterile, minimum 150cm with Y Port)	sterile and pyrogen free, minimum 150cm tube length, blister pack	IV Set "Y" port	WEGO, DRAP Reg # MDIR-0000003	3	5					**8**	**0**	0	0	2			**2**	**10**

Combined scrutiny report

1GDs at Pages No. 98,102,106,110,114, 195,399 are not readable-

2AWB of GD at page No. 118 and 203 is not readable

3Tender approvala are not as per the advertised criteria

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27														
					Name of the firm	IBL KARACHI														
						Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm) **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission.	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered.	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
Shandong Weigao Group Medical Polymer Co. China	940	Blood Bags (CPDA-1)	Single Blood Bags 500ml	Single Bags	WEGO Single Blood Bag (DRAP Reg # MDIR-0000002)	3	5	0	**The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COFG) for the quoted items were checked, and following observations were made;** **1. Shandong Weigao China: Valid Original agency agreement and Valid Original free sale certificates of all the quoted items duly attested from the embassy concerned were present, and Valid full quality assurance confirmation letter was not embassy attested at the time of inspection.** **2. Suzhou Zoey Medical Devices Co. Ltd. China: Valid Original agency agreement and Valid Original free sale certificates of all the quoted items duly attested from the embassy concerned were present, and Valid full quality assurance confirmation letter was not embassy attested at the time of inspection.** **3. Ultramed Egypt: Valid Original agency agreement and Valid Original free sale certificates of all the quoted items duly attested from the embassy concerned were present, and Valid full quality assurance confirmation letter was not embassy attested at the time of inspection.** **4. Kawasumi Thailand: Valid Original agency agreement and Valid Original free sale certificates of all the quoted items duly attested from the embassy concerned were present, and Valid full quality assurance confirmation letter was not embassy attested at the time of**			**8**	0	0	0	0	2		**2**	**10**
Shandong Weigao Group Medical Polymer Co. China	942	Blood Bags (CPDA-1)	Double Blood Bag 500ml	Double Blood Bag	WEGO Double Blood Bag (DRAP Reg # MDIR-0000005)	3	5	0				**8**	0	0	0	0	2		**2**	**10**
Shandong Weigao Group Medical Polymer Co. China	944	Blood Bags (CPDA-1)	Triple Blood Bag 500ml	Triple Blood Bag	WEGO Triple Blood Bag (DRAP Reg # MDIR-0000008)	3	5	0				**8**	0	0	0	0	2		**2**	**10**
Kawasumi Thailand	940	Blood Bags (CPDA-1)	Single Blood Bags 500ml	Single Bags	SB Kawasumi Single Blood Bag (DRAP Reg # MDIR-0000222)	3	5	0				**8**	0	0	0	0	2		**2**	**10**
Kawasumi Thailand	942	Blood Bags (CPDA-1)	Double Blood Bag 500ml	Double Blood Bag	SB Kawasumi Double Blood Bag (DRAP Reg # MDIR-0000227)	3	5	0				**8**	0	0	0	0	2		**2**	**10**
Kawasumi Thailand	944	Blood Bags (CPDA-1)	Triple Blood Bag 500ml	Triple Blood Bag	SB Kawasumi Triple Blood Bag (DRAP Reg # MDIR-0000226)	3	5	0				**8**	0	0	0	0	2		**2**	**10**

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27														
Name of the firm						Ideal Distributors, Rawalpindi														
						Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters														
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score	Product Technical Evaluation						Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm).**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevent certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
1	1136	Nasal Oxygen Cannula	Pediatric		Ideal Med	0	0	0				**0**	0	0	0	0	0		**0**	**0**
2	1137	Nasal Oxygen Cannula	Adult		Ideal Med	0	0	0				**0**	0	0	0	0	0		**0**	**0**
3	1138	Nebulizer mask with chamber and tubing	Pediatric		Ideal Med	0	0	0	The inspection team during inspection made following observations; • Mandatory original documents (LOA, EC, FSC/COPP) of M/S Ningbo Great Mountain China were not presented to the inspection team. • The offered Urine bag is not registered / enlisted with DRAP. Based on the above observations the firm is NOT RECOMMENDED			**0**	0	0	0	0	0		**0**	**0**
4	139	Nebulizer mask with chamber and tubing	Adult		Ideal Med	0	0	0				**0**	0	0	0	0	0		**0**	**0**
5	1154	Oxygen Mask	Adult		Ideal Med	0	0	0				**0**	0	0	0	0	0		**0**	**0**
6	1155	Oxygen Mask	Pediatric		Ideal Med	0	0	0				**0**	0	0	0	0	0		**0**	**0**

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposibles and Sutures for Government MCC 2026-27

Name of the firm: **Injection System Gadoon KP FY 2026-27**

Technical Evaluation Matrix

		Product General Information				Factory Technical Evaluation Parameter									Product technical Evaluation Parameters							
						Documents Based Factory Score				Evaluation Visit Score				Factory Evaluated Score							Product Evaluated Score	Total Technical Score
S.No	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. **(as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.**	Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAP regulations. **(to be evaluated by the MCC expert/s at the time of inspection, Noncompliance to cGMP shall lead to disqualification of the relevant section or firm)**	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section / firm.**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC** **(Certificate Duly attested by Senior Executive of the firm)**	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the	Valid WHO prequalification and / or valid product registration in SRA/WLA country(ies) / and / or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	**3**	**5**	**5**	**6**	**3**	**3**	**2**	**2**	**29**	**5**	**5**	**5**	**6**	**10**	**10**	**41**	**70**
	1018	3 ml Disposable Auto Disable Syringe (Blister Packing) Sterile	3 ml Auto Disable		Biosafe 3 ml Disposable Auto Disable Syringe	**3**	**5**	**5**	**6**	**3**	**3**	**2**	**2**	**29**	**5**	**5**		0	**10**	**10**	**30**	**59**
	1019	5 ml Disposable Auto Disable Syringe (Blister Packing) Sterile	5 ml Auto Disable		Biosafe 5 ml Disposable Auto Disable Syringe	**3**	**5**	**5**	**6**	**3**	**3**	**2**	**2**	**29**	**5**	**5**		0	**10**	**10**	**30**	**59**
	1021	Iml Disposable Insulin Syringe Ordinary Sterile 30 G/31G	Iml Disposable Insulin		Biosafe 1 ml Disposable Insulin Syringe	**3**	**5**	**5**	**6**	**3**	**3**	**2**	**2**	**29**	**5**	**5**		0	**10**	**10**	**30**	**59**
	1022	I mi Disposable Syringe Ordinary (Blister Packing) Sterile	I mi Disposable Syringe		Biosafe 1 ml Disposable Syringe	**3**	**5**	**5**	**6**	**3**	**3**	**2**	**2**	**29**	**5**	**5**		0	**10**	Not recommended	**20**	**49**
	1023	10 ml Disposable Syringe Ordinary (Blister Packing) Sterile	10 ml Disposable Syringe		Biosafe 10ml Disposable Syringe	**3**	**5**	**5**	**6**	**3**	**3**	**2**	**2**	**29**	**5**	**5**		0	**10**	10	**30**	**59**
	1024	20 ml Disposable Syringe Ordinary (Blister Packing) Sterile	20 ml Disposable Syringe		Biosafe 20ml Disposable Syringe	**3**	**5**	**5**	**6**	**3**	**3**	**2**	**2**	**29**	**5**	**5**		0	**10**	10	**30**	**59**
	1025	50 ml Disposable Syringe Ordinary (Blister Packing) Sterile	50 ml Disposable Syringe		Biosafe 50ml Disposable Syringe	**3**	**5**	**5**	**6**	**3**	**3**	**2**	**2**	**29**	**5**	**5**	180-239 Tender approvals are incomplete	0	**10**	10	**30**	**59**
	1026	60 ml Disposable Syringe Ordinary (Blister Packing) Sterile	60 ml Disposable Syringe		Biosafe 60ml Disposable Syringe	**3**	**5**	**5**	**6**	**3**	**3**	**2**	**2**	**29**	**5**	**5**		0	**10**	10	**30**	**59**
	1027	60 ml Disposable Syringe Ordinary with nozzle/catheter tip (Blister packing) sterile	60 ml Disposable Syringe Ordinary with nozzle/catheter tip		Biosafe 60ml Disposable Syringe with nozzle	**3**	**5**	**5**	**6**	**3**	**3**	**2**	**2**	**29**	**5**	**5**		0	**10**	10	**30**	**59**
	1028	50 ml Disposable Syringe Ordinary with luer slip Eccentric tip/nozzle (Blister packing) sterile	50 ml Disposable Syringe Ordinary with luer slip Eccentric tip/nozzle		Biosafe 50ml Disposable Syringe (Luer Slip)	**3**	**5**	**5**	**6**	**3**	**3**	**2**	**2**	**29**	**5**	**5**		0	DTL substandard	10	**20**	**49**
	1119	IV fluid administration set pyrogen free, minimum 150cm tube length, blister pack	IV fluid administration set pyrogen free, minimum 150cm tube length		Biosafe IV Infusion Giving Set	**3**	**5**	**5**	**6**	**3**	**3**	**2**	**2**	**29**	**5**	**5**		0	DTL substandard	10	**20**	**49**
	1120	I/V fluid administration set with additional "Y" injection port Sterile, minimum 150cm tube length, Latex and Pyrogen free, blister pack	I/V fluid administration set with additional "Y" injection port Sterile, minimum 150cm tube length, Latex and Pyrogen free		Biosafe LV Infusion Giving Set with additional "Y" Injection port	**3**	**5**	**5**	**6**	**3**	**3**	**2**	**2**	**29**	**5**	**5**		0	10	10	**30**	**59**

Original Mandatory forms in Hard are not submitted to the MCC

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27														
Name of the firm						Innovate Medical Technology Karachi														
						Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevent certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
Coloplast Demark	MCC formulary No.	Generic Name of item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
Zhejiang Kanglidi MACL China	956	Calcium Alginate Dressing	7.5cm x12.5cm	IMT Kalgistate 10cm x 12.5cm		Not attached	89 Not attested by senior executive of the firm and verification link not provided	**Mandatory DRAP Registeration are not attached in the bid**				**0**			221-253 Tender approvals are incomplete	Not attached	2		**2**	**2**
Zhejiang Kanglidi MACL China	957	Calcium Alginate Dressing	10 cm x 20cm	IMT Kalgistate 10cm x 20cm		Not attached	90 Not attested by senior executive of the firm and verification link not provided					**0**			221-253 Tender approvals are incomplete	Not attached	2		**2**	**2**
Zhejiang Kanglidi MACL China	958	Calcium Alginate Dressing	15cm x 25cm	IMT Kalgistate 15cm x 25cm		Not attached	91 Not attested by senior executive of the firm and verification link not provided					**0**			221-253 Tender approvals are incomplete	Not attached	2		**2**	**2**
Zhejiang Kanglidi MACL China	959	Calcium Alginate Dressing	Rope 2gm	IMT Kalgistate Rope		Not attached	92 Not attested by senior executive of the firm and verification link not provided					**0**			221-253 Tender approvals are incomplete	Not attached	2		**2**	**2**
Coloplast Demark	966	Colostomy bags (Set comprising bag, adhesive ring, and clamp)	40mm,50mm,60mm	Coloplast Alterna Colostomy Complete Set (Bag + Baseplate Clamp) 40mm, 50mm & 60mm		127-129 Not attested by senior executive of the firm and verification link not provided	82 Not attested by senior executive of the firm and verification link not provided	The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COPG) for the quoted items were checked, and following observations were made; 1. Coloplast Denmark: (Hydrocolloid, hydrogel & hydrofiber dressings, Colostomy Sets & Stomahesive paste) Valid full quality assurance and free sale certificates of all the quoted items duly attested from the embassy concerned were present at the time of inspection. 2. Zhejiang Kanglidi Medical Articles Co., Ltd, China: (Calcium Alginate (Kalgistate) Dressings)Valid original EC full quality assurance certificate and free sale certificates of all the quoted items duly attested from the embassy concerned were not present at the time of inspection 3. 20% inventory of the quoted items, adequate qualified HR, Cold Chain facility, Good Storage practices and SOPs for expiry management were satisfactory/present. **The firm is only RECOMMENDED for the items being imported from Coloplast Denmark.**				**0**			221-253 Tender approvals are incomplete	Not attached	2		**2**	**2**
Coloplast Demark	1110	Hydrogel dressing	10cm x10cm	Comfeel Plus Dressing		127-129 Not attested by senior executive of the firm and verification link not provided	82 Not attested by senior executive of the firm and verification link not provided					**0**	5	149 COA are not matching	221-253 Tender approvals are incomplete	Not attached	2		**7**	**7**

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: IPRAM INTERNATIONAL ISLAMABAD

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters						Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters							
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualifications of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualificatio n of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better (**Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product.**). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	4	5	5	37	70
5's	111	Atracurium Injection 10mg/ml	50mg	Injectable	Ipracurium 50mg	2	2	3	0	5	4	**The inspection team observed the following deficiencies during the inspection:** **1. Most of the pressure gauges installed on production and utility equipment were found non-functional/out of order, which may affect proper monitoring and control of critical process parameters.** **2. Several in-process materials were found without proper identification labels, indicating inadequate material status control and poor GMP compliance.** **3. Injection products requiring storage conditions of 2-8 C were stored in -3 C temperature.** **4. Batch identification and status details were not displayed in the production area, resulting in inadequate traceability and batch segregation.** **5. Multiple equipment items were found uncleaned after use, posing a potential risk of cross-contamination and demonstrating non-compliance with cleaning procedures.** **6. Filled capsules placed in the in-process quarantine area were found without labeling and status identification.** **7. Expired working standards were found in the Quality Control laboratory, indicating inadequate inventory control and monitoring practices.** **8. Unlabeled filled vials having similar appearances but belonging to different batch numbers were found in the production area, creating a significant risk of product mix-up and misidentification.** **9. Raw materials were found without any status labels indicating whether the materials were approved, released, rejected, or under quarantine.** **10. Unlabeled Imipenem/Cilastatin material was observed in the production area without any documented evidence regarding its sampling, quarantine, release, or usage status, indicating poor material traceability and control.** **Based on the above observations the firm is Not Recommended**						16		5	5	4	126 Atracurim 10 and unsigned S.S attached.	0	14	30
100's	240	Diclofenac Sodium 25mg/ml	75mg	Injectable	Inflamac injection	2	2	3	0	5	4						16		5	5	163, 164 and 139 are same invoice for 5cc for ipracurium (white) instead of amber	5	0	15	31
5's	347	Ketorolac 30mg	30mg	Injectable	Iprolac injection	2	2	3	0	5	4						16		5	5	189 Proof of purchase and Picture of Iprolac not attached	5		15	31
1's	4166	Amikacin Sulphate	100mg	Injectable	Ipracin 100mg	2	2	3	0	5	4						16		201 GD and AWB are not matching	0	215 Proof of purchase NA and 164 picture of Diclofenac attached.	5		5	21
1's	5167	Amikacin Sulphate	250mg	Injectable	Ipracin 250mg	2	2	3	0	5	4						16		201 GD and AWB are not matching	0	242, 215 Proof of purchase NA and 164 picture of Diclofenac attached.	5		5	21
1's	6168	Amikacin Sulphate	500mg	Injectable	Ipracin 500mg	2	2	3	0	5	4						16		201 GD and AWB are not matching	0	265, 242, 215 Proof of purchase NA and 164 picture of Diclofenac attached.	5		5	21
1's	7202	Cefepime Inj 500mg	500mg	Injectable	Pime Inj	2	2	3	0	5	4						16		278 GD not attached	0	2	5		7	23
1's	8203	Cefepime Inj 1gm	1gm	Injectable	Pime Inj	2	2	3	0	5	4						16		278 GD not attached	0	2	5		7	23
5's	9204	Cefixime Capsule	400 mg	Capsule	Cilicef Capsule	2	2	3	0	5	4						16		5	419, 448 COA of micornized attached	4	414 S.S are not singed and stamped		9	25
30ml	10205	Cefixime D/S	100 mg/5ml	Susp	Cilicef	2	2	3	0	5	4						16		5	497, 469 COA of micornized attached	4	469 S.S are not singed and stamped		9	25
30ml	11206	Cefixime D/S	200 mg/5ml	Susp	Cilicef Forte	2	2	3	0	5	4						16		5	497, 469 COA of micornized attached	4	469 S.S are not singed and stamped		9	25
1's	12207	Cefoperazone + Sulbactum	1gm	Injectable	Cefosub	2	2	3	0	5	4						16		562 GD and AWB are not matching	0	2	5		7	23
1's	13208	Cefoperazone + Sulbactum	2gm	Injectable	Cefosub	2	2	3	0	5	4						16		562 GD and AWB are not matching	0	2	5		7	23
1's	14209	Cefotaxime	250 mg	Injectable	Hypertax inj	2	2	3	0	5	4						16		Edtd 751 AwB is unclear	0	2	5		7	23
1's	15210	Cefotaxime	500 mg	Injectable	Hypertax inj	2	2	3	0	5	4						16		Edtd 751 AwB is unclear	0	2	5		7	23
1's	16211	Cefotaxime	1gm	Injectable	Hypertax inj	2	2	3	0	5	4						16		Edtd 751 AwB is unclear	0	2	5		7	23
1's	17215	Ceftazidime	500mg	Injectable	Ipradime	2	2	3	0	5	4						16		905 GD not attached with AwB		2	5		7	23
1's	18216	Ceftazidime	1gm	Injectable	Ipradime	2	2	3	0	5	4						16		905 GD not attached with AwB		2	5		7	23
1's	19217	Ceftriaxone Sodium	500mg	Injectable	Sky Zone	2	2	3	0	5	4						16		5	5	2	5		17	33
1's	20218	Ceftriaxone Sodium	1gm	Injectable	Sky Zone	2	2	3	0	5	4						16		5	5	2	5		17	33
12's	21225	Cephradine	500mg	Capsule	Ipraceph	2	2	3	0	5	4						16		5	5	1143 same EHGC as for Cefixime	5		15	31
1's	22260	Imipenem + Cilastatin	500 mg	Injectable	Imicid	2	2	3	0	5	4						16		5	5	0	5		15	31
1's	23272	Meropenem	500 mg	Injectable	Cilipenem	2	2	3	0	5	4						16							0	16
1's	24273	Meropenem	1gm	Injectable	Cilipenem	2	2	3	0	5	4						16			1-1695	Technical bid is not signed and stamped (mandatory) by senior executive of the firm.			0	16
2x5's	25376	Mecobalamine	500mcg	Injectable	Methymin	2	2	3	0	5	4						16			108	Mandatory KP Professional tax cerificate not attached.				

2x7's	26	517	Omeprazole	40mg	Capsule	Iprazole	2	2	3	0	5	4	16							0	16
2x7's	27	518	Esomeprazole	40mg	Capsule	Exporam	2	2	3	0	5	4	16							0	16
14's	28	753	Pregablin	50mg	Capsule	Ipragab	2	2	3	0	5	4	16							0	16
14's	29	754	Pregablin	75mg	Capsule	Ipragab	2	2	3	0	5	4	16							0	16
14's	30	755	Pregablin	150mg	Capsule	Ipragab	2	2	3	0	5	4	16							0	16
1's	31	912	Cholecalciferol (Vitamin D.3)	1ml	Injectable	D.Drop Inj	2	2	3	0	5	4	16							0	16

						Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27													
Name of the firm						Jawad Traders Peshawar												
S. No.		Product General Parameter				Technical Evaluation Matrix												
						Principal's and Importer's Evaluation Parameters												
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score	Product Technical Evaluation						Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided**	Availability of minimum 20% inventroy of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the time of inspection at the warehouse at the tim eof inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** **(Certificate duly attaested by senior executive of the firm)**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US free sale certificate of the quoted products, **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	5	6	**29**	5	5	5	6	10	10	**41**	**70**
1	919	Adhesive Paper Tape	1"x5y	HK(Huikang)		Not attached	89 Not attested by the Senior Executive of the firm and online verification link not provided	Not attached	**The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COFG) for the quoted items were checked against the following Manufacturers.** **1. Tianchang Hengsheng Medical Devices Co Ltd. China.** **2. Zhejiang Huikang Medical China.** **3. Super Health Medical (Aingdao co limited China).** **I. Valid Agency agreement, valid confirmation letter and valid original free sale certificates of the quoted items duly attested by the Embassy concerned were present at the time of inspection.** **II. 20% Inventory of the Disposable Sterile Latex Surgical Gloves (Powdered & Powder-Free) Size 6.5 & 7 (TopMed+), Adhesive paper tape 1, 2, 3 & 4 inches (HK(Huikang) and IV Cannula 18G, 20G & 22G (Topmed+) was not available at the time of inspection. Adequate qualified HR, Cold Chain facility, Good Storage practices and SOPs for expiry management were satisfactory/present.** **In view of the above the firm is RECOMMENDED for the Disposable Sterile Latex Surgical Gloves (Powdered & Powder-Free) Size 7.5 and 8.0 of Tianchang Hengsheng Medical Devices Co Ltd. China and IV Canula size 24G of Super Health Medical (Aingdao) China only.**		**0**	5	5	Tender approvals are incomplete	Copies of CE are not duly attested by the senior executive of the firm)	10	10	**25**	**25**
2	920	Adhesive Paper Tape	2"x5y	HK(Huikang)		Not attached	89 Not attested by the Senior Executive of the firm and online verification link not provided	Not attached				**0**	Not attached	0	Tender approvals are incomplete	Copies of CE are not duly attested by the senior executive of the firm)	10	10	**20**	**20**
3	921	Adhesive Paper Tape	3"x5y	HK(Huikang)		Not attached	89 Not attested by the Senior Executive of the firm and online verification link not provided	Not attached				**0**	5	5	Tender approvals are incomplete	Copies of CE are not duly attested by the senior executive of the firm)	10	10	**25**	**25**
4	922	Adhesive Paper Tape	4"x5y	HK(Huikang)		Not attached	89 Not attested by the Senior Executive of the firm and online verification link not provided	Not attached				**0**	Not attached	0	Tender approvals are incomplete	Copies of CE are not duly attested by the senior executive of the firm)	10	10	**20**	**20**
Super Health Medical (Aingdao) Co., Ltd. No 236 Heyuan Road, High Tech Zone, Qindao China	1123	IV-Cannula (Sterile having wings+injection port in sterilized blister packing radio-opaque,latex pyrogen & PVC Free)	18G	TopMed+		Not attached	90 Not attested by the Senior Executive of the firm and online verification link not provided	Not attached				**0**	5	5	Tender approvals are incomplete	Copies of CE are not duly attested by the senior executive of the firm)	10	10	**25**	**25**
Super Health Medical (Aingdao) Co., Ltd. No 236 Heyuan Road, High Tech Zone, Qindao China	1126	IV-Cannula (Sterile having wings+injection port in sterilized blister packing radio-opaque,latex pyrogen & PVC Free)	20G	TopMed+		Not attached	89 Not attested by the Senior Executive of the firm and online verification link not provided	Not attached				**0**	5	5	Tender approvals are incomplete	Copies of CE are not duly attested by the senior executive of the firm)	10	10	**25**	**25**
Super Health Medical (Aingdao) Co., Ltd. No 236 Heyuan Road, High Tech Zone, Qindao China	1129	IV-Cannula (Sterile having wings+injection port in sterilized blister packing radio-opaque,latex pyrogen & PVC Free)	22G	TopMed+		Not attached	89 Not attested by the Senior Executive of the firm and online verification link not provided	Not attached				**0**	5	5	Tender approvals are incomplete	Copies of CE are not duly attested by the senior executive of the firm)	DTL Substandard	10	**15**	**15**
Super Health Medical (Aingdao) Co., Ltd. No 236 Heyuan Road, High Tech Zone, Qindao China	1134	IV-Cannula (Sterile having wings With heparin stopper inside sterilized blister packing radio-opaque,latex pyrogen & PVC Free)	24G	TopMed+		Not attached	89 Not attested by the Senior Executive of the firm and online verification link not provided	Not attached	5	5	6	**16**	114 Not mentioned in the AWB and GD	0	Tender approvals are incomplete	Copies of CE are not duly attested by the senior executive of the firm)	DTL substandard	10	**10**	**26**

Page No Remarks

65DRAP Registeration of IV. Cannul not attached
107I.V cannula are not covered in the Scope of COPP
77Declaration of Conformity is not attested from the concened embassay.

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27														
Name of the firm						Jawad Traders Peshawar														
						Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal/ Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks.	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
Tianchang HengSheng Medical Devices Co., Ltd, Qinlan Industrial Park Tianchang City, Anhui Province, China	1052	Disposable Sterile Latex Surgical Gloves (Powder-Free)	7.5,	TopMed+		Not attached	Not attested vy the Senior executive	Not attached	5	6	6	**17**	5	5	Tender approvals are incomplete	0	Declaration of conformity is not attested.	16	**26**	**43**
Tianchang HengSheng Medical Devices Co., Ltd, Qinlan Industrial Park Tianchang City, Anhui Province, China	1052	Disposable Sterile Latex Surgical Gloves (Powder-Free)	8	TopMed+		Not attached	Not attested vy the Senior executive	Not attached	5	6	6	**17**	5	5	Tender approvals are incomplete	0	Declaration of conformity is not attested.	16	**26**	**43**
Tianchang HengSheng Medical Devices Co., Ltd, Qinlan Industrial Park Tianchang City, Anhui Province, China	1053	Disposable Sterile Latex Surgical Gloves (Powdered)	7.5,	TopMed+		Not attached	Not attested vy the Senior executive	Not attached	5	6	6	**17**	5	5	Tender approvals are incomplete	0	Declaration of conformity is not attested.	16	**26**	**43**
Tianchang HengSheng Medical Devices Co., Ltd, Qinlan Industrial Park Tianchang City, Anhui Province, China	1053	Disposable Sterile Latex Surgical Gloves (Powdered)	8	TopMed+		Not attached	Not attested vy the Senior executive	Not attached	5	6	6	**17**	5	5	Tender approvals are incomplete	0	Declaration of conformity is not attested.	16	**26**	**43**
Tianchang HengSheng Medical Devices Co., Ltd, Qinlan Industrial Park Tianchang City, Anhui Province, China	1052	Disposable Sterile Latex Surgical Gloves (Powder-Free)	6.5	TopMed+		Not attached	Not attested vy the Senior executive	Not attached	The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COFG) for the quoted items were checked against the following Manufacturers: 1. Tianchang Hengsheng Medical Devices Co Ltd. China. 2. Zhejiang Hulkang Medical China. 3. Super Health Medical (Aingdao co limited China). I. Valid Agency agreement, valid confirmation letter and valid original free sale certificates of the quoted items duly attested by the Embassy concerned were present at the time of inspection.			**0**	5	5	Tender approvals are incomplete	0	Declaration of conformity is not attested.	16	**26**	**26**
Tianchang HengSheng Medical Devices Co., Ltd, Qinlan Industrial Park Tianchang City, Anhui Province, China	1052	Disposable Sterile Latex Surgical Gloves (Powder-Free)	7	TopMed+		Not attached	Not attested vy the Senior executive	Not attached				**0**	5	5	Tender approvals are incomplete	0	Declaration of conformity is not attested.	16	**26**	**26**
Tianchang HengSheng Medical Devices Co., Ltd, Qinlan Industrial Park Tianchang City, Anhui Province, China	1053	Disposable Sterile Latex Surgical Gloves (Powdered)	6.5	TopMed+		Not attached	Not attested vy the Senior executive	Not attached	II. 20% Inventory of the Disposable Sterile Latex Surgical Gloves (Powdered & Powder-Free) Size 6.5 & 7 (TopMed+), Adhesive paper tape 1, 2, 3 & 4 inches (HK(Huikang) and IV Cannula 18G, 20G & 22G (Topmed+) was not available at the time of inspection. Adequate qualified HR, Cold Chain facility, Good Storage practices and SOPs for expiry management were satisfactory/present.			**0**	5	5	Tender approvals are incomplete	0	Declaration of conformity is not attested.	16	**26**	**26**
Tianchang HengSheng Medical Devices Co., Ltd, Qinlan Industrial Park Tianchang City, Anhui Province, China	1053	Disposable Sterile Latex Surgical Gloves (Powdered)	,7.0,	TopMed+		Not attached	Not attested vy the Senior executive	Not attached	**In view of the above the firm is RECOMMENDED for the Disposable Sterile Latex Surgical Gloves (Powdered & Powder-Free) Size 7.5 and 8.0 of Tianchang Hengsheng Medical Devices Co Ltd. China and IV Canula size 24G of Super Health Medical (Aingdao) China only.**			**0**	5	5	Tender approvals are incomplete	0	Declaration of conformity is not attested.	16	**26**	**26**

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: IHK Pharma Pvt. Ltd.

S. No.	Product General Information					Technical Evaluation Matrix											Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Factory Technical Evaluation Parameters										Total Factory Evaluated Score	Product Technical Parameters									
						Documents Based Factory Score						Factory Evaluation Visit Score															
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. Copies of relevant certificates duly attested by the senior executive of the firm)	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: i. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial	Stability studies of quoted item/s duly attested by the QA incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. i-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**9**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**5**	**3**	**4**	**5**	**5**	**37**	**70**
	4	Metronidazole	500mg	infusion	J-Metro 100 ml	2	2	3	Not attached	5	4	**2**	**2**	**2**	**2**	**2**	**26**	Not attached	0	5	0	0	Picture not attached	5	0	**10**	**36**
	64	Paracetamol	1000 mg	infusion	J-Para 100 ml	2	2	3	Not attached	5	4	**2**	**2**	**2**	**2**	**2**	**26**	Not attached	0	5	0	0	Picture not attached	5	0	**10**	**36**
	263	Levofloxacin	5mg/ml	infusion	J-Levo 100 ml	2	2	3	Not attached	5	4	**2**	**2**	**2**	**2**	**2**	**26**	Not attached	0	0	0	0	Picture not attached	5	0	**5**	**31**
	628	Dextrose	10%	infusion	JHK-SOL 10 % 500 ml	2	2	3	Not attached	5	4	**2**	**2**	**2**	**2**	**2**	**26**	Not attached	5	5	0	0	Picture not attached	5	0	**15**	**41**
	629	Dextrose	10%	infusion	JHK-SOL 10 % 1000 ml	2	2	3	Not attached	5	4	**2**	**2**	**2**	**2**	**2**	**26**	Not attached	5	5	0	0	Picture not attached	5	0	**15**	**41**
	630	Dextrose	5%	infusion	JHK-SOL 5 % 100 ml	2	2	3	Not attached	5	4	**2**	**2**	**2**	**2**	**2**	**26**	Not attached	5	5	0	0	Picture not attached	5	0	**15**	**41**
	631	Dextrose	5%	infusion	JHK-SOL 5 % 500 ml	2	2	3	Not attached	5	4	**2**	**2**	**2**	**2**	**2**	**26**	Not attached	5	5	0	0	Picture not attached	5	0	**15**	**41**
	632	Dextrose	5%	infusion	JHK-SOL 5 % 1000 ml	2	2	3	Not attached	5	4	**2**	**2**	**2**	**2**	**2**	**26**	Not attached	5	5	0	0	Picture not attached	5	0	**15**	**41**
	633	Dextrose + Sodium chloride	5%+0.45 %	infusion	JHK-SOL DS1/2 500 ml	2	2	3	Not attached	5	4	**2**	**2**	**2**	**2**	**2**	**26**	Not attached	5	5	0	0	Picture not attached	5	0	**15**	**41**
	634	Dextrose + Sodium chloride	5%+0.9 %	infusion	JHK-SOL DS 500 ml	2	2	3	Not attached	5	4	**2**	**2**	**2**	**2**	**2**	**26**	Not attached	5	5	0	0	Picture not attached	5	0	**15**	**41**
	635	Dextrose + Sodium chloride	5%+0.9 %	infusion	JHK-SOL DS 1000 ml	2	2	3	Not attached	5	4	**2**	**2**	**2**	**2**	**2**	**26**	Not attached	5	5	0	0	Picture not attached	5	0	**15**	**41**
	646	Normal Saline	0.90%	infusion	JHK-SOL NS 100 ml	2	2	3	Not attached	5	4	**2**	**2**	**2**	**2**	**2**	**26**	Not attached	5	5	0	0	Picture not attached	5	0	**15**	**41**
	647	Normal Saline	0.90%	infusion	JHK-SOL NS 500 ml	2	2	3	Not attached	5	4	**2**	**2**	**2**	**2**	**2**	**26**	Not attached	5	5	0	0	Picture not attached	5	0	**15**	**41**
	649	Normal Saline	0.90%	infusion	JHK-SOL NS 1000 ml	2	2	3	Not attached	5	4	**2**	**2**	**2**	**2**	**2**	**26**	Not attached	5	5	0	0	Picture not attached	5	0	**15**	**41**
	656	Ringer's Lactate + 5 % Dextrose	Ringer's Lactate + 5 % Dextrose	infusion	JHK SOL RLD 500 ml	2	2	3	Not attached	5	4	**2**	**2**	**2**	**2**	**2**	**26**	Not attached	GD attached at page No. 1019 & 1051 for Calcium chloride is older than 24 months	0	5	0	Picture not attached	5	0	**10**	**36**
	657	Ringer's Lactate + 5 % Dextrose	Ringer's Lactate + 5 % Dextrose	infusion	JHK SOL RLD 1000 ml	2	2	3	Not attached	5	4	**2**	**2**	**2**	**2**	**2**	**26**	Not attached	GD attached at page No. 1019 & 1051 for Calcium chloride is older than 24 months	0	5	0	Picture not attached	5	0	**10**	**36**
	658	Ringer's Lactate solution	Ringer's Lactate solution	infusion	JHK SOL RLD 500 ml	2	2	3	Not attached	5	4	**2**	**2**	**2**	**2**	**2**	**26**	Not attached	GD attached at page No. 1019 & 1051 for Calcium chloride is older than 24 months	0	5	0	Picture not attached	5	0	**10**	**36**
	659	Ringer's Lactate solution	Ringer's Lactate solution	infusion	JHK SOL RLD 1000 ml	2	2	3	Not attached	5	4	**2**	**2**	**2**	**2**	**2**	**26**	Not attached	GD attached at page No. 1019 & 1051 for Calcium chloride is older than 24 months	0	5	0	Picture not attached	5	0	**10**	**36**
	664	sodium chloride + dextrose	0.18 % + 4.3%	infusion	JHK SOL Peads 500 ml	2	2	3	Not attached	5	4	**2**	**2**	**2**	**2**	**2**	**26**	Not attached	GD attached at page No. 1019 & 1051 for Calcium chloride is older than 24 months	0	5	0	Picture not attached	5	0	**10**	**36**
	665	Sterile Water for Injection	sterile water for injection 5 ml	Injection	JHK SOL WFI 5 ml	2	2	3	Not attached	5	4	**2**	**2**	**2**	**2**	**2**	**26**	Not attached	0	0	0	0	Picture not attached	5	0	**5**	**31**

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: JSK MEDICA PVT LTD

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP). **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm)**.	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities).	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this column for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
6's	1	189	Azithromycin	250mg	Capsules	JSKocen	2	2	3	Not attached	5	6	2	2	2	2	2	**28**	Not attached	5	5	5	Not attached	4	5	Not attached	**24**	**52**
15ml	2	192	Azithromycin	200mg/5ml	Suspension	JSKocen	2	2	3	Not attached	5	6	2	2	2	2	2	**28**	Not attached	5	5	5	Not attached	4	5	Not attached	**24**	**52**
5's	3	204	Cefixime	400mg	Capsules	CB-Get	2	2	3	Not attached	5	6	2	2	2	2	2	**28**	Not attached	5	5	5	Not attached	4	5	Not attached	**24**	**52**
30ml	4	205	Cefixime	100mg/5mL	Suspension	CB-Get	2	2	3	Not attached	5	6	2	2	2	2	2	**28**	Not attached	5	5	5	Not attached	4	5	Not attached	**24**	**52**
30ml	5	206	Cefixime	200mg/5mL	Suspension	CB-Get Suspension	2	2	3	Not attached	5	6	2	2	2	2	2	**28**	Not attached	5	5	5	Not attached	4	5	Not attached	**24**	**52**
12's	6	225	Cephradine	500mg	Capsules	Vefec	2	2	3	Not attached	5	6	2	2	2	2	2	**28**	Not attached	5	5	5	Not attached	4	5	Not attached	**24**	**52**
60ml	7	228	Cephradine	125mg/5mL	Suspension	Vefec	2	2	3	Not attached	5	6	2	2	2	2	2	**28**	Not attached	5	5	5	Not attached	4	5	Not attached	**24**	**52**
60ml	8	229	Cephradine	250mg/5mL	Suspension	Vefec	2	2	3	Not attached	5	6	2	2	2	2	2	**28**	Not attached	5	5	5	Not attached	4	5	Not attached	**24**	**52**
10's	9	230	Ciprofloxacin	250mg	Tablets	Ceval	2	2	3	Not attached	5	6	2	2	2	2	2	**28**	Not attached	5	5	5	Not attached	4	5	Not attached	**24**	**52**
10's	10	231	Ciprofloxacin	500mg	Tablets	Ceval	2	2	3	Not attached	5	6	2	2	2	2	2	**28**	Not attached	5	5	5	Not attached	4	5	Not attached	**24**	**52**
60ml	11	237	Clarithromycin	125mg/5mL	Suspension	IB-Clar	2	2	3	Not attached	5	6	2	2	2	2	2	**28**	Not attached	5	5	5	Not attached	4	5	Not attached	**24**	**52**
10's	12	264	Levofloxacin	250mg	Tablets	Levelone	2	2	3	Not attached	5	6	2	2	2	2	2	**28**	Not attached	5	5	5	Not attached	4	5	Not attached	**24**	**52**
10's	13	265	Levofloxacin	500mg	Tablets	Levelone	2	2	3	Not attached	5	6	2	2	2	2	2	**28**	Not attached	5	5	5	Not attached	4	5	Not attached	**24**	**52**
5's	14	275	Moxifloxacin	400mg	Tablet	Meberg	2	2	3	Not attached	5	6	2	2	2	2	2	**28**	Not attached	5	5	5	Not attached	4	5	Not attached	**24**	**52**
30's	15	342	Tenofovir Disproxil	300mg	Tablet	Tenoberg	2	2	3	Not attached	5	6	2	2	2	2	2	**28**	Not attached	5	5	5	Not attached	4	5	Not attached	**24**	**52**
14's	16	518	Esomeprazole	40mg	Capsules	Esamal	2	2	3	Not attached	5	6	2	2	2	2	2	**28**	Not attached	5	5	5	Not attached	4	5	Not attached	**24**	**52**
14's	17	522	Pantoprazole	40mg	Tablets	Pantberg	2	2	3	Not attached	5	6	2	2	2	2	2	**28**	Not attached	5	5	5	Not attached	4	5	Not attached	**24**	**52**
10's	18	725	Escitalopram Oxalate	10mg	Tablets	Ei-Ram	2	2	3	Not attached	5	6	2	2	2	2	2	**28**	Not attached	5	5	5	Not attached	4	5	Not attached	**24**	**52**

						Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27															
					Name of the firm	KS Agency Karachi															
S. No.		Product General Parameter				Technical Evaluation Matrix														Product Evaluated Score	Total Technical Score
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation								
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the time of inspection at the warehouse at the tim eof inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** **(Certificate duly attaested by senior executive of the firm)**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US free sale certificate of the quoted products.	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s, Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	5	6	**29**	5	5	5	6	10	10	**41**	**70**
Huaiyin Medi ICL China	1320	Black Braided Silk 17mm, 1/2 circle round bodied taper point needle, strand length 75cm Size 4/0	Black Braided Silk Size 4/0, 16mm ½ Circle Round Body Needle	GLYSILK		Not attached	5	47 Verification QR code is unclear	5	5	6		5	5	145-226 Tender approvals are incomplete	2	10	10	**27**	**32**
Huaiyin Medi ICL China	1325	Black Braided Silk 31mm, ½ circle round bodied, taper point needle, Strand length 75cm Sizes 2/0	Black Braided Silk Size 2/0, 30mm ½ Circle Round Body Needle	GLYSILK		Not attached	5	48 Verification QR code is unclear	5	5	6		5	5	145-226 Tender approvals are incomplete	2	10	10	**27**	**32**
Huaiyin Medi ICL China	1327	Black Braided Silk 31mm, 1/2 circle round bodied taper point needle, Strand length 75cm Size 0	Black Braided Silk Size 0, 30mm ½ Circle Round Body Needle	GLYSILK		Not attached	5	49 Verification QR code is unclear	5	5	6		5	5	145-226 Tender approvals are incomplete	2	10	10	**27**	**32**
Huaiyin Medi ICL China	1328	Black Braided Silk 40mm, ½ circle round bodied taper point needle, Strand length 75cm Sizes 1	Black Braided Silk Size 1, 40mm ½ Circle Round Body Needle	GLYSILK		Not attached	5	50 Verification QR code is unclear	5	5	6		5	5	145-226 Tender approvals are incomplete	2	10	10	**27**	**32**
Huaiyin Medi ICL China	1329	Black Braided Silk 30mm, ½ circle round bodied taper point needle, Strand length 75cm Sizes 1	Black Braided Silk Size 1, 30mm ½ Circle Round Body Needle	GLYSILK		Not attached	5	51 Verification QR code is unclear	5	5	6		5	5	145-226 Tender approvals are incomplete	2	DTL substandard	10	**17**	**22**
Huaiyin Medi ICL China	1330	Black Braided Silk 40mm, 3/8 circle conventional or curved cutting needle, Strand length 75cm Sizes 1	Black Braided Silk Size 1, 40mm 3/8 Curved Cutting Needle	GLYSILK		Not attached	5	52 Verification QR code is unclear	5	5	6		5	5	145-226 Tender approvals are incomplete	2	10	10	**27**	**32**
Huaiyin Medi ICL China	1331	Black Braided Silk 40mm, 1/2 circle round bodied taper point needle, strand length 75cm Size 2	Black Braided Silk Size 2, 40mm ½ Circle Round Body Needle	GLYSILK		Not attached	5	53 Verification QR code is unclear	5	5	6		5	5	145-226 Tender approvals are incomplete	2	10	10	**27**	**32**
Huaiyin Medi ICL China	1357	Polyglycolic Acid 17mm, ½ circle round bodied taper point needle, strand length 70cm Size 5/0	Polyglycolic Acid Size 5/0, 17mm ½ Circle Round Body Needle	GLYTIN		Not attached	5	54 Verification QR code is unclear	5	5	6		5	5	145-226 Tender approvals are incomplete	2	10	10	**27**	**32**
Huaiyin Medi ICL China	1358	Polyglycolic Acid 17mm, ½ circle round bodied needle, Strand length 75cm Size 4/0	Polyglycolic Acid Size 4/0, 16mm ½ Circle Round Body Needle	GLYTIN		Not attached	5	55 Verification QR code is unclear	5	5	6		5	5	145-226 Tender approvals are incomplete	2	10	10	**27**	**32**
Huaiyin Medi ICL China	1360	Polyglycolic Acid 22mm, ½ circle round bodied taper point, Strand length 75cm Size 3/0	Polyglycolic Acid Size 3/0, 20mm ½ Circle Round Body Needle	GLYTIN		Not attached	5	56 Verification QR code is unclear	5	5	6		5	5	145-226 Tender approvals are incomplete	2	DTL substandard	10	**17**	**22**
Huaiyin Medi ICL China	1362	Polyglycolic Acid 30mm, ½ circle round bodied taper point, strand length 75cm Sizes 2/0	Polyglycolic Acid Size 2/0, 30mm ½ Circle Round Body Needle	GLYTIN		Not attached	5	57 Verification QR code is unclear	5	5	6		5	5	145-226 Tender approvals are incomplete	2	10	10	**27**	**32**
Huaiyin Medi ICL China	1363	Polyglycolic Acid 40mm, ½ circle round bodied tapper point needle, strand length 75cm Sizes 0	Polyglycolic Acid Size 0, 40mm ½ Circle Round Body Needle	GLYTIN		Not attached	5	58 Verification QR code is unclear	5	5	6		5	5	145-226 Tender approvals are incomplete	2	10	10	**27**	**32**

Huaiyin Medi ICL China	1365	Polyglycolic Acid 40mm, ½ circle round bodied tapper point needle, strand length 75cm Sizes 1	Polyglycolic Acid Size 1, 40mm ½ Circle Round Body Needle	GLYTIN		Not attached	5	59 Verification QR code is unclear	5	5	6		5	5	145-226 Tender approvals are incomplete	2	10	10	**27**	**32**
Huaiyin Medi ICL China	1366	Polyglycolic Acid 40mm, ½ circle round bodied taper point needle, strand length 75cm Sizes 2	Polyglycolic Acid Size 2, 40mm ½ Circle Round Body Needle	GLYTIN		Not attached	5	60 Verification QR code is unclear	5	5	6		5	5	145-226 Tender approvals are incomplete	2	10	10	**27**	**32**
Huaiyin Medi ICL China	1375	Polypropylene 13mm, 3/8 circle round bodied taper point double armed needle, strand length 60cm Size 6/0	Polypropylene Size 6/0, 13mm 3/8 Circle Taper Point Double Needle	GLYLENE		Not attached	5	61 Verification QR code is unclear	5	5	6		5	137 COA is unclear weihter 1/2 or 3/8	145-226 Tender approvals are incomplete	2	10	10	**22**	**27**
Huaiyin Medi ICL China	1379	Polypropylene 16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm Sizes 4/0	Polypropylene Size 4/0, 16mm 3/8 Curved Cutting Needle	GLYLENE		Not attached	5	62 Verification QR code is unclear	5	5	6		5	5	145-226 Tender approvals are incomplete	2	10	10	**27**	**32**
Huaiyin Medi ICL China	1381	Polypropylene 19mm, 3/8 circle conventional or curved cutting needle, strand length 45cm Sizes 3/0	Polypropylene Size 3/0, 20mm 3/8 Curved Cutting Needle	GLYLENE		Not attached	5	63 Verification QR code is unclear	5	5	6		5	5	145-226 Tender approvals are incomplete	2	10	10	**27**	**32**
Huaiyin Medi ICL China	1382	Polypropylene 26mm, 1/2 circle round bodied taper point double armed needle, strand length 75cm Sizes 3/0	Polypropylene Size 3/0, 26mm ½ Circle Round Body Double Needle	GLYLENE		Not attached	5	64 Verification QR code is unclear	5	5	6		5	5	145-226 Tender approvals are incomplete	2	10	10	**27**	**32**
Huaiyin Medi ICL China	1386	Polypropylene 26mm, 3/8 circle conventional or curved cutting needle, strand length 45cm Sizes 2/0	Polypropylene Size 2/0, 25mm 3/8 Curved Cutting Needle	GLYLENE		Not attached	5	65 Verification QR code is unclear	5	5	6		5	5	145-226 Tender approvals are incomplete	2	10	10	**27**	**32**
Huaiyin Medi ICL China	1388	Polypropylene 30mm, 1/2 circle round bodied taper point needle, strand length 75cm Sizes 2/0	Polypropylene Size 2/0, 30mm ½ Circle Round Body Needle	GLYLENE		Not attached	5	66 Verification QR code is unclear	5	5	6		5	5	145-226 Tender approvals are incomplete	2	10	10	**27**	**32**
Huaiyin Medi ICL China	1390	Polypropylene 60mm, straight cutting needle, strand length 75cm Sizes 2/0	Polypropylene Size 2/0, 60mm Straight Cutting Needle	GLYLENE		Not attached	5	67 Verification QR code is unclear	5	5	6		5	5	145-226 Tender approvals are incomplete	2	10	10	**27**	**32**
Huaiyin Medi ICL China	1392	Polypropylene 40mm, 1/2 circle round bodied taper point needle, strand length 75cm Sizes 1	Polypropylene Size 1, 40mm ½ Circle Round Body Needle	GLYLENE		Not attached	5	68 Verification QR code is unclear	5	5	6		5	5	145-226 Tender approvals are incomplete	2	10	10	**27**	**32**

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name: KAIZEN PHARMACEUTICALS PVT LTD

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters										Total Factory Evaluated	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score					Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month)**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil,	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt.		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**5**	**3**	**4**	**5**	**5**	**37**	**70**
1	9	Tinidazole	Tablet 500mg	Tablet	Tinibact	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0		5	IMS not attached	**15**	**43**
2	45	Ibuprofen	Suspension 200mg/5ml	Suspension	Torfen	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0		5	IMS not attached	**15**	**43**
3	46	Ibuprofen	Suspension 100mg/5ml	Suspension	Torfen	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0		5	IMS not attached	**15**	**43**
4	89	Mycophenolate Mofetil	Tablet 500mg	Tablet	Revograf	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0		5	IMS not attached	**15**	**43**
5	90	Mycophenolate Sodium	Tablet 180mg	Tablet	Actorgan	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0		5	IMS not attached	**15**	**43**
6	91	Mycophenolate Sodium	Tablet 360mg	Tablet	Actorgan	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0		5	IMS not attached	**15**	**43**
7	94	Tacrolimus	Capsule 1mg	Capsule	Unigraf	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0	No supporting documents, pictures of the immediate containers and proof of purchases of the immediate containers have been provided in the bid	5	IMS not attached	**15**	**43**
8	95	Tacrolimus	Capsule 0.5mg	Capsule	Unigraf	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0		5	IMS not attached	**15**	**43**
9	96	Tofacitinib	Tablet 5mg	Tablet	Tofacit	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0		5	IMS not attached	**15**	**43**
10	110	Deferasirox	Tablet 250mg	Tablet	Revisorix	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	Page No. 838	0	0	0		5	IMS not attached	**5**	**33**
11	113	Deferasirox	Tablet 500mg	Tablet	Revisorix	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	Page No. 838	0	0	0		5	IMS not attached	**5**	**33**
12	157	Levocetirizine as dihydrochloride	syrup 2.5mg/5ml	Syrup	Welcet	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0		5	IMS not attached	**15**	**43**
13	158	Levocetirizine HCl	Tablet (5mg)	Tablet	Welcet	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0		5	IMS not attached	**15**	**43**
14	189	Azithromycin	Tablet 250mg	Tablet	Servaz	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	GD is not matchable with COA Page No. 853	0	0	0		5	IMS not attached	**5**	**33**
15	190	Azithromycin	Tablet 500mg	Tablet	Servaz	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	GD is not matchable with COA Page No. 853	0	0	0		5	IMS not attached	**5**	**33**

16	192	Azithromycin	Suspension 200mg/5ml	Suspension	Servaz	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	GD is not matchable with COA Page No. 853	0	0	0	of the immediate containers and proof of purchases of the immediate containers have been provided in the bid	5	IMS not attached	**5**	**33**
17	230	Ciprofloxacin	Tablets 250mg	Tablet	Cipotent	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	GD is not matchable with COA Page No. 862	0	0	0		5	IMS not attached	**5**	**33**
18	231	Ciprofloxacin	Tablets 500mg	Tablet	Cipotent	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	GD is not matchable with COA Page No. 862	0	0	0		5	IMS not attached	**5**	**33**
19	266	Lincomycin HCl	Capsule 500mg	Capsule	Mylinco	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	Not matching Page No. 868	0	0	0		5	IMS not attached	**5**	**33**
20	519	Ondansetron	Tablet 8mg	Tablet	Unisetron	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	GD is older than 24 months	0	0	0		5	IMS not attached	**5**	**33**
21	525	Prucalopride	Tablet 2mg	Tablet	Prucalax	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	5	5	0	0		5	IMS not attached	**15**	**43**
22	533	Zine Sulfate	Syrup 20MG	Syrup	Unizine	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	GD is expiredV33:V40 at page No. 885	0	0	0		5	IMS not attached	**5**	**33**
23	696	Solifenacin As Succinate	Tablet 10mg	Tablet	Vesiwel	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	GD is expired at Page No. 895	0	0	0		5	IMS not attached	**5**	**33**
24	719	Duloxetine HCL	Capsule 30mg	Capsule	Produlox	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	No GD is provided at page No. 901	0	0	0		5	IMS not attached	**5**	**33**
25	720	Duloxetine lcl	Capsule 60mg	Capsule	Produlox	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	No GD is provided at page No. 901	0	0	0		5	IMS not attached	**5**	**33**
26	721	Divalproex Sodium	250mg Tablet	Tablet	Divalpro	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	Not provided in the bid	0	0	0		5	IMS not attached	**5**	**33**
27	722	Divalproex Sodium	500mg tablet	Tablet	Divalpro	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	Not provided in the bid	0	0	0		5	IMS not attached	**5**	**33**
28	801	Doxofylline	Tablet 400mg	Tablet	Profylline	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	GD and COA are not matchable page No. 910-911	0	0	0		5	IMS not attached	**5**	**33**
29	802	Doxofylline	Syrup 100mg/5ml	Syrup	Profylline	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	GD and COA are not matchable page No. 910-911	0	0	0		5	IMS not attached	**5**	**33**
30	912	Osscin Mineral Complex 830mg + Vitamin D (400 IU)	Tablet	Tablet	Ossvit-D	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	GD is older than 24 months page No. 917	0	0	0		5	IMS not attached	**5**	**33**
31	913	Osscin Mineral Complex 250mg + Vitamin D (400 IU)	Suspension	Suspension	Ossvit-D	2	2	3	0	5	6	**2**	**2**	**2**	**2**	**2**	**28**	0	GD is older than 24 months page No. 917	0	0	0		5	IMS not attached	**5**	**33**

Original Mandatory

TECHNICAL EVALUATION PROFORMA, FOR PROCUREMENT OF ANTICANCER MEDICINES IN GOVT. MCC FY 2026-27

		Name of the firm with Complete Address	**Kaizen Pharmaceuticals Karachi**
		Manufacturer / Importer	

		Mandatory Requirements.	**YES / NO**		**In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:**		**YES/NO**	
1		**National Tax Number (NTN) of the Firm for Income Tax, and**			1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and		
2		**Last year Income Tax Return of the Firm; and**			2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.		
3		**Sale Tax Registration Certificate of the Firm; and**			3	Valid DRAP Approved Price List of the quoted item/s.		
4		**Certificate of Professional Tax of the Firm.**						
5		**Certificate of compliance to cold chain requirements from an independent third party (e.g. DRAP, PSQCA, PCSIR, Non-Compliance to international reference standards or absence of Cold Chain requirements shall lead to disqualification of the relevant product that requires cold chain.**						

		In case of being Importers, the Firm should provide attested copies of the following documents also:	**YES/NO**	
1		Valid Drugs Sales License for the importer; and	Yes	
2		Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	Yes	
3		Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	Yes	
4		Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and	Yes	
5		Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods. Non provision of this document shall lead to disqualification of the firm; and	Yes	
6		Valid DRAP approved Price List of the quoted items.	Yes	

		Technical Evaluation Parameters	**Active Pharmaceutical Ingredient source gradation** **(For API or finished product). i) The bidder (local manufacturer / multi-national manufacturer / importer) shall provide Analytical/Quality Assurance/ Approved Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades.** **Certificate of Analysis/ Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreement/ approval with the original manufacturer duly verified/attested by official of the company.** **Detailed purchase trail of the Active Pharmaceutical Ingredient/ Finished product from the claimed source must be submitted (any proof of purchase such as Goods Declaration Certificate along with Airway Bill/ Bill of Lading/Invoice etc.) by the bidder.** **Maximum marks for this criterion are 40.**	**Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW) study Certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities)/ WHO Listed Authorities MLA Countries** **OR** **BE/ BS Certificate with evidence as to its authenticity) from Category A countries.** **Bio-Equivalence (BE) of the quoted product to be conducted against the originator.** **Original Innovator products do not require bio- equivalence certificate and shall get 10 marks automatically.The bidder shall provide the documents to establish the proof of Inventor / originator. All other branded generics require BE studies.** **Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid.** **Maximum marks for this criterion are 10.**	**Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug. In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article)** **Mandatory: Online verification link must be provided to verify the Clinical Trial/ Clinical Studies submitted for the quoted items.**	**Factory/ Importer Based Evaluation Score (MANDATORY)**	**Sample Evaluation by End User Committee** **Samples will be examined per following parameters as follows:** **a. Labelling and Packing Rules 1986** **b. Outer packing** **c. Inner packing** **d. Physical appearance.** **Product which has unsatisfactory packing/labeling will be technically Disqualified.** **Maximum score for this criterion is 1.**	**Past Performance (Last two years).** **i) Good Performance Certificates of these institutions must be produced in order to be eligible for 5 mark per institution upto a maximum of 5 marks.** **ii) Only supply orders will not get any marks.** **iii) The bidders have to undertake that they have never been blacklisted or debarred.** **Maximum marks for this criterion are 5.** **iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.**	**Total Technical Score**
			Category A – Approved By: • United States Food & Drug Administration (USFDA) • European Medicines Agency (EMA) • Medicines & Healthcare Products Regulatory Agency (MHRA), UK • Therapeutic Goods Administration (TGA), Australia • Pharmaceutical Medical Agency (PHARMAC), New Zealand • Pharmaceutical & Medical Devices Agency (PMDA), Japan • Swissmedic Agency For therapeutic drugs (swiss medic), Switzerland • Health Canada • Health Sciences Authority (HAS), Singapore • National Administration of Drugs, Food & Medicines (ANMAT), Argentina Drug Regulatory Authorities of the FIA (Stringent Regulatory Authorities) / WHO Listed Authorities MLA countries	Category B – Approved By: • Agência Nacional de Vigilância Sanitária (ANVS), Brazil • Central Drugs Standard Control Organization (CDSCO), India • Drug Regulatory Authority, Pakistan • National Pharmaceutical Control Bureau (NPCB), Malaysia • Food & Drug Administration, South Korea • Ministry of Health, Egypt • Ministry of Health, Turkey China Food & Drug Administration • Any other source not mentioned in Category-A	Study/Certificate submitted/verified by a Stringent Regulatory Authority. BE testing must be done using at least 12 subjects. Biowaiver is acceptable only for BCS class I drugs and for Category A Country.	No BE/BW certificate obtained. Bid is quoted/quoted from a Non-Stringent country mentioned at S No. 2 above).	No BE/BW Certificate.	In case the study is published in Category "A" journal listed in HEC Journal Recognition System (HJRS) Database (HJRS-S) Standard Operating Procedure Publication Policy, 2024 and List of National Recognized Research Journals by HEC, 3 marks per original research article shall be awarded (maximum up to 6 marks).	In case the study is published in Category "A" journal listed in HEC Journal Recognition System (HJRS) Database (HJRS-S) Standard Operating Procedure Publication Policy, 2024 and List of National Recognized Research Journals by HEC, 2 marks per original research article shall be awarded (maximum up to 6 marks).	Product/original article published in category "A" journal of the HJRS- Journals as per HEC Journals Policy, 2024 and List of National Recognized Research Journals as per HEC shall not be awarded marks.	**Pre Physical inspection of the premises of the bidders The Technical Evaluation Committee shall be carried out in accordance with the Rule 25 (6)(b), SCH-I (C) 3 (d), section V (b)(3) (ii) of the approved BIDS of Govt. MCC FY 2026-27**	satisfactory	unsatisfactory	i) Substantial quantity of supplies of anti-cancer medicines made to private sector Teaching Hospitals (Shaukat Khanum Memorial Cancer Hospital, Shaukat Khanum Hospital, Lahore/ Peshawar, CMH Rawalpindi and Hayatabad Medical Complex, Peshawar (KRL International hospital Islamabad, with Good Satisfactory Performance Certificates from these institutions shall be given 5 marks per institution. Only those who provide good performance certificate issued in the last 24 months. No marks will be given the supply orders except CMH Rawalpindi where supply orders coupled with delivery challans & invoices will be considered for award of marks. 1 mark per agreement up to a maximum of 5 marks	
SOURCE	MCC formulary No.	Generic Name of Item	Strength	Dosage-Form	Brand Name	40	30	10	5	0	9	6	0	5	1	0	5	70
Manufacturer	1405	Cabozantinib (S) - Malate	20mg Tablet	Tablet	Cabozantin		30			The firm was inspected as per technical evaluation criteria for manufacturer of Oncology medicines and General Medicines, and following observations were made: (Oncology medicines Section) There was no production at the time of inspection of the firm, however, the cGMP practices were assessed with the available staff Compromised cGMP Adherence; i. Dust cakes were formed on the floor of changing room of the oncology medicines production section. ii. The production personnel demonstrated inadequate knowledge and understanding of the approved SOPs governing the operation of the BSCO (Bag-in/Bag-Out) contained transfer system utilized in the manufacturing of highly potent oncology products, reflecting deficiencies in cGMP training and operational compliance. iii. The production and Quality Control personnel were found inadequately trained regarding personnel flow controls and operation of air curtain systems designed for containment and prevention of cross-contamination during handling and manufacturing of potent oncology drugs, indicating non-compliance with cGMP requirements relating to personnel qualification and training. iv. An uncovered electrical outlet was observed in the ceiling of the production area, constituting a potential source of contamination and thereby compromising the environmental integrity and contamination control measures required for manufacturing of the quoted products in compliance with cGMP standards. v. Poor documentation compliance was observed in the section. vi. At the time of inspection, no manufacturing operations were in process and there was only one pharmacist present. vii. Personnel deployed in the oncology manufacturing section were inadequately screened for fitness and periodic health examination as required under cGMP guidelines for personnel handling highly potent and hazardous oncology products. viii. No evidence of periodic qualification, revalidation, or performance verification of the purified water treatment and distribution system used for highly potent oncology medicines manufacturing was made available during inspection, indicating non-compliance with cGMP requirements relating to validation and control of critical utility systems. ix. No proper records of routine sanitization and preventive maintenance of the dedicated water treatment and recirculation system handling return water generated during the manufacturing of highly potent oncology medicines were produced before the inspection team, thereby compromising assurance of the quality, contamination control, and suitability of water utilized in oncology production processes. In view of the above the firm is NOT-RECOMMENDED for Oncology Section only.				1			31
Manufacturer	1406	Cabozantinib (S) - Malate	40mg Tablet	Tablet	Cabozantin		30								1			31
Manufacturer	1407	Cabozantinib (S) - Malate	60mg Tablet	Tablet	Cabozantin		30								1			31
Manufacturer	1504	Lenvatinib Mesylate	10mg Capsules	Capsules	Lenvadonib		30								1			31
Manufacturer	1505	Lenvatinib Mesylate	4mg Capsules	Capsules	Lenvadonib		30								1			31
Manufacturer	1578	Nilotinib 200mg Cap	200mg Capsule	Capsules	Nilonib		30								1			31
Manufacturer	1583	Olaparib	150mg Tablet	Tablet	Olarib		30								1			31
Manufacturer	1586	Osimeretinib	Tablet 8mg	Tablet	Usimeriob		30								1			31
Manufacturer	1587	Osimeriob Mesylate	80mg Tablet	Tablet	Osimeriob		30								1			31
Manufacturer	1593	Palbociclib	100mg Tablet	Tablet	Palbolib		30								1			31
Manufacturer	1594	Palbociclib	125mg Tablet	Tablet	Palbolib		30								1			31
Manufacturer	1609	Taxanib	150mg Tablet	Tablet	Tuxolin		30								1			31
Manufacturer	1621	Olaparaciclovir	Tablet 450mg	Tablet	Pirfolgan		30								1			31

Evaluation Criteria for Manufacturers of Cotton & Related Goods for Government MCC 2026-27

Name of Firm: Karim Industries Lahore

		S. No.	General Product Information				Technical Evaluation Matrix															
							Factory Technical Evaluation Parameters										Factory Evaluated Score	Product Evaluation Parameters			Product Evaluated Score	Total Technical Score
							Documents Based Factory Score						Evaluation visit Score									
			MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
								Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e FY 2023-24 or latest. A minimum turnover of PKR 100 million is required for award of marks in this parameter. (The document shall be attested by a Senior executive of the firm)	Functional and effective Airconditioning & Ventilation System as per the requirements laid down by DRAP **(Evaluated by the MCC expert/s at the time of inspection, Non functionality of the Air Conditioning & Ventilation system in specified section shall lead to disqualification of the section or firm)**	Adequate availability of equipment / instruments in QC labs performing relevant official tests as well as compliance to Good laboratory practices (GLP) in all Labs and Current Good Manufacturing Practices (cGMP) throughout the production facility. **(Evaluated by the MCC expert/s at the time of inspection, Non availability of adequate and appropriate equipment / instruments and non-compliance to GLP , cGMP shall lead to disqualification of the relevant section or firm)**	Appropriate storage of raw material, in process and finished goods with compliance to Good storage practices (GSP) **(To be evaluated by the MCC expert/s at the time of inspection, Non compliance to GSP shall lead to disqualification of the relevant section or firm)**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)		
DRAP registration	Corrected formulary number		MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	3	3	**4**	5	3	6	6	6	6	**45**	5	10	10	**25**	**70**
MDMR-000064	969	1	957	Cotton (Surgical) Corded BPC	200gm		Medi Cot	3	3	3	4	5	3	6	6	6	6	**45**	4	10	10	**24**	**69**
	970	2	958	Cotton (Surgical) Corded BPC	100gm		Medi Cot	3	3	3	4	5	3	6	6	6	6	**45**	4	10	10	**24**	**69**
MDME-0000035	971	3	969	Cotton Bandage (Surgical) B.P Type II	6.5cm x 4m		Medi Band	3	3	3	4	5	3	6	6	6	6	**45**	4	10	10	**24**	**69**
MDME-0000035	972	4	960	Cotton Bandage (Surgical) B.P Type II	7.5cm x 4m		Medi Band	3	3	3	4	5	3	6	6	6	6	**45**	4	10	10	**24**	**69**
MDME-0000035	973	5	961	Cotton Bandage (Surgical) B.P Type II	10cm x 4m		Medi Band	3	3	3	4	5	3	6	6	6	6	**45**	4	10	10	**24**	**69**
MDME-0000035	974	6	962	Cotton Bandage (Surgical) B.P Type II	15cm x 4m		Medi Band	3	3	3	4	5	3	6	6	6	6	**45**	4	10	10	**24**	**69**
MDME-0000098	981	7	969	Crepe Bandage	7.5cm x 4.5m		Medi Crepe	3	3	3	4	5	3	6	6	6	6	**45**	4	10	10	**24**	**69**
MDME-0000098	982	8	970	Crepe Bandage	10cm x 4.5m		Medi Crepe	3	3	3	4	5	3	6	6	6	6	**45**	4	10	10	**24**	**69**
MDME-0000098	983	9	971	Crepe Bandage	15cm x 4.5m		Medi Crepe	3	3	3	4	5	3	6	6	6	6	**45**	4	10	10	**24**	**69**
MDME-0000115	1097	10	1082	Gauze Cloth Roll Packing	1m x 20m		Soft Gauze	3	3	3	4	5	3	6	6	6	6	**45**	4	10	10	**24**	**69**
MDME-0000115	1098	11	1083	Gauze Cloth Roll Packing	1m x 40m		Soft Gauze	3	3	3	4	5	3	6	6	6	6	**45**	4	10	10	**24**	**69**
MDMR-000226	1184	12	1163	Paraffin Gauze Dressing (Tulle) with Chlorohexidine (Antiseptic)	10cm x 10cm		Septi Grass Tulle	3	3	3	4	5	3	6	6	6	6	**45**	4	10	10	**24**	**69**
MDMR-000226	1185	13	1164	Paraffin Gauze Dressing (Tulle) with Chlorohexidine (Antiseptic)	15cm x 20cm		Septi Grass Tulle	3	3	3	4	5	3	6	6	6	6	**45**	4	10	10	**24**	**69**
MDMR-000064	1186	14	1165	Paraffine Gauze Dressing (Tulle) with Framycetin (Antibiotic)	10cm x 10cm		Medi Sofra Tulle	3	3	3	4	5	3	6	6	6	6	**45**	4	10	10	**24**	**69**
MDMR-000065	1192	15	1171	Plaster of Paris (POP) Bandage	15cm x 2.7m		Medi Plast	3	3	3	4	5	3	6	6	6	6	**45**	4	10	10	**24**	**69**
MDMR-000065	1193	16	1172	Plaster of Paris (POP) Bandage	10cm x 2.7m		Medi Plast	3	3	3	4	5	3	6	6	6	6	**45**	4	10	10	**24**	**69**
	1217	17	1196-A	Sterile Gauze Dressing Pad (X-Ray Detectable Radiopaque) (BPC) (8ply)	10cm x 10cm		Soft Gauze	3	3	3	4	5	3	6	6	6	6	**45**	4	Non Forumulary	Non Forumulary	**4**	**49**
	1217	18	1196-B	Sterile Gauze Dressing Pad (X-Ray Detectable Radiopaque) (USP-Type-IV) (8ply)	10cm x 10cm		Me Soft Gauze	3	3	3	4	5	3	6	6	6	6	**45**	4	10	10	**24**	**69**
	1218	19	1197	Sterile Gauze Dressing Pad (X-Ray Detectable Radiopaque) (BPC) (8ply)	15cm x 15cm		Soft Gauze	3	3	3	4	5	3	6	6	6	6	**45**	4	Non Forumulary	Non Forumulary	**4**	**49**
MDMR-000067	1219	20	1198	Sterile Gauze Dressing (X-Ray Detectable Radiopaque) (8P)	30cm x 30cm		Medi Lap Sponges	3	3	3	4	5	3	6	6	6	6	**45**	4	Non Forumulary	Non Forumulary	**4**	**49**
MDME-0000116	1220	21	1199-A	Sterile Gauze Dressing Pad (BPC) (8ply)	10cm x 10cm		Soft Gauze	3	3	3	4	5	3	6	6	6	6	**45**	4	10	10	**24**	**69**
MDME-0000117	1220	22	1199-B	Sterile Gauze Dressing Pad (USP-Type-IV) (8ply)	10cm x 10cm		Me Soft Gauze	3	3	3	4	5	3	6	6	6	6	**45**	4	10	10	**24**	**69**
MDME-0000116	1221	23	1200	Sterile Gauze Dressing Pad (BPC) (8ply)	15cm x 15cm		Soft Gauze	3	3	3	4	5	3	6	6	6	6	**45**	4	Non Forumulary	Non Forumulary	**4**	**49**

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm | **LAB DIAGNOSTIC SYSTEM**

Technical Evaluation Matrix

S. No.	Product General Information					Principal's and Importer's Evaluation Parameters								Suppliers Technical Score	Product Technical Evaluation								Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation					Importer's Evaluation				Product Technical Parameters							Product Availability		
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/ies /regulatory body in the case of SRA/WLA countries (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the ware house at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good storage practices (GSP) for storage of finished goods. Functional and effective Air-conditioning & Ventilation System and effective cold chain (thermo-labile drugs). The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Nonadherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s (ware mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC experts at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 15, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies). Trail of principal manufacturer shall be established from the respective GD. CoA and other supporting documents. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of	Valid WHO prequalification and / or Valid product registration in SRA country(ies) / Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) and / or Valid certificate of the availability of the quoted item in the US market. **04 marks shall be awarded in the Primary certificate, and 1 mark for additional certificate, up to a maximum of 06 (04+01+01) marks.** **Certificates on company's own letter heads shall not be acceptable.** **copies of relevant certificates duly attested by the senior executive of the firm)** Online verification link shall	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase: **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	**2**	**2**	**2**	**5**	**5**	**4**	**5**	**5**	**30**	**5**	**5**	**5**	**5**	**6**	**4**	**5**	**5**	**40**	**70**
Nanjing King Friend Biochemcial Pharma CN	2	351	Enoxaparin	40mg	INJ	Vinox 40mg PFS (2PFS's)	0	0	0		0	**4**	**5**	**5**	**14**		DRAP NOC is not attached	0			only Picture attached, COA not attached	Stability study not attested by the Q.C	0	**0**	**14**
Nanjing King Friend Biochemcial Pharma CN	3	352	Enoxaparin	60mg	INJ	Vinox 60mg PFS(2PFS's)	0	0	0		0	**4**	**5**	**5**	**14**		DRAP NOC is not attached	0			only Picture attached, COA not attached	Stability study not attested by the Q.C	0	**0**	**14**
Nanjing King Friend Biochemcial Pharma CN	4	353	Enoxaparin	80mg	INJ	Vinox 80mg PFS (2PFS's)	0	0	0		0	**4**	**5**	**5**	**14**		DRAP NOC is not attached	0			only Picture attached, COA not attached	Stability study not attested by the Q.C	0	**0**	**14**
Nanjing King Friend Biochemcial Pharma CN	5	370	Heparin Sodium	5000 IU/ml	INJ	Hepalid injection 5000IU/ml, 5ml vial	0	0	0		0	**4**	**5**	**5**	**14**		DRAP NOC is not attached	0		**4**	Proof of purchase not attached with COA at page No. 701.	5	0	**9**	**23**
Vins Bioproducts Ltd India	6	595	Diphtheria Anti-Toxin	10,000iu	INJ	Diphtheria Anti-Toxin					0	**4**	**5**	**5**	**14**		GD not attached	0			Proof of purchase not attached with COA at page No. 1078			**0**	**14**
Incepta Pharmaceuticals Vaccine Div, Bangladesh	8	602	Meningococcal Vaccine	-	INJ	Ingovax ACWY						**4**	**5**	**5**	**14**		5	0			COA not attached with proof of pruchase/invoice	Stability studies not attested by the QC		**5**	**19**
Sinovac, Biotech	9	609	Polio Vaccine (Inactivated)	-	INJ	Inactivated Polio Vaccine						**4**	**5**	**5**	**14**		GD not attached	0			COA not attached with proof of pruchase/invoice			**0**	**14**
Changehun Zhuoyi Biological CN	10	611	Purified Vero Cell Rabies Vaccine (PVRV)	2.5IU	INJ	Bioshoot	0	0	0		Calibration certificate not attested by Quality Head	**4**	**5**	**5**	**14**		5	5				5		**15**	**29**
Xian Libang Pharm Co Ltd	12	652	Lipid Fat Emulsion	20%	INJ (INF)	Liposole MCT/LCT-250ML						**4**	**5**	**5**	**14**		5	5			Proof of purchase not attached with immediate continer.			**10**	**24**
Naprod Lifesciences India	1	148	Voriconazole	200mg	INJ	Vencozole 200mg inj	NA	NA	**2**		0	• NAPROD LIFE SCIENCES INDIA (VORIOCONAZOLE INJ 200MG) Original mandatory documents were not presented to the inspection team. • VIRCHOW BIOTECH PVT LTD (IMMUNO GLOBULIN) Original mandatory documents presented are issued after the bid opening date.			**2**	**0**	**5**	**5**	0	**0**	only Picture of immediate container is attached.	Stability studies not performed by the principal manufacturer	0	**10**	**12**
Hualan Biologica Vaccine, CN	11	625	Trivalent Influenza VACCINE	-	INJ	Vironza Vaccine						• HUALAN BIOLOGICAL VACCINE CHINA COPP of the offered products was not apostille/attested, cGMP not presented at the time of inspection.			**0**		5	0			Proof of purchase not attached with immediate continer.			**5**	**5**
Virchow Biotech Pvt Ltd, India	7	599	Human Immunoglobulins for IV administration	5%	INJ	Viglobulin 5% 50 ml					Calibration certificate not attested by Quality Head of the firm	**Based on the above observations the firm is Recommended for its quoted products,** **Except for** **Voriconazole Inj (Naprod Lifesciences India), Human Immunoglobulin (Virchow Biotech Pvt Ltd), Trivalent Influenza Vaccine (Hualan biological vaccine Inc China), Inj. Rituximab 100mg and 500mg (Actero Middle East Iran).**			**0**		5	5			COA not attached with proof of pruchase/invoice for immediate container	Stability studies are not attested by the QC.		**10**	**10**

SCRUTINY REPORT

1130-136	ISO certificates 45001, 14001 and 9001 of the principal manufacturer of M/S Nanjing King Friend Biochemical Pharma China are not from the IAF accredited body.
2413. 416,	Importing country in COPP by USFDA for Enoxaparin is Syrina instead of Pakistan
3641-671	Documents are not fulfilling the advertised criteria as envisaged in column No, 21 of the technical evaluation proforma.
4722-734	Documents are not fulfilling the advertised criteria as envisaged in column No, 21 of the technical evaluation proforma.
5737-748	Documents are not as per advertised criteria.
6755-764	Calibration certificates are not relevant to the prinicipal manufacturer i.e. Vins Bioproducts Ltd.
71085-1203	Calibration certificate not attested by Quality Head of the firm
81646-1647	The scope of Eudra GMP for Incepta Pharmaceuticals does not cover the sterile meningococcal vaccines.
91648-1831	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted item i.e. Meningococcal vaccine are not attached.
101884-1887	COA of Incepta Pharmaceuticals Ltd, not attested from the Quality Head of the firm.
112634-2642	The ISO certificates are not from IAF accredited body and not verifiable online.
123116-3118	The ISO certificates are not from IAF accredited body and not verifiable online.
133147-3190	Certificate of calibration are in chinese language and inconclusive.

TECHNICAL EVALUATION PROFORMA, FOR PROCUREMENT OF ANTICANCER MEDICINES IN GOVT. MCC FY 2026-27

Name of the firm with Complete Address: LAB DIAGNOSTIC SYSTEM

Manufacturer / Importer: IMPORTER

		Mandatory Requirements.	YES / NO		In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:		YES/NO
1		National Tax Number (NTN) of the Firm for Income Tax, and	YES		1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and	YES
2		Last year Income Tax Return of the Firm; and	YES		2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition;	YES
3		Sale Tax Registration Certificate of the Firm; and	NO		3	Valid DRAP Approved Price List of the quoted item/s.	YES
4		Certificate of Professional Tax of the Firm.	YES				
5		Certificate of compliance to cold chain standards issued by an authorized third party (e.g. DRAP, PSQCA, PCSIR. Non-Compliance or non-submission of valid certificate of compliance of Cold Chain requirements shall lead to disqualification of the relevant product that requires cold chain.	NO				

		In case of being Importers, the Firm should provide attested copies of the following documents also:	YES/NO	
1		Valid Drugs Sales License for the importer; and	YES	
2		Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	YES	Except Rituximab 100mg and 500mg, both are registered after the bid opening
3		Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and		
4		Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin. Non-provision of the certificate/ certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and		
5		Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods. Non provision of this document shall lead to disqualification of the firm; and		
6		Valid DRAP/approved Price List of the quoted items.		

			Technical Evaluation Parameters			Active Pharmaceutical Ingredient source gradation (For API or finished product), i) The bidder (local manufacturer / multi-national manufacturer / importer) shall provide Analytical/Quality Assurance/ Approval Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades. Certificate of Analysis/ Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreement/ approval with the original manufacturer duly attested/verified by official of the company. Detailed purchase trail of the Active Pharmaceutical Ingredient/ Finished product from the claimed source must be submitted (any proof of purchase such as Goods Declaration Certificate along with Airway Bill/ Bill of Lading/Invoice etc.) by the bidder. Maximum marks for this criterion are 40.	Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW) Study/Certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities)/ WHO Listed Authorities WLA Countries BE/BS Certificate with evidence as to its authenticity) from Category A countries. Bio-Equivalence (BE) of the quoted product to be conducted against the originator. Original innovator products do not require bio- equivalence certificate and shall get 10 marks automatically.The bidder shall provide the documents to establish the proof of inventor/ originator. All other branded generics require BE studies Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid. Maximum marks for this criterion are 10.	Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug, In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article) Mandatory: Online verification link must be provided to verify the Clinical Trial/ Clinical Studies submitted for the quoted items.	Factory/ Importer Based Evaluation Score (MANDATORY)	Sample Evaluation by End User Committee Samples will be examined per following parameters as follows: a. Labelling and Packing Rules 1986 b. Outer packing c. Inner packing d. Physical appearance. Product which has unsatisfactory packing/labeling will be technically Disqualified. Maximum score for this criterion is 1.	Past Performance (Last two years). i) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks. ii) Only supply orders will not get any marks. iii) Poor Performance Certificates from those who have been blacklisted or debarred. Maximum marks for this criterion are 5. iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TMO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.	Total Technical Score
						Category A – Approved By: • United States Food & Drug Administration (US FDA) • European Medicines Agency (EMA) • Medicines & Health Care Products Regulatory Agency (MHRA), UK • Therapeutic Goods Administration (TGA), Australia • Pharmaceutical Medical Agency (PMDA)/(MLIT), Japan • Pharmaceutical & Medical Devices Agency (PMDA), Japan • Swissmedic, Switzerland • Health Canada • Health Sciences Authority (HAS), Singapore • National Administration of Drugs, Food & Medical Technology (ANMDMT), Romania Drug Regulatory Authorities of the SRA, Stringent Regulatory Authorities) / WHO Listed Authorities WLA countries	Category B – Approved By: • Agência Nacional de Vigilância Sanitária (ANVS), Brasil • Central Drug Standard Control Organization (CDSCO), India • Drug Regulatory Authority, Pakistan • National Pharmaceutical Control Bureau (NPCB), Malaysia • Food & Drug Administration, South Korea • Ministry of Health, Egypt • Ministry of Health, Turkey • China Food & Drug Administration • Any other source not mentioned in Category-A	Study/Certificate accepted/certified by a Category A Country Regulatory Authority, BE study must be conducted in at least 12 subjects. Bio-waiver is acceptable only in injectable forms if issued by Category A Country.	BE/BS/BW Certificate obtained for a quoted product from Category B Country (as mentioned at S No. 1 above)	BE/BS/BW certificate.	In case the study is published in Category "N" journal listed in HEC Journal Recognition System (HJRS) 'Database' Journals & Publications Policy 2023 and List of National Recognized Journals as per HEC, 2 marks per original research article shall be awarded (maximum up to 6 marks).	In case the study is published in Category "N" journal listed in HEC Journal Recognition System (HJRS) 'Database' Journals & Publications Policy 2023 and List of National Recognized Journals as per HEC, 2 marks per original research article shall be awarded (maximum up to 6 marks).	Evidence/original article published in category "N" journal of the list of HEC recognized in Publication Policy 2023 and List of National Recognized Journals as per HEC, 2 marks per published article shall be awarded (maximum up to 6 marks).	For Physical inspection of the premises of the bidders (Manufacturer/Importer) shall be carried out in accordance with PR 29.4(b), SCC 9.2(C) & (I), Section V (1) (3) (4) of the approved RDD of Govt. MCC FY 2026-27	Satisfactory	Unsatisfactory	a) Substantial quantity of supplies of anti-cancer medicines made to private sector Teaching Hospitals namely: The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore / Peshawar, CMH Rawalpindi, Rawalpindi Institute of Cardiology, Peshawar, Indus International Hospital Islamabad, with Good/Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued to them by the above mentioned institutions. b) Supply orders except CMH Rawalpindi where supply orders coupled with delivery challans & invoices will be considered for award of marks. c) mark per agreement up to a maximum of 5 marks	
SOURCE	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	40	30	10	5	0	9	6	0	5	1	0	5	70	
Acrovo Middle East Iran	1456	Bevacizumab 100 mg	100mg	Inj	Biocizin		30			0			0	5	0			35	sample not provided
Acrovo Middle East Iran	1457	Bevacizumab 400 mg	400mg	Inj	Biocizin		30			0			0	5	0			35	sample not provided
Nanjing King Friend Biochemical Pharmaceutical Pvt Ltd	1217	Fulvestrant 250 mg PFS -2	250mg	Inj	Faclozade		30			0			0	5	1			36	
Acrovo Middle East Iran	1525	Rituximb 140 mg	140mg	Cap.	Anti-mirika		30			0			0	5	1			36	
Jiangsu Hengrui Pharmaceutical Co Ltd China	1276	Nab-Paclitaxel	100mg	Inj	NabPaclad		30			0			0	5	1			36	
Acrovo Middle East Iran	1278	Nilotinib 200 mg Cap -28	200mg-28s Packing	Capsule	Nonib		30			0			0	5	1			36	
Acrovo Middle East Iran	1284	Palbociclib 125 mg Tab -21	125mg-21 tabs	Tablet	Bloci		30			0			0	5	0			35	Manufacturer and importer information not available on Outer carton
Jiangsu Hengrui Pharmaceutical Co Ltd China	1600	HC G-Asparaginase	375IRU	Inj	Wegarpa		30			0			0	5	1		1	37	
Acrovo Middle East Iran	1618	Rituximab 100 mg	100mg	Inj	Rituxiver		30			0			0	• ACTORO MIDDLE EAST IRAN All mandatory documents of the quoted items in original were checked, and the warehouse was inspected by the inspection team for evaluation of adherence to the required criteria of physical inspection for importers and found complying except Pharmacovigi, billing and billing which are registered with DRAP after bid opening 14-4-26	0			30	sample not provided
Acrovo Middle East Iran	1619	Rituximab 500 mg	500mg	Inj	Rituxiver		30			0			0		0			30	sample not provided

Scrutiny Report	pdf page 1/1002-1088 2/1055 3 44322	The COA for Bevacizumab, Bevzilnib are of Hetero Lab instead of Acrovo Middle East, Iran. Validity of the COPP of Ibrutinib 140mg capsule is not mentioned on the certificate. The COA for Palbociclib is of Hetero Lab India instead of Acrovo Middle East Iran. The performance certificate issued by Shaukat Khanum Hospital is older than the advertised criteria.	

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: Legacy Pharmaceuticals Peshawar

S. No.		Product General Information				Technical Evaluation Matrix																				
						Factory Technical Evaluation Parameters												Product Evaluation Parameters								
						Documents Based Factory Score						Factory Evaluation Visit Score					Total Factory Evaluated Score	Product Technical Parameters							Total Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly	Stability studies of quoted item/s duly attested by the QC incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
1's	137	Fluconazole	150mg	Caps.	Fluzox				0	66-97 (Valid Calibration Certificates are not attested by Quality head of the firm)	11-The document are not attested by a Senior executive of the firm	2	2	2	2	2	**10**	0	157 GD and AWB are not matching	0	0	0	Alu-Lau foil not attached	Not attached	0	**0**	**0**
14's	161	Montelukast	5mg	Tab.	Montekast				0	66-97 (Valid Calibration Certificates are not attested by Quality head of the firm)	11-The document are not attested by a Senior executive of the firm	2	2	2	2	2	**10**	0	5		0	0	Alu-Lau foil not attached	Not attached	0	**5**	**10**
6's	189	Azithromycin	250mg	Tab.	Legzith				0	66-97 (Valid Calibration Certificates are not attested by Quality head of the firm)	11-The document are not attested by a Senior executive of the firm	2	2	2	2	2	**10**	0	5		0	0	Alu-Lau foil not attached	Not attached	0	**5**	**10**
10's	189	Azithromycin	250mg	Caps.	Legzith				0	66-97 (Valid Calibration Certificates are not attested by Quality head of the firm)	11-The document are not attested by a Senior executive of the firm	2	2	2	2	2	**10**	0	5		0	0	Not attested by the Senior executive of the firm	Not attached	0	**5**	**10**
6's	190	Azithromycin	500mg	Tab.	Legzith				0	66-97 (Valid Calibration Certificates are not attested by Quality head of the firm)	11-The document are not attested by a Senior executive of the firm	2	2	2	2	2	**10**	0	5		0	0	Alu-Lau foil not attached	Not attached	0	**5**	**10**
15ml	192	Azithromycin	200mg/5ml	Dry Susp.	Legzith				0	66-97 (Valid Calibration Certificates are not attested by Quality head of the firm)	11-The document are not attested by a Senior executive of the firm	2	2	2	2	2	**10**	0	5		0	0	Alu-Lau foil not attached	Not attached	0	**5**	**10**
5's	204	Cefixime	400 mg	Caps.	Lexime				0	66-97 (Valid Calibration Certificates are not attested by Quality head of the firm)	11-The document are not attested by a Senior executive of the firm	2	2	2	2	2	**10**	0	5		0	0	Not attested by the Senior executive of the firm	Not attached	0	**5**	**10**
30ml	205	Cefixime	100mg/5ml	Dry Susp	Lexime	**58-59-60 (Not attested by senior executive of the firm, Mandatory)**			0	66-97 (Valid Calibration Certificates are not attested by Quality head of the firm)	11-The document are not attested by a Senior executive of the firm	2	2	2	2	2	**10**	0	5	Not duly attested by the senior executive of the firm	0	0	Alu-Lau foil not attached	Not attached	0	**5**	**10**
30ml	206	Cefixime	200mg/5ml	Dry Susp	Lexime				0	66-97 (Valid Calibration Certificates are not attested by Quality head of the firm)	11-The document are not attested by a Senior executive of the firm	2	2	2	2	2	**10**	0	5		0	0	(Documents duly attested by the Senior executive of the firm).	Not attached	0	**5**	**10**
10's	230	Ciprofloxacin	250 mg	Tab.	Legocip				0	66-97 (Valid Calibration Certificates are not attested by Quality head of the firm)	11-The document are not attested by a Senior executive of the firm	2	2	2	2	2	**10**	0	5		0	0	Alu-Lau foil not attached	Not attached	0	**5**	**10**
10's	231	Ciprofloxacin	500mg	Tab.	Legocip				0	66-97 (Valid Calibration Certificates are not attested by Quality head of the firm)	11-The document are not attested by a Senior executive of the firm	2	2	2	2	2	**10**	0	5		0	0	Alu-Lau foil not attached	Not attached	0	**5**	**10**
10's	264	Levofloxacin	250 mg	Tab.	Levobac				0	66-97 (Valid Calibration Certificates are not attested by Quality head of the firm)	11-The document are not attested by a Senior executive of the firm	2	2	2	2	2	**10**	0	5		0	0	Alu-Lau foil not attached	Not attached	0	**5**	**10**
10's	265	Levofloxacin	500mg	Tab.	Levobac				0	66-97 (Valid Calibration Certificates are not attested by Quality head of the firm)	11-The document are not attested by a Senior executive of the firm	2	2	2	2	2	**10**	0	5		0	0	Alu-Lau foil not attached	Not attached	0	**5**	**10**
5's	275	Moxifloxacin	400mg	Tab.	Legamox				0	66-97 (Valid Calibration Certificates are not attested by Quality head of the firm)	11-The document are not attested by a Senior executive of the firm	2	2	2	2	2	**10**	0	5		0	0	Alu-Lau foil not attached	Not attached	0	**5**	**10**

14's	517	Omeprazole	40 mg	Capsule	Ompecid		0	66-97 (Valid Calibration Certificates are not attested by Quality head of the firm)	11-The document are not attested by a Senior executive of the firm	2	2	2	2	2	**10**	0	5		0	0	Not attested by the Senior executive of the firm	Not attached	0	**5**	**10**
14's	518	Esomeprazole	40mg	Cap.	Lesozol		0	66-97 (Valid Calibration Certificates are not attested by Quality head of the firm)	11-The document are not attested by a Senior executive of the firm	2	2	2	2	2	**10**	0	5		0	0	Not attested by the Senior executive of the firm	Not attached	0	**5**	**10**

Original Mandatory forms in Hard are not submitted to the MCC

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: LINEAR PHARMA ISLAMABAD

Technical Evaluation Matrix

S. No.	Product General Information					Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities).	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner:		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**5**	**3**	**4**	**5**	**5**	**37**	**70**
	11	Atracurium	10mg/ml 5ml	Inj.	Atracure	0	0	0	0	0	2	The inspection team made the following observations during inspection: 1. The entire plant was found in a static condition, with no production activities in operation at the time of inspection. 2. No valid calibration tag was found affixed to the weighing balance installed in the RMS area. 3. The UV light installed in the dispensing booth was found non-functional at the time of inspection. 4. The material transfer room was found without an HVAC system. 5. Multiple cracks were observed in the production area, indicating inadequate facility maintenance. 6. In-process materials/items stored in the quarantine area were found without date identification and corresponding Batch Manufacturing Record (BMR) details. 7. The accelerated stability chamber was found non-functional. 8. During the review of stability studies for Inj. Amacef 2gm (B.No. I-1064), assay testing during batch manufacturing was performed by HPLC, while stability samples were analyzed using a non-pharmacopeial UV spectrophotometric method. A similar observation was noted for Cefepime injections. This inconsistency in analytical methodology compromises the reliability, specificity, and validity of the stability data. 9. Various chemicals in the Quality Control Laboratory were found expired. **Based on the above observations the firm is NOT RECOMMENDED**							**2**	0	NA	0	0	**0**	0	0	0	**0**	**2**
	19	Ketamine	50mg/ml, 10ml	Inj.	Ketnaar	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	0	0	**0**	**2**
	47	Ketorolac	30mg/ml	Inj.	Ketomol	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	5	0	**5**	**7**
	51	Meloxicam	15mg	Tab.	Orthicam	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	5	0	**5**	**7**
	52	Meloxicam	7.5mg	Tab.	Orthicam	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	5	0	**5**	**7**
	137	Fluconazole	150mg	Cap.	Forcon	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	5	0	**5**	**7**
	141	Itraconazole	100mg	Cap.	Itracure	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	5	0	**5**	**7**
	160	Montelukast	10mg	Tab.	Linakast	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	5	0	**5**	**7**
	161	Montelukast	5mg	Tab.	Linakast	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	0	0	**0**	**2**
	166	Amikacin	100mg	Inj.	Romika	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	0	0	**0**	**2**
	168	Amikacin	500mg	Inj.	Romika	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	0	0	**0**	**2**
	207	Cefoperazone Sulbactam	1gm	Inj.	Linzone	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	0	0	**0**	**2**
	208	Cefoperazone Sulbactam	2gm	Inj.	Linzone	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	5	0	**5**	**7**
	209	Cefotaxime	250mg	Inj.	Lifrax	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	5	0	**5**	**7**
	210	Cefotaxime	500mg	Inj.	Lifrax	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	0	0	**0**	**2**
	211	Cefotaxime	1gm	Inj.	Lifrax	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	5	0	**5**	**7**
	215	Ceftazidime	500mg	Inj.	Lifzim	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	0	0	**0**	**2**
	216	Ceftazidime	1gm	Inj.	Lifzim	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	0	0	**0**	**2**
	218	Ceftriaxone	1gm	Inj.	Amacef	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	0	0	**0**	**2**
	219	Ceftriaxone	2gm	Inj.	Amacef	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	5	0	**5**	**7**
	220	Cefuroxime	1.5gm	Inj.	E-Xim	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	0	0	**0**	**2**
	222	Cefuroxime	125mg	Susp.	E-Xim	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	0	0	**0**	**2**
	342	Tenofovir	300mg	Tab.	Uni-Vir	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	5	0	**5**	**7**
	275	Moxifloxacin	400mg	Tab.	Averox	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	5	0	**5**	**7**
	453	Methyldopa	250mg	Tab.	M-Dopa	0	0	0	0	0	2						**2**	0	5	5	0	**0**	0	0	0	**10**	**12**
	510	Itopride	150mg	Tab.	Itodil	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	0	0	**0**	**2**
	519	Ondansetron	8mg	Tab.	Periset	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	0	0	**0**	**2**
	520	Ondansetron	8mg	Inj.	Periset	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	5	0	**5**	**7**
	686	Febuxostat	80mg	Tab.	Stat-Lin	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	0	0	**0**	**2**
	697	Tamsulosin	0.4mg	Cap.	Lamt	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	5	0	**5**	**7**
	719	Duloxetine	30mg	Cap.	Dulox	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	5	0	**5**	**7**
	720	Duloxetine	60mg	Cap.	Dulox	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	5	0	**5**	**7**
	725	Escitalopram	10mg	Tab.	S-Linear	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	5	0	**5**	**7**
	735	Levetiracetam	250mg	Tab.	Levetec	0	0	0	0	0	2						**2**	0	5	5	0	**0**	0	0	0	**10**	**12**
	736	Levetiracetam	500mg	Tab.	Levetec	0	0	0	0	0	2						**2**	0	5	5	0	**0**	0	0	0	**10**	**12**

	743	Olanzapine	10mg	Tab.	Zopera	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	5	0	**5**	**7**
	742	Olanzapine	5mg	Tab.	Zopera	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	5	0	**5**	**7**
	753	Pregabalin	50mg	Cap.	Ismalin	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	5	0	**5**	**7**
	754	Pregabalin	75mg	Cap.	Ismalin	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	5	0	**5**	**7**
	755	Pregabalin	150mg	Cap.	Ismalin	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	5	0	**5**	**7**
	761	Risperidone	2mg	Tab.	Lirc	0	0	0	0	0	2						**2**	0	NA	0	0	**0**	0	0	0	**0**	**2**
	203	Cefepime	1gm	Inj.	Lin-Pime	Toll Manufactured, page 71											**0**										Toll Manufactured, page 71
	202	Cefepime	500mg	Inj.	Lin-Pime	Toll Manufactured, page 71											**0**										Toll Manufactured, page 71

ALL MCC FORMULARY NUMBER are INCORRECT

Page 61-183 The DRAP registrations of the following items are not attached: Ketamine, Montelukast 5mg, Cefepime, Tenofovir, Moxifloxacin, Methyldopa, Itopride 150mg, Ondansetron 8mg tab, Duloxetine, Olanzapine, Risperidone

ISOs ARE NOT FROM PNAC ACCREDITED BODY

CALIBRATION CERTIFICATE OF STABILITY CHAMBERS IS ATTACHED, only (1186 PAGE)

A bulk of IRRELEVANT DOCUMENTS ATTACHED IN THE BID,

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: LISKO PAKISTAN Pvt. Ltd.

S. No.	Product General Information					Factory Technical Evaluation Parameters — Documents Based Factory Score				Factory Evaluation Visit Score					Total Factory Evaluated	Technical Evaluation Matrix				Product Evaluation Parameters — Product Technical Parameters					Total Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber.(Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-**	Raw material, in-process and finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC experts).	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC experts at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 500ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant	Certificate of Analysis (CoA) issued by manufacturer of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient's (API) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where those documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission.	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: B. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded.	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s or Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**3**	**5**	**5**	**5**	**4**	**37**	**70**
	50	Mefenamic Acid 50mg/5ml Suspension	50mg	suspension	Parsamic	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	0	4	5	0	**19**	**47**
	66	Tramadol Hcl 37.5mg + Paracetamol 325mg tablet	37.5/325mg	tablet	Tramofix Plus Tablet	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	Paracetamol GD is local, hence no API marks are applicable	4	5	0	**19**	**47**
	141	Itraconazole 100mg capsule	100mg	capsule	Conatis Capsule	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	0	4	5	0	**19**	**47**
	145	Nystatin 100,000 units/ml Oral Drops		Drops	Mystatin Oral Drops	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	Page No. 316 needs clarification	0	4	5	0	**19**	**47**
	147	Terbinafine tablet 250mg	250mg	tablet	Turbo tablet	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	Page No. 356 needs clarification	0	4	5	0	**19**	**47**
	153	Cefdinire tablet 10mg	10mg	tablet	Cefin Tablet	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	0	0	4	5	0	**19**	**47**
	154	Cefdinire syrup 5mg/5ml	5mg/5ml	syrup	Cefinish Syrup	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	0	0	4	5	0	**19**	**47**
	155	Chloropheniramine Maleate 4mg tablet	4mg	tablet	Histagic Tablet	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	0	0	4	5	0	**19**	**47**
	156	Chlorophenirammine Maleate 2mg/5ml syrup	2mg/5ml	syrup	Histagic Syrup	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	0	0	4	5	0	19	**47**
	169	Amoxicillin 250mg capsule	250mg	capsule	Amoxipen Capsule	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		GD provided is for micronized powder 552	0	0	0	4	5	0	9	**37**
	170	Amoxicillin 500mg capsule	500mg	capsule	Amoxipen Capsule	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		GD provided is for micronized powder 553	0	0	0	4	5	0	9	**37**
	171	Amoxicillin 125mg/5ml dry suspension	125mg/5ml	suspension	Amoxipen Dry Suspension	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	0	0	4	5	0	19	**47**
	173	Amoxicillin 250mg/5ml dry suspension	250mg/5ml	suspension	Amoxipen Forte suspension	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	0	0	4	5	0	19	**47**
	185	Ampicillin 250mg + Cloxacillin 250mg Capsule	250mg	Capsule	Penciclox Capsule	**2**	**2**	**3**	Not attached	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**	not attached	Only GD of Ampicillin is provided at Page No. 680. No cloxacillin GD available	0	0	0	4	5	0	9	**37**
	188	Ampicillin 125mg + Cloxacillin 125mg Capsule	125+125mg	Capsule	Penciclox Capsule	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		Only GD of Ampicillin is provided at Page No. 680. No cloxacillin GD available	0	0	0	4	5	0	9	**37**
	256	Amoxycillin 250mg + Flucloxacillin 250mg capsule	250+250mg	capsule	Flumoxipen Capsule	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		t of amoxicillin is micronized at page 7	0	API is not clear provided at page 743.	0	4	5	0	9	**37**
	275	Mixoflroxacin tablet 400mg	400mg	tablet	Mawrik Tablet	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	API needs clarification at page 780	0	4	5	0	19	**47**
	371	Iron polymaltose complex 100mg tablet	100mg	tablet	Full Iron Tablet	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	0	0	4	5	0	19	**47**
	372	Iron III hydroxide Polymaltose complex eq.to elemental Iron 50mg/5ml syrup	50mg/5ml	syrup	Full Iron Syrup	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	0	0	4	5	0	19	**47**
	401	Amlodipine 5mg tablet	5mg	tablet	Amlis Tablet	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		GD at page 869 is not clear	0	0	0	4	5	0	9	**37**
	402	Amlodipine 10mg tablet	10mg	tablet	Amlis Tablet	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		GD at page 907 is not clear	0	0	0	4	5	0	9	**37**
	503	Domperidone tablet 10mg	10mg	tablet	Domis Tablet	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	0	0	4	5	0	19	**47**
	504	Domperidone 5mg/5ml suspension	5mg/5ml	suspension	Domis-SP suspension	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	API is not clear provided at page 990	0	4	5	0	19	**47**
	505	Omiteverine 40mg tablet	40mg	tablet	Omitab Tablet	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	API is not clear provided at page 1029	0	4	5	0	19	**47**
	517	Omeprazole 40mg capsule	40mg	capsule	Omez Capsule	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	0	0	4	5	0	19	**47**
	518	Esomeprazole 40mg capsule	40mg	capsule	Esmen Capsule	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	0	0	4	5	0	19	**47**
	532	Zinc sulphate tablet 20mg	20mg	tablet	Zinkrot Tablet	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	0	0	4	5	0	24	**52**
	533	Zinc Sulphate syrup 20mg/5ml	20mg/5ml	syrup	Zinkrot Syrup	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	0	0	4	5	0	19	**47**
	572	Rhinoprost 200mg tablet	200mg	tablet	Loecrot Tablet	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	0	0	4	5	0	19	**47**
	697	Famiudron Capsule 0.4mg	0.4mg	tablet	Mytamax Capsule	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	API is not clear provided at page No. 1258	0	4	5	0	19	**47**
	810	Salbutamol tablet 2mg	2mg	tablet	Mentol Tablet	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	API is not clear provided at page No. 1287	0	4	5	0	19	**47**
	812	Salbutamol syrup 2mg/5ml	2mg/5ml	syrup	Mentol Syrup	**2**	**2**	**3**		**5**	**6**	**2**	**2**	**2**	**2**	**2**	**20**		5	5	API is not clear provided at page No. 1287	0	4	5	0	19	**47**

Bidding firm name not mentioned on the mandatory CoA

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm | **Lucky Core Industries, Hattar**

S. No.		Product General Information				Technical Evaluation Matrix																					
						Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulatory No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, in-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC experts). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (Form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better (**Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the QA incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICT accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulatory No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
50's	469	Propranolol Tablet	10 mg	Oral	federal Tablet	2	2	3	5	5	6	2	2	2	2	2	**33**	0	0	0	0	0	0	0	0	**0**	**33**
50's	469	Propranolol Tablet	40 mg	Oral	federal Tablet	2	2	3	5	5	6	2	2	2	2	2	**33**	0	0	0	0	0	0	0	0	**0**	**33**
28's	471	Rosuvastatin Tablet	10 mg	Oral	Xenestor Tablet	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	0	0	0	**15**	**48**
1's	557	Hydrocortisone Injection	100 mg	Injectable	Hy-Cortisone Injection	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	5	0	0	2	0	**24**	**57**
1's	558	Hydrocortisone Injection	250 mg	Injectable	Hy-Cortisone Injection	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	5	0	0	2	0	**24**	**57**
1's	569	Methyl Prednisolone Injection	500 mg	Injectable	Hy-solone Injection	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	0	0	0	**15**	**48**
1000's	576	Prednisolone Tablet	5 mg	Oral	Deltacortril Tablet	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	0	0	0	**16**	**49**
150 ml	674	Sodium Acid Citrate Syrup	150 ml	Oral	Diralka Syrup	2	2	3	5	5	6	2	2	2	2	2	**33**	0	5	5	0	0	0	0	0	**20**	**53**

Pagelnamarks
MandatoryThe documents attached for the award of marks for column 5, 6, 7,9, 19, 20, 21, 22, and 24 are not duly attested by the senior executive of the firm
20PO is attached instead of Call Deposit Reciept or Security Deposit reciept contrary to Para o5 of the MCC NIT.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm | **Lucky Core Industries, Hattar**

S. No.		Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Technical Evaluation Matrix										Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Evaluation Parameters											
																		Product Technical Parameters											
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan .. **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the Firm).**	Raw material, in-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP) **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal /manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient's (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better (**Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the QA/C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
29	427's	407	Atenolol Tablet	50 mg	Oral	Tenormin Tablet	60 SITE Plant BV	60 SITE Plant BV	3	5	5	6	2	2	2	2	2	**29**		5		5	0	5	1	5	**11**	**40**
30	428's	408	Atenolol Tablet	100 mg	Oral	Tenormin Tablet	60 SITE Plant BV	60 SITE Plant BV	3	5	5	6	2	2	2	2	2	**29**		5		5	0	5	1	5	**11**	**40**
31	468's	448	Lisinopril Tablet	5 mg	Oral	Zestril Tablet	60 SITE Plant BV	60 SITE Plant BV	3	5	5	6	2	2	2	2	2	**29**		0		0	0	0	0	0	**0**	**29**
32	469's	449	Lisinopril Tablet	10 mg	Oral	Zestril Tablet	60 SITE Plant BV	60 SITE Plant BV	3	5	5	6	2	2	2	2	2	**29**		0		0	0	0	0	0	**0**	**29**

PageRemarks

MandatoryThe documents attached for the award of marks for column 5, 6, 7,9, 19, 20, 21, 22, and 24 are not duly attested by the senior exectutive of the firm

20PO is attached instead of Call Deposit Reciept or Security Deposit reciept contrary to Para 05 of the MCC NIT.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: Lucky Core Industries, Hattar

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm)**.	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
1	5's	47	Ketorolac Injection	30 mg	Injectable	Ketrodil Injection	2	2	3	5	5	6	2	2	2	2	2	**33**		5	5	0	0		5	1319 less than 1 % share	**15**	**48**
2	200's	48	Mefenamic Acid Tablet	250 mg	Oral	Ponstan Tablet	2	2	3	5	5	6	2	2	2	2	2	**33**		5	5	0	0		5	1333 Less than 1 % share	**15**	**48**
3	200's	49	Mefenamic Acid Tablet	500 mg	Oral	Ponstan Tablet	2	2	3	5	5	6	2	2	2	2	2	**33**		5	5	0	0		5	1333 Less than 1 % share	**15**	**48**
4	90 ml	50	Mefenamic Susp	50 mg	Oral	Ponstan Susp	2	2	3	5	5	6	2	2	2	2	2	**33**		5	5	0	0		1325 Not attached	1334 Less than 1 % share	**10**	**43**
5	56 ml	145	Nystatin Oral Drops	100,000 IU	Oral	Nilstat Drops	2	2	3	5	5	6	2	2	2	2	2	**33**		5	5	5	0		5	3	**23**	**56**
6	100's	169	Amoxycillcin Capsule	250 mg	Oral	Wymox Capsule	2	2	3	5	5	6	2	2	2	2	2	**33**		5	5	0	0	1385 Caps Shells Not attached	5	1	**16**	**49**
7	50's	170	Amoxycillcin Capsule	500 mg	Oral	Wymox Capsule	2	2	3	5	5	6	2	2	2	2	2	**33**		5	5	0	0	1385 Caps Shells Not attached	5	1	**16**	**49**
8	90 ml	171	Amoxycillcin Susp	125 mg	Oral	Wymox Suspension	2	2	3	5	5	6	2	2	2	2	2	**33**		1414 Invoice of Compacted attached	0	0	0	1420 Invoice & COA not attached	5	1	**6**	**39**
9	90 ml	173	Amoxycillcin Susp	250 mg	Oral	Wymox Suspension	2	2	3	5	5	6	2	2	2	2	2	**33**		1414 Invoice of Compacted attached	0	0	0	1420 Invoice & COA not attached	5	1	**6**	**39**
10	6's	189	Azithromycin Capsule	250 mg	Oral	Azocyd Capsule	2	2	3	5	5	6	2	2	2	2	2	**33**		5	5	5	0	Not attached	5	1481 Less than 1% share	**20**	**53**
11	6's	190	Azithromycin Capsule	500 mg	Oral	Azocyd Capsule	2	2	3	5	5	6	2	2	2	2	2	**33**		5	5	5	0	Not attached	5	1481 Less than 1% share	**20**	**53**
12	15 ml	192	Azithromycin Susp	200 mg	Oral	Azocyd Susp	2	2	3	5	5	6	2	2	2	2	2	**33**		5	5	5	0	Not attached	5	1481 Less than 1% share	**20**	**53**
13	5's	204	Cefixime Capsule	400 mg	Oral	Corinef Capsule	2	2	3	5	5	6	2	2	2	2	2	**33**		Not attached	Not attached	Not attached	0	Not attached	Not attached	1481 Less than 1% share	**0**	**33**
14	30 ml	205	Cefixime Susp	100 mg	Oral	Corinef Suspension	2	2	3	5	5	6	2	2	2	2	2	**33**		Not attached	Not attached	Not attached	0	Not attached	Not attached	1481 Less than 1% share	**0**	**33**
15	1's	207	Cefoperazone+Salbactam Injection	1 gm	Injectable	Zonbac Injection	2	2	3	5	5	6	2	2	2	2	2	**33**		5	5	1523 API source is for ampicillin and	0	0	5	1533 Less than 1% share	**15**	**48**
16	1's	208	Cefoperazone+Salbactam Injection	2 gm	Injectable	Zonbac Injection	2	2	3	5	5	6	2	2	2	2	2	**33**		5	5	1523 API source is for ampicillin and	0	0	5	1533 Less than 1% share	**15**	**48**
17	1's	218	Ceftriaxone Injection	1 gm	Injectable	Fortexone Injection	2	2	3	5	5	6	2	2	2	2	2	**33**		5	5	1572 API source is older than 10	0	1574 Invoice & COA not attached	5	1579 Less than 1% share	**15**	**48**
18	1's	219	Ceftriaxone Injection	2 gm	Injectable	Fortexone Injection	2	2	3	5	5	6	2	2	2	2	2	**33**		5	5	1572 API source is older than 10	0	1574 Invoice & COA not attached	1576 Not attached	1579 Less than 1% share	**10**	**43**
19	12's	224	Cephradine	250 mg	Oral	Ceptin Capsule	2	2	3	5	5	6	2	2	2	2	2	**33**		5	5	Not attached	0	0	5	1631 Less than 1% share	**15**	**48**
20	12's	225	Cephradine	500 mg	Oral	Ceptin Capsule	2	2	3	5	5	6	2	2	2	2	2	**33**		5	5	Not attached	0	0	5	1631 Less than 1% share	**15**	**48**
21	90 ml	228	Cephradine	125 mg	Oral	Ceptin Susp	2	2	3	5	5	6	2	2	2	2	2	**33**		1621 Cephradine compacted attached	1621 Cephradine compacted attached	Not attached	0	0	5	1631 Less than 1% share	**5**	**38**
22	90 ml	229	Cephradine	250 mg	Oral	Ceptin Susp	2	2	3	5	5	6	2	2	2	2	2	**33**		1621 Cephradine compacted attached	1621 Cephradine compacted attached	Not attached	0	0	5	1631 Less than 1% share	**5**	**38**
23	1's	260	Imipenem+Cilastatin Sodium	500 mg	Injectable	Stanem Injection	2	2	3	5	5	6	2	2	2	2	2	**33**		5	5	5	0	0	5	1695 Less than 1 % share	**20**	**53**
24	1's	272	Meropenem Injection	500 mg	Injectable	Merpen Injection	2	2	3	5	5	6	2	2	2	2	2	**33**		5	5	5	0	1723 Invoice and COA not attached	5	1	**21**	**54**
25	1's	273	Meropenem Injection 1 gm	1 gm	Injectable	Merpen Injection	2	2	3	5	5	6	2	2	2	2	2	**33**		5	5	5	0	1723 Invoice and COA not attached	5	1	**21**	**54**
26	5's	275	Moxfloxacin Tablet 400 mg	400 mg	Injectable	Moximax Tablet	2	2	3	5	5	6	2	2	2	2	2	**33**									**0**	**33**
27	1's	279	Piperacillin + Tazobactam	2.25 gm	Injectable	Tazopip Injection	2	2	3	5	5	6	2	2	2	2	2	**33**		5	5	5	0	2	5	1791 Less than 1 % share	**22**	**55**
28	1's	280	Piperacillin + Tazobactam	4.5 gm	Injectable	Tazopip Injection	2	2	3	5	5	6	2	2	2	2	2	**33**		5	5	5	0	2	5	1791 Less than 1 % share	**22**	**55**

PageRemarks

MandatoryThe documents attached for the award of marks for column 5, 6, 7,9, 19, 20, 21, 22, and 24 are not duly attested by the senior exectutive of the firm

20PO is attached instead of Call Deposit Reciept or Security Deposit reciept contrary to Para o5 of the MCC NIT.

Bidding firm name not mentioned on the mandatory CDR

						Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27														
					Name of the firm	M.Islam & Sons Malakand I.V Cannula FY 2026-27														
S. No.		Product General Parameter				Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the time of inspection at the warehouse at the tim eof inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** **(Certificate duly attested by senior executive of the firm)**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US free sale certificate of the quoted products, **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **Online verification link shall be provided.** **(copies of relevant certificates duly attested by the senior executive of the firm)**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	5	6	**29**	5	5	5	6	10	10	**41**	**70**
1	1122.	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	**16G**	Tuoren IV Cannula		67-IV Cannula is not covered in the scope	5	Not attached	5	5	6	**21**	**1301-GD not attached**	0	Not attached	2	0	10	**12**	**33**
2	1123.	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	**18G**	Tuoren IV Cannula			5	Not attached	5	5	6	**21**	**5**	5	Not attached	2	10	10	**32**	**53**
3	1125.	I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing, The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	**18G**	Tuoren IV Cannula			5	Not attached	5	5	6	**21**	**5**	5	Not attached	2	10	10	**32**	**53**
4	1126.	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	**20G**	Tuoren IV Cannula			5	Not attached	5	5	6	**21**	**5**	5	Not attached	2	DTL substandard	10	**22**	**43**
5	1128.	I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing, The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	**20G**	Tuoren IV Cannula			5	Not attached	5	5	6	**21**	**5**	5	Not attached	2	10	10	**32**	**53**
6	1129.	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	**22G**	Tuoren IV Cannula			5	Not attached	5	5	6	**21**	**5**	5	Not attached	2	10	10	**32**	**53**
7	1131.	I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing, The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	**22G**	Tuoren IV Cannula			5	Not attached	5	5	6	**21**	5	5	Not attached	2	10	10	**32**	**53**
8	1132.	I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing, The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	**24G**	Tuoren IV Cannula			5	Not attached	5	5	6	**21**	**5**	5	Not attached	2	DTL substandard	10	**22**	**43**
9	1134.	I.V Cannula (Sterile having wings with heparin stopper inside sterilized blister packing, The cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	**24G**	Tuoren IV Cannula			5	Not attached	5	5	6	**21**	**5**	5	Not attached	2	DTL substandard	10	**22**	**43**

M/s Henan Tuoren Medical Device Co., Ltd

Weiyuan industrial zone, Menggang, Changyuan county, 453400 Henna Province, People Republic of China

Original Mandatory forms in Hard are not submitted to the MCC

						Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27														
					Name of the firm	M.Islam & Sons (Sutures) FY 2026-27													
S. No.		Product General Parameter				Technical Evaluation Matrix												Product Evaluated Score	Total Technical Score
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score							
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the time of inspection at the warehouse at the tim eof inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** **(Certificate duly attaested by senior executive of the firm)**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note, Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US free sale certificate of the quoted products, **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **Online verification link shall be provided.** **(copies of relevant certificates duly attested by the senior executive of the firm)**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	5	6	**29**	5	5	5	6	10	10	**41**	**70**
1	1320	Black Braided Silk	17mm, 1/2 circle round bodied taper point needle, strand length 75cm 4/0		RTMED SILK	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
2	1321	Black Braided Silk	30mm, 1/2 circle round bodied taper point needle, Strand length 75cm 3/0		RTMED SILK	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
3	1322	Black Braided Silk	26mm, 1/2 circle round bodied taper point needle, Strand length 75cm 3/0		RTMED SILK	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
4	1323	Black Braided Silk	26mm, 3/8 circle conventional or curved cutting needle, Strand length 45 cm 3/0		RTMED SILK	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
5	1324	Black Braided Silk	17mm, 1/2 circle round bodied taper point needle, Strand length 75cm 3/0		RTMED SILK	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
6	1325	Black Braided Silk	31mm, 1/2 circle round bodied, taper point needle, Strand length 75cm 2/0		RTMED SILK	3	5		5	5	6	**24**	0	0		2	Sample NA	Sample NA	**2**	**26**
7	1326	Black Braided Silk	26mm, 1/2 circle round bodied taper point needle, Strand length 75cm 2/0		RTMED SILK	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
8	1327	Black Braided Silk	31mm, 1/2 circle round bodied taper point needle, Strand length 75cm 0		RTMED SILK	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
9	1328	Black Braided Silk	40mm, 1/2 circle round bodied taper point needle, Strand length 75cm 1		RTMED SILK	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
10	1329	Black Braided Silk	30mm, 1/2 circle round bodied taper point needle, Strand length 75cm 1		RTMED SILK	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
11	1330	Black Braided Silk	40mm, 3/8 circle conventional or curved cutting needle, Strand length 75cm 1		RTMED SILK	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
12	1331	Black Braided Silk	40mm, 1/2 circle round bodied taper point needle, strand length 75cm 2		RTMED SILK	3	5	157 US FDA link attached instead of certificate	5	5	6	**24**	5	5	Not attached	2	10	10	**32**	**56**
13	1335	Polyglactin 910/PGLA	13mm, 1/2 circle round bodied taper point needle, strand length 45 cm 6/0		RTMED PGLA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
14	1337	Polyglactin 910/PGLA	13mm, 3/8 circle conventional or curved cutting needle, Strand length 45 cm 5/0		RTMED PGLA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
15	1338	Polyglactin 910/PGLA	13mm, 1/2 circle round bodied taper point needle, strand length 45 cm 5/0		RTMED PGLA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
16	1339	Polyglactin 910/PGLA	16mm, 3/8 circle conventional or curved cutting needle, strand length 75cm 4/0		RTMED PGLA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
17	1340	Polyglactin 910/PGLA	19mm, 3/8 circle conventional or curved cutting needle, strand length 45cm 4/0		RTMED PGLA	3	5		5	5	6	**24**	0	0		2	Sample NA	Sample NA	**2**	**26**
18	1341	Polyglactin 910/PGLA	19mm, 3/8 circle reverse cutting needle, strand length 45cm 4/0		RTMED PGLA	3	5		5	5	6	**24**	0	0		2	Sample NA	Sample NA	**2**	**26**
19	1342	Polyglactin 910/PGLA	22mm, 1/2 circle round bodied taper point, strand length 70 cm 4/0		RTMED PGLA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
20	1343	Polyglactin 910/PGLA	16mm, 3/8 circle conventional or curved cutting needle, Strand length 75cm 3/0		RTMED PGLA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
21	1344	Polyglactin 910/PGLA	19mm, 3/8 circle reverse cutting needle, Strand length 75cm 3/0		RTMED PGLA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
22	1345	Polyglactin 910/PGLA	22mm, 1/2 circle round bodied taper point, strand length 70 cm 3/0		RTMED PGLA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
23	1346	Polyglactin 910/PGLA	26mm, 1/2 circle round bodied taper point, strand length 70 cm 3/0		RTMED PGLA	3	5		5	5	6	**24**	0	0		2	Sample NA	Sample NA	**2**	**26**
24	1347	Polyglactin 910/PGLA	26mm, 1/2 circle round bodied taper point, strand length 70 cm 2/0		RTMED PGLA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**

25	1348	Polyglactin 910/PGLA	31mm, 1/2 circle round bodied taper point, Strand length 70 cm 2/0		RTMED PGLA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
26	1349	Polyglactin 910/PGLA	36mm, 1/2 circle round body taper cut needle, strand length 90 cm 2/0		RTMED PGLA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
27	1350	Polyglactin 910/PGLA	45mm, 1/2 circle round bodied taper cut needle, strand length 75 cm 2/0		RTMED PGLA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
28	1351	Polyglactin 910/PGLA	36mm, 1/2 circle round bodied taper point, strand length 90 cm 0		RTMED PGLA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
29	1352	Polyglactin 910/PGLA	40mm, 1/2 circle round bodied taper point, strand length 90 cm 0		RTMED PGLA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
30	1353	Polyglactin 910/PGLA	40mm, 1/2 circle round bodied taper point, strand length 70 cm 1		RTMED PGLA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
31	1354	Polyglactin 910/PGLA	45mm, 1/2 circle round bodied taper cut needle, strand length 75cm 1		RTMED PGLA	3	5	157 US FDA link attached instead of certificate	5	5	6	**24**	5	5	Not attached	2	10	10	**32**	**56**
32	1355	Polyglactin 910/PGLA	40mm, 1/2 circle round bodied taper point, strand length 90 cm 2		RTMED PGLA	3	5		5	5	6	**24**	0	0		2	10	10	**22**	**46**
33	1356	Polyglactin 910/PGLA	45mm, 1/2 circle round bodied taper cut needle, strand length 75cm 2		RTMED PGLA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
34	1357	Polyglycoic Acid	17mm, 1/2 circle round bodied taper point needle, Strand length 70cm 5/0		RTMED PGA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
35	1358	Polyglycoic Acid	17mm, 1/2 circle round bodied needle, Strand length 75cm 4/0		RTMED PGA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
36	1359	Polyglycoic Acid	22mm, 1/2 circle round bodied tapper point needle, Strand length 75cm 4/0		RTMED PGA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
37	1360	Polyglycoic Acid	22mm, 1/2 circle round bodied taper point, strand length 75 cm 3/0		RTMED PGA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
38	1361	Polyglycoic Acid	25mm, 1/2 circle round bodied taper point, strand length 75 cm 2/0		RTMED PGA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
39	1362	Polyglycoic Acid	30mm, 1/2 circle round bodied taper point, strand length 75 cm 2/0		RTMED PGA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
40	1363	Polyglycoic Acid	40mm, 1/2 circle round bodied tapper point needle, strand length 75 cm 0		RTMED PGA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
41	1364	Polyglycoic Acid	30mm, 1/2 circle round bodied tapper point needle, strand length 75 cm 1		RTMED PGA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
42	1365	Polyglycoic Acid	40mm, 1/2 circle round bodied tapper point needle, strand length 75 cm 1		RTMED PGA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
43	1366	Polyglycoic Acid	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm 2		RTMED PGA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
44	1367	Polyglycoic Acid	48mm, 1/2 circle round bodied taper point needle, strand length 75 cm 2		RTMED PGA	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
45	1372	Polypropylene	9.3mm, 3/8 circle round bodied taper point double armed needle, strand length 60cm 7/0		RTMED PROLENE	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
46	1374	Polypropylene	13mm, 1/2 circle round bodied taper point double armed needle, strand length 60cm 6/0		RTMED PROLENE	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
47	1375	Polypropylene	13mm, 3/8 circle round bodied taper point double armed needle, strand length 60cm 6/0		RTMED PROLENE	3	5		5	5	6	**24**	0	0		2	Sample NA	Sample NA	**2**	**26**
48	1376	Polypropylene	16mm, 3/8 circle cutting needle, strand length 90cm 6/0		RTMED PROLENE	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
49	1377	Polypropylene	13mm, 1/2 circle round bodied taper point double armed needle, strand length 60cm 5/0		RTMED PROLENE	3	5		5	5	6	**24**	0	0		2	Sample NA	Sample NA	**2**	**26**
50	1378	Polypropylene	16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm 5/0		RTMED PROLENE	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
51	1379	Polypropylene	16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm 4/0		RTMED PROLENE	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
52	1380	Polypropylene	26mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm 4/0		RTMED PROLENE	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
53	1381	Polypropylene	19mm, 3/8 circle conventional or curved cutting needle, strand length 45cm 3/0		RTMED PROLENE	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
54	1382	Polypropylene	26mm, 1/2 circle round bodied taper point double armed needle, strand length 75cm 3/0		RTMED PROLENE	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
55	1383	Polypropylene	30 mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm 3/0		RTMED PROLENE	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
56	1384	Polypropylene	26mm, 1/2 circle round bodied taper point needle, strand length 75cm 2/0		RTMED PROLENE	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
57	1385	Polypropylene	26mm, 3/8 circle reverse cutting needle, strand length 45cm 2/0		RTMED PROLENE	3	5		5	5	6	**24**	0	0		2	Sample NA	Sample NA	**2**	**26**
58	1386	Polypropylene	26mm, 3/8 circle conventional or curved cutting needle, strand length 45cm 2/0		RTMED PROLENE	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
59	1387	Polypropylene	26mm, 1/2 circle round bodied taper cut double armed needle, strand length 75cm 2/0		RTMED PROLENE	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
60	1388	Polypropylene	30mm, 1/2 circle round bodied taper point needle, strand length 75cm 2/0		RTMED PROLENE	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**
61	1389	Polypropylene	55mm, straight cutting needle, strand length 75cm 2/0		RTMED PROLENE	3	5		5	5	6	**24**	5	5		2	10	10	**32**	**56**

62	1390	Polypropylene	60mm, straight cutting needle, strand length 75cm 2/0		RTMED PROLENE	3	5
63	1391	Polypropylene	40mm, 1/2 circle round bodied taper point needle, strand length 75cm 0		RTMED PROLENE	3	5
64	1392	Polypropylene	40mm, 1/2 circle round bodied taper point needle, strand length 75cm 1		RTMED PROLENE	3	5
65	1393	Polyamide	6.5mm 3/8 circle micropoint spatula double needle strand length 30cm 10/0		RTMED POLYAMIDE	3	5

5	5	6	**24**	5	5		2	10	10	**32**	**56**
5	5	6	**24**	5	5		2	10	10	**32**	**56**
5	5	6	**24**	5	5		2	10	10	**32**	**56**
5	5	6	**24**	5	5		2	10	10	**32**	**56**

M/s Shandong Haidike Medical Products Co., Ltd

88 meters west of Tainfu Road, Dongcheng office, Shan County Heze City Shandong Province, China

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27														
Name of the firm						M.Islam & Sons (Mesh) FY 2026-27														
						Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevent certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
1	1427	Polypropylene	Polypropylene Mesh 30cm*30cm	JS BANA		0	5	284-Link attached instead of certificate	5	6	6	**22**	5	5	Not attached	Not attached	2	16	**28**	**50**
2	1428	Polypropylene	Polypropylene Mesh 15cm*15cm	JS BANA		0	5		5	6	6	**22**	5	5			2	16	**28**	**50**
3	1430	Polypropylene	Polypropylene Mesh 6cm*11cm	JS BANA		0	5		5	6	6	**22**	5	5			2	16	**28**	**50**

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27														
					Name of the firm	MA Traders NDI Peshawar FY 2026-27														
						Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies)	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
		MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
Ningbo Great Mountain	1	933.	Bacterial filter, HME Filter and Viral filter (HCV, HBS+HIV etc.)	Adult	MED SURG		3	5	93, 199, 467-Link attached instead of Certificate, or US FDA agent certificate attached	5	6	6	**25**	5		Tender approvals need co-relation of all documents	205- The manufacturing site is not	2	16	**23**	**48**
Guangdong Baihe	2	984.	CVP Line (Single Lumen)	Different Sizes	MED SURG			5		5	6	6	**22**	5	5			2	16	**28**	**50**
Guangdong Baihe	3	985.	CVP Line (Double Lumen)	Different Sizes	MED SURG			5		5	6	6	**22**	5	5			2	16	**28**	**50**
Guangdong Baihe	4	986.	CVP Line (Triple Lumen)	Different Sizes	MED SURG			5		5	6	6	**22**	5	5		instead of F	2	16	**28**	**50**
Guangdong Baihe	5	992.	Dialysis Catheters (Double Lumen)	16cm x 12F	MED SURG			5		5	6	6	**22**	5	5			2	16	**28**	**50**
Guangdong Baihe	6	993.	Dialysis Catheters (Double Lumen)	20cm x 12F	MED SURG			5		5	6	6	**22**	5	5			2	16	**28**	**50**
Plastimed	7	1030.	Disposable Sterile Arterial Blood Gas Syringe with Needle (Blister Packing)	2ml	Plastimed			5		5	6	6	**22**	5	5		actory speci	2	16	**28**	**50**
Ningbo Great Mountain	8	1059.	Disposable Non-Sterile Nitrile Examination Gloves (Powdered)	Size: Small, Medium, Large	MED SURG		3	5		5	6	6	**25**	5	5		205- The manufacturing site is	2	16	**28**	**53**
Shanghai Zhichen	9	1071.	E.C.G. Sticking Electrodes	50MM	PRIMAX		Not attached	Not attached		5	6	6	**17**	5	5			2	16	**28**	**45**
Plastimed	10	1135.	IV Flow Regulator	(Dial a Flow)	Plastimed			5		5	6	6	**22**	5	5		actory speci	2	16	**28**	**50**
Ningbo Great Mountain	11	1156.	Nasal Oxygen Cannula	Neonatal	MED SURG		3	5		5	6	6	**25**	5	5		205- The manufacturing site is	2	16	**28**	**53**
Ningbo Great Mountain	12	1157.	Nasal Oxygen Cannula	Pediatric	MED SURG		3	5		5	6	6	**25**	5	5			2	16	**28**	**53**

Ningbo Great Mountain	13	1158.	Nasal Oxygen Cannula	Adult	MED SURG		3	5	93, 199, 467-Link attached instead of Certificate, or US FDA agent certificate attached	5	6	6	**25**	5	5	Tender approvals need co-relation of all documents		2	16	**28**	**53**
Ningbo Great Mountain	14	1159.	Nebulizer mask With Chamber and Tubing	Pediatric	MED SURG		3	5		5	6	6	**25**	5	5			2	16	**28**	**53**
Ningbo Great Mountain	15	1160.	Nebulizer mask With Chamber and Tubing	Adult	MED SURG		3	5		5	6	6	**25**	5	5			2	16	**28**	**53**
Ningbo Great Mountain	16	1169.	Non-Rebreathing Mask	Adult	MED SURG		3	5		5	6	6	**25**	5	5			2	16	**28**	**53**
Ningbo Great Mountain	17	1170.	Non-Rebreathing Mask	Pediatric	MED SURG		3	5		5	6	6	**25**	5	5			2	16	**28**	**53**
Ningbo Great Mountain	18	1175.	Oxygen Mask	Adult	MED SURG		3	5		5	6	6	**25**	5	5			2	16	**28**	**53**
Ningbo Great Mountain	19	1176.	Oxygen Mask	Pediatric	MED SURG		3	5		5	6	6	**25**	5	5			2	16	**28**	**53**
Plastimed	20	1177.	Oropharyngeal Airway	Size 0	Plastimed			5		5	6	6	**22**	5	5			2	16	**28**	**50**
Plastimed	21	1178.	Oropharyngeal Airway	Size 1	Plastimed			5		5	6	6	**22**	5	5			2	16	**28**	**50**
Plastimed	22	1179.	Oropharyngeal Airway	Size 2	Plastimed			5		5	6	6	**22**	5	5			2	16	**28**	**50**
Plastimed	23	1180.	Oropharyngeal Airway	Size 3	Plastimed			5		5	6	6	**22**	5	5		actory speci	2	16	**28**	**50**
Plastimed	24	1181.	Oropharyngeal Airway	Size 4	Plastimed			5		5	6	6	**22**	5	5			2	16	**28**	**50**
Plastimed	25	1182.	Oropharyngeal Airway	Size 5	Plastimed			5		5	6	6	**22**	5	5			2	16	**28**	**50**
Plastimed	26	1183.	Oropharyngeal Airway	Size 6	Plastimed			5		5	6	6	**22**	5	5			2	16	**28**	**50**
Ningbo Great Mountain	27	1210.	Suction Connecting Tube with Yankauer Suction Handle/ Tip	3M & 2.5M	MED SURG		3	5		5	6	6	**25**	5	5		205- The manufacturing site is not matching with the registeration	2	16	**28**	**53**
Ningbo Great Mountain	28	1223.	Sterile Suction Catheter	5 Fr	MED SURG		3	5		5	6	6	**25**	5	5			2	16	**28**	**53**
Ningbo Great Mountain	29	1224.	Sterile Suction Catheter	6 Fr	MED SURG		3	5		5	6	6	**25**	5	5			2	16	**28**	**53**
Ningbo Great Mountain	30	1225.	Sterile Suction Catheter	8 Fr	MED SURG		3	5		5	6	6	**25**	5	5			2	16	**28**	**53**
Ningbo Great Mountain	31	1226.	Sterile Suction Catheter	10 Fr	MED SURG		3	5		5	6	6	**25**	5	5			2	16	**28**	**53**
Ningbo Great Mountain	32	1227.	Sterile Suction Catheter	12 Fr	MED SURG		3	5		5	6	6	**25**	5	5			2	16	**28**	**53**
Ningbo Great Mountain	33	1228.	Sterile Suction Catheter	14 Fr	MED SURG		3	5		5	6	6	**25**	5	5			2	16	**28**	**53**
Ningbo Great Mountain	34	1229.	Sterile Suction Catheter	16 Fr	MED SURG		3	5		5	6	6	**25**	5	5			2	16	**28**	**53**
Ningbo Great Mountain	35	1230.	Sterile Suction Catheter	18 Fr	MED SURG		3	5		5	6	6	**25**	5	5			2	16	**28**	**53**
Ningbo Great Mountain	36	1232.	Stop Cock 3 way with extension	"15cm Extenssion Tube"	MED SURG		3	5		5	6	6	**25**	5	5			2	16	**28**	**53**
Ningbo Great Mountain	37	1290.	Urine Bag With let	"2000ml With T-Valve / Push-Pull	MED SURG		3	5		5	6	6	**25**	5	5			2	16	**28**	**53**
Ningbo Great Mountain	38	1293.	Ventilator Circuit	Without and Water Trap	MED SURG		3	5		5	6	6	**25**	5	5			2	16	**28**	**53**

M/s Guangdong Baihe Medical Technology Co., Ltd

No. 89, Taoyuan East Road, Nanhai, Foshan, Guang

M/s Ningbo Great Mountain Medical Instruments Co., Ltd.

M/s Shanghai Zhichen Medical Technology Co., Ltd.,

No. 686 Nanfeng highway, Fengxiang District, Shanghai China.

M/s Plasti-med Ltd

Sti. Deri OSB mahallesi, yan sanayl cad. No. 13 tuzla anonym sirketi/ Islambul, Turkey.

TECHNICAL EVALUATION PROFORMA, FOR PROCUREMENT OF ANTICANCER MEDICINES IN GOVT. MCC FY 2026-27

Name of the firm with Complete Address	MACTER INTERNATIONAL KARACHI
Manufacturer / Importer	MANUFACTURER

	Mandatory Requirements.	YES / NO		In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:		YES/NO	In case of being Importers, the Firm should provide attested copies of the following documents also:		YES/NO	
1	National Tax Number (NTN) of the Firm for Income Tax, and	YES		1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP), and	YES	1	Valid Drugs Sales License for the importer; and		
2	Last year Income Tax Return of the Firm; and	YES		2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.	YES	2	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and		
3	Sale Tax Registration Certificate of the Firm; and	YES		3	Valid DRAP Approved Price List of the quoted item/s.	NO	3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and		
4	Certificate of Professional Tax of the Firm.	YES					4	Valid cGMP Certificate of Pharmaceutical Product (COPP) / Gel Certificate/Export Permit/Free Sale Letter of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and		
5	Certificate of compliance to cold chain requirements from manufacturing third party e.g. DRAP, PSQCA, PCSIR. Non-Compliance to international reference standards or absence of Cold Chain requirements shall lead to disqualification of the relevant product that requires cold chain.	NO					5	Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods. Non provision of this document shall lead to disqualification of the firm; and		
							6	Valid DRAP approved Price List of the quoted items.		

			Technical Evaluation Parameters			Active Pharmaceutical Ingredient source gradation (For API or finished product). i) The bidder (local manufacturer / imported) shall provide Analytical/Quality Assurance/ Approval Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades. Certificate of Analysis/ Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importer must submit agency agreement/ approval with the original manufacturer duly attested/verified by official of the company. Detailed purchase trail of the Active Pharmaceutical Ingredient / Finished product from the claimed source must be submitted (any proof of purchase such as Goods Declaration Certificate along with Airway Bill/ Bill of Lading/invoice etc.) by the bidder. Maximum marks for this criterion are 40.		Bio-Equivalence (BE) / Bio- Similar (BS) or bio-waiver (BW) Study/Certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities)/ WHO Listed Authorities WLA Countries BE/ BS Certificate with evidence as to its authenticity(s) from Category A countries. Bio-Equivalence (BE) of the quoted product to be conducted against the originator. Original innovator products do not require bio- equivalence certificate and would get 10 marks automatically.The bidder shall provide the documents as proof of the proof of inventor/ originator. All other branded generics require BE studies Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid. Maximum marks for this criterion are 10.	Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug. In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article) Mandatory: Online verification link must be provided to verify the Clinical Trial/ Clinical Studies submitted for the quoted items.	Factory/ Importer Vaued Evaluation Score (MANDATORY)	Sample Evaluation by End User Committee Samples will be examined per following parameters as follows: a. Labeling and Packing Rules 1986 b. Shelf life c. Inner packing d. Physical appearance. Product which has unsatisfactory labeling/ labeling will be technically disqualified. Maximum score for this criterion is 1.		Post Performance (Last two years). i) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks. ii) Only supply orders will not get any marks. iii) The bidders have to undertake that they have never been blacklisted or debarred. Maximum marks for this criterion are 5. iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWC marks shall be deducted for poor past performance irrespective of successful supplies or Performance at any other institute.	Total Technical Score
				Category A – Approved By: • United States Food & Drug Administration (USFDA) • European Medicines Agency (EMA) • Medicines & Healthcare Products Regulatory Agency (MHRA), UK • Therapeutic Goods Administration (TGA), Australia • Pharmaceutical Medical Agency (PHARMAC), New Zealand • Pharmaceutical & Medical Devices Agency (PMDA), Japan • Swiss Agency For Therapeutic drugs (Swiss medic), Switzerland • Health Canada • Health Sciences Authority (HAS), Singapore • National Administration of Drugs, Food & Medical technology (ANMAT), Argentina Drug Regulatory Authorities of Per WA (Stringent Regulatory Authorities) / WHO Listed Authorities WLA countries	Category B – Approved By: • Agência Nacional de Vigilância Sanitária (ANVS), Brasil • Central Drugs Standard Organization (CDSCO), India • Drug Regulatory Authority, Pakistan • National Pharmaceutical Control Bureau (NPCB), Malaysia • Food & Drug Administration, South Korea • Ministry of Health, Egypt • Ministry of Health, Russia • China Food & Drug Administration • Any other source not mentioned in Category-A	Study/Certificate completed/ certified by a Drug Regulatory Authority. BE testing must be done using at least 12 subjects. Bio-waiver is acceptable only for products mentioned in the list Category A Country	Bio-Wiv/ Certificate obtained for a quoted product from Category A country. (Latest / Renewed as in No. 1 above)	No Bio-Wiv/ BW Certificate.	In case the study is published in the Pakistan Journal listed in HEC Journal Recognition System (HJRS) Database/ Scientific Publication Policy 2016 and List of National Recognized Research Journals by HEC. 7 marks per original/ research article shall be awarded maximum up to 9 marks).	Access the study is published in Category "B" journal listed in HEC Journal Recognition System (HJRS) Database/ Scientific Publication Policy 2016 and List of National Recognized Research Journals by HEC. 7 marks per original/ research article shall be awarded maximum up to 9 marks).	Review/ original research article guidelines as per HEC Journal of the HJRS/ Scientific Publication Policy 2016 and List of National Recognized Research Journals as per HEC shall not be awarded marks.	The Physical Inspection of the premises of the bidders (Manufacturer/ Importer) shall be carried out in accordance with the SOPs of the DMC of PC, PMDC-2019 (2) (3) (5) of the approved Rules of Govt. MCC FY 2026-27	Satisfactory	Unsatisfactory	a. Substantial quantity of supplies of anti-cancer medicines made to private sector/ Teaching Hospitals (Minimum supplies of 1 million rupees) i.e. Aga Khan Khanum Hospital, Lahore / Peshawar, CMH Rawalpindi and Hayatabad Medical Complex, Peshawar, Shifa International hospital Islamabad, with Good Satisfactory Performance Certificates from these institutions must be produced in order to be eligible for 1 mark per institution who provide good performance certificate issued in the last 24 months. No marks will be given. b. Supplies in Khyber Pakhtunkhwa where supply orders coupled with delivery challans & invoices will be considered for award of marks. c. 1 mark per agreement up to a maximum of 5 marks.	
SOURCE	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	40	30	10	5	0	9	6	0	5	1	0	5	70
Shandong Anxin China, Guangxi Kingday China	1471	Capecitabine	500 mg	Tab.	Xeloda	30				0			0	5	Toll Manufacturing		0	30
Intas India	1601	Pegylated Filgrastim	6 mg	Injection	Pegstim	30				0			0	5	Toll Manufacturing		0	30

scrutiny report
1)Documents of 2 different sources of Capecitabine are attached.
2)Capecitabine is manufactured by Pharmasol as mentioned in Registration of the product. Toll Manufactured items are not allowed in MCC bidding

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: MACTER INTERNATIONAL KARACHI

S. No.	Product General Information					Technical Evaluation Matrix: Factory Technical Evaluation Parameters — Documents Based Factory Score						Factory Evaluation Visit Score					Total Factory Evaluated Score	Product Evaluation Parameters — Product Technical Parameters								Total Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month)**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm)**.	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
	99	Zoledronic Acid	4 mg	injection	Macdronic 4 mg	2	2	3	4	5	6	2	2	2	2	2	**32**	0	5	5	0	0	Image NA	5	1	**16**	**48**
	160	Montelukast Sodium	10 mg	Tablets	MNTK Tabs 10mg	2	2	3	4	5	6	2	2	2	2	2	**32**	0	AWB not matching with GD- Page 198	0	0	0	Image NA	5	1	**6**	**38**
	351	Enoxaparin Sodium	40mg	injection	Hepanox 40mg	2	2	3	4	5	6	2	2	2	2	2	**32**	0	5	5	0	0	Image NA	5	Percent market share is less tha 1%	**15**	**47**
	352	Enoxaparin Sodium	60 mg	injection	Hepanox 60mg	2	2	3	4	5	6	2	2	2	2	2	**32**	0	5	5	0	0	Image NA	5	Percent market share is less tha 1%	**15**	**47**
	370	Heparin Sodium	5000IU	injection	Inhixa Solution for injection	2	2	3	4	5	6	2	2	2	2	2	**32**	0	5	5	0	0	Image NA	5	1	**16**	**48**
	403	Amlodipine (as besylate) + Valsartan	5mg+80mg	Tablets	Amsart Tabs 5/80mg	2	2	3	4	5	6	2	2	2	2	2	**32**	0	GDs of Amlodipine and valsartan are older than 24 months - 03/2023- Page 217 and 225	0	0	0	Image NA	5	Percent market share is less tha 1%	**5**	**37**
	404	Amlodipine (as besylate) + Valsartan	5mg+160mg	Tablets	Amsart Tabs 5mg/160mg	2	2	3	4	5	6	2	2	2	2	2	**32**	0	GDs of Amlodipine and valsartan are older than 24 months - 03/2023- Page 217 and 225	0	0	0	Image NA	5	Percent market share is less tha 1%	**5**	**37**
	405	Amlodipine (as besylate) + Valsartan	10mg+160mg	Tablets	Amsart Tabs 10mg/160mg	2	2	3	4	5	6	2	2	2	2	2	**32**	0	GDs of Amlodipine and valsartan are older than 24 months - 03/2023- Page 217 and 225	0	0	0	Image NA	5	Percent market share is less tha 1%	**5**	**37**
	406	Amlodipine (as besylate) + Valsartan + Hydrochlorothiazide	10mg+160mg+12.5 mg	Tablets	AMSART-H 10MG/160MG/12.5MG TABS 28's	2	2	3	4	5	6	2	2	2	2	2	**32**	0	GDs of Amlodipine and valsartan are older than 24 months - 03/2023- Page 217 and 225	0	0	0	Image NA	5	Percent market share is less tha 1%	**5**	**37**
	471	Rosuvastatin	10 mg	Tablets	Omnitor Tabs 10mg	2	2	3	4	5	6	2	2	2	2	2	**32**	0	GD of Rosuvastatin is older than 24 months- 12/2023- Page 422- AWB is also not matching- Page 423	0	0	0	Image NA	5	Percent market share is less tha 1%	**5**	**37**
	791	Beclomethasone + Salbutamol	50mcg+100mcg	inhaler	Salnon Inh 100/50mcg - HFA	2	2	3	4	5	6	2	2	2	2	2	**32**	0	AWB of Salbutamol is not matching with the GD- Page 440-441, 552,553	0	0	0	Image NA	5	Percent market share is less tha 1%	**5**	**37**
	797	Budesonide + Formoterol	200mcg+6mcg	Rota Capsule	Venticort DPI Capsule 200mcg - 30's	2	2	3	4	5	6	2	2	2	2	2	**32**	0	AWB of Budesonide is not matching with the GD on Page 463-464 GD of Formoterol is older than 2 years- Page 476	0	0	0	Image NA	5	2	**7**	**39**
	799	Budesonide + Formoterol	400mcg+12mcg	Rota Capsule	Venticort DPI Capsule 400mcg - 30's	2	2	3	4	5	6	2	2	2	2	2	**32**	0	AWB of Budesonide is not matching with the GD on Page 463-464 GD of Formoterol is older than 2 years- Page 476	0	0	0	Image NA	5	2	**7**	**39**
	803	Salmeterol + Fluticasone propionate	25mcg+125mcg	inhaler	Salmicort Inh 25/125mcg - HFA	2	2	3	4	5	6	2	2	2	2	2	**32**	0	AWB of Salmeterol is not matching with GD-Page 526-527	0	0	0	Image NA	5	1	**6**	**38**
	814	Salbutamol	100 mcg	inhaler	Inspirol Inh.100mcg	2	2	3	4	5	6	2	2	2	2	2	**32**	0	AWB of Salbutamol is not matching with the GD- Page 440-441, 552,553	0	0	0	Image NA	5	Percent market share is less tha 1%	**5**	**37**

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm | **Maple Pharmaceuticles (Pvt.) Limited**

	S. No.	Product General Information				Technical Evaluation Matrix: Factory Technical Evaluation Parameters — Documents Based Factory Score						Factory Evaluation Visit Score					Total Factory Evaluated Score	Product Evaluation Parameters — Product Technical Parameters							Total Product Evaluated Score	Total Technical Score
		MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
							Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment /instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., Fr 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC experts), as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, in-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid coa/tisk/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of WIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **(02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: i. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better (**Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received		
		MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70
DRAP REG	48788	1	35	Aceclofenac	100mg	Tab.	Acelo	2	2	3	0	5	**The firm was inspected as per technical evaluation criteria and following**					12	0	0	0	0		0			5	17
	55418	2	41	Diclofenac Sodium	50mg	Tab.	Dicloram	2	2	3	0	5						12	0	0	0	0		0			15	27
	55416	3	48	Mefenamic Acid	250mg	Tab.	Mefcid	2	2	3	0	5						12	0	0	0	0		0			5	17
	55413	4	49	Mefenamic Acid	500mg	Tab.	Mefcid	2	2	3	0	5						12	0	0	0	0		0			5	17
	78238	5	66	Tramadol+Paracetamol	37.5+325mg	Tab.	Doloraid	2	2	3	0	5						12	0	0	0	0		0			5	17
	35574	6	160	Montelukast	10mg	Tab.	Mapoxi	2	2	3	0	5						12	0	5	5	0		0			15	27
	35754	7	161	Montelukast	5mg	Tab.	Mapoxi	2	2	3	0	5						12	0	5	5	0		0			15	27
	105384	8	189	Azithromycine 250mg	250mg	Tab.	Mapzit	2	2	3	0	5						12	0	5	5	0		0			15	27
	105385	9	190	Azithromycine 500mg	500mg	Tab.	Mapzit	2	2	3	0	5						12	0	5	5	0		0			15	27
	70681	10	230	Ciprofloxacin	250mg	Tab.	Ciprozee	2	2	3	0	5						12	0	0	0	0		0			5	17
	70688	11	231	Ciprofloxacin	500mg	Tab.	Ciprozee	2	2	3	0	5						12	0	0	0	0		0			5	17
	13921	12	417	Captopril	25mg	Tab.	Capril	2	2	3	0	5						12	0	0	0	0		0			5	17
	34945	13	421	Clopidogrel75mg	75mg	Tab.	Loclog	2	2	3	0	5						12	0	5	5	0		0			15	27
	55422	14	433	Glyceryl Trinitrate	2.6mg	Tab.	Glyrate Sr	2	2	3	0	5						12	0	5	5	5		0			20	32
	55423	15	434	Glyceryl Trinitrate	6.4mg	Tab.	Glyrate Sr	2	2	3	0	5						12	0	5	5	5		0			20	32
	110372	16	445	Isosorbide-5-Mononitrate	25mg	Tab.	Monis	2	2	3	0	5						12	0	0	0	0		0			15	27
	13359	17	446	Isosorbide-5-Mononitrate	40mg	Tab.	Monis	2	2	3	0	5						12	0	0	0	0		0			15	27
		18	450	Losartan Htz	50mg + 12.5mg	Tab.	Losaan-H Tablet	2	2	3	0	5						12	0	0	0	0		0			15	27
	78111	19	451	Losartan Potassium	25mg	Tab.	Losaan	2	2	3	0	5						12	0	0	0	0		0			15	27
	31717	20	452	Losartan Potassium	50mg	Tab.	Losaan	2	2	3	0	5						12	0	0	0	0		0			15	27
?		21	471	Rosuvastatin	10mg	Tab.	Rostatin	2	2	3	0	5						12	0	0	0	0		0			5	17
	3888	22	549	Glimepiride	1mg	Tab.	Glyper	2	2	3	0	5						12	0	0	0	0		0			5	17
	32026	23	550	Glimepiride	2mg	Tab.	Glyper	2	2	3	0	5						12	0	0	0	0		0			5	17
	32027	24	551	Glimepiride	3mg	Tab.	Glyper	2	2	3	0	5						12	0	0	0	0		0			5	17
		25	552	Glimepiride	4mg	Tab.	Glyper	2	2	3	0	5						12	0	0	0	0		0			5	17

NOTE:

IQVIA/ IMS Ranking is 190 Number so the marks
Application for the renewal of DRAP registration for Mefenamic acid 250 and 500mg is not attached in PDF PAGE 234
GD of Mefenamic acid is expired so the GD and COA score is zero.
Application for the renewal of DRAP Reagistration for Losartan potassium 25mg is not attached in PDF
Stability studies od Losartan potassium 25mg is not attached in PDF. While stability studies of Losartan k 50mg is expired.
Application for the renewal of Clopidogrl 25mg DRAP Regcaptopril 25mg DRA
Captopril GD does not match with Airway bill, so GD score is zero and also COA
Application for the renewal of clopidogrl 75mg is not attached
Rosuvastatin GD Airway bill is not available so GD and COA is zero,
Glimiopride GD is incomplete so GD AND COA is zero
Tramadol GD and COA are available, But GD of Paracetamol is not available so GD AND COA of
Ciprofloxacin 250mg and 500mg GD and COA are not attached in PDF.
API Source of approximatly all items are not attached in PDF.
Immediate container and packing material pictures are not attached in PDF so the score for immediate container is zero.

25MG AND 50MG is not attached in pdf

DRAP Reg no is not attached in PDF

Page NO 266

Stability studies are also expired.

Dolarid us zero

TECHNICAL EVALUATION PROFORMA, FOR PROCUREMENT OF ANTICANCER MEDICINES IN GOVT. MCC FY 2026-27

Name of the firm with Complete Address	MARTIN DOW LIMITED
Manufacturer / Importer	IMPORTER (ONCOLOGY MEDICINES)

		Mandatory Requirements.	YES / NO	YES	In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:		YES/NO	In case of being Importers, the Firm should provide attested copies of the following documents also:		YES/NO	
1		National Tax Number (NTN) of the Firm for Income Tax, and		YES	1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and	NA	1	Valid Drugs Sales License for the importer; and	YES	
2		Last year Income Tax Return of the Firm; and		YES	2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.	YES	2	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	YES	
3		Sale Tax Registration Certificate of the Firm; and		YES	3	Valid DRAP Approved Price List of the quoted item/s.	YES	3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	YES	
4		Certificate of Professional Tax of the Firm.		YES				4	Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and	Yes	
5		Certificate of compliance to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR. Non-Compliance to international reference standards or absence of Cold Chain requirements shall lead to disqualification of the relevant product that requires cold chain.		YES				5	Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods. Non provision of the document shall lead to disqualification of the firm; and	yes	
								6	Valid DRAP approved Price List of the quoted item/s.	Yes	

		Technical Evaluation Parameters			Active Pharmaceutical Ingredient source gradation (for API or finished product). i) The bidder (local manufacturer / multi-national manufacturer / importer) shall provide Analytical/Quality Assurance/ Approval Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades. Certificate of Analysis/ Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreement/ approval with the original manufacturer duly attested/verified by official of the company. ii) Sealed purchase bill of the Active Pharmaceutical Ingredients/ Finished product from the claimed source must be submitted (any proof of purchase such as Goods Declaration Certificate along with Invoice) with Bid at the time of submission etc.) by the bidder. Maximum marks for this criterion are 40.		Bio-Equivalence (BE) / Bio- Similar (BS) or bio-waiver (BW) Study/Certificate from an accredited lab of SRA countries (Stringent Regulatory Authority(s)/ WHO Listed Authorities MLA Countries (BE/BS Certificate with evidence as to its authenticity) from Category A countries. Bio-Equivalence (BE) of the quoted product to be conducted against the originator. Original innovator products do not require bio- equivalence certificate and shall get 10 marks automatically.The bidder shall provide the documents to establish the proof of inventor/ originator. All other branded generics require BE studies. Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid. Maximum marks for this criterion are 10.		Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug. In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article) Mandatory: Online verification link must be provided to verify the Clinical Trial/ Clinical Studies submitted for the quoted items.		Factory/ Importer Based Evaluation Score (MANDATORY)	Sample Evaluation by End User Committee Samples will be examined per following parameters as follows: a. Labeling and Packing Rules 1986 b. Outer packing c. Inner packing d. Physical appearance. Product which has unsatisfactory packing/labeling will be technically Disqualified. Maximum score for this criterion is 1.		Past Performance (Last two years). i) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks. ii) Only supply orders will not get any marks. iii) The bidders have to undertake that they have never been blacklisted or debarred. Maximum marks for this criterion are 5. iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.	Total Technical Score
					Category A – Approved By: • United States Food & Drug Administration (US FDA) • European Medicines Agency (EMA) • Medicines & Healthcare Products Regulatory Agency (MHRA) • Therapeutic Goods administration (TGA), Australia. • Pharmaceutical Medical Agency (PHARMAC), New Zealand • Japan Pharmaceutical & Medical Devices Agency (PMDA), Japan • Swiss Agency For therapeutic drugs (Swiss medic), Switzerland	Category B – Approved By: • Agência Nacional de Vigilância Sanitária (ANVS), Brazil • Central Drug Standard Control Organization (CDSCO), India • Drug Regulatory Authority, Pakistan • National Pharmaceutical Control Bureau (NPCB), Malaysia • Food & Drug Administration, South Korea • Ministry of Health, Egypt • Ministry of Health, Turkey • China Food & Drug Administration • Any other source not mentioned in Category-A	Study/Certificate accepted/certified by a Category A Country Regulatory Authority, BE testing must be done using the US Reference. Bio-waiver is acceptable only in injectable forms if issued by Category A Country.	BE/BS/BW certificate obtained for a quoted product from Category B Country (as mentioned at S.No. 1 above).	BE/BS/BW Certificate.	Drawn the study is published in Category "N" (named Listed in HEC Journal Recognition System (HJRS) Database/ Journals in Publication Policy 2023 and List of National Recognized Journals as per HEC, 2 marks per original research article shall be awarded (maximum up to 6 marks).	In case the study is published in Category "N" (named listed in HEC Journal Recognition System (HJRS) Database/ Journals in Publication Policy 2023 and List of National Recognized Journals as per HEC, 2 marks per original research article shall be awarded (maximum up to 6 marks).	Product assigned grade published in category "Y" (named listed in HJRS Journals in Publication Policy 2023 and List of National Recognized Journals as per HEC shall not be awarded marks.	The Physical inspection of the premises of the bidders (Manufacturer/Importer) shall be carried out in accordance with FR 26.4(b), SCC 9 (SCC 8.3), Section V (c) (i) (K) of the approved Bidds of Govt. MCC FY 2026-27	satisfactory	unsatisfactory	ii) Substantial quantity of supplies of anti-cancer medicines made to private sector Teaching Hospitals namely: The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar, CMH Rawalpindi and Hayatabad Medical Complex, Peshawar during the last three years should be backed by Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 24 months. No marks will be given. Only supply orders without satisfactory/ letter supply orders coupled with delivery challans & invoices will be considered for award of marks.	
SOURCE	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	40	10	10	5	0	9	6	0	5	1	0	5	70
Deva Holding anonim Turky	1462	Bortezomib	3.5mg	Inj	Velkaso Injection Powder for Solution	0	10	0	0	0	0	0	0		1		1	27
Deva Holding anonim Turky	1512	Dilotinib	150mg	Tab	Tamimib	0	10	0	0	0	0	0	0		1		1	27
Laboratorios Farmaleo NV, Spain	1517	Fulvestrant	250mg/5ml	Inj	Fulvedex	DRAP registered Name of the quoted item do not reflect any correlation with the documents provided by the principal source	0	0	0	0	9	0	0		1		1	7
Geneci France	1522	Granisetron Hydrochloride	1mg	Tab	Kytril	40	0	0	0	0	9	0	0		1		2	8
Geneci France	1523	Granisetron Hydrochloride	3mg/3ml	Inj	Kytril IV Ampoule	40	0	0	0	0	9	0	0		1		2	8
Deva Holding anonim Turky	1530	Imatinib	100mg	Tab	Imadev Film Coated	0	DRAP registration provided at page No. 1161 is at the name of IMADI while agency agreement at page No. 1161 is at the name of IMATIB	0	0	0	0	0	0		1		1	#VALUE!
Deva Holding anonim Turky	1531	Imatinib	400mg	Tab	Imadev Film Coated	0	DRAP registration provided at page No. 1161 is at the name of IMADI while agency agreement at page No. 1161 is at the name of IMATIB	0	0	0	0	0	0		1		1	#VALUE!
Deva Holding anonim Turky	1599	Pazopanib	400mg	Tab	Vopazi Film Coated	0	10	0	5	0	0	0	0		1		1	27
Jinan Pharmaceutical Co ltd China	1626	Sunitinib	25mg	Cap	Alvosuni	0	10	0	5	0	0	0	0		1		1	27
Reliance Life Sciences India	1629	Temozolomide	100mg	Cap	Temorel	0	10	0	0	0	0	0	0		1		2	28
Reliance Life Sciences India	1630	Temozolomide	140mg (Sample is 20 mg)	Cap	Temorel	0	10	0	0	0	0	0	0				2	27

TECHNICAL EVALUATION PROFORMA, FOR PROCUREMENT OF ANTICANCER MEDICINES IN GOVT. MCC FY 2026-27

Name of the firm with Complete Address: MARTIN DOW MARKER, QUETTA

Manufacturer / Importer

		Mandatory Requirements.	YES / NO		In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:		YES/NO		In case of being Importers, the Firm should provide attested copies of the following documents also:		YES/NO	
1		National Tax Number (NTN) of the Firm for Income Tax, and	Yes		1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and			1	Valid Drugs Sales License for the importer; and		
2		Last year Income Tax Return of the Firm; and	Yes		2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.			2	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and		
3		Sale Tax Registration Certificate of the Firm; and	Yes		3	Valid DRAP Approved Price List of the quoted item/s.			3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and		
4		Certificate of Professional Tax of the Firm.	Yes						4	Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and		
5		Certificate of compliance to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR, Non-Compliance to international reference standards or absence of Cold Chain requirements shall lead to disqualification of the relevant product that requires cold chain.	Yes						5	Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods. Non provision of this document shall lead to disqualification of the firm; and		
									6	Valid DRAP approved Price List of the quoted items.		

		Technical Evaluation Parameters	Active Pharmaceutical Ingredient source gradation (For API or finished product), i) The bidder (local manufacturer / multi-national manufacturer / importer) shall provide Analytical/Quality Assurance/ Approval Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades. Certificate of Analysis/ Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers with current agency agreement/ approval with the original manufacturer duly verified/attested by official of the company. Detailed purchase trail of the Active Pharmaceutical Ingredient / finished product from the claimed source must be submitted (any proof of purchase such as Goods Declaration Certificate along with Airway Bill/ Bill of Lading/Invoice etc.) by the bidder. Maximum marks for this criterion are 40.	Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW) study/Certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities)/ WHO Listed Authorities MLA Countries OR (BE/BS) Certificate with evidence as to its authenticity) from Category A countries. Bio-Equivalence (BE) of the quoted product to be conducted against the originator. Original innovator products do not require bio- equivalence certificate and shall get 10 marks automatically.The bidder shall provide the documents to establish the proof of inventor/ originator. All other branded generics require BE studies. Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid. Maximum marks for this criterion are 10.	Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug. In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article) Mandatory: Online verification link must be provided to verify the Clinical Trial/ Clinical Studies submitted for the quoted items.	Factory / Importer Based Evaluation Score (MANDATORY)	Sample Evaluation by End User Committee Samples will be examined per following parameters as follows: a. Labeling and Packing Rules 1986 b. Outer packing c. Inner packing d. Physical appearance. Product which has unsatisfactory packing/labeling will be technically Disqualified. Maximum score for this criterion is 1.	Past Performance (Last two years). i) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks. ii) Only supply orders will not get any marks. iii) The bidders have to undertake that they have never been blacklisted or debarred. Maximum marks for this criterion are 5. iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, THO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.	Total Technical Score
			Category A – Approved By: • United States Food & Drug Administration (US FDA) • European Medicines Agency (EMA) • Medicines & Healthcare Products Regulatory Agency (MHRA) • Therapeutic Goods Administration (TGA), Australia • Pharmaceutical Medical Agency (PHARMAC), New Zealand • Japan Pharmaceutical & Medical Devices Agency (PMDA), Japan • Swiss Agency For therapeutic drugs (Swissmedic), Switzerland • Health Canada • Health Sciences Authority (HAS), Singapore • National Administration of Drugs, Food & Medical technology (ANMAT), Argentina Drug Regulatory Authorities of the WA (Stringent Regulatory Authorities) / WHO Listed Authorities MLA countries	Category B – Approved By: • Agência Nacional de Vigilância Sanitária (ANVS), Brazil • Central Drug Standard Control Organization (CDSCO), India • Drug Regulatory Authority, Pakistan • National Pharmaceutical Control Bureau (NPCB), Malaysia • Food & Drug Administration, South Korea • Ministry of Health, Egypt • Ministry of Health, Turkey • China Food & Drug Administration • Any other source not mentioned in Category-A	Study/Certificate duly/precertified by a Category A Country Regulatory Authority. BE testing must be done using the Reference Product approved in country/state only by injectable forms if issued by Category A Country.	As bio-BW certificate obtained for a quoted product from Category-B Country (as mentioned at S No. 1 above).	No Bio-BE/BW certificate.	As now the study is published in Category "B" journal listed in HEC Journal Recognition System (HJRS) / Database/ Directory of Publication Policy 2023 and List of National Recognized Research Journals (as per HEC, 2 months per original research article shall be awarded maximum up to 6 marks).	As now the study is published in Category "A" journal listed in HEC Journal Recognition System (HJRS) / Database/ Journals as Publication Policy 2023 and List of National Recognized Research Journals (as per HEC, 3 months per original research article shall be awarded maximum up to 9 marks).	Students original thesis published in category "Y" journal of the HJRS/ Journals as per Publication Policy 2023 and List of National Recognized Journals as per HEC shall not be awarded marks.	The Physical inspection of the premises of the bidders (Manufacturer/Importer) shall be carried out in accordance with FR 29, 4(b), SCC 9 (DCC 8.2), Section V (G) (i) (k) of the approved SBDS of Govt. MCC FY 2026-27	satisfactory	unsatisfactory	i) Substantial quantity of supplies of anti-cancer medicines made to private sector hospitals namely: The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar, Dow Ressalpindi and Hayatabad Medical Complex, Peshawar shall be considered positively provided that no such satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 24 months. No marks will be given for supply orders except CMH Rawalpindi where supply orders coupled with delivery challans & invoices will be considered for award of marks. 1 mark per agreement up to a maximum of 5 marks	
SOURCE	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	40	30	10	5	0	9	6	0	5	1	0	5	70
MERC (SWITZERLAND / NETHERLAND	1447	Avelumab	200mg/10ml	Inj	Bavencio	40	0				3			5	1			70
Merck HC Germany	1478	Cetuximab	100mg, 5mg/ml	Inj	Erbitux									5		1		70
Oddston Toll manufacturing	1444	Anastrozole	1mg	Tab	O-Trozole	TOLL MANUFACTURED	TOLL MANUFACTURED	TOLL MANUFACTURED	TOLL MANUFACTURED	TOLL MANUFACTURED	MANUFACTURED			5			2	70
GALEN MEDICARE INDIA	1462	Bortezomib	3.5mg	Inj	OnBort	40	0							5		0		70
GALEN MEDICARE INDIA	1604	Pemetrexed	100mg	Inj	PemXort	40	0							5		0		70
GALEN MEDICARE INDIA	1605	Pemetrexed	500mg	Inj	PemXort	40	0							5		0		70

COMP AT 1421 PAGE IS NOT READABLE

FREE SALE CERTIFICATES WITH AVELUMAB ARE NOT ATTACHED

ANASTRAZOLE AT PAGE 1499 IS TOLL MANUFACTURED BY WILSHIRE

CETUXIMAB DOCUMENTS ARE NOT READABLE (1386 PAGE)

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: MEDICON PHARMACEUTICALS PESHAWAR

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC exper/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this colounm for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g.,	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70
1	170	amoxicillin	500 mg	Capsules	Medixil	2	2	3	0	5	2						14	0	5	5	0	0	4	0	0	14	28
2	171	amoxicillin	125 mg/5ml	Dry Suspension	Medixil	2	2	3	0	5	2						14	0	5	5	0	0	4	0	0	14	28
3	204	cefixime	400 mg	Capsule	Medigate	2	2	3	0	5	2						14	0	5	5	0	0	4	0	0	14	28
4	205	cefixime	100mg/5ml	Dry Suspension	Medigate	2	2	3	0	5	2						14	0	5	5	0	0	4	0	0	14	28
5	206	cefixime	200mg/5ml	Dry Suspension	Medigate	2	2	3	0	5	2						14	0	5	5	0	0	0	0	0	10	24
6	231	ciprfloxacin	500 mg	Tablet	Medilox	2	2	3	0	5	2						14	0	0	0	0	0	4	0	0	4	18
7	268	Linezolid	600 mg	Tablet	Lanzomed	2	2	3	0	5	2						14	0	0	0	0	0	4	0	0	4	18
8	269	Linezolid	100 mg/5ml	Dry Suspension	Lanzomed	2	2	3	0	5	2						14	0	0	0	0	0	4	0	0	4	18
9	59	Paracetamol	500 mg	Tablet	Menadol	2	2	3	0	5	2						14	0	5	5	0	0	4	0	0	14	28

The firm was inspected by the inspection team as per technical evaluation criteria, and the following observations were made;
Poor Adherence to cGMP:
1. HVAC system was non- functional in the production area at the time of inspection.
2. Fluidized bed dryer, Mixer and granulator were placed in congested area in a filthy environment with no labeling over any machine showing that either the machines are in rest or operation.
3. In RMS the quarantine and released areas were not properly segregated and no sampling labels were pasted.
4. Hygrometer, weighing balance and thermometers were not calibrated.
5. No dedusting mechanism was available in Raw material receiving bay.
6. Raw materials like capsule shells were placed with active ingredients having no segregation.
7. No magnehelic pressure was maintained throughout the production area to avoid contamination and cross contamination.
8. over all cleaning environment/hygiene was very poor, found open holes in the production area for seepage.
9. No Temperature control was found for Aluminum foils, the packaging material.
10. Capsule shells were placed at 32% relative humidity while 45% to 65% humidity required as manufacturer own specs.
Poor Good Laboratory Practices (GLP)
11. No real time stability chamber was available; two stability chambers were available with out of order temperature and humidity (40C & 60%).
12. No SOP and mechanism was available for stability of the Products.
13. Quoted items were not placed in stability chambers.
14. No preparation and expiry date were mentioned on the reagents.
15. All working standards were found with no potency and any label for information regarding the standards used in QC testing.
16. NO Supporting data in hard for release of APIS and raw materials available at QC.
17. No testing documents for working standards were available.
18. No HPLC data was available for testing of cefixime API and dosage form.
19. The analysis for APIS were carried out by spectrophotometer on Photometric mode which is against the prescribed official specifications.
20. No primary standards were available in QC.
21. Standard was not available for cefexime and empty bottles were shown to the team.
In view of the above the firm is NOT RECOMMENDED.

Report

1.CDR date not visible on page 32
2.no GD/invoice of ciprofloxacin only gate pass attached on page 139.
3.No GD of linezolid attached at page 129 hence no marks awarded
4.GD/Invoice is NOT coupled with Coa
5.in stability studies no NLT studies are mentioned an shows incomplete satbility data
6. no pic of immediate container of amoxicillin 250mg/5ml.

						Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27														
Name of the firm: MEDILINK PESHAWAR																			
S. No.		Product General Parameter				Technical Evaluation Matrix													
						Principal's and Importer's Evaluation Parameters													
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score	Product Technical Evaluation						Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the time of inspection at the warehouse at the tim eof inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** **(Certificate duly attaested by senior executive of the firm)**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US free sale certificate of the quoted products, **02 marks for each certification, up to a**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	5	6	**29**	5	5	5	6	10	10	**41**	**70**
	1320	Black Braided Silk	4/0 17mm ½ circle round body 75cm	Medico silk		Not attached	128 ISO 13485 certificate is not issued by authorized IAF accredation body, Online verification link is not provided.	Not attached	5	5	6	**16**	143 GD Of Silk 1 attached	148 Not visible and donot cover quoted spics	0	0	10	Not recommended	**10**	**26**
	1321	Black Braided Silk	3/0 30mm ½ circle round body 75cm	Medico silk		Not attached	0	Not attached	5	5	6	**16**	157 GD of Silk 1 attached	161 Not visible and donot cover quoted spics	0	0	10	Not recommended	**10**	**26**
	1322	Black Braided Silk	3/0 26mm ½ circle round body 75cm	Medico silk		Not attached	0	Not attached	5	5	6	**16**	170 Same GD attached repeatedly	148 Not visible and donot cover quoted spics	0	0	10	Not recommended	**10**	**26**
	1325	Black Braided Silk	2/0 31mm ½ circle round body 75cm	Medico silk		Not attached	0	Not attached	5	5	6	**16**	Same GD attached repeatedly	175 Not visible and donot cover quoted spics	0	0	10	Not recommended	**10**	**26**
	1327	Black Braided Silk	0 31mm ½ circle round body 75cm	Medico silk		Not attached	0	Not attached	5	5	6	**16**	Same GD attached repeatedly	148 Not visible and donot cover quoted spics	0	0	10	Not recommended	**10**	**26**
	1328	Black Braided Silk	1 40mm ½ circle round body 75cm	Medico silk		Not attached	0	Not attached	5	5	6	**16**	Same GD attached repeatedly	148 Not visible and donot cover quoted spics	0	0	10	Not recommended	**10**	**26**
	1329	Black Braided Silk	1 30mm ½ circle round body 75cm	Medico silk		Not attached	0	Not attached	5	5	6	**16**	Same GD attached repeatedly	148 Not visible and donot cover quoted spics	0	0	10	Not recommended	**10**	**26**
	1330	Black Braided Silk	1 40mm 3/8 circle conventional cutting 75cm	Medico silk		Not attached	0	Not attached	5	5	6	**16**	Same GD attached repeatedly	148 Not visible and donot cover quoted spics	0	0	10	Not recommended	**10**	**26**
	1331	Black Braided Silk	2 40mm ½ circle round body 75cm	Medico silk		Not attached	0	Not attached	5	5	6	**16**	259 GD of size 0 attached	264 Not visible and donot cover quoted spics	0	0	10	Not recommended	**10**	**26**
	1353	Polyglycolide-co-lactide	1 40mm ½ round body 70cm	Medico PGLA		Not attached	0	Not attached	5	5	6	**16**	273 GD is older than 02 years	0	0	0	10	Not recommended	**10**	**26**
	1358	Polyglycolic acid	4/0 17mm ½ round body 75cm	Medico PGA		Not attached	0	Not attached	5	5	6	**16**	284 Size not mentioned	289 Not visible and size not mentioned	0	0	10	Not recommended	**10**	**26**
	1359	Polyglycolic acid	4/0 22mm ½ round body 75cm	Medico PGA		Not attached	0	Not attached	5	5	6	**16**	Size not mentioned	303 Not visible	0	0	10	Not recommended	**10**	**26**
	1360	Polyglycolic acid	3/0 22mm ½ round body 75cm	Medico PGA		Not attached	0	Not attached	5	5	6	**16**	Needle specification are not mentioned in NOC	316 Not visible	0	0	10	Not recommended	**10**	**26**
	1361	Polyglycolic acid	2/0 25mm ½ round body 75cm	Medico PGA		Not attached	0	Not attached	5	5	6	**16**	Needle specification are not mentioned in NOC	329 Not visible	0	0	10	Not recommended	**10**	**26**
	1362	Polyglycolic acid	2/0 30mm ½ round body 75cm	Medico PGA		Not attached	0	Not attached	5	5	6	**16**	Needle specification are not mentioned in NOC	357 not visible no specification	0	0	10	Not recommended	**10**	**26**
	1363	Polyglycolic acid	40mm, 1/2 circle round bodied tapper point needle, strand length 75 cm	Medico PGA		Not attached	0	Not attached	5	5	6	**16**	Needle specification are not mentioned in NOC	357 not visible no specification	0	0	10	Not recommended	**10**	**26**
	1365	Polyglycolic acid	30mm, 1/2 circle round bodied tapper point needle, strand length 75 cm	Medico PGA		Not attached	0	Not attached	5	5	6	**16**	367Needle specification are not mentioned in NOC	371 not visible no specification	0	0	10	Not recommended	**10**	**26**
	1366	Polyglycolic acid	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm	Medico PGA		Not attached	0	Not attached	5	5	6	**16**	Needle specification are not mentioned in NOC	Same CoA attached for all items which is not visible and have no specification	0	0	10	Not recommended	**10**	**26**
	1367	Polyglycolic acid	48mm, 1/2 circle round bodied taper point needle, strand length 75 cm	2 Medico PGA		Not attached	0	Not attached	5	5	6	**16**	Needle specification are not mentioned in NOC	Same CoA attached for all items which is not visible and have no specification	0	0	10	Not recommended	**10**	**26**
	1374	Polypropylene Monofilament	13mm, 1/2 circle round bodied taper point double armed needle, strand length 60cm	6/0 Medico Prolene		Not attached	0	Not attached	5	5	6	**16**	Needle specification are not mentioned in NOC	Same CoA attached for all items which is not visible and have no specification	0	0	10	Not recommended	**10**	**26**
	1375	Polypropylene Monofilament	13mm, 3/8 circle round bodied taper point double armed needle, strand length 60cm	6/0 Medico Prolene		Not attached	0	Not attached	5	5	6	**16**	Needle specification are not mentioned in NOC	Same CoA attached for all items which is not visible and have no specification	0	0	10	Not recommended	**10**	**26**
	1378	Polypropylene Monofilament	16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	5/0 Medico Prolene		Not attached	0	Not attached	5	5	6	**16**	Needle specification are not mentioned in NOC	Same CoA attached for all items which is not visible and have no specification	0	0	10	Not recommended	**10**	**26**

1380	Polypropylene Monofilament	26mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm	4/0 Medico Prolene		Not attached	0	Not attached	5	5	6	**16**	Needle specification are not mentioned in NOC	Same CoA attached for all items which is not visible and have no specification	0	0	10	Not recommended	**10**	**26**
1381	Polypropylene Monofilament	19mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	3/0 Medico Prolene		Not attached	0	Not attached	5	5	6	**16**	Needle specification are not mentioned in NOC	Same CoA attached for all items which is not visible and have no specification	0	0	10	Not recommended	**10**	**26**
1382	Polypropylene Monofilament	26mm, 1/2 circle round bodied taper point double armed needle, strand length 75cm	3/0 Medico Prolene		Not attached	0	Not attached	5	5	6	**16**	Needle specification are not mentioned in NOC	Same CoA attached for all items which is not visible and have no specification	0	0	10	Not recommended	**10**	**26**
1383	Polypropylene Monofilament	30 mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm	3/0 Medico Prolene		Not attached	0	Not attached	5	5	6	**16**	Needle specification are not mentioned in NOC	Same CoA attached for all items which is not visible and have no specification	0	0	10	Not recommended	**10**	**26**
1384	Polypropylene Monofilament	26mm, 1/2 circle round bodied taper point needle, strand length 75cm	2/0 Medico Prolene		Not attached	0	Not attached	5	5	6	**16**	Needle specification are not mentioned in NOC	Same CoA attached for all items which is not visible and have no specification	0	0	10	Not recommended	**10**	**26**
1385	Polypropylene Monofilament	26mm, 3/8 circle reverse cutting needle, strand length 45cm	2/0 Medico Prolene		Not attached	0	Not attached	5	5	6	**16**	Needle specification are not mentioned in NOC	Same CoA attached for all items which is not visible and have no specification	0	0	10	Not recommended	**10**	**26**
1386	Polypropylene Monofilament	26mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	2/0 Medico Prolene		Not attached	0	Not attached	5	5	6	**16**	Needle specification are not mentioned in NOC	Same CoA attached for all items which is not visible and have no specification	0	0	10	Not recommended	**10**	**26**
1387	Polypropylene Monofilament	26mm, 1/2 circle round bodied taper cut double armed needle, strand length 75cm	2/0 Medico Prolene		Not attached	0	Not attached	5	5	6	**16**	Needle specification are not mentioned in NOC	Same CoA attached for all items which is not visible and have no specification	0	0	10	Not recommended	**10**	**26**
1388	Polypropylene Monofilament	30mm, 1/2 circle round bodied taper point needle, strand length 75cm	2/0 Medico Prolene		Not attached	0	Not attached	5	5	6	**16**	Needle specification are not mentioned in NOC	Same CoA attached for all items which is not visible and have no specification	0	0	10	Not recommended	**10**	**26**
1389	Polypropylene Monofilament	55mm, straight cutting needle, strand length 75cm	2/0 Medico Prolene		Not attached	0	Not attached	5	5	6	**16**	Needle specification are not mentioned in NOC	Same CoA attached for all items which is not visible and have no specification	0	0	10	Not recommended	**10**	**26**
1390	Polypropylene Monofilament	60mm, straight cutting needle, strand length 75cm	2/0 Medico Prolene		Not attached	0	Not attached	5	5	6	**16**	Needle specification are not mentioned in NOC	Same CoA attached for all items which is not visible and have no specification	0	0	10	Not recommended	**10**	**26**
1392	Polypropylene Monofilament	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	1 Medico Prolene		Not attached	0	Not attached	5	5	6	**16**	Needle specification are not mentioned in NOC	Same CoA attached for all items which is not visible and have no specification	0	0	10	Not recommended	**10**	**26**
1418	Polydioxanone Monofilament	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	2/0 Medico Polydioxanone		Not attached	0	Not attached	5	5	6	**16**	628 Older than 02 years	0	0	0	DTL Substandard	Not recommended	**0**	**16**
1422	Polydioxanone Monofilament	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	1 Medico Polydioxanone		Not attached	0	Not attached	5	5	6	**16**	628 Older than 02 years	0	0	0	DTL Substandard	Not recommended	**0**	**16**
1326	Black Braided Silk	2/0 26mm ½ circle round body 75cm	Medico silk		Not attached	0	Not attached	Not recommended by inspection team			**0**	Same GD attached repeatedly	148 Not visible and donot cover quoted spics	0	0	10	Not recommended	**10**	**10**

Page	Remarks
42	The FBR is not matching with the GDs value/WBOC trail.
	The net weight in GD and AWB are different.
66-69	Free Sale certificate is not embassy attested
66-69	Conventional cutting are not covered in the Free sale certificate
66-69	Thread Length of sutures of all quoted items are not covered in the Free sale certificate
88	EC certificate attached is expired.
128	IAS does not issue ISO 13485

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27														
			Name of the firm			MEDILINK PESHAWAR														
						Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant sections/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm).**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevent certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
	1423	Nylon Monofilament	10/0 6mm 3/8 circle spatula double 30cm	Medico Nylon		Nylon 10/0 is not covered in the mandatory Free sale certificate						**0**						Not Recommended	**0**	**0**

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: Medipak Limited

S. No.		Product General Information				Technical Evaluation Matrix															
						Factory Technical Evaluation Parameters Factory Evaluation Visit Score					Total Factory Evaluated	Product Evaluation Parameters Product Technical Parameters								Total Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this colounm for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables,	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**5**	**3**	**4**	**5**	**5**	**37**	**70**
	670	Compound Sodium Lactate (Ringer's Lactate)	500ml	IVInf	Medisol Hartmann's (with Flatcap)						**22**	5	5	5	5	0	No pictures of the quoted items are provided in the original Bid	**5**	1	**26**	**48**
	658	0.9% Sodium Chloride	500ml	IVInf	Medisol N.S (with Flatcap)						**22**	5	5	5	0	0	No pictures of the quoted items are provided in the original Bid	**5**	1	**21**	**43**
	63	Paracetamol	100ml	IVInf	Panafin IV Infusion						**22**	0	NO GD/COA, FORM 3, Form 7 attached in the bid	0	0	0	No pictures of the quoted items are provided in the original Bid	**5**	0	**5**	**27**
	638	Dextrose 5%	100ml	IVInf	Medisol 5% IV Solution with Double Eurocap						**22**	0	5	5	0	0	No pictures of the quoted items are provided in the original Bid	**5**	0	**15**	**37**
	656	0.9% Sodium Chloride	100ml	IVInf	Medisol NS IV Solution with Double Eurocap						**22**	0	5	5	0	0	No pictures of the quoted items are provided in the original Bid	**5**	1	**16**	**38**
	4	Metronidazole	500mg/100ml	100ml	IVInf						**22**	0	NO GD/COA, FORM 3, Form 7 attached in the bid	0	0	0	No pictures of the quoted items are provided in the original Bid	**5**	0	**5**	**27**
	669	Compound Sodium Lactate (Ringer's Lactate)	250ml	IVInf	Medisol Hartmann's IV Infusion Double Eurocap						**22**	5	5	5	5	0	No pictures of the quoted items are provided in the original Bid	**5**	1	**26**	**48**
	657	0.9% Sodium Chloride	250ml	IVInf	Medisol NS IV Infusion with Double Eurocap	The firm was inspected as per technical evaluation criteria. However, both cGMP certificate of both the plants (Sundar Industrial Estate, Lahore & Quaid-E-Azam Industrial Estate Kot Lahkhpat, Lahore was expired at the time of inspection. In view of the above, the firm is NOT RECOMMENDED for award of factory evaluation visit score for the quoted items.						**22**	5	5	5	0	0	No pictures of the quoted items are provided in the original Bid	**5**	1	**21**	**43**
	643	Dextrose 5% + 0.9% Sodium Chloride	250ml	IVInf	Medisol 5 IV Infusion with Double Eurocap						**22**	5	5	5	0	0	No pictures of the quoted items are provided in the original Bid	**5**	0	20	42
	639	Dextrose 5%	250ml	IVInf	Medisol 5% IV Infusion with Double Eurocap						**22**	5	5	5	0	0	No pictures of the quoted items are provided in the original Bid	**5**	0	20	42
	628	Balanced Electrolyte Solution	250ml	Sol	Medisol B.E.S						**22**	5	5	5	5	0	No pictures of the quoted items are provided in the original Bid	**5**	0	25	47
	839	Moxifloxacin	5ml	Eye Drop	Medimox						**22**	0	GD provided at page No. 1579 is older than 12 months		0	0	No pictures of the quoted items are provided in the original Bid	**5**	2	7	29
	832	Dorzolamide 2% + Timolol 0.5%	5ml	EyeDrop	Medisopt						**22**	0	5	5	0	0	No pictures of the quoted items are provided in the original Bid	**5**	2	17	39
	852	Tobramycin + Dexamethasone	5ml	Eye Drop	Mebradex						**22**	0	GD provided is not coupled with AWB/ BL at page No. 1724		0	0	No pictures of the quoted items are provided in the original Bid	**5**	0	5	27
	827	Ciprofloxacin	5ml	Eye Drop	Ciprofloxacin						**22**	0	GD provided at Page No 1687 is older than 12 months		0	0	No pictures of the quoted items are provided in the original Bid	**5**	0	5	27
	851	Tobramycin	5ml	Eye Drop	Tobramycin						**22**	0	GD provided is not coupled with AWB/ BL at page No. 1724		0	0	No pictures of the quoted items are provided in the original Bid	**5**	0	5	27
	850	Timolmazole	5ml	Eye Drop	Meditium 0.5%						**22**	0	0	0	0	0	No pictures of the quoted items are provided in the original Bid	**5**	0	5	27
	830	Dexamethasone Sodium Phosphate	5ml	Eye Drop	Medidax						**22**	0	GD provided at 1809 is older than 24 months		0	0	No pictures of the quoted items are provided in the original Bid	**5**	0	5	27
	837	Latanaprost	2.5ml	Eye Drop	Modilatin						**22**	0			0	0	No pictures of the quoted items are provided in the original Bid	**5**	0	5	27

Scrutiney Report

GMP of both plants (Kot Lakhpat + Sundar Industrial estate) attached at Page No. 85,86,87 are expired

Original Mandatory forms in Hard are not submitted to the MCC

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposibles and Sutures for Government MCC 2026-27

Name of the firm: MEDIPAK LIMITED

S.No		Product General Information				Technical Evaluation Matrix															
						Factory Technical Evaluation Parameter								Factory Evaluated Score	Product technical Evaluation Parameters						Product Evaluated Score	Total Technical Score
						Documents Based Factory Score				Evaluation Visit Score												
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million – 6 marks	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. **(as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.**	Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAP regulations. **(to be evaluated by the MCC expert/s at the time of inspection, Noncompliance to cGMP shall lead to disqualification of the relevant section or firm)**	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section / firm.**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC** **(Certificate Duly attested by Senior Executive of the firm)**	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form, Moreover, the approval(s) shall be duly attested by the concerned	Valid WHO prequalification and / or valid product registration in SRA/WLA country(ies) / and / or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	6	3	3	2	2	29	5	5	5	6	10	10	41	70
	1119	Infusion Giving Set in Blister Pack	-	Drip Set	Mediset SF-35 Blister (sterile and pyrogen free, minimum 150cm tube length, blister pack)	**3**	0	**5**	**6**	The firm was inspected as per technical evaluation criteria. However, both cGMP certificate of both the plants (Sundar Industrial Estate, Lahore & Quaid-E-Azam Industrial Estate Kot Lahkhpat, Lahore was expired at the time of inspection. In view of the above, the firm is NOT RECOMMENDED for award of factory evaluation visit score for the quoted items.				**14**	0	0	0	0	**10**	**10**	**10**	**24**
	1120	Infusion Giving Set with Luer Lock & Y Connector (20 Drops/Min)	-	Drip Set	Mediset AV-20 (Sterile, minimum 150cm length tubing, latex and pyrogen free, blister pack)	**3**	0	**5**	**6**					**14**	0	0	0	0	**10**	**10**	**10**	**24**

Scrutiny Report

GMP of both plants (Kot Lakhpat + Sundar Industrial estate) attached at Page No. 85,86,87 are expired

Evaluation Criteria for Manufacturers of Non Drugs Items for Govt MCC 2026-27

Name of the firm: MEDIPAK LIMITED

S.No	MCC formulary No.	Product General Information 1	2	3	4	Factory Technical Evaluation Parameter – Documents Based Factory Score 5	6	7	8	Evaluation Visit Score 9	10	11	12	Factory Evaluated Score 13	Technical Evaluation Matrix 14	15	16	17	18	Product Evaluated Score 19	Total Technical Score 20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. **(as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.**	Adherence to Current Good Manufacturing Practices in line with the DRAP regulations. **(to be evaluated by the MCC expert/s, Non compliance to cGMP shall lead to disqualification of the relevant section or firm)**	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section (s) / firm.**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC** **(Certificates duly attested by Senior Executive of the firm)**	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. **In case of Non-provision matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.**	Physical examination of the quoted item/s by the MCC expert/s, Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	6	5	5	5	5	**39**	5	5	5	6	10	**31**	**70**
	651	Acid & Basic Concentrate for Bicarb Haemio Dialysis	4 Litre	Dialysis Sol	Medisol AC+BC (PET Bottle)	3	5	5	6	The firm was inspected as per technical evaluation criteria. However, both cGMP certificate of both the plants (Sundar Industrial Estate, Lahore & Quaid-E-Azam Industrial Estate Kot Lahkhpat, Lahore was expired at the time of inspection. In view of the above, the firm is NOT RECOMMENDED for award of factory evaluation visit score for the quoted items.				**19**	GDs attached at page No. 2073, 2074 are older than 24 months	0	No related document provided	No related document provided		**0**	**19**

Scrutiny Report

GMP of both plants (Kot Lakhpat + Sundar Industrial estate) attached at Page No. 85,86,87 are expired

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: MEGA PHARMA LAHORE

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualificatio n of the section/s or firm)**.	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities).	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this column for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g.,	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
	41	Diclofenac Sodium enteric coated	Tab 50mg		Megafenac	2	2	3	0	5	4	The firm was inspected as per technical evaluation criteria. The observations made are as follows; Non-Compliance with Good Storage Practices (GSP) In the Raw Material Store (RMS), an open bag containing powder excipient was found placed without any identification label or status label. The excipient bag lacked essential traceability information including material name, batch number, quarantine/release status, and date of opening. The absence of proper labelling and status identification compromises material traceability, inventory management, and status control systems required under cGMP and Good Storage Practices (GSP). The open and improperly identified condition of the excipient increases the risk of contamination, material mix-up, and unauthorized use during manufacturing operations. Deficient HVAC and Environmental Control Systems In the tablet compression area, the Relative Humidity (RH) was recorded at 92% during inspection, indicating serious failure of environmental and humidity control systems. The excessively high humidity conditions observed in the compression area are unsuitable for pharmaceutical manufacturing operations and may adversely affect granule properties, compression characteristics, product stability, dissolution profile, and overall product quality. The HVAC system was found non-functional in the production areas at the time of inspection, compromising temperature control, humidity regulation, air filtration, and contamination prevention systems required under cGMP. Failure of the HVAC system also compromises maintenance of controlled manufacturing conditions and proper environmental management within production areas. Differential pressure gauges installed at all production sites were found out of order and non-functional during inspection. Non-functional pressure gauges compromise monitoring and maintenance of appropriate air pressure differentials between manufacturing areas, thereby increasing the risk of cross-contamination, dust migration, and uncontrolled airflow. The absence of effective pressure monitoring systems reflects inadequate environmental monitoring and deficient engineering control systems within the facility. All doors within the production area were observed containing							**16**	0	5	5	0	0	0	5	0	**15**	**31**
	51	Meloxicam	Tab 15mg		Movera	2	2	3	0	5	4						**16**	0	GD is older than 24 months-01/2019, Page: 1011	0	0	0	0	5	0	**5**	**21**
	52	Meloxicam	Tab 7.5mg		Movera	2	2	3	0	5	4						**16**	0	GD is older than 24 months-01/2019, Page: 1011	0	0	0	0	5	0	**5**	**21**
	65	Paracetamol + Orphenadrine	Tab 450mg / 35mg		Megagesic	2	2	3	0	5	4						**16**	0	5	5	0	0	0	5	0	**15**	**31**
	67	Tizanidine	Tab 4mg		Zandic	2	2	3	0	5	4						**16**	0	GD is older than 24 months-01/2021, Page: 740	0	0	0	0	5	0	**5**	**21**
	93	Leflunomide	Tab 20mg		Lefona	2	2	3	0	5	4						**16**	0	5	5	0	0	0	5	0	**15**	**31**
	144	Fluconazole	Tab / Cap 50mg		Ranzo	2	2	3	0	5	4						**16**	0	5	5	0	0	0	5	0	**15**	**31**
	145	Fluconazole	Tab / Cap 150mg		Ranzo	2	2	3	0	5	4						**16**	0	5	5	0	0	0	5	0	**15**	**31**
	161	Cetirizine	Tab 10mg		Daisy	2	2	3	0	5	4						**16**	0	5	5	0	0	0	5	0	**15**	**31**
	166	Levocitirizine	Tab 5mg		Zosper	2	2	3	0	5	4						**16**	0	GD is older than 24 months-12/2020, Page: 753	0	0	0	0	5	0	**5**	**21**
	167	Loratadine	Tab 10mg		Megalor	2	2	3	0	5	4						**16**	0	5	5	0	0	0	5	0	**15**	**31**
	169	Montelukast	Tab 5mg		Mykast	2	2	3	0	5	4						**16**	0	5	5	0	0	0	5	0	**15**	**31**
	168	Montelukast	Tab 10mg		Mykast	2	2	3	0	5	4						**16**	0	5	5	0	0	0	5	0	**15**	**31**
	199	Azithromycin	Tab 250mg		Macromax	2	2	3	0	5	4						**16**	0	GD is older than 24 months-09/2020, Page: 1054	0	0	0	0	5	0	**5**	**21**
	200	Azithromycin	Tab 500mg		Macromax	2	2	3	0	5	4						**16**	0	GD is older than 24 months-09/2020, Page: 1054	0	0	0	0	5	0	**5**	**21**
	202	Azithromycin	Dry Susp. 200mg / 5ml		Macromax	2	2	3	0	5	4						**16**	0	GD is older than 24 months-09/2020, Page: 1054	0	0	0	0	5	0	**5**	**21**
	209	Cefaclor	Susp. 250mg / 5ml		X-Clor	2	2	3	0	5	4						**16**	0	GD is older than 24 months-02/2021, Page: 1062	0	0	0	0	5	0	**5**	**21**
	214	Cefixime	Cap 400mg		C-Span	2	2	3	0	5	4						**16**	0	5	5	0	0	0	5	0	**15**	**31**
	215	Cefixime	Dry Susp. 100mg/5ml		C-Span	2	2	3	0	5	4						**16**	0	5	5	0	0	0	5	0	**15**	**31**
	216	Cefixime	Dry Susp. 200mg/5ml		C-Span DS	2	2	3	0	5	4						**16**	0	5	5	0	0	0	5	0	**15**	**31**
	223	Cefpodoxime	Dry Susp. 40mg / 5ml		Megadoxim	2	2	3	0	5	4						**16**	0	5	5	5	0	0	5	0	**20**	**36**
	232	Cefuroxime	Dry Susp. 125mg/5ml		Celoxime	2	2	3	0	5	4						**16**	0	5	5	5	0	0	5	0	**20**	**36**
	240	Ciprofloxacin	Tab 250mg		Riteflox	2	2	3	0	5	4						**16**	0	5	5	0	0	0	5	0	**15**	**31**
	241	Ciprofloxacin	Tab 500mg		Riteflox	2	2	3	0	5	4						**16**	0	5	5	0	0	0	5	0	**15**	**31**
	244	Clarithromycin	Tab 250mg		Megamycin	2	2	3	0	5	4						**16**	0	GD is older than 24 months-05/2019, Page No. 820	0	0	0	0	0	0	**0**	**16**
	245	Clarithromycin	Tab 500mg		Megamycin	2	2	3	0	5	4						**16**	0	GD is older than 24 months-05/2019, Page No. 820	0	0	0	0	0	0	**0**	**16**
	274	Levofloxacin	Tab 250mg		Leocin	2	2	3	0	5	4						**16**	0	5	5	0	0	0	5	0	**15**	**31**
	275	Levofloxacin	Tab 500mg		Leocin	2	2	3	0	5	4						**16**	0	5	5	0	0	0	5	0	**15**	**31**

	278	Linezolid	Tab 600mg		Megalid	2	2	3	0	5	4	Improperly sealed doors compromise maintenance of required air differential pressures and controlled airflow patterns between various production rooms. The defective door sealing condition adversely affects containment integrity, environmental control, and contamination prevention systems required under cGMP guidelines for pharmaceutical manufacturing facilities.In view of the above, the firm is NOT RECOMMENDED for award of factory evaluation visit score for the quoted items.	**16**	0			0	0	0	5	0	**5**	**21**
	284	Moxifloxacin	Tab 400mg		Moxifar	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	410	Amlodipine + Valsertan	Tab 5mg+80mg		Megadip-V	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	411	Amlodipine + Valsertan	Tab 5mg+160mg		Megadip-V	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	412	Amlodipine + Valsertan	Tab 10mg+160mg		Megadip-V	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	414	Atenolol	Tab 50mg		ATL	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	415	Atenolol	Tab 100mg		ATL	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	459	Losartan Potassium	Tab 50mg		Megasar	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	464	Metoprolol	Tab 100mg		Megatop	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	478	Rosuvastatin	Tab 10mg		Rousmeg	2	2	3	0	5	4		**16**	0	Gd is older than 24 months, 01/2021, Page No. 890.	0	0	0	0	5	0	**5**	**21**
	506	Domperidone	Tab 10mg		Protomic	2	2	3	0	5	4		**16**	0	5	5	US FDA inspection is done only for fexofenadine and	0	0	5	0	**15**	**31**
	510	Famotidine	Tab 40mg		Curofam	2	2	3	0	5	4		**16**	0	GD is older than 24 months, 12/2019, Page. 920	0	0	0	0	5	0	**5**	**21**
	520	Omeprazole	Cap 40mg		Megazole	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	543	Glibenclamide	Tab 5mg		Glucoban	2	2	3	0	5	4		**16**	0	GD is older than 24 months, 03/2022, Page: 950	0	0	0	0	5	0	**5**	**21**
	544	Gliclazide	Tab 80mg		Glide	2	2	3	0	5	4		**16**	0			0	0	0		0	**0**	**16**
	545	Glimepride	Tab 1mg		Megapride	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	546	Glimepride	Tab 2mg		Megapride	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	547	Glimepride	Tab 3mg		Megapride	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	548	Glimepride	Tab 4mg		Megapride	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	705	Duloxetine	Cap 30mg		Simbalta	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	706	Duloxetine	Cap 60mg		Simbalta	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	711	Escitalopram	Tab 10mg		Esse	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	712	Flouxetine HCl	Cap 20mg		Deprezac	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	721	Levetiracetam	Tab 250mg		Tiracit	2	2	3	0	5	4		**16**	0	GD is older than 24 months, 06/2022, Page: 1131	0	0	0	0	5	0	**5**	**21**
	722	Levetiracetam	Tab 500mg		Tiracit	2	2	3	0	5	4		**16**	0	GD is older than 24 months, 06/2022, Page: 1131	0	0	0	0	5	0	**5**	**21**
	727	Olanzapine	Tab 5mg		Olanzar	2	2	3	0	5	4		**16**	0	GD is older than 24 months, 07/2020, Page: 995	0	0	0	0	5	0	**5**	**21**
	728	Olanzapine	Tab 10mg		Olanzar	2	2	3	0	5	4		**16**	0	GD is older than 24 months, 07/2020, Page: 995	0	0	0	0	5	0	**5**	**21**
	738	Pregabalin	Cap 50mg		Pregra	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	739	Pregabalin	Cap 75mg		Pregra	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	509	Drotaverine	Tab 40mg		Spasmeg	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	408	Amlodipine Besylate	Tab 5mg		Megadip	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	409	Amlodipine Besylate	Tab 10mg		Megadip	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	746	Resperidone	Tab 2mg		Dawn	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	747	Resperidone	Tab 4mg		Dawn	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	573	Sitagliptin + Metformin	Tab 50mg/500mg		Megsita-M	2	2	3	0	5	4		**16**	0	GD is older than 24 months, 02/2021, Page: 958	0	0	0	0	5	0	**5**	**21**
	574	Sitagliptin + Metformin	Tab 50mg/1000mg		Megsita-M	2	2	3	0	5	4		**16**	0	GD is older than 24 months, 02/2021, Page: 958	0	0	0	0	5	0	**5**	**21**
	666	Allopurinol	Tab 300mg		Agout	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	238	Cephradine	Dry Susp 125mg/5ml		Merric	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	239	Cephradine	Dry Susp 250mg/5ml		Merric	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	234	Cephradine	Cap 250mg		Merric	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**
	235	Cephradine	Cap 500mg		Merric	2	2	3	0	5	4		**16**	0	5	5	0	0	0	5	0	**15**	**31**

Scrutiny report

1Pack sizes shall be provided as per the advertised Schedule of requirements & Additional Packs are not allowed if not advertised
2Documents of pantoprazole are attached while not mentioned in the quoted products list- Page 923
3Documents of Metronidazole are attached while not mentioned in the quoted products list- Page 1005- GD at Page 1005 is older than 24 months- 07/2021
4Documents ofTramadol are attached while not mentioned in the quoted products list- Page 1028- GD at Page 1028 is older than 24 months- 07/2021
5Documents of Mecobalamin are attached while not mentioned in the quoted products list- Page 1063
6Documents of Bisoprolol are attached while not mentioned in the quoted products list- Page 1084
7Documents of Febuxostat are attached while not mentioned in the quoted products list- Page 1693
8Documents of Ibuprofen are attached while not mentioned in the quoted products list- Page 1162
9Documents of Esomeprazole are attached while not mentioned in the quoted products list- Page 1247
10Images provided does not show the Strips and bottles whether the strips are Alu Alu, Alu PVC, Bottles are glass bottles or PET bottles.
11CoAs and API Source accreditation are not awarded in cases where GDs are not present or are invalid.
12 IMS ranking, IMS product share not present in the bid.

TECHNICAL EVALUATION PROFORMA, FOR PROCUREMENT OF ANTICANCER MEDICINES IN GOVT. MCC FY 2026-27

Name of the firm with Complete Address: MERIXIL PHARMA ISLAMABAD

Manufacturer / Importer: IMPORTER

		Mandatory Requirements.	YES / NO		In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:		YES/NO		In case of being Importers, the Firm should provide attested copies of the following documents also:	YES/NO	
1		National Tax Number (NTN) of the Firm for Income Tax, and	YES		1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and		1	Valid Drugs Sales License for the importer; and	YES	
2		Last year Income Tax Return of the Firm; and	YES		2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.		2	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	YES	
3		Sale Tax Registration Certificate of the Firm; and	YES		3	Valid DRAP Approved Price List of the quoted item/s.		3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	YES	
4		Certificate of Professional Tax of the Firm.	YES					4	Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and	YES	
5		Certificate of compliance to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR, Non-Compliance of cold chain requirements shall lead to non-issuance of Cold Chain requirements shall lead to disqualification of the relevant product that requires cold chain.	YES					5	Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods. Non provision of this document shall lead to disqualification of the firm; and	YES	
								6	Valid DRAP approved Price List of the quoted items.	NO	

		Technical Evaluation Parameters	Active Pharmaceutical Ingredient source gradation (For API or finished product). i) The bidder (local manufacturer / multi-national manufacturer / importer) shall provide Analytical/Quality Assurance/ Approval Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades. Certificate of Analysis/ Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreement/ approval with the original manufacturer duly attested/ hverified by official of the company. Detailed purchase trail of the Active Pharmaceutical Ingredient/ Finished product from the claimed source must be submitted (any proof of purchase such as Goods Declaration Certificate along with Airway Bill/ Bill of Lading/Invoice etc.) by the bidder. Maximum marks for this criterion are 40.	Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW) Study/Certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities)/ WHO Listed Authorities MLA Countries OR BE/ BS Certificate with evidence as to its authenticity) from Category A countries. Bio-Equivalence (BE) of the quoted product to be conducted against the originator. Original innovator products do not require bio- equivalence certificate and shall get 10 marks automatically.The bidder shall provide the documents to establish the proof of inventor/ originator. All other branded generics require BE studies. Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid. Maximum marks for this criterion are 10.	Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug, In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article) Mandatory: Online verification link must be provided to verify the Clinical Trial/ Clinical Studies submitted for the quoted items.	Factory/ Importer Based Evaluation Score (MANDATORY)	Sample Evaluation by End User Committee Samples will be examined per following parameters as follows: a. Quality Control Packing Rules 1986 b. Outer packing c. Inner packing d. Physical appearance. Product which has unsatisfactory packing/labeling will be technically Disqualified. Maximum score for this criterion is 1.		Post Performance (Last two years). i) Good Performance Certificates of these institutions must be produced in order to be awarded 1 mark per institution upto a maximum of 5 marks. ii) Only supply orders will not get any marks. iii) The bidders have to undertake that they have never been blacklisted or debarred. Maximum marks for this criterion are 5. iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.	Total Technical Score
			Category A – Approved By: • United States Food & Drug Administration (USFDA) • European Medicines Agency (EMA) • Medicines & Healthcare Products Regulatory Agency (MHRA), UK • Therapeutic Goods Administration (TGA), Australia • Pharmaceutical Medical Agency (PHARMAC), New Zealand • Pharmaceutical & Medical Devices Agency (PMDA), Japan • Swissmedic for therapeutic drugs (Swissmedic), Switzerland • Health Canada • Health Sciences Authority (HAS), Singapore • National Administration of Drugs, Food & Medicines (ANMAT), Argentina Drug Regulatory Authorities of the WLA (Stringent Regulatory Authorities) / WHO Listed Authorities MLA countries	Category B – Approved By: • Agência Nacional de Vigilância Sanitária (ANVS), Brazil • Central Drugs Standard Control Organization (CDSCO), India • Drug Regulatory Authority, Pakistan • National Pharmaceutical Control Bureau (NPCB), Malaysia • Food & Drug Administration, South Korea • Ministry of Health, Egypt • Ministry of Health, Iran • China Food & Drug Administration • Any other source not mentioned in Category-A	Study/ certificate accepted/certified by a Stringent Regulatory Authority. BE testing must be done using at least 12 subjects. Bio-waiver is acceptable only for injectable forms of insulin by Category A Country.	BE/BS/BW certificate obtained for a quoted product from Category B country, is also considered as it has 5 above).	BE/ BS/ BW Certificate.	In case the study is published in Category "A" journal listed in the Professional Practice 2023 and a part of National Recognized Journals as per PMDC, 2 marks per original research article shall be awarded maximum up to 6 marks).	In case the study is published in Category "B" journal listed in the Professional Practice 2023 and a part of National Recognized Journals as per PMDC, 2 marks per original research article shall be awarded maximum up to 6 marks).	Studies/ original articles published in any category "C" journal of the SERO/ Journals listed in Professional Practice 2023 and List of National Recognized Journals as per PMDC, 1 marks per original research article shall be awarded maximum up to 6 marks).	The Physical inspection of the premises of the bidders (Manufacturer/ Importer) shall be carried out in accordance with ISO 19 (E) 2015, ICH Q7, GMP, WHO TRS 970 (53) 2003 & PSB approved Rules of Govt. MCC FY 2026-27	satisfactory	unsatisfactory	5. Substantial quantity of supplies of anti-cancer medicines made to private sector Teaching hospitals (Shifa International Hospital Islamabad, Rehman Medical Institute Peshawar, Aga Khan Hospital, Lahore Peshawar, Ziauddin Hospital and Hayatabad Medical Complex, Peshawar (Max International Hospital Islamabad, with Good Satisfactory Performance Certificates from these institutions shall be awarded 1 mark per institution (in those who provide good performance certificate issued in the last 24 months. No marks will be given for supply orders except OMH Rawalpindi where supply orders coupled with delivery challans & invoices will be considered for award of marks. 1 mark per agreement up to a maximum of 6 marks	
SOURCE	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	**40**	**30**	**10**	**5**	**0**	**9**	**6**	**0**	**5**	**1**	**0**	**5**	**70**
XIAMEN AMOYTOP BIOTECH CO. LTD, CHINA	85	Filgrastim	300 mcg	inj.	Topneuter		30	0			0			5	1		3	39
SEACROSS PHARMACEUTICALS, UK	1454	Bendamustine	100 mg	inj.	Bendamustine Seacross	40		0			0			5	1		3	49
NORMON MADRID SPAIN	1471	Capecitabine	500 mg	Tab.	Capecitabine Normon	40		0			0			5	1		3	49
BIOLYSE PHARMA CANADA	1501	Docetaxel	20 mg	inj.	Biodoce	40		0			0			5	1		3	49
BIOLYSE PHARMA CANADA	1502	Docetaxel	80 mg	inj.	Biodoce	40		0			0			5	1		3	49
NORMON MADRID SPAIN	1514	Exemestane	25 mg	Tab.	Exemestane Normon	40		0			0			5	1		3	49
SEACROSS PHARMACEUTICALS, UK	1517	Fulvestrant	250 mg	inj. / PFS	Fulvestrant Seacross	40		0			0			5	1		3	49
NORMON MADRID SPAIN	1530	Imatinib	100 mg	Tab.	Imatinib Normon	40		0			0			5	1		3	49
GP PHARM SPAIN	1552	Leuprolide Acetate Depot	22.5 mg	KIT	Lutrate 22.5	40		0			0			5	1		3	49
BIOLYSE PHARMA CANADA	1592	Paclitaxel	300 mg	inj.	Biopac 300mg	40		0			0			5	1		3	49
ERGEN PHARMA IRELAND	1629	Temozolomide	100 mg	Cap.	Temoeirgen 100mg	40		0			0			5	1		3	49
ERGEN PHARMA IRELAND	1630	Temozolomide	20 mg	Cap.	Temoeirgen 20mg	40		0			0			5	1		3	49

Scrutiny Report
1:Clinical trial bioequivalence of capecitabine is not published- not present online Page-317
2Page 366, 368, 367, 369 are not in English language
3Study at Page 401 is not published, not available online
4Study at Page 402 is not published, not available online
5Study at Page 442 is not published, not available online

MKB PHARMA PESHAWAR

	Product General Information				Technical Evaluation Matrix																					
					Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
					Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission.	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this column for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product).	Stability studies of quoted item/s duly attested by the Q,C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of		
MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**5**	**3**	**4**	**5**	**5**	**37**	**70**
51	Meloxicam	15 mg	Tab.	Mobiclex	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		NA	NA	0	0	4	5		**9**	**31**
52	Meloxicam	7.5mg	Tab.	Mobiclex	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		NA	NA	0	0	4	5		**9**	**31**
65	Paracetamol + Orphenadrine	450 mg/35 mg	Tab.	Cetamol Plus	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		NA	NA	0	0	4	5		**9**	**31**
137	Fluconazole	150mg	Cap.	Mycocin	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	4	5		**19**	**41**
138	Fluconazole	50mg/5mL	Suspension	Mycocin	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	USP TYPE-III NOT MENTIONED IN COA	5		**15**	**37**
160	Montelukast	10mg	Tab.	Prevasma	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	4	5		**19**	**41**
161	Montelukast	5mg	Tab.	Prevasma	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	4	5		**19**	**41**
162	Montelukast	4mg	Sachet	Prevasma	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	4	5		**19**	**41**
189	Azithromycin	250mg	Cap.	Zithrox	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	4	5		**19**	**41**
190	Azithromycin	500mg	Tab.	Zithrox	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	4	5		**19**	**41**
192	Azithromycin	200mg/5mL	Dry Susp.	Zithrox	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	4	5		**19**	**41**
204	Cefixime	400mg	Cap.	Cefispec	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	4	5		**19**	**41**
205	Cefixime	100 mg/5ml	Dry Susp.	Cefispec	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	USP TYPE-III NOT MENTIONED IN COA	5		**15**	**37**
206	Cefixime	200 mg/5ml	Dry Susp.	Cefispec DS	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	USP TYPE-III NOT MENTIONED IN COA	5		**15**	**37**
213	Cefpodoxime	40 mg/5mL	Dry Susp.	Cefpogen	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	USP TYPE-III NOT MENTIONED IN COA	5		**15**	**37**
224	Cephradine	250 mg	Cap.	Qualicef	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	4	5		**19**	**41**
225	Cephradine	500mg	Cap.	Qualicef	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	4	5		**19**	**41**
229	Cephradine	250mg/5mL	Dry Susp.	Qualicef	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	USP TYPE-III NOT MENTIONED IN COA	5		**15**	**37**
230	Ciprofloxacin	250mg	Tab.	Ciprobid	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	4	5		**19**	**41**
231	Ciprofloxacin	500mg	Tab.	Ciprobid	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	4	5		**19**	**41**
264	Levofloxacin	250 mg	Tab.	Leoquin	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	4	5		**19**	**41**
265	Levofloxacin	500 mg	Tab.	Leoquin	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	4	5		**19**	**41**
275	Moxifloxacin	400 mg	Tab.	Moxipro	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	4	5		**19**	**41**
300	Artemether + Lumefantrine	40 mg/240mg	Tab.	Lumesin	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		NA	NA	0	0	4	5		**9**	**31**
301	Artemether + Lumefantrine	80 mg/480mg	Tab.	Lumesin Con	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		NA	NA	0	0	4	5		**9**	**31**
302	Artemether + Lumefantrine	15 mg/ 90 mg/5mL	Susp.	Lumesin	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		NA	NA	0	0	USP TYPE-III NOT MENTIONED IN COA	5		**5**	**27**
372	Iron Hydroxide poly maltose complex	50 mg/5ml	Syp.	Hbfer	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	4	5		**19**	**41**
377	Mecobalamin	500mcg	Tab.	Nerish	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		NA	NA	0	0	4	5		**9**	**31**
471	Rosuvastatin	10mg	Tab.	Russal	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		NA	NA	0	0	4	5		**9**	**31**
497	Aluminium Hydroxide + Magnesium Hydroxide + Simethicone	5mg/5mL 80mg/5mL 25mg/5	Susp.	Trijex	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		NA	NA	0	0	4	5		**9**	**31**
503	Domperidone	10mg	Tab.	Peptidon	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	4	5		**19**	**41**
504	Domperidone	5mg/5mL	Susp.	Peptidon	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	4	5		**19**	**41**
518	Esomeprazole	40mg	Cap.	Score	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	4	5		**19**	**41**

526	Simethicone	40 mg/mL	Oral Drops	Semthic	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		NA	NA	0	0	4	5		**9**	**31**
535	Clomiphene Citrate	50mg	Tab.	Clomitrates	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		NA	NA	0	0	4	5		**9**	**31**
581	Sitagliptin + Metformin	.50 mg/500 mg	Tab.	Sitaspec	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	4	5		**19**	**41**
582	Sitagliptin + Metformin	50mg /1000 mg	Tab.	Sitaspec	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	4	5		**19**	**41**
697	Tamsulosin HCl	0.4mg	Cap.	Xhyva SR	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	4	5		**19**	**41**
725	Escitalopram	10mg	Tab.	Talospec	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		NA	NA	0	0	4	5		**9**	**31**
753	Pregabalin	50mg	Cap.	Prebacit	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		NA	NA	0	0	4	5		**9**	**31**
754	Pregabalin	75mg	Cap.	Prebacit	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		NA	NA	0	0	4	5		**9**	**31**
755	Pregabalin	150mg	Cap.	Prebacit	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		NA	NA	0	0	4	5		**9**	**31**
800	Diphenhydramine+ Aminophylline+ Ammonium Chloride	g / 5mL 32mg / 5mL 30mg /	Syrup	Alvon	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		NA	NA	0	0	4	5		**9**	**31**
801	Doxofylline	400mg	Tab.	Ventidox	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	4	5		**19**	**41**
802	Doxofylline	100mg/5mL	Syrup	Ventidox	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		5	5	0	0	4	5		**19**	**41**
908	Alfacalcidol	0.5mcg	Tab.	Bonjour	**2**	**2**	**3**		**5**		**2**	**2**	**2**	**2**	**2**	**22**		NA	NA	0	0	4	5		**9**	**31**

DRAP APPROVED PRICE LIST NOT PROVIDED INSTEAD ON COMPANYS OWN LETTER HEAD MRP IS PROVIDED PAGE 47

Myocin Susp DRAP registration not attached

PAGE 140, USFDA FULL EIR REPORT NOT ATTACHED FOR MS SYNERGENE

PAGE 256 FDA REGISTRATION LINK IS ATTACHED ONLY WHICH DOES NOT FULFILL THE CRITERIA FOR AWARD OF MARKS

PAGE 357 FDA REGISTRATION LINK IS ATTACHED ONLY WHICH DOES NOT FULFILL THE CRITERIA FOR AWARD OF MARKS

PAGE 518, GD COA OF LUMEFANTRINE NOT ATTACHED IN BID

PAGE 609, EIR REPORT ATTACHED FOR DOMEPERIDONE IS ONLY FOR PANTOPRAZOLE AND FEXOFENADINE

TECHNICAL EVALUATION PROFORMA, FOR PROCUREMENT OF ANTICANCER MEDICINES IN GOVT. MCC FY 2026-27

	Name of the firm with Complete Address	MSA PHARMA , LAHORE
	Manufacturer / Importer	IMPORTER

		Mandatory Requirements.	YES / NO		In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:		YES/NO
1		National Tax Number (NTN) of the Firm for Income Tax, and	YES		1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and	
2		Last year Income Tax Return of the Firm; and	NO		2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.	
3		Sale Tax Registration Certificate of the Firm; and	YES		3	Valid DRAP Approved Price List of the quoted item/s.	
4		Certificate of Professional Tax of the Firm.	NO				
5		Certificate of compliance to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR. Non-Compliance to international reference standards or absence of Cold Chain requirements shall lead to disqualification of the relevant product that requires cold chain.	NO				

		In case of being Importers, the Firm should provide attested copies of the following documents also:	YES/NO	
1		Valid Drugs Sales License for the importer; and	YES	
2		Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	NO	
3		Valid Agency Agreement with the Foreign Principal/ Manufacturer entity/ies; and	NO	
4		Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods; Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and	NO	
5		Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods. Non provision of this document shall lead to disqualification of the firm; and	NO	
6		Valid DRAP approved Price List of the quoted item.	NO	

		Technical Evaluation Parameters	Active Pharmaceutical Ingredient source gradation (For API or finished product). i) The bidder (local manufacturer / multi-national manufacturer / importer) shall provide Analytical/Quality Assurance/ Approval Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades. Certificate of Analysis/ Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreements/ approval with the original manufacturer duly attested/verified by official of the company. Detailed purchase trail of the Active Pharmaceutical Ingredient/ Finished product from the claimed source/ manufacturer along proof of purchase such as Goods Declaration Certificate along with Invoice/ Bill of Lading/ Invoice etc.) by the bidder. Maximum marks for this criterion are 40.	Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW) Study/ Certificate from an accredited lab of DRA countries (Stringent Regulatory Authorities)/ WHO Listed Authorities WLA Countries BE/BS Certificate with evidence as to its authenticity) from Category A countries. Bio-Equivalence (BE) of the quoted product to be conducted against the originator. Original innovator products do not require bio- equivalence certificate and shall get 10 marks automatically.The bidder shall provide the documents to establish the proof of inventor/ originator. All other branded generics require BE studies Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid. Maximum marks for this criterion are 10.	Clinical Trial: Clinical studies assessing the safety and efficacy of the quoted drug, in case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article) Mandatory: Online verification link must be provided to verify the Clinical Trial/ Clinical Studies submitted for the quoted items.	Factory/ Importer Based Evaluation Score (MANDATORY)	Sample Evaluation by End User Committee Samples will be examined per following parameters as follows: a. Labelling and Packing Rules 1986 b. Inner packing c. Outer packing d. Physical appearance. Product which has unsatisfactory packing/labeling will be technically disqualified. Maximum score for this criterion is 1.	Past Performance (Last two years). i) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks. ii) Late supply orders will not get any marks. iii) The bidders have to undertake that they have never been blacklisted or debarred. Maximum marks for this criterion are 5. iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.	Total Technical Score
			Category A – Approved By: • United States Food & Drug Administration (US-FDA) • European Medicines Agency (EMA) • Medicines & Healthcare Products Regulatory Agency (MHRA-UK) • Therapeutic Goods Administration (TGA), Australia. • Pharmaceutical Medical Agency (PHARMAC), New Zealand • Pharmaceutical & Medical Devices Agency (PMDA), Japan • Swiss Agency For therapeutic drugs, Switzerland/ Liechtenstein • Health Canada • Health Sciences Authority (HAS), Singapore • National Administration of Drugs, Food & Medical technology (ANMAT), Argentina • Any other source approved by WHA Stringent Regulatory Authorities / WHO Listed Authorities WLA countries	Category B – Approved By: • Agência Nacional de Vigilância Sanitária (ANVS), Brazil • Central Drug Standard Control Organization (CDSCO), India • Drug Regulatory Authority, Pakistan • National Pharmaceutical Control Bureau (NPCB), Malaysia • Food & Drug Administration, Saudi Arabia • Ministry of Health, Egypt • Ministry of Health, Turkey • China Food & Drug Administration • Any other source not mentioned in Category-A	Study certificate completed/ certified by a Category A Country Regulatory Authority. BE testing must be done using the "Gold Standard" the extent is acceptable only is injectable forms if issued by Category A Country.	BE/BS/BW certificate received but a quoted product from Category B Country (as mentioned at S.No. 1 above)	No BE/BS/BW certificate.	In case the study is published in Category "N" journal listed in HEC Journal Recognition System (HJRS) Database (Medical Publication Policy 2023 and List of National Recognized Journals as per HEC shall not be awarded marks.	In case the study is published in Category "Y" journal listed in HEC Journal Recognition System (HJRS) Database (Medical Publication Policy 2023 and List of National Recognized Journals as per HEC shall be awarded marks (Research article shall be awarded maximum up to 9 marks).	Studies conducted on the products published in category "Y" journal listed in HEC Journal Recognition System (HJRS) Database (Medical Publication Policy 2023 and List of National Recognized Journals as per HEC shall not be awarded marks.	The Physical inspection of the premises of the bidders (Manufacturer/Importer) shall be carried out in accordance with TR 25.4(b), SC 9 (DCC 9.3), Section V (1) (1) (c) of the Approved SSDs of Govt. MCC FY 2026-27	Satisfactory	Unsatisfactory	a) Substantial quantity of supplies of anti-cancer medicines made to private sector Teaching Hospitals namely: The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar, Ziauddin Hospital and Hepatobiliary Medical Complex, Peshawar and Hepatobiliary Medical Complex, Peshawar and issued satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 24 months. No marks will be given for unsatisfactory performance. Late supply orders coupled with delivery challans & invoices will be considered for award of marks. 1 mark per agreement up to a maximum of 5 marks	
			0	0	0	0	0	0	0	5	1	0	5	70

Pack size	SOURCE	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name											
14's	NON FORMULARY	1427	Acacitidine	100mg	Tablet	Acarest 300mcg		0		0				0	The firm was inspected as per technical evaluation criteria. However, the quoted items were non formulary i.e. the advertised specification for inj Acacitidine 100mg whereas the firm has quoted 300mg, like wise the advertised dosage form Lenvatinib 10mg, 4mg Capsule whereas the firm has physical stock of Lenvatinib in both strengths in 10mg form of Capsules. In view of the above, the firm is NOT RECOMMENDED	Non Formulary		0	
30's	NON FORMULARY Getmed Pharmaceuticals Ltd., Bangladesh	1546	Lenvatinib	10mg	Tablet	Lenvasure 10mg		0		0				0			Sample presented in capsule form	0	
30's	NON FORMULARY Getmed Pharmaceuticals Ltd. Bangladesh	1545	Lenvatinib	4mg	Tablet	Lenvasure 4mg		0		0				0			Sample presented in capsule form	0	

SCRUTINY REPORT

	pdf page	
1	23	The quoted item formulary No. for Acacitidine 100mg tablet is non formulary.
2	23	The formulary No. for the quoted items for Lenvantinib 10mg and 4mg are wrongly mentioned in the technical bid (1520 & 1521). The correct formulary No. as per approved EID are 1544 & 1545)
3	23, 47-50, 68-71	The quoted product list has offered Tablet dosage form for the item Lenvatinib whereas the DRAP product registrations and COPP certificates has mentioned Capsule form. Hence, both the strengths are non-formulary
4		No documents regarding clinical trials and past performance are attached for award of marks.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: MTI MEDICAL PVT LTD, LAHORE

| S. No. | Product General Information | | | | | Technical Evaluation Matrix | | | | |

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27														
					Name of the firm	MULLER & PHIPPS KARACHI														
						Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
Convatec UK	875	Hydrocolloid Gel	GRANUGEL HYDROCOLLOID GEL WITH NOZZLE (15 GRAM)	Tube	GRANUGEL	3	5	0	The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COFG) for the quoted items were checked, and following observations were made; 1. ConvaTec Limited UK/Dominican Republic: All mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP) for the quoted items were not present at the time of inspection. The Authorized representative stated that all the Original documents are submitted in DRAP. 2. Fresenius Kabi Gmbh, Germany. All mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP) for the quoted items were not present at the time of inspection. The Authorized representative stated that all the Original documents are submitted in DRAP. 3. AstraZeneca Pakistan Pvt Limited. All mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP) for the quoted items were not present at the time of inspection. The Authorized representative stated that all the Original documents are submitted in DRAP. 4. 20% inventory of the quoted items, adequate qualified HR, Cold Chain facility, Good Storage practices and SOPs for expiry management were satisfactory/ present. In view of the above the firm is NOT–RECOMMENDED.			**8**	5	5	0	1	2		**13**	**21**
Convatec UK	956	Calcium Alginate Dressing	KALTostat DRESSING (7.5X12CM)	Dressing	KALTostat	3	5	0				**8**	5	5	0	1	2		**13**	**21**
Convatec UK	957	Calcium Alginate Dressing	KALTostat DRESSING (10X20CM)	Dressing	KALTostat	3	5	0				**8**	5	5	0	1	2		**13**	**21**
Convatec UK	958	Calcium Alginate Dressing	KALTostat DRESSING (15X25CM)	Dressing	KALTostat	3	5	0				**8**	5	5	0	1	2		**13**	**21**
Convatec UK	959	Calcium Alginate Dressing Rope	KALTostat ROPE (2GM)	Dressing	KALTostat	3	5	0				**8**	5	5	0	1	2		**13**	**21**
Convatec Dominican Republ	965	Colostomy bags (Set)	Multiple sizes (38mm to 70mm) with adhesive ring & clamp	Piece	NATURA / SUR-FIT	Dominican republic site not covered in 14001- Page 311	5	0				**5**	5	5	0	1	2		**13**	**18**
Convatec UK	1080	Extra Thin Hydrocolloid Dressing	DUODERM EXTRATHIN DRESSING 15X15CM	Dressing	DUODERM	3	5	0				**8**	5	5	0	1	2		**13**	**21**
Convatec UK	1111	Hydro fiber Dressing	AQUACEL AG+ EXTRA 10X10CM	Dressing	AQUACEL	3	5	0				**8**	5	5	0	1	2		**13**	**21**
Convatec UK	1112	Hydro fiber dressing with silver	AQUACEL AG+ EXTRA 20X30CM	Dressing	AQUACEL	3	5	0				**8**	5	5	0	1	2		**13**	**21**
Convatec UK	1113	Hydro fiber dressing with silver	AQUACEL AG+ EXTRA 15X15CM	Dressing	AQUACEL	3	5	0				**8**	5	5	0	1	2		**13**	**21**
Convatec UK	1114	Hydrocolloid Dressing (Different sizes)	Multiple DUODERM variants	Dressing	DUODERM	3	5	0				**8**	5	5	0	1	2		**13**	**21**
Convatec Dominican Republ	1231	Colostomy Paste	STOMAhesive PASTE (56.7G)	Tube	STOMAhesive	Dominican republic site not covered in 14001- Page 311	5	0				**5**	5	5	0	1	2		**13**	**18**

Duoderm Extrathin is not covered in the US free sale on Page 330

Tender approvals are not as per advertised criteria

TECHNICAL EVALUATION PROFORMA, FOR PROCUREMENT OF ANTICANCER MEDICINES IN GOVT. MCC FY 2026-27

	Name of the firm with Complete Address	MULLER & PHIPPS KARACHI
	Manufacturer / Importer	IMPORTER

		Mandatory Requirements.	YES / NO		In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:		YES/NO
1		National Tax Number (NTN) of the Firm for Income Tax, and	YES		1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and	
2		Last year Income Tax Return of the Firm; and	YES		2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.	
3		Sale Tax Registration Certificate of the Firm; and	YES		3	Valid DRAP Approved Price List of the quoted item/s.	
4		Certificate of Professional Tax of the Firm.	YES				
5		Certificate of compliance to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR. Non-Compliance to international reference standards or absence of Cold Chain requirements shall lead to disqualification of the relevant product that requires cold chain.	NO	Only SOP for cold chain of Muller & Phipps is provided- Compliance from an authority is not present			

	In case of being Importers, the Firm should provide attested copies of the following documents also:	YES/NO	
1	Valid Drugs Sales License for the importer; and	yes	
2	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	No	Items are not registered under Muller & Phipps
3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	Yes	
4	Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and	Yes	
5	Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s. Non provision of this document shall lead to disqualification of the firm; and	Yes	
6	Valid DRAP approved Price List of the quoted items.	Yes	

			Technical Evaluation Parameters			Active Pharmaceutical Ingredient source gradation (For API or finished product). i) The bidder (local manufacturer / multi-national manufacturer / importer) shall provide Analytical/Quality Assurance/ Approval Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades. Certificate of Analysis/ Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreement/ approval with the original manufacturer duly attested/verified by official of the company. Detailed purchase trail of the Active Pharmaceutical Ingredient/ Finished product from the claimed source must be submitted (any proof of purchase such as Goods Declaration Certificate along with Airway Bill/ Bill of Lading/invoice etc.) by the bidder. Maximum marks for this criterion are 40.		Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW) Study/Certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities)/ WHO Listed Authorities WLA Countries (BE/ BS Certificate with evidence as to its authenticity) from Category A countries. Bio-Equivalence (BE) of the quoted product to be conducted against the originator. Original innovator products do not require bio- equivalence certificate and shall get 10 marks automatically.The bidder shall provide the documents to establish the proof of inventor/ originator. All other branded generics require BE studies Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid. Maximum marks for this criterion are 10.			Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug. In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article) Mandatory: Online verification link must be provided to verify the Clinical Trial/ Clinical Studies submitted for the quoted items.			Factory / Importer Based Evaluation Score (MANDATORY)	Sample Evaluation by End User Committee Samples will be examined per following parameters as follows: a. Labeling and Packing Rules 1986 b. Outer packing c. Inner packing d. Physical appearance. Product which has unsatisfactory packing/labeling will be technically Disqualified. Maximum score for this criterion is 1.		Past Performance (Last two years). 1) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks. 2) Only supply orders will not get any marks. 3) The bidders have to undertake that they have never been blacklisted or debarred. Maximum marks for this criterion are 5. 4) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.	Total Technical Score
						Category A – Approval By: • United States Food & Drug Administration (US-FDA) • European Medicines Agency (EMA) • Medicines & Healthcare Products Regulatory Agency (MHRA), UK • Therapeutic Goods Administration (TGA), Australia. • Pharmaceutical Medical Agency (PHARMAC), New Zealand • Pharmaceutical & Medical Devices Agency (PMDA), Japan • Swiss Agency For therapeutic drugs (Swiss-medic), Switzerland • Health Canada • Health Sciences Authority (HAS), Singapore • National Administration of Drugs, Food & Medical technology (ANMAT), Argentina Drug Regulatory Authorities of the SRA (Stringent Regulatory Authorities) / WHO Listed Authorities WLA countries	Category B – Approved By: • Agência Nacional de Vigilância Sanitária (ANVS), Brazil • Central Drug Standard Control Organization (CDSCO), India • Drug Regulatory Authority, Pakistan • National Pharmaceutical Control Bureau (NPCB), Malaysia • Food & Drug Administration, South Korea • Ministry of Health, Egypt • Ministry of Health, Turkey • China Food & Drug Administration • Any other source not mentioned in Category-A	Study/certificate accepted/certified by a Category A Country Regulatory Authority. BE testing must be done using at least 12 subjects. Bio-waiver is acceptable only to injectable forms if issued by Category A Country.	BE/BS/BW certificate obtained for a quoted product from Category B Country (as mentioned at S No. 1 above).	No BE/BS/BW Certificate.	In case the study is published in Category "W" journal listed in HEC Journal Recognition System (HJRS) Database/ Journals & Publication Policy 2024 and List of National Recognized Journals as per HEC, 3 marks per original research article shall be awarded maximum up to 9 marks).	In case the study is published in Category "X" journal listed in HEC Journal Recognition System (HJRS) Database/ Journals & Publication Policy 2024 and List of National Recognized Journals as per HEC, 2 marks per original research article shall be awarded maximum up to 6 marks).	Studies/cogitated article published in category "Y" journal of the HJRS/ Journals & Publication Policy 2024 and List of National Recognized Journals as per HEC shall not be awarded marks.	The Physical Inspection of the premises of the bidders (Manufacturer/Importer) shall be carried out in accordance with ITB 25.4(h), SCC 5 (GCC 6.3), Section V (1) (j) (h) of the approved BSDS of Govt. MCC FY 2026-27	Satisfactory	Unsatisfactory	1) Substantial quantity of Supplies of anti-cancer medicines made to private sector Teaching Hospitals namely: The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar, CMH Rawalapindi and Hayatabad Medical Complex, Peshawar , Shifa Interntional hospital Islamabad, with Good/Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 24 months. No marks will be given for supply orders except CMH Rawalpindi where supply orders coupled with delivery challans & invoices will be considered for award of marks. 1 mark per agreement up to a maximum of 5 marks	
SOURCE	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	40	30	10	5	0	9	6	0	5	1	0	5	70
Astrazeneca	1505	Durvalumab	500mg	Inj	Imfinzi Injection 500mg/10ml	40		10	The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COFG) for the quoted items were checked, and following observations were made; 1. AstraZeneca Pakistan Pvt Limited. All mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP) for the quoted	9						2	61
Astrazeneca	1517	Fulvestrant	250mg	Inj	Faslodex 250mg Solution for Injection	40		10			6						2	58
Astrazeneca	1583	Olaparib	150mg	Tab/Cap	Lynparza Tab 150mg	40		10			9						2	61

Astrazeneca	1587	Osimertinib	80mg	Tab/Cap	TAGRISSO TAB 80MG BL 3X10	**40**		**10**	**of inspection. The Authorized representative stated that all the Original documents are submitted in DRAP. 4. 20% inventory of the quoted items, adequate qualified HR, Cold Chain facility, Good Storage practices and SOPs for expiry management were satisfactory/ present. In view of the above the firm is NOT–RECOMMENDED.**	**9**						**2**	**61**
Astrazeneca	1636	Trastuzumab Deruxtecan	100mg	Inj	Enhertu 100mg Powder for Concentrate for solution for infusion	**40**		**10**		**9**						**2**	**61**

All oncology products are registered under the name of Astrazeneca Pharmaceuticals- not Muller & Phipps-

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: NEUTRO PHARMA LAHORE

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs) and Form-7. Moreover, in	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate,**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
HUBEI	4	Metronidazole	500mg/100ml	Infusion, Pack of 1's, carton of 100 infusions, packed in carton	NeuSol-MTZ	2	2	3	4	5	6	2	2	2	2	2	**32**	0	0	0	0	0	0	5	0	**5**	**37**
AARTI	41	DICLOFENAC SODIUM	75MG/3ML	INJECTION, AMPOULE OF 3ML, Pack of 5's	HEUMATIC	2	2	3	4	5	6	2	2	2	2	2	**32**	0	5	5	0	0	0	5	0	**15**	**47**
SINOPHARM	217	Ceftriaxone (as sodium) I.V	500mg	Injection. Glass vial, individually packed in carton with solvent	Vexa	2	2	3	4	5	6	2	2	2	2	2	**32**	0	5	5	0	0	0	Not provided	0	**10**	**42**
SINOPHARM	218	Ceftriaxone (as sodium) I.V	1g	Injection. Glass vial, individually packed in carton with solvent	Vexa	2	2	3	4	5	6	2	2	2	2	2	**32**	0	5	5	0	0	0	5	0	**15**	**47**
COHANCE	504	Drotaverine	40mg/2ml	Injection, 2ml, pack of 25's	SPRASID	2	2	3	4	5	6	2	2	2	2	2	**32**	0	5	5	0	0	0	5	0	**15**	**47**
ZHEJIANG	536	Dexamethasone	4mg/ml	Inj pack of 25's with Leaflet	NEUDEX	2	2	3	4	5	6	2	2	2	2	2	**32**	0	0	0	0	0	0	5	0	**5**	**37**
SALINEN	646	Normal Saline Infusion	0.9% (100ml)	Infusion pack of 100 infusions or less packed in master carton	NeuSol-NS	2	2	3	4	5	6	2	2	2	2	2	**32**	0	0	0	0	0	0	5	1	**6**	**38**
IN HOUSE	665	Sterile Water for Injection 5ml	5ml	Injection	Neutroline	2	2	3	4	5	6	2	2	2	2	2	**32**	0	0	0	0	0	0	5	0	**5**	**37**

Scrutiny Report
1CNIC at Page No. 25 is not readable
2Docs at Page 816,817,818 are not readable
3Ceftriaxone is procured from 2 sources
4GD of metronidazole is not coupled with airway bill-Page 893, 869
5GD of Dexamethasone is not coupled with airway bill- Page No. 914
6GD of Sodium Chloride is not coupled with airway bill- Page 932
7EudraGMP of Sodium Chloride (API Source) is expired in 2024- Page 928
8GD at Page 955 is not readable
9Certificate of suitibility is not acceptable as API source accreditation
10Images of DRAP Approved packaging are not attached in the bid.
11IMS market share of less than 1% cannot be awarded
12Tender approvals are not applicable to general medicines

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm | **Next Pharma Lahore**

S. No.		Product General Information				Technical Evaluation Matrix																					
						Factory Technical Evaluation Parameters						Factory Evaluation Visit Score					Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score												Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 10001:45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by the value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment/ instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2025-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs * Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) as evaluated at the time of inspection by the MCC expert(s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, regs. **No evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Biowaivability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA/ EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/CSP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non-provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacoporial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or Next (**Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the QC incharge of the firm().	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the tender shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals= 01 mark 04 Tender approvals= 02 marks 06 Tender approvals= 03 marks 08 Tender approvals= 04 marks 10 or more Tender approvals= 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70
1	41	Diclofenac Sodium	50mg	Tab	Painext 50mg	2	2	3	0	5	4	2	2	2	2	2	26	Not attached	GD of diclofenac seems tampered need clarification at page 945 (left	0	0	0	Picture of the DRAP approved immediate container NA	5	Not attached	5	31
2	66	Tramadol HCL + Paracetamol	37.5/325mg	Tab	Paranext-T 37.5/325mg	2	2	3	0	5	4	2	2	2	2	2	26	Not attached	GD of paracetamol date is hidden hence no marks awarded on page no	0	0	0		5	Not attached	5	31
3	151	Betahistine Dihydrotartrate	16mg	Tab	Genhist 16mg	2	2	3	0	5	4	2	2	2	2	2	26	Not attached	5	5	0	0		5	Not attached	15	41
4	160	Montelukast Sodium	10mg	Tab	Aimont 10mg	2	2	3	0	5	4	2	2	2	2	2	26	Not attached	5	5	0	0		5	Not attached	15	41
5	231	Ciprofloxacin	500mg	Tab	Alacep 500mg	2	2	3	0	5	4	2	2	2	2	2	26	Not attached	No GD of cipro only awb attached On page 996 hence no marks awarded		0	0		5	Not attached	5	31
6	268	Linezolid	600mg	Tab	Linianex 600mg	2	2	3	0	5	4	2	2	2	2	2	26	Not attached	5	5	0	0		5	Not attached	15	41
7	372	Elemental Iron (as Iron III Hydroxide Polymaltose Complex)	50mg/5ml	Syp	HB-More Syrup 120ml	2	2	3	0	5	4	2	2	2	2	2	26	Not attached	5	5	0	0		5	Not attached	15	41
8	402	Amlodipine as Besylate	10mg	Tab	Amlonect 10mg	2	2	3	0	5	4	2	2	2	2	2	26	Not attached	5	5	0	0		5	Not attached	15	41
9	403	Amlodipine + Valsartan	5/80mg	Tab	Vehel-AM 5/80mg	2	2	3	0	5	4	2	2	2	2	2	26	Not attached	5	5	0	0		5	Not attached	15	41
10	404	Amlodipine + Valsartan	5/160mg	Tab	Vehel-AM 5/160mg	2	2	3	0	5	4	2	2	2	2	2	26	Not attached	5	5	0	0		5	Not attached	15	41
11	405	Amlodipine + Valsartan	10/160mg	Tab	Vehel-AM 10/180mg	2	2	3	0	5	4	2	2	2	2	2	26	Not attached	5	5	0	0		5	Not attached	15	41
12	421	Clopidogrel	75mg	Tab	Clopinet 75mg	2	2	3	0	5	4	2	2	2	2	2	26	Not attached	5	5	0	0		5	Not attached	15	41
13	471	Rosuvastatin	10mg	Tab	Rosunect 10mg	2	2	3	0	5	4	2	2	2	2	2	26	Not attached	5	5	0	0		5	Not attached	15	41
14	503	Domperidone	10mg	Tab	Domflash 10mg Plain	2	2	3	0	5	4	2	2	2	2	2	26	Not attached	5	5	0	0		5	Not attached	15	41
15	504	Domperidone	5mg/5ml	Syp	Domflash Suspension 120	2	2	3	0	5	4	2	2	2	2	2	26	Not attached	5	5	0	0		5	Not attached	15	41
16	517	Omeprazole	40mg	Cap	Omecap 40mg	2	2	3	0	5	4	2	2	2	2	2	26	Not attached	5	5	0	0		5	Not attached	15	41
17	518	Esomeprazole	40mg	Cap	Esonact 40mg	2	2	3	0	5	4	2	2	2	2	2	26	Not attached	5	5	0	0		5	Not attached	15	41
18	540	Empagliflozin	10mg	Tab	Empanect 10mg	2	2	3	0	5	4	2	2	2	2	2	26	Not attached		5	0	0		No stability study hence no marks awarded	Not attached	10	36
19	546	Gliclazide	30mg	Tab	Glinect MR 30mg	2	2	3	0	5	4	2	2	2	2	2	26	Not attached	RWB is not readible hence marks may not be provided	0	0	0		5	Not attached	5	31
20	547	Gliclazide	60mg	Tab	Glinect MR 60mg	2	2	3	0	5	4	2	2	2	2	2	26	Not attached	RWB is not readible hence marks may not be provided	0	0	0		5	Not attached	5	31
21	581	Sitagliptin + Metformin	50/500mg	Tab	Stanect 50/500mg	2	2	3	0	5	4	2	2	2	2	2	26	Not attached	5	5	0	0		5	Not attached	15	41
22	582	Sitagliptin + Metformin	50/1000mg	Tab	Stanect 50/1000mg	2	2	3	0	5	4	2	2	2	2	2	26	Not attached	5	5	0	0		5	Not attached	15	41
23	697	Tamsulosin HCL	0.4mg	Cap	Tamlin MR 0.4mg	2	2	3	0	5	4	2	2	2	2	2	26	Not attached	5	5	0	0		5	Not attached	15	41
24	725	Escitalopram	10mg	Tab	Glestal 10mg	2	2	3	0	5	4	2	2	2	2	2	26	Not attached	5	5	0	0		5	Not attached	15	41
25	754	Pregabalin	75mg	Cap	Restoren 75mg	2	2	3	0	5	4	2	2	2	2	2	26	Not attached	RWB not readible needs clarication at 1165	0	0	0		5	Not attached	5	31

Original Mandatory forms in Hard are not submitted to the MCC

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: Nicholas Pharma

S. No.		Product General Information				Technical Evaluation Matrix																					
						Factory Technical Evaluation Parameters												Product Evaluation Parameters									
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks. 2. Firms having**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm)**.	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
1	202	Cefepime	500mg	Inj	Nefipime 500mg Injection	2	2	3	0	5	2	0	0	2	2	2	**20**	0	0	0	0	0	2	5	0	**7**	**27**
2	203	Cefepime	1gm	Inj	Nefipime 1gm Injection	2	2	3	0	5	2	0	0	2	2	2	**20**	0	0	0	0	0	2	5	0	**7**	**27**
3	204	Cefixime	400mg	Capsule	Neproxime 400mg Capsule	2	2	3	0	5	2	0	0	2	2	2	**20**	0	5	5	0	0	2	5	0	**17**	**37**
4	205	Cefixime	30ml/5ml	Dry Susp	Neproxime Dry Suspension 100mg/5ml	2	2	3	0	5	2	0	0	2	2	2	**20**	0	5	5	0	0	2	5	0	**17**	**37**
5	206	Cefixime	30ml/5ml	Dry Susp	Neproxime Dry Suspension 200mg/5ml	2	2	3	0	5	2	0	0	2	2	2	**20**	0	5	5	0	0	2	5	0	**17**	**37**
6	207	Cefoperazone +	1gm	Inj	Niclobact 1gm Injection	2	2	3	0	5	2	0	0	2	2	2	**20**	0	5	5	5	0	2	5	0	**22**	**42**
7	208	Cefoperazone +	2gm	Inj	Niclobact 2gm Injection	2	2	3	0	5	2	0	0	2	2	2	**20**	0	5	5	5	0	2	5	0	**22**	**42**
8	215	Ceftazidime	500mg	Inj	Nezidine 500mg Injection	2	2	3	0	5	2	0	0	2	2	2	**20**	0	0	0	page 410 Not according to criteria	0	2	5	0	**7**	**27**
9	216	Ceftazidime	1gm	Inj	Nezidine 1gm Injection	2	2	3	0	5	2	0	0	2	2	2	**20**	0	0	0	page 410 Not according to criteria	0	2	5	0	**7**	**27**
10	217	Ceftriaxone	500mg	Inj	Ceftriaxone 500mg Injection	2	2	3	0	5	2	0	0	2	2	2	**20**	0	5	5	older than ten years	0	2	5	0	**17**	**37**
11	218	Ceftriaxone	1gm	Inj	Ceftriaxone 1gm Injection	2	2	3	0	5	2	0	0	2	2	2	**20**	0	5	5	older than ten years	0	2	5	0	**17**	**37**
12	219	Ceftriaxone	2gm	Inj	Ceftriaxone 2gm Injection	2	2	3	0	5	2	0	0	2	2	2	**20**	0	5	5	older than ten years	0	2	5	0	**17**	**37**
13	272	Meropenem	500mg	Inj	Nocopen 500mg Injection	2	2	3	0	5	2	The inspection team during inspection made following observations; 1. Overall cleanliness of the Carbapenem manufacturing section was found compromised. Dust accumulation was observed on floors, walls, and equipment surfaces. 2. Workers were not adhering to proper personal protection and uniform protocols in the carbapenem area. 3. Meropenem API/Intermediate of the *same batch* but with *different trade names* was found stored in the In-Process Quarantine area without proper identification and labeling. 4. Material in the in-process quarantine area lacked appropriate status labels (e.g., Quarantine, In-Process, Released, or Rejected), indicating a serious failure in material traceability and GMP compliance. 5. No proper segregation was maintained for materials with different trade names but same batch, increasing the risk of labeling errors during packaging. 6. General GMP compliance in the carbapenem section was found deficient, particularly in areas of material handling, identification, and status control. Based on the above observations the firm is RECOMMENDED for all quoted items except Carbapenems.							**14**	0	5	5	page 410 Not according to criteria	0	2	5	0	**17**	**31**
14	273	Meropenem	1gm	Inj	Nocopen 1gm Injection	2	2	3	0	5	2						**14**	0	5	5	page 410 Not according to criteria	0	2	5	0	**17**	**31**

Report
1.GD and Coa of cifipime not matching no drap clerance at page 74 hence no marks awarded
2.GD and coa of ceftazidime not matching hence no marks awarded.
3.no IMS share hence no marks awarded.

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposibles and Sutures for Government MCC 2026-27

Name of the firm NISA SF LAHORE / MURIDKE

Technical Evaluation Matrix

S.No	MCC formulary No.	Product General Information 1	2	3	4	Factory Technical Evaluation Parameter: Documents Based Factory Score 5	6	7	8	Evaluation Visit Score 9	10	11	12	Factory Evaluated Score 13	Product technical Evaluation Parameters 14	15	16	17	18	19	Product Evaluated Score 20	Total Technical Score 21
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. **(as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.**	Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAP regulations. **(to be evaluated by the MCC expert/s at the time of inspection, Noncompliance to cGMP shall lead to disqualification of the relevant section or firm)**	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications /	Valid WHO prequalification and / or valid product registration in SRA/WLA country(ies) / and / or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	**3**	**5**	**5**	**6**	**3**	**3**	**2**	**2**	**29**	**5**	**5**	**5**	**6**	**10**	**10**	**41**	**70**
	1018	A/D SYRINGE	3ML		BM AUTO DISABLE SYRINGE 3ML	0	0	5	**6**	**3**	**3**	**2**	**2**	**21**	0	0	0	0	**10**	**10**	**20**	**41**
	1019	A/D SYRINGE	5ML		BM AUTO DISABLE SYRINGE 5ML	0	0	5	**6**	**3**	**3**	**2**	**2**	**21**	0	0	0	0	**10**	**10**	**20**	**41**
	1021	DISPOSABLE INSULIN SYRINGE	1ML 31GX5/16		BM DISPOSABLE INSULINE SYRINGE 1ML	0	0	5	**6**	**3**	**3**	**2**	**2**	**21**	5	0	0	0	**10**	**10**	**25**	**46**
	1022	DISPOSABLE SYRINGE	1ML		BM DISPOSABLE SYRINGE 1ML	0	0	5	**6**	**3**	**3**	**2**	**2**	**21**	0	0	0	0	**10**	**10**	**20**	**41**
	1023	DISPOSABLE SYRINGE	10ML		BM DISPOSABLE SYRINGE 10ML	0	0	5	**6**	**3**	**3**	**2**	**2**	**21**	0	0	0	0	**10**	**10**	**20**	**41**
	1024	DISPOSABLE SYRINGE	20ML		BM DISPOSABLE SYRINGE 20ML	0	0	5	**6**	**3**	**3**	**2**	**2**	**21**	0	0	0	0	**10**	**10**	**20**	**41**
	1025	DISPOSABLE SYRINGE	50ML LUER LOCK		BM DISPOSABLE SYRINGE 50ML (LUER LOCK)	0	0	5	**6**	**3**	**3**	**2**	**2**	**21**	0	0	0	0	**10**	**10**	**20**	**41**
	1027	DISPOSABLE SYRINGE	60ML FEEDING TIP		BM DISPOSABLE SYRINGE 60ML (FEEDING TIP)	0	0	5	**6**	**3**	**3**	**2**	**2**	**21**	0	0	0	0	**10**	**10**	**20**	**41**
	1028	DISPOSABLE SYRINGE	50ML SIDE NOZZLE		BM DISPOSABLE SYRINGE 50ML (SIDE NOZZLE)	0	0	5	**6**	**3**	**3**	**2**	**2**	**21**	0	0	0	0	**10**	**10**	**20**	**41**
	1119	IV SET	150CM		BM INFUSION SET 150CM	0	0	5	**6**	**3**	**3**	**2**	**2**	**21**	0	0	0	0	**10**	**10**	**20**	**41**
	1120	IV SET	Y PORT		BM INFUSION SET Y PORT	0	0	5	**6**	**3**	**3**	**2**	**2**	**21**	0	0	0	0	**10**	**10**	**20**	**41**
	1124	IV CANNULA	WITH WINGS WITH INJECTION PORT 18G		BM IV CANNULA WITH WINGS WITH INJECTION PORT 18G	0	0	5	**6**	**3**	**3**	**2**	**2**	**21**	5	0	0	0	**DTL Substandard**	**10**	**15**	**36**
	1127	IV CANNULA	WITH WINGS WITH INJECTION PORT 20G		BM IV CANNULA WITH WINGS WITH INJECTION PORT 20G	0	0	5	**6**	**3**	**3**	**2**	**2**	**21**	5	0	0	0	**DTL Substandard**	**10**	**15**	**36**
	1130	IV CANNULA	WITH WINGS WITH INJECTION PORT 22G		BM IV CANNULA WITH WINGS WITH INJECTION PORT 22G	0	0	5	**6**	**3**	**3**	**2**	**2**	**21**	5	0	0	0	**DTL Substandard**	**10**	**15**	**36**
	1133	IV CANNULA	WITH WINGS WITH INJECTION PORT 24G		BM IV CANNULA WITH WINGS WITH INJECTION PORT 24G	0	0	5	**6**	**3**	**3**	**2**	**2**	**21**	5	0	0	0	**DTL Substandard**	**10**	**15**	**36**

Scrutiny report

1ISO certifications at Page No. 100 and 103 are not from a PNAC accredited body

2GDs at page Nos. 391,397,399,400,402,405,409,411,414,416,419,421,422,428,429,430 are not readable

3CoAs of imported raw materials done by principal manufacturer are not provided- rather the CoAs of finished products done by NISA SF are provided which does not fulfill the advertised criteria

4Tender approvals from Page No. 630 onwards does not fulfill the advertised criteria (not attested from the PE concerned)

Evaluation Criteria for Manufacturers of Non Drugs Items for Govt MCC 2026-27

Name of the firm | **NISA SF LAHORE**

Technical Evaluation Matrix

		Product General Information				Factory Technical Evaluation Parameter								Factory Evaluated Score						Product Evaluated Score	Total Technical Score
						Documents Based Factory Score				Evaluation Visit Score											
S.No	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. **(as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.**	Adherence to Current Good Manufacturing Practices in line with the DRAP regulations. **(to be evaluated by the MCC expert/s, Non compliance to cGMP shall lead to disqualification of the relevant section or firm)**	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. **(As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section (s) / firm.**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC** **(Certificates duly attested by Senior Executive of the firm)**	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded**.	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. **02 marks for each certification, up to a maximum of 06**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	6	5	5	5	5	**39**	5	5	5	6	10	**31**	**70**
	1135	DOSIFLOW PLUS FLOW REGULATOR	EXTENSION LINE		BM DOSIFLOW PLUS FLOW REGULATOR EXTENSION LINE	0	0	5	**6**	5	5	5	5	**31**	0	0	0	0	**10**	**10**	**41**
	1137	IV BURETTE	100ML		BM IV BURETTE 100ML	0	0	5	**6**	5	5	5	5	**31**	5	0	0	0	**10**	**15**	**46**
	1200	SCALP VEIN SET	21G		BM SCALP VEIN SET 21G	0	0	5	**6**	5	5	5	5	**31**	0	0	0	0	**10**	**10**	**41**
	1200	SCALP VEIN SET	22G		BM SCALP VEIN SET 22G	0	0	5	**6**	5	5	5	5	**31**	0	0	0	0	**10**	**10**	**41**
	1200	SCALP VEIN SET	23G		BM SCALP VEIN SET 23G	0	0	5	**6**	5	5	5	5	**31**	0	0	0	0	**10**	**10**	**41**
	1200	SCALP VEIN SET	24G		BM SCALP VEIN SET 24G	0	0	5	**6**	5	5	5	5	**31**	0	0	0	0	**10**	**10**	**41**
	1200	SCALP VEIN SET	25G		BM SCALP VEIN SET 25G	0	0	5	**6**	5	5	5	5	**31**	0	0	0	0	**10**	**10**	**41**
	1200	SCALP VEIN SET	27G		BM SCALP VEIN SET 27G	0	0	5	**6**	5	5	5	5	**31**	0	0	0	0	**10**	**10**	**41**
	1204	NELATON CATHETER	14FR		BM DISPOSABLE NELATON CATHETER 14FR	0	0	5	**6**	5	5	5	5	**31**	0	0	0	0	**10**	**10**	**41**
	1205	NELATON CATHETER	16FR		BM DISPOSABLE NELATON CATHETER 16FR	0	0	5	**6**	5	5	5	5	**31**	0	0	0	0	**10**	**10**	**41**
	1210	SUCTION TUBE	2M		BM SUCTION TUBE 2M WITH YANKAUER	0	0	5	**6**	5	5	5	5	**31**	0	0	0	0	**10**	**10**	**41**
	1225	SUCTION CATHETER	8FR		BM SUCTION CATHETER 8FR	0	0	5	**6**	5	5	5	5	**31**	5	0	0	0	**10**	**10**	**41**
	1226	SUCTION CATHETER	10FR		BM SUCTION CATHETER 10FR	0	0	5	**6**	5	5	5	5	**31**	5	0	0	0	**10**	**10**	**41**

	1228	SUCTION CATHETER	14FR		BM SUCTION CATHETER 14FR	0	0	5	**6**	5	5	5	5	**31**	5	0	0	0	**10**	**10**	**41**
	1229	SUCTION CATHETER	16FR		BM SUCTION CATHETER 16FR	0	0	5	**6**	5	5	5	5	**31**	5	0	0	0	**10**	**10**	**41**
	1232	STOP COCK 3 WAY	WITH EXTENSION		BM DISPOSABLE 3 WAY STOP COCK WITH EXTENSION	0	0	5	**6**	5	5	5	5	**31**	5	0	0	0	**10**	**10**	**41**
	946	Blood transfusion set	150CM NORMAL WITH LEUCOCYTES FILTERS		BM DISPOSABLE BLOOD TRANSFUSION SET	0	0	5	**6**	5	5	5	5	**31**	5	0	0	0	**10**	**10**	**41**

							Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27														
					Name of the firm		NOOR INTERNATIONAL KARACHI														
							Technical Evaluation Matrix														
							Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
							Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
		MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
							Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item's during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item's from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item's, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facility/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevent certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
		MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
Kossan International Malysia	**1**	1052	Disposable Sterile Latex Surgical Gloves (Powder Free)	6.5, 7.0, 7.5, 8.0, Size	Pair	Intouch	The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COFG) for the quoted items were checked, and following observations were made; 1. Kossan Sdn Bdh Malaysia: All mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP) for the quoted items were checked. Valid Original agency agreement was submitted in DRAP. The DRAP Enlistment/Registration of Disposable non-sterile Nitrile Examination gloves (Powder free) Intouch, was not issued by the DRAP, instead application with fee challan was present. Valid Original Declaration of Conformity certificate was not present at the time of inspection. 2. Disposable Sterile Latex Surgical Gloves (Powdered & Powder Free) Intouch. Valid Original Free sale certificate was present at the time of inspection, and Valid Original EU Quality Assurance System certificate was not present at the time of inspection. 4. 20% inventory of the quoted items, except Disposable Sterile Latex Surgical Gloves Powdered 7.0 and Disposable Non-Sterile Nitrile Examination Gloves Powder Free Medium & Large, adequate qualified HR, Cold Chain facility, Good Storage practices and SOPs for expiry management were satisfactory/ present. 5. The Disposable Non-Sterile Nitrile Examination Gloves Powder Free Medium & Large were in the name of DYCO instead of quoted brand of INTOUCH. In view of the above the firm is NOT–RECOMMENDED.				**0**	0	0	0	0	0	16	**16**	**16**
Kossan International Malysia	**2**	1053	Disposable Sterile Latex Surgical Gloves (Powdered)	6.5, 7.0, 7.5, 8.0, Size	Pair	Intouch							**0**	0	0	0	0	0	16	**16**	**16**
Kossan International Malysia	**3**	1058	Disposable Non-sterile Nitrile Examination Gloves (Powder Free)	Size: Small, Medium, and Large	Pack of 100 gloves	Intouch							**0**	0	0	0	0	0	16	**16**	**16**

SCRUTINY REPORT **PDF**

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: Novamed Pharmaceuticals Pvt Limited.

Technical Evaluation Matrix

S. No.	Product General Information					Factory Technical Evaluation Parameters: Documents Based Factory Score					Factory Evaluation Visit Score					Total Factory Evaluated Score	Product Evaluation Parameters: Product Technical Parameters							Total Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 10001:r45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment/ instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) on all labs.+ Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), ss area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Biowavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/CSP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the tarriff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies). **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm). **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this cohosum for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the QA/C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency,ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
Packing	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	22	5	5	5	4	3		5	5	27	70
10's	1	Clarithromycin	250mg	Tablet	Arithro 250Mg Tab				0	5	10 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0		5			1,345-1,497 COAs Unprinted Alu foil or Alu Alu foil attached		0	0	0
10's	2	Clarithromycin	500mg	Tablet	Arithro 500Mg Tab				0	5	11 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0		5			1,750 COAs Unprinted Alu foil or Alu Alu foil attached		0	0	0
20's	3	Atenolol	50mg	Tablet	B-Loc 50Mg Tab (20'S)				0	5	12 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0		5			1,351 COAs Unprinted Alu foil or Alu Alu foil attached		0	0	0
10's	4	Ciprofloxacin	250mg	Tablet	Ciproxin 250Mg Tab				0	5	13 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0		5			1,352 COAs Unprinted Alu foil or Alu Alu foil attached		0	0	0
10's	5	Ciprofloxacin	500mg	Tablet	Ciproxin 500Mg Tab				0	5	14 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0		5			1,353 COAs Unprinted Alu foil or Alu Alu foil attached		0	0	0
10's	6	Cetirizine	10mg	Tablet	Elcin 10Mg Tab (10'S)				0	5	15 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0	1216 GD not attached				1,354 COAs Unprinted Alu foil or Alu Alu foil attached		0	0	0
10's	7	Loratadine	10mg	Tablet	Elarin 10Mg Tab (10'S)				0	5	16 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0	1131, 1212 GD expired	0	0	0	1,355 COAs Unprinted Alu foil or Alu Alu foil attached	0	0	0	0
30's	8	Diclofasinir	30mg	Tablet	Dasnir 60Mg Tab 30'S				0	5	17 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0		5			1,356 COAs Unprinted Alu foil or Alu Alu foil attached	Not attached	0	0	0
100's	9	Doxycycline	100mg	Capsules	Decticine 100Mg Cap				0	5	18 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0	1260 Expired				1,357 COAs Unprinted Alu foil or Alu Alu foil attached	Not attached	0	0	0
20's	10	Glimepiride	2mg	Tablet	Diabryl 2Mg 20'S Tab				0	5	19 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0		5			1,358 COAs Unprinted Alu foil or Alu Alu foil attached		0	0	0
20's	11	Glimepiride	3mg	Tablet	Diabryl 3Mg 20'S				0	5	20 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0		5			1,359 COAs Unprinted Alu foil or Alu Alu foil attached		0	0	0
30's	12	Glimepiride	4mg	Tablet	Diabryl 4Mg 30'S Tab				0	5	21 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0		5			1,360 COAs Unprinted Alu foil or Alu Alu foil attached		0	0	0
100's	13	42	Diclofenac Sodium enteric	50mg	Tablet	Dianic 50Mg Tab (100'S				0	5	22 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0		5			1,361 COAs Unprinted Alu foil or Alu Alu foil attached		0	0	0
100's	14	43	Diclofenac Sodium (IM/IV for	75mg	Injection	Dianic 75Mg/3Ml				0	5	23 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0		5			1,362 COAs Unprinted Alu foil or Alu Alu foil attached		0	0	0
30's	15	50	Domperidone	10mg	Tablet	Dovomit 10Mg Tab 50'S				0	5	24 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0	1141 Not attached				1,363 COAs Unprinted Alu foil or Alu Alu foil attached		0	0	0
120 ml	16	372	Iron Hydroxide polymaltose	50mg	Syrup	Fer-P 120Ml Syp				0	5	25 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0		5				Not attached	0	0	0
30's	17	373	Iron Hydroxide polymaltose	100mg/0.35mg	Tablet	Fer-P Plus Tab 30'S				0	5	26 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0		5			1,349 COAs Unprinted Alu foil or Alu Alu foil attached	Not attached	0	0	0
100's	18	508	Famotidine	40mg	Tablet	flo-Acid Tab 40Mg 100'S				0	5	27 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0	1142 GD NA				1,349 COAs Unprinted Alu foil or Alu Alu foil attached	1636.20 mg attached	0	0	0
1's	19	469	Cefepime	1gm	Injection	flovapime 1g Inj				0	5	28 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0		5	3		1,364 COA not provided with proof of purchase		0	0	0
1's	20	203	Cefepime	500mg	Injection	flovapime 500mg Inj				0	5	29 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0		5	3		1,365 COA are not in enclosed attached, 1497 - 1525 COAs of immediate container attached only		0	0	0
10's	21	264	Levofloxacin	250mg	Injection	Dryilevo 250Mg Tab				0	5	30 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0	1173 GD is older		1		1,365 COA are not in enclosed attached, 1497 - 1525 COAs of immediate container attached only		0	0	0
10's	22	265	Levofloxacin	500mg	Tablet	Dryilevo 500Mg Tab				0	5	31 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0	1173 GD is older		1		1,365 COA are not in enclosed attached, 1497 - 1525 COAs of immediate container attached only		0	0	0
10's	23	516	Omeprazole	40mg	Capsule	D-Zole 40Mg Cap (10'S)				0	5	32 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0		5	1		1,365 COA are not in enclosed attached, 1497 - 1525 COAs of immediate container attached only		0	0	0
1's	24	521	Omeprazole	40mg	Injection	D-Zole 40mg Injection				0	5	33 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0		5	3		1,365 COA are not in enclosed attached, 1497 - 1525 COAs of immediate container attached only		0	0	0
1's	25	213	Cefotaxime Sodium	1gm	Injection	Pure-Xim 1gm Injection				0	5	34 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0		5	3		1,365 COA are not in enclosed attached, 1497 - 1525 COAs of immediate container attached only		0	0	0
1's	26	209	Cefotaxime Sodium	250mg	Injection	Pure-Xim 250Mg				0	5	35 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0		5	3		1,365 COA are not in enclosed attached, 1497 - 1525 COAs of immediate container attached only		0	0	0
1's	27	210	Cefotaxime Sodium	500mg	Injection	Pure-Xim 500Mg				0	5	36 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0		5	3		1,365 COA are not in enclosed attached, 1497 - 1525 COAs of immediate container attached only		0	0	0
10's	28	712	Escitalopram	10mg	Tablet	Relax 10Mg Tab (10'S)				0	5	37 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0	1233 Expired		1		1,365 COA are not in enclosed attached, 1497 - 1525 COAs of immediate container attached only	Not attached	0	0	0
100's	29	425	Clopidogrel	75mg	Tablet	Scadop 75Mg Tab				0	5	38 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0		5	3		1,365 COA are not in enclosed attached, 1497 - 1525 COAs of immediate container attached only		0	0	0
14's	30	517	Esomeprazole	40mg	Capsule	S-Zole 40Mg Caps 14'S				0	5	39 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0		5	1		1,365 COA are not in enclosed attached, 1497 - 1525 COAs of immediate container attached only		0	0	0
1's	31	766	Ephedrine Hydrochloride	50ml	Injection	Sphex Inj 350mg 50ml				0	5	40 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0		5	3	Manufactured for LDS	1,365 COA are not in enclosed attached, 1497 - 1525 COAs of immediate container attached only		0	0	0
1's	32	766	Ephedrine Hydrochloride	100ml	Injection	Sphex Inj 350mg 100ml				0	5	41 Documents are not attested by a Senior executive of the firm.	2	2	2	2	2	0	0		5	3	Manufactured for LDS	1,365 COA are not in enclosed attached, 1497 - 1525 COAs of immediate container attached only		0	0	0

228 -230 Not attested

Original Mandatory forms in Hard are not submitted to the MCC

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: Novartis General Medicine Importer Karachi FY 2026-27

S. No.		Product General Information				Technical Evaluation Matrix																	
						Principal's and Importer's Evaluation Parameters							Suppliers Technical Score	Product Technical Evaluation							Product Availability	Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation				Importer's Evaluation				Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
						Valid ISO 14001:2015 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm). **Online verification link shall be avoided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm). **Online verification link shall be provided**	If old accreditation of manufacturing site is in relevant sectors by the US-FDA or official accreditation body/ies /regulatory body in the case of SRA/WLA countries duly attested by senior executive of the firm). **Online verification link shall be avoided**	Valid calibration certificates for equipment / instruments used in the Factory for Measuring, weighing, Assay/ Analysis of raw materials, in-process samples and finished products during the manufacturing of the quoted products. **Valid Calibration Certificates attested by Quality head of the firm).**	Availability of minimum 20% inventory of the total import of the quoted item(s) having last one year (certificate in the files duly signed by the senior executive of the firm to be evaluated by the MCC reports). **Non availability of the 20% stock at the core home at the time of inspection of the importer shall lead to disqualification of the quoted item(s).**	Adherence to Good Storage practices (GSP) for storage of finished goods. Functional and effective Air-conditioning & Ventilation Systems and effective cold chain (thermo-labile drugs). The physical inspection committee/ MCC reports to be evaluated for adherence to GSP in accordance to the laid down criteria and terms and conditions of the Drug Regulations framed by the DRAP. **Nonadherence to GSP, as evaluated by the MCC reports/ at the time of inspection shall lead to disqualification of the firm.**	Adequate availability of qualified, Presence of Category-A Pharmacist/s (one mandatory), & relevant Human Resource **Certified by the senior executive of the firm to be evaluated by the MCC reports/ at the time of inspection as non compliance to this parameter shall lead to disqualification of the firm).**		Recontinability/ Biocequivalence study conducted by WHO Justified Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority body of SRA/WLAs country (ies).). For hydrogels, bio-similarity studies shall be provided for round of marks in this parameter. and / or Bio-waiver certificate from an accredited Lab of SRA countries (Invitgaro Regulatory Authorities). In case of Large volume parenteral i.e., gasster than 100ml up to 1L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of invention / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bioavailability is not applicable. Proof not company's own letter head shall not be acceptable.	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs (Form-M) or Commercial Invoice till at BAS of Landing for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of purchases through third party importers, the DRAP** shall lock **NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC.**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 15, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD documents for CoA will not be considered.**	Active Pharmaceutical Ingredient's (API's) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA /PMDA/ Swiss Medic or Health Canada or by regulatory authority body of SRA/WLAs country (ies). Trail of principal manufacturer shall be established from the respective GD. CoA and other supporting documents. Wherever, in case of product/quoted item having multiple APIs, the marks for API, CoA, APIs source accreditation shall be awarded only where those documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA country(ies)/ Valid free-sale certificate issued by regulatory body of any SRA/WLA country(ies). and / or Valid certificate of the availability of the quoted item in the US market. **Full marks shall be awarded in the Primary certificate and 1 mark for additional certificate, up to a maximum of 04 (0+0+01+02) marks.** **Certificates on company's own letter heads shall not be acceptable.** **Copies of relevant certificates duly attested by the senior executive of the firm).** **Online verification link shall be provided**	Valid Certificate of Analysis of the Type-1 class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other 2. Specification against which material has been tested e.g., European Pharmacopoeia, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 3. Type of Glass material for Liquid ampoules must be USP-class 1 (Non-compliance shall lead to disqualification of the quoted product). 4. Glass material for Liquid & Dry Powder Suspensions must be USP Type 3 to better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** a. For Dry Powder Injectables, i. For USP Type 1 glass 4 marks will be awarded. ii. For USP Type 2 glass 2 marks will be awarded. iii. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **Documents duly attested by the Senior executive of the firm)**	Validity studies of quoted item/s duly attested by the QA/ incharge of the firm.	Availability of quoted item/s on Purchase Advice as per recent most data of IMS/IQVIA/ Health not older than twelve (12) months. 0-10% market share = 1 mark 11-20% market share = 2 marks 21-30% market share = 3 marks 30% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from tertiary care Govt. Hospitals, Health related Govt. projects and / or ICT accredited tertiary care Private Hospitals. Marks shall be awarded in the following manner: 01 Tender approvals: 01 mark 02 Tender approvals: 02 marks 03 Tender approvals: 03 marks 04 Tender approvals: 04 marks 05 or more Tenders approvals: 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the senior executive of the firm and accompanied with purchase orders, delivery challan, invoice/ economy card/ dosipe from the concerned procuring entity/purchasing agent,/govt, etc. The bank statement showing the encashment/ remittance against the cheque received shall also be submitted with each purchase order.			
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	2	5	5	4	5	5	30	5	5	5	5	6	4	5	5	40	70
	001	Amiodarone	2mg	Cab.	Aflotor		02-ISO 14001 is expired		5		4	5	5	19		0	COA not attached	0		0		Not attached	Not attached	19	24
	002	Ciprofloxa	10 mg	Cab.	Ciprobay		02-ISO 14001 is expired		5		4	5	5	19		0	COA not attached	0	Not attached	0		Not attached	Not attached	5	24
	078	Cefixime + Sucralfate	200mg	Cab.	Xpecia		02-ISO 14001 is expired		5		4	5	5	19		0	COA not attached	0		4				23	47
	1023	Ketorolide I.AR	10mg	Vial	Sandoketo I.AR 10mg		02-ISO 14001 is expired		5	131-164 Calibervation certificates	4	5	5	19	100-104 ANDA link attached instead of certificate	0	COA not attached	0	Not attached	4		Not attached	Not attached	5	24
	01024	Ketorolide I.AR	30mg	Vial	Sandoketo I.AR 30mg		02-ISO 14001 is expired		5	are not according to the criteria	4	5	5	19		0	COA not attached	0	Not attached	4		Not attached	Not attached	5	24
	019	Paculitaxel	30mg	Vial	Eugatax 30mg									0		0		0		4		Not attached		29	29
	020	Paculitaxel	5 MG/ cc IV 0.05M	Vial	Paxus									0		0	COA not attached	0	Not attached	4		Not attached		17	17

- Original Mandatory Forms in Hard are not submitted to the MCC

TECHNICAL EVALUATION PROFORMA, FOR PROCUREMENT OF ANTICANCER MEDICINES IN GOVT. MCC FY 2026-27

		Name of the firm with Complete Address	**Novartis /Nouveaux Pharma Limited Karachi**
		Manufacturer / Importer	**Importer**

		Mandatory Requirements.	**YES / NO**		**In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:**		**YES/NO**
1		**National Tax Number (NTN) of the Firm for Income Tax, and**	YES		1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and	NA
2		**Last year Income Tax Return of the Firm; and**	Yes		2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.	NA
3		**Sale Tax Registration Certificate of the Firm; and**	Yes		3	Valid DRAP Approved Price List of the quoted item/s.	NA
4		**Certificate of Professional Tax of the Firm.**	Yes				
5		**Certificate of compliance to cold chain requirements from an independent third party e.g. DRAP, PSQCA, PCCSB. Non-Compliance to international reference standards or absence of Cold Chain requirements shall lead to disqualification of the relevant product that requires cold chain.**	Yes				

		In case of being Importers, the Firm should provide attested copies of the following documents also:	**YES/NO**	
1		Valid Drugs Sales License for the importer; and	Yes	
2		Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	Yes	
3		Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	Yes	
4		Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and	yes	
5		Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods. Non provision of this document shall lead to disqualification of the firm; and	Yes	
6		Valid DRAP approved Price List of the quoted items.	Yes	

						Active Pharmaceutical Ingredient source gradation **(For API or finished product). i) The bidder (local manufacturer / multi-national manufacturer / importer) shall provide Analytical/Quality Assurance/ Approved Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades.** **Certificate of Analysis/ Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreement/ approval with the original manufacturer duly verified/attested by official of the company.** **Detailed purchase trail of the Active Pharmaceutical Ingredient/ finished product from the claimed source must be submitted (any proof of purchase such as Goods Declaration Certificate along with Airway Bill/ Bill of Lading/Invoice etc.) by the bidder.** **Maximum marks for this criterion are 40.**	**Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW) study Certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities)/ WHO Listed Authorities MLA Countries** **(BE/BS Certificate with evidence as to its authenticity) from Category A countries.** **Bio-Equivalence (BE) of the quoted product to be conducted against the originator.** **Original innovator products do not require bio- equivalence certificate and shall get 10 marks automatically.The bidder shall provide the documents to establish the proof of inventor / originator. All other branded generics require BE studies.** **Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid.** **Maximum marks for this criterion are 10.**			**Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug. In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article)** **Mandatory: Online verification link must be provided to verify the Clinical Trial/ Clinical Studies submitted for the quoted items.**		**Factory/ Importer Based Evaluation Score (MANDATORY)**	**Sample Evaluation by End User Committee** **Samples will be examined per following parameters as follows:** **a. Labeling and Packing Rules 1986** **b. Outer packing** **c. Inner packing** **d. Physical appearance.** **Product which has unsatisfactory packing/labeling will be technically Disqualified.** **Maximum score for this criterion is 1.**		**Past Performance (Last two years).** **i) Good Performance Certificates of these institutions must be produced in order to be eligible for 5 mark per institution upto a maximum of 5 marks.** **ii) Only supply orders will not get any marks.** **iii) The bidders have to undertake that they have never been blacklisted or debarred.** **Maximum marks for this criterion are 5.** **iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.**	**Total Technical Score**
		Technical Evaluation Parameters				Category A – Approved By: • United States Food & Drug Administration (USFDA) • European Medicines Agency (EMA) • Medicines & Healthcare Products Regulatory Agency (MHRA), UK • Therapeutic Goods Administration (TGA), Australia • Pharmaceutical Medical Agency (PHARMAC), New Zealand • Pharmaceutical & Medical Devices Agency (PMDA), Japan • Swissmedic Agency For therapeutic drugs (swiss medic), Switzerland • Health Canada • Health Sciences Authority (HAS), Singapore • National Administration of Drugs, Food & Medical Devices (ANMAT), Argentina Drug Regulatory Authorities of the FRA (Stringent Regulatory Authorities) / WHO Listed Authorities MLA countries.	Category B – Approved By: • Agência Nacional de Vigilância Sanitária (ANVS), Brazil • Central Drugs Standard Control Organization (CDSCO), India • Drug Regulatory Authority, Pakistan • National Pharmaceutical Control Bureau (NPCB), Malaysia • Food & Drug Administration, South Korea • Ministry of Health, Egypt • Food & Drug Authority, Iran • China Food & Drug Administration • Any other source not mentioned in Category-A	Study/Certificate conducted/verified by a Stringent Regulatory Authority. BE testing must be done using at least 12 subjects. Biowaiver is acceptable only for BCS class I drugs (as mentioned in Cat. A Country).	BE/BS/BW certificate obtained for a quoted product(s) from Cat. B countries (as mentioned at S No. 2 above).	No BE/BS/BW certificate.	In case the study is published in Category "A" journal listed in HEC Journal Recognition System (HJRS) Freelance Journals as per HEC Journal Recognition Policy 2023 and List of National Recognized Journals as per HEC, 3 marks per original research article shall be awarded (maximum up to 6 marks).	In case the study is published in Category "B" journal listed in HEC Journal Recognition System (HJRS) Freelance Journals as per HEC Journal Recognition Policy 2023 and List of National Recognized Journals as per HEC, 2 marks per original research article shall be awarded (maximum up to 6 marks).	Product original invoice produced in category "A" approved of the HJRS Journals as per HEC Journal Recognition Policy 2023 and List of National Recognized Journals as per HEC shall not be awarded marks.	**Pre Physical inspection of the premises of the bidders the Technical Evaluation Committee shall be satisfied with the PE Ordy, QC) (QC SLE, section V (iii) (b) of the approved BSDS of Govt. MCC FY 2026-27**	satisfactory	unsatisfactory	i) Submission quantity of supplies of anti-cancer medicines in order to provide sector Teaching hospitals Lady Reading Hospital Peshawar, Khyber Teaching Hospital Peshawar, Khyber Medical University Peshawar, Khyber Medical College Peshawar, DHQ Hospital Mardan, Saidu Teaching Hospital Swat, Ayub Teaching Hospital Abbottabad, Mardan Medical Complex, Peshawar Institute of Nuclear Medicine, Oncology & Radiotherapy (INMOR) Hayatabad Medical Complex, Peshawar Shifa International Hospital Islamabad, with Good Satisfactory Performance Certificates from these institutions must be produced in order to be eligible for 5 marks per institution upto a maximum of 5 marks. ii) Only supply orders will not get any marks. iii) The bidders have to undertake that they have never been blacklisted or debarred. Maximum marks for this criterion are 5. iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.	
SOURCE	MCC formulary No.	Generic Name of Item	Strength	Dosage-Form	Brand Name	40	30	10	5	0	9	6	0	5	1	0	5	70
	1	1928	Bromfenac	0.5mg	Tab	Bromdac 25mg	40		10			9	6		5	1		Not attached	59
	2	1929	Bromfenac	0.5mg	Tab	Bromdac 50mg	40		10			9	6		5	1		Not attached	59
	3	1930	Imatinib	400mg	Tab	Glivec 400mg	40		10			9	6		5	1		Not attached	59
	4	1931	Imatinib	400mg	Tab	Imanib 400mg	40		10			9	6		5	1		Not attached	59
	5	1934	Lapatinib	250mg	Tab	Tykerb 250mg	40		10			9	6		5	1		Not attached	59
	6	1935	Lapatinib	1.5gm	Tab	Lapatag 1.5gm	40		10			9	6		5	1		Not attached	59
	7	1937	Nilotinib	200mg	Cap	Tasigna 200mg	40		10			9	6		5	1		Not attached	59
	8	1938	Nilotinib	150mg	Tab	Nilotinib 150mg	40		10			9	6		5	1		Not attached	59
	9	1939	Nilotinib	200mg	Tab	Nilotinib 200mg	40		10			9	6		5	1		Not attached	59
	10	1940	Nilotinib	300mg	Tab	Nilotinib 300mg	40		10			9	6		5	1		Not attached	59
	11	1941	Nilotinib	400mg	Tab	Nilotinib 400mg	40		10			9	6		5	1		Not attached	59
	12	1942	Sorafenib	200mg	Tab	Nexavar 200mg	40		10			9	6		5	1		Not attached	60
	13	1943	Sorafenib	50mg	Tab	Jakavi 50mg	40		10			9	6		5	1		Not attached	60
	14	1944	Sorafenib	5mg	Tab	Jakavi 5mg	40		10			9	6		5	1		Not attached	60

2nd study for Panzopanib: The study has no mention of novartis Pharma

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm — **Olive Laboratories, Rawalpindi**

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g.,	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
1	65	Paracetamol + Orphenadrine citrate	450mg+35mg	Tab	Geprol	2	2	3	0	0	2	2	2	2	2	2	**19**	0	0	0	0	0	0	0	0	**0**	**19**
Citi Pharma 2	59	Paracetamol	500mg	Tab	Setamol	2	2	3	0	0	2	2	2	2	2	2	**19**	0	0	0	0	0	0	0	0	**0**	**19**
3	452	Losartan Potassium	50mg	Tab	Cardive	2	2	3	0	0	2	2	2	2	2	2	**19**	0	0	0	0	0	0	0	0	**0**	**19**
4	159	Loratidine	10mg	Tab	Alicare	2	2	3	0	0	2	2	2	2	2	2	**19**	0	0	0	0	0	0	0	0	**0**	**19**
Pure & Cure India 5	160	Monteulkast	10mg	Tab	Olicast	2	2	3	0	0	2	2	2	2	2	2	**19**	0	0	0	0	0	0	0	0	**0**	**19**
6	5147	Omeprazole	40mg	Cap	Meprolive	2	2	3	0	0	2	2	2	2	2	2	**19**	0	0	0	0	0	0	0	0	**0**	**19**
7	518	Esomeprazole	40mg	Cap	Esolive	2	2	3	0	0	2	2	2	2	2	2	**19**	0	0	0	0	0	0	0	0	**0**	**19**
8	522	Pantoprazole	40mg	Tab	Pantolive	2	2	3	0	0	2	2	2	2	2	2	**19**	0	0	0	0	0	0	0	0	**0**	**19**
9	752	Pregabalin	50mg	Cap	Gaboliv	2	2	3	0	0	2	2	2	2	2	2	**19**	0	0	0	0	0	0	0	0	**0**	**19**
10	754	Pregabalin	75mg	Cap	Gaboliv	2	2	3	0	0	2	2	2	2	2	2	**19**	0	0	0	0	0	0	0	0	**0**	**19**

Scrutiny report

148-94	Calibration certificates are not duly attested from senior executive of the firm.
298-118	COA, and GDs are either not readible or not matching with the principal of raw materials.
3	Relevant documents for award of marks in column 8, 17, 20, 21, 22, 23 & 24 could not be found in the technical bid.
4	Valid Product registration of the quoted products could not be found in the technical bid.
	Original Mandatory forms in Hard are not submitted to the MCC

		TECHNICAL EVALUATION PROFORMA, FOR PROCUREMENT OF ANTICANCER MEDICINES IN GOVT. MCC FY 2026-27									
		Name of the firm	ONCOGEN PHARMA KARACHI								
		Manufacturer / Importer	MANUFACTURER								
		Mandatory Requirements.	YES / NO		In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:		YES/NO		In case of being Importers, the Firm should provide attested copies of the following documents also:		YES/NO
1		National Tax Number (NTN) of the Firm for Income Tax, and	YES		1	Valid Drugs Manufacturing License issued by the Drugs Regulatory	YES		1	Valid Drugs Sales License for the importer; and	
2		Last year Income Tax Return of the Firm; and	YES		2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted	YES		2	Valid Product Registration Certificate issued by the	
3		Sale Tax Registration Certificate of the	YES		3	Valid DRAP Approved Price List of the quoted	YES		3	Valid Agency Agreement	
4		Certificate of Professional Tax of the Firm.	YES						4	Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the	
5		Certificate of compliance to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR. Non-Compliance to international reference standards or absence of Cold Chain	YES						5	Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s. Non	
									6	Valid DRAP approved	

			Technical Evaluation Parameters			**Active Pharmaceutical Ingredient source gradation** **(For API or finished product). i) The bidder (local manufacturer / multi-national manufacturer / importer) shall provide Analytical/Quality Assurance/ Approval Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades.** **Certificate of Analysis/ Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreement/ approval with the original manufacturer duly attested/verified by official of the company.**		**Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW) Study/Certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities)/ WHO Listed Authorities WLA Countries** **(BE/BS Certificate with evidence as to its authenticity) from Category A countries.** **Bio-Equivalence (BE) of the quoted product to be conducted against the originator. Original innovator products do not require bio- equivalence certificate and shall get 10 marks automatically.The bidder shall provide the documents to establish the proof of inventor/ originator. All other branded generics require BE studies** **Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid.** **Maximum marks for this criterion are 10.**			**Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug. In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article)** **Mandatory: Online verification link must be provided to verify the Clinical Trial/ Clinical Studies submitted for the quoted items.**			**Factory/ Importer Based Evaluation Score (MANDATORY)**	**Sample Evaluation by End User Committee** **Samples will be examined per following parameters as follows:** **a. Labeling and Packing Rules 1986** **b. Outer packing** **c. Inner packing** **d. Physical appearance.** **Product which has unsatisfactory packing/labeling will be technically Disqualified.** **Maximum score for this criterion is 1.**		**Past Performance (Last two years).** **1) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks.** **2) Only supply orders will not get any marks.** **3) The bidders have to undertake that they have never been blacklisted or debarred.** **Maximum marks for this criterion are 5.** **4) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.**	**Total Technical Score**
						Category A – Approval By: • United States Food & Drug Administration (US-FDA) • European Medicines Agency (EMA) • Medicines & Healthcare Products Regulatory Agency (MHRA), UK • Therapeutic Goods Administration (TGA), Australia. • Pharmaceutical Medical Agency (PHARMAC), New Zealand • Pharmaceutical & Medical Devices Agency (PMDA), Japan • Swiss Agency For therapeutic drugs (Swiss-medic), Switzerland • Health Canada • Health Sciences Authority (HAS),	Category B – Approved By: • Agência Nacional de Vigilância Sanitária (ANVIS), Brazil • Central Drug Standard Control Organization (CDSCO), India • Drug Regulatory Authority, Pakistan • National Pharmaceutical Control Bureau (NPCB), Malaysia • Food & Drug Administration, South Korea • Ministry of Health, Egypt • Ministry of Health, Turkey • China Food & Drug Administration • Any other source not mentioned in Category-A	Study/certificate accepted/certified by a Category A Country Regulatory Authority. BE testing must be done using at least 12 subjects. Bio-waiver is acceptable only to injectable forms if issued by Category A Country.	BE/BS/BW certificate obtained for a quoted product from Category B Country (as mentioned at S No. 1 above).	No BE/BS/BW Certificate.	In case the study is published in Category "W" journal listed in HEC Journal Recognition System (HJRS) Database/ Journals & Publication Policy 2024 and List of National Recognized Journals as per HEC, 3 marks per original research article shall be awarded maximum up to 9 marks).	In case the study is published in Category "X" journal listed in HEC Journal Recognition System (HJRS) Database/ Journals & Publication Policy 2024 and List of National Recognized Journals as per HEC, 2 marks per original research article shall be awarded maximum up to 6 marks).	Studies/original article published in category "Y" journal of the HJRS/ Journals & Publication Policy 2024 and List of National Recognized Journals as per HEC shall not be awarded marks.	**The Physical Inspection of the premises of the bidders (Manufacturer/Importer) shall be carried out in accordance with ITB 25.4(h), SCC 5 (GCC 8.3), Section V (1) (J) (K) of the approved BSDS of Govt. MCC FY 2026-27**	Satisfactory	Unsatisfactory	1) Substantial quantity of Supplies of anti-cancer medicines made to private sector Teaching Hospitals namely: The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar, CMH Rawalapindi and Hayatabad Medical Complex, Peshawar , Shifa Interntional hospital Islamabad, with Good/Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 24 months. No marks will be given for supply orders except CMH Rawalpindi where supply orders coupled with delivery challans & invoices will be considered for award of marks. 1 mark per agreement up to a maximum of 5 marks	
SOURCE	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	**40**	**30**	**10**	**5**	**0**	**9**	**6**	**0**	**5**	**1**	**0**	**5**	**70**
	1437	Abiraterone	250mg	Tablet	Abytiga 250mg Tablet	**40**			5					**5**	**1**		4	55
	1471	Capecitabine	500mg	Tablet	Pectibine 500mg Tablet	**40**			5					**5**	**1**		4	55
	1501	Docetaxel	20mg	Injectable	Doxiant 20mg Injection		30							**5**	**1**		4	40
	1502	Docetaxel	80mg	Injectable	Doxiant 80mg Injection		30							**5**	**1**		4	40
	1503	Doxorubicin	10mg	Injectable	Doxetran 10mg Injection		30							**5**	**1**		4	40
	1504	Doxorubicin	50mg	Injectable	Doxetran 50mg Injection		30							**5**	**1**		4	40

	1530	Imatinib	100mg	Tablet	Imatigliv 100mg Tablet		30		5					5	1		4	45
	1531	Imatinib	400mg	Tablet	Imatigliv 400mg Tablet		30		5					5	1		4	45
	1542	Lenalidomide	10mg	Capsule	Lemiryl 10mg Capsule	40								5	1		4	50
	1543	Lenalidomide	25mg	Capsule	Lemiryl 25mg Capsule	40								5	1		4	50
	1544	Lenvatinib	10mg	Capsule	Lenvagen 10mg Capsule		30							5	1		4	40
	1545	Lenvatinib	4mg	Capsule	Lenvagen 04mg Capsule		30							5	1		4	40
	1578	Nilotinib	200mg	Capsule	Nilosigna 200mg Capsule		30		5					5	1		4	45
	1587	Osimertinib	80mg	Tablet	Osivant 80mg Tablet	40								5	1		4	50
	1591	Paclitaxel	150mg	Injectable	Pacnogen 150mg Injection		30							5	1		4	40
	1592	Paclitaxel	300mg	Injectable	Pacnogen 300mg Injection		30							5	1		4	40
	1593	Palbociclib	100mg	Tablet	Oncolib 100mg Tablet	40			5					5	1		4	55
	1594	Palbociclib	125mg	Tablet	Oncolib 125mg Tablet	40			5					5	1		4	55
	1599	Pazopanib	400mg	Tablet	Pazorene 400mg Tablet		30							5	1		4	40
	1621	Ruxolitinib	15mg	Tablet	Jaklitinib 15mg Tablet		30							5	1		4	40
	1622	Ruxolitinib	5mg	Tablet	Jaklitinib 05mg Tablet		30							5	1		4	40

SCRUTINY REPORT

1RAPTIM RESEARCH IS NOT AN ACCREDITED LAB OF SRA COUNTRY

2EIR REPORT FOR PAZOPANIB IS NOT COMPLETE- DOES NOT SHOW THE PRODUCT /QUOTED ITEM Page-1012

3EIR REPORT FOR RUXOLITINIB IS NOT COMPLETE- DOES NOT SHOW THE PRODUCT /QUOTED ITEM Page-1027

4CLINICAL TRIALS / CLINICAL STUDIES ARE NOT PRESENT

54 PERFORMANCE CERTIFICATES OF TPCP, SHIFA INTERNATIONAL, SKM AND CMH PINDI ARE CONSIDERED FOR AWARD OF MARKS

6US FDA (EIR) report at Page No. 398 does not have any detail regarding raw material of imatinib (no details of inspection)

7API source gradation of Nilotinib at Page No. 660, 661 does not have any detail regarding the raw material of Nilotinib

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm OPTH PHARMA KARACHI

S. No.		Product General Information				Technical Evaluation Matrix																					
						Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for Certificates on company's own letter heads shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan.		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**5**	**3**	**4**	**5**	**5**	**37**	**70**
	4	Metronidazole	0.5 % w/v	Infusion	M ZOL	**2**	**2**	**3**	0	**5**	2						**14**	**0**	NA	0	0	0	GLASS COA NOT AT	0	0	**0**	**14**
	166	Amikacin Sulphate	100 mg	Injection	AMISUL 100MG	**2**	**2**	**3**	0	**5**	2						**14**	**0**	**5**	**5**	0	0	OA NOT ATTACHE	0	0	**10**	**24**
	168	Amikacin Sulphate	500 mg	Injection	AMISUL 500MG	**2**	**2**	**3**	0	**5**	2						**14**	**0**	**5**	**5**	0	0	OA NOT ATTACHE	0	0	**10**	**24**
	232	Ciprofloxacin	200 mg/100 ml	Infusion	INFU C	**2**	**2**	**3**	0	**5**	2						**14**	**0**	**5**	**5**	0	0	100ML GLASS COA NOT ATTACHED INSTEAD 250ML	0	0	**10**	**24**
	290	Moxifloxacin	400 mg/250 ml	Infusion	OPILOX	**2**	**2**	**3**	0	**5**	2						**14**	**0**	**5**	**5**	0	0	2	0	0	**12**	**26**
	584	Triamcinolone Acetonide	40 mg/ml	Injection	K KORT	**2**	**2**	**3**	0	**5**	2						**14**	**0**	**5**	**5**	0	0	OA NOT ATTACHE	0	0	**10**	**24**
	820	Acyclovir	3%w/w	Eye Ointment	OPHTH CYCLOVIR	**2**	**2**	**3**	0	**5**	2						**14**	**0**	IS EXPIRED PAGE 2	0	0	0	OA NOT ATTACHE	0	0	**0**	**14**
	826	Chloramphenicol	0.5% w/v	Eye Drop	OPHTH CHLOR	**2**	**2**	**3**	0	**5**	2						**14**	**0**	NOT ATTACHED	NOT ATTACHED	0	0	OA NOT ATTACHE	0	0	**0**	**14**
	827	Ciprofloxacin	0.3 w/v	Eye drop	OPHTH CIL	**2**	**2**	**3**	0	**5**	2						**14**	**0**	NOT ATTACHED	NOT ATTACHED	0	0	OA NOT ATTACHE	0	0	**0**	**14**
	830	Dexamethasone	0.1 %w/v	Eye drop	OPHTH DEX	**2**	**2**	**3**	0	**5**	2						**14**	**0**	**5**	**5**	0	0	OA NOT ATTACHE	0	0	**10**	**24**
	834	Fluorescein	0.6 mg	Strip	OPHTH FLUOROSTRIP	**2**	**2**	**3**	0	**5**	2						**14**	**0**	NOT ATTACHED	NOT ATTACHED	0	0	OA NOT ATTACHE	0	0	**0**	**14**
	838	Levobunolol	0.5% w/v	Eye Drop	OPHTH LEVO	**2**	**2**	**3**	0	**5**	2						**14**	**0**	IS EXPIRED PAGE 3	0	0	0	OA NOT ATTACHE	0	0	**0**	**14**
	839	Moxifloxacin	0.5 % w/v	Eye drop	OPMOX	**2**	**2**	**3**	0	**5**	2						**14**	**0**	**5**	**5**	0	0	OA NOT ATTACHE	0	0	**10**	**24**
	846	Proparacaine	0.5 %w/v	Eye drop	OPCAINE	**2**	**2**	**3**	0	**5**	2						**14**	**0**	**5**	**5**	0	0	OA NOT ATTACHE	0	0	**10**	**24**
	848	Tetracycline	1% w/w	Eye Ointment	OPHTH TETRACYCL	**2**	**2**	**3**	0	**5**	2						**14**	**0**	**5**	**5**	0	0	OA NOT ATTACHE	0	0	**10**	**24**
	851	Tobramycin	0.3 % w/v	Eye drop	OPHTH TOBRA	**2**	**2**	**3**	0	**5**	2						**14**	**0**	0	0	0	0	OA NOT ATTACHE	0	0	**0**	**14**
	852	Tobramycin +Dexamethas	0.3%+0.1 %w/v	Eye drop	OPHTH TOBRA -D	**2**	**2**	**3**	0	**5**	2						**14**	**0**	0	0	0	0	OA NOT ATTACHE	0	0	**0**	**14**
	854	Tropicamide	1% w/v	Eye drop	OPHTH DILATE	**2**	**2**	**3**	0	**5**	2						**14**	**0**	0	0	0	0	OA NOT ATTACHE	0	0	**0**	**14**
	879	Lignocaine	2%	Gums Jelly	ANSCON	**2**	**2**	**3**	0	**5**	2						**14**	**0**	0	0	0	0	OA NOT ATTACHE	0	0	**0**	**14**

The firm was inspected as per technical evaluation criteria and the following observations were made by the inspection team:

Non-adherence to Good Storage Practices (GSP):

1. **One drum of metronidazole was available in the RMS and other excipients were stacked alongside the active pharmaceutical ingredient.**
2. **No temperature monitoring log was maintained in the general medicine raw material store, indicating inadequate environmental monitoring.**
3. **No designated and segregated quarantine areas (General medicine and Sutures) were available in the RMS for proper storage and status segregation of incoming raw materials pending approval or release.**
4. **The raw materials of all the quoted items were insufficient to cope the need of the health care facilities of the MCC purchasing entities.**

Non-Compliance to current Good Manufacturing Practices (cGMP):

5. **Gaps were present in the classified areas of the Sutures manufacturing section.**
6. **There was no air differentials in the PAL-MAL (personnel flow and material flow) passages in the sterile manufacturing areas (Sutures and Infusions).**
7. **The EO sterilization chamber of sutures was opening outside in open air/corridor.**
8. **Poor documentation practices were observed.**
9. **There was no production of sterile ophthalmic products at the time of inspection to ascertain the cGMP.**

In view of the above the firm is NOT-RECOMMENDED.

BID FORM-1 IS CHANGED AND INCOMPLETE AT PAGE 14
GD AT PAGE 176 IS EXPIRED FOR METRONIDAZOLE
GD AT 401 AND COA AT 402 FOR TOBRAMYCIN ARE NOT MATCHING
GD & COA FOR TROPICAMIDE & LIDOCAINE ATTACHED AT PAGE 433 AND 434 ARE NOT MATCHING

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposibles and Sutures for Government MCC 2026-27

Name of the firm OPHTH PHARMA KARACHI

S.No	MCC formulary No.	Product General Information				Technical Evaluation Matrix: Factory Technical Evaluation Parameter – Documents Based Factory Score				Evaluation Visit Score				Factory Evaluated Score	Product technical Evaluation Parameters					Product Evaluated Score	Total Technical Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. **(as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.**	Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAP regulations. **(to be evaluated by the MCC expert/s at the time of inspection, Noncompliance to cGMP shall lead to disqualification of the relevant section or firm)**	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section / firm.**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC** **(Certificate Duly attested by Senior Executive of the firm)**	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note.. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and / or valid product registration in SRA/WLA country(ies) / and / or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**3**	**5**	**5**	**6**	**3**	**3**	**2**	**2**	**29**	**5**	**5**	**5**	**6**	**10**	**10**	**41**	**70**
	1311	20mm, 1/2 circle round bodied taper point needle, strand length 70cm	4/0	CATGUT	.T CHROMIC CATGUT SUTUR	**3**	**5**		4	**The firm was inspected as per technical evaluation criteria and the following observations were made by the inspection team:** **Non-adherence to Good Storage Practices (GSP):** **1. One drum of metronidazole was available in the RMS and other excipients were stacked alongside the active pharmaceutical ingredient.** **2. No temperature monitoring log was maintained in the general medicine raw material store, indicating inadequate environmental monitoring.** **3. No designated and segregated quarantine areas (General medicine and Sutures) were available in the RMS for proper storage and status segregation of incoming raw materials pending approval or release.** **4. The raw materials of all the quoted items were insufficient to cope the need of the health care facilities of the MCC purchasing entities.** **Non-Compliance to current Good Manufacturing Practices (cGMP):** **5. Gaps were present in the classified areas of the Sutures manufacturing section.** **6. There was no air differentials in the PAL-MAL (personnel flow and material flow) passages in the sterile manufacturing areas (Sutures and Infusions).** **7. The EO sterilization chamber of sutures was opening outside in open air/corridor.** **8. Poor documentation practices were observed.** **9. There was no production of sterile ophthalmic products at the time of inspection to ascertain the cGMP.** **In view of the above the firm is NOT-RECOMMENDED.**		**12**	457 Size not mentioned	459 Not attached	0	0	**10**	Not recommended	**10**	**22**
	1312	20mm, 1/2 circle round bodied taper point needle, strand length 70cm	3/0	CATGUT	.T CHROMIC CATGUT SUTUR	**3**	**5**		4					**12**	457 Size not mentioned	459 Not attached	0	0	**10**	Not recommended	**10**	**22**
	1313	30mm, 1/2 circle round bodied taper point needle, strand length 70cm	2/0	CATGUT	.T CHROMIC CATGUT SUTUR	**3**	**5**		4					**12**	5	5	0	0	**10**	Not recommended	**20**	**32**
	1315	40mm, 1/2 circle round bodied taper point needle,	0	CATGUT	.T CHROMIC CATGUT SUTUR	**3**	**5**		4					**12**	457 Size not mentioned	459 Not attached	0	0	**10**	Not recommended	**10**	**22**
	1317	40mm, 1/2 circle round bodied taper point needle, strand length 70cm	1	CATGUT	.T CHROMIC CATGUT SUTUR	**3**	**5**		4						457 Size not mentioned	459 Not attached	0	0	**10**	Not recommended	**10**	**10**
	1319	40mm, 1/2 circle round bodied taper point needle, strand length 70cm	2	CATGUT	.T CHROMIC CATGUT SUTUR	**3**	**5**		4						5	5	0	0	**10**	Not recommended	**20**	**20**
	1322	26mm, 1/2 circle round bodied taper point needle, Strand length 75cm	3/0	SILK	B.T SILK SUTURE	**3**	**5**		4						478 GD of catgut attached	0	0	0	**10**	Not recommended	**10**	**10**
	1328	40mm, 1/2 circle round bodied taper point needle, Strand length 75cm	1	SILK	B.T SILK SUTURE	**3**	**5**		4						478 GD of catgut attached	0	0	0	**10**	Not recommended	**10**	**10**
	1329	30mm, 1/2 circle round bodied taper point needle, Strand length 75cm	1	SILK	B.T SILK SUTURE	**3**	**5**		4						478 GD of catgut attached	0	0	0	**10**	Not recommended	**10**	**10**
	1330	40mm, 3/8 circle conventional or curved cutting needle, Strand length 75cm	1	SILK	B.T SILK SUTURE	**3**	**5**		4						478 GD of catgut attached	0	0	0	**10**	Not recommended	**10**	**10**
	1331	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	2	SILK	B.T SILK SUTURE	**3**	**5**		4						478 GD of catgut attached	0	0	0	**10**	Not recommended	**10**	**10**
	1362	30mm, 1/2 circle round bodied taper point, strand length 75 cm	2/0	SILK	B.T SILK SUTURE	**3**	**5**		4						478 GD of catgut attached	0	0	0	**10**	Not recommended	**10**	**10**
	1363	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm	0	SILK	B.T SILK SUTURE	**3**	**5**	118-144 Equip/instrument for Assay/analysis not atttached	4						478 GD of catgut attached	0	0	0	**10**	Not recommended	**10**	**10**
	1365	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm	1	SILK	B.T SILK SUTURE	**3**	**5**		4						478 GD of catgut attached	0	0	0	**10**	Not recommended	**10**	**10**
	1366	40mm, 1/2 circle round bodied taper point needle, strand length 75 cm	2	SILK	B.T SILK SUTURE	**3**	**5**		4						478 GD of catgut attached	0	0	0	**10**	Not recommended	**10**	**10**
	1367	48mm, 1/2 circle round bodied taper point needle, strand length 75 cm	2	SILK	B.T SILK SUTURE	**3**	**5**		4						478 GD of catgut attached	0	0	0	**10**	Not recommended	**10**	**10**
	1374	13mm, 1/2 circle round bodied taper point double armed needle, strand length 60cm	6/0	POLYPROPYLENE	B.T. POLYPROPYLENE SUTURE	**3**	**5**		4						509 GD Not attached	510 COA not attached	0	0	**10**	Not recommended	**10**	**10**
	1377	13mm, 1/2 circle round bodied taper point double armed needle, strand length 60cm	5/0	POLYPROPYLENE	B.T. POLYPROPYLENE SUTURE	**3**	**5**		4						509 GD Not attached	511 COA not attached	0	0	**10**	Not recommended	**10**	**10**
	1386	26mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	2/0	POLYPROPYLENE	B.T. POLYPROPYLENE SUTURE	**3**	**5**		4						5	512 COA not attached	0	0	**10**	Not recommended	**15**	**15**
	1388	30mm, 1/2 circle round bodied taper point needle, strand length 75cm	2/0	POLYPROPYLENE	B.T. POLYPROPYLENE SUTURE	**3**	**5**		4						5	513 COA not attached	0	0	**10**	Not recommended	**15**	**15**
	1389	55mm, straight cutting needle, strand length 75cm	2/0	POLYPROPYLENE	B.T. POLYPROPYLENE SUTURE	**3**	**5**		4						5	514 COA not attached	0	0	**10**	Not recommended	**15**	**15**
	1390	60mm, straight cutting needle, strand length 75cm	2/0	POLYPROPYLENE	B.T. POLYPROPYLENE SUTURE	**3**	**5**		4						5	515 COA not attached	0	0	**10**	Not recommended	**15**	**15**
	1391	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	0	POLYPROPYLENE	B.T. POLYPROPYLENE SUTURE	**3**	**5**		4						5	516 COA not attached	0	0	**10**	Not recommended	**15**	**15**
	1392	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	1	POLYPROPYLENE	B.T. POLYPROPYLENE SUTURE	**3**	**5**		4						5	517 COA not attached	0	0	**10**	Not recommended	**15**	**15**
	1430	Polypropylene	6cm x 11cm	Surgical Mesh	SURGIMESH	**3**	**5**		4						0	0	0	0	**10**	Not recommended	**10**	**10**

Page	Remarks
464-472, 523	GD, COA and AWB of the catgut needles are not matching.
498	Enlistment under MDR 2017 are not attached

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27															
Name of the firm						OPTISURG Karachi															
						Technical Evaluation Matrix															
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation							Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm).**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of Finished quoted item/s from the Principal as Manufacturer mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevent certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
Yimaz Medikal -Mustaga Nazlier Budak Mah. Turkiye	1123	Keratome Ophthalmic Knife 3.2	1	Surgical	Oryum Knife 3.20 mm YM-320: 3.20mm Slit Knife, Yilmaz Bio Medikal, Turkey 3.2mm	Not attached		Not attached	The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COFG) for the quoted items were checked, and following observations were made: Yilmaz Medikal Mustafa, Turkey Valid original DRAP Enlistment, valid original agency agreement, & valid original free sale certificate for the quoted items were present at the time of inspection. However, the firm failed to produce original GMP/CE certificate for its quoted item. The CE certificate shown was also expired (Exp = 26-05-2024). In view of the above, the firm is NOT-RECOMMENDED for award of importer evaluation visit score for the quote items.			**5**	GD not attached	GD not attached	Tender approvals are not according to the criteria	0	0		**0**	**5**
Yimaz Medikal -Mustaga Nazlier Budak Mah. Turkiye	1152	Oryum Knife YM-15A: 15º Stab	1	Surgical	Oryum Knife YM-15A: 15º Stab Knife, straight, Yilmaz Bio Medikal., Turkey 15 degree	Not attached		Not attached				**5**	GD not attached	GD not attached	Tender approvals are not according to the criteria	0	0		**0**	**5**
												0							**0**	**0**
												0							**0**	**0**

Page 35-47

Remarks

Mandatory EC/cGMP and other documents are in foreign language

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: Shuka Pakistan (Importer) Karachi

S. No.		Product General Information				Technical Evaluation Matrix																	
						Principal's and Importer's Evaluation Parameters								Product Technical Evaluation									
						Principal Manufacturer Evaluation					Importer's Evaluation				Product Technical Parameters						Product Availability		
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
		M/s Guang dongDoubaiPharmaceuticalCo., Ltdligh & New-technologyIndustrieDevelopmentArea, RongguiStreet, ShundeDistrict,Foshan City,GuaZhina				Valid ISO 10001/45001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (IAF), (IAF) attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (IAF), (IAF) attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (IAF), (IAF) attested by senior executive of the firm) **Online verification link shall be provided**	Valid accreditation of manufacturing unit in relevant sections by the US-FDA or official accreditation body/ies /regulatory body in the case of SRA/WLA countries (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **Valid Calibration Certificates attested by Quality head of the firm).**	Availability of statement 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC experts). **Non availability of the 20% stock at the start hour at the time of inspection of the inspector shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good storage practices (GSP) for storage of finished goods. Functional and effective Air-conditioning & Ventilation System and effective cold chain (thermo-viable drugs). The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down requirements of Pharmaceutical and Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Nonadherence to GSP, as evaluated by the MCC experts at the time of inspection, shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s (core mandatory), & relevant Human Resource **Certified by the senior executive of the firm & evaluated / confirmed by MCC experts at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**	**Suppliers Technical Score**	Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA/WLAs country (ies).) For Sachgrads, bio-similarity studies shall be provided for award of marks in this parameter. Bio-waiver certificate from an accredited lab of SRA countries (Surrogate Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 2L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill/ or Bill of Lading for the quoted item/s, duly attested by senior executive the cutoff time for submission of bids. **In case of purchases through third party importers a valid Power of Attorney/ Assurance/ NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer or by mentioned in the goods declaration (GD) provided in column 15, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient's (API's) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA/WLAs country (ies). Trail of principal manufacturer shall be established from the respective GD, CoA and other supporting documents. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA country(ies) / Valid free-sale certificate issued by regulatory body of any SRA/WLA country(ies) and / or Valid certificate of the availability of the quoted item in the US market. **04 marks shall be awarded to the Primary certificate, and 3 marks for secondary certificate, up to a maximum of 06 (04+01+01) marks.** **Certificates on company's own letter heads shall not be acceptable.** **Copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this cokumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: Type of glass (Type 1 glass / Type 2 glass / Type 3 glass (NP/HP/LP/HDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to no award of marks in this parameter). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injection, i. For USP Type 1 glass 4 marks will be awarded. ii. For USP Type 2 Glass 2 marks will be awarded. iii. For product where USP Type 1 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm)**	Validity shelves of quoted item/s duly attested by the QAC inchange of the firm).	Availability of quoted items in Pakistan market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-20% market share = 2 marks 21-30% market share = 3 marks 30% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the Tender shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 01 or less Tender approvals= 01 marks 04 Tender approvals= 02 marks 06 Tender approvals= 03 marks 08 Tender approvals= 04 marks 10 or more Tender approvals= 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the encashment of cheque against the cheque received shall also be submitted with each purchase order.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	2	5	5	4	5	5	30	5	5	5	5	6	4	5	5	40	70
	4852121553	Cefotaxim	250 ml	Inj.(Iv) 250ml	Kefotil	Not attached	0	0	725 Document is in foreign		4	5	5	18	0	0	0	0	0	0	0	902 Tender approvals are not according to the ab Criteria	24	42
		Samt gauntee is for the FY 2025-26 and expiry is 10-02-27												0									0	0

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm | **Otsuka Pakistan Karachi (Manufacturer)**

Technical Evaluation Matrix

S. No.	Product General Information					Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters										
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th positions shall be awarded 1 mark.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC experts). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC experts at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/ USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient's (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of WITInd submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with freeze/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this colouson for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or more clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the Q.C. incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent more data of IMS/IQVIA /Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be verifiable through publicly available procurement records, purchase orders, delivery challan, invoices/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70
1	627	Ammo Acid Solution 3% *	500 ml	INJ.(IV)	Pan Amin-G	2	2	3	47 IMS rankign not attached	5	6	2	2	2	2	2	28	5	5	5	0	0	4	5	0	24	52
2	627	Ammo Acid Solution 5% *	400 ml	INJ.(IV)	Aminoven-400	2	2	3		5	6	2	2	2	2	2	28	5	5	5	0	0	4	5	0	24	52
3	627	Ammo Acid Solution 8%	500 ml	INJ.(IV)	Aminoblean- Inj.	2	2	3		5	6	2	2	2	2	2	28	5	5	5	0	0	4	5	0	24	52
																	0									0	0

Page Remarks
25 Mandatory Bid Security is not according to the adver. BSDs Mandatory 7 is not attached .
475 Tender approvals are not according to the ad. criteria.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: PDH Pharmaceuticals Lahore

Product General Information				Technical Evaluation Matrix																				
				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters							Total Product Evaluated Score	Total Technical Score
				Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters								
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
				Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) is evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item's from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products, In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: i. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade.	Stability studies of quoted item's duly attested by the QAC incharge of the firm),	Availability of quoted item's in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICJ accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.			
Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70
IBUPROFEN SUSP	100mg/5ml	Susp	IBUMIL SUSP	2	2	3	0	5	4						0	0	5	5			4			0	0
Mefenamic Acid	250 mg	Tab.	Mefadil Tabs	2	2	3	0	5	4						0	0	5	5			590 COA and POP not matching			0	0
Mefenamic Acid	500 mg	Tab.	Mefadil Forte	2	2	3	0	5	4						0	0	5	5			590 COA and POP not matching			0	0
Paracetamol	500 mg	Tab.	Paracetamol	2	2	3	0	5	4						0	0	5	5			637			0	0
Paracetamol	120 mg / 5 ml	Susp	Anamol	2	2	3	0	5	4						0	0	5	5			659 COA not attached			0	0
Clotrimazole	500 mg	Vaginal tablet	Fiorsclean	2	2	3	0	5	4						0	0	5	5						0	0
Cetirizine	10 mg	Tab.	Cezine Tablets 10mg	2	2	3	0	5	4	The firm was inspected as per technical evaluation criteria. Non-Adherence to Good Manufacturing Practices & Non Functional HVAC System 1. In general tablet blistering section, the temperature observed was 28.8 and RH 44% at the time of inspection. Whereas the Batch Manufacturing Record (BMR) Document No. QA/QF/013, the limit were Temperature (25 ± 2) and RH 45 ± 5%). 2. HVAC was not functional at the time of inspection in tablet compression area, the temperature recorded was 29.7 . 3. Monometer gauges in tablet compression, and liquid filling area were out of order. 4. The weighing balance at dispensing booth of Raw material store was not calibrated at the time of inspection. 5. The presence of gaps in all doors within the production area compromised the ability to maintain differential air pressure between the various rooms of production. 6. Critical equipment such as HVAC, pressure gauges, and a weighing balance were either non-functional or uncalibrated at the time of inspection, indicating poor CGMP compliance. In view thereof, the firm is RECOMMENDED ONLY FOR ORAL CEPHALOSPORINS.					0	0	0	5	5	720 COA not attached			0	0
Cetirizine	5 mg/5 ml	Syp	Cezine Syp 1mg /	2	2	3	0	5	4						0	0	5	5			744 COA not attached			0	0
Chlorpheniramine Maleate	4 mg	Tab.	Allerphene Tabs	2	2	3	0	5	4						0	0					757 COA not attached			0	0
Chlorpheniramine Maleate	2 mg/5 ml	Syp	Allerphene Syp	2	2	3	0	5	4						0	0					765 GD COA not attached			0	0
Levocetirizine	2.5 mg/5 ml	syp	Levocezine Syp	2	2	3	0	5	4						0	0	5	5			4			0	0
Montelukast	10 mg	Tab.	Montana 10mg Tablets	2	2	3	0	5	4						0	0	5	5			813 COA and POP not matching			0	0
Montelukast	5 mg	Tab.	Montana 5mg Tablets	2	2	3	0	5	4						0	0	5	5			813 COA and POP not matching			0	0
Montelukast	4 mg	Sachet	Montana 4mg	2	2	3	0	5	4						0	0	5	5			4			0	0
Cefixime	400 mg	Cap	Cefixre Caps	2	2	3	0	5	4	2	2	2	2	2	0	0	5	5			4			0	0
Cefixime	100 mg/5ml	Dry Susp	Cefixore Susp	2	2	3	0	5	4	2	2	2	2	2	0	0	5	5			4			0	0
Cefixime	200 mg/5ml	Dry Susp	Cefixore DS Susp	2	2	3	0	5	4	2	2	2	2	2	0	0	5	5			4			0	0
Cephradine	250 mg	Cap	DYNACEF Cap	2	2	3	0	5	4	2	2	2	2	2	0	0	5	5			4			0	0
Cephradine	500 mg	Cap	DYNACEF DS Cap	2	2	3	0	5	4	2	2	2	2	2	0	0	5	5			4			0	0
Cephradine	125mg / 5 ml	Dry Susp.	DYNACEF Susp	2	2	3	0	5	4	2	2	2	2	2	0	0	5	5			4			0	0
Cephradine	250 / 5ml	Dry Susp.	DYNACEF Susp	2	2	3	0	5	4	2	2	2	2	2	0	0	5	5			4			0	0
Ciprofloxacin	250 mg	Tab.	Kuin Tablets	2	2	3	0	5	4						0	0	5	5			1001 COA and POP not			0	0
Ciprofloxacin	500 mg	Tab.	Kuin Tablets	2	2	3	0	5	4						0	0	5	5			1001 COA and POP not			0	0
Levofloxacin	250 mg	Tab.	Quest Tablets	2	2	3	0	5	4						0	0	5	5			1049 COA and POP NM			0	0
Levofloxacin	500 mg	Tab.	Quest Tablets	2	2	3	0	5	4						0	0	5	5			1049 COA and POP NM			0	0
Linezolid	600mg	Tab.	OXALIDE TABS	2	2	3	0	5	4						0	0	5	5			1099 COA and POP NM			0	0
Linezolid	100mg/5ml	Suspension	OXALIDE Susp	2	2	3	0	5	4						0	0	5	5			4			0	0
Iron Hydroxide poly maltose	syp. 50 mg/5ml,	Syp 60 ml	PD-Bion	2	2	3	0	5	4						0	0	Not attached	Not attached			Not attached			0	0
Iron Hydroxide poly maltose	syp. 50 mg/5ml	Oral Drops 30 ml	PD-Bion Drops	2	2	3	0	5	4						0	0	Not attached	Not attached			Not attached			0	0
Losartan + Hydrochlorothiazide	50 mg+12.5mg	Tab.	Giozar - D Tablets 50mg	2	2	3	0	5	4	The firm was inspected as per technical evaluation criteria. Non-Adherence to Good Manufacturing Practices & Non Functional HVAC System 1. In general tablet blistering section, the temperature observed was 28.8 and RH 44% at the time of inspection. Whereas the Batch Manufacturing Record (BMR) Document No. QA/QF/013, the limit were Temperature (25 ± 2) and RH 45 ± 5%). 2. HVAC was not functional at the time of inspection in tablet compression area, the temperature recorded was 29.7 . 3. Monometer gauges in tablet compression, and liquid filling area were out of order. 4. The weighing balance at dispensing booth of Raw material store was not calibrated at the time of inspection. 5. The presence of gaps in all doors within the production area compromised the ability to maintain differential air pressure between the various rooms of production. 6. Critical equipment such as HVAC, pressure gauges, and a weighing balance were either non-functional or uncalibrated at the time of inspection, indicating poor CGMP compliance. In view thereof, the firm is RECOMMENDED ONLY FOR ORAL CEPHALOSPORINS.					0	0	0	1163 GD of HCTZ expired	0	1179 COA of ALU ALU attached			0	0
Losartan Potassium	50 mg	Tab.	Giozar Tabs	2	2	3	0	5	4						0	0	5	5			C			0	0
Domperidone	10 mg	Tab.	Stominant Tabs	2	2	3	0	5	4						0	0	5	5			1228 COA and POP NM			0	0
Domperidone	5 mg/5ml	Susp	Stominant Susp	2	2	3	0	5	4						0	0	5	5			4			0	0
Famotidine	40 mg	Tab.	Famron Tabs	2	2	3	0	5	4						0	0	5	5			1228 COA and POP NM			0	0
Esomeprazole	40 mg	Cap	Solzer Caps 40mg	2	2	3	0	5	4						0	0	5	5			4			0	0
Sodium Acid Citrate	1.315 gm/5ml	Liq	Alkacitron Syrup	2	2	3	0	5	4						0	0	1313 AWB not visible				4			0	0
Diphenhydramine+ Aminophylline+ Ammonium Chloride	8mg+32mg+30 mg /5ml	Syp	Vindril Syrup	2	2	3	0	5	4						0	0	5	5			4			0	0
Salbutamol	2mg/5ml	Syp	Butamin Syrup	2	2	3	0	5	4						0	0	1375 GD expired	0			4			0	0
Chloramphenicol	0.5 % w/v	Eye Drops	Neo-Phenicol Eye	2	2	3	0	5	4						0	0	5	5			4			0	0
Ciprofloxacin	0.3% w/v	Eye Drops	Kuinopt Eye	2	2	3	0	5	4						0	0	5	5			4			0	0
Tobramycin	0.3% w/v	Eye Drops	NEOBREX EYE	2	2	3	0	5	4						0	0	5	5			4			0	0

Incomplete
701DRAP
Original Mandatory forms in Hard are not submitted to the MCC

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: PACIFIC PHARMACEUTICALS LAHORE

S. No.	Product General Information					Factory Technical Evaluation Parameters: Documents Based Factory Score						Factory Evaluation Visit Score					Total Factory Evaluated Score	Technical Evaluation Matrix: Product Evaluation Parameters: Product Technical Parameters							Total Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO ERMS/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan. **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th positions shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC experts, as non-availability or non-functionality of stability chambers and or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, in-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GMP shall lead to disqualification of the sections.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the sections or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP. **(Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the relevant section / firm.** | Availability of Functional and validated HVAC with all relevant equipment, testing, sys. **As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to disqualification of the relevant section / firm.**		Renewal/ability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA/ MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA/WLAs country (ies).). and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant Stringent Regulatory Authority where the firm claims the Prod. Bio-equivalency / bio-waiver is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases though third party importers a valid trad/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted in the technical item. Non provision of the above shall lead to award of zero marks in this column for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-corrosive type) or Type I borosilicate glass (Non-leachable). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided, the firm shall be disqualified at this section (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 6-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 01 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agencies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	Offered Product Formulary No.s	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
	47	46	Ibuprofen	200 mg / 5ml 90ml	Susp.	Albert Suspension 90ml	NA	NA	NA	NA	NA	NA						**0**	NA	NA	NA	NA	NA	NA	NA	NA	**0**	**0**
	59	58	Paracetamol	80mg/0.8ml 30ml	Oral Drops	Pacipar 80 mg / 0.8 ml Infant Drops	NA	NA	NA	NA	NA	NA						**0**	NA	NA	NA	NA	NA	NA	NA	NA	**0**	**0**
Neschem	188	187	Azithromycin	200mg/ 5 ml; 15ml	Susp.	Azithro 200mg/5ml Suspension	3	3	3	3	3	3						**15**	5	5	5	5	5	5	5	5	**5**	**25**
Neschem	189	188	Azithromycin	250 mg	Tab.	Azithro 250mg Tab	2	2	2	2	0	0						**10**	0	5	0	0	0	0	0	0	**0**	**15**
Neschem	190	189	Azithromycin	500 mg	Tab.	Azithro 500mg Tab	2	2	2	2	0	0						**10**	0	5	0	0	0	0	0	0	**0**	**15**
	400	419	Bisoprolol	2.5mg	Tab.	Fabrizid 5	NA	NA	NA	NA	NA	NA						**0**	NA	NA	NA	NA	NA	NA	NA	NA	**0**	**0**
	534	535	Clomiphene Citrate	50mg	Tab.	Clomid Tab 50mg	NA	NA	NA	NA	NA	NA						**0**	NA	NA	NA	NA	NA	NA	NA	NA	**0**	**0**
	538	539	Cyclosporin/one	25mg	Cap.	Eckfort 10 mg Tablet	NA	NA	NA	NA	NA	NA						**0**	NA	NA	NA	NA	NA	NA	NA	NA	**0**	**0**
	1522	1745	Lamivudin 2.5 mg Tab	2.5mg	Tab.	Retrovir Tab 2.5mg	NA	NA	NA	NA	NA	NA						**0**	NA	NA	NA	NA	NA	NA	NA	NA	**0**	**0**
Hangzhou Hollypharm Biotech	4	1594	Metronidazole	500 mg	Inf.	Metronex 500mg/100ml infusion iv	2	2	2	2	0	0						**10**	0	5	5	0	0	0	0	0	**10**	**20**
	41	1947*1%	Diclofenac Sodium (BM/IV for	75 mg/ml	Inj.	Paridiclo 75mg/3ml Injection	NA	NA	NA	NA	NA	NA						**0**	NA	NA	NA	NA	NA	NA	NA	NA	**0**	**0**
	215	250ml	Moxifloxacin	400 mg/250ml	Inf.	Nitro 400mg/250ml Infusion	NA	NA	NA	NA	NA	NA						**0**	NA	NA	NA	NA	NA	NA	NA	NA	**0**	**0**
	628	636ml	Dextrose	10%	IV Inf.	Paridex 100 10% IV Infusion 500ml	NA	NA	NA	NA	NA	NA						**0**	NA	NA	NA	NA	NA	NA	NA	NA	**0**	**0**
	629	1000ml	Dextrose	10%	IV Inf.	Paridex 100 10% IV Infusion 1000ml	NA	NA	NA	NA	NA	NA						**0**	NA	NA	NA	NA	NA	NA	NA	NA	**0**	**0**
	630	1000ml	Dextrose	5%	IV Inf.	Paridex 50 5% IV Infusion 1000ml	NA	NA	NA	NA	NA	NA						**0**	NA	NA	NA	NA	NA	NA	NA	NA	**0**	**0**
	631	500ml	Dextrose	5%	IV Inf.	Paridex 50 5% IV Infusion 500ml	NA	NA	NA	NA	NA	NA						**0**	NA	NA	NA	NA	NA	NA	NA	NA	**0**	**0**
	632	1000ml	Dextrose	5%	IV Inf.	Paridex 50 5% IV Infusion 1000ml	NA	NA	NA	NA	NA	NA						**0**	NA	NA	NA	NA	NA	NA	NA	NA	**0**	**0**
	634	1000ml	Dextrose + Sodium Chloride	5% +0.9%	IV Inf.	Paridex 5/0.9	NA	NA	NA	NA	NA	NA						**0**	NA	NA	NA	NA	NA	NA	NA	NA	**0**	**0**
	635	1000ml	Dextrose + Sodium Chloride	5% +0.3%	IV Inf.	Paridex 5/0.3 1000ml	NA	NA	NA	NA	NA	NA						**0**	NA	NA	NA	NA	NA	NA	NA	NA	**0**	**0**
	646	100ml	Normal Saline	0.90%	IV Inf.	Paricel NS IV Infusion 100ml	NA	NA	NA	NA	NA	NA						**0**	NA	NA	NA	NA	NA	NA	NA	NA	**0**	**0**
	647	500ml	Normal Saline	0.90%	IV Inf.	Paricel NS IV Infusion 500ml	NA	NA	NA	NA	NA	NA						**0**	NA	NA	NA	NA	NA	NA	NA	NA	**0**	**0**
	649	2000ml	Normal Saline	0.90%	IV Inf.	Paricel NS IV Infusion 2000ml	NA	NA	NA	NA	NA	NA						**0**	NA	NA	NA	NA	NA	NA	NA	NA	**0**	**0**
	656	500ml	Ringer's Lactate Soln.		IV Inf.	Paricael RL IV Infusion 500ml	NA	NA	NA	NA	NA	NA						**0**	NA	NA	NA	NA	NA	NA	NA	NA	**0**	**0**
	657	1000ml	Ringer's Lactate Soln.		IV Inf.	Paricael RL IV Infusion 1000ml	NA	NA	NA	NA	NA	NA						**0**	NA	NA	NA	NA	NA	NA	NA	NA	**0**	**0**

Scrutiny Report

POF	
128-29 255-421	The firm has quoted wrong formulary No.s for their quoted products in its technical proposal to the Govt. MCC FY 2026-27 except the formulary No.s for their quoted items i.e., 189, 190 and 4. No calibration certificate/s for major equipments such as HPLC, FTIR are attached in the technical bid.
3	COA of Azithromycin Tablet are not attached in the bid. Hence, marks may not be awarded.
4	Invoice/proof of purchase for immediate container are not attached in the bid. Hence, marks may not be awarded in relevant column.
5	Stability studies are not attested by the QC incharge of the firm for the eligible quoted items.
6	IMS market share for Metronidazole infusion is not attached in the technical bid for award of marks in column 24.
7	cGMP certificate for the infusion plant is not attached in the technical bid.

Evaluation Criteria for Manufacturers of Non Drugs Items for Govt MCC 2026-27

Name of the firm: PAKTEX KAMOKE/LAHORE

Technical Evaluation Matrix

			Product General Information				Factory Technical Evaluation Parameter													
							Documents Based Factory Score				Evaluation Visit Score				Factory Evaluated Score				Product Evaluated Score	Total Technical Score
	S.No	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
							Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. **(as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.**	Adherence to Current Good Manufacturing Practices in line with the DRAP regulations. **(to be evaluated by the MCC expert/s, Non compliance to cGMP shall lead to disqualification of the relevant section or firm)**	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section (s) / firm.**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC** **(Certificates duly attested by Senior Executive of the firm)**	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. **02 marks for each certification, up to a maximum of 06 marks.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
		MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	6	5	5	5	5	**39**	5	5	5	6	10	**31**	**70**
		1139	Isopropyl Alcohol 70% Disposable Nonwoven Swabs	3cm x 3cm 2ply with 70% IPA	Pro Pak Alcohol Swab	Pro Pak Alcohol Swab	3	5	5	**2**	5	5	5	5	**35**	0	**0**	Tender approvals are incomplete	0	10	**10**	**45**
		1152	Disposable Face Mask. (Medical mask, good breathability, and clearly identifiable internal and external faces) (As per WHO or alternative	Adult	Pak Band Face Mask	Pak Band Face Mask	3	5	5	**2**	5	5	5	5	**35**	0	**0**	Tender approvals are incomplete	0	10	**10**	**45**
		1162	Non-Medicated sterilized adhesive post-operative wound dressing	6cm x 7cm	Propore Self-Adhesive Wound Dressing	Propore Self-Adhesive Wound Dressing	3	5	5	**2**	5	5	5	5	**35**	0	**0**	Tender approvals are incomplete	0	10	**10**	**45**
		1163	Non-Medicated sterilized adhesive post-operative wound dressing	9cm x 10cm	Propore Self-Adhesive Wound Dressing	Propore Self-Adhesive Wound Dressing	3	5	5	**2**	5	5	5	5	**35**	0	**0**	Tender approvals are incomplete	0	10	**10**	**45**
		1164	Non-Medicated sterilized adhesive post-operative wound dressing	9cm x 15cm	Propore Self-Adhesive Wound Dressing	Propor Self-Adhesive Wound Dressing	3	5	5	**2**	5	5	5	5	**35**	0	**0**	Tender approvals are incomplete	0	10	**10**	**45**
		1165	Non-Medicated sterilized adhesive post-operative wound dressing	9cm x 20cm	Propore Self-Adhesive Wound Dressing	Propor Self-Adhesive Wound Dressing	3	5	5	**2**	5	5	5	5	**35**	0	**0**	Tender approvals are incomplete	0	10	**10**	**45**
		1166	Non-Medicated sterilized adhesive post-operative wound dressing	9cm x 25cm	Propore Self-Adhesive Wound Dressing	Propor Self-Adhesive Wound Dressing	3	5	5	**2**	5	5	5	5	**35**	0	**0**	Tender approvals are incomplete	0	10	**10**	**45**
		1167	Non-Medicated sterilized adhesive post-operative wound dressing	9cm x30cm	Propore Self-Adhesive Wound Dressing	Propor Self-Adhesive Wound Dressing	3	5	5	**2**	5	5	5	5	**35**	0	**0**	Tender approvals are incomplete	0	10	**10**	**45**
		967	Cord Clamp	Standard Size Sterile		Neo Care	3	5	5	**2**	5	5	5	5	**35**	0	**0**	proper trial of the supporting documents not attached	0	11	**11**	**46**

Evaluation Criteria for Manufacturers of Cotton & Related Goods for Government MCC 2026-27

			Name of Firm			Paktex Industries Kamoke, Lahore																
						Technical Evaluation Matrix																
	S. No.		General Product Information				Factory Technical Evaluation Parameters										Factory Evaluated Score	Product Evaluation Parameters			Product Evaluated Score	Total Technical Score
							Documents Based Factory Score						Evaluation visit Score									
		MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
							Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body. (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e FY 2023-24 or latest. A minimum turnover of PKR 100 million is required for award of marks in this parameter. (The document shall be attested by a Senior executive of the firm)	Functional and effective Airconditioning & Ventilation System as per the requirements laid down by DRAP **(Evaluated by the MCC expert/s at the time of inspection, Non functionality of the Air Conditioning & Ventilation system in specified section shall lead to disqualification of the section or firm)**	Adequate availability of equipment / instruments in QC labs performing relevant official tests as well as compliance to Good laboratory practices (GLP) in all Labs and Current Good Manufacturing Practices (cGMP) throughout the production facility. **(Evaluated by the MCC expert/s at the time of inspection, Non availability of adequate and appropriate equipment / instruments and non-compliance to GLP , cGMP shall lead to disqualification of the relevant section or firm)**	Appropriate storage of raw material, in process and finished goods with compliance to Good storage practices (GSP) **(To be evaluated by the MCC expert/s at the time of inspection, Non compliance to GSP shall lead to disqualification of the relevant section or firm)**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover,	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)		
		MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**3**	**3**	**3**	**4**	**5**	**3**	**6**	**6**	**6**	**6**	**45**	**5**	**10**	**10**	**25**	**70**
		971	Cotton Bandages (Surgical) B.P Type II	6.5 cm x 4 m	Open Wove Bandage B.P-II	Open Wove Bandage B.P-II	3	3	3	**4**	5	3	6	6	6	6	**45**	Tender approvals are incomplete	10	10	**20**	**65**
		972	Cotton Bandages (Surgical) B.P Type II	7.5 cm x 4m	Open Wove Bandage B.P-II	Open Wove Bandage B.P-II	3	3	3	**4**	5	3	6	6	6	6	**45**	Tender approvals are incomplete	10	10	**20**	**65**
		973	Cotton Bandages (Surgical) B.P Type II	10 cm x 4 m	Open Wove Bandage B.P-II	Open Wove Bandage B. P-II	3	3	3	**4**	5	3	6	6	6	6	**45**	Tender approvals are incomplete	10	10	**20**	**65**
		974	Cotton Bandages (Surgical) B.P Type II	15 cm x 4 m	Open Wove Bandage B.P-II	Open Wove Bandage B.P-II	3	3	3	**4**	5	3	6	6	6	6	**45**	Tender approvals are incomplete	10	10	**20**	**65**
		981	Crepe Bandages BPC	7.5cm x 4.5m	Easylite Cotton Crepe Bandage B.P.C	Easylite Cotton Crepe Bandage B.P.C	3	3	3	**4**	5	3	6	6	6	6	**45**	Tender approvals are incomplete	DTL Substandard	10	**10**	**55**
		982	Crepe Bandages BPC	10cm x 4.5m	Easylite Cotton Crepe Bandage B.P.C	Easylite Cotton Crepe Bandage B.P.C	3	3	3	**4**	5	3	6	6	6	6	**45**	Tender approvals are incomplete	10	10	**20**	**65**
		983	Crepe Bandages BPC	15cm x 4.5m	Easylite Cotton Crepe Bandage B.P.C	Easylite Cotton Crepe Bands	3	3	3	**4**	5	3	6	6	6	6	**45**	Tender approvals are incomplete	DTL Substandard	10	**10**	**55**
		1097	Gauze Cloth Roll packing	100 cm x 20 m	Ortho Gauze Roll	Ortho Gauze Roll	3	3	3	**4**	5	3	6	6	6	6	**45**	Tender approvals are incomplete	10	10	**20**	**65**
		1098	Gauze Cloth Roll packing	100 cm x 40m	Ortho Gauze Roll	Ortho Gauze Roll	3	3	3	**4**	5	3	6	6	6	6	**45**	Tender approvals are incomplete	10	10	**20**	**65**
		1184	Paraffin Gauze dressing (Tulle) with Chlorhexidine	10cm x 10cm	Sera Tulle Antiseptic Tulle Dressing with Chlorhexidine Acetate 0.5 % B.P Sterile	Sera Tulle Antiseptic Tulle Dressing with Chlorhexidine Acetate 0.5 % B.P.	3	3	3	**4**	5	3	6	6	6	6	**45**	Tender approvals are incomplete	10	10	**20**	**65**
		1217	Sterile Gauze Dressing Pad (X-ray detectable Radiopaque) (USP-Type IV/BP-Type-II/BPC)	Blister pack 10x10cm, 8ply	Pak Band Gauze Swab B.P with X-Ray Detectable Thread Sterile	Pak Band Gauze Swab BP	3	3	3	**4**	5	3	6	6	6	6	**45**	Tender approvals are incomplete	10	10	**20**	**65**
		1217	Sterile Gauze Dressing Pad (X-ray detectable Radiopaque) (USP-Type IV/BP-Type-II/BPC)	Blister pack 10x10cm, 8ply	Pak Band Gauze Swab U.S.P-IV with X-Ray Detectable Thread Sterile	Pak Band Gauze Swab USP IV	3	3	3	**4**	5	3	6	6	6	6	**45**	Tender approvals are incomplete	Non Formulary	Non Formulary	**0**	**45**
		1218	Sterile Gauze Dressing Pad (X-ray detectable Radiopaque) (USP-Type IV/BP-Type-II/BPC)	Blister pack 15x15cm, 8ply	Pak Band Gauze Swab B.P with X-Ray Detectable Thread Sterile	Pak Band Gauze Swab USP IV	3	3	3	**4**	5	3	6	6	6	6	**45**	Tender approvals are incomplete	Non Formulary	Non Formulary	**0**	**45**
		1219	Sterile Gauze Dressing Pad (X-ray detectable Radiopaque) (USP-Type IV/BP-Type-II/BPC)	Blister pack 30x30cm, 4ply	Pak Band X-Ray Detectable Abdominal Lap Sponge B.P-Type-II Sterile	Pak Band Gauze	3	3	3	**4**	5	3	6	6	6	6	**45**	Tender approvals are incomplete	10	10	**20**	**65**
		1220	Sterile Gauze Dressing Pad (USP-Type IV/BP-Type-II/BPC)	Blister pack 10x10 cm, 8ply	Pak Band Gauze Swab U.S.P-IV Sterile	Pak Band Gauze	3	3	3	**4**	5	3	6	6	6	6	**45**	Tender approvals are incomplete	10	10	**20**	**65**
		1220	Sterile Gauze Dressing Pad (USP-Type IV/BP-Type-II/BPC)	Blister pack 10x10 cm, 8ply	Pak Band Gauze Swab B.P Sterile	Pak Band Gauze	3	3	3	**4**	5	3	6	6	6	6	**45**	Tender approvals are incomplete	DTL Misbranded	10	**10**	**55**

		1221	Sterile Gauze Dressing Pad (USP-Type IV/BP-Type-II/BPC)	Blister pack 15x15 cm, 8 ply	Pak Band Gauze Swab B.P Sterile	Pak Band Gauze	3	3	3	**4**	5	3	6	6	6	6	**45**	Tender approvals are incomplete	10	10	**20**	**65**

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm PHARMASOL LAHORE

S. No.		Product General Information				Technical Evaluation Matrix																						
						Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firms having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firms).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC experts/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC experts/s). **Non-compliance to GMP guidelines shall lead to disqualification of the section/s or firm).**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP. **(Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, maps. **(As evaluated by the MCC experts at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, complied with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC.**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE), or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. For Glass material for vials, the glass material must be USP Type 3 or better (**Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the QC incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data or IMS/IQVIA Health not older than two/ten (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the holder shall provide Tender Approvals (not older than two/five 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: I02 Tender approvals- 02 mark I04 Tender approvals- 02 marks I06 Tender approvals- 03 marks I08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity (purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**5**	**3**	**4**	**5**	**5**	**37**	**70**
	47	Ketorolac	30 mg/ml	Inj.	Ketrol	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	0				4	5		**9**	**30**
	86	Hydroxyurea	500 mg	Cap.	Hydroxa	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	0				0	NA		**0**	**21**
	244	Colistimethate	1 MIU	Inj.	Colistim	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	NOT MATCHING WITH COA	0			0	NA		**0**	**21**
	260	Imipenem+Cilastatin	500mg+500 mg	Inj.	Cilastipen	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	5	5			0	NA		**10**	**31**
	243	Colistimethate	2 MIU	Inj.	Colistim	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	NOT MATCHING WITH COA	0			0	NA		**0**	**21**
	268	Linezolid	600 mg	Tab.	Xolid	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	0				0	5		**5**	**26**
	271	Linezolid	600 mg/300 ml	Inj.	Xolid	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	0				0	5		**5**	**26**
	272	Meropenem	500 mg	Inj.	Merosol	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	0	5			0	5		**10**	**31**
	273	Meropenem	1g	Inj.	Merosol	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	5	5			0	5		**15**	**36**
	292	Rifaxamin	550 mg	Tab.	Rifaxol	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	0				0	5		**5**	**26**
	295	Vancomycin	500 mg	Inj.	Vancosol	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	451- GD IS BLURR				0	5		**5**	**26**
	296	Vancomycin	1g	Inj.	Vancosol	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	451- GD IS BLURR				0	5		**5**	**26**
	341	Sofosbuvir	400 mg	Tab.	Foxviral	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	0				0	5		**5**	**26**
	557	Hydrocortisone	100 mg	Inj.	Hicartif	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	5	5			0	5		**15**	**36**
	558	Hydrocortisone	250 mg	Inj.	Hicartif	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	5	5			0	5		**15**	**36**
	569	Methyl Prednisolone	500 mg	Inj.	Solomed	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	5	5			0	5		**15**	**36**
	570	Methyl Prednisolone	1g	Inj.	Solomed	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	5	5			0	5		**15**	**36**
	581	Sitagliptin+Metformin	50 mg +500 mg	Tab.	Sitamin	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	0	0			0	5		**5**	**26**
	582	Sitagliptin+Metformin	50 mg+ 1000 mg	Tab.	Sitamin	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	0	0			0	5		**5**	**26**
	725	Escitalopram	10 mg	Tab.	Selpram	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	0	0			0	5		**5**	**26**
	754	Pregabalin	75 mg	Cap.	Gabrix	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	0	0			0	5		**5**	**26**
	827	Ciprofloxacin	5 ml	Eye Drop	Ciproxol	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	5	5			0	5		**15**	**36**
	839	Moxifloxacin	5ml	Eye Drop	Moxol ED	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	5	5			0	NA		**10**	**31**
	852	Tobramycin+Dexamethasone	5ml	Eye Drop	Tobracort ED	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	0	0			0	5		**5**	**26**
	870	Fusidic Acid	15g	Cream	Futcyn	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	0	0			0	5		**5**	**26**
	891	Silver Sulfadiazine	50 g	Cream	Silverex	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	5	5			0	5		**15**	**36**
	894	Terbinafine	10 g	Cream	Tegsol	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	5	5			0	5		**15**	**36**
	914	Cholecaliferol	5mg	Inj.	Oraject-D	**0**	**0**	**0**	0	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**21**	0	461- BLURR	0			0	5		**5**	**26**

DML OF PHARMAGEN IS ATTACHED AT PAGE 13

CGMP OF PHARMAGEN IS ATTACHED, THAT TOO IS EXPIRED AT PAGE 163

ISO 9001 AND 14001 ARE NOT FROM PNAC ACCREDITED SGS PAKISTAN PAGE 163-165. FURTHERMORE, ISO 45001 IS NOT COVERED IN THE SCOPE OF SGS PAKISTAN

PAGE 213 AND 215, GD AND COA OF COLISTEMETHATE ARE NOT MATCHING

GDs till 307 page are not readable hence marks not awarded in COA as well because raw material source cannot be ascertained. Furthermore, COAs are not coupled with form-3, form-7 and DRAP Clearence certificate

page 310, GD AND COA OF ESCITALOPRAM ARE NOT MATCHING

340 PAGE, GD AND COA OF FUSIDIC ACID ARE NOT MATCHING

PAGE 355 GD AND COA OF HYDROXYUREA ARE NOT MATCHING,

IRRELEVENT DOCUMENTS AFTER GDS TILL 547 (PERFORMANCE QUALIFICATION) ARE ATTACHED

PROOF OF PURCHASE OF SOME IMMEDIATE CONTAINERS ARE NOT PROVIDED, COA OF SOME ARE MISSING, WHILE SOME VIALS ARE USP TYPE-III. ALMONIUM FIOL IMMEDIATE CONTAINER DOCUMENTS ARE NOT ATTACHED.

Original Mandatory forms in Hard are not submitted to the MCC

TECHNICAL EVALUATION PROFORMA, FOR PROCUREMENT OF ANTICANCER MEDICINES IN GOVT. MCC FY 2026-27

		Name of the firm with Complete Address
		Manufacturer / Importer

PHARMASOL LAHORE

MANUFACTURER

		Mandatory Requirements.	**YES / NO**		**In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:**		**YES/NO**
1		**National Tax Number (NTN) of the Firm for Income Tax, and**	YES		1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and	NO
2		**Last year Income Tax Return of the Firm; and**	YES		2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.	NO
3		**Sale Tax Registration Certificate of the Firm; and**	YES		3	Valid DRAP Approved Price List of the quoted item/s.	NO
4		**Certificate of Professional Tax of the Firm.**	YES				
5		**Certificate of compliance to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR. Non-Compliance to international reference standards or absence of Cold Chain requirements shall lead to disqualification of the relevant product that requires cold chain.**	NO				

		In case of being Importers, the Firm should provide attested copies of the following documents also:	**YES/NO**	
1		Valid Drugs Sales License for the importer; and		
2		Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and		
3		Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and		
4		Valid eCOMP Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and		
5		Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s. Non provision of this document shall lead to disqualification of the firm; and		
6		Valid DRAP approved Price List of the quoted item/s.		

		Technical Evaluation Parameters	**Active Pharmaceutical Ingredient source gradation** **(For API or finished product), i) The bidder (local manufacturer / multi-national manufacturer / importer) shall provide Analytical/Quality Assurance/ Approval Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades.** **Certificate of Analysis/ Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreement/ approval with the original manufacturer duly attested/verified by official of the company.** **Detailed purchase trail of the Active Pharmaceutical Ingredient/ Finished product from the claimed source must be submitted (any proof of purchase such as Goods Declaration Certificate along with Airway Bill/ Bill of Lading /Invoice etc.) by the bidder.** **Maximum marks for this criterion are 40.**	**Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW) Study/Certificate from an accredited lab of IRA countries (Stringent Regulatory Authorities)/ WHO Listed Authorities MIA Countries** **BE/ BS/ Certificate with evidence as to its authenticity) from Category A countries.** **Bio-Equivalence (BE) of the quoted product to be conducted against the originator.** **Original innovator products do not require bio- equivalence certificate and shall get 10 marks automatically.The bidder shall provide the documents to establish the proof of inventor/ originator. All other branded generics require BE studies** **Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid.** **Maximum marks for this criterion are 10.**	**Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug, In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article)** **Mandatory: Online verification link must be provided to verify the Clinical Trial/ Clinical Studies submitted for the quoted items.**	**Factory/ Importer Based Evaluation Score (MANDATORY)**	**Sample Evaluation by End User Committee** **Samples will be examined per following parameters as follows:** **a. Labeling and Packing Rules 1986** **b. Shelf packing** **c. Insert packing** **d. Physical appearance.** **Product which has unsatisfactory packing/labeling will be technically disqualified.** **Maximum score for this criterion is 1.**		**Past Performance (Last two years).** **i) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks.** **ii) Any supply orders will not get any marks.** **iii) The bidders have to undertake that they have never been blacklisted or debarred.** **Maximum marks for this criterion are 5.** **iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, THO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.**	**Total Technical Score**
			Category A – Approved By: • United States Food & Drug Administration (US FDA) • European Medicines Agency (EMA) • Medicines & Healthcare Products Regulatory Agency (MHRA, UK) • Therapeutic Goods Administration (TGA), Australia. • Pharmaceutical Medical Agency (PHARMAC), New Zealand • Swiss Agency for Therapeutic Products (Swissmedic), Switzerland • Health Canada • Health Sciences Authority (HAS), Singapore • National Administration of Drugs, Food & Medical technology (ANMAT), Argentina Drug Regulatory Authorities of the IMA (Stringent Regulatory Authorities) / WHO Listed Authorities MIA countries	Category B – Approved By: • Agência Nacional de Vigilância Sanitária (ANVS), Brasil • Central Drug Standard Control Organization (CDSCO), India • Drug Regulatory Authority, Pakistan • National Pharmaceutical Control Bureau (NPCB), Malaysia • Food & Drug Administration, South Korea • Ministry of Health, Egypt • Ministry of Health, Turkey • China Food & Drug Administration • Any other source not mentioned in Category-A	Study/certificate issued/certified by a Category A Country Regulatory Authority. BE testing must be done using the USP/ BP/ EP/ JP BE waiver is acceptable only to injectable forms if issued by Category A Country.	Bio-Wv/BW certificate obtained for a quoted product from Category B Country (as mentioned at S No. 1 above).	No Bio-Wv/ BW certificate.		In case the study is published in "E" journal listed in HEC Journal Recognition System (HJRS) Database / Journals as per HEC / 2 weeks pre-original research article shall be awarded maximum up to 6 marks)	In case the study is published in Category "E" journal listed in HEC Journal Recognition System (HJRS) Database/ Journals as per Publication Policy 2023 and List of National Recognized Journals as per HEC / 2 weeks pre-original research article shall be awarded maximum up to 6 marks)		Random/assigned sample performance as category "E" journal of the HJRS/ Journals as per Publication Policy 2023 and List of National Recognized Journals as per HEC/ 2 weeks pre-original research article shall be awarded maximum up to 6 marks)	**The Physical Inspection of the premises of the bidder/ Manufacturer/importer) shall be carried out in accordance with PR 25.4(5), SO 5 (2)(c) & (f), Section V (1) (i) (v) of the approved SOPs of Govt. MCC FY 2026-27**	Satisfactory	Unsatisfactory	5) Substantial quantity of supplies of anti-cancer medicines made to private sector Teaching Hospitals namely: The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar, CMH Rawalpindi and Hayatabad Medical Complex, Peshawar in the preceding financial year (2024-25) and Good Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 24 months. No marks will be given. Any supply orders will not get any marks where supply orders coupled with delivery challans & invoices will be considered for award of marks. 1 mark per agreement up to a maximum of 5 marks	
SOURCE	**MCC formulary No.**	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**40**	**30**	**10**	**5**	**0**	**9**	**6**	**0**	**5**	**1**	**0**	**5**	**70**
NANTONG JINGHUA PHARMA CHINA	1436	5 Fluorouracil	500 mg	Inj.	Fluorosol	COMP NOT ATTACHED								5	1			
GRAND WUYAO (JIANGSU) PHARMA CHINA	1458	Bicalutamide	50 mg	Tab.	Bitamid	COMP NOT ATTACHED								5	1			
	1501	Docetaxel	20 mg	Inj.	Dotaxol									5	1			
	1502	Docetaxel	80 mg	Inj.	Dotaxol									5	1			
	1563	Methotrexate	10 mg	Tab.	Trexate	432-GD IS not readable, COMP ALSO NOT ATTACHED								5	1			
	1564	Methotrexate	1g	Inj.	Trexate									5	1			
	1592	Paclitaxel	300 mg	Inj.	Petaxel	COMP NOT ATTACHED								5	1			
	1621	Ruxolitinib	15 mg	Tab.	Mylomib									5	1			
	1622	Ruxolitinib	5 mg	Tab.	Mylomib									5	1			
	1625	Sorafenib	200 mg	Tab.	Sonib	GD & COA ARE NOT MATCHING AND COMP OF API SOURCE NOT ATTACHED								5	1			
Changzhou Pharmaceutical China	1631	Thalidomide	100 mg	Cap.	Thalimid	AGENCY AGREEMENT NOT ATTACHED	0							5	1			
HUBEI HONCH PHARMA CHINA	1634	Vinblastine	10 mg	Inj.	Blavin	AGENCY AGREEMENT NOT ATTACHED								5	1			
	1644	Vincristine	1 mg	Inj.	Crisvin	AGENCY AGREEMENT NOT ATTACHED								5	1			
	1645	Vincristine	2 mg	Inj.	Crisvin	AGENCY AGREEMENT NOT ATTACHED								5	1			

DRAP REGISTRATION OF BITAMID NOT ATTACHED

PAST PERFORMANCE OF IRRELEVENT HOSPITALS ARE ATTACHED 950 AND ONWARDS

TECHNICAL EVALUATION PROFORMA, FOR PROCUREMENT OF ANTICANCER MEDICINES IN GOVT. MCC FY 2026-27

	Name of the firm with Complete Address	PHARMEVO KARACHI
	Manufacturer / Importer	IMPORTER

		Mandatory Requirements.	YES / NO		In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:		YES/NO
1		National Tax Number (NTN) of the Firm for Income Tax, and	YES		1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and	
2		Last year Income Tax Return of the Firm; and	YES		2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.	
3		Sale Tax Registration Certificate of the Firm; and	YES		3	Valid DRAP Approved Price List of the quoted item/s.	
4		Certificate of Professional Tax of the Firm.	YES				
5		Certificate of compliance to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR. Non-Compliance to international reference standards or absence of Cold Chain requirements shall lead to disqualification of the relevant product that requires cold chain.					

		In case of being Importers, the Firm should provide attested copies of the following documents also:	YES/NO		Offered brand names	Brand names in cCOPP
1		Valid Drugs Sales License for the importer; and	NO			
2		Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	YES			
3		Valid Agency Agreement with the Foreign Principal/ Manufacturer entity/ies; and	YES			
4		Valid cCOPP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and	YES			
5		Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s. Non provision of this document shall lead to disqualification of the firm. and	NO	Brand name variations	Abraxane Nanoxel Transoptin	Bonkrip Bonfilos/Nanoxia vertical
6		Valid DRAP approved Price List of the quoted items.	yes			

			Technical Evaluation Parameters			Active Pharmaceutical Ingredient source gradation (For API or finished product). i) The bidder (local manufacturer / multi-national manufacturer / importer) shall provide Analytical/Quality Assurance/ Approval Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades. Certificate of Analysis/ Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreement/ approval with the original manufacturer duly attested/verified by official of the company. Detailed purchase trail of the Active Pharmaceutical Ingredient/ Finished product from the claimed source must be submitted (any proof of purchase such as Goods Declaration Certificate along with Airway Bill/ Bill of Lading/invoice etc.) by the bidder. Maximum marks for this criterion are 40.	Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW) study/ Certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities)/ WHO Listed Authorities MIA Countries (BE/BS Certificate with evidence as to its authenticity) from Category A countries. Bio-Equivalence (BE) of the quoted product to be conducted against the originator. Original innovator products do not require bio- equivalence certificate and shall get 10 marks automatically.The bidder shall provide the documents to establish the proof of inventor/ originator. All other branded generics require BE studies. Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid. Maximum marks for this criterion are 10.	Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug, In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article) Mandatory: Online verification link must be provided to verify the Clinical Trial/ Clinical Studies submitted for the quoted items.	Factory/ Importer Based Evaluation Score (MANDATORY)	Sample Evaluation by End User Committee Samples will be examined per following parameters as follows: a. Labeling and Packing Rules 1986 b. Outer packing c. Inner packing d. Physical appearance. Product which has unsatisfactory packing/labeling will be technically Disqualified. Maximum score for this criterion is 1.	Past Performance (Last two years). i) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks. ii) Non supply orders will not get any marks. iii) The bidders have to undertake that they have never been blacklisted or debarred. Maximum marks for this criterion are 5. iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at NMC, Peshawar, TWO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.	Total Technical Score
						Category A – Approved By: • United States Food & Drug Administration (US FDA) • European Medicines Agency (EMA) • Medicines & Healthcare Products Regulatory Agency (MHRA, UK) • Therapeutic Goods Administration (TGA), Australia. • Pharmaceutical Medical Agency (PHARMAC), New Zealand • Pharmaceutical & Medical Devices Agency (PMDA), Japan • Swiss Agency For therapeutic drugs (Swiss-medic), Switzerland • Health Canada • Health Sciences Authority (HAS), Singapore • National Administration of Drugs, Food & Medical technology (ANMAT), Argentina Drug Regulatory Authorities of the SRA (Stringent Regulatory Authorities) / WHO Listed Authorities MIA countries	Category B – Approved By: • Aghthaa National de Vigilence Sanitaire (ANVS), Brazil • Central Drug Standard Control Organization (CDSCO), India • Drug Regulatory Authority, Pakistan • National Pharmaceutical Control Bureau (NPCB), Malaysia • Ministry of Food and Drug Safety, South Korea • Ministry of Health, Egypt • Ministry of Health, Turkey • China Food & Drug Administration • Any other source not mentioned in Category-A	Study/ certificate accepted/ certified by a Category A Country Regulatory Authority. (BE testing must be done using USP Reference Standard. Bio-waiver is acceptable only in injectable forms if issued by Category A Country.	No BE/BW certificate obtained for a approved product from Category B Country (as mentioned at S.No. 1 above).	No BE/BW certificate.	In case the study is published in Category "N" journal listed in HEC Journal Recognition System (HJRS) Database/ Research Publication Policy 2016 and List of National Recognized Research Journals as per HEC journal recognized in year of publication/ Research Journals as per HEC standard but not enlisted in any of the above categories, as per HEC Journal Recognition System (HJRS) Database/ Research Publication Policy 2016 and List of National Recognized Research Journals as per HEC standard but not enlisted in any of the above categories, as per HEC Journal Recognition System (HJRS) Database/ Research Publication Policy 2016 and List of National Recognized Research Journals as per HEC original research article shall be awarded maximum up to 6 marks).	Reviewer/assigned article published in category "Y", instead of the HJRS/ Journals mentioned in the Policy 2016 and List of National Recognized Research Journals as per HEC shall not be awarded marks.	The Physical Inspection of the premises of the bidder/ Manufacturer/Importer shall be carried out in accordance with ITR 28.4(b), ICC 5 (ICC 5.3), Section V (C) (i) (h) of ERA approved SOPs of Govt. MCC FY 2026-27	Satisfactory	Unsatisfactory	i) Substantiated quantity of supplies of anti-cancer medicines made to private sector/ teaching hospitals namely: The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar, Dow Rawalpindi and Hayatabad Medical Complex, Peshawar in the preceding two years shall be awarded 1 mark each. Good Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 36 months. No marks will be given. ii) Non supply orders will not get any marks. Short supply orders coupled with delivery challans & invoices will be considered for award of marks. 1 mark per agreement up to a maximum of 5 marks	
SOURCE	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	40	30	10	5	0	9	6	0	5	1	0	5	70
JSC BIOCAD Russia	1456	Bevec	400 mg Inj.	inj	Bevacizumab		30		5		3			5	1		2	46
JSC BIOCAD Russia	1457	Bevec	2.5mg	Tab	Bevacizumab		30		5		3			5	1		2	46
	1546	Retzole	100 mg Inj.	inj	Letrozole		The item is registered with Radiant Pharma & not Pharmevo- Registration certificate attached at Page 791 of bid		5		0			5	1		2	13
JSC BIOCAD Russia	1618	RITUXIM	100mg/10ml	inj	Rituximab		30		5		3			5	1		2	46
JSC BIOCAD Russia	1619	RITUXIM	500mg/50ml	inj	Rituximab		30		5		3			5	1		2	46
JSC BIOCAD Russia	1634	Trasxeptin	440mg	inj	Trastuzumab 440mg		30		5		3			5	1		2	46
									5									

Scrutiny report
1Journal of article at Page 851 is not indexed in web of science
2Report at Page 880 is on company own letter head.
3Journal of article at Page 922 is not indexed in web of science
FO instead of CDA submitted, with no firm name.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: PHARMEVO KARACHI

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm).**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm)**.	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this colounm for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product).	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
	160	Montelukast Sodium			Aireez	2	2	3	5	5	6	The firm was inspected as per technical evaluation criteria and following observations were made; Non-compliance with cGMP Requirements: 1. No disposable shoe covers or other gowning materials/equipment were available at the entrance section of the changing room of solid dosage manufacturing section. 2. The change room was maintained in poor hygienic and untidy condition. 3. Filthy footwear of workers, intended for use within the production area, was found lying in the change room. 4. Raw materials were transferred from the Raw Material Store (RMS), located approximately 50 meters away from the production area, through open air and on uncovered trolleys, thereby compromising material protection and contamination control. 5. Paint and walls of the material transfer bay was filthy and cracked. 6. In the in-process RMS the raw material were stacked alongside the walls. 7. The floor of the production bay was found filthy, dusty, and indicative of inadequate cleaning and sanitation practices. 8. The walls of the granulation section were cracked and filthy, while a large pipe along with exposed pipe fittings was observed passing openly through the granulation area, compromising the integrity and hygienic condition of the manufacturing environment. 9. No relevant staff was present to assist the inspection team in the inspection of other section such as infusion and QC section. In view of the above findings, the firm is NOT-RECOMMENDED.						**23**	0	5	5	0	0	2	5	1	**18**	**41**
	797	Budesonide + Formoterol			Busonide	2	2	3	5	5	6						**23**	0	Airway bill is not matching with GD-Page 320	0	0	0	CoA of Capsule Shells not provided in the bid	0	1	**1**	**24**
	799	Budesonide + Formoterol			Busonide	2	2	3	5	5	6						**23**	0	Airway bill is not matching with GD-Page 320	0	0	0	CoA of Capsule Shells not provided in the bid	0	1	**1**	**24**
	450	Losartan Potassium + Hydrochlorothiazide			Diu Tansin	2	2	3	5	5	6						**23**	0	Airway bill of Losartan is not matching with GD- Page 327	0	0	0	2	5	Market Share is <1%, Page 693	**7**	**30**
	760	Quetapine Fumarate	100mg		Evokalm	2	2	3	5	5	6						**23**	0	Airway bill is not matching with GD Page 313	0	0	0	2	5	1	**8**	**31**
	550	Glimepiride			Evopride	2	2	3	5	5	6						**23**	0	0	0	0	0	2	5	1	**8**	**31**
	552	Glimepiride			Evopride	2	2	3	5	5	6						**23**	0	0	0	0	0	2	5	1	**8**	**31**
	577	Vildagliptin			Galvecta	2	2	3	5	5	6						**23**	0	5	5	0	0	2	0	Market Share is <1%, Page 693	**12**	**35**
	807	Ipratropiom Bromide + Salbutamol			Iprazyme-S	2	2	3	5	5	6						**23**	0	0	0	0	0	0	0	Market Share is <1%, Page 693	**0**	**23**
	735	Levetiracetam			Klevra	2	2	3	5	5	6						**23**	0	0	0	0	0	2	5	Market Share is <1%, Page 693	**7**	**30**
	736	Levetiracetam			Klevra	2	2	3	5	5	6						**23**	0	0	0	0	0	2	0	Market Share is <1%, Page 693	**2**	**25**
	470	Ramipril			Ramipace	2	2	3	5	5	6						**23**	0	0	0	0	0	2	0	2	**4**	**27**
	452	Losartan Potassium			Tansin	2	2	3	5	5	6						**23**	0	0	0	0	0	2	5	1	**8**	**31**
	413	Candesartan Cilexetil			Treatan	2	2	3	5	5	6						**23**	0	5	5	0	0	2	5	1	**18**	**41**
	414	Candesartan Cilexetil			Treatan	2	2	3	5	5	6						**23**	0	5	5	0	0	2	5	1	**18**	**41**
	415	Candesartan Cilexetil			Treatan	2	2	3	5	5	6						**23**	0	5	5	0	0	2	5	1	**18**	**41**
	416	Candesartan + Hydrochlorothiazide			Treatan	2	2	3	5	5	6						**23**	0	5	5	0	0	2	5	1	**18**	**41**
	819	Tiotropium			Tiocap	2	2	3	5	5	6						**23**	0	0	0	0	0	CoA of Capsule Shells not provided in the bid	0	1	**1**	**24**
	753	Pregabalin			Xilica	2	2	3	5	5	6						**23**	0	Airway bill is not matching with GD-Page 309	0	0	0	CoA of Capsule Shells not provided in the bid	5	1	**6**	**29**
	754	Pregabalin			Xilica	2	2	3	5	5	6						**23**	0	Airway bill is not matching with GD-Page 309	0	0	0	CoA of Capsule Shells not provided in the bid	5	1	**6**	**29**
	275	Moxifloxacin			Zilfom	2	2	3	5	5	6						**23**	0	5	5	0	0	CoA of Capsule Shells not provided in the bid	5	Market Share is <1%, Page 693	**15**	**38**
	517	Omeprazole			Zoltar	2	2	3	5	5	6						**23**	0	5	5	0	0	CoA of Capsule Shells not provided in the bid	5	Market Share is <1%, Page 693	**15**	**38**

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: PLATINUM PHARMACEUTICALS PVT. LTD. KARACHI

S. No.	Product General Information					Factory Technical Evaluation Parameters											Total Factory Evaluated	Technical Evaluation Matrix				Product Evaluation Parameters Product Technical Parameters				Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score																
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment/ instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)as in Schedule B of DRAP). **(Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, in-process and finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC experts). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert's at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where those documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NITI bid submission. **Online verification link shall be provided**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where those documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NITI bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies). **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. Copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspension must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products whose USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the QA/C incharge of the firm). 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with such purchase order.	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA/ Health not older than twelve (12) months.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
1	9	FINDAZOLE	500 MG Tablets	Tablets	PREVENT	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	**19**	**49**
2	35	Aceclofenac 100mg	100 MG Tablets	Tablets	ACELISH	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	**19**	**49**
3	39	DICLOFENAC SODIUM	100mg Tablets	Tablets	FASTAID	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	**19**	**49**
4	41	DICLOFENAC SODIUM	50 MG Tablets	Tablets	FASTAID	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	**19**	**49**
5	89	MYCOPHENOLATE MOFETIL CAP Micronized	250MG Tablets	Tablets	MYGRAF	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	1	**20**	**50**
6	94	TACROLIMUS	1MG Capsules	Capsules	INOGRAF	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	2	**21**	**51**
7	95	TACROLIMUS	0.5MG Capsules	Capsules	INOGRAF	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	2	**21**	**51**
8	137	FLUCONAZOLE - USP	150 MG Capsules	Capsules	FUNGIS	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	**19**	**49**
9	153	Cetirizine Di-hydrochloride	10 MG Tablets	Tablets	AVEC	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
10	154	Cetirizine Di-hydrochloride	5mg/5ml Syrup	Syrup	AVEC	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
11	157	Levocetirizine (as 2HCl) 2.5mg	2.5MG/5ML Syrup	Syrup	ALVIGO	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
12	158	Levocetirizine dihydrochloride eq to Levocetirizine 5mg	5MG Tablets	Tablets	ALVIGO	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
13	160	MONTELUKAST SODIUM - USP	10 MG Tablets	Tablets	LUKOMON	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
14	161	MONTELUKAST SODIUM - USP	5 MG Tablets	Tablets	LUKOMON	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
15	189	AZITHROMYCIN DIHYDRATE	250 MG Tablets	Tablets	PLAZO	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
16	190	AZITHROMYCIN DIHYDRATE	500 MG Tablets	Tablets	PLAZO	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
17	192	AZITHROMYCIN DIHYDRATE	200mg/5ml Suspension	Suspension	PLAZO	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
18	204	*CEFDIME TRIHYDRATE (MICRONIZED) - USP	400MG Capsules	Capsules	CEFTAS CAP	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	Not provided in the bid	19	49
19	205	CEFDIME TRIHYDRATE	100MG/5ML Dry Susp	Dry Suspension	CEFTAS SUSP	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	Not provided in the bid	19	49
20	206	CEFDIME TRIHYDRATE (MICRONIZED) - USP	250MG/5ML Dry Susp	Dry Suspension	CEFTAS SUSP	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	Not provided in the bid	19	49
21	212	CEFPODOXIME PROXETIL	100mg Tablets	Tablets	CEFPOWER	2	2	3	4	5	4	2	2	2	2	2	**30**	0	GD is not coupled with AWB provided at page No. 2338	0	0	0	4	5	0	9	39
22	213	CEFPODOXIME PROXETIL	40MG/5ML Suspension	Suspension	CEFPOWER	2	2	3	4	5	4	2	2	2	2	2	**30**	0	GD is not coupled with AWB provided at page No. 2338	0	0	0	4	5	0	9	39
23	230	*CIPROFLOXACIN HCL -USP	250 MG Tablets	Tablets	SUPHOS	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
24	231	*CIPROFLOXACIN HCL -USP	500 MG Tablets	Tablets	SUPHOS	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
25	264	LEVOFLOXACIN HEMIHYDRATE	250MG Tablets	Tablets	FLOXOLEV	2	2	3	4	5	4	2	2	2	2	2	**30**	0	GD is not provided in the bid	0	0	0	4	5	Not provided in the bid	9	39
26	265	LEVOFLOXACIN HEMIHYDRATE	250MG Tablets	Tablets	FLOXOLEV	2	2	3	4	5	4	2	2	2	2	2	**30**	0	GD is not provided in the bid	0	0	0	4	5	Not provided in the bid	9	39
27	266	LINCOMYCIN HCL MONOHYDRATE- USP	250mg Capsules	Capsules	NOVELINK	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
28	275	Moxifloxacin HCl eq. to Moxifloxacin 400mg	400MG Tablets	Tablets	ARBIMOX	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
29	300	Artemether ..... 40mg + Lumefantrine 240mg	40/240mg Tablets	Tablets	HI SERVIN	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
30	301	Artemether ..... 80mg + Lumefantrine 480mg	80/480 mg Tablets	Tablets	HI SERVIN	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
31	302	Each 5ml Contains: Artemether ..... 15mg Lumefantrine 90mg	15mg + 90mg / 5ml	Suspension	HI SERVIN	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
32	310	DIHYDROARTEMISININ+*PIPERAQUINE PHOSPHATE	40mg + 320mg Tablet	Tablets	ARTEQUINE	2	2	3	4	5	4	2	2	2	2	2	**30**	0	GD of piperaquine phosphate provided at page No. 2257 is older than 24 months	0	0	0	4	5	0	9	39
33	371	Iron III Polymaltose Complex + Folic Acid	100/0.75mg Tablets	Tablets	APOFER	2	2	3	4	5	4	2	2	2	2	2	**30**	0	GD of folic acid is not provided in the original bid	0	0	0	4	5	0	9	39
34	372	*IRON POLYMALTOSE COMPLEX	Syrup 50mg/5ml	Syrup	APOFER	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
35	401	Amlodipine Besylate 5mg	5MG Tablets	Tablets	CABOK	2	2	3	4	5	4	2	2	2	2	2	**30**	0	GD of Amlodipine provided at page No. 2274 is older than 24 months	0	0	0	4	5	0	9	39
36	402	Amlodipine Besylate 10mg	10 MG Tablets	Tablets	CABOK	2	2	3	4	5	4	2	2	2	2	2	**30**	0	GD of Amlodipine provided at page No. 2274 is older than 24 months	0	0	0	4	5	0	9	39
37	407	Atenolol 50mg	50 MG Tablets	Tablets	CARDIAXEN	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
38	408	ATENOLOL - BP	100 MG Tablets	Tablets	CARDIAXEN	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
39	421	Clopidogrel 75mg	75 MG Tablets	Tablets	CLOPIDO	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
40	450	Losartan Potassium + Hydrochlorothiazide	50mg + 12.5mg	Tablets	LOSAR	2	2	3	4	5	4	2	2	2	2	2	**30**	0	GD of hydrochlorothiazide is not provided in the original bid	0	0	0	4	5	0	9	39
41	452	LOSARTAN POTASSIUM - USP	50mg Tablets	Tablets	LOSAR	2	2	3	4	5	4	2	2	2	2	2	**30**	0	GD of hydrochlorothiazide is not provided in the original bid	0	0	0	4	5	0	9	39
42	503	DOMPERIDONE MALEATE - BP	10MG Tablets	Tablets	EMISET	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
43	504	DOMPERIDONE BASE - BP	1mg/ml Suspension	Suspension	EMISET	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
44	507	Famotidine 40mg	40 MG Tablets	Tablets	REDUCID	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
45	535	CLOMIPHENE CITRATE	50MG Tablets	Tablets	FERTICLO	2	2	3	4	5	4	2	2	2	2	2	**30**	0	GD/COA not provided in the bid	0	0	0	4	5	0	9	39
46	538	DINOPROSTONE - USP (Non to use)	1mg Tablets	Tablets	PREGLAN	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	24	54
47	572	MISOPROSTOL USP HPMC 1% DISPERSION	200MCG Tablets	Tablets	MISOPROS	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	1	20	50
48	584	CIBOLONE	2.5mg Tablet	Tablet	LOBION	2	2	3	4	5	4	2	2	2	2	2	**30**	0	GD is not coupled with AWB provided at page No. 2599	0	0	0	4	5	2	11	41
49	697	Lansoloxis hydrochloride	0.4 MG Capcules	Capsules	ALFAMAX	2	2	3	4	5	4	2	2	2	2	2	**30**	0	0	0	0	0	0	5	5	5	35
50	703	*CARBAMAZEPINE Micronized/Sub grade BP	200 MG Tablets	Tablets	SEIZUNIL	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	1	20	50
51	704	*CARBAMAZEPINE Micronized/Sub grade BP	100MG/5ML Suspension	Suspension	SEIZUNIL	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	1	20	50
52	715	Co-dergocrine mesylate 1.5mg	1.5 MG Tablets	Tablets	CEREGIN	2	2	3	4	5	4	2	2	2	2	2	**30**	0	0	0	0	0	0	5	2	7	37
53	725	ESCITALOPRAM OXALATE ..	10 MG Tablets	Tablets	ESCADEP	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
54	726	*FLUOXETINE HCL - USP	20 MG Capsules	Capsules	PROZYN	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
55	733	LAMOTRIGINE	50 MG Tablets	Tablets	LAMONIL	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
56	734	Each tablet contains: Lavodopa ..... 250mg Carbidopa..... 25mg	250mg + 25mg Tablet	Tablets	NEUDOPA	2	2	3	4	5	4	2	2	2	2	2	**30**	0	GD/ AWB is not provided in the original bid	0	0	0	4	5	0	9	39
57	735	LEVETIRACETAM	250 MG Tablets	Tablets	LEVOTAM	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	No COA is attached in the bid Page No. 2812-2814	0	0	4	5	0	14	44
58	736	LEVETIRACETAM	500 MG Tablets	500 MG Tablets	LEVOTAM	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	No COA is attached in the bid Page No. 2812-2815	0	0	4	5	0	14	44
59	737	LEVETIRACETAM	100mg/ml Oral Solution	Oral Solution	LEVOTAM	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	No COA is attached in the bid Page No. 2812-2816	0	0	4	5	0	14	44
60	742	*OLANZAPINE	5MG Tablets	Tablets	ICHIZAP	2	2	3	4	5	4	2	2	2	2	2	**30**	0	GD attached at page No. 2425 is older than 24 months	0	0	0	4	5	Not provided in the bid	9	39
61	743	*OLANZAPINE	10 MG Tablets	Tablets	ICHIZAP	2	2	3	4	5	4	2	2	2	2	2	**30**	0	GD attached at page No. 2425 is older than 24 months	0	0	0	4	5	Not provided in the bid	9	39
62	744	Oxcarbazepine.....300mg	300 MG Tablets	Tablets	TELOX TAB	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	Not provided in the bid	19	49
63	745	Oxcarbazepine.....600mg	600MG Tablets	Tablets	TELOX TAB	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	Not provided in the bid	19	49
64	753	*PREGABALIN - USP	50 MG CAPSULE	CAPSULE	PROGABTON	2	2	3	4	5	4	2	2	2	2	2	**30**	0	GD provided at page No. 2431 is older than 24 months	0	0	0	4	5	0	9	39
65	754	*PREGABALIN - USP	75 MG CAPSULE	CAPSULE	PROGABTON	2	2	3	4	5	4	2	2	2	2	2	**30**	0	GD provided at page No. 2431 is older than 24 months	0	0	0	4	5	0	9	39
66	760	QUETIAPINE FUMARATE	100 MG Tablets	Tablets	QUETAP	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	COA is not provided in the bid Page No. 2877-2881	0	0	4	5	Not provided in the bid	14	44
67	761	Risperidone 2mg	2 MG Tablets	Tablets	REVOC	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
68	762	Risperidone 4mg	4 MG Tablets	Tablets	REVOC	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	0	19	49
69	765	SODIUM VALPROATE - BP	250mg/5ml Syrup	Syrup	DAPAXAN	2	2	3	4	5	4	2	2	2	2	2	**30**	0	5	5	0	0	4	5	1	20	50

70	766	Espirenate 50mg	50MG Tablets	Tablets	TOPIRAMA	2	2	3	4	5	4	2	2	2	2	2	30	0	GD attached at page No. 2439 is older than 24 months	0	0	0	4	5	0	9	39
71	791	Salbutamol Mesilatum ---- 100mcg Bacloneflunene Dipropionate 100mcg	100mcg Inhaler	Inhaler	SALBECLO	2	2	3	4	5	4	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49
72	801	Dosodyline 400mg Tablet	400mg Tablets	Tablets	UNIFYLINE	2	2	3	4	5	4	2	2	2	2	2	30	0	5	5	0	0	4	5	Not provided in the bid	19	49
73	802	Each 5ml contains Dosodyline ... 100mg	100mg/5ml Syrup	Syrup	UNIFYLINE	2	2	3	4	5	4	2	2	2	2	2	30	0	5	5	0	0	4	5	Not provided in the bid	19	49
74	808	KETOTIFEN HYDROGEN FUMERATE	1mg Tablets	Tablets	PROASMA	2	2	3	4	5	4	2	2	2	2	2	30	0	5	5	0	0	4	5	1	20	50
75	809	KETOTIFEN HYDROGEN FUMERATE	1mg/5ml Syrup	Syrup	PROASMA	2	2	3	4	5	4	2	2	2	2	2	30	0	5	5	0	0	4	5	1	20	50
76	817	Terbutaline Sulfate	1.5mg/ml Syrup	Syrup	BRETHIN	2	2	3	4	5	4	2	2	2	2	2	30	0	5	No COA provided in the bid	0	0	4	5	1	15	45
77	870	FUSIDIC ACID HEMIHYDRATE-EP	2%	Cream	INFACID	2	2	3	4	5	4	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49
78	908	Alfacalcidol 0.5mcg	0.5 MCG Tablets	Tablets	ALFA-D	2	2	3	4	5	4	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49
79	912	Ossein Mineral complex ..... 450mg - Vitamin D... 400iu	450mg + 400iu Tablets	Tablets	OSSOBON	2	2	3	4	5	4	2	2	2	2	2	30	0	5	5	0	0	4	5	1	20	50
80	913	Vitamin D... 400iu Ossein Hydroxyapatite compound 250mg	400iu + 250mg Suspension	Suspension	OSSOBON	2	2	3	4	5	4	2	2	2	2	2	30	0	5	5	0	0	4	5	1	20	50
81	1541	Leflunomide	20 MG Tablets	Tablets	LEFNODE	2	2	3	4	5	4	2	2	2	2	2	30	0	5	5	0	0	4	5	0	19	49

Original Mandatory forms in Hard are not submitted to the MCC

						Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27															
Name of the firm						POPULAR INTERNATIONAL KARACHI															
S. No.		Product General Parameter				Technical Evaluation Matrix															
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the time of inspection at the warehouse at the tim eof inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** **(Certificate duly attaested by senior executive of the firm)**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US free sale certificate of the quoted products, **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **Online verification link shall be provided.** **(copies of relevant certificates duly attested by the senior executive of the firm)**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	5	6	**29**	5	5	5	6	10	10	**41**	**70**
Covidien USA Covidien Dominican Republic	1338	13mm, 1/2 circle round bodied taper point needle, strand length 45 cm	5/0	POLYSORB, SIZE 5-0, 13MM, 1/2 CIRCLE, TAPER POINT, UNDYED	Polysorb	0	5	5	5	5	6	**26**	5	**5**	**0**	4	10	10	**34**	**60**
Covidien USA Covidien Dominican Republic	1343	16mm, 3/8 circle conventional or curved cutting needle, Strand length 75cm	3/0	POLYSORB, SIZE 3-0, 16MM, 3/8 CIRCLE, REVERSE CUTTING, VIOLET	Polysorb	0	5	5	5	5	6	**26**	5	**5**	**0**	4	10	10	**34**	**60**
Covidien USA Covidien Dominican Republic	1353	40mm, 1/2 circle round bodied taper point, strand length 70 cm	1	POLYSORB, SIZE 1, 40MM, 1/2 CIRCLE, TAPER POINT, VIOLET	Polysorb	0	5	5	5	5	6	**26**	5	**0**	**0**	4	10	10	**29**	**55**
Covidien USA Covidien Dominican Republic	1355	40mm, 1/2 circle round bodied taper point, strand length 90 cm	2	POLYSORB, SIZE 2, 40MM, 1/2 CIRCLE, TAPER POINT, VIOLET	Polysorb	0	5	5	5	5	6	**26**	5	**5**	**0**	4	10	10	**34**	**60**
Covidien USA Covidien Dominican Republic	1364	30mm, 1/2 circle round bodied tapper point needle, strand length 75 cm	1	POLYSORB, SIZE 1, 30MM, 1/2 CIRCLE, TAPER POINT, VIOLET	Polysorb	0	5	5	5	5	6	**26**	5	**5**	**0**	4	10	10	**34**	**60**
Covidien USA Covidien Dominican Republic	1401	13mm, 3/8 circle round bodied taper point double armed needle, strand length 45cm	6/0	MAXON, SIZE 6-0, 13MM, 3/8 CIRCLE, TAPER POINT, DOUBLE NEEDLED, GREEN	Maxon	0	5	5	5	5	6	**26**	0	**0**	**0**	4	10	10	**24**	**50**
Covidien USA Covidien Dominican Republic	1405	17mm, 1/2 circle round bodied taper point double needle, strand length 75cm	5/0	MAXON, SIZE 5-0, 17MM, 1/2 CIRCLE, TAPER POINT, DOUBLE NEEDLED, GREEN	Maxon	0	5	5	5	5	6	**26**	5	**5**	**0**	4	10	10	**34**	**60**
Covidien USA Covidien Dominican Republic	1410	20mm, 1/2 circle round bodied taper point needle, strand length 70cm	4/0	MAXON, SIZE 4-0, 20MM, 1/2 CIRCLE, TAPER POINT, GREEN	Maxon	0	5	5	5	5	6	**26**	0	**0**	**0**	4	10	10	**24**	**50**
Covidien USA Covidien Dominican Republic	1413	26mm, 1/2 circle round bodied taper point needle, strand length 75cm	3/0	MAXON, SIZE 3-0, 26MM, 1/2 CIRCLE, TAPER POINT, GREEN	Maxon	0	5	5	5	5	6	**26**	5	**5**	**0**	4	10	10	**34**	**60**
Covidien USA Covidien Dominican Republic	1422	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	1	MAXON, SIZE 1, 40MM, 1/2 CIRCLE, TAPER POINT, 150CM, LOOP, GREEN	Maxon	0	5	5	5	5	6	**26**	0	**0**	**0**	4	10	10	**24**	**50**
Polysutura Brazil	1372	9.3mm, 3/8 circle round bodied taper point double armed needle, strand length 60cm	Quoted item is 9mm	SURGIPRO II, SIZE 7-0, 9MM, 3/8 CIRCLE, TAPER POINT, DOUBLE NEEDLED, BLUE	Surgipro	0	0	0	5	5	6	**16**	5	**5**	**0**	0	10	10	**30**	**46**
Polysutura Brazil	1377	13mm, 1/2 circle round bodied taper point double armed needle, strand length 60cm	5/0	SURGIPRO, SIZE 5-0, 13MM, 1/2 CIRCLE, TAPER POINT, DOUBLE NEEDLED, BLUE	Surgipro	0	0	0	5	5	6	**16**	5	**5**	**0**	0	10	10	**30**	**46**
Polysutura Brazil	1382	26mm, 1/2 circle round bodied taper point double armed needle, strand length 75cm	3/0	SURGIPRO II, SIZE 3-0, 26MM, 1/2 CIRCLE, TAPER POINT, DOUBLE NEEDLED, BLUE	Surgipro	0	0	0	5	5	6	**16**	5	**5**	**0**	0	10	10	**30**	**46**

Polysutura Brazil	1384	26mm, 1/2 circle round bodied taper point needle, strand length 75cm	2/0	SURGIPRO II, SIZE 2-0, 25MM, 1/2 CIRCLE, TAPER POINT, DOUBLE NEEDLED, BLUE	Surgipro	0	0	0	5	5	6	**16**	5	**5**	**0**	0	10	10	**30**	**46**
Polysutura Brazil	1390	60mm, straight cutting needle, strand length 75cm	2/0	SURGIPRO, SIZE 2-0, 60MM, STRAIGHT, CONVENTIONAL CUTTING, BLUE	Surgipro	0	0	0	5	5	6	**16**	5	**5**	**0**	0	10	10	**30**	**46**
Polysutura Brazil	1391	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	0	SURGIPRO II, SIZE 0, 40MM, 1/2 CIRCLE, TAPER POINT, BLUE	Surgipro	0	0	0	5	5	6	**16**	5	**5**	**0**	0	10	10	**30**	**46**
Polysutura Brazil	1392	40mm, 1/2 circle round bodied taper point needle, strand length 75cm	1	SURGIPRO II, SIZE 1, 40MM, 1/2 CIRCLE, TAPER POINT, BLUE	Surgipro	0	0	0	5	5	6	**16**	5	**5**	**0**	0	10	10	**30**	**46**
Polysutura Brazil	1396	17mm, 1/2 circle round bodied taper cut double needle, strand length 75cm	2/0	TI-CRON, SIZE 2-0, 17MM, 1/2 CIRCLE, TAPERCUTTING, DOUBLE NEEDLED, BLUE	Ticron	0	0	0	5	5	6	**16**	5	**5**	**0**	0	10	10	**30**	**46**
Polysutura Brazil	1398	26mm, 1/2 circle round bodied taper point double needle, strand length 90cm	2/0	TI-CRON, SIZE 2-0, 26MM, 1/2 CIRCLE, TAPER POINT, DOUBLE NEEDLED, BLUE	Ticron	0	0	0	5	5	6	**16**	5	**5**	**0**	0	10	10	**30**	**46**
Polysutura Brazil	1342	22mm, 1/2 circle round bodied taper point, strand length 70 cm	4/0	POLYGLACTIN, SIZE 4-0, 22MM, 1/2 CIRCLE, TAPER POINT, VIOLET	Polyglactin	0	0	0	5	5	6	**16**	5	**0**	**0**	0	10	10	**25**	**41**
Polysutura Brazil	1,345	22mm, 1/2 circle round bodied taper point, strand length 70 cm	3/0	POLYGLACTIN, 3-0, 22MM, 1/2 CIRCLE, TAPER POINT, VIOLET	Polyglactin	0	0	0	5	5	6	**16**	5	**5**	**0**	0	10	10	**30**	**46**
Polysutura Brazil	1346	26mm, 1/2 circle round bodied taper point, Strand length 70 cm	3/0	POLYGLACTIN, 3-0, 26MM, 1/2 CIRCLE, TAPER POINT, VIOLET	Polyglactin	0	0	0	5	5	6	**16**	5	**5**	**0**	0	10	10	**30**	**46**
Polysutura Brazil	1347	26mm, 1/2 circle round bodied taper point, Strand length 70 cm	2/0	POLYGLACTIN, 2-0, 26MM, 1/2 CIRCLE, TAPER POINT, VIOLET	Polyglactin	0	0	0	5	5	6	**16**	5	**0**	**0**	0	10	10	**25**	**41**
Polysutura Brazil	1362	30mm, 1/2 circle round bodied taper point, strand length 75 cm	2/0	POLYGLACTIN, 2-0, 30MM, 1/2 CIRCLE, TAPER POINT, VIOLET, 1X36 FOILS	Polyglactin	0	0	0	5	5	6	**16**	5	**0**	**0**	0	10	10	**25**	**41**

Non Formulary	1,360	22mm, 1/2 circle round bodied taper point, strand length 75cm	Quoted item is 70 cm	POLYGLACTIN, 3-0, 22MM, 1/2 CIRCLE, TAPER POINT, VIOLET	Polyglactin															
Non Formulary	1352	40mm, 1/2 circle round bodied taper point, strand length 90 cm	Quoted item is 70 cm	POLYGLACTIN, 0, 40MM, 1/2 CIRCLE, TAPER POINT, VIOLET	Polyglactin															
Non Formulary	1362	30mm, 1/2 circle round bodied taper point, strand length 75 cm	Quoted item is 70 cm	POLYGLACTIN, 2-0, 30MM, 1/2 CIRCLE, TAPER POINT, VIOLET, 1X36 FOILS	Polyglactin															
Non Formulary	1365	40mm, 1/2 circle round bodied tapper point needle, strand length 75 cm	Quoted item is 70 cm	POLYGLACTIN, 1, 40MM, 1/2 CIRCLE, TAPER POINT, VIOLET	Polyglactin															
Non Formulary	1380	26mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm	Quoted item is 75cm	SURGIPRO II, SIZE 4-0, 25MM, 1/2 CIRCLE, TAPER POINT, DOUBLE NEEDLED, BLUE	Surgipro															
Non Formulary	1386	26mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	Quoted item is 24mm	POLYSORB, SIZE 2-0, 24MM, 3/8 CIRCLE, PREMIUM REVERSE CUTTING, UNDYED	Polysorb															

Scrutiny Report

1Documents at Page 988-1054 are not in english Language

2GDs at Page 1429,1432,1436, 1451, 1460,1470,1485, 1488, 1492,1531,1539,1542,1547, are older than 2 years

3Awb at 1455 is not matching with GD at 1451

4Poor repititive and irrelevnt documentation

Bank gaurantee expiry is 17-08-26

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27														
				Name of the firm		POPULAR INTERNATIONAL KARACHI														
						Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevent certificates**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
	Covidien USA Covidien Dominican Republic	1371	6.5mm, 3/8 circle round bodied taper point double armed needle, strand length 40cm	8/0	SURGIPRO II, SIZE 8-0, 6.5MM, 3/8 CIRCLE, TAPER POINT, DOUBLE NEEDLED, BLUE	Surgipro	0	5	5	5	6	6	**27**	5	**5**	0	0	4	16	**30**	**57**
Steel rotogrip not mentioned in DRAP Registration	Covidien USA Covidien Dominican Republic	1425	48mm, 1/2 circle round bodied taper cut point needle, strand length 45cm	5	STEEL, SIZE 5, 48MM, 1/2 CIRCLE, TAPERCUTTING, 4 X, UNDYED	Steel Rotogrip	0	5	5	5	6	6	**27**	0	**0**	0	0	4	16	**20**	**47**
	Covidien USA Covidien Dominican Republic	1426	48mm, 1/2 circle round bodied taper cut point needle, strand length 45cm	4	STEEL, SIZE 4, 48MM, 1/2 CIRCLE, REVERSE CUTTING, 2 X, UNDYED	Steel Rotogrip	0	5	5	5	6	6	**27**	5	**5**	0	0	4	16	**30**	**57**
		1427	Polypropylene	30x30	PPM3030//PPM3030 PARIETENE MACRO PP 30X30CM X1	Parietene	0	5	0	5	6	6	**22**	5	**5**	0	1	2	16	**29**	**51**
		1428	Polypropylene	15x15	PPM1515X6//PPM1515X6 PARIETENE MACRO PP 15X15CMX6	Parietene	0	5	0	5	6	6	**22**	5	**5**	0	1	2	16	**29**	**51**
		1429	Polypropylene	15x10	PPM1510X6//PPM1510X6 PARIETENE MACRO PP 15X10CMX6	Parietene	0	5	0	5	6	6	**22**	5	**5**	0	1	2	16	**29**	**51**
		1430	Polypropylene	6x11	PPM1106X6//PPM1106X6 PARIETENE MACRO PP 11X6CMX6	Parietene	0	5	0	5	6	6	**22**	5	**5**	0	1	2	16	**29**	**51**

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: RA HEALTHCARE (SMC) PVT LTD

HEAD OFFICE- ISLAMABAD / WAREHOUSE KARACHI

Technical Evaluation Matrix

S. No.	Product General Information					Principal's and Importer's Evaluation Parameters								Suppliers Technical Score	Product Technical Evaluation							Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation					Importer's Evaluation				Product Technical Parameters						Product Availability		
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/ies /regulatory body in the case of SRA/WLA countries (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the ware house at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good storage practices (GSP) for storage of finished goods. Functional and effective Air-conditioning & Ventilation System and effective cold chain (thermo-labile drugs). The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Nonadherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is/are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 15, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies). Trail of principal manufacturer shall be established from the respective GD. CoA and other supporting documents. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the	Valid WHO prequalification and / or Valid product registration in SRA country(ies) / Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) and / or Valid certificate of the availability of the quoted item in the US market. **04 marks shall be awarded to the Primary certificate, and 1 mark for additional certificate, up to a maximum of 06 (04+01+01) marks.** **Certificates on company's own**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase: **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	**2**	**2**	**2**	**5**	**5**	**4**	**5**	**5**	**30**	**5**	**5**	**5**	**5**	**6**	**4**	**5**	**5**	**40**	**70**
	18	Isoflurane	250ml	Inhalation	Aerrane	**2**	**2**	0	5	**5**	**The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COFG) for the quoted items were checked, and following observations were made;** **1. Baxter Health Care Corporation USA: (ISOFLORANE) Valid Agency Agreement duly attested from the embassy concerned was not present at the time of inspection for the quoted item. Valid original CoPP duly attested from the embassy concerned was present at the time of inspection for the quoted item.** **2. 20% inventory of the quoted item, ISOFLORANE was not available, however, adequate qualified HR, Cold Chain facility, Good Storage practices and SOPs for expiry management were satisfactory/ present at the time of inspection.** **In view of the above facts the firm is NOT-RECOMMENDED.**				**14**	**5**	5	5	0	**4**	**4**	5	0	**28**	**42**

Scrutiny report

1Technical proposal at Page No. 55 contain only Isoflurane, while on Page 56 it contain both Isoflurane and sevoflurane

2ISO 9001 at Page 82 is for Baxter Switzerland which is for warehousing and distribution

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm | RASCO PHARMACEUTICALS LAHORE

S. No.		Product General Information				Factory Technical Evaluation Parameters — RASCO						Factory Evaluation Visit Score					Total Factory Evaluated Score	Technical Evaluation Matrix — Product Evaluation Parameters — Product Technical Parameters							Total Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 13001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million – 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs * Functional Stability Chamber (Both Accelerated and Real Time)as in Schedule-B of DRAP) **(Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule-B of DRAP) (as evaluated at the time of inspection by the MCC experts). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or having and/or logs, shall lead to Disqualification of the relevant section/ firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA/WLAs.country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid traillink/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columnn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Liquid vials/bottles/cartridges must be USP Type 3 or better (**Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**		Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70
Anyang Dongtain Pharmaceutical	1.	41.	Diclofenac Sodium enteric coated	50 mg	Tab.	Arac Tablet	2	2	3	1	0	6						14	0	0	0	Informations are hidden in EiR Report (Page No. 737)	0	0	0	0	0	14
Medi Pharma Drug House	2.	47.	Ketorolac	30 mg/ml	Inj.	Tromol	2	2	3	1	0	6						14	0	5	0	Not attached	0	0	0	0	5	19
Ningbo Smart Pharmaceutical	3.	48.	Mefenamic Acid	250 mg	Tab.	Rasmic	2	2	3	1	0	6						14	0	0	0	0	0	0	0	0	0	14
Ningbo Smart Pharmaceutical	4.	49.	Mefenamic Acid	50 mg/5ml	Susp.	Rasmic	2	2	3	1	0	6						14	0	0	0	0	0	0	0	0	0	14
Hubei Jiudeng Pharmaceutical CN	5.	59.	Paracetamol	500 mg	Tab.	Rascodol	2	2	3	1	0	6						14	0	5	0	5	0	0	0	10	24
RLFine Chem Pvt Ltd.	6.	65.	Paracetamol + Orphenadrine	450 mg/35 mg	Tab.	Rotol Tab	2	2	3	1	0	6						14	0	5	0	5	0	0	0	5	19
B.M.P Bulk Medicines GMBH	7.	66.	Paracetamol+Tramadol	325mg/37.5 mg	Tab.	Tomdol	2	2	3	1	0	6						14	0	5	0	5	0	0	0	10	24
	8.	69.	Tramadol HCl	50 mg/ml 2cc	Inj.	Tomdol	2	2	3	1	0	6						14	0	5	0	5	0	0	0	10	24
Supriya Lifesciences	9.	153.	Cetirizine	10 mg	Tab.	Rozen	2	2	3	1	0	6						14	0	5	0	5	0	0	0	10	10
Supriya Lifesciences	10.	154.	Cetirizine	5 mg/5 ml	Syp.	Rozen	2	2	3	1	0	6						14	0	5	0	5	0	0	0	10	24
Hema Pharmaceuticals India	11.	158.	Levocetirizine	5 mg	Tab.	Le-Vin	2	2	3	1	0	6						14	0	5	0	0	0	0	0	5	19
Monapen Laboratories India	12.	159.	Loratadine	10 mg	Tab.	Lortec	2	2	3	1	0	6						14	0	5	0	5	0	0	0	10	24
Monapen Laboratories India	13.	160.	Montelukast	10 mg	Tab.	Vikast-10	2	2	3	1	0	6						14	0	5	0	0	0	0	0	5	19
Monapen Laboratories India	14.	161.	Montelukast	5 mg	Tab.	Vikast-5	2	2	3	1	0	6						14	0	5	0	0	0	0	0	5	19
NexChem Pharma CN	15.	189.	Azithromycin	250 mg	Tab. / Cap.	A-Z KD	2	2	3	1	0	6						14	0	5	0	0	0	0	0	5	19
NexChem Pharma CN	16.	190.	Azithromycin	500 mg	Tab. / Cap.	A-Z KD	2	2	3	1	0	6						14	0	5	0	0	0	0	0	5	19
Citi Pharma, Pak	17.	204.	Cefixime	400 mg	Cap.	Cefico	2	2	3	1	0	6	2	2	2	2	2	24	0	5	0	0	0	0	0	5	29
Sinopharm Weigida Pharma CN	18.	218.	Ceftriaxone	1gm/Vial	Inj.	Bactiphin	2	2	3	1	0	6	2	2	2	2	2	24	0	5	0	older than the advertised criteria	0	0	0	5	29
CarryFor Pharma PK	19.	224.	Cephradine	250 mg	Cap.	Relosef	2	2	3	1	0	6	2	2	2	2	2	24	0	5	0	0	0	0	0	5	29
CarryFor Pharma PK	20.	225.	Cephradine	500 mg	Cap.	Relosef	2	2	3	1	0	6	2	2	2	2	2	24	0	5	0	0	0	0	0	5	29
	21.	230.	Ciprofloxacin	250 mg	Tab.	Cip-Rx	2	2	3	1	0	6						14	0	GD not attached	0	0	0	0	0	0	0	14
	22.	231.	Ciprofloxacin	500 mg	Tab.	Cip-Rx	2	2	3	1	0	6						14	0	GD not attached	0	0	0	0	0	0	0	14
Alpha Chem Ltd	23.	247.	Co-Trimoxazole (Sulphamethoxazole +Trimethoprim)	400 mg + 80mg/5 ml	Susp.	Rascotran DS	2	2	3	1	0	6						14	0	5	0	0	0	0	0	5	19
Shandong	24.	251.	Doxycycline	100 mg	Cap.	Voxicin Cap	2	2	3	1	0	6						14	0	5	0	0	0	0	0	5	19
Ningxia Taijcin Biotech CN	25.	266.	Lincomycin	500 mg	Cap.	Lincoras	2	2	3	1	0	6						14	0	5	0	0	0	0	0	5	19
	26.	275.	Moxifloxacin	400 mg	Tab.	Moxilin	2	2	3	1	0	6						14	0	GD not attached	0	0	0	0	0	0	0	14
Optimus Drugs, India	27.	292.	Rifaximin	550 mg	Tab.	Rufexa	2	2	3	1	0	6						14	0	5	0	0	0	0	0	5	19
Raghaya Lifesciences, India	28.	401.	Amlodipine Besylate	5 mg	Tab.	Rasdipin-	2	2	3	1	0	6						14	0	5	0	0	0	0	0	5	19
	29.	404.	Amlodipine + Valsartan	5mg+160 mg	Tab.	Emloten 5/160mg	2	2	3	1	0	6						14	0	Valsartan GD not attached	0	0	0	0	0	0	0	14
Synthmed Labs India	30.	421.	Clopidogrel	75 mg	Tab.	Nilclot	2	2	3	1	0	6						14	0	5	0	0	0	0	0	5	19
Monapen Laboratories India	31.	471.	Rosuvastatin	10 mg	Tab.	R-Vastin	2	2	3	1	0	6						14	0	5	0	0	0	0	0	5	19
Lohitha Lifesciences India	32.	503.	Domperidone	10 mg	Tab.	Residone	2	2	3	1	0	6						14	0	5	0	0	0	0	0	5	19
Lohitha Lifesciences India	33.	504.	Domperidone	5 mg/5ml	Susp.	Residone	2	2	3	1	0	6						14	0	5	0	0	0	0	0	5	19
SMS Lifesciences India	34.	507.	Famotidine	40 mg	Tab.	Famtac	2	2	3	1	0	6						14	0	5	0	0	0	0	0	5	19
Jiang Jushou Pharma	35.	703.	Carbamazepine	200 mg	Tab.	Kabrokin	2	2	3	1	0	6						14	0	5	0	0	0	0	0	5	19
Jiang Huhai Pharma In	36.	735.	Levetiracetam	250 mg	Tab.	Le-Tact	2	2	3	1	0	6						14	0	5	0	0	0	0	0	5	19
Jiang Huhai Pharma In	37.	736.	Levetiracetam	500mg	Tab.	Le-Tact 500mg	2	2	3	1	0	6						14	0	5	0	0	0	0	0	5	19
Jiang Huhai Pharma In	38.	737.	Levetiracetam	100 mg/ml/Scc	Inj.	Le-Tact	2	2	3	1	0	6						14	0	5	0	0	0	0	0	5	19
Suraj Laboratories	39.	742.	Olanzapine	5mg	Tab.	Olancin-5	2	2	3	1	0	6						14	0	5	0	0	0	0	0	5	19
Suraj Laboratories	40.	743.	Olanzapine	10 mg	Tab.	Olancin-10	2	2	3	1	0	6						14	0	5	0	0	0	0	0	5	19
Bakul Pharma India	41.	788.	Acefylline	125 mg /5ml	Syp.	Restyl-Cough	2	2	3	1	0	6						14	0	5	0	0	0	0	0	5	19
ave Pharma CN, Aam	42.	800.	Diphenhydramine+ Aminophylline+ Ammonium Chloride	8mg+32mg+3.0 mg /5ml	Syp.	Rescolin	2	2	3	1	0	6						14	0	Ammonium Chloride GD not attached	0	0	0	0	0	0	0	14

The inspection team at the time of inspection observed that,
Non Adherence to Good Storage Practices
1. In dedusting area no dedicated vacuum cleaner was present at the time of inspection.
2. Raw material Store was congested, and personal movement was impossible. Numerous excipient bags were placed on the pellets but directly in contact with walls.
3. In the RMS, markedly damaged floor were observed at the time of inspection.
4. In RMS, waste-water drain of air condition was in direct contact with the excipient bags.
5. Sterile Ceftazidime and Avibactam sodium bearing batch No. 6003CK85.IS of 6KG was stored in the general section with other active pharmaceutical ingredients despite dedicated cephalosporin section.
6. In sampling booth, balance was not calibrated at the time of inspection.
7. Filter of fluidized bed dryer for psychotropic section was in the gallery and was chocked.
8. Seepage was observed on the walls in the main corridor of production area and fungus growth was found in the surrounding edges.
9. Air condition water waste drain of RMS was in the main corridor.
10. In in-process quarantine, finished product of Tramadol P bearing batch No. 6D040 was kept in blue containers in polyethylene bags and no hygrometer and temperature device was in the area.
11. HVAC ducts were cracked and loosely fitted in different sections of general production area, and visible dust particles were observed.
12. In syrup section, visible water drops were found in the ceilings.
13. Open rusted electric main board was found in the liquid filling area and paint was peeled off from the walls.
14. In capsule filling area, the temperature noted was 19.6 & relative humidity was 58% whereas the batch manufacturing record of Cap. Prisma (Omeprazole 40mg) has limits of temperature NMT 30 & RH of NMT 45%.
15. In the vial and ampoule de-cartoning area, paint was peeled from the walls and visible fungal growth was seen.

In view of the above, firm is RECOMMENDED only for CEPHALOSPORINS for award of factory evaluation visit score for the quoted items.

Scrutiny report
1.
2.
3.
4.
5.

PDF Page
537
542
547

Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products are not attached in the technical bid.
Date of issuance in GD for Diclofenac sodium is not readible in the technical bid.
Date of issuance in GD for Mefanamic Acid is not readible in the technical bid
All COA are not duly attested by the Senior Executive of the firm. Hence, marks may not be awarded in respective column.
Documents required for award of marks in column 22 i.e., Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer are not duly attested by the senior executive of the firm.

6.		Documents required for award of marks in column 21 are not attached in the original bid.
7.		Stability studies of quoted item/s are not duly attested by the Q.C incharge of the firm.
8.	533-535	IMS market share for the quoted items are less than 1%. Hence, marks may not be awarded in column 24.
9.		No relevant documents for award of marks in column 17 are attached in the technical bid.
10.	781-788	The adresses of principal source mentioned in the API documents are not matching with the adresses mentioned in form-3 & 7.
11.	811-823	Documents attached are not fulfilling the advertised criteria for award of marks in API sources for Mometukast.
12.	844-846	Documents attached are either not valid or the adresses of the principal manuacturer are not matching in Bid form 3 & 7.

Original Mandatory forms in Hard are not submitted to the MCC

Evaluation Criteria for Manufacturers of Cotton & Related Goods for Government MCC 2026-27

		Name of Firm				Rehman Rainbow															
S. No.		General Product Information				Technical Evaluation Matrix															
						Factory Technical Evaluation Parameters											Product Evaluation Parameters				
						Documents Based Factory Score						Evaluation visit Score				Factory Evaluated Score				Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body. (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e FY 2023-24 or latest. A minimum turnover of PKR 100 million is required for award of marks in this parameter. (The document shall be attested by a Senior executive of the firm)	Functional and effective Airconditioning & Ventilation System as per the requirements laid down by DRAP **(Evaluated by the MCC expert/s at the time of inspection, Non functionality of the Air Conditioning & Ventilation system in specified section shall lead to disqualification of the section or firm)**	Adequate availability of equipment / instruments in QC labs performing relevant official tests as well as compliance to Good laboratory practices (GLP) in all Labs and Current Good Manufacturing Practices (cGMP) throughout the production facility. **(Evaluated by the MCC expert/s at the time of inspection, Non availability of adequate and appropriate equipment / instruments and non-compliance to GLP , cGMP shall lead to disqualification of the relevant section or firm)**	Appropriate storage of raw material, in process and finished goods with compliance to Good storage practices (GSP) **(To be evaluated by the MCC expert/s at the time of inspection, Non compliance to GSP shall lead to disqualification of the relevant section or firm)**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	3	3	4	5	3	6	6	6	6	**45**	5	10	10	**25**	**70**
	969	Cotton (Surgical) Corded BPC	200 gm		Surgee Cotton	3	3	3	4	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**
	970	Cotton (Surgical) Corded BPC	100 gm		Surgee Cotton	3	3	3	4	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**
	971	Cotton Bandages (Surgical) B.P Type II	6.5 cm x 4 m		Surgee Bandage	3	3	3	4	5	3	6	6	6	6	**45**	0	10	DTL Substandard	**10**	**55**
	972	Cotton Bandages (Surgical) B.P Type II	7.5 cm x 4m		Surgee Bandage	3	3	3	4	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**
	973	Cotton Bandages (Surgical) B.P Type II	10 cm x 4 m		Surgee Bandage	3	3	3	4	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**
	974	Cotton Bandages (Surgical) B.P Type II	15 cm x 4 m		Surgee Bandage	3	3	3	4	5	3	6	6	6	6	**45**	0	10	DTL Substandard	**10**	**55**
	981	Crepe Bandages BPC	7.5cm x 4.5m		Surgee Crepe Bandage	3	3	3	4	5	3	6	6	6	6	**45**	0	10	DTL Substandard	**10**	**55**
	980	Crepe Bandages BPC	10cm x 4.5m		Surgee Crepe Bandage	3	3	3	4	5	3	6	6	6	6	**45**	0	10	DTL Substandard	**10**	**55**
	981	Crepe Bandages BPC	15cm x 4.5m		Surgee Crepe Bandage	3	3	3	4	5	3	6	6	6	6	**45**	0	10	DTL Substandard	**10**	**55**
	1081	Eye Pads sterile	6cm x 8cm		Surgee Optic	3	3	3	4	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**
	1097	Gauze Cloth Roll packing	100 cm x 20m		Surgee Absorbent Gauze Cloth	3	3	3	4	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**
	1098	Gauze Cloth Roll packing	100 cm x 40m		Surgee Absorbent Gauze Cloth	3	3	3	4	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**
	1184	Paraffin Gauze dressing (Tulle) with Chlorhexidine	10x10 cm		Surgee Tulle	3	3	3	4	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**
	1184	Paraffin Gauze dressing (Tulle) with Chlorhexidine	15x20 cm		Surgee Tulle	3	3	3	4	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**
	1217	Sterile Gauze Dressing Pad (X-ray detectable Radi	Blister pack 10x10cm, 8 ply		Surgee Gauze(St.)	3	3	3	4	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**
	1218	Sterile Gauze Dressing Pad (X-ray detectable Radi	Blister pack 15x15cm, 8 ply		Surgee Gauze(St.)	3	3	3	4	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**
	1219	Sterile Gauze Dressing Pad (X-ray detectable Radi	Blister pack 30x30cm, 4 ply		Surgee Gauze/Sponges(St.)	3	3	3	4	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**
	1220	Sterile Gauze Dressing Pad(USP-Type IV/BP-Type-	Blister pack 10x10 cm, 8 ply		Surgee Gauze(St.)	3	3	3	4	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**
	1221	Sterile Gauze Dressing Pad(USP-Type IV/BP-Type-	Blister pack 15x15 cm, 8 ply		Surgee Gauze(St.)	3	3	3	4	5	3	6	6	6	6	**45**	0	10	10	**20**	**65**

REPORT
Tender approvals are incomplete

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm | **RELIZON PHARMACEUTICALS LAHORE**

Technical Evaluation Matrix

S. No.	Product General Information				Factory Technical Evaluation Parameters						Factory Evaluation Visit Score					Total Factory Evaluated Score	Product Evaluation Parameters							Total Product Evaluated Score	Total Technical Score
					Documents Based Factory Score												Product Technical Parameters								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th positions shall be awarded 1 mark.**	Valid calibration certificates for equipment/ instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA/WLAs countries (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product-registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. Copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this column for the respective item.** For award of marks, the certificate of analysis must clearly mention: i. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Flasks (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. ii. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). iii. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or lower **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded, b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the QA/C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent more data of IMS/IQVIA Health not older than twelve (12) months, 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be supported with relevant documentary evidence such as purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70
1	8	Nitazoxanide Dry Susp.		susp	Nitazon	2	2	3	0	5	2						14	0	0	0	0	0	0	0	0	0	14
2	59	Paracetamol 500mg Tablets		tab	Relmol	2	2	3	0	5	2						14	0	0	0	0	0	0	0	0	0	14
3	66	Paracetamol + Tramadol		tab	Tracine-P	2	2	3	0	5	2						14	0	0	0	0	0	0	0	0	0	14
4	137	Pharmacetic Cephalil 150mg		susp	Fusion	2	2	3	0	5	2						14	0	5	5	0	0	0	5	5	20	34
5	138	Pharmacetic Dry Susp.		tab	Fusion	2	2	3	0	5	2						14	0	5	5	0	0	0	5	5	20	34
6	143	Cefpirome 40mg (alpha)		tab	Cefrozon	2	2	3	0	5	2						14	0	5	5	0	0	0	5	5	20	34
7	150	Montelukast Tab. 10mg		tab	Asmukast	2	2	3	0	5	2						14	0	0	0	0	0	0	0	0	0	14
8	189	Azithromycin Tab. 250mg		tab	Azith	2	2	3	0	5	2						14	0	5	5	0	0	0	5	5	20	34
9	190	Azithromycin Tab. 500mg		tab	Azith	2	2	3	0	5	2						14	0	5	5	0	0	0	5	5	20	34
10	192	Azithromycin Dry Susp.		susp	Azith	2	2	3	0	5	2						14	0	5	5	0	0	0	5	5	20	34
11	230	Ciprofloxacin Tab. 250mg		tab	Lupicip	2	2	3	0	5	2						14	0	5	5	0	0	0	5	5	20	34
12	231	Ciprofloxacin Tab. 500mg		tab	Lupicip	2	2	3	0	5	2						14	0	5	5	0	0	0	5	5	20	34
13	364	Levofloxacin Tab. 250mg		tab	Rahxi	2	2	3	0	5	2						14	0	0	0	0	0	0	5	5	5	19
14	365	Levofloxacin Tab. 500mg		tab	Rahxi	2	2	3	0	5	2						14	0	0	0	0	0	0	5	5	5	19
15	368	Linezolid Tab. 600mg		tab	Linezon	2	2	3	0	5	2						14	0	5	5	0	0	0	5	5	20	34
16	369	Linezolid 100mg/5ml susp.		susp	Linezon	2	2	3	0	5	2						14	0	5	5	0	0	0	5	5	20	34
17	375	Moxifloxacin Tab. 400mg		tab	Moxizon	2	2	3	0	5	2						14	0	0	0	0	0	0	0	0	0	14
18	400	Artemether + Lumefantrine		tab	Malazon	2	2	3	0	5	2						14	0	5	5	0	0	0	5	5	20	34
19	401	Artemether + Lumefantrine		tab	Malazon	2	2	3	0	5	2						14	0	5	5	0	0	0	5	5	20	34
20	402	Artemether + Lumefantrine		susp	Malazon	2	2	3	0	5	2						14	0	5	5	0	0	0	5	5	20	34
21	339	Oseltamivir Cap 75mg		cap	Oseltazon	2	2	3	0	5	2						14	0	0	0	0	0	0	0	0	0	14
22	342	Tenofovir Disoproxil Fumarate		tab	Revir	2	2	3	0	5	2						14	0	0	0	0	0	0	0	0	0	14
23	507	Famotidine Tab. 40mg		tab	Famoxon	2	2	3	0	5	2						14	0	0	0	0	0	0	0	0	0	14
24	517	Omeprazole Cap. 40mg		tab	Lupizole	2	2	3	0	5	2						14	0	0	0	0	0	0	0	0	0	14
25	534	Omeprazole Cap. 20mg		cap	Lupizole	2	2	3	0	5	2						14	0	0	0	0	0	0	0	0	0	14
26	518	Pantoprazole Cap. 40mg		cap	Pasoni	2	2	3	0	5	2						14	0	5	5	0	0	0	5	5	20	34
27	521	Pantoprazole Tab. 20mg		tab	Paparato	2	2	3	0	5	2						14	0	0	0	0	0	0	0	0	0	14
28	522	Pantoprazole Tab. 40mg		tab	Paparato	2	2	3	0	5	2						14	0	0	0	0	0	0	0	0	0	14
29	581	Sitagliptin + Metformin Tab.		tab	Lusimet	2	2	3	0	5	2						14	0	5	5	0	0	0	5	5	20	34
30	582	Sitagliptin + Metformin Tab.		tab	Lusimet	2	2	3	0	5	2						14	0	5	5	0	0	0	5	5	20	34
31	753	Pregabalin Cap. 50mg		cap	Gabazon	2	2	3	0	5	2						14	0	0	0	0	0	0	0	0	0	14
32	754	Pregabalin Cap. 75mg		cap	Gabazon	2	2	3	0	5	2						14	0	0	0	0	0	0	0	0	0	14
33	755	Pregabalin Cap. 150mg		cap	Gabazon	2	2	3	0	5	2						14	0	0	0	0	0	0	0	0	0	14
34	309	Ascorbic Acid 500mg tab		cap	Retic-C	2	2	3	0	5	2						14	0	5	5	0	0	0	5	5	20	34
35	719	Duloxetine 30mg Cap		cap	Dural	2	2	3	0	5	2						14	0	5	5	0	0	0	5	5	20	34
36	720	Duloxetine 60mg Cap		cap	Dural	2	2	3	0	5	2						14	0	5	5	0	0	0	5	5	20	34
37	2549	Methylene Blue		tab	Methzon	2	2	3	0	5	2						14	0	5	5	0	0	0	5	5	20	34
38	49	Mefenamic Acid 500mg Tab		tab	Mefnizon	2	2	3	0	5	2						14	0	0	0	0	0	0	0	0	0	14

The inspection team at the time of inspection observed that,
NON ADHERENCE TO GOOD STORAGE PRACTICES
A. In the Raw Material store, the temperature at the time of inspection of was 33.1 & Humidity was 49% as per the installed hygrometer.
B. In the in-process quality control lab, the weighing balance was non functional.
C. In the dry suspension area, bottle blower was out of order.
D. Dispensed materials in the Raw Material Store (RMS) were not properly labeled, creating ambiguity regarding material identity, status, and traceability—violating GDP (Good Documentation Practices) and GMP principles.
NON ADHERENCE TO CGMP
In the corridor of production area, numerous cartons of Finished product of Tablet Dompizon Domperidone Maleate (B.P) 10mg) ware placed without any label status.

POOR ADHERANCE TO GOOD LABORATORY PRACTICES (GLP)
A. Accelerated stability chamber was not functional at the time of inspection, temperature noted was 24.4 & Relative Humidity was 49%.
B. Real time stability chamber was not functional at the time of inspection, temperature noted was 28 & Relative Humidity was 45.2 %.

NON-FUNCTIONAL HVAC SYSTEM AND ENVIRONMENTAL CONTROL
F. In the dry granulation area, HVAC was not functional at the time of inspection and the temperature recorded was 30.5 .

In view of the above, the firm is NOT RECOMMENDED for award of factory evaluation visit score for the quoted items.

report
1.no focal person info in bid form 1 and not a single oage in the bid is signed and stamped
2.no GD of paracetamol attached on ljaqe 165 hence no marks awarded in paracetamol and tramadol + paracetamo quoted product
3.GD of famotidine seems tempered need clarification on page 231
4.invoice and batch no of levofloxacin is not matching on ljaqe 301 needs calrification
5.GD and Coa batch nos not matching at oage 351 for item mefanamic acid needc clarification.
7.tender approval trail not established hence no m,arks awarded.

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27														
Name of the firm						RENACON FAISALABAD														
						Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters														
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score	Product Technical Evaluation						Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevent certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
Jiangxi Sanxin Medtec Co Ltd China	1093	Fistula Cannula Needle 16G (Arterial & Venous, Sterile, small holes along the circumference of end portion, Luer lock activated anti refulx value & safety cap). The canula shouold be radio-opaque, as well as latex, pyrogen and PVC free)	16G		Renav	3	5	0	The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COFG) for the quoted items were checked, and following observations were made: Jiangxi Sanxin Medtec Co Ltd China Valid original DRAP Enlistment certificate for the quoted items, letter of authorization, free sale certificate apostilled in original were present at the time of inspection. However, the firm failed to produce original valid CE/MDR certificate for the quoted items to the inspection team. Hence, the firm is NOT-RECOMMENDED for the imported quoted items.			**8**	5	5	0	0	2	16	**28**	**36**
Jiangxi Sanxin Medtec Co Ltd China	1093	Fistula Cannula Needle 17G (Arterial & Venous, Sterile, small holes along the circumference of end portion, Luer lock activated anti refulx value & safety cap). The canula shouold be radio-opaque, as well as latex, pyrogen and PVC free)	17G		Renav	3	5	0				**8**	5	5	0	0	2	16	**28**	**36**
Jiangxi Sanxin Medtec Co Ltd China	1108	Sterile Disposable hemodialysis blood tubing set	6.4mm		Renaline	3	5	0				**8**	5	5	0	0	2	16	**28**	**36**
Jiangxi Sanxin Medtec Co Ltd China	1106	Hemodialyzer	1.8m2		Renaf	3	5	0				**8**	5	5	0	0	2	16	**28**	**36**

Evaluation Criteria for Manufacturers of Non Drugs Items for Govt MCC 2026-27

Name of the firm RENACON FAISALABAD

Technical Evaluation Matrix

		Product General Information				Factory Technical Evaluation Parameter								Factory Evaluated Score						Product Evaluated Score	Total Technical Score
						Documents Based Factory Score				Evaluation Visit Score											
S.No	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. **(as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.**	Adherence to Current Good Manufacturing Practices in line with the DRAP regulations. **(to be evaluated by the MCC expert/s, Non compliance to cGMP shall lead to disqualification of the relevant section or firm)**	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. **(As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the**	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Institutes, Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. **02 marks for each**	Physical examination of the quoted item/s by the MCC expert/s, Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	6	5	5	5	5	**39**	5	5	5	6	10	**31**	**70**
	651	Haemodialysis Concentrate	-	Part A- Solution Part B-Powder	Renacarb Hemodialysis Concentrate	3	5	5	6	5	5	5	5	**39**	5	5	Not attached	Not attached	10	**20**	**59**
	651	Haemodialysis Concentrate	-	Part A- Solution Part B-Powder	Renacit-S Hemodialysis Concentrate	3	5	5	6	5	5	5	5	**39**	5	5	Not attached	Not attached	10	**20**	**59**

Item enlistment at Page No. 31 and 33 are with Renacon Lahore
Tender approvals are not as per the advertised criteria

TECHNICAL EVALUATION PROFORMA, FOR PROCUREMENT OF ANTICANCER MEDICINES IN GOVT. MCC FY 2026-27

		Name of the firm with	REVIVE HEALTHCARE
		Manufacturer / Importer	IMPORTER

		Mandatory Requirements.	YES / NO		In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:		YES/NO		In case of being Importers, the Firm should provide attested copies of the following documents also:		YES/NO	
1		National Tax Number (NTN) of the Firm for Income Tax, and	YES		1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and		1	Valid Drugs Sales License for the importer; and	YES	
2		Last year Income Tax Return of the Firm; and	YES		2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.		2	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding	YES	
3		Sale Tax Registration Certificate of the	YES		3	Valid DRAP Approved Price List of the quoted item/s.		3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies;	YES	
4		Certificate of Professional Tax of the Firm.	YES					4	Valid cGMP/ Certificate of Pharmaceutical Product (CDPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s, Certificate on company's own letter head shall not be	YES	
5		Certificate of compliance to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR. Non-Compliance to international reference standards or absence of Cold Chain requirements shall lead to	YES					5	Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s. Non provision of this document shall lead to disqualification of the firm; and	YES	
								6	Valid DRAP approved Price List of the quoted	No	

		Technical Evaluation Parameters	Active Pharmaceutical Ingredient source gradation (For API or finished product). i) The bidder (local manufacturer / multi-national manufacturer / importer) shall provide Analytical/Quality Assurance/ Approval Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades. Certificate of Analysis/ Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreement/ approval with the original manufacturer duly attested/verified by official of the company. Detailed purchase trail of the Active Pharmaceutical Ingredient/ Finished product from the claimed source must be submitted (any proof of purchase such as Goods Declaration Certificate along with Airway Bill/ Bill of Lading/invoice etc.) by the bidder. Maximum marks for this criterion are 40.		Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW) Study/Certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities)/ WHO Listed Authorities WLA Countries BE/BS Certificate with evidence as to its authenticity) from Category A countries. Bio-Equivalence (BE) of the quoted product to be conducted against the originator. Original innovator products do not require bio- equivalence certificate and shall get 10 marks automatically.The bidder shall provide the documents to establish the proof of inventor/ originator. All other branded generics require BE studies Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid.			Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug. In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article) Mandatory: Online verification link must be provided to verify the Clinical Trial / Clinical Studies submitted for the quoted items.			Factory/ Importer Based Evaluation Score (MANDATORY)	Sample Evaluation by End User Committee Samples will be examined per following parameters as follows: a. Labeling and Packing Rules 1986 b. Outer packing c. Inner packing d. Physical appearance. Product which has unsatisfactory packing/labeling will be technically Disqualified. Maximum score for this criterion is 1.		Past Performance (Last two years). 1) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks. 2) Only supply orders will not get any marks. 3) The bidders have to undertake that they have never been blacklisted or debarred. Maximum marks for this criterion are 5. 4) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.	Total Technical Score
			Category A – Approved By: • United States Food & Drug Administration (US-FDA) • European Medicines Agency (EMA) • Medicines & Healthcare Products Regulatory Agency (MHRA), UK • Therapeutic Goods Administration (TGA), Australia. • Pharmaceutical Medical Agency (PHARMAC), New Zealand • Pharmaceutical & Medical Devices Agency (PMDA), Japan • Swiss Agency For therapeutic drugs (Swiss-medic), Switzerland • Health Canada • Health Sciences Authority (HAS), Singapore • National Administration of Drugs, Food & Medical technology (ANMAT), Argentina Drug Regulatory Authorities of the SRA	Category B – Approved By: • Agência Nacional de Vigilância Sanitária (ANVS), Brasil • Central Drug Standard Control Organization (CDSCO), India • Drug Regulatory Authority, Pakistan • National Pharmaceutical Control Bureau (NPCB), Malaysia • Food & Drug Administration, South Korea • Ministry of Health, Egypt • Ministry of Health, Turkey • China Food & Drug Administration • Any other source not mentioned in Category-A	Study/certificate accepted/certified by a Category A Country Regulatory Authority. BE testing must be done using at least 12 subjects. Bio-waiver is acceptable only to injectable forms if issued by Category A Country.	BE/BS/BW certificate obtained for a quoted product from Category B Country (as mentioned at S No. 1 above).	No BE/BS/BW Certificate.	In case the study is published in Category "B" journal listed in HEC Journal Recognition System (HJRS) Database/ Journals & Publication Policy 2024 and List of National Recognized Journals as per HEC, 3 marks per original research article shall be awarded maximum up to 9 marks).	In case the study is published in Category "X" journal listed in HEC Journal Recognition System (HJRS) Database/ Journals & Publication Policy 2024 and List of National Recognized Journals as per HEC, 2 marks per original research article shall be awarded maximum up to 6 marks).	Studies/original article published in category "Y" journal of the HJRS/ Journals & Publication Policy 2024 and List of National Recognized Journals as per HEC shall not be awarded marks.	The Physical Inspection of the premises of the bidders (Manufacturer/Importer) shall be carried out in accordance with ITB 25.4(b), SCC 5 (GCC 8.3), Section V (1) (i) (k) of the approved BSDS of Govt. MCC FY 2026-27	Satisfactory	Unsatisfactory	1) Substantial quantity of Supplies of anti-cancer medicines made to private sector Teaching Hospitals namely: The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar, CMH Rawalapindi and Hayatabad Medical Complex, Peshawar , Shifa international hospital Islamabad, with Good/Satisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 24 months. No marks will be given for supply orders except CMH Rawalpindi where supply orders coupled with delivery challans & invoices will be considered for award of marks. 1 mark per agreement up to a maximum of 5 marks	
SOURCE	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	40	30	10	5	0	9	6	0	5	1	0	5	70
Qilu Pharmaceutical (Hainan) China	1462	Bortezomib	3.5 mg	Injection	REVIBORT	40		0			0				1		2	43
Qilu Pharmaceutical (Hainan) China	1471	Capecitabine	500 mg	Capsules	RETABIN	40		0			6				1		2	49
SPAL Pvt Ltd India	1476	Carfilzomib	60 mg	Injection	CARF SPAL	40		0			0			The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COPG) for the quoted items were checked, and following observations were made; SPAL Pvt Ltd India Valid original DRAP registration certificate for the quoted items, letter of authorization, & original COPP was available at the time of inspection. Jenphar Bangladesh Valid original DRAP registration certificate for the quoted items, letter of authorization, & original COPP was available. However, the COPP was issued in 2023 but validity was not mentioned whereas the periodicity of inspection was mentioned as 2 years. Qilu Pharmaceutical (Hainan) China Valid original DRAP registration certificate for the quoted items, letter of authorization, & original COPP were available. However, the COPP for Cap. Lenvatinib, Inj. Nab-Paclitaxel and were expired at the time of inspection. Moreover, Not a single pack as a physical stock of Cap. Ibrutinib 140mg & Inj. Nab-Paclitaxel 100mg were present at the time of inspection. In view of the above, the firm is RECOMMENDED for award of marks in factory evaluation score Except for Cap-Lenvatinib 4mg, Inj. Nab-Paclitaxel 100mg and Cap. Ibrutinib 140mg.	1		2	43
Jenphar Bangladesh	1525	Ibrutinib	140 mg	Capsules	IBRUNIB		30	0			0					SNP	2	32
Qilu Pharmaceutical (Hainan) China	1545	Lenvatinib	4 mg	Capsules	LENVIXA	40		0			0				1		2	43
Qilu Pharmaceutical (Hainan) China	1576	NAB-Paclitaxel	100 mg	Injection	PACLIXA	40		0			3				1		2	46
Qilu Pharmaceutical (Hainan) China	1605	Pemetrexed	500 mg	Injection	PEMIXA	40		0			0				1		2	43

Scrutiny report
1Studies on Page 47,53 and 82 is does not mention products of Qilu Pharmaceuticals Qilu
2Studies on Page 98,101, 106 is does not mention products of Qilu Pharmaceuticals Qilu
3Page 58 is Contract award from SKM not performance certificate
4Studies on Page 122,129, is does not mention products of Qilu Pharmaceuticals Qilu
5Clinical trial on Page 155 is not published
6Studies on Page 162,169, 177 is does not mention products of Qilu Pharmaceuticals Qilu
7Studies on Page 201 does not mention products of Qilu Pharmaceuticals Qilu
8Studies on Page 234,237,240 does not mention products of Qilu Pharmaceuticals Qilu

TECHNICAL EVALUATION PROFORMA, FOR PROCUREMENT OF ANTICANCER MEDICINES IN GOVT. MCC FY 2026-27

Name of the firm with Complete Address: Roche Pakistan (Oncology) FY 2026-27

Manufacturer / Importer:

	Mandatory Requirements.	YES / NO		In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:		YES/NO	In case of being Importers, the Firm should provide attested copies of the following documents also:	YES/NO	
1	National Tax Number (NTN) of the Firm for Income Tax, and	YES		1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and		1 Valid Drugs Sales License for the importer; and	YES	
2	Last year Income Tax Return of the Firm; and	YES		2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.		2 Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	YES	
3	Sale Tax Registration Certificate of the Firm; and	YES		3	Valid DRAP Approved Price List of the quoted item/s.		3 Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	YES	
4	Certificate of Professional Tax of the Firm.						4 Valid cGMP/ Certificate of Pharmaceutical Product (CoPP)/ Certificate of Medicinal Product (CMP) of the Principal Manufacturer for the quoted item/s in the country of origin and in the country of origin of the quoted imported goods, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and	Yes	
5	Certificate of compliance to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR. Non-Compliance to international reference standards or absence of Cold Chain requirements shall lead to disqualification of the relevant product that requires cold chain.						5 Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods. Non provision of this document shall lead to disqualification of the firm; and	YES	
							6 Valid DRAP approved Price List of the quoted items.	YES	

Technical Evaluation Parameters

	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	Active Pharmaceutical Ingredient source gradation (For API or finished product). i) The bidder (local manufacturer / importer) shall provide Analytical/Quality Assurance/ Approval Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades. Certificate of Analysis/ Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreement/ approval with the original manufacturer duly attested/verified by official of the company. Detailed purchase trail of the Active Pharmaceutical Ingredient/ Finished product from the claimed source must be submitted (any proof of purchase such as Goods Declaration Certificate along with Airway Bill/ Bill of Lading/ Invoice etc.) by the bidder. Maximum marks for this criterion are:40.	Bio-Equivalence (BQ) / Bio- Similar (BQ) or Bio-waiver (BW) Study Certificate from an accredited lab. of ISN countries (Stringent Regulatory Authorities) / WHO Listed Authorities WLA Countries (BE/BS Certificate with evidence as to its authenticity) from Category A countries. Bio-Equivalence (BQ) of the quoted product to be conducted against the originator. Original innovator products do not require bio- equivalence certificate and shall get 10 marks automatically. The bidder shall provide the documents to establish the proof of inventor/ originator. All other branded generics require BE studies Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid. Maximum marks for this criterion are 10.	Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug. In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article) Mandatory: Online verification link must be provided to verify the Clinical Trial/ Clinical Studies submitted for the quoted items.	Factory/ Importer Based Evaluation Score (MANDATORY)	Sample Evaluation by End User/ Committee Samples will be examined per following parameters as follows: a. Labeling and Packing Rules 1986 b. Outer packing c. Inner packing d. Physical appearance. Product which has unsatisfactory packing/labeling will be technically Disqualified. Maximum score for this criterion is 1.	Past Performance (Last two years). i) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks. ii) Only supply orders will not get any marks. iii) Those firms who have supplied but they have never been blacklisted or debarred. Maximum marks for this criterion are 5. iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.	Total Technical Score
						Category A – Approved By: • United States Food & Drug Administration (USFDA) • European Medicines Agency (EMA) • Medicines & Healthcare Products Regulatory Agency (MHRA), UK • Therapeutic Goods Administration (TGA), Australia • Pharmaceutical Medical Agency (PHARMAC), New Zealand • Pharmaceutical & Medical Devices Agency (PMDA), Japan • Swiss Agency For Therapeutic drugs (Swiss medic), Switzerland • Health Canada • Health Sciences Authority (HAS), Singapore • National Administration of Drugs, Food & Medical technology (ANMAT), Argentina Drug Regulatory Authorities of the WLA (Stringent Regulatory Authorities)/ WHO Listed Authorities WLA countries	Category B – Approved By: • Saudi Food & Drug Authority (SFDA) • National Drug Standard Control Organization (CDSCO), India • Drug Regulatory Authority, Pakistan • National Pharmaceutical Control Bureau (NPCB), Malaysia • Food & Drug Administration, South Korea • Health Canada • Ministry of Health, Turkey • China Food & Drug Administration • Any other source not mentioned in Category A	Study/ certificate accepted/issued by a Category A Country Regulatory Authority. All testing must be done using at least 12 subjects. Applicable for injectable only. For injectable forms if issued by Category A Country.	BE/BS/BW certificate obtained for a quoted product from Category B country (as mentioned at S. No. 1 above).	Yes BE/BS/BW Certificate.	In case the study is published in Category "A" journal listed in the Publication Policy 2019 and List of National Recognized Journals as per HEC, 2 marks per original research article shall be awarded (maximum up to 4 marks).	In case the study is published in Category "B" journal listed in the Publication Policy 2019 and List of National Recognized Journals as per HEC, 2 marks per original research article shall be awarded (maximum up to 4 marks).	Product is original/ innovator (Yes) or Generic (No) as per category "A" issued by the claimed of the SRRA/ Stringent Regulatory Authority.	The Physical inspection of the premises of the bidder/ manufacturer/ importer shall be carried out in accordance with the Rules, SRO, Schedule, Notification, Act, Ordinance etc. (Rules 29, 30, SRO 1, SRO 19, SRO 42, Schedule – F (1) (2) (4) of the approved Rules of Govt. MCC FY 2026-27	Satisfactory	Unsatisfactory	i. Substantial quantity of supplies of anti-cancer medicines supplied to the Cancer Hospitals in the country. The Aga Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar, CMH Rawalpindi and Hyderabad Medical Complex, Peshawar 05/5x international hospital reputed, with satisfactory supply performance from these institutions (mandatory). Made shall only be provided to those who provide good performance certificate issued in the last 36 months. No marks will be given for supply orders except CMH Rawalpindi where supply orders along with delivery challans & invoices will be considered for award of marks. 5 mark per agreement up to a maximum of 5 marks	
SOURCE						40	30	10	5	0	9	6	0	5	1	0	5	70
	1439	Adotrastuzumab Inj.	100mg	Inj.	Kadcyla 100mg	40		10			9			5	1		3	68
	1440	Adotrastuzumab Inj.	160mg	Inj.	Kadcyla 160mg	40		10			9			5	1		3	68
	1442	Alectinib 150 Cap	150mg	Cap.	Alecensa Cap 150mg	40		10			3			5	1		3	62
	1446	Atezolizumab 1200 mg Inj.	1,200mg	Inj.	Tecentriq 1200mg Inj	40		10			9			5	1		3	68
	1456	Bevacizumab 100 mg Inj.	100mg	Inj.	Avastin 100mg/4ml Inj	40		10			9			5	1		3	68
	1457	Bevacizumab 400 mg Inj.	400mg	Inj.	Avastin 400mg/16ml Inj	40		10			9			5	1		3	68
	1581	Obinutuzumab 1000 mg Inj.	1000mg	Inj.	Gazyva 1000mg Inj	40		10			9			5	1		3	68
	1607	Pertuzumab/Trastuzumab 1200/600mg Inj.	1,200mg/600mg	Inj.	Phesgo 1200mg/600mg Vial	40		10			3			5	1		3	62
	1608	Pertuzumab 420 mg Inj.	420mg	Inj.	Perjeta 420mg Inj	40		10			9			5	1		3	68
	1609	Polatuzumab 140mg Inj	140mg	Inj.	Polivy 140mg Vial	40		10			6			5	1		3	65
	1618	Rituximab IV 100 mg Inj.	100mg	Inj.	Ristova 100mg/10ml Vial	40		10			9			5	1		3	68
	1619	Rituximab IV 500 mg Inj.	500mg	Inj.	Ristova 500mg/50ml Vial	40		10			6			5	1		3	68
	1620	Rituximab S/C 1400 mg Inj.	1,400mg	Inj. S/C	Mabthera Vial 1400mg/11.7ml SC	40		10			6			5	1		3	65
	1634	Trastuzumab 440 mg IV Inj.	440mg	Inj.	Herceptin 440mg Vial	40		10			9			5	1		3	68
	1635	Trastuzumab 600 mg S/C Inj.	600mg	Inj. S/C	Herceptin SC 600mg Vial	40		10			9			5	1		3	68

24754AUM is issued to AGP
266926rds international is issued to AGP
25989rs/ P.Os are attached with S.C and Invoice of CMH Rwpdi

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: Roche Pakistan (Gen. Med. Importer) FY 2026-27

Technical Evaluation Matrix

S. No.	Product General Information					Principal's and Importer's Evaluation Parameters								Suppliers Technical Score	Product Technical Evaluation							Product Availability	Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation					Importer's Evaluation				Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
						Valid ISO 13485:EGEC certificate of the facility where the quoted product is manufactured. Certificate must be issued by the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured. Certificate must be issued by the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured. Certificate must be issued by the country of origin duly accredited with International Accreditation Forum (IAF), duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid accreditation of manufacturing unit in relevant sections by the US-FDA or any other stringent regulatory authority body in the case of MRA/MLA countries duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid calibration certificates for equipment / instruments used in the manufacturing process of the quoted item. Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **Valid Calibration Certificates attested by Quality head of the firm).**	Availability of minimum 20% inventory of the total import of the quoted item/s in the form of finished goods, strictly duly signed by the senior executive of the firm & evaluated by the MCC team(s). **Non availability of the 20% stock at the store house at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good storage practices (GSP) for storage of finished goods. Temperature mapping, air conditioning & ventilation System and effective cold chain (thermo-labile drugs). The physical inspection committee/ MCC team(s) may visit the warehouse for the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Unsatisfactory in GSP, as evaluated by the MCC experts at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Pomerace of Category-A Pharmacists from mandatory) & relevant Human Resource **(Conducted by the senior executive of the firm & evaluated by the MCC experts at the time of inspection in non-compliance to this parameter shall lead to disqualification of the firm).**		Bioavailability/ Bioequivalence study conducted by WHO/ Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of MRA/MLAs country (ies). and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries. (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 1L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of investor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of exported finished quoted item/s from Pakistan (Country of origin) duly attested by Customs or Bill of Lading for the quoted item/s), not older than 24 months on the cutoff date for submission of bids. **In case of purchases through third party importers a valid trad link/DSA/clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of finished quoted items from the Principal Manufacturer as per Pharmacopoeial standards (latest edition) provided in column 15, duly attested by the senior executive of the firm. **In case of Non-provision of matching CoA the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredients (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of MRA/MLAs country (ies). Exil of principal manufacturer shall be established from the respective GD. CoA and other supporting documents. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA country(ies) / Valid Non-sale certificate issued by regulatory body of any SRA/MLA country(ies) and / or Valid certificate of the availability of the quoted item in the US market. **Both marks shall be awarded to the Primary certificate, and 1 mark for additional certificate, up to a maximum of 06 (04+01+01) marks.** **Certificates on company's own letter heads shall not be acceptable.** **Copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase. **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: i. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical Grade. ii. Type of Glass material for Liquid antipodes must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). iii. Type of Glass material for Oral Syrups / Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** i. For Dry Powder Injectables a. For USP Type 1 Glass 4 marks will be awarded. b. For USP Type 1 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm)**	Reliable markets of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistan market as per recent stock data of IMS/IQVIA Health not older than twelve (12) months. i. 0-10% market share = 1 mark ii 10-30% market share = 2 marks iii 30-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transactions against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	2	5	5	4	5	5	30	5	5	5	5	6	4	5	5	40	70
	84	Ranizumab	6mg /0.05ml	Inj.	Xabysmo 6mg/0.05ML	2	2	2	5	5	4	5	5	30	479-Purple book attached instead of Certificate	5	5	5	**582 BLA attached instead of US Free sale**	4	5	887-1012-Tender approvals attached instead of IMS /IQVIA	**24**	**54**
	92	Donelizumab	300mg/10ml	Inj	Donevus 300mg/10ml	2	2	2	5	5	4	5	5	30	479-Purple book attached instead of Certificate	5	5	Not attached	**583 BLA attached instead of US Free sale**	4	5	887-1012-Tender approvals attached instead of IMS /IQVIA	**19**	**49**
	98	Inclisiumab	162mg/0.9ml	Inj (PFS)	Actemra 162mg/0.9ML	2	2	2	5	5	4	5	5	30	479-Purple book attached instead of Certificate	5	5	Not Attached	**584 BLA attached instead of US Free sale**	4	5	887-1012-Tender approvals attached instead of IMS /IQVIA	**19**	**49**
	358	Epoetin-β	6000 IU	Inj (PFS)	Recormon Inj 6000 PFS	2	2	2	5	5	4	5	5	30	479-Purple book attached instead of Certificate	5	5	5	**585 BLA attached instead of US Free sale**	4	5	887-1012-Tender approvals attached instead of IMS /IQVIA	**24**	**54**
														0										
														0										
														0										

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2025-26

Name of Firm

S. No.	Product General Information				Technical Evaluation Matrix									Product Evaluated Score	Total Technical Score
					Principal's and Importer's Evaluation Parameters								Suppliers Technical Score	Product Technical Evaluation										
					Principal Manufacturer Evaluation					Importer's Evaluation				Product Technical Parameters							Product Availability		
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
					Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or WHO or official accreditation body/ies /regulatory body in the case of SRA countries (duly attested by senior executive of the firm)	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the ware house at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good storage practices (GSP) for storage of finished goods. Functional and effective Air-conditioning & Ventilation System and effective cold chain (thermo-labile drugs). **Nonadherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, Presence of Category-A Pharmacist/s is/are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bid and study must be available on WHO Website) and/or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and/or In case of Large volume parenteral (>100ml to SL as per USP) product validation report shall be submitted. and/or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / biosimilarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail link/LDRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 15, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	API/s source accredited by WHO, US-FDA, EMA, MHRA, TGA, PMDA, Swiss Medic or Health Canada or by regulatory authority of SRAs countries. Trail of principal manufacturer shall be established from the respective GD. CoA and other supporting documents. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission.	Valid WHO prequalification and / or Valid product registration in SRA country(ies) / Valid free sale certificate issued by regulatory body of any SRA country(ies) and / or Valid certificate of the availability of the quoted item in the US market. 2 mark for each certification, up to a maximum of 06 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with invoice/proof of purchase: For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product). 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health. Less than 5 % market share = 0 mark 5-10% market share = 01 mark 11-30% market share = 02 marks 31-50% market share = 03 marks 50% and above market share = 05 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than 2 years) from other Secondary & Tertiary Govt. Hospitals outside Khyber Pakhtunkhwa or JCI accredited private entities/hospitals of other provinces of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks **Note.** **Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength**		
	Ref. No. of item in MCC formulary	Generic Name of Item	Dosage Form with Strength	Trade Name	**2**	**2**	**2**	**5**	**5**	**4**	**5**	**5**	**30**	**5**	**5**	**5**	**5**	**6**	**4**	**5**	**5**	**40**	**70**
													0									**0**	**0**

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: ROCK PHARMA

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm)**.	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability / Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
1	35	Aceclofenac	100 mg	Tab.	Acanef Tablet 100mg	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	5	Not attached	4	5	0	**24**	**48**
2	41	Diclofenac Sodium enteric coated	50 mg	Tab.	Rodic 50mg Tablet	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	0	Not attached	4	5	0	**19**	**43**
3	59	Paracetamol	500 mg	Tab.	Puma 500mg Tablet	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	5	Not attached	4	5	0	**24**	**48**
4	68	Tizanidine	4mg	Tab.	Ronelin 4mg Tablet	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	5	Not attached	4	5	0	**24**	**48**
5	160	Montelukast	10 mg	Tab.	Rocktel 10mg Tablet	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	5	Not attached	4	5	0	**24**	**48**
6	161	Montelukast	5 mg	Tab.	Rocktel 5mg Tablet	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	5	Not attached	4	5	0	**24**	**48**
7	300	Artemether + Lumefantrine	40 mg/240mg	Tab.	Arttillery 40/240 Tablet	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	0	Not attached	4	5	0	**19**	**43**
8	301	Artemether + Lumefantrine	80 mg/480mg	Tab.	Arttillery 80/480 Tablet	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	0	Not attached	4	5	0	**19**	**43**
9	403	Amlodipine + Valsartan	5mg+80 mg	Tab.	Vallypine Tablets 5/80mg	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	0	Not attached	4	5	0	**19**	**43**
10	404	Amlodipine + Valsartan	5mg+160 mg	Tab.	Vallypine Tablets 5/160mg	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	0	Not attached	4	5	0	**19**	**43**
11	405	Amlodipine + Valsartan	10 mg+160mg	Tab.	Vallypine Tablet 10/160mg	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	0	Not attached	4	5	0	**19**	**43**
12	407	Atenolol	50 mg	Tab.	Rocard 50mg Tablet	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	0	Not attached	4	5	0	**19**	**43**
13	408	Atenolol	100 mg	Tab.	Rocard 100mg Tablet	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	0	Not attached	4	5	0	**19**	**43**
14	418	Carvedilol	6.25 mg	Tab.	Revolol 6.25mg Tablet	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	5	Not attached	4	5	0	**24**	**48**
15	419	Carvedilol	12.5 mg	Tab.	Revolol 12.5mg Tablet	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	5	Not attached	4	5	0	**24**	**48**
16	450	Losartan + Hydrochlorothiazide	50mg+12.5mg	Tab.	Rosar-H Tablet	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	0	Not attached	4	5	0	**19**	**43**

17	451	Losartan Potassium	25 mg	Tab.	Rosar 25mg Tablet	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	0	Not attached	4	5	0	**19**	**43**
18	452	Losartan Potassium	50 mg	Tab.	Rosar 50mg Tablet	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	0	Not attached	4	5	0	**19**	**43**
19	497	Aluminium Hydroxide + Magnesium Hydroxide + Simethicone	215mg+80mg+25mg	Susp.	Rokgel Suspension	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	0	Not attached	4	5	0	**19**	**43**
20	499	Bisacodyl	5 mg	Tab.	Belasco 5mg Tablet	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	0	Not attached	0	5	0	**15**	**39**
21	500	Dimenhydrinate	12.5mg/4ml	Syp.	Dimate Syrup	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	0	0	0	Not attached	4	5	0	**9**	**33**
22	503	Domperidone	10 mg	Tab.	Vomax 10mg Tablet	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	5	Not attached	4	5	0	**24**	**48**
23	504	Domperidone	5 mg/5ml	Susp.	Vomax Suspension	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	5	Not attached	4	5	0	**24**	**48**
24	513	Loperamide	2mg	Cap.	Lopim 2mg Capsule	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	0	0	0	Not attached	4	5	0	**9**	**33**
25	517	Omeprazole	40 mg	Cap.	Zes Capsule 40mg	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	0	Not attached	4	5	0	**19**	**43**
26	522	Pantoprazole	40mg	Tab.	Pantoloon 40mg Tab	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	0	0	5	Not attached	4	5	0	**14**	**38**
27	526	Simethicone	40 mg/ml	Oral Drops	Simethro 40mg Drops	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	5	Not attached	4	5	0	**24**	**48**
28	549	Glimepiride	1mg	Tab.	Retryl 1mg Tablet	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	0	Not attached	4	5	0	**19**	**43**
29	550	Glimepiride	2mg	Tab.	Retryl 2mg Tablet	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	0	Not attached	4	5	0	**19**	**43**
30	551	Glimepiride	3mg	Tab.	Retryl 3mg Tablet	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	0	Not attached	4	5	0	**19**	**43**
31	552	Glimepiride	4mg	Tab.	Retryl 4mg Tablet	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	0	Not attached	4	5	0	**19**	**43**
32	581	Sitagliptin + Metformin	50 mg/500 mg	Tab.	Tiglit-M Tab 50/500 Tablet	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	0	Not attached	4	5	0	**19**	**43**
33	582	Sitagliptin + Metformin	50mg /1000mg	Tab.	Tiglit-M Tab 50/1000 Tablet	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	0	Not attached	4	5	0	**19**	**43**
34	725	Escitalopram	10 mg	Tab.	Escirok 10mg Tablet	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	0	Not attached	4	5	0	**19**	**43**
35	753	Pregabalin	50 mg	Cap.	Roglin 50mg Capsules	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	5	Not attached	4	5	0	**24**	**48**
36	754	Pregabalin	75mg	Cap.	Roglin 75mg Capsules	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	5	Not attached	4	5	0	**24**	**48**
37	755	Pregabalin	150 mg	Cap.	Roglin 150mg Capsules	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	5	Not attached	4	5	0	**24**	**48**
38	812	Salbutamol	2mg/5ml	Syp.	Ezibreath Syrup 60ml	2	2	3	Not attached	5	2	2	2	2	2	2	**24**	0	5	5	5	Not attached	4	5	0	**24**	**48**

TECHNICAL EVALUATION PROFORMA, FOR PROCUREMENT OF ANTICANCER MEDICINES IN GOVT. MCC FY 2026-27

Name of the firm with — **ROTEX PHARMA PVT LTD**

Manufacturer / Importer — **MANUFACTURER**

		Mandatory Requirements.	YES / NO		In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:		YES/NO
1		National Tax Number (NTN) of the Firm for Income Tax, and	YES		1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and	YES
2		Last year Income Tax Return of the Firm; and	YES		2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.	YES
3		Sale Tax Registration Certificate of the Firm; and	YES		3	Valid DRAP Approved Price List of the quoted item/s.	YES
4		Certificate of Professional Tax of the Firm.	YES				
5		Certificate of compliance to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR. Non-Compliance to cold chain standards or absence of standards at absence of Cold Chain requirements shall lead to disqualification of the relevant product that requires cold chain.	NO				

		In case of being Importers, the Firm should provide attested copies of the following documents also:	YES/NO	
1		Valid Drugs Sales License for the importer; and		
2		Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and		
3		Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and		
4		Valid cGMP/ Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item/s issued by relevant authority of the country of origin of the quoted imported goods, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to		
5		Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported goods. Non provision of this document shall lead to disqualification of the firm; and		
6		Valid DRAP approved Price List of the quoted items.		

		Technical Evaluation Parameters	Active Pharmaceutical Ingredient source gradation (For API or finished product), i) The bidder (local manufacturer / multi-national manufacturer / importer) shall provide Analytical/Quality Assurance/ Approval Certificate for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades. Certificate of Analysis/ Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreement/ approval with the original manufacturer duly attested/verified by official of the company. Detailed purchase trail of the Active Pharmaceutical Ingredient/ Finished product from the claimed source must be submitted (any proof of purchase such as Goods Declaration Certificate along with Airway Bill/ Bill of Lading/invoice etc.) by the bidder. Maximum marks for this criterion are 40.	Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW) Study/Certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities)/ WHO Listed Authorities WLA Countries (BE/BS Certificate with evidence as to its authenticity) from Category A countries. Bio-Equivalence (BE) of the quoted product to be conducted against the originator. Original innovator products do not require bio- equivalence certificate and shall get 10 marks automatically. The bidder shall provide the documents to establish the proof of inventor/ originator. All other branded generics require BE studies Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid. Maximum marks for this criterion are 10.	Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug. In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article) Mandatory: Online verification link must be provided to verify the Clinical Trial/ Clinical Studies submitted for the quoted items.	Factory/ Importer Based Evaluation Score (MANDATORY)	Sample Evaluation by End User Committee Samples will be examined per following parameters as follows: a. Labeling and Packing Rules 1986 b. Outer packing c. Inner packing d. Physical appearance. Product which has unsatisfactory packing/labeling will be technically Disqualified. Maximum score for this criterion is 1.		Past Performance (Last two years). 1) Good Performance Certificates of these institutions must be produced in order to be eligible for 1 mark per institution upto a maximum of 5 marks. 2) Duly supply orders will not get any marks. 3) The bidders have to undertake that they have never been blacklisted or debarred. Maximum marks for this criterion are 5. 4) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.	Total Technical Score
			Category A – Approved By: • United States Food & Drug Administration (USFDA) • European Medicines Agency (EMA) • Medicines & Healthcare Products Regulatory Agency (MHRA), UK • Therapeutic Goods Administration (TGA), Australia. • Pharmaceutical Medical Agency (PMDA), Japan • Swiss Agency For therapeutic drugs (Swiss-medic), Switzerland Category B – Approved By: • Health Sciences Authority (HAS), Singapore • National Administration of Drugs, Food & Medical technology (ANMAT), Argentina Drug Regulatory Authorities of the WA (Stringent Regulatory Authorities) / WHO Listed Authorities WLA countries.	Category B – Approved By: • Agência Nacional de Vigilância Sanitária (ANVS), Brazil • Central Drug Standard Control Organization (CDSCO), India • Drug Regulatory Authority, Pakistan • National Pharmaceutical Control Bureau (NPCB), Malaysia • Food & Drug Administration, South Korea • Ministry of Health, Egypt • Health Canada, Canada China Food & Drug Administration • Any other source not mentioned in Category-A	Study/certificate accepted/certified by a Stringent Regulatory Authority. BE testing must be done using at least 12 subjects. Bio-waiver is acceptable only on injectable forms if issued by Category-A Country.	BE/BS/BW certificate obtained for a quoted product from Category-B Country (as mentioned at S.No. 1 above).	Bio BE/BS/BW Certificate.									
		SOURCE	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	40	30	10	5	0	9	6	0	5	1	0	5	70
1's	1	MANTOG JINGHUA Pharma CN	1436	5 Fluorouracil	500mg	Inj	Oncofu 500mg Inj		0			0			0	5	1		0	6
120's	2	ANHUI HARIANG Pharma CN	1472	Capecitabine	500mg	Tab	Capex 500mg Tab		0			0			0	5	1		0	6
1's	3	Shandong Boyuan Pharma CN	1472	Carboplatin	150mg	Inj	Xelpac 150mg		30			0			0	5	1		0	36
1's	4	Shandong Boyuan Pharma CN	1472	Carboplatin	450mg	Inj	Xelpac 450mg		30			0			0	5	1		0	36
1's	5	Khandelwal Lab India	1486	Cyclophosphamide	1gm	Inj	Oncofos 1g		30			0			0	5	1		0	36
1's	6	Shandong Boyuan Pharma CN	1529	Rosfamide	1gm	Inj	Rosafos 1g		30			0			0	5	1		0	36
1's	7	Shandong Boyuan Pharma CN	1529	Rosfamide	2gm	Inj	Rosafos 2g		30			0			0	5	1		0	36
60's	8	KUKULE LIFE SCIENCES IND	1530	Imatinib	100mg	Tab/cap	Gvec 100mg		30			0			0	5	1		0	36
30's	9	KUKULE LIFE SCIENCES IND	1531	Imatinib	400mg	Tab/cap	Gvec 400mg		30			0			0	5	1		0	36
1's	10	Adley Lab India	1566	Methotrexate	1gm	Inj	Metu 1gm		30			0			0	5	1		0	36
1's	11	Adley Lab India	1565	Methotrexate	50gm	Inj	Metu 50mg		30			0			0	5	1		0	36
112's	12	Shandong Lixin Pharma	1578	Nilotinib	200mg	Cap	Rotigna 200mg		30			0			0	5	1		0	36
28's	13	Anhui Chico Chem CN	1599	Panopanib	400mg	Tab	PNP 400mg		30			0			0	5	1		0	36
60's	14	ANHUI HARIANG Pharma CN	1623	Ruxolitinib	15mg	Tab	IFK 15mg		30			0			0	5	1		0	36
60's	15	ANHUI HARIANG Pharma CN	1623	Ruxolitinib	5mg	Tab	IFK 5mg		30			0			0	5	1		0	36
30's	16	BDR life sciences India	1626	Sunitinib	50mg	Tab/Cap	Sunex 50mg		30			0			0	5	1		0	36
1's	17	Suzhou Lixin Pharma	1630	Temozolomide	100mg	Cap	Temomide 100mg		30			0			0	5	1		0	36
1's	18	Suzhou Lixin Pharma	1630	Temozolomide	20mg	Cap	Temomide 20mg		30			0			0	5	1		0	36

Scutiny Report

PDF
165-69
162-63
3
4
5

To ascertain the principal source of acquisition for the quoted item i.e. 5-Fluorouracil, GD is not attached with the Airway bill/bill of lading. Moreover, the COA is also not attested by official of the company.
COA of Capecitabine is not attested by official of the company.
No documents related to the Bio-Equivalence (BE) / Bio- Similar (BS) or Bio-waiver (BW) Study/Certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities)/ WHO Listed Authorities WLA Countries are attached in the technical bid.
No documents regarding Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug. In case if the quoted item are attached in the technical bid of the firm.
No documents related to the Past Performance are attached in the technical bid.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: Sj & G Pharma Karachi

S. No.		Product General Information				Technical Evaluation Matrix												Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Technical Parameters									
						Documents Based Factory Score						Factory Evaluation Visit Score															
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs = Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Biosavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC.**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 ((02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columm for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note, Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
60 ml	8	Nitazoxanide	60ml	Susp	Diatazox susp.	Online verification link not provided			5	5	6	The firm was inspected as per technical evaluation criteria, and following observations were made; Raw Material Store (RMS) 1. Segregation & Storage: Active pharmaceutical ingredients (APIs) and excipients were stored in the same area with inadequate physical separation (e.g., use of simple sheaths), creating a significant risk of cross-contamination and material mishandling during dispensing. 2. Environmental Control: The designated HVAC system was non-functional. A split-type air conditioning unit (standing AC) was installed, which is incapable of consistently maintaining temperature and relative humidity within the required pharmacopeial or licensed storage limits. 3. Storage Practices (Stacking): Storage did not comply with Good Storage Practices (GSP). Observed issues included excessive stack height, heavier containers placed on upper racks, stock contacting the ceiling, and absence of dedicated loading/unloading bays or equipment, increasing the risk of container damage and personnel injury. 4. Segregation of Material Types: Veterinary medicines were stored in the same RMS area as raw materials intended for human use, violating regulatory requirements for segregation to prevent cross-contamination and mix-ups. 5. Dispensing Equipment Cross-Use: The same laminar flow hood (LFH) was used for dispensing both veterinary and human-use products, posing a high risk of cross-contamination, contrary to cGMP requirements for dedicated or validated shared equipment. 6. Warehouse Congestion & Accessibility: Racks in the RMS were congested and arranged with insufficient aisle width, resulting in difficult or unsafe stock handling, increasing the likelihood of container damage, mix-ups, and accidents. 7. Container Integrity & Storage Orientation: Drums containing APIs were observed stored inappropriately (e.g., inverted or upside down), which may compromise container integrity, promote material segregation, and cause inaccurate dispensing. 8. Material Flow & Logistics: Material receipt, storage, and dispatch for both veterinary and human products followed the same unidirectional flow within the RMS, increasing the risk of cross-contamination and logistical errors. 9. Cephalosporin Section – Housekeeping & Segregation: The cephalosporin-dedicated RMS area was poorly maintained. Stock was stacked directly against walls without clear segregation of APIs, excipients, or intermediates, violating containment requirements for high-potency/high-hazard compounds. Overall cGMP Compliance 1. HVAC Non-Functionality: The HVAC system for the facility was non-functional. Environmental control relied on non-validated wall-mounted air conditioning units, which are unsuitable for pharmaceutical manufacturing or storage areas. 2. Water Accumulation (Contamination Risk): Condensate water from air conditioning units was collected in open drums within the packaging area, presenting a clear microbiological contamination risk and potential harborage for pests. 3. Humidity Non-Compliance (Packaging Area): Observed relative humidity in the packaging area was 76%, exceeding the standard cGMP limit (e.g., ≤60% or as per product-specific requirements), risking hygroscopic material degradation. 4. Fire Safety Non-Compliance: Fire extinguishers located in the main corridor of the cephalosporin section were found to be expired, posing a critical safety risk and non-conformance with local and international fire safety regulations. 5. Humidity Non-Compliance (Quarantine Area): Relative humidity in the quarantine area was 75%, outside acceptable limits, potentially compromising the stability of materials awaiting disposition. 6. Storage of Capsule Shells: Capsule shells were stored in open drums without secure, humidity-proof closure in an environment with relative humidity of 75%, likely exceeding the manufacturer's recommended storage conditions (typically ≤35–45% RH). 7. Humidity Non-Compliance (General Section): General manufacturing/storage area relative humidity was 80%, well above acceptable pharmaceutical limits, increasing risk of microbial growth and degradation of moisture-sensitive materials. 8. Facility Integrity (Cephalosporin Packaging Section): The ceiling was damaged and paint was peeled off from the walls in the cephalosporin packaging section, creating potential for particulate contamination, product adulteration, and non-compliance with GMP facility maintenance standards. 9. No Standard Operating Procedures (SOPs) or associated documentation records (e.g., logbooks, dispensing records, cleaning logs, material movement registers, line clearance forms, or training records) were available for critical operations in either the general section or the cephalosporin section of the raw material store (RMS). In view of the above the firm is NOT RECOMMENDED.			**16**	0	356 AWB not attached			0	415- not attached	0	0	**0**	**16**
30's	35	Aceclofenac	100mg	Tab	Acenac tabs 100mg				5	5	6						**16**	0	286 DRAP Reg NA			0		5	0	**5**	**21**
1's	62	Paracetamol	150mg/ml	Inj	Fevagesic				5	5	6						**16**	0	245 GD and COA are not matching	245 GD and COA are not matching		0		5	0	**5**	**21**
10's	65	Tramadol+paracetamol	325mg/37.5mg	Tab	Taxidol-p tab.				5	5	6						**16**	0	325 GD COA NA			0		0	0	**0**	**16**
10's	68	Tizanidine HCL	4mg	Tab	Tenz 4mg				5	5	6						**16**	0	Not attached			0		0	0	**0**	**16**
100 ml Vial	99	Zoledronic acid	5mg/100ml	Inj	Edonax injection 5mg/100ml				5	5	6						**16**	0	291 DRAP Reg NA			0		0	0	**0**	**16**
1's	137	Fluconazole	150mg	Cap	Dotara 150mg				5	5	6						**16**	0	Not Attached			0		0	0	**0**	**16**
14's	160	Montelukast sodium	10mg	Tab	Conkast 10 mg				5	5	6						**16**	0	388 AWB Not attached			0		5	0	**5**	**21**
14's	161	Montelukast sodium	5mg	Tab	Conkast 5 mg				5	5	6						**16**	0	388 not AWB			0		5	0	**5**	**21**
2ml Vial	166	Amikacin sulfate	100mg	Inj	Kovex 100mg				5	5	6						**16**	0	361 AWB not attached			0		0	0	**0**	**16**
2ml Vial	167	Amikacin sulfate	250mg	Inj	Kovex 250mg				5	5	6						**16**	0	361 AWB not attached			0		5	0	**5**	**21**
2ml Vial	168	Amikacin sulfate	500mg	Tab	Kovex 500mg				5	5	6						**16**	0	361 AWB not attached			0		5	0	**5**	**21**
30 ml	189	Azithromycin	30ml	Susp	Zolecta susp. 30ml				5	5	6						**16**	0	5	5		0		Not attached	0	**10**	**26**
1's	190	Azithromycin	Not mentioned	Inj	Zolecta injection				5	5	6						**16**	0	5	5		0		Not attached	0	**10**	**26**
1's	207	Cefoperazone + Sulbactam	1g	Inj	Sulbaxone 1g				5	5	6						**16**	0	5	5	5	0	2	5	0	**22**	**38**
1's	208	Cefoperazone + Sulbactam	2g	Inj	Sulbaxone 2g				5	5	6						**16**	0	5	5	5	0	2	5	0	**22**	**38**
1's	211	Cefotaxime Sodium	1gm	Inj	Fastimax Inj.				5	5	6						**16**	0	5	5		0	2	5	0	**17**	**33**
10's	212	Cefpodoxime proxetil	100mg	Tab	Cefprox tab				5	5	6						**16**	0	339 AWB not attached			0	415- not attached	5	0	**5**	**21**
50 ml	213	Cefpodoxime proxetil	40mg	Susp	Cefprox susp.40mg 50ml				5	5	6						**16**	0	339 AWB not attached			0		5	0	**5**	**21**
1's	218	Ceftriaxone	1gm	Inj	Cefast Inj1g				5	5	6						**16**	0	200 GD and COA are not matching	200 GD and COA are not matching		0	2	5	0	**7**	**23**
10's	268	Linezolid	600mg	Tab	Nezkil tab				5	5	6						**16**	0	5	5		0		5	0	**15**	**31**
60 ml	269	Linezolid	100mg/5ml	Susp	Nezkil susp. 100mg/5ml				5	5	6						**16**	0	5	5		0		Not attached	0	**10**	**26**
1's	270	Linezolid	600mg	inf	Cazid 600mg inf				5	5	6						**16**	0	5	5		0		Not attached	0	**10**	**26**
100 ml Vial	270	Linezolid	200mg	inf	Nezkil infusion 200mg				5	5	6						**16**	0	5	5		0		Not attached	0	**10**	**26**
1's	271	Linezolid	200mg	inf	Cazid 200mg inf				5	5	6						**16**	0	5	5		0		Not attached	0	**10**	**26**
300 ml Vial	271	Linezolid	600mg	inf	Nezkil infusion 600mg				5	5	6						**16**	0	5	5		0		Not attached	0	**10**	**26**
1's	272	Meropenem	500mg	Inj	Merocon 500mg				5	5	6						**16**	0	5	5		0		5	**1**	**16**	**32**
1's	273	Meropenem	1gm	Inj	Merocon 1g 1's				5	5	6						**16**	0	5	5		0			**1**	**11**	**27**
5's	275	Moxifloxacin	400mg	Tab	Moxibact tab				5	5	6						**16**	0	331 AWB not attached			0		5	0	**5**	**21**
1's	295	Vancomycin	500mg	Inj	Maparix 500mg Inj 1's				5	5	6						**16**	0	5	5	5	0		5	0	**20**	**36**
1's	296	Vancomycin	1gm	Inj	Maparix 1g Inj 1's				5	5	6						**16**	0	5	5	5	0		5	0	**20**	**36**
1's	321	Acyclovir	250mg	Inj	Herpex 250 Inj 1's				5	5	6						**16**	0	5	5		0		5	0	**15**	**31**
1's	322	Acyclovir	500mg	Inj	Herpex 500mg Inj 1's				5	5	6						**16**	0	5	5		0	415- not attached	5	0	**15**	**31**
1's	516	Omeprazole	40mg	Inj	Vify 40mg Inj 1's				5	5	6						**16**	0	5	5		0		5	0	**15**	**31**
14's	517	Omeprazole	40mg	Cap	Vify 40mg Cap 14's				5	5	6						**16**	0	5	5		0			0	**10**	**26**
14's	521	Pantoprazole	20mg	Tab	Panizox tab. 20mg				5	5	6						**16**	0	312 DRAP Reg NA			0		5	0	**5**	**21**
25's	537	Dexamethasone	4mg/5ml	Inj	Dexamethasone				5	5	6						**16**	0	270 DRAP Reg not attatched			0		5	0	**5**	**21**
1's	688	Ibandronate	1mg/ml	Inj	Bionic inj				5	5	6						**16**	0	300 DRAP reg NA			0		0	0	**0**	**16**
1's	689	Ibandronate	150mg	Tab	Bionic tabs				5	5	6						**16**	0	300 DRAP reg NA			0		0	0	**0**	**16**
30's	903	Alfacalcidol (α-3mcg tablets)	2.5mcg	Tab	Bone-lift				5	5	6						**16**	0	309 GD COA NA			0		5	0	**5**	**21**
30's	912	Essen mineral complex + vitamin d	830mg	Tab	Bonmin tab 830mg				5	5	6						**16**	0	370 AWB Not attached			0		0	0	**0**	**16**
120 ml	912	Essen mineral complex + vitamin d	120ml	Susp	Bonmin Susp. 120ml				5	5	6						**16**	0	370 AWB Not attached			0		0	0	**0**	**16**
5's	914	Cholecalciferol	20000IU	Inj	Care D3				5	5	6						**16**	0	5	5		0		5	0	**15**	**31**
10's	1522	Granisetron	1mg	Tab	Grasiron tab				5	5	6						**16**	0	350 AWB Not attached			0		0	0	**0**	**16**
5's	1523	Granisetron	1mg/ml	Inj	Grasiron inj				5	5	6						**16**	0	350 AWB Not attached			0		0	0	**0**	**16**
30's	1541	Leflunomide 20mg	20mg	Tab	Cara 20mg tab				5	5	6						**16**	0	298 GD COA NA			0		0	0	**0**	**16**

Page	Remarks
11	**Mandatory Bid form -1 is not according the advertised BSDs**
33	**Mandatory Professional tax certificate is expire on 30-06-25**
56	**Online verification link for ISOs not attached**

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm	S.N.B Pharmaceuticals Pvt. Ltd

S. No.		Product General Information				Technical Evaluation Matrix																					
						Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in Schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or**	Availabilty of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to Import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan.		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**5**	**3**	**4**	**5**	**5**	**37**	**70**
	302	Artemether + Lumefantrine	15mg+90mg/5 ml	Dry Powder Suspension	SN Lumart	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid	The firm was inspected by the inspection team as per technical evaluation criteria, and the following observations were made; Poor Adherence to cGMP: 1. HVAC system was non- functional in the production area at the time of inspection. 2. Integrity testing of HEPA filters in different sections were not carried out as per the cGMP requirement. 3. In in-process quarantine the materials placed were not labelled. 4. Hygrometer, weighing balance and thermometers were not calibrated. 5. No maghnehic pressure was maintained throughout the production area to avoid contamination and cross contamination. Poor Good Laboratory Practices (GLP) 6. Quoted products were found in stability chambers but record of stability was not maintained. 7. No SOP and mechanism was available for stability of the Products. **In view of the above the firm is NOT RECOMMENDED.**					**12**	0	5	5		0	4	**5**		**19**	**31**
	192	Azithromycin	200mg/5ml	Dry Powder Suspension	SN ZOR	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid						**12**	0	5	5		0	4	**5**		**19**	**31**
	237	Clarithromycin	125mg/5ml	Dry Powder Suspension	SN Clar	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid						**12**	0	5	5		0	4	**5**		**19**	**31**
	189	Azithromycin	250mg	Capsule	SN ZOR	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid						**12**	0	5	5		0	4	**5**		**19**	**31**
	190	Azithromycin	500mg	Capsule	SN ZOR	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid						**12**	0	5	5		0	4	**5**		**19**	**31**
	234	Clarithromycin	250mg	Tablet	SN Clar	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid						**12**	0	5	5		0	4	**5**		**19**	**31**
	300	Artemether + Lumefantrine	40mg +240mg	Tablet	SN Lumart	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid						**12**	0	5	5		0	4	**5**		**19**	**31**
	301	Artemether + Lumefantrine	80mg +450mg	Tablet	SN Lumart	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid						**12**	0	5	5		0	4	**5**		**19**	**31**
	205	Cefixime Trihydrate	100mg/5ml	Dry Powder Suspension	SN Xime	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid						**12**	0	5	5	No API source accreditation certificate attached	0	4	**5**	NO IMS/IQVIA related data is provided in the bid	**19**	**31**
	228	Cephradine Monohydrate	125mg/5ml	Dry Powder Suspension	SN SEF	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid						**12**	0	5	5		0	4	**5**		**19**	**31**
	229	Cephradine Monohydrate	250mg/5ml	Dry Powder Suspension	SN SEF	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid						**12**	0	5	5		0	4	**5**		**19**	**31**
	204	Cefixime	400mg	Capsule	SN XIME	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid						**12**	0	5	5		0	4	**5**		**19**	**31**
	224	Cephradine	250mg	Capsule	SN SEF	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid						**12**	0	5	5		0	4	**5**		**19**	**31**
	225	Cephradine	500mg	Capsule	SN SEF	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid						**12**	0	5	5		0	4	**5**		**19**	**31**
	68	Tizanidine	4mg	Tablet	SN Skelax	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid						**12**	0	5	5		0	4	**5**		**19**	**31**
	230	Ciprofloxacin HCL	250mg	Tablet	SN CIP	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid						**12**	0	5	5		0	4	**5**		**19**	**31**
	231	Ciprofloxacin HCL	500mg	Tablet	SN CIP	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid						**12**	0	5	5		0	4	**5**		**19**	**31**

	504	Domperidone	5mg/5ml	SUSP	SN DOMP	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid		**12**	0	5	5		0	4	**5**		**19**	**31**
	60	Paracetamol	120mg/5ml	SUSP	SN DOL	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid		**12**	0	5	5		0	4	**5**		**19**	**31**
	60	Paracetamol	120mg/5ml	SUSP	SN DOL	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid		**12**	0	5	5		0	4	**5**		**19**	**31**
	809	Ketotifen (as Fumarate)	1mg/5ml	SYRUP	Kettin	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid		**12**	0	GD coupled with AWB/BL is not attached in the original bid	0		0	4	**5**		**9**	**21**
	725	Escitalopram	10mg	Tablet	SN CIT	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid		**12**	0	5	5		0	4	**5**		**19**	**31**
	503	Domperidone	10mg	Tablet	SN DOMP	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid		**12**	0	5	5		0	4	**5**		**19**	**31**
	264	Levofloxacin Hemihydrate	250mg	Tablet	MyLevo	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid		**12**	0	GD attached at page No. 471 is older than 24 months	0		0	4	**5**		**9**	**21**
	264	Levofloxacin Hemihydrate	500mg	Tablet	MyLevo	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid		**12**	0	GD attached at page No. 471 is older than 24 months	0		0	4	**5**		**9**	**21**
	507	Famotidine	40mg	Tablet	Zainotidine	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid		**12**	0	GD attached at page No. 513 is older than 24 months	0		0	4	**5**		**9**	**21**
	697	Tamsulosin Hydrochloride	0.4mg	Capsule	SN ALPHA	**2**	**2**	**3**	Not provided in the bid	**5**	Not provided in the bid		**12**	0	5	No COA is attached for the quoted item		0	PIC of the quoted item is not provided in the bid Nor Invoice of the immediate container is attached	No stability study related data is provided in the bid		**5**	**17**

				Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27														
Name of the firm				Sadiqain Health Care, Islamabad														
				Technical Evaluation Matrix														
				Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
				Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
				Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevent certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of Item	Strength	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
Inter surgical Uk	921	Bacterial filter,HME Filter and Viral filter (HCV, HBS+HIV etc.)	Inter-Guard breathing filter	3	5	545-Link attached instead of certificate	5	6	6	**25**	5	Not attached	593- Tender approvals are incomplete	477-Verification link not provided	2	16	**23**	**48**
Inter surgical Lithuania	922	Bain Circuit Adult	anti-microbial Mapleson D	3	5		5	6	6	**25**	5	5			2	16	**28**	**53**
Inter surgical UK	923	Bain Circuit Peads	Mapleson F Jackson Rees	3	5		5	6	6	**25**	5	5			2	16	**28**	**53**
Inter surgical UK	1046	Disposable sterile catheter mount	Flexible fixed elbow catheter mount	3	5		5	6	6	**25**	5	5			2	16	**28**	**53**
Inter surgical Lithuania	1124	Laryngeal Mask	Solus, laryngeal mask airway	3	5		5	6	6	**25**	5	5			2	16	**28**	**53**
Inter surgical UK	1135	Nasal Oxygen Cannula (Neonatal)	nasal cannula curved prong	3	5		5	6	6	**25**	5	5			2	16	**28**	**53**

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: Saffron Pharmaceuticals Faisalabad

S. No.	MCC formulary No.	Product General Information				Technical Evaluation Matrix: Factory Technical Evaluation Parameters — Documents Based Factory Score			Factory Evaluation Visit Score								Total Factory Evaluated Score	Product Evaluation Parameters — Product Technical Parameters								Total Product Evaluated Score	Total Technical Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e, FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert's at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of investor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non-provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP Class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to	Stability studies of quoted Item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	5	5	5	37	70
1x5.x	1	40	Diclofenac Sodium (IM/IV for	25 mg/ml	Inj.	Sofac	2	2	3		5	6	2	2	2	2	2	28	0	5	5	0	0	4	0	14	42
2x10s	2	41	Diclofenac Sodium enteric	50 mg	Tab.	Sofac	2	2	3		5	6	2	2	2	2	2	28	0	5	5	0	0	4	0	14	42
1x10.x	3	66	Paracetamol+Tramadol	325mg/37.5 mg	Tab.	Tofon-P	2	2	3		5	6	2	3	2	2	2	28	0	1212 Older than 2 years		0	0	0	5	5	33
2x10s	4	153	Cetirizine	10 mg	Tab.	Cetriz	2	2	3		5	6	2	5	2	2	2	28	0	5	5	5	0	4	5	19	47
2x10s	5	158	Levocetrizine	5 mg	Tab.	Xyncet	2	2	3		5	6	2	2	2	2	2	28	0	5	5	0	0	0	5	15	43
1x14s	6	160	Montelukast	10 mg	Tab.	Solkast	2	2	3		5	6	2	2	2	2	2	28	0	0	0	0	0	0	0	0	28
1.x	7	166	Amikacin Sulphate	100mg	Inj.	Sefkin	2	2	3		5	6	2	2	2	2	2	28	0	5	5	5	0	4	5	24	52
1.x	8	167	Amikacin Sulphate	250mg	Inj.	Sefkin	2	2	3		5	6	2	5	2	2	2	28	0	5	5	5	0	4	5	24	52
1.x	9	168	Amikacin Sulphate	500mg	Inj.	Sefkin	2	2	3		5	6	2	2	2	2	2	28	0	5	5	5	0	4	5	24	52
1x6s	10	189	Azithromycin	250 mg	Tab. / Cap.	Azomk	2	2	3		5	6	2	2	2	2	2	28	0	5	5	5	0	4	5	24	52
1x6s	11	190	Azithromycin	500 mg	Tab. / Cap.	Azomk	2	2	3		5	6	2	3	2	2	2	28	0	5	5	5	0	4	5	24	52
15ml	12	192	Azithromycin	200 mg/5ml	Dry Susp.	Azomk	2	2	3		5	6	2	2	2	2	2	28	0	5	5	5	0	0	5	20	48
1x	13	204	Cefixime	400 mg	Cap.	Godacef	2	2	3		5	6	2	3	2	2	2	28	0	5	5	5	0	4	5	24	52
30ml	14	205	Cefixime	100 mg/5ml	Dry Susp.	Godacef	2	2	3		5	6	2	2	2	2	2	28	0	378 Older than 2 years		0	0	0	5	5	33
30ml	15	206	Cefixime	200 mg/5ml	Dry Susp.	Godacef	2	2	3		5	6	2	3	2	2	2	28	0	378 Older than 2 years		0	0	0	5	5	33
1.x	16	207	Cefoperazone + Sulbactam	1gm/Vial	Inj.	Safo	2	2	3		5	6	2	3	2	2	2	28	0	5	5	0	0	0	5	15	43
1.x	17	208	Cefoperazone + Sulbactam	2 gm/Vial	Inj.	Safo	2	2	3		5	6	2	3	2	2	2	28	0	5	5	0	0	0	5	15	43
1.x	18	217	Ceftriaxone	500 mg/Vial	Inj.	Sunnet	2	2	3		5	6	2	3	2	2	2	28	0	5	5	0	0	0	5	15	43
1.x	19	218	Ceftriaxone	1gm/Vial	Inj.	Sunnet	2	2	3		5	6	2	3	2	2	2	28	0	5	5	0	0	0	5	15	43
1.x	20	219	Ceftriaxone	2 gm Vial	Inj.	Sunnet	2	2	3		5	6	2	3	2	2	2	28	0	5	5	0	0	0	5	15	43
10s	21	230	Ciprofloxacin	250 mg	Tab.	Lucid	2	2	3		5	6	2	2	2	2	2	28	0	Not attached	0	0	0	0	Not attached	0	28
10s	22	231	Ciprofloxacin	500 mg	Tab.	Lucid	2	2	3		5	6	2	2	2	2	2	28	0	Not attached	0	0	0	0	Not attached	0	28
10s	23	264	Levofloxacin	250 mg	Tab.	Locus	2	2	3		5	6	2	2	2	2	2	28	0	Not attached	0	0	0	0	Not attached	0	28
10s	24	265	Levofloxacin	500 mg	Tab.	Locus	2	2	3		5	6	2	2	2	2	2	28	0	Not attached	0	0	0	0	Not attached	0	28
5.x	25	275	Moxifloxacin	400 mg	Tab.	Maxvid	2	2	3		5	6	2	2	2	2	2	28	0	Not attached	0	0	0	0	Not attached	0	28
3x10s	26	371	Iron Hydroxide poly maltose	100 mg	Tab.	Xyfar F	2	2	3		5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	10	38
2x10.x	27	377	Mecobalamin	500mcg	Tab.	Bionil	2	2	3		5	6	2	2	2	2	2	28	0	6/12 AWB not matching		0	0	5	0	5	33
2x10.x	28	401	Amlodipine Besylate	5 mg	Tab.	Hypezin	2	2	3		5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	15	43
2x10s	29	402	Amlodipine Besylate	10 mg	Tab.	Hypezin	2	2	3		5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	15	43
1x14s	30	403	Amlodipine + Valsartan	5mg+80 mg	Tab.	Presto	2	2	3		5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	15	43
1x14s	31	404	Amlodipine + Valsartan	5mg+160 mg	Tab.	Presto	2	2	3		5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	15	43
1x14s	32	985	Amlodipine + Valsartan	10 mg+160mg	Tab.	Presto	2	2	3		5	6	2	2	2	2	2	28	0	5	5	0	0	5	0	15	43
2x14s	33	409	Bisoprolol	2.5mg	Tab.	Safcor	2	2	3		5	6	2	2	2	2	2	28	0	5	5	0	0	0	Not attached	10	38
1x14s	34	410	Bisoprolol	5 mg	Tab.	Safcor	2	2	3	Not attached	5	6	2	2	2	2	2	28	0	5	5	0	0	0	Not attached	10	38
1x14s	35	411	Bisoprolol	10 mg	Tab.	Safcor	2	2	3		5	6	2	2	2	2	2	28	0	5	5	0	0	0	Not attached	10	38
10s	36	421	Clopidogrel	75 mg	Tab.	Plagrel	2	2	3		5	6	2	2	2	2	2	28	0	Not attached	0	0	0	0	Not attached	0	28
2x10s	37	450	Losartan + Hydrochlorothiazide	50 mg+12.5mg	Tab.	Sar K Plus	2	2	3		5	6	2	2	2	2	2	28	0	Not attached	0	0	0	0	Not attached	0	28
2x10s	38	452	Losartan Potassium	50 mg	Tab.	Sar K	2	2	3		5	6	2	2	2	2	2	28	0	Not attached	0	0	0	0	Not attached	0	28
1x10s	39	471	Rosuvastatin	10 mg	Tab.	Rostor	2	2	3		5	6	2	2	2	2	2	28	0	Not attached	0	0	0	0	5	5	33
15ml	40	491	Fluticasone	50 mcg/ Actu.	Nasal Spray	Flexivate	2	2	3		5	6	2	2	2	2	2	28	0	Not attached	0	0	0	0	5	5	33
1x10s	41	507	Famotidine	40 mg	Tab.	Apsin	2	2	3		5	6	2	2	2	2	2	28	0	5	5	0	0	0	5	15	43
14s	42	518	Esomeprazole	40mg	Cap.	Ecofil	2	2	3		5	6	2	2	2	2	2	28	0	0	0	0	0	0	Not attached	0	28
2x10.x	43	539	Hydroquinetzone	10mg	Tab.	Hytron	2	2	3		5	6	2	2	2	2	2	28	0	0	0	0	0	0	Not attached	0	28
2x10.x	44	549	Glimepiride	1mg	Tab.	Safgo	2	2	3		5	6	2	2	2	2	2	28	0	5	5	0	0	0	Not attached	10	38
2x10	45	550	Glimepiride	2mg	Tab.	Safgo	2	2	3		5	6	2	2	2	2	2	28	0	5	5	0	0	0	5	15	43
2x10	46	551	Glimepiride	3mg	Tab.	Safgo	2	2	3		5	6	2	3	2	2	2	28	0	5	5	0	0	0	Not attached	10	38
2x10	47	552	Glimepiride	4mg	Tab.	Safgo	2	2	3		5	6	2	3	2	2	2	28	0	5	5	0	0	0	5	15	43
3x10.x	48	553	Glimepiride + Metformin	1 mg/500mg	Tab.	Safgo Met	2	2	3		5	6	2	2	2	2	2	28	0	5	5	0	0	0	5	15	43
3x10.x	49	554	Glimepiride + Metformin	2 mg/500mg	Tab.	Safgo Met	2	2	3		5	6	2	2	2	2	2	28	0	5	5	0	0	0	5	15	43
1x10.x	50	572	Misoprostol	200 mcg	Tab.	Cytotol	2	2	3		5	6	2	2	2	2	2	28	0	5	5	0	0	0	5	15	43
2x7.x	51	581	Sitagliptin + Metformin	50 mg/500 mg	Tab.	Alosita Met	2	2	3		5	6	2	2	2	2	2	28	0	5	5	0	0	0	5	15	43
2x7.x	52	582	Sitagliptin + Metformin	50mg /1000	Tab.	Alosita Met	2	2	3		5	6	2	2	2	2	2	28	0	5	5	0	0	0	5	15	43
	53	754	Pregabalin	75mg	Cap.	Higuh	2x7.x	2	3		5	6	2	2	2	2	2	26	0	696 OD is expired		0	0	0	4	4	30
2x10.x	54	801	Doxofylline	400mg	Tab/Cap.	Doxolin	1x10	2	3		5	6	2	2	2	2	2	26	0	0	0	0	0	0	Not attached	4	30
	55	802	Doxofylline	100mg/5ml	Syp.	Doxolin	60ml	2	3		5	6	2	2	2	2	2	26	0	0	0	0	0	0	Not attached	0	26
	56	856	Betamethasone dipropionate	0.05%	Oint.	Provate	20 gm	2	3		5	6	2	2	2	2	2	26	0	5	5	607 Expired	0	0	0	5	15	41
	57	857	Betamethasone dipropionate	0.05%	Cream	Provate	20 gm	2	3		5	6	2	2	2	2	2	26	0	5	5	607 Expired	0	4	5	19	45
	58	858	Betamethasone dipropionate	0.05%	Lot.	Provate	20 ml	2	3		5	6	2	3	2	2	2	26	0	5	5	607 Expired	0	4	5	19	45
	59	860	Betamethasone Dipropionate	0.05 % + 0.1%	Cream	Provate G	15 gm	2	3		5	6	2	3	2	2	2	26	0	658.0TM2N GD expired	0	607 Expired	0	4	5	9	35
	60	861	Betamethasone Dipropionate	0.05 % +0.1 %	Oint.	Provate G	15gm	2	3		5	6	2	2	2	2	2	26	0	658 OTM2N GD expired	0	607 Expired	0	4	5	9	35
	61	870	Fusidic acid	2%	Cream	Fucort	15gm	2	3		5	6	2	2	2	2	2	26	0	0	0	5	0	4	5	24	50
	62	871	Fusidic acid	2%	Oint.	Fucort	15gm	2	3		5	6	2	2	2	2	2	26	0	0	0	5	0	4	5	24	50
	63	894	Terbinafine	1%	Cream	Enfuid	10gm	2	3		5	6	2	2	2	2	2	26	0	0	0	5	0	4	5	24	50
	64	895	Terbinafine		Lot.	Enfuid	20ml	2	3		5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	15	41
	65	914	Cholecalciferol (Vitamin D3)	2000000 IU	IM/ Oral Inj.	Dyslet 3	1ml	2	3		5	6	2	2	2	2	2	26	0	5	5	0	0	0	5	15	41
												2	2	2	2	2	10	0								

Original Mandatory forms in Hard are not submitted to the MCC

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: SAMI PHARMACEUTICALS KARACHI

S. No.		Product General Information				Technical Evaluation Matrix																					
						Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 13001/14501 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, regs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLAs country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalificatoon and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. Copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the 1ype / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate crentainer of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product) 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**5**	**3**	**4**	**5**	**5**	**37**	**70**
	36	Aceclofenac	100mg	Tab	ALKERIS	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**0**	**5**	**5**	**1045- FDA registration link provided only**		**4**	**5**	**2**	**21**	**54**
	85	Filgrastim	300mcg	Inj	NEOFIL	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**0**	**5**	**5**	**0**		**4**	**5**	**1**	**20**	**53**
	148	Betahistine	8mg	Tab	ENIER	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**0**	**5**	**5**	**0**		**4**	**5**	**2**	**21**	**54**
	149	Betahistine	16mg	Tab	ENIER	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**0**	**5**	**5**	**0**		**4**	**5**	**2**	**21**	**54**
	162	Amikacin	25mg	Inj	GRASIL	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**0**	**5**	**5**	**0**		**4**	**5**	**5**	**24**	**57**
	163	Amikacin	50mg	Inj	GRASIL	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**0**	**5**	**5**	**0**		**4**	**5**	**5**	**24**	**57**
	292	Rifaximin	550mg	Tab	NIXAF	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**0**	**5**	**5**	**0**		**4**	**5**	**1**	**20**	**53**
	384	Rivaroxaban	10mg	Tab	RITBAN	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**0**	**5**	**5**	**0**		**4**	**5**	**1**	**20**	**53**
	385	Rivaroxaban	15mg	Tab	RITBAN	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**0**	**5**	**5**	**0**		**4**	**5**	**1**	**20**	**53**
	386	Rivaroxaban	20mg	Tab	RITBAN	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**0**	**5**	**5**	**0**		**4**	**5**	**1**	**20**	**53**
	408	Bisoprolol	2.5mg	Tab	ACTIM	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**0**	**5**	**5**	**5**		**4**	**5**	**1**	**25**	**58**
	409	Bisoprolol	5mg	Tab	ACTIM	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**0**	**5**	**5**	**5**		**4**	**5**	**1**	**25**	**58**
	410	Bisoprolol	10mg	Tab	ACTIM	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**0**	**5**	**5**	**5**		**4**	**5**	**1**	**25**	**58**
	555	Human Insulin	70/30 100 IU/1ml	Inj	SAMULIN	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**0**	**5**	**5**	**5**		**4**	**5**	**0**	**24**	**57**
	789	Doxofylline	400mg	Tab	FYLOD	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**0**	**5**	**5**	**0**		**4**	**5**	**2**	**21**	**54**

EDQM CERTIFICATE DOES NOT FULL FILL CRITERIA FOR THE AWARD OF MARKS 1046 PAGE

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm SANTE KARACHI

S. No.		Product General Information				Technical Evaluation Matrix																					
						Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/EQVIA ranking of the leading manufacturer firm (by value) in Pakistan **12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/EQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC experts). **Non-adherence to GSP shall lead to disqualifications of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in assessment of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC experts at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal /manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **32 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non-provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/EQVIA/ Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/EQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note, Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**5**	**3**	**4**	**5**	**5**	**37**	**70**
	850	Timolol maleate 0.5%	0.50%	Eye Drop	Betalol Solution	**2**	**2**	**3**	3	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**31**	0	246- GD IS EXPIRED	0	0	0	4	5	0	**9**	**40**
	839	Moxifloxacin (Hydrochlorde 5.0mg)	5mg	Eye Drop	Megamox Ophthalmic Solution	**2**	**2**	**3**	3	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**31**	0	5	5	0	0	4	5	1	**20**	**51**
	826	Chloramphenicol 0.5%	0.50%	Eye Drop	Santochlor Solution	**2**	**2**	**3**	3	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**31**	0	5	5	0	0	4	5	0	**19**	**50**
	852	Tobramycin 0.3%, Dexamethasone 0.1%	0.3% + 0.1%	Eye Drop	Santodex Sterile Ophthalmic Suspension	**2**	**2**	**3**	3	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**31**	0	5	5	0	0	4	5	1	**20**	**51**
	855	Acyclovir 3%	3%	Oint.	Santovir Ointment	**2**	**2**	**3**	3	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**31**	0	5	5	0	0	4	5	1	**20**	**51**
	821	HPMC 0.3% Dextran 0.1%	0.3% + 0.1%	Eye Drop	Tears Forte Ophthalmic Solution	**2**	**2**	**3**	3	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**31**	0	5	5	0	0	4	5	1	**20**	**51**
	824	Brinzolamide 1% w/v Brimonidine	1.00%	Eye Drop	Zolabrin Ophthalmic	**2**	**2**	**3**	3	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**31**	0	5	5	0	0	4	5	1	**20**	**51**
	68	Tizanidine as Hydrochloride.. 4mg	4mg	Tab.	Zantid Tablets 4mg	**2**	**2**	**3**	3	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**31**	0	5	5	0	0	4	5	0	**19**	**50**
	870	Fusidic Acid 2%	2%	Cream	Fusac Cream	**2**	**2**	**3**	3	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**31**	0	5	5	0	0	COA not attached-page 848	5	0	**15**	**46**
	894	Terbinafine Hcl 1%	1%	Cream	Terbisan Cream	**2**	**2**	**3**	3	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**31**	0	5	5	0	0	4	5	1	**20**	**51**
	147	Terbinafine HCl 250mg	250mg	Tab.	Terbisan Forte Tablets 250mg	**2**	**2**	**3**	3	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**31**	0	5	5	0	0	4	5	1	**20**	**51**

						Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27															
					Name of the firm	**Saru International Medical Devices Karachi**														
S. No.		**Product General Parameter**				**Technical Evaluation Matrix**													**Product Evaluated Score**	**Total Technical Score**
						Principal's and Importer's Evaluation Parameters							**Product Technical Evaluation**							
						Principal Manufacturer Evaluation			**Importer's Evaluation**			**Suppliers Technical Score**								
	MCC formulary No.	**1**	**2**	**3**	**4**	**5**	**6**	**7**	**8**	**9**	**10**	**11**	**12**	**13**	**14**	**15**	**16**	**17**	18	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the time of inspection at the warehouse at the tim eof inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** **(Certificate duly attaested by senior executive of the firm)**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note, Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US free sale certificate of the quoted products, **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **Online verification link shall be provided.** **(copies of relevant certificates duly attested by the senior executive of the firm)**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	5	6	**29**	5	5	5	6	10	10	**41**	**70**
Yucel Medikal ve Tekstil Urunleri San. Tic. Ltd. Sti.	917	Absorbable Haemostatic Gelatine Sponges	80x50x10mm	CLINISPONGE (Absorbable Haemostatic Gelatin Sponge)		0	5	141-143 Link attached instead of certificate	5	5	6	**21**	**55-105 AWB and COA are not attached**		Not attached	2	10	10	**22**	**43**
Jiangxi 3L Medical Group Co, Ltd, China	919	Adhesive Tapes (Paper)	1" x 5yards	3L Surgical Tape (Microporous , Paper) Surgical Tape		0	5		5	5	6	**21**				2	10	10	**22**	**43**
Jiangxi 3L Medical Group Co, Ltd, China	920	Adhesive Tapes (Paper)	2" x 5yards	3L Surgical Tape (Microporous , Paper) Surgical Tape		0	5		5	5	6	**21**				2	10	10	**22**	**43**
Jiangxi 3L Medical Group Co, Ltd, China	923	Adhesive Tapes (Plastic)	1" x 10yards	3L Transparent Surgical Tape (PE)		0	5		5	5	6	**21**				2	10	10	**22**	**43**
Jiangxi 3L Medical Group Co, Ltd, China	925	Adhesive Tapes (Plastic)	3" x 10yards	3L Transparent Surgical Tape (PE)		0	5		5	5	6	**21**				2	10	10	**22**	**43**

Bidding firm name not mentioned on the mandatory CDR

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27															
Name of the firm						Saru International Karachi (NDI) FY 2026-27															
						Technical Evaluation Matrix															
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation							Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevent certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
Euromed for Medical Industries (S.A.E) Egypt	995	Disposable Endotracheal Tube without Cuff	2.5 mm	Euro Tracheal Tube without Cuff		0	5	Not attached	5	6	6	**22**	**55-105 AWB and COA are not attached with GDs**		Tender approvals are not incomplete	0	2	16	**18**	**40**

						Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27														
					Name of the firm	**Sehat Medical Devices (Importer) Lahore**														
S. No.		**Product General Parameter**				**Technical Evaluation Matrix**													**Product Evaluated Score**	**Total Technical Score**
						Principal's and Importer's Evaluation Parameters							**Product Technical Evaluation**							
						Principal Manufacturer Evaluation			**Importer's Evaluation**			**Suppliers Technical Score**								
	MCC formulary No.	**1**	**2**	**3**	**4**	**5**	**6**	**7**	**8**	**9**	**10**	**11**	**12**	**13**	**14**	**15**	**16**	**17**	18	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the time of inspection at the warehouse at the tim eof inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals-01 mark 04 Tender approvals-02 marks 06 Tender approvals-03 marks 08 Tender approvals-04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US free sale certificate of the quoted products, **02 marks for each certification, up to a**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	5	6	**29**	5	5	5	6	10	10	**41**	**70**
Weihi Jierul Medical Products	**1129**	**I/V Cannula (Sterile having wings + injection port in sterilized blister packing**	Cannula / Brannula 22G			Not attached	5	384-510K summary attached instead of unit accreditation certificate	**Weihi Jierul Medical Products, China The firm did not produced their original documents (Original DRAP registration, Valid Original Agency Agreement, and Valid original embassy attested/apostilled COPP/GMP/Free sales certificates of the Principal Manufacturer regarding their quoted items to the inspection team at the time of inspection. Hence, the firm is NOT-RECOMMENDED for their imported quoted items.**				361 GD is from WEIHAI WEIGAO MEDICAL INTERNATIONAL CO., LTD. AWB is not attached	0	599- Tender approvals are either not attested or incomplete as per the adv. Criteria	0	Sample Not provided		**0**	**0**
Weihi Jierul Medical Products	**1131**	**I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing,**	Cannula / Brannula 22G				5							0		0	Sample Not provided		**0**	**0**
Weihi Jierul Medical Products	**1132**	**I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing,**	Cannula / Brannula 24G				5							0		0	Sample Not provided		**0**	**0**

M/s Weihai Jierui Medical Products Co. Ltd.

No. 6-1 Weigao West Road, Weihai, Torch High-Tech, Science Park 264210 Weihai, Shandong, China.

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposibles and Sutures for Government MCC 2026-27

Name of the firm Sehat Medical Devices Lahore

		Product General Information				Technical Evaluation Matrix															
						Factory Technical Evaluation Parameter									Product technical Evaluation Parameters						
						Documents Based Factory Score				Evaluation Visit Score				Factory Evaluated Score							Product Evaluated Score	Total Technical Score
S.No	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. **(as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.**	Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAP regulations. **(to be evaluated by the MCC expert/s at the time of inspection, Noncompliance to cGMP shall lead to disqualification of the relevant section or firm)**	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section / firm.**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the**	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications	Valid WHO prequalification and / or valid product registration in SRA/WLA country(ies) / and / or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. **02 marks for each**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	6	3	3	2	2	29	5	5	5	6	10	10	41	70
1	946	Blood Transfusion Set Standard	Bt Set	Bt Set	SMD	3	5	5	4	3	3	2	2	27	5	5		0	10	10	20	47
2	1119	I/V fluid administration set	IV Set B	IV Set B	SMD	3	5	5	4	3	3	2	2	27	5	5		0	10	10	20	47
3	1017	Disposable Auto Disable Syringe (Blister packing) sterile	2ml	2ml	SMD	3	5	5	4	3	3	2	2	27	5	5		0	DTL Substandard	10	10	37
4	1022	Disposable Syringe Ordinary (Blister packing) sterile	1ml	1ml	SMD	3	5	5	4	3	3	2	2	27	5	5		0	DTL Substandard	10	10	37
5	1021	Disposable Insuline Syringes With Needle, Blister Pack, 30 / 31 G,	Insulin	Insulin	SMD	3	5	5	4	3	3	2	2	27	5	5	599 Tender approvals are either not attested or incomplete as per adv.criteria	0	10	10	20	47
6	1018	Disposable Syringes With Auto Lock, Blister Pack 3ML	3ml	3ml	SMD	3	5	5	4	3	3	2	2	27	5	5		0	10	10	20	47
7	1019	Disposable Syringes With Auto Lock, Blister Pack 5ML	5ml	5ml	SMD	3	5	5	4	3	3	2	2	27	5	5		0	10	10	20	47
8	1023	Disposable Syringes With Luer Lock, Blister Pack 10ML	10ml	10ml	SMD	3	5	5	4	3	3	2	2	27	5	5		0	10	10	20	47
9	1120	I/V fluid administration set with additional "Y" injection port	IV Set Eco	IV Set Eco	SMD	3	5	5	4	3	3	2	2	27	5	5		0	10	10	20	47
10	1024	Disposable Syringes With Luer Lock, Blister Pack 20ML	20ml	20ml	SMD	3	5	5	4	3	3	2	2	27	5	5		0	0	10	10	37

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm — **Seraph Pharmaceuticals Islamabad**

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters — Documents Based Factory Score						Factory Evaluation Visit Score					Total Factory Evaluated	Product Evaluation Parameters — Product Technical Parameters							Total Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availabilty of functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this colounm for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead | Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70
1	15	Dexmedetomidine	0.1mg/ml	Inj.	Dexmeda	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				5		**5**	**26**
2	35	Aceclofenac	100mg	Tab.	Aspic	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				5		**5**	**26**
3	37	Baclofen	10mg	Tab.	Liorex	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				5		**5**	**26**
4	47	Ketorolac	30mg/ml	Inj.	Cilokat	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				5		**5**	**26**
5	56	Nalbuphine	10mg	Inj.	Sernaib	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				Not provided in the bid		**0**	**21**
6	57	Nalbuphine	20mg	Inj.	Sernaib	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				Not provided in the bid		**0**	**21**
7	66	Paracetamol Tramadol	325mg/37.5mg	Tab.	Ovodol	**2**	**2**	**3**	0	Major analytical and qualitative equipments needed for API, in process and Finished goods and their calibration certificates are not provided in the bid	**4**	**2**	**2**	**2**	**2**	**2**	**21**	No Bioavailability/ Bioequivalence study related data has been submitted in the bid	GDs attached are not readable,	0	No API source accreditation has been attached	No Valid WHO prequalification or valid product registration is provided in the bid	No proof of purchases, pictures of the Drap approved immediate container packaging has been provided in the bid	Stability data at page No. 1430 is for Ovodol Plus	No IMS/IQVIA data of the quoted products in pakistani market has been provided in the bid	**0**	**21**
8	27	Tramadol HCl	50mg/ml	Inj.	Ovodol	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				Stability data at page No. 1430 is for Ovodol Plus		**0**	**21**
9	147	Terbinafine	250mg	Tab.	Sebifin	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				5		**5**	**26**
10	150	Betahistine	8mg	Tab.	Tigo	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				5		**5**	**26**
11	151	Betahistine	16mg	Tab.	Tigo	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				5		**5**	**26**
12	158	Levocetirizine	5mg	Tab.	Levoser	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				5		**5**	**26**
13	160	Montelukast	10mg	Tab.	Zarang	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				5		**5**	**26**

14	161	Montelukast	5mg	Tab.	Zarang	2	2	3	0	Major analytical and qualitative equipments needed for API, in process and Finished goods and their calibration certificates are not provided in the bid	4	2	2	2	2	2	21	No Bioavailability/ Bioequivalence study related data has been submitted in the bid	GDs attached are not readable,	0	No API source accreditation has been attached	No Valid WHO prequalification or valid product registration is provided in the bid	No proof of purchases, pictures of the Drap approved immediate container packaging has been provided in the bid	5	No IMS/IQVIA data of the quoted products in pakistani market has been provided in the bid	5	26
15	189	Azithromycin	250mg	Tab./Cap.	Azikem	2	2	3	0		4	2	2	2	2	2	21			0				5		5	26
16	190	Azithromycin	500mg	Tab./Cap.	Azikem	2	2	3	0		4	2	2	2	2	2	21			0				5		5	26
17	202	Cefepime	500mg/vial	Inj.	Cerapime	2	2	3	0		4	2	2	2	2	2	21			0				5		5	26
18	203	Cefepime	1gm/vial	Inj.	Cerapime	2	2	3	0		4	2	2	2	2	2	21			0				Not provided in the bid		0	21
19	204	Cefixime	400mg	Cap.	Trispan	2	2	3	0		4	2	2	2	2	2	21			0				5		5	26
20	205	Cefixime	100mg/5ml	Dry Susp.	Trispan	2	2	3	0		4	2	2	2	2	2	21			0				5		5	26
21	206	Cefixime	200 mg/5ml	Dry Susp.	Trispan	2	2	3	0		4	2	2	2	2	2	21			0				5		5	26
22	207	Cefoperazone + Sulbactam	1gm/Vial	Inj.	Cefbac	2	2	3	0		4	2	2	2	2	2	21			0				5		5	26
23	208	Cefoperazone + Sulbactam	2 gm/Vial	Inj.	Cefbac	2	2	3	0		4	2	2	2	2	2	21			0				Not provided in the bid		0	21
24	213	Cefpodoxime	40 mg/5ml	Dry Susp.	Cefipod	2	2	3	0		4	2	2	2	2	2	21			0				5		5	26
25	215	Ceftazidime	500 mg/Vial	Inj.	Certum	2	2	3	0		4	2	2	2	2	2	21			0				Not provided in the bid		0	21
26	216	Ceftazidime	1gm/Vial	Inj.	Certum	2	2	3	0		4	2	2	2	2	2	21			0				Not provided in the bid		0	21
27	217	Ceftriaxone	500 mg/Vial	Inj.	Droncef	2	2	3	0		4	2	2	2	2	2	21			0				5		5	26
28	218	Ceftriaxone	1gm/Vial	Inj.	Droncef	2	2	3	0		4	2	2	2	2	2	21			0				5		5	26
29	219	Ceftriaxone	2 gm Vial	Inj.	Droncef	2	2	3	0		4	2	2	2	2	2	21			0				5		5	26
30	230	Ciprofloxacin	250mg	Tab.	Ciptec	2	2	3	0		4	2	2	2	2	2	21			0				5		5	26
31	231	Ciprofloxacin	500mg	Tab.	Ciptec	2	2	3	0		4	2	2	2	2	2	21			0				5		5	26
32	264	Levofloxacin	250mg	Tab.	Lexus	2	2	3	0		4	2	2	2	2	2	21			0				5		5	26

33	265	Levofloxacin	500mg	Tab.	Lexus	**2**	**2**	**3**	0	**4**	**2**	**2**	**2**	**2**	**2**	**21**		0			5	**5**	**26**
34	268	Linezolid	600mg	Tab.	Lizobact	**2**	**2**	**3**	0	**4**	**2**	**2**	**2**	**2**	**2**	**21**		0			Not provided in the bid	**0**	**21**
35	275	Moxifloxacin	400mg	Tab.	Moxer	**2**	**2**	**3**	0	**4**	**2**	**2**	**2**	**2**	**2**	**21**		0			5	**5**	**26**
36	375	Iron Sucrose	20mg/ml	Inj.	serose	**2**	**2**	**3**	0	**4**	**2**	**2**	**2**	**2**	**2**	**21**		0			5	**5**	**26**
37	403	Amlodipine + Valsartan	5mg + 80mg	Tab.	AmVal	**2**	**2**	**3**	0	**4**	**2**	**2**	**2**	**2**	**2**	**21**		0			5	**5**	**26**
38	404	Amlodipine + Valsartan	5mg + 160mg	Tab.	AmVal	**2**	**2**	**3**	0	**4**	**2**	**2**	**2**	**2**	**2**	**21**		0			5	**5**	**26**
39	405	Amlodipine + Valsartan	10mg + 160mg	Tab.	AmVal	**2**	**2**	**3**	0	**4**	**2**	**2**	**2**	**2**	**2**	**21**		0			5	**5**	**26**
40	471	Rosuvastatin	10mg	Tab.	Roscard	**2**	**2**	**3**	0	**4**	**2**	**2**	**2**	**2**	**2**	**21**		0			5	**5**	**26**
41	517	Omeprazole	40mg	Cap.	Meraz	**2**	**2**	**3**	0	**4**	**2**	**2**	**2**	**2**	**2**	**21**		0			5	**5**	**26**
42	518	Esomeprazole	40mg	Cap.	Empro	**2**	**2**	**3**	0	**4**	**2**	**2**	**2**	**2**	**2**	**21**		0			5	**5**	**26**
43	519	Ondansetron	8mg	Tab.	Onderaph	**2**	**2**	**3**	0	**4**	**2**	**2**	**2**	**2**	**2**	**21**		0			5	**5**	**26**
44	520	Ondansetron	2mg/ml	Inj.	Onderaph	**2**	**2**	**3**	0	**4**	**2**	**2**	**2**	**2**	**2**	**21**		0			5	**5**	**26**
45	522	Pantoprazole	40mg	Tab.	Camree	**2**	**2**	**3**	0	**4**	**2**	**2**	**2**	**2**	**2**	**21**		0			5	**5**	**26**
46	581	Sitagliptin + Metformin	50mg/500mg	Tab.	Xitaglip	**2**	**2**	**3**	0	**4**	**2**	**2**	**2**	**2**	**2**	**21**		0			5	**5**	**26**
47	582	Sitagliptin + Metformin	50mg/1000mg	Tab.	Xitaglip	**2**	**2**	**3**	0	**4**	**2**	**2**	**2**	**2**	**2**	**21**		0			5	**5**	**26**
48	586	Vildagliptin	50mg	Tab.	Veld	**2**	**2**	**3**	0	**4**	**2**	**2**	**2**	**2**	**2**	**21**		0			5	**5**	**26**
49	688	Ibandronic Acid	1mg/ml	Inj.	Ibelac	**2**	**2**	**3**	0	**4**	**2**	**2**	**2**	**2**	**2**	**21**		0			5	**5**	**26**
50	689	Ibandronic Acid	150mg	Tab.	Ibelac	**2**	**2**	**3**	0	**4**	**2**	**2**	**2**	**2**	**2**	**21**		0			5	**5**	**26**
51	719	Duloxetine	30mg	Cap.	Neuxil	**2**	**2**	**3**	0	**4**	**2**	**2**	**2**	**2**	**2**	**21**		0			Not provided in the bid	**0**	**21**

52	720	Duloxetine	60mg	Cap.	Neuxil	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				Not provided in the bid		**0**	**21**
53	725	Escitalopram	10mg	Tab.	S-ISO	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				5		**5**	**26**
54	733	Lamotrigine	50mg	Tab.	Lamoraf	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				5		**5**	**26**
55	735	Levetiracetam	250mg	Tab.	Cevisto	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				Not provided in the bid		**0**	**21**
56	736	Levetiracetam	500mg	Tab.	Cevisto	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				Not provided in the bid		**0**	**21**
57	737	Levetiracetam	100mg/ml	Inj.	Cevisto	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				Not provided in the bid		**0**	**21**
58	741	Mirtazapine	15mg	Tab.	Xiety	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				5		**5**	**26**
59	753	Pregabalin	50mg	Cap.	Preget	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				5		**5**	**26**
60	754	Pregabalin	75mg	Cap.	Preget	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				5		**5**	**26**
61	755	Pregabalin	150mg	Cap.	Preget	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				Not provided in the bid		**0**	**21**
62	760	Quetiapine	100mg	Tab.	Cequel	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				5		**5**	**26**
63	761	Risperidone	2mg	Tab.	Oris	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				5		**5**	**26**
64	762	Risperidone	4mg	Tab.	Oris	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				5		**5**	**26**
65	766	Topiramate	50mg	Tab.	Topival	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				5		**5**	**26**
66	878	Isotretinoin +	0.05% + 2% w/w	Gel	Emytrongel	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				Not provided in the bid		**0**	**21**
67	886	Permethrin	(blank)	Lot.	Pernit	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				5		**5**	**26**
68	894	Terbinafine	(blank)	1% Cream	Sebifin	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				5		**5**	**26**
69	1444	Anastrozole	1mg	Tab	Anbrez	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				Not provided in the bid		**0**	**21**
70	1546	Letrozole	2.5mg	Tab.	Selet	**2**	**2**	**3**	0		**4**	**2**	**2**	**2**	**2**	**2**	**21**			0				5		**5**	**26**

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27															
					Name of the firm	SHAAD TRADERS PESHAWAR															
						Technical Evaluation Matrix															
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail/link/DRAP clearance NOC between the principal**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Medical related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate.	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
Pleasure Latex Products Malaysia	485	Male Latex Condom		Condom	Mixfum	3	5	0	5	6	6	**25**	5	5	0	1	2	16	**29**	**54**
A1 Globe SDN BHD Malaysia	1058	Disposable Non-Sterile Nitrile Examination Gloves (Powder Free)	Small, Medium & Large	Gloves	Shaad Glove	0	5	0	5	6	6	**22**	5	5	0	0	2	16	**28**	**50**

Scrutiny Report

1US FDA of Pleasure Latex Malaysia at Page 100 onwards is for Ultrasonic imaging system- and not the quoted product

2Tender approvals are not as per the advertised criteria

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: SHAIGAN PHARMA RAWALPINDI

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks.	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection). Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from **In case of**	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered.	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
1	51	Meloxicam	15mg	Tab	**Mits 15mg Tablets**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	0	5	0	**20**	**45**
2	52	Meloxicam	7.5mg	Tab	**Mits 7.5mg Tablets**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	**24**	**49**
3	63	Paracetamol	1000 mg	Inf.	**Acetosol 1g/100ml Infusion**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	0	0	4	5	0	**19**	**44**
4	65	Paracetamol + Orphenadrine	450 mg/35 mg	Tab	**Acetofen Tablets**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	0	0	4	5	0	**19**	**44**
5	66	Paracetamol+Tramadol	325mg +37.5mg	Tab	**Co-Benz Tablets**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	0	0	4	5	0	**19**	**44**
6	141	Itraconazole	100mg	Cap	**Sporay Capsule**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	0	0	4	5	0	**19**	**44**
7	144	Miconazole	2%	Gel	**Micasept Oral Gel**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	0	0	0	5	0	**15**	**40**
8	147	Terbinafine	250mg	Tab	**Ternifer 250mg Tablet**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	0	0	0	0	4	5	0	**9**	**34**
9	167	Amikacin Sulphate	250MG	Inj	**Glykin-250 mg Injection**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	1	25	**50**
10	202	Cefepime	500mg/Vial	Inj	**Cepime-500mg Injection**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	24	**49**
11	203	Cefepime	1000mg/Vial	Inj	**Cepime-1000mg Injection**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	24	**49**
12	207	Cefoperazone + Sulbactam	1g/Vial	Inj	**Deezon Plus 1g Injection**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	0	5	0	20	**45**
13	208	Cefoperazone + Sulbactam	2g/Vial	Inj	**Deezon Plus 2g Injection**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	0	5	0	20	**45**
14	211	Cefotaxime Sodium	1000mg/Vial	Inj	**Cliver-1000 Injection**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	24	**49**
15	215	Ceftazidime	500mg/Vial	Inj	**Ceftiz-500 Injection**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	24	**49**
16	216	Ceftazidime	1000mg/Vial	Inj	**Ceftiz-1000 Injection**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	0	5	0	20	**45**
17	217	Ceftriaxone	500mg/Vial	Inj	**Celtis I.V-500 Injection**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	0	0	0	5	0	15	**40**
18	218	Ceftriaxone	1000mg/Vial	Inj	**Celtis I.V-1000 Injection**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	0	0	0	5	0	15	**40**
19	251	Doxycycline	100mg	Cap	**Doxycap Capsule**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	0	0	0	0	4	5	0	9	**34**
20	300	Artemether + Lumefantrine	40 mg/240mg	Tab	**Temprin DS Tablets**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	24	**49**

21	301	Artemether + Lumefantrine	80 mg/480mg	Tab	**Temprin Plus Tablets**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	0	5	0	20	**45**
22	375	Iron Sucrose	20MG/ML	Inj	**Irose Injection**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	24	**49**
23	391	Warfarin Sodium	1mg	Tab	**Warfin 1mg Tablets**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	5	29	**54**
24	392	Warfarin Sodium	2.5mg	Tab	**Warfin 2.5mg Tablets**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	5	29	**54**
25	393	Warfarin Sodium	5mg	Tab	**Warfin 5mg Tablets**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	5	29	**54**
26	403	Amlodipine + Valsartan	5mg+ 80mg	Tab	**Diasar 5/80 Tablets**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	24	**49**
27	404	Amlodipine + Valsartan	5mg+ 160mg	Tab	**Diasar 5/160 Tablets**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	24	**49**
28	405	Amlodipine + Valsartan	10mg+ 160mg	Tab	**Diasar 10/160 Tablets**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	24	**49**
29	471	Rosuvastatin	10mg	Tab	**Xell-10 Tablets**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	24	**49**
30	507	Famotidine	40mg	Tab	**Famot 40 Tablets**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	24	**49**
31	516	Omeprazole	40 mg / Vial	Inj	**Vyber 40 I.V**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	1	25	**50**
32	517	Omeprazole	40mg	Cap	**Vyber- 40 Capsules**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	1	25	**50**
33	519	Ondansetron	8mg	Tab	**Zedron Tablets 8mg**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	24	**49**
34	520	Ondansetron	2 mg/ml	Inj	**Zedron Injection 8mg**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	0	5	0	20	**45**
35	535	Clomiphene Citrate	50MG	Tab	**Fertab Tablets**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	24	**49**
36	538	Dinoprostone	3mg	Vag Tab	**Ditone E2 Tablet**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	0	0	4	5	0	19	**44**
37	540	Empagliflozin	10mg	Tab	**Emdagan 10 Tablets**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	0	0	4	5	0	19	**44**
38	541	Empagliflozin	25mg	Tab	**Emdagan 25 Tablets**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	0	0	4	5	0	19	**44**
39	550	Glimepiride	2mg	Tab	**Dilgem-2 Tablets**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	0	0	4	5	0	19	**44**
40	552	Glimepiride	4mg	Tab	**Dilgem-4 Tablets**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	0	0	4	5	0	19	**44**
41	581	Sitagliptin + Metformin	50 mg/500 mg	Tab	**Admit-50/500 Tablets**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	24	**49**
42	582	Sitagliptin + Metformin	50 mg/1000 mg	Tab	**Admit-50/1000 Tablets**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	24	**49**
43	586	Vildagliptin	50mg	Tab	**Oritide-50 Tablets**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	24	**49**
44	753	Pregabalin	50mg	Cap	**Pegalin 50 Capsulses**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	24	**49**
45	754	Pregabalin	75mg	Cap	**Pegalin 75 Capsules**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	24	**49**
46	755	Pregabalin	150mg	Cap	**Pegalin150 Capsules**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	24	**49**
47	831	Diclofenac Sodium	0.1% w/v	Eye Drops	**Spiny Ophthalmic Solution**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	24	**49**
48	832	Dorzolamide + Timolol	2 + 0.5%	Eye Drops	**Tilomide Ophthalmic Solution**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	0	0	4	5	0	19	**44**
49	839	Moxifloxacin	0.5% w/v	Eye Drops	**Mionex Ophthalmic Solution**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	1	25	**50**
50	852	Tobramycin + Dexamethasone	0.3% + 0.1%	Eye Drops	**Mydex Ophthalmic Suspension**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	24	**49**
51	870	Fusidic acid	2%	Cream	**Fudic Cream**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	1	25	**50**
52	871	Fusidic acid	2%	Ointment	**Fudic Ointment**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	1	25	**50**
53	878	Isotretinoin + Erythromycin	0.05 %+ 2% (W/V)	Gel	**Isotin-E Gel**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	0	0	4	5	0	19	**44**
54	885	Permethrin	5% w/w	Cream	**Skab Cream**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	0	0	4	5	1	20	**45**
55	886	Permethrin	5% w/w	lotion	**Skab Lotion**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	0	0	4	5	1	20	**45**
56	894	Terbinafine	1%	Cream	**Ternifer Cream**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	5	0	4	5	0	24	**49**
57	914	Cholecalciferol (Vitamin D3)	200,000 IU	IM/Oral Inj	**D- Cad 3 Injection 5mg/5ml**	0	0	0	4	5	6	2	2	2	2	2	**25**	0	5	5	0	0	4	5	0	19	**44**

Original Mandatory forms in Hard are not submitted to the MCC
ISOTEN E GEL: The API source accredation certificate of Isotritinion is attached in PDF but the API Source accridation certificate is not attached in PDF so the score in column no 20 for this item is zero.
SKAB CREAM AND LOTION: The API source accredation certifiacte is not attached so the score in column no 20 for both cream and lotion is zero.

D CARD 3 INJ: The API source accredation certificate of vit D 3 is not attached so the score in column no 20 is zero.
SPORY CAP: API source accredation certificate of Itraconazole is not attached in pdf so the score in column 20 is zero.
TETNIFER 20MG TAB: GD, COA AND API accredation certificates are not available in PDF.
CELTIS IV INJ 500MG AND 1000MG: The API accredation certificate is not attached in pdf so score in column 20 is zero.
DITON E 2 TAB: API Source accredation certificate is not available in pdf so score at column 20 is zero.
EMDAGEN 10MG AND 25MG: API source accredation certifiacte is not available.so score in column 20 is zero.
DILGEM 2 AND 4MG TAB: API source accredation certificate is not avialable so the score in column 20 is zero.
DIZONE PLUS INJ: Picture of immediate container of both strength of Dezone plus inj are not available in pdf. So the score fothis item in immediate container is zero.
CEFTIZ 1000MG INJ: Picture of immediate container of Ceftiz 1000mg inj is not available in pdf so the score in immediate container column is zero.
CELTIS IV INJ 500MG AND 1000MG: Picture of immediate container of both strength are no avialable so the score is zero.
TEMPRIN PLUS TAB: Immediate container picture is not attached in pdf so the score for immediate conatiner iz zero.
ZEDRON INJ: Immediate container picture is not attached in pdf so the score for immediate conatiner is zero.
MITZ 15MG TAB: Immediate conatiner picture is not attached in pdf so the score for immediate container is zero.
MICACEPT ORAL GEL: The specification for oral gel tube are not attached similarly COA is also not available in pdf so the score fot immediate container is zero.

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: SHROOQ PHARMACEUTICALS Pvt. Ltd

Technical Evaluation Matrix

S. No.	Product General Information					Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm)**.	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products.	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm)	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade.	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm). Marks shall be awarded in the following manner: 02 Tender approvals- 01	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner:		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**5**	**3**	**4**	**5**	**5**	**37**	**70**
1	4.	Metronidazole	500 mg	Inf.	METICAL INFUSION	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4	The firm was inspected as per technical evaluation criteria. The following observations were found during the inspection; Non Adherence to Good Storage Practices 1. In Raw material store, Expired Cetyl Alcohol bearing batch No. 1EA064B were found with expiry date of 13-01-2026. 2. In RMS, excipients and active pharmaceutical ingredients were placed mixed together and were in direct contact with walls. 3. Expired mint powder flavor 500gm bottle was placed in the RMS with released label bearing with batch No. 006/49667 and expiry date of 03-2025. 4. 100kg of Tween-60 bearing lot No. Ab22424 with expiry of 28-04-26 was placed with release label in the Raw material store at the time of inspection. 5. 25kg of Polysorbate-80 bearing lot No. 20240321 and expiry date of 20-03-2026 was found in the RMS with released label. 6. Ledipasver 5Kg bearing batch No. PILPS-PVP 2308001 with expiry date 07-08-2025 was present at the time of inspection in raw material store with released label. 7. The sampling booth of RMS was not calibrated and No log book was available at the time of inspection. 8. Expired Chemical with the name of orange oil bearing batch No. 82156 with expiry date of 08-12-2025 were found in Ceph RMS and with released label. Non Functional HVAC System 9. HVAC was not functional in the Cephalosporin section at the time of inspection. 10. Cracks were found in the vinyl flooring of cephalosporin section. In view of the above, the firm is NOT-RECOMMENDED for award of factory evaluation visit score for the quoted items.	16	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	5	21
2	36.	Aceclofenac	100 mg	Tab.	CLOF TAB	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4						16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	15	31
3	41.	Diclofenac Sodium (IM/IV for Infusion)	25 mg/ml	Inj.	BALAX INJ	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4						16	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	5	21
4	46.	Ibuprofen	200 mg/ 5 ml	Susp.	GLARE DS	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4						16	Bioavailability/ Bioequivalence study is not attache in the bid	GD coupled with AWB/BL is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	5	21
5	48.	Ketorolac	30 mg/ml	Inj.	KEROOQ	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4						16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	15	31
6	52.	Meloxicam	15 mg	Tab.	LOXIRAX 15	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid						0	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	0	No IMS/IQVIA data of the quoted item is provided in the bid	0	0
7	53.	Meloxicam	7.5 mg	Tab.	LOXIRAX 7.5	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid						0	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	0	No IMS/IQVIA data of the quoted item is provided in the bid	0	0
8	66.	Paracetamol + Orphenadrine	450 mg/35 mg	Tab.	SIC TAB	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4						16	Bioavailability/ Bioequivalence study is not attache in the bid	Invoice/ GD is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	5	21
9	67.	Paracetamol+Tramadol	325mg/37.5 mg	Tab.	FORTADOL TAB	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4						16	Bioavailability/ Bioequivalence study is not attache in the bid	Invoice/ GD is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	5	21
10	69.	Tizanidine	4mg	Tab.	TIZAX	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4						16	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	5	21
11	70.	Tramadol HCl	50 mg/ml	Inj.	TRAMROOQ INJ	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4						16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	15	31
12	77.	Mebendazole	100 mg/5ml	Susp.	MEBIZIN SUSP	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4						16	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	5	21
13	108.	Deferasirox	250mg	Tab.	EFESIR TAB 250	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4						16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	15	31
14	111.	Deferasirox	500mg	Tab.	EFESIR TAB 500	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4						16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	15	31
15	133.	Fluconazole	2 mg/ml	Inf.	COZIL INFUSION	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4						16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	15	31

16	134.	Fluconazole	50 mg	Tab. / Cap.	CONARD CAP	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
17	135.	Fluconazole	150 mg	Tab. / Cap.	COZIL 150	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
18	139.	Itraconazole	100 mg	Cap.	TRIZOX CAP	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid
19	140.	Miconazole	2%	Skin Cream	ALBIMIN CREAM	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
20	145.	Terbinafine	250 mg	Tab.	TERMI TAB	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
21	147.	Voriconazole	200 mg	Tab.	VCZ TAB	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
22	156.	Levocetirizine	5 mg	Tab.	Marvel 5 mg	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
23	157.	Loratadine	10 mg	Tab.	lortin 10 mg	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
24	158.	Montelukast	10 mg	Tab.	AEROMAX 10 MG TAB	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
25	160.	Montelukast	4 mg	Sachet	AIRVENT TAB	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
26	189.	Azithromycin	250 mg	Tab. / Cap.	CINZIT 250 MG	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
27	190.	Azithromycin	500 mg	Tab. / Cap.	CINZIT 500 MG	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
28	192.	Azithromycin	200 mg/5ml	Dry Susp.	CINZIT DRY SUSP	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
29	204.	Cefixime	400 mg	Cap.	ISOCEF CAP 400	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
30	205.	Cefixime	100 mg/5ml	Dry Susp.	ISOCEF SUSP	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
31	206.	Cefixime	200 mg/5ml	Dry Susp.	ISOCEF DS SUSP	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
32	207.	Cefoperazone + Sulbactam	1gm/Vial	Inj.	RAZOBACT 1 G	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
33	208.	Cefoperazone + Sulbactam	2 gm/Vial	Inj.	RAZOBACT 2 G	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
34	212.	Cefpodoxime	100 mg	Tab.	CEFPORITE CAP	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
35	213.	Cefpodoxime	40 mg/5ml	Dry Susp.	CEFPORITE SUSP	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
36	215.	Ceftazidime	500 mg/Vial	Inj.	CIZIDIM 500	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
37	216.	Ceftazidime	1gm/Vial	Inj.	CIZIDIM 1G	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
38	217.	Ceftriaxone	500 mg/Vial	Inj.	SAFE ONE 500	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
39	218.	Ceftriaxone	1gm/Vial	Inj.	SAFE ONE 1 G	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
40	221.	Cefuroxime	250 mg	Tab.	DAYCEF CAP	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4

The firm was inspected as per technical evaluation criteria.
The following observations were found during the inspection;
Non Adherence to Good Storage Practices

1. In Raw material store, Expired Cetyl Alcohol bearing batch No. 1EA064B were found with expiry date of 13-01-2026.
2. In RMS, excipients and active pharmaceutical ingredients were placed mixed together and were in direct contact with walls.
3. Expired mint powder flavor 500gm bottle was placed in the RMS with released label bearing with batch No. 006/49667 and expiry date of 03-2025.
4. 100kg of Tween-60 bearing lot No. Ab22424 with expiry of 28-04-26 was placed with release label in the Raw material store at the time of inspection.
5. 25kg of Polysorbate-80 bearing lot No. 20240321 and expiry date of 20-03-2026 was found in the RMS with released label.
6. Ledipasver 5Kg bearing batch No. PILPS-PVP 2308001 with expiry date 07-08-2025 was present at the time of inspection in raw material store with released label.
7. The sampling booth of RMS was not calibrated and No log book was available at the time of inspection.
8. Expired Chemical with the name of orange oil bearing batch No. 82156 with expiry date of 08-12-2025 were found in Ceph RMS and with released label.

Non Functional HVAC System

9. HVAC was not functional in the Cephalosporin section at the time of inspection.
10. Cracks were found in the vinyl flooring of cephalosporin section.

In view of the above, the firm is NOT-RECOMMENDED for award of factory evaluation visit score for the quoted items.

16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
0	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	0	No IMS/IQVIA data of the quoted item is provided in the bid	**0**	**0**
16	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	GD coupled with AWB/BL is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	GD coupled with AWB/BL is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	0	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	0	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	0	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	0	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	0	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	0	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	0	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**

	41	222.	Cefuroxime	125 mg/5ml	Dry Susp.	DAYCEF SUSP	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
	42	230.	Ciprofloxacin	250 mg	Tab.	M.CIP 250 MG	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
	43	231.	Ciprofloxacin	500 mg	Tab.	M.CIP 500 MG	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
	44	232.	Ciprofloxacin	200 mg/100ml	Inf.	M.CIP INFUSION	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
	45	263.	Levofloxacin	5 mg/ml	Inf.	LEFEXY INFUSION	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
DRAP registration is not provided in the bid	46	264.	Levofloxacin	250 mg	Tab.	LEFEXY TAB 250 MG	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid
	47	265.	Levofloxacin	500 mg	Tab.	LEFEXY TAB 500 MG	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
	48	268.	Linezolid	600mg	Tab.	Inzox tab	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
	49	269.	Linezolid	100mg/5ml	Suspension	Inzox susp	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
	50	270.	Linezolid	2 mg/ml	Inf.	inzox infusion	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
	51	275.	Moxifloxacin	400 mg	Tab.	occunet tab	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
	52	292.	Rifaximin	550 mg	Tab.	XIMIN TAB	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
	53	299.	Artemether	80 mg/ml	Inj.	MAXLUM INJECTION	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
DRAP registration is not provided in the bid	54	300.	Artemether + Lumefantrine	40 mg/240mg	Tab.	MAXLUM DS	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid
DRAP registration is not provided in the bid	55	301.	Artemether + Lumefantrine	80 mg/480mg	Tab.	MAXLUM FORTE	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid
DRAP registration is not provided in the bid	56	302.	Artemether + Lumefantrine	15 mg/ 90 mg/5ml	Susp.	MAXLUM SUSP	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid
DRAP registration is not provided in the bid	57	370.	Iron Hydroxide poly maltose complex	100 mg	Tab.	REDIFER TAB	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid
	58	371.	Iron Hydroxide poly maltose complex	50 mg/5ml	Syp.	NOVARISE SYRUP	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
	59	375.	Mecobalamin	500 mcg	Inj.	HIREX INJ	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
	60	376.	Mecobalamin	500mcg	Tab.	HIREX TAB	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
	61	400.	Amlodipine Besylate	5 mg	Tab.	S.DIP 5 MG	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
	62	401.	Amlodipine Besylate	10 mg	Tab.	S.DIP 10 MG	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
	63	402.	Amlodipine + Valsartan	5mg+80 mg	Tab.	AV 5/80	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
	64	403.	Amlodipine + Valsartan	5mg+160 mg	Tab.	AV 5/160	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
	65	450.	Losartan Potassium	25 mg	Tab.	LAPSED 25 MG	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4

16	Bioavailability/ Bioequivalence study is not attache in the bid	GD coupled with AWB/BL is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	GD coupled with AWB/BL is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	GD coupled with AWB/BL is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	GD coupled with AWB/BL is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
0	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	0	No IMS/IQVIA data of the quoted item is provided in the bid	**0**	**0**
16	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
0	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	0	No IMS/IQVIA data of the quoted item is provided in the bid	**0**	**0**
0	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	0	No IMS/IQVIA data of the quoted item is provided in the bid	**0**	**0**
0	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	0	No IMS/IQVIA data of the quoted item is provided in the bid	**0**	**0**
0	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	0	No IMS/IQVIA data of the quoted item is provided in the bid	**0**	**0**
16	Bioavailability/ Bioequivalence study is not attache in the bid	GD coupled with AWB/BL is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**

66	451.	Losartan Potassium	50 mg	Tab.	LAPSED 50 MG	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
67	470.	Rosuvastatin	10 mg	Tab.	ROVIP 10 MG	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
68	489.	Ciprofloxacin HCl	0.30%	Ear Drops	M.CIP EYE DROP	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
69	490.	Fluticasone	50 mcg/Actu.	Nasal Spray	LUTICA NASAL SPRAY	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
70	502.	Domperidone	10 mg	Tab.	Dome one tab	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
71	503.	Domperidone	5 mg/5ml	Susp.	Dome one syrup	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
72	506.	Famotidine	40 mg	Tab.	FOMEN 40 MG	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
73	509.	Itopride	150mg	Tab.	ITOTEC TAB / ITOTEC CAP	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
74	516.	Omeprazole	40 mg	Cap.	MEPCID 40 MG	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
75	517.	Esomeprazole	40mg	Cap.	ESOZIL 40 MG/ ESOMALT 40 MG	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
76	518.	Ondansetron	8 mg	Tab.	DANTRON TAB	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid
77	519.	Ondansetron	2 mg/ml	Inj.	DANTRON INJ	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
78	521.	Pantoprazole	40mg	Tab.	PENTIUN TAB/ PRADA CAP	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
79	522.	Phloroglucinol + Trimethyl Phloroglucinol	80 mg + 80 mg	Tab.	SIMPHLOR TAB	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid
80	523.	Phloroglucinol + Trimethyl Phloroglucinol	40 mg + 0.04mg	Inj.	SIMPHLOR INJ	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid
81	531.	Zinc Sulphate	20 mg	Tab.	ZINMOR TAB	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
82	532.	Zinc Sulphate	20 mg/5ml	Syp.	ZINMOR OD SYRUP	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
83	534.	Clomiphene Citrate	50 mg	Tab.	INFERTI TAB	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
84	548.	Glimepiride + Metformin	1 mg/500mg	Tab.	METME TAB	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
85	549.	Glimepiride + Metformin	2 mg/500mg	Tab.	METME PLUS TAB	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
86	572.	Sitagliptin + Metformin	50 mg/500 mg	Tab.	MELIPT 50/500	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
87	573.	Sitagliptin + Metformin	50mg /1000 mg	Tab.	MELIPT 50/1000	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
88	673.	Febuxostat	40 mg	Tab.	FABINEX 40 MG	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
89	674.	Febuxostat	80 mg	Tab.	FABINEX 80 MG	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
90	676.	Ibandronic Acid	1mg/ml	Inj.	BONPAC INJ	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4

16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	GD coupled with AWB/BL is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	GD coupled with AWB/BL is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
0	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	0	No IMS/IQVIA data of the quoted item is provided in the bid	**0**	**0**
16	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
0	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	0	No IMS/IQVIA data of the quoted item is provided in the bid	**0**	**0**
0	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	0	No IMS/IQVIA data of the quoted item is provided in the bid	**0**	**0**
16	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	GD coupled with AWB/BL is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	GD coupled with AWB/BL is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	GD coupled with AWB/BL is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**

91	677.	Ibandronic Acid	150mg	Tab.	BANPOC TAB	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
92	685.	Tamsulosin HCl	0.4mg	Cap.	TOPZIN CAP	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
93	701.	Clozapine	25mg	Tab.	ZIPIX 25 MG	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
94	702.	Clozapine	100 mg	Tab.	ZIPIX 100 MG	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
95	707.	Duloxetine	30 mg	Cap.	YENTREVE 30 MG	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid
96	708.	Duloxetine	60 mg	Cap.	YENTREVE 60 MG	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid
97	713.	Escitalopram	10 mg	Tab.	CITALAX 10 MG	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid
98	714.	Fluoxetine HCl	20 mg	Cap.	TEXLOF CAP	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
99	716.	Fluphenazine Decanoate	25 mg/ml	Inj.	FLUDEC INJ	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
100	723.	Levetiracetam	250 mg	Tab.	LEVETRAL 250 MG	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid
101	724.	Levetiracetam	500mg	Tab.	LEVETRAL 500 MG	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid
102	730.	Olanzapine	5mg	Tab.	OLPIN 5 MG	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid
103	731.	Olanzapine	10 mg	Tab.	OLPIN 10 MG	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid
104	732.	Oxcarbazepine	300 mg	Tab.	OXAZE 300 MG	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
105	733.	Oxcarbazepine	600 mg	Tab.	OXAZE 600 MG	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
106	742.	Pregabalin	75mg	Cap.	GABMARK 75 MG	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
107	743.	Pregabalin	150 mg	Cap.	GABMARK 150 MG	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
108	748.	Quetiapine	100 mg	Tab.	QUTIRATE 100 MG	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid
109	749.	Risperidone	2mg	Tab.	RISMAL 2 MG	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid
110	750.	Risperidone	4 mg	Tab.	RISMAL 4 MG	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid
111	752.	Sertraline	100 mg	Tab.	SERGEX 100 MG	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid
112	754.	Topiramate	50 mg	Tab.	AMTEC 50 MG	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid
113	759.	Venlafaxine	75 mg	Tab.	VELANE TAB/ XINFAX XR CAP	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
114	818.	Dexamethasone	0.1% w/v	Eye Drops	S-DEX EYE DROP	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4
115	820.	Dorzolamide + Timolol	2 + 0.5%	Eye Drops	OLMA D EYE DROPS	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4

16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	GD coupled with AWB/BL is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	GD coupled with AWB/BL is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
0	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	0	No IMS/IQVIA data of the quoted item is provided in the bid	**0**	**0**
0	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	0	No IMS/IQVIA data of the quoted item is provided in the bid	**0**	**0**
0	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	0	No IMS/IQVIA data of the quoted item is provided in the bid	**0**	**0**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
0	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	0	No IMS/IQVIA data of the quoted item is provided in the bid	**0**	**0**
0	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	0	No IMS/IQVIA data of the quoted item is provided in the bid	**0**	**0**
0	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	0	No IMS/IQVIA data of the quoted item is provided in the bid	**0**	**0**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
16	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
0	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	0	No IMS/IQVIA data of the quoted item is provided in the bid	**0**	**0**
0	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	0	No IMS/IQVIA data of the quoted item is provided in the bid	**0**	**0**
0	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	0	No IMS/IQVIA data of the quoted item is provided in the bid	**0**	**0**
0	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	0	No IMS/IQVIA data of the quoted item is provided in the bid	**0**	**0**
16	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
16	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**

116	827.	Moxifloxacin	0.5% w/v	Eye Drops	MXN EYE DROP	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4	**16**	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
117	837.	Timolol Maleate	0.25%	Eye Drops	OLMA EYE DROPS	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4	**16**	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
118	838.	Timolol Maleate	0.5% w/v	Eye Drops	OLMA EYE DROPS	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4	**16**	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
119	839.	Tobramycin	0.3% w/v	Eye Drops	TCIN EYE DROP	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4	**16**	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
120	844.	Betamethasone dipropionate	0.05%	Oint.	PROCORT OINT	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid	**0**	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	0	No IMS/IQVIA data of the quoted item is provided in the bid	**0**	**0**
121	845.	Betamethasone dipropionate	0.05%	Cream	PROCORT CREAM	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4	**16**	Bioavailability/ Bioequivalence study is not attache in the bid	GD coupled with AWB/BL is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
122	846.	Betamethasone dipropionate	0.05%	Lot.	PROCORT LOTION	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4	**16**	Bioavailability/ Bioequivalence study is not attache in the bid	GD coupled with AWB/BL is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
123	851.	Clobetasol Propionate	0.05% w/w	Cream	GLOBETA CREAM	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4	**16**	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
124	856.	Fluocinolone Acetonide	0.03%	Cream	LUTICA CREAM	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4	**16**	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
125	858.	Fusidic acid	2%	Cream	FUSIMIN CREAM	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	DRAP registration is not provided in the bid	No IMS/IQVIA ranking of the firm is attached in the bid	0	DRAP registration is not provided in the bid	**0**	Bioavailability/ Bioequivalence study is not attache in the bid	DRAP registration is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	0	No IMS/IQVIA data of the quoted item is provided in the bid	**0**	**0**
126	866.	Isotretinoin + Erythromycin	0.05 %+ 2% w/w	Gel	ISONEX PLUS GEL	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4	**16**	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
127	882.	Terbinafine	1%	Cream	QTEC CREAM	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4	**16**	Bioavailability/ Bioequivalence study is not attache in the bid	5	5	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**15**	**31**
128	902.	Cholecalciferol (Vitamin D3)	200000 IU	IM/ Oral Inj.	SD 3 INJ	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4	**16**	Bioavailability/ Bioequivalence study is not attache in the bid	GD coupled with AWB/BL is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
129	1482.	Eltrombopag 25mg Tab.			ETROMO 25 MG	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4	**16**	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
130	1517.	Leflunomide	20 mg	Tab.	LEFLINE TAB	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4	**16**	Bioavailability/ Bioequivalence study is not attache in the bid	GD coupled with AWB/BL is not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**
131	1522.	Letrozole 2.5 mg Tab.			ZORTEL TAB	2	2	3	No IMS/IQVIA ranking of the firm is attached in the bid	5	4	**16**	Bioavailability/ Bioequivalence study is not attache in the bid	Not provided in the bid	0	No API source accreditation certificate is attached in the bid	No WHO prequalification, SRA registration or Free sale is attached	No certificate of the type/ class of material for immediate container is provided in the bid	5	No IMS/IQVIA data of the quoted item is provided in the bid	**5**	**21**

PO instead of CDR submitted with no firm name.

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: Sind Medical Store (Gen. Med IMP) Karachi

S. No.		Product General Information				Technical Evaluation Matrix																	
						Principal's and Importer's Evaluation Parameters								Suppliers Technical Score	Product Technical Evaluation							Product Availability	Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation					Importer's Evaluation				Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
						Valid ISO 18001:45001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/ies /regulatory body in the case of SRA/WLA countries (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the ware house at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good storage practices (GSP) for storage of finished goods. Functional and effective Air-conditioning & Ventilation System and effective cold chain (thermo-labile drugs). The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Nonadherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is/are mandatory)), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC experts at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of purchases through third party importers a valid mail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 15, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies). Trail of principal manufacturer shall be established from the respective GD. CoA and other supporting documents. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be	Valid WHO prequalification and / or Valid product registration in SRA country(ies) / Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) and / or Valid certificate of the availability of the quoted item in the US market. **04 marks shall be awarded in the Primary certificate, and 1 mark for additional certificate, up to a maximum of 06 (04+01+01) marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase: **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or most closely	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	2	5	5	4	5	5	30	5	5	5	5	6	4	5	5	40	70
Serum Institute India	602	Purified Vero Cell Rabies Vaccine (PVRV)	1ml	Vial	RABIVAX-S	0	0	0	0	800 one Calb cert attached	The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COFG) for the quoted items were checked, and following observations were made; 1. Serum institute of India Pvt Ltd: Valid original cGMP and Free sale certificate duly attested from the embassy concerned were present at the time of inspection. 2. Wuxi Yushou Medical appliances China: DRAP Registration of 50ml not available. Valid Original Quality Management System Certificate and free sale certificates for the quoted items duly attested from the embassy concerned were not present at the time of inspection. 3. DemeTECH Corporation USA: The manufacturing site mentioned in the DRAP product Registration is DemeTECH Corp., 5980 Maimi Lakes, USA while Full quality assurance certificate and agency agreement are on other site i.e., DemeTECH 14175 Miami Lakes USA. Full quality assurance certificate of DemeTECH 14175 Miami Lakes USA stand expired on 26-05-2024, however, Confirmation letter with transition timeline till 31-12-2027 (class III, class IIb) by the concerned certification body issued to DemeTECH Corp., 5980 Maimi Lakes, USA instead of DemeTECH 14175 Miami Lakes USA. Propopylene Mesh and Catgut are not covered in the Full Quality Assurance Certificate. 4. 20% inventory of the quoted items, adequate qualified HR, Cold Chain facility, Good Storage practices and SOPs for expiry management were satisfactory/ present, except stocks of Poly glycolic acid 4/0 17mm (01 piece), Polypropylene 2/0 30mm & 60 mm (0 piece) , Polyglalactin 910 6/0 13mm (03 pieces). The firm is RECOMMENDED only for the quoted items of Serum institute of India Pvt Ltd.	0	0	5	5		4	4	5	Tender approval are incomplete	23	23
SK Plasma, Co. Pvt Ltd, Korea	660	Salt free Albumin	50ml	Vial	SK Plazma	963 Verification link not provided	0	0	0	0				0	0	5	5		0	0	5		15	15
SK Plasma, Co. Pvt Ltd, Korea	661	Salt free Albumin	100ml	Vial	SK Plazma	963 Verification link not provided	Not attached	0	0	0				0	0	0	5		0	0	5		10	10

Pages

Remarks
784 Mandatory bid form 5 and forumulary No are not according the adv. Criteria
Mandatory bid form 5 and forumulary No are not according the adv. Criteria

BP Specifications

(Product License Holder & Manufacturer: M/s Serum Institute of India Pvt. Ltd., 212/2, Hadapsar, Pune 411028 Maharashtra State, India.)

(Product License Holder & Manufacturer: M/s Serum Institute of India Pvt. Ltd., Room No. 1, First Floor, Survey No. 46/1-4, Kadayia Village, Nani Daman-396210, C/o Sovereign Pharma Pvt. Ltd., Survey No. 46/1-4, Kadayia Village, Nani Daman-396210, India.)

(Product License Holder & Manufacturer: M/s SK Plasma Co., Ltd., 157 Saneopdanji-gil, Pungsan-eup, Andong-si Gyeongsangbuk-do, Republic of Korea.)

						Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27														
				Name of the firm		Sind Medical Store Karachi (Sutures)													
S. No.		Product General Parameter				Technical Evaluation Matrix											Product Evaluated Score	Total Technical Score
						Principal's and Importer's Evaluation Parameters													
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score	Product Technical Evaluation							
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the time of inspection at the warehouse at the tim eof inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** **(Certificate duly attaested by senior executive of the firm)**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US free sale certificate of the quoted products, **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **Online verification link shall be provided.** **(copies of relevant certificates duly attested by the senior executive of the firm)**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		

Name of Owner Operator
DEMETECH CORP.
5980 Miami Lakes Drive
Miami Lakes, FL
USA 33014

	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	5	6	29	5	5	5	6	10	10	41	70
6	1311	CatGut, Brown, Size 4/0, 20mm 1/2 Circle Round Body 75cm	4/0	DemeGUT			5	5	The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/COPP/COFG) for the quoted items were checked, and following observations were made; 1. Serum institute of India Pvt Ltd: Valid original cGMP and Free sale certificate duly attested from the embassy concerned were present at the time of inspection. 2. Wuxi Yushou Medical appliances China: DRAP Registration of 50ml not available. Valid Original Quality Management System Certificate and free sale certificates for the quoted items duly attested from the embassy concerned were not present at the time of inspection. 3. DemeTECH Corporation USA: The manufacturing site mentioned in the DRAP product Registration is DemeTECH Corp., 5980 Miami Lakes, USA while Full quality assurance certificate and agency agreement are on other site i.e., DemeTECH 14175 Miami Lakes USA. Full quality assurance certificate of DemeTECH 14175 Miami Lakes USA stand expired on 26-05-2024, however, Confirmation letter with transition timeline till 31-12-2027 (class III, class IIb) by the concerned certification body issued to DemeTECH Corp., 5980 Miami Lakes, USA instead of DemeTECH 14175 Miami Lakes USA. Propropylene Mesh and Catgut are not covered in the Full Quality Assurance Certificate. 4. 20% inventory of the quoted items, adequate qualified HR, Cold Chain facility, Good Storage practices and SOPs for expiry management were satisfactory/ present, except stocks of Poly glycolic acid 4/0 17mm (01 piece), Polypropylene 2/0 30mm & 60 mm (0 piece) , Polygalactin 910 6/0 13mm (03 pieces). The firm is RECOMMENDED only for the quoted items of Serum institute of India Pvt Ltd.		**5**	5		2	10	10	**27**	**32**
7	1312	CatGut, Brown, Size 3/0, 20mm 1/2 Circle Round Body 75cm	3/0	DemeGUT			5	5					**5**	5		2	10	10	**27**	**32**
8	1313	CatGut, Brown, Size 2/0,30mm 1/2 Circle Round Body 75cm	2/0	DemeGUT			5	5					**5**	5		2	10	10	**27**	**32**
9	1315	CatGut, Brown, Size 0, 40mm 1/2 Circle Round Body 75cm	0	DemeGUT			5	5					**5**	5		2	10	10	**27**	**32**
10	1317	CatGut, Brown, Size 1, 40mm 1/2 Circle Round Body 75cm	1	DemeGUT			5	5					**5**	5		2	10	10	**27**	**32**
11	1319	CatGut, Brown, Size 2, 40mm 1/2 Circle Round Body 75cm	2	DemeGUT			5	5					**349, 558, 559 GD is expired or not relevant**			2	10	10	**22**	**#VALUE!**
12	1320	Silk, Black, Size 4/0, 16mm 1/2 Circle Round Body 75cm	4/0	DemeGUT			5	5								2	10	10	**22**	**22**
13	1322	Silk, Black, Size 3/0, 25mm 1/2 Circle Round Body 75cm	3/0	DemeSilk			5	5					5	5		2	10	10	**27**	**32**
14	1323	Silk, Black, Size 3/0, 25mm 3/8 Circle Curved Cutting 75 cm	3/0	DemeSilk			5	5					5	5		2	10	10	**27**	**32**
15	1327	Silk, Black, Size 0, 30mm 1/2 Circle Round Body 75cm	0	DemeSilk		Not attached	5	5					5	5	511-744 Tender approvals are incomplete and not according to adv. Criteria	2	10	10	**27**	**32**
16	1328	Silk, Black, Size 1, 40mm 1/2 Circle Round Body 75cm	1	DemeSilk			5	5					5	5		2	10	10	**27**	**32**
17	1329	Silk, Black, Size 1, 30mm 1/2 Circle Round Body 75cm	1	DemeSilk			5	5					**349, 558, 559 GD is expired or not relevant**			2	10	10	**22**	**#VALUE!**
18	1331	Silk, Black, Size 2, 40mm 1/2 Circle Round Body 75cm	2	DemeSilk			5	5					5	5		2	10	10	**27**	**32**
19	1333	Polyglactin 910, Violet, size 6/0, 8 mm 1/4 Circle Conventional Spatula DOUBLE needle 45 cm	6/0	DemeCRYL			5	5					349, 558, 559 GD is expired or not relevant	0		2	10	10	**22**	**#VALUE!**
20	1335	Polyglactin910, colorless, size 6/0,13 mm 1/2 circle Roundbody needle 45 cm	6/0	DemeCRYL			5	5						0		2	10	10	**22**	**22**
21	1345	Polyglactin910, violet, size 3/0, 22 mm 1/2 circle Roundbody needle 70 cm	3/0	DemeCRYL			5	5						0		2	10	10	**22**	**22**
22	1346	Polyglactin910, violet, size 3/0, 26 mm 1/2 circle Roundbody Plus needle 75 cm	3/0	DemeCRYL			5	5						0		2	10	10	**22**	**22**
23	1347	Polyglactin910, violet, size 2/0, 26 mm 1/2 circle Roundbody Plus needle 75 cm	2/0	DemeCRYL			5	5						0		2	10	10	**22**	**22**
24	1348	Polyglactin910, violet, size 2/0, 31 mm 1/2 circle Roundbody Plus needle 75 cm	2/0	DemeCRYL			5	5						0		2	10	10	**22**	**22**

25	1352	Polyglactin910, violet, size 0, 40 mm 1/2circle Roundbody needle 90 cm	0	DemeCRYL		5	5		0		2	10	10	**22**	**22**
26	1353	Polyglactin910, violet, size 1, 40 mm 1/2circle Roundbody needle 90 cm	1	DemeCRYL		5	5	5	0		2	10	10	**22**	**27**
27	1357	Poly Glycolic Acid, Violet, Size 5/0, 16mm 1/2 Circle Round Body 75cm	5/0	Deme SORB		5	5	5	5		2	10	10	**27**	**32**
28	1358	Poly Glycolic Acid, Violet, Size 4/0,17mm 1/2 Circle Rou nd Body 75cm	4/0	Deme SORB		5	5	0	0		2	10	10	**22**	**22**
29	1359	Poly Glycolic Acid, Violet, Size 4/0, 20mm 1/2 Circle Round Body 75cm	4/0	Deme SORB		5	5	5	5		2	10	10	**27**	**32**
30	1360	Poly Glycolic Acid, Violet, Size 3/0, 24mm 1/2 Circle Round Body 75cm	3/0	Deme SORB	Not attached	5	5	5	5	511-744 Tender approvals are incomplete and not according to adv. Criteria	2	DTL substandard	10	**17**	**22**
31	1361	Poly Glycolic Acid, Violet, Size 2/0,25mm 1/2 Circle Round Body 75cm	2/0	Deme SORB		5	5	5	5		2	10	10	**27**	**32**
32	1362	Poly Glycolic Acid, Violet, Size 2/0,30mm 1/2 Circle Round Body 75cm	2/0	Deme SORB		5	5	349, 558, 559 GD is expired or not relevant			2	10	10	**22**	**#VALUE!**
33	1363	Poly Glycolic Acid, Violet, Size 0, 40mm 1/2 Circle Round Body 75cm	0	Deme SORB		5	5	5	5		2	10	10	**27**	**32**
34	1364	Poly Glycolic Acid, Violet, Size1, 30mm 1/2 Circle Round Body 75cm	1	Deme SORB		5	5	5	5		2	10	10	**27**	**32**
35	1365	Poly Glycolic Acid, Violet, Size1, 40mm 1/2 Circle Round Body 75cm	1	Deme SORB		5	5	349, 558, 559 GD is expired or not relevant			2	10	10	**22**	**#VALUE!**
36	1366	Poly Glycolic Acid, Violet, Size2, 40mm 1/2 Circle Round Body 75cm	2	Deme SORB		5	5				2	10	10	**22**	**22**
37	1367	Poly Glycolic Acid, Violet, Size 2, 45mm 1/2 Circle Round Body Heavy 75cm	2	Deme SORB		5	5				2	10	10	**22**	**22**
38	1372	Polypropylene, Blue, Size 7/0, 8mm 3/8 Circle Round Body Double Needle 75 cm	7/0	DemeLENE		5	5	5	5		2	10	10	**27**	**32**
39	1375	Polypropylene, Blue, Size 6/0, 13mm 3/8 Circle Round Body Double Needle 60 cm	6/0	DemeLENE		5	5	5	5		2	10	10	**27**	**32**
40	1377	Polypropylene, Blue, Size 5/0, 13mm 1/2 Circle Round Body Double Needle 75 cm	5/0	DemeLENE		5	5	5	5		2	10	10	**27**	**32**
41	1379	Polypropylene, Blue, Size 4/0, 16mm 3/8 Circle Curve Cutting 75 cm	4/0	DemeLENE		5	5	349, 558, 559 GD is expired or not relevant			2	10	10	**22**	**#VALUE!**
42	1381	Polypropylene, Blue, Size 3/0, 19mm 3/8 Circle Reverse Cutting Heavy 75 cm	3/0	DemeLENE		5	5				2	10	10	**22**	**22**
43	1382	Polypropylene, Blue, Size 3/0, 25mm 1/2 Circle Round Body Double Needle 75 cm	3/0	DemeLENE		5	5				2	10	10	**22**	**22**
44	1384	Polypropylene, Blue, Size 2/0, 25mm 1/2 Circle Round Body 75 cm	2/0	DemeLENE		5	5	5	5		2	10	10	**27**	**32**
45	1386	Polypropylene, Blue, Size 2/0, 24mm 3/8 Circle Curved Cutting 75 cm	2/0	DemeLENE		5	5	5	5		2	10	10	**27**	**32**
46	1387	Polypropylene, Blue, Size 2/0, 25mm 1/2 Circle Round Body Double Needle 75 cm	2/0	DemeLENE		5	5	5	5		2	10	10	**27**	**32**
47	1388	Polypropylene, Blue, Size 2/0, 30mm 1/2 Circle Round Body 75 cm	2/0	DemeLENE		5	5	5	5		2	10	10	**27**	**32**
48	1389	Polypropylene, Blue, Size 2/0, 55mm Straight Curved Cutting 90 cm	2/0	DemeLENE		5	5	5	5		2	10	10	**27**	**32**
49	1390	Polypropylene, Blue, Size 2/0, 60mm Straight Curved Cutting75 cm	2/0	DemeLENE		5	5	5	5		2	10	10	**27**	**32**
50	1391	Polypropylene, Blue, Size 0, 40mm 1/2 Circle Round Body 75 cm	0	DemeLENE		5	5	5	5		2	10	10	**27**	**32**
51	1392	Polypropylene, Blue, Size 1, 40mm 1/2 Circle Round Body 75 cm	1	DemeLENE		5	5	5	5		2	10	10	**27**	**32**
52	1393	Nylon, Black,size 10/0,6.5mm 3/8 Circle, Micropoint Curved Spatula DOUBLE needle, 30cm	10/0	DemeLON		5	5	5	5		2	10	10	**27**	**32**
53	1395	Polyester, Green, size 3/0, 26 mm 1/2 Circle Round Bodied (DOUBLE) needle 100 cm	3/0	DemeBOND		5	5	349, 558, 559 GD is expired or not relevant			2	10	10	**22**	**#VALUE!**
54	1396	Polyester, Green, size 2/0, 17 mm 1/2 Circle Round Bodied (DOUBLE) needle 90 cm	2/0	DemeBOND		5	5	5	5		2	10	10	**27**	**32**

55	1398	Polyester, Green, size 2/0, 26 mm 1/2 Circle Round Bodied (DOUBLE) needle 90 cm	2/0	DemeBOND			5	5	5	5		2	10	10	**27**	**32**
56	1427	Polypropylene Mesh size 30cm x 30cm	30cmx30cm	DemeLENE MESH			5	5	349, 558, 559 GD is expired or not relevant			2	10	10	**22**	**#VALUE!**
57	1428	Polypropylene Mesh size 15cm x 15cm	15cmx15cm	DemeLENE MESH			5	5	5	5		2	10	10	**27**	**32**
58	1430	Polypropylene Mesh size 6cm x 11cm	6cmx11cm	DemeLENE MESH			5	5	349, 558, 559 GD is expired or not relevant			2	10	10	**22**	**#VALUE!**

Page

Remarks

All Generic name of quoted items are not according to the adv. Bid form-05.
Mandatory bid form-01 is incomplete.

						Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27															
					Name of the firm	**Sind Medical Store (Syringes) Karachi**														
S. No.		**Product General Parameter**				**Technical Evaluation Matrix**													**Product Evaluated Score**	**Total Technical Score**
						Principal's and Importer's Evaluation Parameters							**Product Technical Evaluation**							
						Principal Manufacturer Evaluation			**Importer's Evaluation**			**Suppliers Technical Score**								
	MCC formulary No.	**1**	**2**	**3**	**4**	**5**	**6**	**7**	**8**	**9**	**10**	**11**	**12**	**13**	**14**	**15**	**16**	**17**	18	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the time of inspection at the warehouse at the tim eof inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** **(Certificate duly attaested by senior executive of the firm)**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note, Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US free sale certificate of the quoted products, **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **Online verification link shall be provided.** **(copies of relevant certificates duly attested by the senior executive of the firm)**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	5	6	**29**	5	5	5	6	10	10	**41**	**70**
1	1021	Disposable Insulin Syringes 1ml	1ml	Yushou		3	5	231 Certificate not attached	The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COFG) for the quoted items were checked, and following observations were made; 1. Serum institute of India Pvt Ltd: Valid original cGMP and Free sale certificate duly attested from the embassy concerned were present at the time of inspection. 2. Wuxi Yushou Medical appliances China: DRAP Registration of 50ml not available. Valid Original Quality Management System Certificate and free sale certificates for the quoted items duly attested from the embassy concerned were not present at the time of inspection. 3. DemeTECH Corporation USA: The manufacturing site mentioned in the DRAP product Registration is DemeTECH Corp., 5980 Maimi Lakes, USA while Full quality assurance certificate and agency agreement are on other site i.e., DemeTECH 14175 Miami Lakes USA. Full quality assurance certificate of DemeTECH 14175 Miami Lakes USA stand expired on 26-05-2024, however, Confirmation letter with transition timeline till 31-12-2027 (class III, class IIb) by the concerned certification body issued to DemeTECH Corp., 5980 Maimi Lakes, USA instead of DemeTECH 14175 Miami Lakes USA. Propropylene Mesh and Catgut are not covered in the Full Quality Assurance Certificate. 4. 20% inventory of the quoted items, adequate qualified HR, Cold Chain facility, Good Storage practices and SOPs for expiry management were satisfactory/ present, except stocks of Poly glycolic acid 4/0 17mm (01 piece), Polypropylene 2/0 30mm & 60 mm (0 piece) , Polyglalactin 910 6/0 13mm (03 pieces). The firm is RECOMMENDED only for the quoted items of Serum institute of India Pvt Ltd.	**8**	**5**	5	511-744 Tender approvals are incomplete	2	10	10	**27**	**32**
2	1023	Disposable Syringes 10ml	1ml	Yushou		3	5					**8**	**5**	5		2	10	10	**27**	**32**
3	1024	Disposable Syringes 20ml	1ml	Yushou		3	5					**8**	**5**	5		2	10	10	**27**	**32**
4	1025	Disposable Syringes 50ml Ordinary	50ml	Yushou		3	5					**8**	**467 GD is older**	0		2	10	10	**22**	**#VALUE!**

M/s WUXI YUSHOU MEDICAL APPLIANCES CO., LTD
No. 115 Nongxinhe Road, Dongbeitang Town, Wuxi City Jiangsu Province, CHINA

Drug Regulatory Authority Pakistan
Government of Pakistan

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: STALLION PHARMACEUTICALS PVT LTD

S. No.		Product General Information				Technical Evaluation Matrix: Factory Technical Evaluation Parameters — Documents Based Factory Score						Factory Evaluation Visit Score					Total Factory Evaluated Score	Product Evaluation Parameters — Product Technical Parameters								Total Product Evaluated Score	Total Technical Score
	MCC formulary No	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 13485:45601 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **12 months to date ranking will be considered).** Marks shall be awarded in top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top–20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs * Functional Stability Chamber (Both Accelerated and Real Time)as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC experts).	Adherence to GMP guidelines, (as in Schedule-B of DRAP), in term / section of the quoted product (s). **Non-compliance to GMP guidelines shall lead to disqualification of the sections/ or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP). **(Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the sections/ or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC experts at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Surrogate Regulatory Authorities). In case of Large volume parenteral i.e., greater than 150ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm affecting the product in Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted product/s. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 mark shall be awarded to the Primary certificate, and 01 marks for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. Copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columnn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention conformity with DRAP approved specifications. 2. Type of Glass material for Liquid ampoules must be USP Class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-50% market share = 1 mark 51-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or ICI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note- Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70
Pharmagen, Lahore	1	169 Amoxycillin	250mg	Cap.	Inamox Cap 250mg	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	1	20	48
Pharmagen, Lahore	2	170 Amoxycillin	500mg	Cap.	Inamox Cap 500 mg	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	1	20	48
Pharmagen, Lahore	3	171 Amoxycillin	125 mg/5ml (60ml)	Dry Susp.	Inamox Suspension 125mg/5ml (60ml)	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	1	20	48
Pharmagen, Lahore	4	172 Amoxycillin	250 mg/5ml (60 ml)	Dry Susp.	Inamox Suspension 250mg/5ml (60ml)	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	1	20	48
Shandong New Time	5	174 Amoxicillin + Clavulanic Acid	250mg/125mg (375mg)	Tab.	Xiamentin Tablet 375mg	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	18	47
Shandong New Time	6	175 Amoxicillin + Clavulanic Acid	500mg/125mg (625mg)	Tab.	Xiamentin Tablet 625mg	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	18	47
Shandong New Time	7	176 Amoxicillin + Clavulanic Acid	875mg/125mg (1gm)	Tab.	Xiamentin Tablet 1gm	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	18	47
Shandong New Time	8	177 Amoxicillin + Clavulanic Acid	125 mg +31.5mg/5ml (90 ml)	Dry Susp.	Xiamentin Suspension 156.25mg/5ml (60ml)	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	18	47
Shandong New Time	9	178 Amoxicillin + Clavulanic Acid	250 mg +62.5mg/5ml (90 ml)	Dry Susp.	Xiamentin Suspension 312.5mg/5ml (90ml)	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	0	18	47
Shandong New Time	10	180 Amoxicillin + Clavulanic Acid	500 mg +100mg/Vial	Inj.	Xiamentin Inj. 600mg	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	2	5	0	17	45
Shandong New Time	11	181 Amoxicillin + Clavulanic Acid	1gm+200mg/Vial	Inj.	Xiamentin Inj. 1.2gm	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	2	5	0	17	45
DPB Antibiotics India	12	255 Ractosaxillin + Amoxicillin	250 mg +250mg	Cap.	Rustal Cap 500mg	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	4	5	5	24	52
Shenzen Haibin Pharma Ch	13	260 Imipenem + Cilastatin	500 mg+500mg/Vial	Inj.	Primacin Inj. 500mg	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	2	5	1	18	46
Shenzen Haibin Pharma	14	272 Meropenem	500 mg/Vial	Inj.	Meroidin Inj. 500mg	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	2	5	1	18	46
Shenzen Haibin Pharma	15	273 Meropenem	1gm/Vial	Inj.	Meroidin Inj. 1gm	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	2	5	1	18	46
Shandong Qilu Chi	16	278 Piperacillin +Tanobactam	2 gm+0.25gm (2.25gm)/Vial	Inj.	Talzon Inj.2.25gm	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	2	5	1	18	46
Shandong Qilu Chi	17	280 Piperacillin +Tanobactam	4 g(3.5 g (4.5gm)/Vial	Inj.	Talzon Inj. 4.5gm	2	2	3	0	5	6	2	2	2	2	2	28	0	5	5	0	0	2	5	1	18	46

Scrutiny Report PDF
1548-559

Principal source of Piperacillin+Tanobactam is Shandong Qilu, whereas Form 3 and Form 7 are from Shandong Anxin Pharmaceutical Co.
API sources are either from local manufacturer or not as per advertised criteria envisaged in column 20. Hence, marks may not be awarded in respective column,

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: STANLEY PHARMA PESHAWAR

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s)	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
	2	Metronidazole	400mg	Tablet	Riam Tablet	2	2	3	3	5	6	2	2	2	2	2	**31**	0	5	5	0	0	2	5	1	**18**	**49**
	3	Metronidazole	200mg/5ml	Suspension	Riam Suspension	2	2	3	3	5	6	2	2	2	2	2	**31**	0	5	5	0	0	2	5	1	**18**	**49**
	45	Ibuprofen	200mg/5ml	Suspension	Fenbro 8 Plus	2	2	3	3	5	6	2	2	2	2	2	**31**	0	5	5	5	0	2	5	1	**23**	**54**
	46	Ibuprofen	100mg/5ml	Suspension	Fenbro	2	2	3	3	5	6	2	2	2	2	2	**31**	0	5	5	5	0	2	5	1	**23**	**54**
	48	Mefenamic Acid	250mg	Tablet	Kamic Tablet	2	2	3	3	5	6	2	2	2	2	2	**31**	0	5	5	0	0	2	5	1	**18**	**49**
	49	Mefenamic Acid	500mg	Tablet	Kamic	2	2	3	3	5	6	2	2	2	2	2	**31**	0	5	5	0	0	2	5	1	**18**	**49**
	58	Paracetamol	80mg/0.8ml	Drops	Pedrol Drops	2	2	3	3	5	6	2	2	2	2	2	**31**	0	5	5	5	0	2	5	1	**23**	**54**
	59	Paracetamol	500mg	Tablet	Pedrol Tablet	2	2	3	3	5	6	2	2	2	2	2	**31**	0	5	5	5	0	2	5	1	**23**	**54**
	60	Paracetamol	120mg/5ml	Suspension	Pedrol	2	2	3	3	5	6	2	2	2	2	2	**31**	0	5	5	5	0	2	5	1	**23**	**54**
	61	Paracetamol	250mg/5ml	Suspension	Pedrol	2	2	3	3	5	6	2	2	2	2	2	**31**	0	5	5	5	0	2	5	1	**23**	**54**
	65	Paracetamol + Orphenadrine	450 mg+35mg	Tablet	Rid-all Tablet	2	2	3	3	5	6	2	2	2	2	2	**31**	0	5	5	0	0	2	5	0	**17**	**48**
	70	Albendazole	200mg	Tablet	Bendazol Tablet	2	2	3	3	5	6	2	2	2	2	2	**31**	0	5	5	0	0	2	5	0	**17**	**48**
	71	Albendazole	200mg/5ml	Suspension	Bendazol	2	2	3	3	5	6	2	2	2	2	2	**31**	0	5	5	0	0	2	5	0	**17**	**48**
	159	Loratadine	10mg	Tablet	Lorid Tablet	2	2	3	3	5	6	2	2	2	2	2	**31**	0	0	0	0	0	2	5	1	**8**	**39**
	189	Azithromycin	250mg	Capsule	StanzithCapsule	2	2	3	3	5	6	2	2	2	2	2	**31**	0	5	5	0	0	2	5	0	**17**	**48**
	190	Azithromycin	500mg	Tablet	StanzithTablet	2	2	3	3	5	6	2	2	2	2	2	**31**	0	5	5	0	0	2	5	0	**17**	**48**
	230	Ciprofloxacin	250mg	Tablet	Rozid 250 Tablet	2	2	3	3	5	6	2	2	2	2	2	**31**	0	5	5	0	0	2	5	0	**17**	**48**
	231	Ciprofloxacin	500mg	Tablet	Rozid 500 Tablet	2	2	3	3	5	6	2	2	2	2	2	**31**	0	5	5	0	0	2	5	0	**17**	**48**
	251	Doxycycline	100mg	Capsule	Ridox Capsule	2	2	3	3	5	6	2	2	2	2	2	**31**	0	5	0	0	0	2	5	1	**13**	**44**
	368	FerrousSulphate	100mg/5ml	Syrup	F.S Syrup120ml	2	2	3	3	5	6	2	2	2	2	2	**31**	0	5	0	0	0	2	5	0	**12**	**43**
	377	Mecobalamin	500mcg	Tablet	Veril Tablet	2	2	3	3	5	6	2	2	2	2	2	**31**	0	0	0	0	0	2	5	0	**7**	**38**
	497	Aluminium Hydroxide +	215mg + 80mg +	Suspension	Manacid	2	2	3	3	5	6	2	2	2	2	2	**31**	0	0	0	0	0	2	5	2	**9**	**40**
	500	Dimenhydrinate	12.5mg/4ml	Syrup	Dymin Syrup	2	2	3	3	5	6	2	2	2	2	2	**31**	0	0	0	0	0	2	5	1	**8**	**39**
	502	Dimenhydrinate	50mg	Tablet	Dymin Tablet	2	2	3	3	5	6	2	2	2	2	2	**31**	0	0	0	0	0	2	5	1	**8**	**39**
	503	Domperidone	10mg	Tablet	DomtekTablet	2	2	3	3	5	6	2	2	2	2	2	**31**	0	5	5	5	0	2	5	0	**22**	**53**
	504	Domperidone	5mg/5ml	Suspension	DomtekSuspensi	2	2	3	3	5	6	2	2	2	2	2	**31**	0	5	5	5	0	2	5	0	**22**	**53**
	517	Omeprazole	40mg	Capsule	Perl DS Capsule	2	2	3	3	5	6	2	2	2	2	2	**31**	0	0	0	0	0	2	5	0	**7**	**38**
	535	Clomiphen citrate	50mg	Tablet	Hex Tablet	2	2	3	3	5	6	2	2	2	2	2	**31**	0	5	5	0	0	2	5	1	**18**	**49**
	788	Acefyline	125mg/5ml	Syrup	Brophyl Syrup	2	2	3	3	5	6	2	2	2	2	2	**31**	0	0	0	0	0	2	5	1	**8**	**39**
	800	Aminophylline + Diphenhydramine + Amonium Chloride	32mg + 8mg + 30mg /5ml	Syrup	BroxolSyrup	2	2	3	3	5	6	2	2	2	2	2	**31**	0	5	0	0	0	2	5	1	**13**	**44**

Scrutiny report
1GD of Aluminium and Magnesium Hydroxide is not present
2GD of Omeprazole is not present
3GD of Dimenhydrinate is not present
4GD of Mecobalamine is not present
5GD of Acefylline is not present
6CoA of Diphenhydramine is not present
7IMS market share of less than 1% is not awarded
8CoAs and API sources are not awarded where GDs are not present

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27														
Name of the firm						Sudais Associates NDI Peshawar														
						Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters														
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score	Product Technical Evaluation						Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
Henan Maidingkang	966	Colostomy bags (Set comprising bag, adhesive ring, and	57mm, 70mm.	**single**	**MDK**		5	Not attached	The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COFG) for the quoted items were checked, and following observations were made; 1. Chifeng Tianbo Medical Device Co., Ltd., China 2. Promisemed Hangzhou Meditech Co., Ltd., China. 3. Wellex Company limited, Egypt 4. Tiancahng Ganor Medical Devices, China. 5. Henan Maidingkang China. I. Valid Agency Agreement, valid declaration of conformity and valid free sale certificates duly attested from embassy concerned were present at the time of inspection while DRAP registration of infusion Chamber (Burette type) 100 ml of Chifeng Tianbo Medical Device Co., Ltd., China, CVP line Triple 7f X 16cm Lumen (Wellex Egypt) and IV Fluid administration (Winset) of Chifeng Tianbo Medical Device Co., Ltd., China was not available at the time of inspection. II. 20% inventory of the quoted items, adequate qualified HR, Cold Chain facility, Good Storage practices and SOPs for expiry management were satisfactory/present. In view of the above the firm is RECOMMENDED and marks in importer's evaluation parameters for the quoted items may be awarded EXCEPT infusion Chamber (Burette type) 100 ml of Chifeng Tianbo Medical Device Co., Ltd., China, CVP line Triple 7f X 16cm Lumen (Wellex Egypt) and IV Fluid administration (Winset) of Chifeng Tianbo Medical Device Co., Ltd., China.			**5**	5	5			182 EC DOC is expired 31-12-2024 184 FSC of Argentina attached		**10**	**15**
Wellex EGYPT	984	CVP line (Single Lumen)	14Gx20cm , 16Gx20cm	**single**	**wellex**	48 DRAP Registeration Not attached 214 ISO 13485 Verification Link not provided						**0**	5	5			2		**12**	**12**
Wellex EGYPT	986	CVP line (Triple Lumen)	7Fx16cm	**single**	**wellex**							**0**	5	5			2		**12**	**12**
Chifeng Tianbo China	1137	Infusion Chamber (Burette Type)	100 ml	**single**	**Medstream**	60 DRAP Registeration NA 234 ISO attached						**0**	238 GD and AWB are	0			2		**2**	**2**
Henan Maidingkang	1231	Colostomy Paste	60 gram	**single**	**MDK**		5	Not attached				**5**	5	5			182 EC DOC is expired 31-12-2024 184 FSC of Argentina attached			
Tianchang Ganor China	1290	Urine bag with let	2000 ml	**single**	**Star Dry**		5	Not attached				**5**	272 GD, AWB and Registeration are not matching				2			
												0								

Henan Maidingkang Medical Technoloy Co. ,Ltd	Shuangchuangyuan industrial zone, Dingluan town, changyuan city, China

Name and complete address of manufacturer:

M/s Tianchang Ganor Medical Devices Co. Ltd

Shuangliu Village Datong Town, Tianchang City Anhui Province China

Name of Firm (s)	Name of Manufacturer	Name of Medical Device	Deferred for
SUDAIS ASSOCIATES Sudais House, House No: 01 Street No:: 07 Khan bahadar Colony Duran Peshawar KPK	WELLEX Company Ltd Cairo-Ismailia desert Road, Ismailia Public Free Zone, 41639 Ismailia City, Egypt LOA Expiry Date: May 2025	Wellex Central Venuos Catheter Class B Shelf Life: 5 Years Codes: Dimension: 10cm, 16cm, 20cm, 5cm,	clarification of Class of medical device.

1	1		Pakistan. **(ELI- 00031)**	FSC Country of Origin: Egypt Validity: 19th-Sep-2025 FSC Reference Country	6cm, 8cm, 12cm, 13cm, 20cm, 25cm, 30cm, 15cm, 17.5cm

M/S Wellex Company Ltd

Cairo-Ismallia Desert Road,Ismailia Public Free Zone, 41639 City, Egypt

1 110 Expired on 19-09-2025

						Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27															
					Name of the firm	**Sudais Associates Peshawar**															
S. No.		**Product General Parameter**				**Technical Evaluation Matrix**													**Product Evaluated Score**	**Total Technical Score**	
						Principal's and Importer's Evaluation Parameters							**Product Technical Evaluation**								
						Principal Manufacturer Evaluation			**Importer's Evaluation**			**Suppliers Technical Score**									
	MCC formulary No.	**1**	**2**	**3**	**4**	**5**	**6**	**7**	**8**	**9**	**10**	**11**	**12**	**13**	**14**	**15**	**16**	**17**	18	20	
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the time of inspection at the warehouse at the tim eof inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s / are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** **(Certificate duly attaested by senior executive of the firm)**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note, Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US free sale certificate of the quoted products, **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **Online verification link shall be provided.** **(copies of relevant certificates duly attested by the senior executive of the firm)**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	5	6	**29**	5	5	5	6	10	10	**41**	**70**	
Prosmisemed	1021	**Disposable insulin ordinary syringe**	**30G,1ml**	**single**	**verifine**	114 Verification link NA	5	117 license of Insulin syringe instead of manufacturing plant attached 164 510K summary attachached instead of unit accreditation	The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COPG) for the quoted items were checked, and following observations were made; 1. Chifeng Tianbo Medical Device Co., Ltd., China 2. Promisemed Hangzhou Meditech Co., Ltd., China. 3. Wellex Company limited, Egypt 4. Tiancahng Ganor Medical Devices, China. 5. Henan Maidingkang China. I. Valid Agency Agreement, valid declaration of conformity and valid free sale certificates duly attested from embassy concerned were present at the time of inspection while DRAP registration of infusion Chamber (Burette type) 100 ml of Chifeng Tianbo Medical Device Co., Ltd., China, CVP line Triple 7f X 16cm Lumen (Wellex Egypt) and IV Fluid administration (Winset) of Chifeng Tianbo Medical Device Co., Ltd., China was not available at the time of inspection. II. 20% inventory of the quoted items, adequate qualified HR, Cold Chain facility, Good Storage practices and SOPs for expiry management were satisfactory/present. In view of the above the firm is RECOMMENDED and marks in importer's evaluation parameters for the quoted items may be awarded EXCEPT infusion Chamber (Burette type) 100 ml of Chifeng Tianbo Medical Device Co., Ltd., China, CVP line Triple 7f X 16cm Lumen (Wellex Egypt) and IV Fluid administration (Winset) of Chifeng Tianbo Medical Device Co., Ltd., China.			**5**	5	148 Tender approval are incomplete	2			**7**	**12**	
Chifeng Tianbo China	1119	**I/V fluid administration**	**21Gx1 1/2, 150cm**	**single**	**winset**	57-DRAP Registeration not attached	5						168 AWB not readable	0	Not attached	2			**2**	**#REF!**	

Page

Remarks

Generic name of the quoted items are not according to the adv. BSDs.

48Sizes not mentioned

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm | **SWISS PHARMA KARACHI**

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLA country (ies) coupled	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
	47	Ketorolac	30mg/ml	Injection	Lactoro Injection 30mg/ml	0	0	0	2	5	6	The firm was inspected as per technical evaluation criteria and following observations were made; Poor environmental (HVAC) controls: 1. No cGMP-compliant drains were installed in the injectable manufacturing section, compromising proper sanitation and drainage control requirements for sterile pharmaceutical manufacturing areas. 2. A drain located in the production corridor of the injectable section was found improperly sealed and unsecured, as it was not properly screwed/fitted, thereby increasing the risk of contamination ingress and compromising environmental integrity. Compromised Good Storage Practices (GSP): 3. No segregated quarantine area was available in the Raw Material Store (RMS) for proper segregation and status control of incoming materials. 4. Released and quarantine materials were found stored together in the same section, creating risk of material mix-up and unauthorized use of unapproved materials. 5. Raw materials in the General Medicines RMS store were found stacked alongside the walls, contrary to Good Storage Practices and cGMP requirements. 6. Insufficient quantities of the quoted cephalosporin raw materials were available in the store, and the available materials were also found stacked alongside the walls, reflecting poor storage management and non-compliance with Good Storage Practices (GSP). Compromised Good Laboratory Practices (GLP): 7. No optical checking records were available in the injectable manufacturing section, indicating inadequate in-process quality assurance and documentation controls. 8. Poor documentation practices were observed throughout the inspected areas, reflecting non-compliance with Good Documentation Practices (GDP) requirements. 9. Inadequate sterility testing documentation and records were observed in the cephalosporin manufacturing area, compromising traceability and sterility assurance systems. 10. No residue limit records or swab testing evidence related to cleaning validation were observed during the inspection, indicating deficiencies in cleaning validation and contamination control systems. 11. Endotoxin testing records were not available and no proper documentation regarding endotoxin testing was maintained in the cephalosporin manufacturing area, reflecting deficiencies in Quality Control and sterility assurance practices for sterile pharmaceutical products. In view of the above the firm is NOT- RECOMMENDED for sterile and cephalosporin section, except Oral section.							**13**	0	5	5	0	0	0	0	0	**10**	**23**
	59	Paracetamol	500mg	Tablet	Fevamol 500mg Tablets	0	0	0	2	5	6						**13**	0	5	5	0	0	0	5	0	**15**	**28**
	63	Paracetamol	1000mg	Infusion	Swidol 1g Infusion	0	0	0	2	5	6						**13**	0	5	5	0	0	0	5	0	**15**	**28**
	160	Montelukast	10mg	Tablet	Asteck 10mg Tablets	0	0	0	2	5	6						**13**	0	5	5	0	0	0	5	0	**15**	**28**
	161	Montelukast	5mg	Tablet	Asteck 5mg Tablets	0	0	0	2	5	6						**13**	0	5	5	0	0	0	5	0	**15**	**28**
	166	Amikacin Sulphate	100mg	Injection	Mifiate 100mg IM/IV Injection	0	0	0	2	5	6						**13**	0	5	5	0	0	0	5	1	**16**	**29**
	167	Amikacin Sulphate	250mg	Injection	Mifiate 250mg IM/IV Injection	0	0	0	2	5	6						**13**	0	5	5	0	0	0	5	1	**16**	**29**
	168	Amikacin Sulphate	500mg	Injection	Mifiate 500mg IM/IV Injection	0	0	0	2	5	6						**13**	0	5	5	0	0	0	5	1	**16**	**29**
	207	Cefoperazone + Sulbactam	1gm/vial	Injection	Lintasul 1gm Injection	0	0	0	2	5	6						**13**	0	5	5	0	0	0	Stability study with different brand name Page 562	0	**10**	**23**
	208	Cefoperazone + Sulbactam	2gm/vial	Injection	Lintasul 2gm Injection	0	0	0	2	5	6						**13**	0	5	5	0	0	0	Stability study with different brand name Page 556	0	**10**	**23**
	209	Cefotaxime Sodium	250mg/vial	Injection	Bacxime 250mg IM/IV Injection	0	0	0	2	5	6						**13**	0	5	5	0	0	0	5	0	**15**	**28**
	210	Cefotaxime Sodium	500mg/vial	Injection	Bacxime 500mg IM/IV Injection	0	0	0	2	5	6						**13**	0	5	5	0	0	0	5	0	**15**	**28**
	211	Cefotaxime Sodium	1gm/vial	Injection	Bacxime 1gm IM/IV Injection	0	0	0	2	5	6						**13**	0	5	5	0	0	0	5	0	**15**	**28**
	217	Ceftriaxone	500mg/vial	Injection	Stracet 500mg IV Injection	0	0	0	2	5	6						**13**	0	5	5	0	0	0	5	0	**15**	**28**
	218	Ceftriaxone	1gm/vial	Injection	Stracet 1gm IV Injection	0	0	0	2	5	6						**13**	0	5	5	0	0	0	5	0	**15**	**28**
	219	Ceftriaxone	2gm/vial	Injection	Stracet 2gm IV Injection	0	0	0	2	5	6						**13**	0	5	5	0	0	0	5	0	**15**	**28**
	230	Ciprofloxacin	250mg	Tablet	Ciprok 250mg Tablet	0	0	0	2	5	6						**13**	0	5	5	0	0	0	5	0	**15**	**28**
	231	Ciprofloxacin	500mg	Tablet	Ciprok 500mg Tablet	0	0	0	2	5	6						**13**	0	5	5	0	0	0	5	0	**15**	**28**
	232	Ciprofloxacin	200mg/100ml	Infusion	Ciprok 200mg Infusion	0	0	0	2	5	6						**13**	0	5	5	0	0	0	5	0	**15**	**28**
	251	Doxycycline	100mg	Capsule	Diproxine 100mg Capsules	0	0	0	2	5	6						**13**	0	5	5	0	0	0	5	0	**15**	**28**
	371	Iron hydroxide poly maltose complex	50mg/ml	Syrup	Roplex 50mg/5ml Syrup 120ml	0	0	0	2	5	6						**13**	0	0	0	0	0	0	5	0	**5**	**18**
	372	Iron sucrose	20mg/ml	Injection	Roplex-S 100mg/5ml IV Injection	0	0	0	2	5	6						**13**	0	5	5	0	0	0	5	0	**15**	**28**
	375	Mecobalamin	500mcg	Capsules	Nervpower 500mcg Injection	0	0	0	2	5	6						**13**	0	0	0	0	0	0	5	0	**5**	**18**
	376	Tranexamic Acid	500mg	Capsules	Ultramax 500mg Capsules	0	0	0	2	5	6						**13**	0	5	5	0	0	0	5	0	**15**	**28**
	390	Tranexamic Acid	500mg	Injection	Ultramax 500mg Injection	0	0	0	2	5	6						**13**	0	5	5	0	0	0	5	0	**15**	**28**

	401	Amlodipine Besylate	5mg	Tablet	Corcont 5mg Tablet	0	0	0	2	5	6		**13**	0	5	5	0	0	0	5	0	**15**	**28**
	402	Amlodipine Besylate	10mg	Tablet	Corcont 10mg	0	0	0	2	5	6		**13**	0	5	5	0	0	0	5	0	**15**	**28**
	503	Domperidone	10mg	Tablet	Dolium 10mg Tablets	0	0	0	2	5	6		**13**	0	5	5	0	0	0	5	0	**15**	**28**
	504	Domperidone	5mg/5ml	Suspension	Dolium Suspension 120ml	0	0	0	2	5	6		**13**	0	5	5	0	0	0	5	0	**15**	**28**
	517	Omeprazole	40mg	Capsules	Sanamidol 40mg Capsules	0	0	0	2	5	6		**13**	0	5	5	0	0	0	5	0	**15**	**28**
	519	Ondansetron	8mg	Tablet	Onzaril 8mg Tablet	0	0	0	2	5	6		**13**	0	5	5	0	0	0	stability study with different brand name-Page 720	0	**10**	**23**
	520	Ondansetron	2mg/ml	Injection	Onzaril 2mg Injection	0	0	0	2	5	6		**13**	0	5	5	0	0	0	stability study with different brand name-Page 726	0	**10**	**23**
	735	Levetiracetam	250mg	Tablet	Lepitam 250mg Tablets	0	0	0	2	5	6		**13**	0	5	5	0	0	0	5	0	**15**	**28**
	736	Levetiracetam	500mg	Tablet	Lepitam 500mg Tablets	0	0	0	2	5	6		**13**	0	5	5	0	0	0	5	0	**15**	**28**
	761	Risperidone	4mg	Tablet	Kairdon 4mg Tablets	0	0	0	2	5	6		**13**	0	5	5	0	0	0	5	0	**15**	**28**
	762	Risperidone	2mg	Tablet	Kairdon 2mg Tablets	0	0	0	2	5	6		**13**	0	5	5	0	0	0	5	0	**15**	**28**
	914	Cholecalciferol (Vitamin D3)	200000IU	IM/Oral Injection	Lumi-D IM Injection	0	0	0	2	5	6		**13**	0	5	5	0	0	0	5	0	**15**	**28**

Scrutiny report
1Images of DRAP Approved packaging of the quoted items are not attached in the bid.
2ISO certificates on Page 54,55,56 are not from PNAC accredited body
3Pages 29-39, 100-102 are not readable

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposibles and Sutures for Government MCC 2026-27

Name of the firm: SAYYED HEALTHCARE FAISALABAD

Technical Evaluation Matrix

		Product General Information				Factory Technical Evaluation Parameter								Factory Evaluated Score	Product technical Evaluation Parameters						Product Evaluated Score	Total Technical Score
						Documents Based Factory Score				Evaluation Visit Score												
S.No	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of**	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. **(as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.**	Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAP regulations. **(to be evaluated by the MCC expert/s at the time of inspection, Noncompliance to cGMP shall lead to disqualification of the relevant section or firm)**	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section / firm.**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and**	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the	Valid WHO prequalification and / or valid product registration in SRA/WLA country(ies) / and / or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	6	3	3	2	2	29	5	5	5	6	10	10	41	70
	1006	Disposable Auto Disable Syringe (Blister packing) sterile	3 ml	---	Healthcare+	3	5	5	0	3	3	2	2	23	5	5	0	0	10	10	20	43
	1007	Disposable Auto Disable Syringe (Blister packing) sterile	5 ml	---	Healthcare+	3	5	5	0	3	3	2	2	23	5	5	0	0	10	10	20	43

Scrutiny report
1Tender approvals are not as per the advertised criteria
2WHO prequalification is under assessment- Page 158
Original Mandatory forms in Hard are not submitted to the MCC
Bank Gaurantee is 10-02-27

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: TABROS KARACHI

Technical Evaluation Matrix

S. No.	Product General Information					Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters										
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm).**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail-link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item (complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the QC incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	**Generic Name of Item**	**Strength**	**Dosage Form**	**Brand Name**	**2**	**2**	**3**	**5**	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**33**	**5**	**5**	**5**	**5**	**3**	**4**	**5**	**5**	**37**	**70**
	204	Cefixime	400mg	Cap.	FIXITIL				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	256	Fosfomycin	500mg	Cap.	FOCIN				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	2	21	46
	870	Fusidic Acid	2%	Cream	FUSIL				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	885	Permethrin	5%	Cream	SCABRID				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	1	20	45
	894	Terbinafine	1%	Cream	CUTIS				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	NA	1	15	40
	144	Miconazole	2%	Gel	MECROZ				4	5	6	2	2	2	2	2	25	0	5	NA-331 PAGE	0	0	4	5	1	15	40
	236	Clarithromycin	250mg/5ml	GRANULES	E-CLAR				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	237	Clarithromycin	125mg/5ml	GRANULES	E-CLAR				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	238	Clarithromycin	125mg/5ml	GRANULES	E-CLAR				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	895	Terbinafine	20ml	Lotion	CUTIS				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	1	20	45
	884	Mupirocin	2%w/w	Oint.	Mupiderm				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	192	Azithromycin	200mg/5ml	Susp.	KINRA				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	205	Cefixime	100mg/5ml	Susp.	FIXITIL				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	206	Cefixime	200mg/5ml	Susp.	FIXITIL DS				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	213	Cefpodoxime	40mg/5ml	Susp.	ORIBRO				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	159	Cetirizine	1MG/1ML	Syp.	ARIX				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	802	Doxofylline	60ML	Syp.	XOFLY				4	5	6	2	2	2	2	2	25	0	GD COA NOT MATCH	0	0	0	4	5	0	9	34
	65	rphenadrine+Paracetamo	35+450mg	Tab.	DURAGESIC				4	5	6	2	2	2	2	2	25	0	NA-266 PAGE	0	0	0	4	5	1	10	35
	66	Tramadol+Paracetamol	37.5+325mg	Tab.	DURAGESIC-T				4	5	6	2	2	2	2	2	25	0	mol GD COA NOT AT	0	0	0	4	0	1	5	30
	147	Terbinafine	250mg	Tab.	CUTIS				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	153	Cetirizine	10mg	Tab.	ARIX				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	189	Azithromycin	250mg	Tab.	KINRA		36-not from PNAC ACC body		4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	190	Azithromycin	500mg	Tab.	KINRA				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	212	Cefpodoxime	100mg	Tab.	ORIBRO				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	230	Ciprofloxacin	250mg	Tab.	GAVEL				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	231	Ciprofloxacin	500mg	Tab.	GAVEL				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	234	Clarithromycin	250mg	Tab.	E-CLAR				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	235	Clarithromycin	500mg	Tab.	E-CLAR DS				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	257	Fosfomycin Trometamol	3gm	Tab.	FOCIN ULTRA				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	2	21	46
	268	Linezolid	600mg	Tab.	LIZOTEK				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	433	Glyceryl Trinitrate	2.6mg	Tab.	TRYGIL				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	1	20	45
	434	Glyceryl Trinitrate	6.4mg	Tab.	TRYGIL				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	1	20	45
	471	Rosuvastatin	10mg	Tab.	RAST				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	475	Valsartan	40mg	Tab.	VALTEC				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	1	20	45
	476	Valsartan	80mg	Tab.	VALTEC				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	1	20	45
	477	sartan+Hydrochlorothiazi	80/12.5mg	Tab.	CO-VALTEC				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	478	Sacubitril+Valsartan	49/51mg	Tab.	TABRESTO				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	505	Drotaverine	40mg	Tab.	DYTRA				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	523	glucinol+Trimethylphlorog	80+80tablet	Tab.	SPADIX				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	1	20	45
	536	Dexamethasone	5mg	Tab.	DACORN				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	0	19	44
	540	Empagliflozin	10mg	Tab.	ELZAFLO				4	5	6	2	2	2	2	2	25	0	5	376 PAGE-COA NA	0	0	4	5	0	14	39
	541	Empagliflozin	25mg	Tab.	ELZAFLO				4	5	6	2	2	2	2	2	25	0	5	376 PAGE-COA NA	0	0	4	5	0	14	39
	576	Prednisolone	5mg	Tab.	RAPICORT				4	5	6	2	2	2	2	2	25	0	5	5	0	0	4	5	2	21	46

586	Vildagliptin	50mg	Tab.	LIPTIN		4	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**25**	0	5	5	0	0	**4**	5	0	**19**	**44**
801	Doxofylline	400mg	Tab.	XOFLY		4	**5**	**6**	**2**	**2**	**2**	**2**	**2**	**25**	0	GD COA NOT MATCH	0	0	0	**4**	5	0	**9**	**34**

THE ATTACHED GMP AT PAGE 264 FOR TRAMADOL ONLY COVER POVIDONE AND CEFUROXIM.

DRAP REG OF SCABRID NOT ATTACHED AT PAGE 291

DRAP REG OF LINEZOLID NOT ATTACHED AT PAGE 298

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: SCHAZOO PHARMACEUTICAL LABORATORIES

S. No.		Product General Information				Factory Technical Evaluation Parameters — Documents Based Factory Score				Factory Evaluation Visit Score					Total Factory Evaluated	Technical Evaluation Matrix				Product Evaluation Parameters — Product Technical Parameters				Total Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan. **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs (i.e. Functional Stability Chamber (Both Accelarated and Real Time)as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firms).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert(s)). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/ or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter: and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid mail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source, accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to Import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source & accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. Copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables. a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
	89	Mycophenolate Mofetil	500 mg	Tablets	VETO M	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**
	91	Mycophenolate Sodium	360 mg	Tablets	VETO S	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	5	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**10**	**40**
	93	Tacrolimus	1 mg	Capsules	TACMAS	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**
	111	Deferisirox	500 mg	Tablets	MURWI	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD provided at page No. 305 is expired	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**
	156	Levocitrazine	5 mg	Tablets	CITRAFAST	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**
	230	Ciprofloxacin	250 mg	Tablets	CINOX	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**
	231	Ciprofloxacin	500 mg	Tablets	CINOX	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**
	264	Levofloxacin	250 mg	Tablets	LEQUIX	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**
	265	Levofloxacin	500 mg	Tablets	LEQUIX	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**
	299	Artemether	80 mg	Injection	ARTEMEX	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**
	300	Artemether + Lumefantrine	40 mg + 240 mg	Tablets	ARTEMEX L DS	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**
	301	Artemether + Lumefantrine	80mg + 480 mg	Tablets	ARTEMEX L FORTE	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**
	376	Mecobalamin	500 mcg	Tablets	PERIMAC	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	5	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**10**	**40**
	517	Esomeprazole	40 mg	Capsules	ZESPRA	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**
	519	Ondansetron	8 mg/ml	Injection	SHARON	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**
	696	Citicoline	250 mg/2 ml	Injection	CERCOLIN	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**
	713	Escitalopram	10 mg	Tablets	ESLOPRAM	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**
	714	Fluoxetine	20 mg	Capsules	FLOXAC	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**
	754	Topiramate	50 mg	Tablets	TOMAX	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**
	819	Diclofenac Sodium	0.10%	Eye Drops	DICLOMIN	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**
	820	Dorzolamide + Timolol Maleate	2% + 0.5%	Eye Drops	GLAZOL T	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**
	823	Fluorometholone + Neomycin Sulphate	0.1% + 0.5%	Eye Drops	FLOROM N	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	5	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**10**	**40**
	825	Latanoprost	0.005	Eye Drops	LATEP	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**
	827	Moxifloxacin	0.50%	Eye Drops	MOXICIN	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**
	838	Timolol Maleate	0.50%	Eye Drops	TIMOSOL	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**
	839	Tobramycin	0.30%	Eye Drops	TOBRA	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**
	840	Tobramycin + Dexamethasone	0.3% + 0.1%	Eye Drops	TOBRA D	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**
	1522	Letrozole 2.5mg	2.5 mg	Tablets	OMORFIA	Not provided in the bid	2	3	4	5	6	2	2	2	2	2	**30**	No Bioavailability /Bioequivalence study data is provided	GD is not coupled with AWB or BL	0	No API source accredation is attached in the bid	No WHO prequalification or SRA registration is attached in the bid	No COA/ Proof of purchase is provided in the bid	5	No IMS/IQVIA data is provided	**5**	**35**

Bidding firm name not mentioned on the mandatory CDR

						Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27															
Name of the firm:						The Searle Pakistan Pvt Limited Karachi														
S. No.	Product General Parameter					Technical Evaluation Matrix													Product Evaluated Score	Total Technical Score
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation							
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the time of inspection at the warehouse at the tim eof inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** **(Certificate duly attaested by senior executive of the firm)**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US free sale certificate of the quoted products, **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **Online verification link shall be provided.** **(copies of relevant certificates duly attested by the senior executive of the firm)**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	5	6	29	5	5	5	6	10	10	41	70
Abu Dhabi Medical Devices	1021	Disposable Insulin Syringe sterile	1ml	Medeco inject		3	5	0	5	5	6	24	**213 GD is expired**	0	Tender approvals are incomplete	2	10	10	16	40
M/s Jiangsu Shenli Medical Production Co., Ltd 1 20, Changzheng Road, Zhenglu, Changzhou, China	1120	I/V fluid administration set with additional "Y" injection port Sterile, minimum 150cm length tubing, latex, and pyrogen free, blister pack	**177; 120 cm (length is not covered in FSC)**	**Searle flo**		Not attached	5	189 IRC USA certificate attached instead of UD FDA	5	5	6	21	**5**	5	Tender approvals are incomplete	2	10	10	27	48
Abu Dhabi Medical Devices 2	1123	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free) 18G	18G with injection port	Medeco		3	5		5	5	6	24	**5**	5	Tender approvals are incomplete	192 K summary attached	10	10	25	49
Abu Dhabi Medical Devices 3	1125	I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	18G with injection port & heparin stopper	Medeco		3	5		5	5	6	24	**5**	5	Tender approvals are incomplete	193 K summary attached	DTL substandard	10	15	39
Abu Dhabi Medical Devices 4	1126	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	20G with injection port	Medeco		3	5		5	5	6	24	**5**	5	Tender approvals are incomplete	194 K summary attached	DTL substandard	10	15	39
Abu Dhabi Medical Devices 5	1128	I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	20G with injection port & heparin stopper	Medeco		3	5		5	5	6	24	**5**	5	Tender approvals are incomplete	195 K summary attached	DTL substandard	10	15	39
Abu Dhabi Medical Devices 6	1129	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	22G with injection port	Medeco		3	5		5	5	6	24	**5**	5	Tender approvals are incomplete	196 K summary attached	10	10	25	49
Abu Dhabi Medical Devices 7	1131	I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	22G with injection port & heparin stopper	Medeco		3	5		5	5	6	24	**5**	5	Tender approvals are incomplete	197 K summary attached	10	10	25	49
8 Sample not provided	1132	I.V Cannula (Sterile having wings with heparin stopper inside sterilized blister packing. The cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	24G with injection port & heparin stopper	Medeco		3	5		5	5	6	24	**5**	5	Tender approvals are incomplete	198 K summary attached	10	10	25	49
Abu Dhabi Medical Devices 9	1134	I.V Cannula (Sterile having wings with heparin stopper inside sterilized blister packing. The cannula should be radio-opaque, as well as latex, pyrogen, and PVC free)	24G with injection port & heparin stopper	Medeco		3	5		5	5	6	24	**5**	5	Tender approvals are incomplete	199 K summary attached	DTL substandard	10	15	39

Pages

Remarks

11 Mandatory bid form is incomplete

16 Mandatory intergrity pact not attached.

111 Validity is not mentioned on the Certificate

Abu Dhabi Medical Devices Co. L.L.C.

Plot 124, M-43, Mussafah, P O Box 30485, Abu Dhabi, United Arab Emirates

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27														
Name of the firm						The Searle Pakistan Pvt Limited Karachi NDI														
						Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facility/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevent certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
TG MEDICAL SDN. BHD. LOT 6091, JALAN TERATAI BATU 5, OFF JALAN MERU 41050 KLANG SELANGOR DARUL EHSAN MALAYSIA	1052	Disposable Sterile Latex Surgical Gloves (Powder Free)	6.5	Protiex		3	5	149-K symmary attached	5	6	6	**25**	217 AWB is not attached with GD	0	Tender Approvals are incomplete	0	0	16	**16**	**41**
	1052	Disposable Sterile Latex Surgical Gloves (Powder Free)	7	Protiex		3	5	149-K symmary attached	5	6	6	**25**	217 AWB is not attached with GD	0		0	0	16	**16**	**41**
	1052	Disposable Sterile Latex Surgical Gloves (Powder Free)	7.5	Protiex		3	5	149-K symmary attached	5	6	6	**25**	217 AWB is not attached with GD	0		0	0	16	**16**	**41**
	1052	Disposable Sterile Latex Surgical Gloves (Powder Free)	8	Protiex		3	5	149-K symmary attached	5	6	6	**25**	217 AWB is not attached with GD	0		0	0	16	**16**	**41**
	1053	Disposable Sterile Latex Surgical (Powdered)	6.5	Protiex		3	5	149-K symmary attached	5	6	6	**25**	5	5		0	0	16	**26**	**51**
	1053	Disposable Sterile Latex Surgical (Powdered)	7	Protiex		3	5	149-K symmary attached	5	6	6	**25**	5	5		0	0	16	**26**	**51**
	1053	Disposable Sterile Latex Surgical (Powdered)	7.5	Protiex		3	5	149-K symmary attached	5	6	6	**25**	5	5		0	0	16	**26**	**51**
	1053	Disposable Sterile Latex Surgical (Powdered)	8	Protiex		3	5	149-K symmary attached	5	6	6	**25**	5	5		0	0	16	**26**	**51**
	1057	Disposable Non-Sterile Latex Examination Gloves (Powdered)	M	Protiex		3	5	149-K symmary attached	5	6	6	**25**	378 GD not attached			0	0	16	**16**	**41**

Evaluation Criteria for Importers of General Medicines, Drugs, Powder Injectable Products, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: The Searle Company Ltd (Gen. Medicine) Karachi

Technical Evaluation Matrix

S. No.		Product General Information				Principal's and Importer's Evaluation Parameters								Suppliers Technical Score	Product Technical Evaluation							Product Availability	Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation					Importer's Evaluation				Product Technical Parameters									
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
M/s PT. Sanbe Farma, Jl. Industri Cimareme No.8, Desa Cimareme, Kecamatan Ngamprah, Kabupaten Bandung Barat, Indonesia.						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/ies /regulatory body in the case of SRA/WLA countries (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the ware house at the time of inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good storage practices (GSP) for storage of finished goods. Functional and effective Air-conditioning & Ventilation System and effective cold chain (thermo-labile drugs). The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Nonadherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is/are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC experts at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product	Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 15, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA / TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies). Trail of principal manufacturer shall be established from the respective GD, CoA and other supporting documents. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the	Valid WHO prequalification and / or Valid product registration in SRA country(ies) / Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) and / or Valid certificate of the availability of the quoted item in the US market. **04 marks shall be awarded to the Primary certificate, and 1 mark for additional certificate, up to a maximum of 06 (04+01+01) marks.** **Certificates on**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with invoice/proof of purchase: **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this colounm for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil,	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	**2**	**2**	**2**	**5**	**5**	**4**	**5**	**5**	**30**	**5**	**5**	**5**	**5**	**6**	**4**	**5**	**5**	**40**	**70**
PT Sambe Malaysia	28	Propofol MCT/LCT FAT Emulsion	10 mg/ml, Inj 20ml			0	0	0	491 EDQM is not DRA	Not attached	**4**	**5**	**5**	**14**		511 GD of API source not attached	0	511 GD of API source not attached				Tender approvals are incomplete	**0**	**14**

468 COPP is expired

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: TRIGON PHARMA LAHORE

Technical Evaluation Matrix

S. No.	Product General Information					Factory Technical Evaluation Parameters: Documents Based Factory Score						Factory Evaluation Visit Score					Total Factory Evaluated Score	Product Evaluation Parameters: Product Technical Parameters							Total Product Evaluated Score	Total Technical Score
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th positions shall be awarded 1 mark.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) to all labs + Functional Stability Chamber (Both Accelerated and Real Time)as in Schedule B of DRAP). **(Evaluated at the time of inspection by the MCC experts, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC experts). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC experts at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section/ firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities). In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / bio-similarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the transfr date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where those documents are submitted for all APIs/components of the quoted products. In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of NIT/bid submission. **Online verification link shall be provided**	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) **Online verification link shall be provided**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with freeze/re-proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this columns for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Fiants (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product) 3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better **(Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. c. For products when USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s). **(Documents duly attested by the Senior executive of the firm).**	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or FLI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note: Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly supported with documentary evidence in the shape of purchase orders, delivery challan, commercial invoice(s) and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	5	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70
1	86	Nalbuphine	10mg/2ml	inj	Tridin	2	2	3	0	5	2						14	0	5	5	0	0	0	5	0	15	29
2	87	Nalbuphine	20mg/2ml	inj	Tridin	2	2	3	0	5	2						14	0	5	5	0	0	0	5	0	15	29
3	160	Montelukast Sodium	10mg	Tab	Mountaze	2	2	3	0	5	2						14	0	5	5	0	0	0	5	0	15	29
4	166	Amikacin Sulphate	100mg	inj	Cimikan	2	2	3	0	5	2						14	0	0	0	0	0	0	5	0	5	19
5	167	Amikacin Sulphate	250mg	inj	Cimikan	2	2	3	0	5	2						14	0	0	0	0	0	0	5	0	5	19
6	168	Amikacin Sulphate	500mg	inj	Cimikan	2	2	3	0	5	2						14	0	0	0	0	0	0	5	0	5	19
7	203	Cefepime	1gm	inj	Cefegon	2	2	3	0	5	2						14	0	5	5	0	0	0	0	0	10	24
8	202	Cefepime	500mg	inj	Cefegon	2	2	3	0	5	2						14	0	5	5	0	0	0	5	0	15	29
9	209	Cefotaxime	250mg	inj	Trigoran	2	2	3	0	5	2						14	0	5	5	0	0	0	0	0	10	24
10	210	Cefotaxime	500mg	inj	Trigoran	2	2	3	0	5	2						14	0	5	5	0	0	0	0	0	10	24
11	211	Cefotaxime	1gm	inj	Trigoran	2	2	3	0	5	2						14	0	5	5	0	0	0	5	0	15	29
12	234	Clarithromycin	250mg	Tab	Klaricin	2	2	3	0	5	2						14	0	5	5	0	0	0	0	0	10	24
13	235	Clarithromycin	500mg	Tab	Klaricin	2	2	3	0	5	2						14	0	5	5	0	0	0	0	0	10	24
14	237	Clarithromycin	60ml/125mg	Susp	Kosmit	2	2	3	0	5	2						14	0	5	5	0	0	0	0	0	10	24
15	258	Gentamicin	40mg/2ml	Inj	Sudocin	2	2	3	0	5	2						14	0	5	5	0	0	0	0	0	10	24
16	392	Rifaximin	550mg	Tab	Avigun	2	2	3	0	5	2						14	0	5	5	0	0	0	5	0	15	29
17	399	Artemether	80mg	Inj	Trimrad	2	2	3	0	5	2						14	0	5	5	0	0	0	0	0	10	24
18	400	Artemether + Lumefantrine	40/240mg	Tab	Trimrad Tab	2	2	3	0	5	2						14	0	0	0	0	0	0	0	0	0	14
19	401	Artemether + Lumefantrine	80/480mg	Tab	Trimrad Tab	2	2	3	0	5	2						14	0	0	0	0	0	0	0	0	0	14
20	389	Tranexamic Acid	250mg/5ml	Inj	Trismain	2	2	3	0	5	2						14	0	0	0	0	0	0	5	0	5	19
21	372	Iron hydroxide poly maltose complex	60ml/50mg	Susp	Trimaltocose	2	2	3	0	5	2						14	0	0	0	0	0	0	5	0	5	19
22	407	Famotidine	40mg	Tab	Fastine	2	2	3	0	5	2						14	0	5	5	0	0	0	0	0	15	29
23	519	Ondansetron	8mg/4ml	Tab	Teon	2	2	3	0	5	2						14	0	5	5	0	0	0	5	0	15	29
24	521	Pantoprazole	40mg	Tab	Protosid	2	2	3	0	5	2						14	0	5	5	0	0	0	0	0	10	24
25	537	Dexamethasone Sulphate	4mg/1ml	Inj	Deltasalone	2	2	3	0	5	2						14	0	5	5	0	0	0	5	0	15	29
26	585	Triamcinolone Acetonide	40mg/1ml	Inj	TriamcortA	2	2	3	0	5	2						14	0	5	5	0	0	0	5	0	15	29
27	614	Cholecalciferol	1ml	Inj	D-zorn	2	2	3	0	5	2						14	0	5	5	0	0	0	5	0	15	29

The inspection team at the time of inspection observed that;
POOR GOOD STORAGE PRACTICES (GSP)
i. In Raw Material Store, no hygrometer device was found, along with no record of temperature and humidity.
ii. In receiving bay walls were cracked and sampling booth, balance was not calibrated (sticker was expired).
iii. In de-dusting room no vacuum cleaner was found.
iv. Quarantine and released area were not properly segregated.
v. Quarantine labelled was not pasted on the unreleased materials.
vi. Walls of the RMS were cracked, and paint was pealed off (flacks were found in the raw material cartons).
vii. Active materials were not properly labelled i.e., escitalopram carton was not labelled.
viii. Raw material bags were opened and then were not properly sealed.

NON-FUNCTIONAL HVAC
i. HVAC system was non-functional in ampule filling machine section, dry filling section.
ii. Ampule filling machine was semi-automatic, and female workers was found in normal clothing in the sterile filling area.
iii. In opticial checking room ampules were placed without label. Moreover, HVAC was non-functional and Acs were also not installed in the optical checking area, and temperature was too high for working.
iv. Area monitoring record was not produced to the inspection committee.
v. In tablet section HVAC was non-functional in compression and coating section.
vi. HVAC was found non-functional in dry powder suspension.
vii. In syrup section storage tank and pipes were rusted, and overall hygienic conditions were not satisfactory.

Based on the aforementioned findings, the inspection team recommends that the firm be classified as NOT-RECOMMENDED.

Report
1.GD and BL of amikacin on page 169 is not matching hence no m,arks awaarded.
2.no pics of immediate containers of the quoted items hence no marks awarded to all the quoted items at page 154
3.no api soyrce marks to be awarded to all the quoted items.
4.in cefepime only one 1gm stability marks to be awarded.
5.in artemether and lumefantrine ,the GD and awb of lumefantrine is missing hence no marks awarded.
6. no GD of iron hydroxide hence no marks awarded.

		TECHNICAL EVALUATION PROFORMA, FOR PROCUREMENT OF ANTICANCER MEDICINES IN GOVT. MCC FY 2026-27																		
		Name of the firm with Complete Address	**UMAR PHARMA PESHAWAR**																	
		Manufacturer / Importer	**IMPORTER**																	
		Mandatory Requirements.	**YES / NO**		**In case of being a Manufacturer, the Firm should provide attested copies of the following documents also:**		**YES/NO**			**In case of being Importers, the Firm should provide attested copies of the following documents also:**		**YES/NO**								
1		**National Tax Number (NTN) of the Firm for Income Tax, and**	YES		1	Valid Drugs Manufacturing License issued by the Drugs Regulatory Authority of Pakistan (DRAP); and		1	Valid Drugs Sales License for the importer; and	YES										
2		**Last year Income Tax Return of the Firm; and**	YES		2	Valid Product Registration Certificate issued by the DRAP for the item/s quoted by the Firm for this bidding competition.		2	Valid Product Registration Certificate issued by the DRAP for the imported item/s quoted by the Firm for this bidding competition; and	YES										
3		**Sale Tax Registration Certificate of the Firm; and**	YES		3	Valid DRAP Approved Price List of the quoted item/s.		3	Valid Agency Agreement with the Foreign Principal Manufacturer entity/ies; and	YES										
4		**Certificate of Professional Tax of the Firm.**	YES					4	Valid eGMP Certificate of Pharmaceutical Product (COPP)/ Certificate of Medicinal Product (COMP) of the Principal Manufacturer for the quoted item as issued by relevant authority of the country of origin of the quoted imported good/s, Certificate on company's own letter head shall not be acceptable. Non provision of the certificate shall lead to disqualification of the firm. and	YES										
5		**Certificate of compliance to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, PCSIR. Non-Compliance to international reference standards or absence of Cold Chain requirements shall lead to disqualification of the relevant product that requires cold chain.**	NO	verification of storage facility of 2113 is attached				5	Valid Free Sale Certificate for the quoted item/s as issued by relevant authority of the country of origin of the quoted imported good/s. Non provision of the document shall lead to disqualification of the firm; and	NO	COPPs issued in Jan 2022 with Periodicity of routine inspection of No more than 3 years									
								6	Valid DRAP approved Price List of the quoted items.	YES										

		Technical Evaluation Parameters	**Active Pharmaceutical Ingredient source gradation** **(For API or finished product). i) The bidder (local manufacturer / multi-national manufacturer / importer) shall provide Analytical/Quality Assurance/ Approval Certificates for the manufacturing or marketing of each quoted product from any of the following categories of the Drug Regulatory Authority of the Country of Origin to achieve the corresponding evaluation grades.** **Certificate of Analysis/ Quality Assurance Certificate duly verified/attested by official of the company shall be submitted along with the Technical Bid as a mandatory requirement. Importers must submit agency agreement/ approval with the original manufacturer duly attested/verified by official of the company.** **Detailed purchase trail of the Active Pharmaceutical Ingredient/ Finished product from the claimed source must be submitted (any proof of purchase such as Goods Declaration Certificate along with Airway Bill/ Bill of Lading/Invoice etc.) by the bidder.** **Maximum marks for this criterion are 40.**			**Bio-Equivalence (BA) / Bio- Similar (BS) or Bio-waiver (BW) Study/Certificate from an accredited lab of SRA countries (Stringent Regulatory Authorities)/ WHO Listed Authorities WLA Countries** **(BA/BE Certificate with evidence as to its authenticity) from Category A countries.** **Bio-Equivalence (BA) of the quoted product to be conducted against the originator.** **Original innovator products do not require bio- equivalence certificate and are available in market substantially./ The bidder shall provide the documents to establish the proof of innovator/ originator. All other branded generics require BE studies** **Certificate, duly attested by an official of the company in Pakistan is to be submitted along with the Technical Bid.** **Maximum marks for this criterion are 10.**			**Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted drug. In case if the quoted item is Generic the studies must be performed on the Generic and not on the originator. (Must be an original research article)** **Mandatory: Online verification link must be provided to verify the Clinical Trial/ Clinical Studies submitted for the quoted items.**			**Factory/ Importer Based Evaluation Score (MANDATORY)**	**Sample Evaluation by End User Committee** **Samples will be examined per following parameters (Mandatory):** **a. Labelling and Packing Rules 1986** **b. Outer packing** **c. Inner packing** **d. Physical appearance.** **Product which has unsatisfactory packing/labeling will be technically disqualified.** **Maximum score for this criterion is 1.**		**Past Performance (Last two years).** **i) Good Performance Certificates of these Medicines issued by procuring agencies will be eligible for 1 mark per institution upto a maximum of 5 marks.** **ii) Only supply orders will not get any marks.** **iii) The bidders have to undertake that they have never been blacklisted or debarred.** **Maximum marks for this criterion are 5.** **iv) Those firms who have not been regular in supplies for the Project "Treatment of Poor Cancer Patients" at HMC, Peshawar, TWO marks shall be deducted for poor past performance irrespective of substantial supplies or Performance at any other institute.**	**Total Technical Score**
			Category A – Approved By: • Agência Nacional de Vigilância Sanitária (ANVS), Brazil • Central Drug Standard Control Organization (CDSCO), India • Drug Regulatory Authority, Pakistan • National Pharmaceutical Control Bureau (NPCB), Malaysia • Egyptian Drug Authority (EDA), North Korea • Ministry of Health, Egypt • Ministry of Health, Turkey • China Food & Drug Administration • Any other source not mentioned in Category-A			Study/certificate available/submitted by a Category-A Country Regulatory Authority. BE testing must be done using the Reference Product. Bio-waiver is acceptable only as injectable forms if issued by Category-A Country.	No BE/BW/ certificate obtained for Exported product from Category-B Country (as mentioned at S No. 1 above).	No BE/BW/ Certificate.	Browse the web to confirm the item Category "B" / "C" owned listed in MCC licensed Pharmaceutical Factories (PMA) Database/ Directory/ Publication Policy 2015 and List of National Recognized Journals as per MCC. 7 marks per original research article shall be awarded maximum up to 6 marks).	Browse the web to confirm the item Category "B" / "C" owned listed in MCC licensed Pharmaceutical Factories (PMA) Database/ Directory/ Publication Policy 2015 and List of National Recognized Journals as per MCC. 7 marks per original research article shall be awarded maximum up to 6 marks).	Studies/original articles published in category "A" owned of the WHO- Journals, as per MCC Publication Policy 2015 and List of National Recognized Journals as per MCC shall not be awarded marks.	**The Physical inspection of the premises of the bidder (Manufacturer/Importer) shall be carried out in accordance with ITR 25.4(b), GCC 6(GCC 6.3), Section V (c) (ii) (A) of the approved BSDS of Govt. MCC FY 2026-27**	Satisfactory	Unsatisfactory	i) Substandard quantity of supplies of anti-cancer medicines made by private/ Govt/ Teaching Hospitals/ namely- The Agha Khan University Hospital, Karachi, Shaukat Khanum Hospital, Lahore/ Peshawar, CMH Rawalpindi and Hayatabad Medical Complex, Peshawar shall be considered for award of marks only if no such unsatisfactory Performance Certificates from these institutions (mandatory). Marks shall only be provided to those who provide good performance certificate issued in the last 18 months. No marks will be given. ii) Successful supply of quality medicines where supply orders coupled with delivery challans & invoices will be considered for award of marks. 1 mark per agreement up to a maximum of 6 marks	
SOURCE	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	**40**	**30**	**10**	**5**	**0**	**9**	**6**	**0**	**5**	**1**	**0**	**5**	**70**	
Genepharm Greece	1423	Anastrozole	1 Mg	Tab	Geneplex		30	10						5	1		2	48	
Genepharm Greece	1436	Bicalutamide	50 Mg	Tab	Bicamide		30		5					5	1		2	43	
Genepharm Greece	1522	Letrozole	2.5 Mg	Tab	Femaplex		30	10						5	1		2	48	
Genepharm Greece-Pharmacare Malta	1603	Sunitinib	50 Mg	Tab	Egotux		30		5					5	0		2	42	Sample not provided

Scrutiny report
1)100% of the quoted products issued in Jan 2022 shows Periodicity of routine inspections as "No more than 3 years", based on this the COPPs are expired in Jan 2025.
2)Raw material source gradation related documents (trail) is not provided
3)EQAV kind acceptable is raw material source gradation

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: Unisa Pharmaceuticals Industries Nowshera

Technical Evaluation Matrix

S. No.		Product General Information				Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters								Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters										
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **(12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelerated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-adherence to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availablity of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs, available on WHO Website/ US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/WLAs country (ies).) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or Bio-waiver certificate from an accredited lab of	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient/s (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRAs/ WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs), and Form-7. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) **02 marks shall be awarded to the Primary certificate, and 01 mark for additional certificate, up to a maximum of 03 (02+01) marks.** Certificates on company's own letter heads shall not be acceptable.	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE,	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	**33**	5	5	5	5	3	4	5	5	**37**	**70**
1	4	Metronidazole	500 mg	Infusion	Unizol 100ml	2	2	3	1	5	6	2	2	2	2	2	**29**	0	5	5	809 EDQM is not a regulatory body		4	5		**19**	**48**
2	63	Paracetamol	1000 mg	Infusion	Unisol Para 100ml	2	2	3	1	5	6	2	2	2	2	2	**29**	0	5	5	0		4	5		**19**	**48**
3	232	Ciprofloxacin	200 mg/100ml	Infusion	Uniciprox 100ml	2	2	3	1	5	6	2	2	2	2	2	**29**	0	5	5	0		4	5		**19**	**48**
4	263	Levofloxacin	5 mg/ml	Infusion	Unilevoflox 100ml	2	2	3	1	5	6	2	2	2	2	2	**29**	0	721 GD is older than 2 years	0	0		4	5		**9**	**38**
5	636	Dextrose	10%	I.V Infusion	Unisol 10 % 500ml	2	2	3	1	5	6	2	2	2	2	2	**29**	5	5	5	0		4	5		**24**	**53**
6	637	Dextrose	10%	I.V Infusion	Unisol 10% 1000ml	2	2	3	1	5	6	2	2	2	2	2	**29**	5	5	5	0		4	5		**24**	**53**
7	638	Dextrose	5%	I.V Infusion	Unisol 5% 100ml	2	2	3	1	5	6	2	2	2	2	2	**29**	0	5	5	0		4	874-76 Generic is 10%		**14**	**43**
8	640	Dextrose	5%	I.V Infusion	Unisol 5% 500ml	2	2	3	1	5	6	2	2	2	2	2	**29**	5	5	5	0		4	5		**24**	**53**
9	641	Dextrose	5%	I.V Infusion	Unisol 5% 1000ml	2	2	3	1	5	6	2	2	2	2	2	**29**	5	5	5	0		4	5		**24**	**53**
10	642	Dextrose + Sodium Chloride	5% + 0.45%	I.V Infusion	Unisol DS 1/2 500ml	2	2	3	1	5	6	2	2	2	2	2	**29**	5	5	5	0		4	5		**24**	**53**
11	644	Dextrose + Sodium Chloride	5% + 0.9%	I.V Infusion	Unisol DS 500ml	2	2	3	1	5	6	2	2	2	2	2	**29**	5	5	5	0		4	5	Tender approvals are incomplete	**24**	**53**
12	645	Dextrose + Sodium Chloride	5% + 0.9%	I.V Infusion	Unisol DS 1000ml	2	2	3	1	5	6	2	2	2	2	2	**29**	5	5	5	0		4	5		**24**	**53**
13	656	Normal Saline	0.90%	I.V Infusion	Unisol NS 100ml	2	2	3	1	5	6	2	2	2	2	2	**29**	0	5	5	5		4	5		**24**	**53**
14	658	Normal Saline	0.90%	I.V Infusion	Unisol NS 500ml	2	2	3	1	5	6	2	2	2	2	2	**29**	5	5	5	5		4	5		**29**	**58**
15	660	Normal Saline	0.90%	I.V Infusion	Unisol NS 1000ml	2	2	3	1	5	6	2	2	2	2	2	**29**	5	5	5	5		4	5		**29**	**58**
16	667	Ringer's Lactate + Dextrose 5%	Soln.	I.V Infusion	Unisol RLD 500ml	2	2	3	1	5	6	2	2	2	2	2	**29**	5	727, 737, 765, 775, 776 GD of Calcium Chloride not attached	0	801 Macco,		4	5		**14**	**43**
17	668	Ringer's Lactate + Dextrose 5%	Soln.	I.V Infusion	Unisol RLD 1000ml	2	2	3	1	5	6	2	2	2	2	2	**29**	5		0			4	5		**14**	**43**
18	670	Ringer's Lactate	Soln.	I.V Infusion	Unisol RL 500ml	2	2	3	1	5	6	2	2	2	2	2	**29**	5		0			4	5		**14**	**43**
19	671	Ringer's Lactate	Soln.	I.V Infusion	Unisol RL 1000ml	2	2	3	1	5	6	2	2	2	2	2	**29**	5		0			4	5		**14**	**43**
20	676	Sodium Chloride + Dextrose	0.18 % + 4.3%	I.V Infusion	Unisol Peads 500ml	2	2	3	1	5	6	2	2	2	2	2	**29**	646 V.S of Dextrose 10% attached	5	5			4	5		**19**	**48**

Name of product: UNISOL-RLD Infusion 500mL

: UNISOL-RL Infusion 500mL
: Sodium Chloride

Active ingredient :Sodium Chloride
Sodium lactate
Potassium chloride
Calcium chloride $2H_2o$
Dextrose monohydrate

Sodium lactate
Potassium chloride
Calcium chloride $2H_2o$

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposibles and Sutures for Government MCC 2026-27

Name of the firm Unisa Private Limited Kpk

						Technical Evaluation Matrix															
		Product General Information				Factory Technical Evaluation Parameter									Product technical Evaluation Parameters						
						Documents Based Factory Score				Evaluation Visit Score				Factory Evaluated Score							Product Evaluated Score	Total Technical Score
S.No	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. **(as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.**	Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAP regulations. **(to be evaluated by the MCC expert/s at the time of inspection, Noncompliance to cGMP shall lead to disqualification of the relevant section or firm)**	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or**		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks	Valid WHO prequalification and / or valid product registration in SRA/WLA country(ies) / and / or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	6	3	3	2	2	29	5	5	5	6	10	10	41	70
	967	Cord Clamp	N/A	Medical device	UniCORD	**60-Cord Clamp is not covered in the cGMP**				3	3	2	2	10	5	5	Tender approvals are incomplete	0	10	10	20	30
	1018	Disposable Auto Disable Syringe (Blister packing) sterile	3 ml	Medical device	UNILOCK 3CC	3	5	5	6	3	3	2	2	29	5	5	Tender approvals are incomplete	0	10	10	20	49
	1019	Disposable Auto Disable Syringe (Blister packing) sterile	5 ml	Medical device	UNILOCK 5CC	3	5	5	6	3	3	2	2	29	5	5	Tender approvals are incomplete	0	10	10	20	49
	1021	Disposable Insulin Syringe Ordinary sterile	30 G / 31 G, 1ml	Medical device	UNILIN-1	3	5	5	6	3	3	2	2	29	5	5	Tender approvals are incomplete	0	10	10	20	49
	1022	Disposable Syringe Ordinary (Blister packing) sterile	1ml	Medical device	UNIJECT 1CC	3	5	5	6	3	3	2	2	29	5	5	Tender approvals are incomplete	0	10	10	20	49
	1023	Disposable Syringe Ordinary (Blister packing) sterile	10ml	Medical device	UNIJECT 10CC	3	5	5	6	3	3	2	2	29	5	5	Tender approvals are incomplete	0	10	10	20	49
	1024	Disposable Syringe Ordinary (Blister packing) sterile	20ml	Medical device	UNIJECT 20CC	3	5	5	6	3	3	2	2	29	5	5	Tender approvals are incomplete	0	10	10	20	49
	1119	I/V fluid administration set	Sterile and pyrogen free, minimum 150cm tube length, blister pack	Medical device	UNISET	3	5	5	6	3	3	2	2	29	5	5	Tender approvals are incomplete	0	10	10	20	49
	1120	I/V fluid administration set with additional "Y" injection port	Sterile, minimum 150cm length tubing, latex, and pyrogen free, blister pack	Medical device	UNISET with Y-port	3	5	5	6	3	3	2	2	29	5	5	Tender approvals are incomplete	0	10	10	20	49

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposibles and Sutures for Government MCC 2026-27

Name of the firm UNIVERSAL MEDICAL DEVICES, SWABI

S.No	MCC formulary No.	Product General Information				Technical Evaluation Matrix: Factory Technical Evaluation Parameter – Documents Based Factory Score				Evaluation Visit Score				Factory Evaluated Score	Product technical Evaluation Parameters						Product Evaluated Score	Total Technical Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of**	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. **(as evaluated at the time of inspection by the MCC expert/s). Non adherence to GSP shall lead to disqualification of the firm.**	Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAP regulations. **(to be evaluated by the MCC expert/s at the time of inspection. Noncompliance to cGMP shall lead to disqualification of the relevant section or firm)**	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section / firm.**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the**	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand	Valid WHO prequalification and / or valid product registration in SRA/WLA country(ies) / and / or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission.	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	6	3	3	2	2	29	5	5	5	6	10	10	41	70
1	1018	Disposable Auto Disable Syringe (Blister Packing) Sterile 3ml			SKY Auto Disposable Syringe 3ml	3	5	5	0	3	3	2	2	23	5	5	Not attached	Not attached	10	10	30	53
2	1019	Disposable Auto Disable Syringe (Blister Packing) Sterile 5ml			SKY Auto Disposable Syringe 5ml	3	5	5	0	3	3	2	2	23	5	5	Not attached	Not attached	10	10	30	53
3	1022	Disposable Syringe Ordinary (Blister Packing) Sterile 1ml			SKY Disposable Syringe 1ml	3	5	5	0	3	3	2	2	23	5	5	Not attached	Not attached	10	10	30	53
4	1023	Disposable Syringe Ordinary (Blister Packing) Sterile 10ml			SKY Disposable Syringe 10ml	3	5	5	0	3	3	2	2	23	5	5	Not attached	Not attached	10	10	30	53
5	1024	Disposable Syringe Ordinary (Blister Packing) Sterile 20ml			SKY Disposable Syringe 20ml	3	5	5	0	3	3	2	2	23	5	5	Not attached	Not attached	10	10	30	53
6	1119	I/V fluid administration set sterile and pyrogen free, minimum 150cm tube length, blister pack			Sky IV Set (Specification: Hypodermic Needle (21Gx1.1.5") Tube Length: (150cm))	3	5	5	0	3	3	2	2	23	5	5	Not attached	Not attached	10	10	30	53
7	1120	I/V fluid administration set with additional "Y" injection port Sterile, minimum 150cm length tubing, latex, and pyrogen free, blister pack			Sky IV Set with Y Connector (Specification: Hypodermic Needle (21Gx1.1.5") Tube Length: (150cm))	3	5	5	0	3	3	2	2	23	5	5	Not attached	Not attached	10	10	30	53

SCRUTINY REPORT The packing of the formulayr No 1018 to 1024 contian two gauges of needles.

							Evaluation Criteria for Importers/Indenters of Medical Devices, Surgical Disposables and Sutures for Government MCC 2026-27																	
						Name of the firm:	USMAN CO INTERNATIONAL, KARACHI																	
							Technical Evaluation Matrix																	
	S. No.		Product General Parameter				Principal's and Importer's Evaluation Parameters							Product Technical Evaluation							Product Evaluated Score	Total Technical Score
							Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score										
		MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	20
							Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or official accreditation body/regulatory bodies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the time of inspection at the warehouse at the tim eof inspection of the importer shall lead to disqualification of the quoted item/s / firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified, (Presence of Category-A Pharmacist/s is / are mandatory), & relevant Human Resource **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** **(Certificate duly attaested by senior executive of the firm)**	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with	CE mark/ Quality Assurance / Quality Control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union shall be accepted only and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate and/or US free sale certificate of the quoted products, **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
		MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	5	6	**29**	5	5	5	6	10	10	**41**	**70**
1 x 100's	Jiangxi Sanxin Medtec Co. Ltd. China	1	1018	Disposable Auto Disable Syringe (Blister packing) sterile 3ml	**Yi Xin** Auto Disable Syringe with Needle 3cc 24Gx 1"		**Yi Xin** Jiangxi Sanxin Medtec Co. Ltd. China			The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COFG) for the quoted items were checked, and following observations were made; 1. Bicakcilar Global Turkey: Valid Agency Agreement Original and Valid Original free sale certificates of all quoted sizes cannulas/quoted items duly attested from embassy concerned/Apostilled were present at the time of inspection. The Valid Confirmation letter for the quality assurance was not embassy attested/apostilled. 2. Zhangjiang Star Enterprises Co., Ltd China: Valid Agency Agreement Original and Valid Original free sale certificates of all quoted sizes quoted items and quality assurance certificate were not attested from embassy concerned/Apostilled at the time of inspection. 3. Chilecom Medical Devices China: Valid Original production quality assurance Certificate confirmation letter, Original free sale certificates of all the quoted items duly attested from embassy concerned /apostilled were present. 4. Jiayangxi Sanxin China. Valid Agency Agreement Original and Valid Original free sale certificates of all quoted sizes quoted items and quality assurance certificate were not attested from embassy concerned/Apostilled at the time of inspection. 5. 20% inventory of the quoted items, adequate qualified HR, Cold Chain facility, Good Storage practices and SOPs for expiry management were satisfactory/ present at the time of inspection. The firm is RECOMMENDED for all the quoted items of Chilecom Medical Devices China only.											
1 x 100's	Jiangxi Sanxin Medtec Co. Ltd. China	2	1019	Disposable Auto Disable Syringe (Blister packing) sterile 5ml	**YiXin** Auto Disable Syringe with Needle 5cc 23GX1"		**Yi Xin** Jiangxi Sanxin Medtec Co. Ltd. China							5	5		EC expired & without confirmation letter PDF 138-143	10	10	**30**	**30**
1 x 100's	Jiangxi Sanxin Medtec Co. Ltd. China	3	1023	Disposable Syringe Ordinary (Blister packing) sterile 10ml	**UCI Disposable Syringe** with Needle 10 ml 22GX1.25"		**UCI Disposable Syringe** Jiangxi Sanxin Medtec Co. Ltd. China							5	5		EC expired & without confirmation letter PDF 138-144	10	10	**30**	**30**
1 x 50's	Jiangxi Sanxin Medtec Co. Ltd. China	4	1024	Disposable Syringe Ordinary (Blister packing) sterile 20ml	**UCI Disposable Syringe** with Needle 20ml 21G X 1 1/2		**UCI Disposable Syringe** Jiangxi Sanxin Medtec Co. Ltd. China							5	5		EC expired & without confirmation letter PDF 138-145	10	10	**30**	**30**
1 x 20's	Jiangxi Sanxin Medtec Co. Ltd. China	5	1025	Disposable Syringe Ordinary (Blister packing) sterile 50ml	**UCI Disposable Syringe** with Needle 50ml 21G X 1 1/2		**UCI Disposable Syringe** Jiangxi Sanxin Medtec Co. Ltd. China							5	5		EC expired & without confirmation letter PDF 138-146	10	10	**30**	**30**
1 x 20's	Jiangxi Sanxin Medtec Co. Ltd. China	6	1027	Disposable Syringe Ordinary with nozzle/catheter tip (Blister packing) sterile 60ml	**UCI Disposable Syringe** 60ml Catheter Tip		**UCI Disposable Syringe** Jiangxi Sanxin Medtec Co. Ltd. China							5	5		EC expired & without confirmation letter PDF 138-147	10	10	**30**	**30**
	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	7	1123	I/V Cannula (Sterile Having Wings + Injection Port in Sterilized Blister Packing The Cannula Should be Radio-Opaque, as well as Latex, Pyrogen and PVC Free) 18G	I.V. Cannula with Injection Port & Wings Size: 18G		**B. Cat 2 I.V. Cannula**		ISO Expired and verification link not provided PDF 330					5	5		2	10	10	**32**	**32**
	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	8	1125	I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing, The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free) 18G	IV Cannula with Injection Port & In-Stopper Size: 18G		**B. Cat2 IV Cannula**		ISO Expired and verification link not provided PDF 330					5	5		2	DTL Substandard	10	**22**	**22**
	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	9	1126	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free) 20G	I.V. Cannula with Injection Port & Wings Size: 20G		**B. Cat 2 I.V. Cannula**		ISO Expired and verification link not provided PDF 330					5	5		2	DTL Substandard	10	**22**	**22**
	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	10	1128	I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing, The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free) 20G	IV Cannula with Injection Port & In-Stopper Size: 20G		**B. Cat2 IV Cannula**		ISO Expired and verification link not provided PDF 330					5	5		2	10	10	**32**	**32**

	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	11	1129	I/V Cannula (Sterile having wings + injection port in sterilized blister packing. The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free) 22G	I.V. Cannula with Injection Port & Wings Size: 22G		**B. Cat 2 I.V. Cannula**		ISO Expired and verification link not provided PDF 330
	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	12	1131	I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing, The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free) 22G	IV Cannula with Injection Port & In-Stopper Size: 22G		**B. Cat2 IV Cannula**		ISO Expired and verification link not provided PDF 330
	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	13	1132	I/V Cannula (Sterile having wings + injection port with heparin stopper inside sterilized blister packing, The Cannula should be radio-opaque, as well as latex, pyrogen, and PVC free) 24G	IV Cannula with Injection Port & In-Stopper Size: 24G		**B. Cat 2 I.V. Cannula**		ISO Expired and verification link not provided PDF 330
	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	14	1134	I.V Cannula (Sterile having wings with heparin stopper inside sterilized blister packing, The cannula should be radio-opaque, as well as latex, pyrogen, and PVC free) 24G	IV Cannula with Wing & In-Stopper Size: 24G		**B-Cat IV Cannula**		ISO Expired and verification link not provided PDF 330

	5	5		2	10	10	**32**	**32**
	5	5		2	10	10	**32**	**32**
	5	5		2	10	10	**32**	**32**
	5	5		2	DTL Substandard	10	**22**	**22**

							Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27																
						Name of the firm																	
							Technical Evaluation Matrix																
							Principal's and Importer's Evaluation Parameters								Product Technical Evaluation							uct Evaluated Sc	tal Technical Sco
							Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score										
		MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
							Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover,	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies). In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
		MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
1x10's	Chilecom Medical Devices Co. Ltd. China	4	995	Disposable Endotracheal Tube without cuff 2.5mm	**Endosoft** Endotracheal Tube Uncuff Size: 2.5				0	5	6	6	**17**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**43**
1x10's	Chilecom Medical Devices Co. Ltd. China	5	996	Disposable Endotracheal Tube without cuff 3.0mm	**Endosoft** Endotracheal Tube Uncuff Size: 3.0				0	5	6	6	**17**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**43**
1x10's	Chilecom Medical Devices Co. Ltd. China	6	997	Disposable Endotracheal Tube without cuff 3.5mm	**Endosoft** Endotracheal Tube Uncuff Size: 3.5				0	5	6	6	**17**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**43**
1x10's	Chilecom Medical Devices Co. Ltd. China	7	998	Disposable Endotracheal Tube without cuff 4.0mm	**Endosoft** Endotracheal Tube Uncuff Size: 4.0				0	5	6	6	**17**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**43**
1x10's	Chilecom Medical Devices Co. Ltd. China	8	999	Disposable Endotracheal Tube without cuff 5.0mm	**Endosoft** Endotracheal Tube Uncuff Size: 5.0				0	5	6	6	**17**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**43**
1x10's	Chilecom Medical Devices Co. Ltd. China	9	1000	Disposable Endotracheal Tube without cuff 5.5mm	**Endosoft** Endotracheal Tube Uncuff Size: 5.5			Not covered in ISO	0	5	6	6	**17**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**43**
1x10's	Chilecom Medical Devices Co. Ltd. China	10	1006	Disposable Endotracheal Tube with cuff 4.0mm	**Endosoft** Endotracheal Tube Cuff Size: 4.0				0	5	6	6	**17**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**43**
1x10's	Chilecom Medical Devices Co. Ltd. China	11	1007	Disposable Endotracheal Tube with cuff 4.5mm	**Endosoft** Endotracheal Tube Cuff Size: 4.5				0	5	6	6	**17**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**43**
1x10's	Chilecom Medical Devices Co. Ltd. China	12	1008	Disposable Endotracheal Tube with cuff 5.0mm	**Endosoft** Endotracheal Tube Cuff Size: 5.0				0	5	6	6	**17**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**43**
1x10's	Chilecom Medical Devices Co. Ltd. China	13	1009	Disposable Endotracheal Tube with cuff 5.5mm	**Endosoft** Endotracheal Tube Cuff Size: 5.5				0	5	6	6	**17**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**43**
1x10's	Chilecom Medical Devices Co. Ltd. China	14	1010	Disposable Endotracheal Tube with cuff 6.0mm	**Endosoft** Endotracheal Tube Cuff Size: 6.0				0	5	6	6	**17**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**43**

1x10's	Chilecom Medical Devices Co. Ltd. China	15	1011	Disposable Endotracheal Tube with cuff 6.5mm	**Endosoft** Endotracheal Tube Cuff Size: 6.5						0	5	6	6	**17**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**43**
1x10's	Chilecom Medical Devices Co. Ltd. China	16	1012	Disposable Endotracheal Tube with cuff 7.0mm	**Endosoft** Endotracheal Tube Cuff Size: 7.0						0	5	6	6	**17**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**43**
1x10's	Chilecom Medical Devices Co. Ltd. China	17	1013	Disposable Endotracheal Tube with cuff 7.5mm	**Endosoft** Endotracheal Tube Cuff Size: 7.5						0	5	6	6	**17**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**43**
1x10's	Chilecom Medical Devices Co. Ltd. China	18	1014	Disposable Endotracheal Tube with cuff 8.0mm	**Endosoft** Endotracheal Tube Cuff Size: 8.0						0	5	6	6	**17**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**43**
1x6's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	1	962	Chest Drainage Bottle with Tubing	**Thoracic Drainage System** (Chest Drainage Bottle) Length of Tubing 150cm			3	ISO Expired and verification link not provided PDF 320	The firm was inspected as per technical evaluation criteria, all mandatory and embassy attested documents (DRAP Registration, Agency agreement, cGMP/EC, Free Sale certificate/CoPP/COFG) for the quoted items were checked, and following observations were made; 1. Bicakcilar Global Turkey: Valid Agency Agreement Original and Valid Original free sale certificates of all quoted sizes cannulas/quoted items duly attested from embassy concerned/Apostilled were present at the time of inspection. The Valid Confirmation letter for the quality assurance was not embassy attested/apostilled. 2. Zhangjiang Star Enterprises Co., Ltd China: Valid Agency Agreement Original and Valid Original free sale certificates of all quoted sizes quoted items and quality assurance certificate were not attested from embassy concerned/Apostilled at the time of inspection. 3. Chilecom Medical Devices China: Valid Original production quality assurance Certificate confirmation letter, Original free sale certificates of all the quoted items duly attested from embassy concerned /apostilled were present. 4. Jiayangxi Sanxin China. Valid Agency Agreement Original and Valid Original free sale certificates of all quoted sizes quoted items and quality assurance certificate were not attested from embassy concerned/Apostilled at the time of inspection. 5. 20% inventory of the quoted items, adequate qualified HR, Cold Chain facility, Good Storage practices and SOPs for expiry management were satisfactory/ present at the time of inspection. The firm is RECOMMENDED for all the quoted items of Chilecom Medical Devices China only.	**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1x100's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	2	963	Chest Tube (with trocar) Different Size	**Thoracic Catheter With Trocar**, Standard Tip Sizes:12Ch, 16Ch, 20Ch, 24Ch, 28Ch & 32Ch			3	ISO Expired and verification link not provided PDF 320		**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1x100's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	3	964	Chest Tube (without trocar) Different Size	**Thoracic Catheter Without Trocar** Sizes:12Ch, 16Ch, 20Ch,24Ch, 28Ch, 32Ch & 36Ch			3	ISO Expired and verification link not provided PDF 320		**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1 x 150's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	19	1032	Disposable Sterile Nasogastric Tube 4Fr	**Feeding Tube** with Radiopaque Line DEHP free Sizes: 4ch X 50cm	2		3	ISO Expired and verification link not provided PDF 320		**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1 x 150's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	20	1033	Disposable Sterile Nasogastric Tube 5Fr	**Feeding Tube** with Radiopaque Line DEHP free Sizes: 5ch X 50cm	2		3	ISO Expired and verification link not provided PDF 320		**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1 x 200's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	21	1037	Disposable Sterile Nasogastric Tube 12Fr	**Nasogastric Catheter**-Levin Radiopaque Line DEHP free Sizes: 12ch X 121cm	2		3	ISO Expired and verification link not provided PDF 320		**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1 x 150's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	22	1038	Disposable Sterile Nasogastric Tube 14Fr	**Nasogastric Catheter**-Levin Radiopaque Line DEHP free Sizes: 14ch X 121cm	2		3	ISO Expired and verification link not provided PDF 320		**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1 x 150's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	23	1039	Disposable Sterile Nasogastric Tube 16Fr	**Nasogastric Catheter**-Levin Radiopaque Line DEHP free Sizes: 16ch X 121cm	2		3	ISO Expired and verification link not provided PDF 320		**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1 x 150's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	24	1040	Disposable Sterile Nasogastric Tube 18Fr	**Nasogastric Catheter**-Levin Radiopaque Line DEHP free Sizes: 18ch X 121cm	2		3	ISO Expired and verification link not provided PDF 320		**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1 x 120's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	25	1041	Disposable Sterile Nasogastric Tube 20Fr	**Nasogastric Catheter**-Levin Radiopaque Line DEHP free Sizes: 20ch X 121cm	2		3	ISO Expired and verification link not provided PDF 320		**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1 x 50's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	26	1062	Disposable Suction Nozzle	**Yankauer Suction Handle** Bulb Tip W/Vacuum Control			3	ISO Expired and verification link not provided PDF 320		**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1 x 150's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	27	1083	Feeding tube with stopper cap 6Fr	**Feeding Tube** with Radiopaque Line DEHP free Sizes: 6ch X 50cm			3	ISO Expired and verification link not provided PDF 320		**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1 x 150's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	28	1084	Feeding tube with stopper cap 8Fr	**Feeding Tube** with Radiopaque Line DEHP free Sizes: 8ch X 50cm			3	ISO Expired and verification link not provided PDF 320		**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1 x 150's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	29	1085	Feeding tube with stopper cap 10Fr	**Feeding Tube** with Radiopaque Line DEHP free Sizes: 10ch X 50cm			3	ISO Expired and verification link not provided PDF 320		**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1 x 100's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	30	1135	IV Flow Regulator	**B-Flow** (Flow Regulator)			3	ISO Expired and verification link not provided PDF 320		**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**

1 x 100's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	31	1203	Sterile Nelaton Catheter 12Fr	**Nelaton Catheter** Sizes: 12ch X 40cm			3	ISO Expired and verification link not provided PDF 320	**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1 x 100's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	32	1204	Sterile Nelaton Catheter 14Fr	**Nelaton Catheter** Sizes: 14ch X 40cm			3	ISO Expired and verification link not provided PDF 320	**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1 x 100's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	33	1205	Sterile Nelaton Catheter 16Fr	**Nelaton Catheter** Sizes: 16ch X 40cm			3	ISO Expired and verification link not provided PDF 320	**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1 x 80's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	34	1210	Suction Connecting tube with Yankauer suction handle/tip 3M or Less	**Yankauer Suction Connecting** Set+Handle Bulb Tip Cut-to-Fit X 300cm			3	ISO Expired and verification link not provided PDF 320	**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1 x 100's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	35	1225	Sterile Suction Catheter 8Fr	**Suction Catheter** with Kapkon Connector Size: 8ch X 50cm Length			3	ISO Expired and verification link not provided PDF 320	**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1 x 100's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	36	1226	Sterile Suction Catheter 10Fr	**Suction Catheter** with Kapkon Connector Size: 10ch X 50cm Length			3	ISO Expired and verification link not provided PDF 320	**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1 x 100's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	37	1227	Sterile Suction Catheter 12Fr	**Suction Catheter** with Kapkon Connector Size: 12ch X 50cm Length			3	ISO Expired and verification link not provided PDF 320	**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1 x 100's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	38	1228	Sterile Suction Catheter 14Fr	**Suction Catheter** with Kapkon Connector Size: 14ch X 50cm Length			3	ISO Expired and verification link not provided PDF 320	**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1 x 100's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	39	1229	Sterile Suction Catheter 16Fr	**Suction Catheter** with Kapkon Connector Size: 16ch X 50cm Length			3	ISO Expired and verification link not provided PDF 320	**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1 x 100's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	40	1230	Sterile Suction Catheter 18Fr	**Suction Catheter** with Kapkon Connector Size: 18ch X 50cm Length			3	ISO Expired and verification link not provided PDF 320	**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1 x 150's	Bicakcilar Tibbi Cihazlar Sanayi Ve Ticaret A.S., Turkey	41	1232	Stop Cock 3 way with Extension	**Three Way** Stopcock W/tubing 10cm 72 PSI	2		3	ISO Expired and verification link not provided PDF 320	**3**	5	5	Tender approvals are incomplete	Not attached	EC expired & without confirmation letter PDF 131	16	**26**	**29**
1 x 10's	Zhanjiang Star Enterprises Co., Ltd. China	42	1263	Two-Way Foley Catheter (Silicon Coated) 8Fr	**U-Flo** Foley Catheter Latex SC 2-Way 8FR (3-5ML)	2				**0**	5	5	Tender approvals are incomplete	Not attached		16	**26**	**26**
1 x 10's	Zhanjiang Star Enterprises Co., Ltd. China	43	1264	Two-Way Foley Catheter (Silicon Coated) 10Fr	**U-Flo** Foley Catheter Latex SC 2-Way 10FR (3-5ML)	2				**0**	5	5	Tender approvals are incomplete	Not attached		16	**26**	**26**
1 x 10's	Zhanjiang Star Enterprises Co., Ltd. China	44	1265	Two-Way Foley Catheter (Silicon Coated) 12Fr	**U-Flo** Foley Catheter Latex SC 2-Way 12FR (30ML)	2				**0**	5	5	Tender approvals are incomplete	Not attached		16	**26**	**26**
1 x 10's	Zhanjiang Star Enterprises Co., Ltd. China	45	1266	Two-Way Foley Catheter (Silicon Coated) 14Fr	**U-Flo** Foley Catheter Latex SC 2-Way 14FR (30ML)	2				**0**	5	5	Tender approvals are incomplete	Not attached		16	**26**	**26**
1 x 10's	Zhanjiang Star Enterprises Co., Ltd. China	46	1267	Two-Way Foley Catheter (Silicon Coated) 16Fr	**U-Flo** Foley Catheter Latex SC 2-Way 16FR (30ML)	2				**0**	5	5	Tender approvals are incomplete	Not attached		16	**26**	**26**
1 x 10's	Zhanjiang Star Enterprises Co., Ltd. China	47	1268	Two-Way Foley Catheter (Silicon Coated) 18Fr	**U-Flo** Foley Catheter Latex SC 2-Way 18FR (30ML)	2				**0**	5	5	Tender approvals are incomplete	Not attached		16	**26**	**26**
1 x 10's	Zhanjiang Star Enterprises Co., Ltd. China	48	1269	Two-Way Foley Catheter (Silicon Coated) 20Fr	**U-Flo** Foley Catheter Latex SC 2-Way 20FR (30ML)	2				**0**	5	5	Tender approvals are incomplete	Not attached		16	**26**	**26**

Scrutiny Report

PDF

1 105 Letter of authorization of M/S Zhanjiang Star Enterprise Co. have different quoted items strenghts and sizes.

2 106-108 Letter of Authorization needs clarificaiton.

3 299-300 Belgium Free sale is void of validity date on the certificate.

Evaluation Criteria for Manufacturers of Medical Devices, Surgical Disposibles and Sutures for Government MCC 2026-27

Name of the firm: Vikor Health Care Karachi

S.No	MCC formulary No.	Product General Information				Factory Technical Evaluation Parameter: Documents Based Factory Score				Factory Technical Evaluation Parameter: Evaluation Visit Score				Factory Evaluated Score	Technical Evaluation Matrix: Product technical Evaluation Parameters						Product Evaluated Score	Total Technical Score
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
						Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year i.e., FY 2023-24 or latest. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Adherence to Good Storage practices (GSP) for Raw material, In-process and Finished Goods. **(as evaluated at the time of inspection by the MCC expert(s). Non adherence to GSP shall lead to disqualification of the firm.**	Adherence to Current Good Manufacturing Practices (cGMP) in line with the DRAP regulations. **(to be evaluated by the MCC expert/s at the time of inspection, Noncompliance to cGMP shall lead to disqualification of the relevant section or firm)**	Availability of, Functional and validated HVAC, with all relevant equipment, testing, and logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing, and logs shall lead to Disqualification of the relevant section / firm.**	Adequate availability of qualified & relevant Human Resource as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**		Goods Declaration certificate of imported raw material of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC** **(Certificate Duly attested by Senior Executive of the firm)**	Certificate of Analysis of raw material from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 14, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and / or valid product registration in SRA/WLA country(ies) / and / or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Samples evaluation by DTL (Failure to comply with relevant standards shall lead to Disqualification of the quoted products)	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.		
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	6	3	3	2	2	29	5	5	5	6	10	10	41	70
	1290	20mm, 1/2 circle round bodied taper point needle, strand length 70cm	Catgut Chromic Size 4/0M2 20mm, 1/2 circle round bodied premium taper point 76 cm.	SURGILINE Surgigut Chromic (CT224)	All forumulary numbers are not accoriding to the adv. BSDs	3	5	5	2	3	3	2	2	25	5	5	Tender approvals are incomplete	Not attached		10	10	20	45
	1291	20mm, 1/2 circle round bodied taper point needle, strand length 70cm	Catgut Chromic Size 3/0M3, 20mm, 1/2 circle round bodied premium taper point 76 cm.	SURGILINE Surgigut Chromic (CT214)		3	5	5	2	3	3	2	2	25	5	5	Tender approvals are incomplete	Not attached		10	10	20	45
	1292	30mm, 1/2 circle round bodied taper point needle, strand length 70cm	Catgut Chromic Size 2/0M3.5, 30mm 1/2 circle round bodied premium taper point 76cm.	SURGILINE Surgigut Chromic (CT220)		3	5	5	2	3	3	2	2	25	5	5	Tender approvals are incomplete	Not attached		10	10	20	45
	1293	26mm, 1/2 circle round bodied taper point needle, strand length 70cm	Catgut Chromic Size 2/0M3.5, 26mm, 1/2 circle round bodied premium taper point 76cm.	SURGILINE Surgigut Chromic (CT221)		3	5	5	2	3	3	2	2	25	5	5	Tender approvals are incomplete	Not attached		10	10	20	45
	1294	40mm, 1/2 circle round bodied taper point needle, strand length 70cm	Catgut Chromic Size 0M4. 40mm, 1/2 circle heavy round bodied premium taper point 76cm.	SURGILINE Surgigut Chromic (CTH205)		3	5	5	2	3	3	2	2	25	5	5	Tender approvals are incomplete	Not attached		10	10	20	45
	1296	40mm, 1/2 circle round bodied taper point needle, strand length 70cm	Catgut Chromic Size 1M5, 40mm, 1/2 circle round bodied premium taper point 76cm.	SURGILINE Surgigut Chromic (CT205)		3	5	5	2	3	3	2	2	25	5	5	Tender approvals are incomplete	Not attached		10	10	20	45
	1298	40mm, 1/2 circle round bodied taper point needle, strand length 70cm	Catgut Chromic Size 2M6. 40mm 1/2 Circle heavy Round Bodied Premium Taperpoint 76cm.	SURGILINE Surgigut Chromic (CTH201)		3	5	5	2	3	3	2	2	25	5	5	Tender approvals are incomplete	Not attached		10	10	20	45
	1299	17mm, ½ circle round bodied taper point needle, strand length 75cm	Silk Braided Size 4/0M1.5, 16mm, 1/2 circle round bodied premium taper point 76cm.	SURGILINE Silk Braided (ST206)		3	5	5	2	3	3	2	2	25	5	5	Tender approvals are incomplete	Not attached		10	10	20	45
	1300	30mm, 1/2 circle round bodied taper point needle, Strand length 75cm	Silk Braided Size 3/0M2. 30mm 1/2 circle round bodied premium taper point 76cm.	SURGILINE Silk Braided (ST209)		3	5	5	2	3	3	2	2	25	5	5	Tender approvals are incomplete	Not attached		10	10	20	45
	1301	26mm, 1/2 circle round bodied taper point needle, Strand length 75cm	Silk Braided Size 3/0M2. 26 mm 1/2 circle round bodied premium taper point 76cm.	SURGILINE Silk Braided(ST210)		3	5	5	2	3	3	2	2	25	Not attached	Not attached	Tender approvals are incomplete	Not attached		10	10	10	35
	1302	26mm, 3/8 circle conventional cutting needle, Strand length 45 cm	Silk Braided Size 3/0M2. 26mm 3/8 circle triangular body inside cutting 45cm.	SURGILINE Silk Braided (SI301)		3	5	5	2	3	3	2	2	25	Not attached	Not attached	Tender approvals are incomplete	Not attached		10	10	10	35
	1304	31mm, ½ circle round bodied taper point needle, Strand length 75cm	Silk Braided Size 2/0M2. 30mm, 1/2 circle round bodied premium taper point 76cm.	SURGILINE Silk Braided (ST204)		3	5	5	2	3	3	2	2	25	Not attached	Not attached	Tender approvals are incomplete	Not attached		10	10	10	35
	1305	26mm, ½ circle round bodied taper point needle, Strand length 75cm	Silk Braided Size 2/0M2. 26mm, 1/2 circle round bodied premium taper point 76cm.	SURGILINE Silk Braided (ST207)		3	5	5	2	3	3	2	2	25	5	5	Tender approvals are incomplete	Not attached		10	10	20	45
	1306	31mm, ½ circle round bodied needle, Strand length 75cm	Silk Braided Size 0M3.5, 30mm, 1/2 circle round bodied premium taper point 76cm.	SURGILINE Silk Braided (ST202)		3	5	5	2	3	3	2	2	25	5	5	Tender approvals are incomplete	Not attached		10	10	20	45
	1308	30mm, ½ circle round bodied taper point needle, Strand length 75cm	Silk Braided Size 1M4. 30mm, 1/2 circel heavy round bodied premium taper point 76cm.	SURGILINE Silk Braided(STH202)		3	5	5	2	3	3	2	2	25	5	5	Tender approvals are incomplete	Not attached		10	10	20	45
	1310	40mm, ½ circle round bodied taper point needle, Strand length 75cm	Silk Braided Size 2M5. 40mm, 1/2 circle heavy round bodied premium taper point 76cm.	SURGILINE Silk Braided (STH201)		3	5	5	2	3	3	2	2	25	5	5	Tender approvals are incomplete	Not attached		10	10	20	45
	1358	16mm, 3/8 circle conventional or curved cutting needle, strand length 45cm	Polypropylene Blue Monofilament, Size 4/0M1.5, 16mm, 3/8 circle, triangular bodied conventional cutting needle , 45cm.	SURGILINE Surgilene (NX308)		3	5	5	2	3	3	2	2	25	Not attached	Not attached	Tender approvals are incomplete	Not attached		10	10	10	35
	1359	26mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm	Polypropylene Blue Monofilament, Size 4/0M1.5, 26mm, 1/2 circle double round bodied taper point needle, 90cm.	SURGILINE Surgilene (NTD206)		3	5	5	2	3	3	2	2	25	5	5	Tender approvals are incomplete	Not attached		10	10	20	45
	1361	26mm, 1/2 circle round bodied taper point double armed needle, strand length 75cm	Polypropylene Blue Monofilament, Size 3/0M2, 26mm 1/2 circle double round bodied taper point needle, 90cm.	Surgiline Surgilene (NTD203)		3	5	5	2	3	3	2	2	25	Not attached	Not attached	Tender approvals are incomplete	Not attached		10	10	10	35
	1362	30mm, 1/2 circle round bodied taper point double armed needle, strand length 90cm	Polypropylene Blue Monofilament, Size 3/0M2, 30mm, 1/2 circle double round bodied taper point needle, 90cm.	SURGILINE Surgilene (NTD202)		3	5	5	2	3	3	2	2	25	5	5	Tender approvals are incomplete	Not attached		10	10	20	45
	1363	26mm, 1/2 circle round bodied taper point needle, strand length 75 cm	Polypropylene Blue Monofilament, Size 2/0M3, 26mm, 1/2 circle round bodied taper point needle, 75cm.	SURGILINE Surgilene (NT206)		3	5	5	2	3	3	2	2	25	5	5	Tender approvals are incomplete	Not attached		10	10	20	45
	1364	26mm, 3/8 circle reverse cutting needle, strand length 45cm	Polypropylene Blue Monofilament, Size 2/0M3, 26mm, 3/8 circle, triangular bodied reverse cutting needle, 45cm.	SURGILINE Surgilene (NR302)		3	5	5	2	3	3	2	2	25	Not attached	Not attached	Tender approvals are incomplete	Not attached		10	10	10	35
	1367	30mm, 1/2 circle round bodied taper point needle, strand length 75cm	Polypropylene Blue Monofilament, Size 2/0M3, 30mm, 1/2 circle round bodied taper point needle, 75cm.	SURGILINE Surgilene (NT205)		3	5	5	2	3	3	2	2	25	5	5	Tender approvals are incomplete	Not attached		10	10	20	45
	1369	60mm, straight cutting needle, strand length 75cm	Polypropylene Blue Monofilament, Size 2/0M3, 60mm, triangular bodied straight cutting needle 75cm.	SURGILINE Surgilene (NS002)		3	5	5	2	3	3	2	2	25	Not attached	Not attached	Tender approvals are incomplete	Not attached		10	Not Recommended	10	35
	1370	40mm, 1/2 circle round bodied taper point needle, Strand length 75cm	Polypropylene Blue Monofilament, Size 0M3.5, 40mm, 1/2 circle round bodied taper point needle, 75cm.	SURGILINE Surgilene (NT204)		3	5	5	2	3	3	2	2	25	5	5	Tender approvals are incomplete	Not attached		10	10	20	45
	1371	40mm, 1/2 circle round bodied taper point needle, Strand length 75cm	Polypropylene Blue Monofilament, Size 1M4. 40mm, 1/2 circle round bodied taper point needle, 75cm.	SURGILINE Surgilene (NT202)		3	5	5	2	3	3	2	2	25	5	5	Tender approvals are incomplete	Not attached		10	10	20	45

Bidding firm name not mentioned on the mandatory CDR

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm: | **WHO-GMP: 1-100/1-100/NIL**

| S. No. | | Product General Information | | | | | Technical Evaluation Criteria (Out of 100 Marks) | | | | |

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injectable Drugs, Biologicals and IV Fluids for Government MCC 2024-27

| Name of Firm: | | | | | | WIN-HOME LABS LABORAT | | | | | |

Evaluation Criteria for Manufacturers of General Medicine, Drugs, Powder Injetable Drugs, Biologicals and IV Fluids for Government MCC 2026-27

Name of Firm | **WIMITS PHARMACEUTICALS PVT LTD**

Technical Evaluation Matrix

S. No.	Product General Information					Factory Technical Evaluation Parameters											Total Factory Evaluated Score	Product Evaluation Parameters									Total Product Evaluated Score	Total Technical Score
						Documents Based Factory Score						Factory Evaluation Visit Score						Product Technical Parameters											
	MCC formulary.No	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
						Valid ISO 18001/45001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 14001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Valid ISO 9001 certificate of the facility where the quoted product is manufactured, issued by PNAC accredited body (duly attested by senior executive of the firm) **Online verification link shall be provided**	Latest IMS/IQVIA ranking of the leading manufacturer firm (by value) in Pakistan . **12 months to date ranking will be considered).** Marks shall be awarded to top 100 firms of Pakistan as ranked by value by IMS/IQVIA, in the following manner: **1. Firm having (12-Month) Ranking in top-20 positions shall be awarded 5 marks.** **2. Firms having (12-Month) Ranking between 21-40th positions 4 marks.** **3. Firms having (12-Month) ranking between 41st to 60th position shall be awarded 3 marks.** **4. Firms having (12-Month) ranking between 61st to 80th position shall be awarded 2 marks.** **5. Firms having (12-Month) ranking between 81st to 100th position shall be awarded 1 mark.**	Valid calibration certificates for equipment / instruments used in the factory for Measuring, weighing, Assay/ Analysis of raw material, in-process material and finished products for the manufacturing of the quoted products. **(Valid Calibration Certificates attested by Quality head of the firm).**	Valid documents of the Federal Board of Revenue (FBR) showing the total financial turnover of the firm for the last year. Maximum 6 marks shall be awarded in the following manner: Financial turnover of PKR 100 to 500 million - 2 marks. Financial turnover of more than PKR 500 million and upto 1000 million - 4 marks. Financial turnover of more than PKR 1000 million - 6 marks **(The document shall be attested by a Senior executive of the firm)**	Availability of calibrated equipment for analysis of quoted items along with validated methods of testing of the quoted items and adherence to good laboratory practices (GLP) in all labs + Functional Stability Chamber (Both Accelorated and Real Time)(as in Schedule B of DRAP) **(Evaluated at the time of inspection by the MCC expert/s, as non-availability or non-functioning of stability chambers and/or non-adherence to GLP as per schedule-B shall lead to disqualification of the firm).**	Raw material, In-process and Finished good storage (as in Schedule B of DRAP) (as evaluated at the time of inspection by the MCC expert/s). **Non-compliance to GSP shall lead to disqualification of the firm.**	Adherence to cGMP guidelines, (as in Schedule-B of DRAP), in area / section of the quoted product (s). **Non-compliance to cGMP guidelines shall lead to disqualification of the section/s or firm).**	Adequate availability of qualified & relevant Human Resource as per the requirements mentioned in schedule-B of DRAP **(Certified by the senior executive of the firm & evaluated by MCC expert/s at the time of inspection, Non-availability shall lead to disqualification of the section/s or firm).**	Availability of Functional and validated HVAC, with all relevant equipment, testing, logs. **(As evaluated by the MCC expert/s at the time of inspection).** **Non-availability or non-functionality of the HVAC system and/or testing and/or logs, shall lead to Disqualification of the relevant section / firm.**		Bioavailability/ Bioequivalence study conducted by WHO Audited Labs must be attached along with the bio and study must be available on WHO Website) and / or For biologicals, bio-similarity studies shall be provided for award of marks in this parameter. and / or In case of Large volume parenteral i.e., greater than 100ml up to 5L, product validation report (as per WHO/US-FDA/USP guidelines) shall be submitted. and / or Proof of inventor / innovator products from relevant body shall be provided where the firm claims that the bioequivalence / biosimilarity is not applicable. Proof on company's own letter head shall not be acceptable.	Goods Declaration certificate of imported API of the quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months from the cutoff date for submission of bids. In cases where Raw materials are acquired from Local sources valid invoice (s) not older than 24 months shall be considered. **In case of purchases through third party importers a valid trail/link/DRAP clearance NOC between the principal manufacturer and the importer firm shall be established with the firm offering the product to Govt. MCC**	Certificate of Analysis of API from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 18, duly attested by the senior executive of the firm. **In case of Non-provision of matching GD the marks for CoA will not be awarded.**	Active Pharmaceutical Ingredient's (APIs) source accreditation certificate issued by WHO / US-FDA / EMA / MHRA/ TGA/ PMDA/ Swiss Medic or Health Canada or by regulatory authority/body of SRA/WLA country (ies) coupled with Form-3 (form of undertaking to accompany an application for License to import Drugs). In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of NIT/bid submission. Moreover, in case of product/quoted item having multiple APIs, the marks for GD, CoA, APIs source accreditation shall be awarded only where these documents are submitted for all APIs/components of the quoted products	Valid WHO prequalification and / or Valid product registration in SRA/WLA country(ies) and / or Valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) 1 mark for each certification, up to a maximum of 03 marks. **Online verification link shall be provided** Certificates on company's own letter heads shall not be acceptable. (copies of relevant certificates duly attested by the senior executive of the firm) **Note: Valid Certificates for the same brand shall be provided. Certificate on company's own letter head shall not be acceptable.**	Valid Certificate of Analysis of the Type / class of material used for the immediate container of the quoted item/s, as issued by the manufacturer of the material coupled with Invoice/proof of purchase **Picture of the DRAP approved immediate container packaging shall be submitted for each quoted item. Non-provision of the above shall lead to award of zero marks in this coloumn for the respective item.** For award of marks, the certificate of analysis must clearly mention: 1. Materials e.g., Aluminium Foil, PVC, Capsule Shells, Plastic (HDPE, LDPE) or any other material used for the immediate container of the quoted item complying with US, European, British, Japanese pharmacopoeial standards, or must clearly mention that the material is of a Pharmaceutical grade. 2. Type of Glass material for Liquid ampoules must be USP class 1 (Non-compliance shall lead to disqualification of the quoted product). **3. Type of Glass material for Oral Syrups/ Suspensions must be USP Type 3 or better (Non-compliance or non-provision of CoA of glass material shall lead to disqualification of the quoted product).** 4. For Dry Powder Injectables, a. For USP Type 1 glass 4 marks will be awarded. b. For USP Type 2 Glass 2 marks will be awarded. **c. For products where USP Type 3 glass is used or where the CoA of Glass material is not provided shall lead to disqualification of the item (s).** (Documents duly attested by the Senior executive of the firm).	Stability studies of quoted item/s duly attested by the Q.C incharge of the firm).	Availability of quoted item/s in Pakistani market as per recent most data of IMS/IQVIA Health not older than twelve (12) months. 1-10% market share = 1 mark 11-30% market share = 2 marks 31-50% market share = 3 marks 50% and above market share = 5 marks For items specifically used in institutions where IMS/IQVIA data is not applicable the bidder shall provide Tender Approvals (not older than twelve 12 months) from Tertiary Care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.		
	MCC formulary.No	Generic Name of Item	Strength	Dosage Form	Brand Name	2	2	3	5	5	6	2	2	2	2	2	33	5	5	5	5	3	4	5	5	37	70
1	427	Doqamine HCl	40mg/ml	Inj	Doqa	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	5	16
2	40	Diclofenac	25mg/ml	Inj	Painea	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	0	11
3	46	Ibuprofen	100mg/5ml	Susp	Ibuprofen	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	5	16
4	47	Ketorolac	30mg/ml	Inj	Ketomit	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	5	16
5	56	Nalbuphine	1ml/10mg	Inj	Nal-Bex	0	0	0	0	5	6						11	0	5	5	0	0	0	0	0	10	21
6	59	Paracetamol	500mg	Tab	Monador	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	0	11
7	65	Paracetamol+Oz	450mg/35mg	Tab	Paradrine	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	0	11
8	66	Paracetamol+Trai	325mg/37.5mg	Tab	Copod	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	0	11
9	68	Tizadine	4mg	Tab	Xantix	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	0	11
10	69	Tramadol	50mg/1ml	Inj	W-Dol	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	0	11
11	137	Fluconazole	150mg	Tab/Cap	Funol	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	0	11
12	147	Terbinafine	250mg	Tab	Terfin	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	0	11
13	154	Cetrizine	5mg/5ml	Syp	Cetrido	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	0	11
14	160	Montelukast	10	Tab	Asjast	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	0	11
15	219	Ceftriaxone	1gm/vial	Inj	Cefo	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	0	11
16	230	Ciprofloxacin	250mg	Tab	Solo-Cip	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	0	11
17	231	Ciprofloxacin	500mg	Tab	Solo-Cip	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	0	11
18	251	Doxycycline	100mg	Cap	Microdox	0	0	0	0	5	6						11	0	5	5	0	0	0	0	0	10	21
19	275	Moxifloxacin	400mg	Tab	Mox la	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	0	11
20	402	Amlodipine	10mg	Tab	Amowinn	0	0	0	0	5	6						11	0	5	5	0	0	0	0	0	10	21
21	403	Amlodipine	5mg+80mg	Tab	Valta-AM	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	0	11
22	404	Amlodipine	10mg+160mg	Tab	Valta-AM	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	0	11
23	421	Clopidogrel	75mg	Tab	Clopix	0	0	0	0	5	6						11	0	5	5	0	0	0	0	0	10	21
24	431	Furosemide	10mg/ml	Inj	Dosetav	0	0	0	0	5	6						11	0	5	5	0	0	0	0	0	10	21
25	501	Diamethyldrate	50mg/ml	Inj	Maxtrate	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	5	16
26	506	Drotaverine	20mg/ml	Inj	Drotasmit	0	0	0	0	5	6						11	0	5	5	0	0	0	0	0	15	26
27	520	Ondansetron	2mg/ml	Inj	Dyst	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	5	16
28	533	Zinc sulphate	20mg/5ml	Syp	Zinpaim	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	0	11
29	703	Carbamazepine	200mg	Tab	Epic	0	0	0	0	5	6						11	0	5	5	0	0	0	0	0	10	21
30	725	Escitalopram	20mg	Tab	Estipr	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	5	16
31	812	Salbutamol	2mg/5ml	Syp	Ventogal	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	0	11
32	887	Polymyxin B	10000IU/gm	Ointment	Polymit	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	0	11
33	861	Betamethasone	0.05%+0.1%	Oint	Gentibet	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	0	11
34	863	Clobetasole	0.05% w/w	oint	Clobimit	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	0	11
35	891	Silver	1%	Cream	Quazim	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	0	11
36	914	Cholecalciferol	200000 IU	IM/Oral Inj	Cal-Dee	0	0	0	0	5	6						11	0	0	0	0	0	0	0	0	0	11

The inspection team at the time of inspection observed that,
POOR GOOD STORAGE PRACTICES (GSP)
1. In RMS excipients and APIs were stored mixed and were not properly labeled.
2. No HVAC system or dehumidification mechanism was installed in the RMS General and RMS Cephalosporin sections, indicating the absence of proper temperature and humidity control systems, which are critical for raw material storage.
3. In the Finished goods and packaging materials store only one AC was installed, no temperature and humidity record was produced violating basic GMP storage requirements.
4. No storage temperature monitoring record of vitamin-D was produced to the inspection committee.
5. In RMS only ceftwine was found, however, the firm showed an invoice of 2 kg ceftriaxone purchased.

POOR ADHERANCE TO cGMP
6. In retension sample room both veterinary and allopathic medicines were kept on the same shelves with no temperature and humidity records, and hygrometer was also not installed.
7. Purchase invoice record of nalbuphine was not produced to the inspection team at the time of inspection.
8. In ampules section, epoxy flooring was peeled off, thus increasing the chances of contamination.

POOR ADHERANCE TO GOOD LABORATORY PRACTICES (GLP)
9. In stability chamber veterinary products were found mixed along with allopathic products, indicating that no dedicated stability chambers for allopathic products were present at the time of inspection.

NON-FUNCTIONAL HVAC SYSTEM AND ENVIRONMENTAL CONTROL

10. The HVAC system was found non-functional at the time of inspection.

In view of the above, the firm is NOT RECOMMENDED for award of factory evaluation visit score for the quoted items.

SCRUTINY REPORT

1.GD of dimenhydrinate is expired on page 93
2.Gd of escitalopram is expired on page 123
3.GD of montelukast is missing only AWB is present at page 153 hence no marks awarded.
4.No GD is present and only AWB at page 173 henc no marks awarded.
5.Trail of Tramadol is not established at pape 193 hence no marks awarded.
6.GD and COA of ondansetron not matching at page 195 hence no marks awarded.
7.no GD and COA of salbutamol at page 209 hence no marks awarded.
8.GD and COA not matching at page 215 hence no marks awarded.
9.No AWB with GD of terbinafine on page 224 hennce no marks awarded.
10.APIof carbamazepine is of arthi drugs at page 244 instead of bajaj healthcare.
11.GD and AWB at page 259 and 260 is not matching hence no mark awarded
12.GD expired at page 271 hence no marks awarded
13.api source of dopamine is expired at page 277
14. Iso is from acerta which is not PNAC accredited hence no marks awarded.
15.pages of the bid are unamested need clarification

						Evaluation Criteria for Importers/Indenters of Non-Drug Items for Government MCC 2026-27														
Name of the firm						Wirha & Co Rawalpindi														
						Technical Evaluation Matrix														
						Principal's and Importer's Evaluation Parameters							Product Technical Evaluation						Product Evaluated Score	Total Technical Score
						Principal Manufacturer Evaluation			Importer's Evaluation			Suppliers Technical Score								
	MCC formulary No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
			70			Valid ISO 14001 certificate of the facility where the quoted product is manufactured issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF), (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid ISO 13485 certificate of the facility where the quoted product is manufactured, issued by authorized body of the country of origin duly accredited with International Accreditation Forum (IAF) for the country of origin (duly attested by senior executive of the firm). **Online verification link shall be provided.**	Valid accreditation of manufacturing unit or its relevant section/s by the US-FDA or UNFPA or official accreditation body/ies/regulatory body/ies in the case of SRA/WLA countries (duly attested by senior executive of the firm) In cases where the validity period is not explicitly mentioned on the accreditation certificate, the certificate shall be considered valid only if it was issued within the last five (05) years from the date of bid submission. **Online verification link shall be provided.**	Availability of minimum 20% inventory of the total import of the quoted item/s during last one year (certificate to the effect duly signed by the senior executive of the firm & evaluated by the MCC expert/s). **Non availability of the 20% stock at the warehouse at the time of inspection of the importer shall lead to disqualification of the quoted item/s and/or firm)**	Adherence to Good Storage Practices (GSP) for finished goods storage of the quoted item/s. The physical inspection committee/ MCC experts shall verify the compliance to the GSP in accordance to the laid down criteria and terms and conditions of the Drug Sales Rules/ Medical Device Rules/Regulations framed by the DRAP. **Non adherence to GSP, as evaluated by the MCC expert/s at the time of inspection shall lead to Disqualification of the firm.**	Adequate availability of qualified & relevant Human Resource (presence of Category-A pharmacist/s is/are mandatory) as per the requirements laid down in DRAP regulations. **(Certified by the senior executive of the firm & evaluated / confirmed by MCC expert/s at the time of inspection as non-compliance to this parameter shall lead to disqualification of the firm).**		Goods Declaration certificate of imported finished quoted item/s from Pakistan Customs, coupled with valid airway bill or Bill of Lading for the quoted item/s, not older than 24 months on the cutoff date for submission of bids. **In case of supply/purchase through different facilty/third party, a valid trail/link/DRAP clearance NOC between the principal manufacturer and the supplier firm shall be established with the firm offering the product to Govt. MCC** Duly attested by the senior executive of the firm.	Certificate of Analysis of finished quoted item/s from the Principal Manufacturer as mentioned in the goods declaration (GD) provided in column 12, duly attested by the senior executive of the firm. **(In case of non-provision of matching GD the marks for GD will not be awarded).**	Tender Approvals (not older than twelve 12 months) from Tertiary care Govt. Hospitals, Health related Govt. projects and/ or JCI accredited private hospitals of Pakistan. Marks shall be awarded in the following manner: 02 Tender approvals- 01 mark 04 Tender approvals- 02 marks 06 Tender approvals- 03 marks 08 Tender approvals- 04 marks 10 or more Tender approvals- 05 marks Note. Tender approval means award of contract(s) for the quoted product(s) with the same brand name and specifications / strength / dosage form. Moreover, the approval(s) shall be duly attested by the concerned procuring entities and accompanied with purchase orders, delivery challan, invoice/warranty and cheque from the concerned procuring entity/purchasing agency/ies, etc. The bank statement showing the respective transaction against the cheque received shall also be submitted with each purchase order.	Valid WHO prequalification and/or valid product registration in SRA/WLA country(ies) / and/or valid free sale certificate issued by regulatory body of any SRA/WLA country(ies) In cases where the validity period is not explicitly mentioned on the above certificate, the certificate shall be considered valid only if it was issued within the last Ten (10) years from the date of bid submission. 01 mark for each certification, up to a maximum of 03 marks. **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevent certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	CE mark/Quality assurance certificate/Quality control certificate issued by conformity assessment bodies (CABs) enlisted in NANDO database under the relevant European directive for medical devices of European Union and/or Japanese Ministry of Health, Labour and Welfare (JMHLW) certificate, and/or US free sale certificate of the quoted products certificates with same brand name shall be considered. **02 marks for each certification, up to a maximum of 06 marks.** **Certificates on company's own letter heads shall not be acceptable.** **(copies of relevant certificates duly attested by the senior executive of the firm)** **Online verification link shall be provided.**	Physical examination of the quoted item/s by the MCC expert/s. Rejection of the quoted item/s by the MCC expert/s shall lead to disqualification of the said item/s.	**Product Evaluated Score**	**Total Technical Score**
	MCC formulary No.	Generic Name of Item	Strength	Dosage Form	Brand Name	3	5	5	5	6	6	**30**	5	5	5	3	6	16	**40**	**70**
940	**Blood Bags (CPDA-1)**	**Single**	**450 ml - 500 ml**	**500 ML**	**NCS**	0	5	0				**5**	GD not attached				0	16	**16**	**21**
942	**Blood Bags (CPDA-1)**	**Double**	**450 ml - 500 ml**	**500 ML**	**NCS**	0	5	0	All mandstory documents of the quoted items in original were checked, and the warehouse was inspected by the inspection team for evaluation of adherence to the required criteria of physical inspection for importers given under BSDs (Bid solicitation Documents), after which following observations were noted; SOZHOU LAISHI CHINA			**5**	5	75 COA does not specify single double or triple	Tender approvals are incomplete		0	16	**21**	**26**
944	**Blood Bags (CPDA-1)**	**Triple**	**450 ml - 500 ml**	**500 ML**	**NCS**	0	5	0	1. The firm has obtained DRAP enlistment for the quoted products using a German free sale. The criterion in MCC BSDs is a free sale certificate of the country of origin, which is China, the said certificate is issued after bid opening date of issuance is March 12, 2026. **Based on the above observations due to non-fulfillment of the criteria (free sale certificate) the firm is NOT RECOMMENDED for the award of marks as specified for physical inspection in the relevant pro-forma for items of SOZHOU LAISHI CHINA.**			**5**	5			0	16	**21**	**26**
946	**Blood Transfusion Sets**		**Sterile & pyrogen-free, min 125 cm tube, blister pack**		**NCS**	0	5	0				**5**	5	COA not attached			0	16	**21**	**26**

and complete address of manufacturer:

26.02.2026

M/s Suzhou Laishi Transfusion Equipment Co.,

Changsheng Rd., Tongli Town, Wujiang District, Suzhou City, 215217 Jiangsu Province, P.R.China